Induction NN B-NP B-NP
of IN B-PP B-PP
NF-KB NN B-NP B-NP
during IN B-PP B-PP
monocyte NN B-NP B-NP
differentiation NN I-NP I-NP
by IN B-PP B-PP
HIV NN B-NP B-NP
type NN I-NP I-NP
1 CD I-NP B-NP
infection NN I-NP I-NP
. . O O

The DT B-NP B-NP
production NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP I-NP
( ( O O
HIV-1 NN B-NP I-NN
) ) O O
progeny NN B-NP B-NP
was VBD B-VP B-VP
followed VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
U937 NN I-NP I-NP
promonocytic JJ I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
after IN B-PP B-PP
stimulation NN B-NP B-NP
either CC B-PP B-PP
with IN I-PP B-PP
retinoic JJ B-NP B-NP
acid NN I-NP I-NP
or CC O I-NP
PMA NN B-NP I-NP
, , O O
and CC O I-CC
in IN B-PP B-PP
purified VBN B-NP B-NP
human JJ I-NP I-NP
monocytes NNS B-NP I-NP
and CC O I-NP
macrophages NNS B-NP I-NP
. . O O

Electrophoretic JJ B-NP B-NP
mobility NN I-NP I-NP
shift NN I-NP I-NP
assays NNS I-NP I-NP
and CC O I-CC
Southwestern NN B-NP B-NP
blotting NN I-NP I-NP
experiments NNS I-NP I-NP
were VBD B-VP B-VP
used VBN I-VP I-VP
to TO B-VP B-VP
detect VB I-VP I-VP
the DT B-NP B-NP
binding NN I-NP I-NP
of IN B-PP B-PP
cellular JJ B-NP B-NP
transactivation NN I-NP I-NP
factor NN I-NP I-NP
NF-KB NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
double JJ I-NP I-NP
repeat-KB JJ|NN I-NP I-NP
enhancer NN I-NP I-NP
sequence NN I-NP I-NP
located JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
. . O O

PMA NN B-NP B-NP
treatment NN I-NP I-NP
, , O O
and CC B-CONJP I-CC
not RB I-CONJP B-NP
retinoic JJ B-NP I-NP
acid NN I-NP I-NP
treatment NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
U937 NN I-NP I-NP
cells NNS I-NP I-NP
acts VBZ B-VP B-VP
in IN B-PP B-PP
inducing VBG B-VP B-VP
NF-KB NN B-NP B-NP
expression NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
nuclei NNS I-NP I-NP
. . O O

In IN B-PP B-PP
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
from IN B-PP B-PP
monocytes NNS B-NP B-NP
or CC O I-NP
macrophages NNS B-NP I-NP
, , O O
induction NN B-NP B-NP
of IN B-PP B-PP
NF-KB NN B-NP B-NP
occurred VBD B-VP B-VP
only RB B-SBAR B-ADVP
if IN I-SBAR B-PP
the DT B-NP B-NP
cells NNS I-NP I-NP
were VBD B-VP B-VP
previously RB I-VP I-VP
infected VBN I-VP I-VP
with IN B-PP B-PP
HIV-1 NN B-NP B-NP
. . O O

When WRB B-ADVP B-ADVP
U937 NN B-NP B-NP
cells NNS I-NP I-NP
were VBD B-VP B-VP
infected VBN I-VP I-VP
with IN B-PP B-PP
HIV-1 NN B-NP B-NP
, , O O
no DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
NF-KB NN B-NP B-NP
factor NN I-NP I-NP
was VBD B-VP B-VP
detected VBN I-VP I-VP
, , O O
whereas IN O B-PP
high JJ B-NP B-NP
level NN I-NP I-NP
of IN B-PP B-PP
progeny NN B-NP B-NP
virions NNS I-NP I-NP
was VBD B-VP B-VP
produced VBN I-VP I-VP
, , O O
suggesting VBG B-VP B-VP
that IN B-SBAR B-PP
this DT B-NP B-NP
factor NN I-NP I-NP
was VBD B-VP B-VP
not RB I-VP I-VP
required VBN I-VP I-VP
for IN B-PP B-PP
viral JJ B-NP B-NP
replication NN I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
in IN B-PP B-PP
monocytic JJ B-NP B-NP
cell NN I-NP I-NP
lineage NN I-NP I-NP
, , O O
HIV-1 NN B-NP B-NP
could MD B-VP B-VP
mimic VB I-VP I-VP
some DT O B-NP
differentiation/activation JJ B-NP I-NP
stimuli NNS B-NP I-NP
allowing VBG B-VP B-VP
nuclear JJ B-NP B-NP
NF-KB NN I-NP I-NP
expression NN I-NP I-NP
. . O O

Positive JJ B-NP B-NP
and CC I-NP I-NP
negative JJ I-NP I-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
immunoglobulin NN B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
by IN B-PP B-PP
a DT B-NP B-NP
novel JJ I-NP I-NP
B-cell-specific JJ I-NP I-NP
enhancer NN I-NP I-NP
element NN I-NP I-NP
. . O O

A DT B-NP B-NP
new JJ I-NP I-NP
B-cell-specific JJ I-NP I-NP
enhancer NN I-NP I-NP
element NN I-NP I-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
identified VBN I-VP I-VP
3' JJ B-NP B-ADVP
of IN B-PP B-PP
E4 NN B-NP B-NP
and CC O I-CC
the DT B-NP B-NP
octamerlike JJ I-NP I-NP
motifs NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
immunoglobulin NN I-NP I-NP
heavy-chain NN I-NP I-NP
gene NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

Tandem JJ B-NP B-NP
copies NNS I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
67-bp JJ I-NP I-NP
MnlI-AluI NN I-NP I-NP
fragment NN I-NP I-NP
, , O O
when WRB B-ADVP B-ADVP
fused VBN B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
chloramphenicol JJ I-NP I-NP
acetyltransferase NN I-NP I-NP
gene NN I-NP I-NP
driven VBN B-VP B-VP
by IN B-PP B-PP
the DT B-NP B-NP
conalbumin JJ I-NP I-NP
promoter NN I-NP I-NP
, , O O
stimulated VBD B-VP B-VP
transcription NN B-NP B-NP
in IN B-PP B-PP
B NN B-NP B-NP
cells NNS I-NP I-NP
but CC B-PP I-CC
not RB B-PP I-RB
in IN I-PP B-PP
Jurkat NN B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
or CC O I-CC
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Footprinting NN B-NP B-NP
analysis NN I-NP I-NP
revealed VBD B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
identical JJ I-NP I-NP
sequence NN I-NP I-NP
CCGAAACTGAAAAGG NN I-NP I-NP
, , O O
designated VBN B-VP B-VP
E6 NN B-NP B-NP
, , O O
was VBD B-VP B-VP
protected VBN I-VP I-VP
by IN B-PP B-PP
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
from IN B-PP B-PP
B NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
T NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
or CC O I-CC
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Gel NN B-NP B-NP
mobility NN I-NP I-NP
shift NN I-NP I-NP
assays NNS I-NP I-NP
using VBG B-VP B-VP
a DT B-NP B-NP
synthetic JJ I-NP I-NP
E6 NN I-NP I-NP
motif NN I-NP I-NP
detected VBD B-VP B-VP
a DT B-NP B-NP
B-cell-specific JJ I-NP I-NP
complex NN I-NP I-NP
in IN B-PP B-PP
addition NN I-PP B-NP
to TO I-PP B-PP
a DT B-NP B-NP
ubiquitous JJ I-NP I-NP
band NN I-NP I-NP
found VBN B-VP B-VP
also RB B-PP B-ADVP
in IN I-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
and CC O I-CC
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

In IN B-PP B-PP
agreement NN I-PP B-NP
with IN I-PP B-PP
the DT B-NP B-NP
results NNS I-NP I-NP
of IN B-PP B-PP
gel NN B-NP B-NP
retardation NN I-NP I-NP
assays NNS I-NP I-NP
, , O O
tandem JJ B-NP B-NP
copies NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
E6 NN I-NP I-NP
motif NN I-NP I-NP
stimulated VBD B-VP B-VP
transcription NN B-NP B-NP
in IN B-PP B-PP
ARH77 NN B-NP B-NP
and CC O I-NP
Raji NN B-NP I-NP
cells NNS B-NP I-NP
but CC B-PP I-CC
not RB B-PP I-RB
in IN I-PP B-PP
Jurkat NN B-NP B-NP
or CC O I-NP
HeLa NN B-NP I-NP
cells NNS B-NP I-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
a DT B-NP B-NP
mutant JJ I-NP I-NP
E6 NN I-NP I-NP
motif NN I-NP I-NP
lost VBD B-VP B-VP
both CC O I-CC
in FW B-NP B-VP
vitro FW I-NP B-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
and CC B-PP I-CC
in FW B-NP B-NP
vivo FW I-NP I-NP
enhancer NN I-NP I-NP
activity NN I-NP I-NP
. . O O

In IN B-PP B-PP
striking JJ B-NP B-NP
contrast NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
mouse NN I-NP I-NP
Ig NN I-NP I-NP
heavy-chain JJ I-NP I-NP
enhancer NN I-NP I-NP
, , O O
in IN B-PP B-PP
which WDT B-NP B-NP
the DT B-NP B-NP
octamer NN I-NP I-NP
motif NN I-NP I-NP
acts VBZ B-VP B-VP
as IN B-PP B-PP
a DT B-NP B-NP
B-cell-specific JJ I-NP I-NP
enhancer NN I-NP I-NP
element NN I-NP I-NP
, , O O
the DT B-NP B-NP
human JJ I-NP I-NP
enhancer NN I-NP I-NP
contains VBZ B-VP B-VP
an DT B-NP B-NP
octamerlike JJ I-NP I-NP
sequence NN I-NP I-NP
with IN B-PP B-PP
one CD B-NP B-NP
base NN I-NP I-NP
substitution NN I-NP I-NP
which WDT B-NP B-NP
bound VBD B-VP B-VP
octamer-binding JJ B-NP B-NP
proteins NNS I-NP I-NP
with IN B-PP B-PP
only RB B-NP B-NP
very RB I-NP I-NP
low JJ I-NP I-NP
affinity NN I-NP I-NP
and CC O I-CC
showed VBD B-VP B-VP
no DT B-NP B-NP
enhancer NN I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
its PRP$ B-NP B-NP
own JJ I-NP I-NP
. . O O

Interestingly RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
MnlI-AluI NN I-NP I-NP
fragment NN I-NP I-NP
could MD B-VP B-VP
suppress VB I-VP I-VP
the DT B-NP B-NP
basal-level JJ I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
conalbumin JJ I-NP I-NP
promoter NN I-NP I-NP
in IN B-PP B-PP
both CC O I-CC
Jurkat NN B-NP B-NP
and CC O I-NP
HeLa NN B-NP I-NP
cells NNS B-NP I-NP
. . O O

Moreover RB B-ADVP B-ADVP
, , O O
simian JJ B-NP B-NP
virus NN I-NP I-NP
40 CD I-NP I-NP
enhancer NN I-NP I-NP
activity NN I-NP I-NP
was VBD B-VP B-VP
blocked VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
MnlI-AluI NN I-NP I-NP
fragment NN I-NP I-NP
in IN B-PP B-PP
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
but CC B-PP I-CC
not RB B-PP I-RB
in IN I-PP B-PP
B NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Thus RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
novel JJ I-NP I-NP
enhancer NN I-NP I-NP
element NN I-NP I-NP
identified VBN B-VP B-VP
in IN B-PP B-PP
this DT B-NP B-NP
study NN I-NP I-NP
is VBZ B-VP B-VP
probably RB B-ADVP B-ADVP
a DT B-NP B-NP
target NN I-NP I-NP
site NN I-NP I-NP
for IN B-PP B-PP
both CC B-NP I-CC
positive JJ I-NP B-NP
and CC I-NP I-NP
negative JJ I-NP I-NP
factors NNS I-NP I-NP
. . O O

The DT B-NP B-NP
NF NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
independent JJ I-NP I-NP
cis-acting JJ I-NP I-NP
sequences NNS I-NP I-NP
in IN B-PP B-PP
HIV-1 NN B-NP B-NP
LTR NN I-NP I-NP
responsive NN B-ADJP I-NP
to TO B-PP B-PP
T-cell NN B-NP B-NP
activation NN I-NP I-NP
. . O O

The DT B-NP B-NP
rate NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
initiation NN I-NP I-NP
directed VBN B-VP B-VP
by IN B-PP B-PP
the DT B-NP B-NP
long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
( ( O O
LTR NN B-NP B-NP
) ) O O
of IN B-PP B-SBAR
HIV-1 NN B-NP B-NP
increases VBZ B-VP B-VP
in IN B-PP B-PP
response NN I-PP B-NP
to TO I-PP B-PP
mitogenic JJ B-NP B-NP
stimuli NNS I-NP I-NP
of IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Here RB B-ADVP B-ADVP
we PRP B-NP B-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
response NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HIV-1 NN I-NP I-NP
LTR NN I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
governed VBN I-VP I-VP
by IN B-PP B-PP
two CD B-NP B-NP
independent JJ I-NP I-NP
sequences NNS I-NP I-NP
located JJ B-ADJP B-NP
5' JJ B-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
site NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
initiation NN I-NP I-NP
sequences NNS I-NP I-NP
that WDT B-NP B-NP
bind VBP B-VP B-VP
either CC O I-VP
NFAT-1 NN B-NP I-VP
or CC O I-CC
NF NN B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
. . O O

The DT B-NP B-NP
rate NN I-NP I-NP
of IN B-PP B-PP
LTR-directed JJ B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
increased VBD B-VP B-VP
in IN B-PP B-PP
response NN I-PP B-NP
to TO I-PP B-PP
treatment NN B-NP B-NP
with IN B-PP B-PP
either CC O I-CC
a DT B-NP B-NP
phorbol NN I-NP I-NP
ester NN I-NP I-NP
or CC O I-NP
tumor NN B-NP I-NP
necrosis NN I-NP I-NP
factor NN I-NP I-NP
alpha NN I-NP I-NP
if IN B-SBAR B-PP
either CC O I-CC
the DT O B-NP
NFAT-1 NN B-NP I-NP
or CC O I-NP
NF NN B-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
binding NN B-NP I-NP
sites NNS I-NP I-NP
were VBD B-VP B-VP
deleted VBN I-VP I-VP
, , O O
but CC O I-CC
failed VBD B-VP B-VP
to TO I-VP I-VP
respond VB I-VP I-VP
to TO B-PP B-PP
these DT B-NP B-NP
mitogenic JJ I-NP I-NP
stimuli NNS I-NP I-NP
if IN B-SBAR B-PP
both DT B-NP B-NP
sequences NNS I-NP I-NP
were VBD B-VP B-VP
absent JJ B-ADJP B-ADJP
. . O O

The DT B-NP B-NP
HIV-1 NN I-NP I-NP
mutant JJ I-NP I-NP
virus NN I-NP I-NP
containing VBG B-VP I-NP
both CC O I-NP
NF NN B-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
and CC O I-NP
NFAT-1 NN B-NP I-NP
deletion NN B-NP I-NP
was VBD B-VP B-VP
able JJ B-ADJP B-ADJP
to TO B-VP B-VP
replicate VB I-VP I-VP
although IN B-SBAR B-ADVP
at IN B-PP B-PP
a DT B-NP B-NP
much JJ I-NP I-NP
decreased VBN I-NP I-NP
growth NN I-NP I-NP
rate NN I-NP I-NP
, , O O
while IN B-SBAR B-SBAR
the DT B-NP B-NP
deletion NN I-NP I-NP
of IN B-PP B-PP
NFAT-1 NN B-NP B-NP
alone RB B-ADVP B-VP
increased VBD B-VP I-VP
the DT B-NP B-NP
viral JJ I-NP I-NP
growth NN I-NP I-NP
rate NN I-NP I-NP
in IN B-PP B-PP
Jurkat NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Neither CC O B-NP
deletion NN B-NP I-NP
of IN B-PP B-PP
NF NN B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
nor CC O I-NP
deletion NN B-NP I-NP
of IN B-PP B-PP
NFAT-1 NN B-NP B-NP
decreased VBD B-VP B-VP
activation NN B-NP B-NP
of IN B-PP B-PP
viral JJ B-NP B-NP
replication NN I-NP I-NP
by IN B-PP B-PP
phorbol NN B-NP B-NP
ester NN I-NP I-NP
. . O O

Specific JJ B-NP B-NP
depletion NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
B-cell NN I-NP I-NP
population NN I-NP I-NP
induced VBN B-VP B-VP
by IN B-PP B-PP
aberrant JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
interferon NN I-NP I-NP
regulatory JJ I-NP I-NP
factor NN I-NP I-NP
1 CD I-NP I-NP
gene NN I-NP I-NP
in IN B-PP B-PP
transgenic JJ B-NP B-NP
mice NNS I-NP I-NP
. . O O

Interferons NNS B-NP B-NP
( ( O O
IFNs NNS B-NP B-NP
) ) O O
are VBP B-VP B-VP
well RB I-VP I-VP
known VBN I-VP I-VP
both CC O I-CC
as IN B-PP B-PP
antiviral JJ B-NP B-NP
proteins NNS I-NP I-NP
and CC B-PP I-CC
as IN B-PP B-SBAR
potent JJ B-NP B-NP
regulators NNS I-NP I-NP
of IN B-PP B-PP
cell NN B-NP B-NP
growth NN B-NP I-NP
and CC O I-NP
differentiation NN B-NP I-NP
. . O O

In IN B-PP B-PP
fact NN B-NP B-NP
, , O O
IFNs NNS B-NP B-NP
inhibit VBP B-VP B-VP
growth NN B-NP B-NP
of IN B-PP B-PP
various JJ B-NP B-NP
normal JJ I-NP I-NP
and CC I-NP I-NP
transformed VBN I-NP I-NP
cell NN I-NP I-NP
types NNS I-NP I-NP
. . O O

Previously RB B-ADVP B-ADVP
, , O O
a DT B-NP B-NP
nuclear JJ I-NP I-NP
factor NN I-NP I-NP
, , O O
IRF-1 NN B-NP B-NP
( ( O O
interferon NN B-NP B-NP
regulatory JJ I-NP I-NP
factor NN I-NP I-NP
1 CD I-NP I-NP
) ) O O
, , O O
which WDT B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
type NN B-NP B-NP
I CD I-NP I-NP
IFN NN I-NP I-NP
and CC O I-CC
some DT B-NP B-NP
IFN-inducible JJ I-NP I-NP
gene NN I-NP I-NP
promoters NNS I-NP I-NP
, , O O
was VBD B-VP B-VP
identified VBN I-VP I-VP
and CC O I-CC
cloned VBN B-VP B-VP
. . O O

Since IN B-SBAR B-PP
the DT B-NP B-NP
IRF-1 NN I-NP I-NP
gene NN I-NP I-NP
is VBZ B-VP B-VP
both CC O I-CC
virus NN B-NP B-NP
and CC O I-NP
IFN NN B-NP I-NP
inducible JJ B-ADJP I-NP
, , O O
an DT B-NP B-NP
intriguing JJ I-NP I-NP
issue NN I-NP I-NP
is VBZ B-VP B-VP
raised VBN I-VP I-VP
as IN B-PP B-PP
to TO I-PP B-NP
whether IN B-SBAR B-LST
the DT B-NP B-NP
IRF-1 NN I-NP I-NP
gene NN I-NP I-NP
is VBZ B-VP B-VP
functioning VBG I-VP I-VP
in IN B-PP B-PP
IFN-mediated JJ B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
cell NN B-NP B-NP
growth NN B-NP I-NP
and CC O I-NP
differentiation NN B-NP I-NP
. . O O

In IN B-PP B-PP
this DT B-NP B-NP
study NN I-NP I-NP
, , O O
we PRP B-NP B-NP
generated VBD B-VP B-VP
transgenic JJ B-NP B-NP
mice NNS I-NP I-NP
carrying VBG B-VP B-VP
the DT B-NP B-NP
human JJ I-NP I-NP
IRF-1 NN I-NP I-NP
gene NN I-NP I-NP
linked VBN B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
immunoglobulin NN I-NP I-NP
heavy-chain JJ I-NP I-NP
enhancer NN I-NP I-NP
. . O O

In IN B-PP B-PP
the DT B-NP B-NP
transgenic JJ I-NP I-NP
mice NNS I-NP I-NP
, , O O
all PDT B-NP B-NP
the DT I-NP I-NP
lymphoid JJ I-NP I-NP
tissues NNS I-NP I-NP
examined VBN B-VP B-VP
showed VBD B-VP I-VP
a DT B-NP B-NP
dramatic JJ I-NP I-NP
reduction NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
B NN B-NP B-NP
lymphocytes NNS I-NP I-NP
( ( O O
B NN B-NP B-NP
cells NNS I-NP I-NP
) ) O O
. . O O

Preparation NN B-NP B-NP
and CC O I-NP
analysis NN B-NP I-NP
of IN B-PP B-PP
bone NN B-NP B-NP
marrow NN I-NP I-NP
cells NNS I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
chimeric JJ I-NP I-NP
mice NNS I-NP I-NP
indicated VBD B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
bone NN I-NP I-NP
marrow NN I-NP I-NP
is VBZ B-VP B-VP
the DT B-NP B-NP
effective JJ I-NP I-NP
site NN I-NP I-NP
for IN B-PP B-PP
specific JJ B-NP B-NP
depletion NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
B-cell NN I-NP I-NP
population NN I-NP I-NP
. . O O

In IN B-PP B-PP
fact NN B-NP B-NP
, , O O
transgenic JJ B-NP B-NP
bone NN I-NP I-NP
marrow NN I-NP I-NP
cells NNS I-NP I-NP
cocultured VBN B-VP B-VP
with IN B-PP B-PP
a DT B-NP B-NP
bone NN I-NP I-NP
marrow-derived JJ I-NP I-NP
stromal JJ I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
revealed VBD B-VP B-VP
an DT B-NP B-NP
altered JJ I-NP I-NP
B-cell NN I-NP I-NP
maturation NN I-NP I-NP
pattern NN I-NP I-NP
. . O O

Identification NN B-NP B-NP
and CC O I-NP
cloning NN B-NP I-NP
of IN B-PP B-PP
TCF-1 NN B-NP B-NP
, , O O
a DT B-NP B-NP
T NN I-NP I-NP
lymphocyte-specific JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
containing VBG B-VP B-VP
a DT B-NP B-NP
sequence-specific JJ I-NP I-NP
HMG NN I-NP I-NP
box NN I-NP I-NP
. . O O

CD3-epsilon NN B-NP B-NP
expression NN I-NP I-NP
is VBZ B-VP B-VP
controlled VBN I-VP I-VP
by IN B-PP B-PP
a DT B-NP B-NP
downstream JJ I-NP I-NP
T NN I-NP I-NP
lymphocyte-specific JJ I-NP I-NP
enhancer NN I-NP I-NP
element NN I-NP I-NP
. . O O

We PRP B-NP B-NP
report VBP B-VP B-VP
the DT B-NP B-NP
identification NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
T NN I-NP I-NP
cell-specific JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
, , O O
TCF-1 NN B-NP B-NP
, , O O
binding VBG B-VP B-PP
to TO B-PP B-PP
this DT B-NP B-NP
element NN I-NP I-NP
. . O O

The DT B-NP B-NP
multimerized JJ I-NP I-NP
recognition NN I-NP I-NP
motif NN I-NP I-NP
of IN B-PP B-PP
TCF-1 NN B-NP B-NP
constituted VBD B-VP B-VP
a DT B-NP B-NP
T NN I-NP I-NP
cell-specific JJ I-NP I-NP
enhancer NN I-NP I-NP
. . O O

Subsequent JJ B-NP B-NP
cloning NN I-NP I-NP
of IN B-PP B-PP
TCF-1 NN B-NP B-NP
identified VBD B-VP B-VP
three CD B-NP B-NP
splice NN I-NP I-NP
alternatives NNS I-NP I-NP
. . O O

TCF-1 NN B-NP B-NP
contained VBD B-VP B-VP
a DT B-NP B-NP
single JJ I-NP I-NP
DNA-binding JJ I-NP I-NP
HMG NN I-NP I-NP
box NN I-NP I-NP
most RBS B-ADJP B-VP
closely RB I-ADJP B-ADJP
related JJ I-ADJP I-ADJP
to TO B-PP B-PP
similar JJ B-NP B-NP
boxes NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
putative JJ I-NP I-NP
mammalian JJ I-NP I-NP
sex-determining JJ I-NP I-NP
gene NN I-NP I-NP
SRY NN I-NP I-NP
and CC B-PP B-PP
in IN B-PP B-PP
the DT B-NP B-NP
Schizosaccharomyces FW I-NP I-NP
pombe FW I-NP I-NP
Mc NN I-NP I-NP
mating NN I-NP I-NP
type NN I-NP I-NP
gene NN I-NP I-NP
. . O O

TCF-1 NN B-ADVP B-NP
mRNA NN I-ADVP I-NP
was VBD B-VP B-VP
expressed VBN I-VP I-VP
uniquely RB B-ADVP B-ADVP
in IN B-PP B-PP
T NN B-NP B-NP
lymphocytes NNS I-NP I-NP
. . O O

Upon IN B-PP B-PP
cotransfection NN B-NP B-NP
into IN B-PP B-PP
non-T JJ B-NP B-NP
cells NNS I-NP I-NP
, , O O
TCF-1 NN B-NP B-NP
could MD B-VP B-VP
transactivate VB I-VP I-VP
through IN B-PP B-PP
its PRP$ B-NP B-NP
cognate JJ I-NP I-NP
motif NN I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
identify VBP B-VP B-VP
TCF-1 NN B-NP B-NP
as IN B-PP B-PP
a DT B-NP B-NP
T NN I-NP I-NP
cell-specific JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
, , O O
which WDT B-NP B-NP
might MD B-VP B-VP
play VB I-VP I-VP
a DT B-NP B-NP
role NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
establishment NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
mature JJ I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
phenotype NN I-NP I-NP
. . O O

Nuclear JJ B-NP B-NP
factor NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
activates VBZ B-VP B-VP
proenkephalin NN B-NP B-NP
transcription NN I-NP I-NP
in IN B-PP B-PP
T NN B-NP B-NP
lymphocytes NNS I-NP I-NP
. . O O

Upon IN B-PP B-PP
activation NN B-NP B-NP
, , O O
T NN B-NP B-NP
lymphocytes NNS I-NP I-NP
accumulate VBP B-VP B-VP
high JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
neuropeptide NN I-NP I-NP
enkephalin NN I-NP I-NP
which WDT B-NP B-NP
correlate VBP B-VP B-VP
with IN B-PP B-PP
high JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
proenkephalin NN B-NP B-NP
mRNA NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
cells NNS I-NP I-NP
. . O O

Here RB B-ADVP B-ADVP
we PRP B-NP B-NP
investigated VBD B-VP B-VP
the DT B-NP B-NP
transcriptional JJ I-NP I-NP
basis NN I-NP I-NP
for IN B-PP B-PP
these DT B-NP B-NP
changes NNS I-NP I-NP
. . O O

The DT B-NP B-NP
proenkephalin NN I-NP I-NP
promoter NN I-NP I-NP
contains VBZ B-VP B-VP
a DT B-NP B-NP
sequence NN I-NP I-NP
GGGGACGTCCCC NN I-NP I-NP
, , O O
named VBN B-VP B-VP
B2 NN B-NP B-NP
, , O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
similar JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
sequence NN I-NP I-NP
GGGGACTTTCC NN I-NP I-NP
, , O O
the DT B-NP B-NP
binding VBG I-NP I-NP
site NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
nuclear JJ B-NP I-NP
factor NN I-NP I-NP
( ( O O
NF NN B-NP I-NN
) ) O O
-kappa NN B-NP B-NP
B NN I-NP I-NP
. . O O

Activation NN B-NP B-NP
of IN B-PP B-PP
T NN B-NP B-NP
lymphocytes NNS I-NP I-NP
induces VBZ B-VP B-VP
an DT B-NP B-NP
NF-kappa NN I-NP I-NP
B-like JJ I-NP I-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
B2 NN I-NP I-NP
site NN I-NP I-NP
, , O O
concomitant JJ B-ADJP B-ADJP
with IN B-PP B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
proenkephalin NN I-NP I-NP
promoter NN I-NP I-NP
. . O O

Mutations NNS B-NP B-NP
at IN B-PP B-PP
the DT B-NP B-NP
B2 NN I-NP I-NP
site NN I-NP I-NP
abolish VBP B-VP B-VP
this DT B-NP B-NP
transcriptional JJ I-NP I-NP
activation NN I-NP I-NP
. . O O

The DT B-NP B-NP
purified VBN I-NP I-NP
homodimer NN I-NP I-NP
( ( O O
two CD B-NP B-NP
p50s NNS I-NP I-NP
) ) O O
of IN B-PP B-PP
the DT B-NP B-NP
DNA-binding JJ I-NP I-NP
subunit NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
binds VBZ B-VP B-VP
the DT B-NP B-NP
B2 NN I-NP I-NP
site NN I-NP I-NP
of IN B-PP B-PP
proenkephalin NN B-NP B-NP
relatively RB B-ADVP B-ADJP
better JJR I-ADVP I-ADJP
than IN B-SBAR B-PP
does VBZ O B-VP
the DT O B-NP
heterotetramer NN B-NP I-NP
( ( O O
two CD B-NP B-NP
p65s NNS I-NP I-NP
plus CC O I-CC
two CD B-NP B-NP
p50s NNS I-NP I-NP
) ) O O
form NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
factor NN I-NP I-NP
. . O O

Thus RB B-ADVP B-ADVP
, , O O
it PRP B-NP B-NP
appears VBZ B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
T-cell-specific JJ I-NP I-NP
activation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
proenkephalin NN I-NP I-NP
promoter NN I-NP I-NP
is VBZ B-VP B-VP
mediated VBN I-VP I-VP
by IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
as IN B-SBAR B-SBAR
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
is VBZ B-VP B-VP
ubiquitous JJ B-ADJP B-ADJP
and CC O I-CC
the DT B-NP B-NP
transcriptional JJ I-NP I-NP
activation NN I-NP I-NP
through IN B-PP B-PP
the DT B-NP B-NP
B2 NN I-NP I-NP
site NN I-NP I-NP
is VBZ B-VP B-VP
T NN B-NP B-NP
cell NN I-NP I-NP
specific JJ B-ADJP I-NP
, , O O
yet RB B-NP B-NP
another DT I-NP I-NP
T-cell-specific JJ I-NP I-NP
factor NN I-NP I-NP
which WDT B-NP B-NP
synergizes VBZ B-VP B-VP
with IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
should MD B-VP B-VP
be VB I-VP I-VP
considered VBN I-VP I-VP
. . O O

Expression NN B-NP B-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
, , O O
jun NN B-NP B-NP
B NN I-NP I-NP
and CC O I-NP
jun NN B-NP I-NP
D NN I-NP I-NP
proto-oncogenes NNS B-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
peripheral-blood JJ I-NP I-NP
granulocytes NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
found VBN I-VP I-VP
that IN B-SBAR B-PP
purified VBN B-NP B-NP
human JJ I-NP I-NP
peripheral-blood JJ I-NP I-NP
granulocytes NNS I-NP I-NP
express VBP B-VP B-VP
constitutively RB B-NP B-NP
significant JJ I-NP I-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
proto-oncogenes NNS B-NP B-NP
c-jun NN B-NP I-NP
, , O O
jun NN B-NP B-NP
B NN I-NP I-NP
and CC O I-NP
jun NN B-NP I-NP
D NN I-NP I-NP
mRNA NN B-NP I-NP
. . O O

Upon IN B-PP B-PP
functional JJ B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
granulocytes NNS B-NP B-NP
by IN B-PP B-PP
4 CD B-NP B-NP
beta-phorbol NN I-NP I-NP
12-myristate NN I-NP I-NP
13-acetate NN I-NP I-NP
( ( O O
PMA NN B-NP B-NP
) ) O O
, , O O
the DT B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
, , O O
jun NN B-NP B-NP
B NN I-NP I-NP
and CC O I-NP
jun NN B-NP I-NP
D NN I-NP I-NP
transcripts NNS B-NP I-NP
were VBD B-VP B-VP
increased VBN I-VP I-VP
. . O O

The DT B-NP B-NP
three CD I-NP I-NP
jun NN I-NP I-NP
genes NNS I-NP I-NP
showed VBD B-VP B-VP
a DT B-NP B-NP
similar JJ I-NP I-NP
time NN I-NP I-NP
course NN I-NP I-NP
in IN B-PP B-PP
their PRP$ B-NP B-NP
induction NN I-NP I-NP
by IN B-PP B-PP
PMA NN B-NP B-NP
, , O O
maximal JJ B-NP B-NP
mRNA NN I-NP I-NP
levels NNS I-NP I-NP
being VBG B-VP B-VP
reached VBN I-VP I-VP
after IN B-PP B-PP
60 CD B-NP B-NP
min NN I-NP I-NP
of IN B-PP B-PP
induction NN B-NP B-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-PP
expression NN B-NP B-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
, , O O
jun NN B-NP B-NP
B NN I-NP I-NP
and CC O I-NP
jun NN B-NP I-NP
D NN I-NP I-NP
genes NNS B-NP I-NP
might MD B-VP B-VP
be VB I-VP I-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
terminal JJ B-NP B-NP
granulocyte NN I-NP I-NP
differentiation NN I-NP I-NP
or CC B-PP I-CC
in IN B-PP B-PP
regulating VBG B-VP B-VP
granulocyte NN B-NP B-NP
functionality NN I-NP I-NP
. . O O

Platelet-activating JJ B-NP B-NP
factor NN I-NP I-NP
induces VBZ B-VP B-VP
phospholipid JJ B-NP B-NP
turnover NN I-NP I-NP
, , O O
calcium NN B-NP B-NP
flux NN I-NP I-NP
, , O O
arachidonic JJ B-NP B-NP
acid NN I-NP I-NP
liberation NN I-NP I-NP
, , O O
eicosanoid NN B-NP B-NP
generation NN I-NP I-NP
, , O O
and CC O I-CC
oncogene JJ B-NP B-NP
expression NN I-NP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
human JJ I-NP I-NP
B NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
. . O O

Platelet-activating JJ B-NP B-NP
factor NN I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
potent JJ I-NP I-NP
mediator NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
inflammatory JJ I-NP I-NP
response NN I-NP I-NP
. . O O

Studies NNS B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
actions NNS I-NP I-NP
of IN B-PP B-PP
platelet-activating JJ B-NP B-NP
factor NN I-NP I-NP
have VBP B-VP B-VP
centered VBN I-VP I-VP
mainly RB B-PP B-ADVP
around IN I-PP B-PP
neutrophils NNS B-NP B-NP
, , O O
monocytes NNS B-NP B-NP
, , O O
and CC O I-CC
platelets NNS B-NP B-NP
. . O O

In IN B-PP B-PP
this DT B-NP B-NP
report NN I-NP I-NP
we PRP B-NP B-NP
begin VBP B-VP B-VP
to TO I-VP I-VP
uncover VB I-VP I-VP
the DT B-NP B-NP
influence NN I-NP I-NP
of IN B-PP B-PP
platelet-activating NN B-NP B-NP
factor NN I-NP I-NP
on IN B-PP B-PP
B NN B-NP B-NP
lymphocytes NNS I-NP I-NP
. . O O

Employing VBG B-VP B-VP
the DT B-NP B-NP
EBV-transformed JJ I-NP I-NP
human JJ I-NP I-NP
B NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
SKW6.4 NN I-NP I-NP
, , O O
we PRP B-NP B-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
platelet-activating JJ B-NP B-NP
factor NN I-NP I-NP
significantly RB B-ADVP B-ADVP
alters VBZ B-VP B-VP
membrane NN B-NP B-NP
phospholipid JJ I-NP I-NP
metabolism NN I-NP I-NP
indicated VBN B-VP B-VP
by IN B-PP B-PP
the DT B-NP B-NP
incorporation NN I-NP I-NP
of IN B-PP B-PP
32P NN B-NP B-NP
into IN B-PP B-PP
phosphatidylcholine NN B-NP B-NP
, , O O
phosphatidylinositol NN B-NP B-NP
, , O O
and CC O I-CC
phosphatidic JJ B-NP B-NP
acid NN I-NP I-NP
but CC B-PP I-CC
not RB B-ADVP I-RB
significantly RB I-ADVP B-ADVP
into IN B-PP B-PP
phosphatidylethanolamine NN B-NP B-NP
at IN B-PP B-PP
concentrations NNS B-NP B-NP
ranging VBG B-VP B-VP
from IN B-PP B-PP
10(-9) CD B-NP B-NP
to TO B-PP I-NP
10(-6) CD B-NP I-NP
M NN B-NP I-NP
. . O O

The DT B-NP B-NP
inactive JJ I-NP I-NP
precursor NN I-NP I-NP
, , O O
lyso-platelet-activating JJ B-NP B-NP
factor NN I-NP I-NP
, , O O
at IN B-PP B-PP
a DT B-NP B-NP
concentration NN I-NP I-NP
as RB B-ADJP B-ADJP
high JJ I-ADJP I-ADJP
as IN B-PP B-PP
10(-7) CD B-NP B-NP
M NN I-NP I-NP
had VBD B-VP B-VP
no DT B-NP B-NP
effect NN I-NP I-NP
on IN B-PP B-PP
any DT B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
membrane NN I-NP I-NP
phospholipids NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
also RB B-ADVP B-ADVP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
platelet-activating JJ B-NP B-NP
factor NN I-NP I-NP
from IN B-PP B-PP
10(-12) CD B-NP B-NP
to TO I-NP I-NP
10(-6) CD I-NP I-NP
M NN I-NP I-NP
induced VBD B-VP B-VP
rapid JJ B-NP B-NP
and CC I-NP I-NP
significant JJ I-NP I-NP
elevation NN I-NP I-NP
in IN B-PP B-PP
intracellular JJ B-NP B-NP
calcium NN I-NP I-NP
levels NNS I-NP I-NP
, , O O
whereas IN O B-PP
lyso-platelet-activating JJ B-NP B-NP
factor NN I-NP I-NP
was VBD B-VP B-VP
again RB B-ADVP B-ADJP
ineffective JJ B-ADJP I-ADJP
. . O O

We PRP B-NP B-NP
further RB B-ADVP B-ADVP
demonstrate VBP B-VP B-VP
the DT B-NP B-NP
impact NN I-NP I-NP
of IN B-PP B-PP
platelet-activating JJ B-NP B-NP
factor NN I-NP I-NP
binding VBG B-VP B-VP
to TO B-PP B-PP
B NN B-NP B-NP
cells NNS I-NP I-NP
by IN B-PP B-PP
measuring VBG B-VP B-VP
platelet-activating JJ B-NP B-NP
factor NN I-NP I-NP
induced JJ B-NP I-NP
arachidonic JJ I-NP I-NP
acid NN I-NP I-NP
release NN I-NP I-NP
and CC O I-CC
5-hydroxyeicosatetraenoic JJ B-NP B-NP
acid NN I-NP I-NP
production NN I-NP I-NP
. . O O

Moreover RB B-ADVP B-ADVP
, , O O
platelet-activating JJ B-NP B-NP
factor NN I-NP I-NP
was VBD B-VP B-VP
capable JJ B-ADJP B-ADJP
of IN B-PP B-PP
inducing VBG B-VP B-VP
transcription NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
nuclear JJ I-NP I-NP
proto-oncogenes NNS I-NP I-NP
c-fos NN B-NP I-NP
and CC O I-NP
c-jun NN B-NP I-NP
. . O O

Finally RB B-ADVP B-ADVP
we PRP B-NP B-NP
explored VBD B-VP B-VP
the DT B-NP B-NP
possible JJ I-NP I-NP
role NN I-NP I-NP
of IN B-PP B-PP
5-hydroxyeicosatetraenoic JJ B-NP B-NP
acid NN I-NP I-NP
as IN B-PP B-PP
a DT B-NP B-NP
regulator NN I-NP I-NP
of IN B-PP B-PP
arachidonic JJ B-NP B-NP
acid NN I-NP I-NP
liberation NN I-NP I-NP
demonstrating VBG B-VP B-VP
that IN B-SBAR B-PP
endogenous JJ B-NP B-NP
5-lipoxygenase NN I-NP I-NP
activity NN I-NP I-NP
modulates VBZ B-VP B-VP
platelet-activating JJ B-NP B-NP
factor NN I-NP I-NP
induced JJ B-NP I-NP
arachidonic JJ I-NP I-NP
acid NN I-NP I-NP
release NN I-NP I-NP
perhaps RB B-ADVP B-ADVP
acting VBG B-VP B-VP
at IN B-PP B-PP
the DT B-NP B-NP
level NN I-NP I-NP
of IN B-PP B-PP
phospholipase NN B-NP B-NP
A2 NN I-NP I-NP
. . O O

In IN B-PP B-PP
summary NN B-NP B-NP
, , O O
platelet-activating JJ B-NP B-NP
factor NN I-NP I-NP
is VBZ B-VP B-VP
shown VBN I-VP I-VP
here RB I-VP B-ADVP
to TO I-VP B-VP
have VB I-VP I-VP
a DT B-NP B-NP
direct JJ I-NP I-NP
and CC I-NP I-NP
profound JJ I-NP I-NP
effect NN I-NP I-NP
on IN B-PP B-PP
a DT B-NP B-NP
pure JJ I-NP I-NP
B NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
. . O O

A DT B-NP B-NP
novel JJ I-NP I-NP
HIV-1 NN I-NP I-NP
isolate JJ I-NP I-NP
containing VBG B-VP I-NP
alterations NNS B-NP I-NP
affecting VBG B-VP B-VP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
element NN I-NP I-NP
. . O O

Three CD B-NP B-NP
molecular JJ I-NP I-NP
clones NNS I-NP I-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
, , O O
derived VBN B-VP B-VP
from IN B-PP B-PP
a DT B-NP B-NP
single JJ I-NP I-NP
isolate NN I-NP I-NP
( ( O O
AL1 NN B-NP B-NP
) ) O O
, , O O
exhibited VBD B-VP B-VP
distinct JJ B-NP B-NP
replicative JJ I-NP I-NP
and CC I-NP I-NP
cytopathic JJ I-NP I-NP
properties NNS I-NP I-NP
during IN B-PP B-PP
propagation NN B-NP B-NP
in IN B-PP B-PP
a DT B-NP B-NP
human JJ I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
. . O O

The DT B-NP B-NP
phenotypic JJ I-NP I-NP
differences NNS I-NP I-NP
observed VBN B-VP B-NP
were VBD B-VP B-VP
attributable JJ B-ADJP B-ADJP
, , O O
in IN B-PP B-PP
large JJ B-NP B-NP
part NN I-NP I-NP
, , O O
to TO B-PP B-PP
changes NNS B-NP B-NP
affecting VBG B-VP B-VP
the DT B-NP B-NP
viral JJ I-NP I-NP
LTR NN I-NP I-NP
. . O O

Nucleotide NN B-NP B-NP
sequence NN I-NP I-NP
and CC O I-NP
PCR NN B-NP I-NP
analyses NNS I-NP I-NP
demonstrated VBD B-VP B-VP
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
novel JJ B-NP B-NP
duplications NNS B-NP I-NP
or CC O I-NP
deletions NNS B-NP I-NP
involving VBG B-VP B-VP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
motif NN I-NP I-NP
. . O O

These DT B-NP B-NP
changes NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
enhancer NN I-NP I-NP
element NN I-NP I-NP
were VBD B-VP B-VP
identified VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
original JJ I-NP I-NP
AL1 NN I-NP I-NP
virus NN I-NP I-NP
stock NN I-NP I-NP
. . O O

Subcloning NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
variant JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
segments NNS I-NP I-NP
into IN B-PP B-PP
LTR-driven JJ B-NP B-NP
CAT NN I-NP I-NP
expression NN I-NP I-NP
vectors NNS I-NP I-NP
confirmed VBD B-VP B-VP
a DT B-NP B-NP
correlation NN I-NP I-NP
between IN B-PP B-PP
promoter JJ B-NP B-NP
activity NN I-NP I-NP
and CC O I-CC
replicative/cytopathic JJ B-NP B-NP
capacity NN I-NP I-NP
. . O O

1,25-Dihydroxyvitamin NN B-NP B-NP
D3 NN I-NP I-NP
receptor NN I-NP I-NP
RNA NN I-NP I-NP
: : O O
expression NN B-NP B-NP
in IN B-PP B-PP
hematopoietic JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

1,25-Dihydroxyvitamin NN B-NP B-NP
D3 NN I-NP I-NP
( ( O O
1,25(OH)2D3 NN B-NP B-NP
) ) O O
induces VBZ B-VP B-VP
differentiation NN B-NP B-NP
and CC O I-CC
inhibits VBZ B-VP B-VP
proliferation NN B-NP B-NP
of IN B-PP B-PP
myeloid JJ B-NP B-NP
leukemic JJ I-NP I-NP
cells NNS I-NP I-NP
from IN B-PP B-PP
various JJ B-NP B-NP
lines NNS B-NP I-NP
and CC O I-CC
patients NNS B-NP B-NP
; : O O
these DT B-NP B-NP
effects NNS I-NP I-NP
are VBP B-VP B-VP
probably RB I-VP I-VP
mediated VBN I-VP I-VP
through IN B-PP B-PP
the DT B-NP B-NP
1,25(OH)2D3 NN I-NP I-NP
receptor NN I-NP I-NP
. . O O

Little JJ B-NP B-NP
is VBZ B-VP B-VP
known VBN I-VP I-VP
of IN B-PP B-PP
expression NN B-NP B-NP
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
receptor NN I-NP I-NP
RNA NN I-NP I-NP
in IN B-PP B-PP
hematopoietic JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
examined VBD B-VP B-VP
the DT B-NP B-NP
expression NN B-NP I-NP
and CC O I-NP
modulation NN B-NP I-NP
of IN B-PP B-PP
expression NN B-NP B-NP
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
receptor NN I-NP I-NP
RNA NN I-NP I-NP
in IN B-PP B-PP
various JJ B-NP B-NP
proliferating VBG I-NP I-NP
and CC I-NP I-NP
nonproliferating JJ I-NP I-NP
hematopoietic JJ I-NP I-NP
cells NNS I-NP I-NP
. . O O

Constitutive JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
receptor NN I-NP I-NP
RNA NN I-NP I-NP
was VBD B-VP B-VP
detected VBN I-VP I-VP
in IN B-PP B-PP
various JJ B-NP B-NP
kinds NNS I-NP I-NP
of IN B-PP B-PP
hematopoietic JJ B-NP B-NP
cells NNS I-NP I-NP
, , O O
including VBG B-PP B-PP
macrophages NNS B-NP B-NP
and CC O I-CC
activated VBN B-NP B-NP
T NN I-NP I-NP
lymphocytes NNS I-NP I-NP
, , O O
as RB B-CONJP B-CONJP
well RB I-CONJP I-CONJP
as IN I-CONJP I-CONJP
in IN B-PP B-PP
cell NN B-NP B-NP
lines NNS I-NP I-NP
KG-1 NN B-NP I-NP
( ( O O
myeloblasts NNS B-NP B-NP
) ) O O
, , O O
HL-60 NN B-NP B-NP
( ( O O
promyelocytes NNS B-NP B-NP
) ) O O
, , O O
ML-3 NN B-NP B-NP
( ( O O
myelomonoblasts NNS B-NP B-NP
) ) O O
, , O O
U937 NN B-NP B-NP
, , O O
THP-1 NN B-NP B-NP
( ( O O
monoblasts NNS B-NP B-NP
) ) O O
, , O O
K562 NN B-NP B-NP
( ( O O
erythroblasts NNS B-NP B-NP
) ) O O
, , O O
and CC O I-CC
S-LB1 NN B-NP B-NP
( ( O O
HTLV-1-transfected JJ B-NP B-NP
T NN I-NP I-NP
lymphocytes NNS I-NP I-NP
) ) O O
. . O O

Receptor NN B-NP B-NP
transcripts NNS I-NP I-NP
were VBD B-VP B-VP
4.6 CD B-NP B-NP
kilobases NNS B-NP I-NP
( ( O O
kb NN B-NP B-NP
) ) O O
, , O O
and CC O I-CC
no DT B-NP B-NP
variant JJ I-NP I-NP
sizes NNS I-NP I-NP
were VBD B-VP B-VP
observed VBN I-VP I-VP
. . O O

All DT B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
examined VBN B-VP B-VP
in IN B-PP B-PP
this DT B-NP B-NP
group NN I-NP I-NP
also RB B-ADVP B-ADVP
expressed VBD B-VP B-VP
1,25(OH)2D3 NN B-NP B-NP
receptors NNS I-NP I-NP
. . O O

Most JJS B-NP B-NP
B NN I-NP I-NP
lymphocyte NN I-NP I-NP
lines NNS I-NP I-NP
expressed VBD B-VP B-VP
negligible JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
receptor NN I-NP I-NP
RNA NN I-NP I-NP
and CC I-NP I-NP
protein NN I-NP I-NP
; : O O
however RB O B-ADVP
; : O O
analysis NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
lymphoid/myeloid JJ I-NP I-NP
somatic JJ I-NP I-NP
hybrid NN I-NP I-NP
suggested VBD B-VP B-VP
that IN B-SBAR B-PP
suppression NN B-NP B-NP
of IN B-PP B-PP
expression NN B-NP B-NP
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
receptor NN I-NP I-NP
RNA NN I-NP I-NP
in IN B-PP B-PP
B NN B-NP B-NP
lymphocytes NNS I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
a DT B-NP B-NP
dominant JJ I-NP I-NP
characteristic NN I-NP I-NP
. . O O

HL-60 NN B-NP B-NP
cells NNS I-NP I-NP
were VBD B-VP B-VP
cultured VBN I-VP I-VP
with IN B-PP B-PP
10(-7) CD B-NP B-NP
mol/L NN I-NP I-NP
1,25(OH)2D3 NN B-NP I-NP
for IN B-PP B-PP
24 CD B-NP B-NP
to TO I-NP I-NP
72 CD I-NP I-NP
hours NNS I-NP I-NP
, , O O
and CC O I-CC
levels NNS B-NP B-NP
of IN B-PP B-PP
expression NN B-NP B-NP
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
receptor NN I-NP I-NP
and CC O I-CC
its PRP$ B-NP B-NP
RNA NN I-NP I-NP
were VBD B-VP B-VP
examined VBN I-VP I-VP
. . O O

Levels NNS B-NP B-NP
of IN B-PP B-PP
RNA NN B-NP B-NP
coding NN B-VP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
receptor NN I-NP I-NP
were VBD B-VP B-VP
not RB I-VP I-VP
modulated VBN I-VP I-VP
by IN B-PP B-PP
exposure NN B-NP B-NP
to TO B-PP B-PP
high JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
ligand NN B-NP B-NP
. . O O

Levels NNS B-NP B-NP
of IN B-PP B-PP
occupied VBN B-NP B-NP
1,25(OH)2D3 NN I-NP I-NP
receptor NN I-NP I-NP
protein NN I-NP I-NP
increased VBD B-VP B-VP
in IN B-PP B-PP
these DT B-NP B-NP
HL-60 NN I-NP I-NP
cells NNS I-NP I-NP
; : O O
but CC O I-CC
the DT B-NP B-NP
total JJ I-NP I-NP
number NN I-NP I-NP
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
receptors NNS I-NP I-NP
decreased VBD B-VP B-VP
about RB B-NP B-NP
50 CD I-NP I-NP
% NN I-NP I-NP
at IN B-PP B-PP
24 CD B-NP B-NP
hours NNS I-NP I-NP
and CC O I-CC
returned VBD B-VP B-VP
toward IN B-PP B-PP
normal JJ B-NP B-NP
at IN B-PP B-PP
72 CD B-NP B-NP
hours NNS I-NP I-NP
. . O O

Steady-state JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
receptor NN I-NP I-NP
RNA NN I-NP I-NP
were VBD B-VP B-VP
not RB I-VP I-VP
affected VBN I-VP I-VP
by IN B-PP B-PP
terminal JJ B-NP B-NP
differentiation NN I-NP I-NP
of IN B-PP B-PP
HL-60 NN B-NP B-NP
toward IN B-PP B-PP
either CC O I-CC
granulocytes NNS B-NP B-VP
or CC O I-VP
macrophages NNS B-NP B-NP
. . O O

Nondividing JJ B-NP B-NP
macrophages NNS I-NP I-NP
from IN B-PP B-PP
normal JJ B-NP B-NP
individuals NNS I-NP I-NP
also RB B-ADVP B-ADVP
expressed VBD B-VP B-VP
1,25(OH)2D3 NN B-NP B-NP
receptor NN I-NP I-NP
RNA NN I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
nondividing JJ B-NP B-NP
peripheral JJ I-NP I-NP
blood NN I-NP I-NP
lymphocytes NNS I-NP I-NP
from IN B-PP B-PP
normal JJ B-NP B-NP
individuals NNS I-NP I-NP
did VBD B-VP B-VP
not RB I-VP I-VP
express VB I-VP I-VP
1,25(OH)2D3 NN B-NP B-NP
receptor NN I-NP I-NP
RNA NN I-NP I-NP
; : O O
with IN B-PP B-PP
stimulation NN B-NP B-NP
of IN B-PP B-PP
proliferation NN B-NP B-NP
of IN B-PP B-PP
these DT B-NP B-NP
cells NNS I-NP I-NP
, , O O
accumulation NN B-NP B-NP
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
receptor NN I-NP I-NP
RNA NN I-NP I-NP
increased VBD B-VP B-VP
markedly RB B-ADVP B-ADVP
. . O O

Half-life NN B-NP B-NP
( ( O O
t1/2 NN B-NP I-NP
) ) O O
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
receptor NN I-NP I-NP
RNA NN I-NP I-NP
in IN B-PP B-PP
T NN B-NP B-NP
lymphocytes NNS I-NP I-NP
was VBD B-VP B-VP
short JJ B-ADJP B-ADJP
( ( O O
1 CD B-NP B-NP
hour NN I-NP I-NP
) ) O O
as IN B-SBAR B-SBAR
determined VBN B-VP B-VP
by IN B-PP B-PP
measuring VBG B-VP B-VP
decay NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
message NN I-NP I-NP
after IN B-PP B-PP
addition NN B-NP B-NP
of IN B-PP B-PP
actinomycin NN B-NP B-NP
D NN I-NP I-NP
. . O O

Consistent JJ B-ADJP B-VP
with IN B-PP B-PP
this DT B-NP B-NP
short JJ I-NP I-NP
t1/2 NN I-NP I-NP
, , O O
accumulation NN B-NP B-NP
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
receptor NN I-NP I-NP
RNA NN I-NP I-NP
increased VBD B-VP B-VP
in IN B-PP B-PP
cells NNS B-NP B-NP
as IN B-SBAR B-PP
their PRP$ B-NP B-NP
protein NN I-NP I-NP
synthesis NN I-NP I-NP
was VBD B-VP B-VP
inhibited VBN I-VP I-VP
. . O O

Further JJ B-NP B-NP
studies NNS I-NP I-NP
are VBP B-VP B-VP
required VBN I-VP I-VP
to TO B-VP I-VP
understand VB I-VP I-VP
the DT B-NP B-NP
physiologic JJ I-NP I-NP
role NN I-NP I-NP
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
receptors NNS I-NP I-NP
in IN B-PP B-PP
myeloid JJ B-NP B-NP
cells NNS I-NP I-NP
and CC O I-CC
proliferating VBG B-NP B-VP
T NN I-NP B-NP
lymphocytes NNS I-NP I-NP
. . O O

Kappa NN B-NP B-NP
B NN I-NP I-NP
binding NN I-NP I-NP
proteins NNS I-NP I-NP
are VBP B-VP B-VP
constitutively RB I-VP I-VP
expressed VBN I-VP I-VP
in IN B-PP B-PP
an DT B-NP B-NP
IL-2 NN I-NP I-NP
autocrine NN I-NP I-NP
human JJ I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
. . O O

The DT B-NP B-NP
IL-2 NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
IL-2-R NN I-NP I-NP
alpha NN I-NP I-NP
genes NNS B-NP I-NP
are VBP B-VP B-VP
both DT I-VP I-DT
expressed VBN I-VP B-VP
transiently RB B-ADVP B-ADVP
in IN B-PP B-PP
normal JJ B-NP B-NP
T NN I-NP I-NP
lymphocytes NNS I-NP I-NP
after IN B-PP B-PP
Ag NN B-NP B-NP
or CC O I-NP
mitogen NN B-NP I-NP
activation NN B-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
the DT B-NP B-NP
human JJ I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
, , O O
IARC NN B-NP B-NP
301 CD I-NP I-NP
, , O O
expresses VBZ B-VP B-VP
these DT B-NP B-NP
two CD I-NP I-NP
genes NNS I-NP I-NP
constitutively RB B-ADVP B-ADVP
and CC O I-CC
we PRP B-NP B-NP
have VBP B-VP B-VP
previously RB I-VP I-VP
demonstrated VBN I-VP I-VP
that IN B-SBAR B-PP
its PRP$ B-NP B-NP
growth NN I-NP I-NP
depends VBZ B-VP B-VP
on IN B-PP B-PP
the DT B-NP B-NP
autocrine JJ I-NP I-NP
production NN I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
growth NN I-NP I-NP
factor NN I-NP I-NP
and CC O I-CC
high JJ B-NP B-NP
affinity NN I-NP I-NP
IL-2R NN I-NP I-NP
. . O O

To TO B-VP B-VP
dissect VB I-VP I-VP
the DT B-NP B-NP
molecular JJ I-NP I-NP
basis NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
unusual JJ I-NP I-NP
persistent JJ I-NP I-NP
expression NN I-NP I-NP
of IN B-PP B-PP
the DT O B-NP
IL-2 NN B-NP I-NP
and CC O I-NP
IL-2-R NN B-NP I-NP
alpha NN I-NP I-NP
genes NNS B-NP I-NP
in IN B-PP B-PP
these DT B-NP B-NP
IARC NN I-NP I-NP
301 CD I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
, , O O
we PRP B-NP B-NP
have VBP B-VP B-VP
analyzed VBN I-VP I-VP
the DT B-NP B-NP
interactions NNS I-NP I-NP
of IN B-PP B-PP
constitutively RB B-NP B-NP
expressed VBN I-NP I-NP
nuclear JJ I-NP I-NP
proteins NNS I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
5' JJ I-NP I-NP
flanking JJ I-NP I-NP
regions NNS I-NP I-NP
of IN B-PP B-PP
the DT O B-NP
IL-2 NN B-NP I-NP
and CC O I-NP
IL-2-R NN B-NP I-NP
alpha NN I-NP I-NP
genes NNS B-NP I-NP
using VBG B-VP B-VP
both DT B-NP B-NP
DNase NN B-NP I-NP
I CD I-NP I-NP
footprinting NN I-NP I-NP
and CC O I-NP
gel NN B-NP I-NP
retardation NN I-NP I-NP
techniques NNS B-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
found VBN I-VP I-VP
that IN B-SBAR B-SBAR
a DT B-NP B-NP
region NN I-NP I-NP
in IN B-PP B-PP
both DT B-NP B-NP
genes NNS I-NP I-NP
( ( O O
-276 CD B-NP B-NP
to TO O I-NP
-250 CD B-NP I-NP
for IN B-PP B-PP
IL-2-R NN B-NP B-NP
alpha NN I-NP I-NP
and CC O I-CC
-203 CD B-NP B-NP
to TO O B-PP
-183 CD B-NP B-NP
for IN B-PP B-PP
IL-2 NN B-NP B-NP
) ) O O
, , O O
which WDT B-NP B-NP
corresponds VBZ B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
enhancer NN I-NP I-NP
element NN I-NP I-NP
, , O O
is VBZ B-VP B-VP
specifically RB I-VP I-VP
protected VBN I-VP I-VP
by IN B-PP B-PP
nuclear JJ B-NP B-NP
proteins NNS I-NP I-NP
from IN B-PP B-PP
IARC NN B-NP B-NP
301 CD I-NP I-NP
. . O O

In IN B-PP B-PP
agreement NN I-PP B-NP
with IN I-PP B-PP
this DT B-NP B-NP
finding NN I-NP I-NP
, , O O
both CC O I-CC
the DT O B-NP
IL-2 NN B-NP I-NP
and CC O I-NP
IL-2-R NN B-NP I-NP
alpha NN I-NP I-NP
promoters NNS B-NP I-NP
are VBP B-VP B-VP
active JJ B-ADJP B-ADJP
in IN B-PP B-PP
transient JJ B-NP B-NP
transfection NN I-NP I-NP
assays NNS I-NP I-NP
in IN B-PP B-PP
IARC NN B-NP B-NP
301 CD I-NP B-NP
cells NNS I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
mutation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
enhancer NN I-NP I-NP
results VBZ B-VP B-VP
in IN B-PP B-PP
markedly RB B-NP B-NP
attenuated VBN I-NP I-NP
activities NNS I-NP I-NP
of IN B-PP B-PP
both DT B-NP B-NP
promoters NNS I-NP I-NP
. . O O

Two CD B-NP B-NP
proteins NNS I-NP I-NP
binding VBG B-VP B-VP
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
sequence NN I-NP I-NP
, , O O
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
and CC O I-NP
KBF1 NN B-NP I-NP
, , O O
are VBP B-VP B-VP
constitutively RB I-VP I-VP
expressed VBN I-VP I-VP
in IN B-PP B-PP
IARC NN B-NP B-NP
301 CD I-NP B-NP
nuclei NNS I-NP I-NP
and CC O I-CC
induced VBN B-VP B-VP
by IN B-PP B-PP
PMA NN B-NP B-NP
and CC O I-NP
PHA NN B-NP I-NP
in IN B-PP B-PP
Jurkat NN B-NP B-NP
. . O O

They PRP B-NP B-NP
bind VBP B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
motifs NNS I-NP I-NP
with IN B-PP B-PP
different JJ B-NP B-NP
relative JJ I-NP I-NP
affinities NNS I-NP I-NP
that WDT B-NP B-NP
may MD B-VP B-VP
reflect VB I-VP I-VP
their PRP$ B-NP B-NP
different JJ I-NP I-NP
contribution NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
various JJ B-NP B-NP
promoters NNS I-NP I-NP
. . O O

The DT B-NP B-NP
functional JJ I-NP I-NP
domains NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
murine JJ I-NP I-NP
Thy-1 NN I-NP I-NP
gene NN I-NP I-NP
promoter NN I-NP I-NP
. . O O

The DT B-NP B-NP
Thy-1 NN I-NP I-NP
gene NN I-NP I-NP
promoter NN I-NP I-NP
resembles VBZ B-VP B-VP
a DT B-NP B-NP
" [[DQS]] I-NP I-NP
housekeeping JJ I-NP I-NP
" [[DQE]] I-NP I-NP
promoter NN I-NP I-NP
in IN B-PP B-PP
that IN B-SBAR B-SBAR
it PRP B-NP B-NP
is VBZ B-VP B-VP
located JJ B-ADJP B-ADJP
within IN B-PP B-PP
a DT B-NP B-NP
methylation-free JJ I-NP I-NP
island NN I-NP I-NP
, , O O
lacks VBZ B-VP B-VP
a DT B-NP B-NP
canonical JJ I-NP I-NP
TATA NN I-NP I-NP
box NN I-NP I-NP
, , O O
and CC O I-CC
displays VBZ B-VP B-VP
heterogeneity NN B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
5'-end JJ I-NP I-NP
termini NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
mRNA NN I-NP I-NP
. . O O

Using VBG B-VP B-VP
transgenic JJ B-NP B-NP
mice NNS I-NP I-NP
, , O O
we PRP B-NP B-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
this DT B-NP B-NP
promoter NN I-NP I-NP
does VBZ B-VP B-VP
not RB I-VP I-VP
confer VB I-VP I-VP
any DT B-NP B-NP
tissue NN I-NP I-NP
specificity NN I-NP I-NP
and CC O I-CC
is VBZ B-VP B-VP
active JJ B-ADJP B-ADJP
only RB B-PP B-ADVP
in IN I-PP B-PP
a DT B-NP B-NP
position-dependent JJ I-NP I-NP
manner NN I-NP I-NP
. . O O

It PRP B-NP B-NP
can MD B-VP B-VP
only RB I-VP I-VP
be VB I-VP I-VP
activated VBN I-VP I-VP
in IN B-PP B-PP
a DT B-NP B-NP
tissue-specific JJ I-NP I-NP
manner NN I-NP I-NP
by IN B-PP B-PP
elements NNS B-NP B-NP
that WDT B-NP B-NP
lie VBP B-VP B-VP
downstream RB B-ADJP B-ADVP
of IN B-PP B-PP
the DT B-NP B-NP
initiation NN I-NP I-NP
site NN I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
analyzed VBN I-VP I-VP
the DT B-NP B-NP
functional JJ I-NP I-NP
domains NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
minimal JJ I-NP I-NP
Thy-1 NN I-NP I-NP
promoter NN I-NP I-NP
and CC O I-CC
show VB B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
dominant JJ I-NP I-NP
promoter NN I-NP I-NP
elements NNS I-NP I-NP
consist VBP B-VP B-VP
of IN B-PP B-PP
multiple JJ B-NP B-NP
binding VBG I-NP I-NP
sites NNS I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
Sp1 NN I-NP I-NP
, , O O
an DT B-NP B-NP
inverted JJ I-NP I-NP
CCAAT NN I-NP I-NP
box NN I-NP I-NP
, , O O
and CC O I-CC
sequences VBZ B-NP B-VP
proximal JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
start NN I-NP I-NP
site NN I-NP I-NP
. . O O

DNase NN B-NP B-NP
I CD I-NP I-NP
and CC I-NP I-CC
gel NN I-NP B-NP
mobility NN I-NP I-NP
shift NN I-NP I-NP
assays NNS I-NP I-NP
show VBP B-VP B-VP
the DT B-NP B-NP
binding NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
nuclear JJ B-NP B-NP
factors NNS I-NP I-NP
to TO B-PP B-PP
these DT B-NP B-NP
elements NNS I-NP I-NP
, , O O
including VBG B-PP B-PP
Sp1 NN B-NP B-NP
and CC O I-NP
CP1 NN B-NP I-NP
. . O O

Our PRP$ B-NP B-NP
results NNS I-NP I-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
structure NN I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
promoter NN I-NP I-NP
only RB B-ADVP B-ADVP
permits VBZ B-VP B-VP
productive JJ B-NP B-NP
interactions NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
two CD I-NP I-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
Sp1 NN B-NP I-NP
and CC O I-NP
CP1 NN B-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
basal JJ I-NP I-NP
transcription NN I-NP I-NP
machinery NN I-NP I-NP
in IN B-PP B-PP
the DT I-PP B-NP
presence NN I-PP I-NP
of IN I-PP B-PP
enhancer NN B-NP B-NP
sequences NNS I-NP I-NP
. . O O

Comparison NN B-NP B-NP
of IN B-PP B-PP
constitutive JJ B-NP B-NP
and CC I-NP I-NP
inducible JJ I-NP I-NP
transcriptional JJ I-NP I-NP
enhancement NN I-NP I-NP
mediated VBN B-VP B-VP
by IN B-PP B-PP
kappa NN B-NP B-NP
B-related JJ I-NP I-NP
sequences NNS I-NP I-NP
: : O O
modulation NN B-NP B-NP
of IN B-PP B-PP
activity NN B-NP B-NP
in IN B-PP B-PP
B NN B-NP B-NP
cells NNS I-NP I-NP
by IN B-PP B-PP
human JJ B-NP B-NP
T-cell NN I-NP I-NP
leukemia NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
I CD I-NP I-NP
tax NN I-NP I-NP
gene NN I-NP I-NP
. . O O

The DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
sequence NN I-NP I-NP
( ( O O
GGGACTTTCC NN B-NP B-NP
) ) O O
binds VBZ B-VP B-VP
a DT B-NP I-DT
factor NN I-NP I-NN
, , O O
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
, , O O
that WDT B-NP B-NP
is VBZ B-VP B-VP
constitutively RB I-VP I-VP
found VBN I-VP I-VP
in IN B-PP B-PP
its PRP$ B-NP B-NP
functional JJ I-NP I-NP
, , I-NP O
DNA NN I-NP I-NP
binding NN I-NP I-NP
form NN I-NP I-NP
only RB B-PP B-ADVP
in IN I-PP B-PP
B NN B-NP B-NP
lymphocytes NNS I-NP I-NP
. . O O

A DT B-NP B-NP
factor NN I-NP I-NP
with IN B-PP B-PP
apparently RB B-NP B-NP
indistinguishable JJ I-NP I-NP
sequence NN I-NP I-NP
specificity NN I-NP I-NP
can MD B-VP B-VP
be VB I-VP I-VP
induced VBN I-VP I-VP
in IN B-PP B-PP
many JJ B-NP B-NP
other JJ I-NP I-NP
cell NN I-NP I-NP
types NNS I-NP I-NP
, , O O
where WRB B-ADVP B-ADVP
it PRP B-NP B-NP
is VBZ B-VP B-VP
used VBN I-VP I-VP
to TO B-VP I-VP
regulate VB I-VP I-VP
inducible JJ B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
. . O O

For IN B-PP B-PP
example NN B-NP B-NP
, , O O
kappa NN B-NP B-NP
B-related JJ I-NP I-NP
sequences NNS I-NP I-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
shown VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
important JJ B-ADJP B-ADJP
for IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
few JJ I-NP I-NP
inducible JJ I-NP I-NP
genes NNS I-NP I-NP
, , O O
such JJ B-PP B-PP
as IN I-PP I-PP
the DT B-NP B-NP
interleukin NN I-NP I-NP
2 CD I-NP I-NP
receptor NN I-NP I-NP
alpha-chain NN I-NP I-NP
gene NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
beta-interferon NN I-NP I-NP
gene NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
these DT B-NP B-NP
genes NNS I-NP I-NP
are VBP B-VP B-VP
not RB O I-RB
constitutively RB B-ADJP B-ADJP
active JJ I-ADJP I-ADJP
in IN B-PP B-PP
B NN B-NP B-NP
lymphocytes NNS I-NP I-NP
, , O O
suggesting VBG B-VP B-VP
that IN B-SBAR B-PP
other JJ B-NP B-NP
regulatory JJ I-NP I-NP
mechanisms NNS I-NP I-NP
must MD B-VP B-VP
play VB I-VP I-VP
a DT B-NP B-NP
role NN I-NP I-NP
in IN B-PP B-PP
determining VBG B-VP B-VP
the DT B-NP B-NP
patterns NNS I-NP I-NP
of IN B-PP B-PP
expression NN B-NP B-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
investigated VBN I-VP I-VP
the DT B-NP B-NP
constitutive JJ I-NP I-NP
and CC I-NP I-NP
inducible JJ I-NP I-NP
transcriptional JJ I-NP I-NP
activity NN I-NP I-NP
mediated VBN B-VP B-VP
by IN B-PP B-PP
five CD B-NP B-NP
kappa NN I-NP I-NP
B-related JJ I-NP I-NP
sequence NN I-NP I-NP
elements NNS I-NP I-NP
in IN B-PP B-PP
two CD B-NP B-NP
different JJ I-NP I-NP
cell NN I-NP I-NP
types NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
in IN B-PP B-PP
S194 NN B-NP B-NP
plasma NN I-NP I-NP
cells NNS I-NP I-NP
the DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
each DT B-NP B-NP
element NN I-NP I-NP
correlates VBZ B-VP B-VP
well RB B-ADVP B-ADVP
with IN B-PP B-PP
the DT B-NP B-NP
relative JJ I-NP I-NP
affinity NN I-NP I-NP
of IN B-PP B-PP
B-cell-derived JJ B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
for IN B-PP B-PP
that DT B-NP B-NP
element NN I-NP I-NP
. . O O

This DT B-NP B-NP
leads VBZ B-VP B-VP
to TO B-PP B-PP
significantly RB B-NP B-NP
lower RBR I-NP I-NP
transcription NN I-NP I-NP
enhancement NN I-NP I-NP
by IN B-PP B-PP
sites NNS B-NP B-NP
derived VBN B-VP B-VP
from IN B-PP B-PP
the DT O B-NP
interleukin NN B-NP I-NP
2 CD I-NP I-NP
receptor NN I-NP I-NP
or CC O I-NP
T-cell NN B-NP I-NP
receptor NN I-NP I-NP
genes NNS B-NP I-NP
in IN B-PP B-PP
S194 NN B-NP B-NP
cells NNS B-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
in IN B-PP B-PP
either CC O I-CC
EL-4 NN B-NP B-NP
( ( I-NP O
T NN I-NP I-NP
) ) O O
cells NNS B-NP I-NP
or CC O I-NP
S194 NN O I-NP
cells NNS B-NP I-NP
, , I-NP O
both DT I-NP B-NP
lower-affinity JJ O I-NP
sites NNS O I-NP
can MD O B-VP
be VB O I-VP
significantly RB B-PP I-VP
induced VBN B-NP I-VP
by IN I-NP B-PP
the DT I-NP B-NP
tax NN I-NP I-NP
gene NN O I-NP
product NN B-NP I-NP
of IN I-NP B-PP
human JJ I-NP B-NP
T-cell NN I-NP I-NP
leukemia NN I-NP I-NP
virus NN I-NP I-NP
type NN B-VP I-NP
I CD O I-NP
, , O O
showing VBG B-NP B-VP
that IN I-NP B-PP
NF-kappa NN I-NP B-NP
B NN B-VP I-NP
activity NN I-VP I-NP
can MD I-VP B-VP
be VB B-PP I-VP
modulated VBN I-PP I-VP
even RB B-NP B-ADVP
in IN I-NP B-PP
a DT I-NP B-NP
B-cell NN B-NP I-NP
line NN B-ADVP I-NP
that WDT O B-NP
constitutively RB B-NP B-VP
expresses VBZ I-NP I-VP
this DT O I-DT

Isolation NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
rel-related JJ I-NP I-NP
human JJ I-NP I-NP
cDNA NN I-NP I-NP
that WDT B-NP B-NP
potentially RB B-ADVP B-VP
encodes VBZ B-VP I-VP
the DT B-NP B-NP
65-kD JJ I-NP I-NP
subunit NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
( ( O O
published VBN B-NP B-NP
erratum NN I-NP I-NP
appears VBZ B-VP B-VP
in IN B-PP B-PP
Science NNP B-NP B-NP
1991 CD I-NP I-NP
Oct NNP I-NP I-NP
4 CD I-NP I-NP
; : I-NP O
254 CD I-NP B-NP
( ( I-NP O
5028 CD I-NP B-NP
) ) I-NP O
: : I-NP O
11 CD I-NP B-NP
) ) O O

A DT B-NP B-NP
DNA NN I-NP I-NP
probe NN I-NP I-NP
that WDT B-NP B-NP
spanned VBD B-VP B-VP
a DT B-NP B-NP
domain NN I-NP I-NP
conserved VBN B-VP B-VP
among IN B-PP B-PP
the DT B-NP B-NP
proto-oncogene NN I-NP I-NP
c-rel NN I-NP I-NP
, , O O
the DT B-NP B-NP
Drosophila NN I-NP I-NP
morphogen NN I-NP I-NP
dorsal NN I-NP I-NP
, , O O
and CC O I-CC
the DT B-NP B-NP
p50 NN I-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
subunit NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
was VBD B-VP B-VP
generated VBN I-VP I-VP
from IN B-PP B-PP
Jurkat NN B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
complementary JJ I-NP I-NP
DNA NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
polymerase NN I-NP I-NP
chain NN I-NP I-NP
reaction NN I-NP I-NP
( ( O O
PCR NN B-NP B-NP
) ) O O
and CC O I-CC
degenerate JJ B-NP B-NP
oligonucleotides NNS I-NP I-NP
. . O O

This DT B-NP B-NP
probe NN I-NP I-NP
was VBD B-VP B-VP
used VBN I-VP I-VP
to TO B-VP B-VP
identify VB I-VP I-VP
a DT B-NP B-NP
rel-related JJ I-NP I-NP
complementary JJ I-NP I-NP
DNA NN I-NP I-NP
that WDT B-NP B-NP
hybridized VBD B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
2.6-kilobase JJ I-NP I-NP
messenger NN I-NP I-NP
RNA NN I-NP I-NP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
human JJ O B-NP
T NN B-NP I-NP
and CC O I-NP
B NN B-NP I-NP
lymphocytes NNS B-NP I-NP
. . O O

In FW B-NP B-NP
vitro FW I-NP I-NP
transcription NN B-NP I-NP
and CC O I-NP
translation NN B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
complementary JJ I-NP I-NP
DNA NN I-NP I-NP
resulted VBD B-VP B-VP
in IN B-PP B-PP
the DT B-NP B-NP
synthesis NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
protein NN I-NP I-NP
with IN B-PP B-PP
an DT B-NP B-NP
apparent JJ I-NP I-NP
molecular JJ I-NP I-NP
size NN I-NP I-NP
of IN B-PP B-PP
65 CD B-NP B-NP
kilodaltons NNS B-NP I-NP
( ( O O
kD NN B-NP B-NP
) ) O O
. . O O

The DT B-NP B-NP
translated VBN I-NP I-NP
protein NN I-NP I-NP
showed VBD B-VP B-VP
weak JJ B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
with IN B-PP B-PP
a DT B-NP B-NP
specificity NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
binding VBG I-NP I-NP
motif NN I-NP I-NP
. . O O

This DT B-NP B-NP
protein-DNA JJ I-NP I-NP
complex JJ I-NP I-NP
comigrated VBN B-VP B-VP
with IN B-PP B-PP
the DT B-NP B-NP
complex NN I-NP I-NP
obtained VBN B-VP B-VP
with IN B-PP B-PP
the DT B-NP B-NP
purified VBN I-NP I-NP
human JJ I-NP I-NP
p65 NN I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
subunit NN I-NP I-NP
and CC O I-NP
binding NN B-NP I-NP
was VBD B-VP B-VP
inhibited VBN I-VP I-VP
by IN B-PP B-PP
I NN B-NP B-NP
kappa NN I-NP I-NP
B-alpha NN I-NP I-NP
and CC O I-NP
-beta NN B-NP I-NP
proteins NNS B-NP I-NP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
the DT B-NP B-NP
65-kD JJ I-NP I-NP
protein NN I-NP I-NP
associated VBN B-VP B-VP
with IN B-PP B-PP
the DT B-NP B-NP
p50 NN I-NP I-NP
subunit NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
probe NN I-NP I-NP
to TO B-VP B-VP
form VB I-VP I-VP
a DT B-NP B-NP
complex NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
same JJ I-NP I-NP
electrophoretic JJ I-NP I-NP
mobility NN I-NP I-NP
as IN B-PP B-PP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B-DNA JJ I-NP I-NP
complex NN I-NP I-NP
. . O O

Therefore RB B-ADVP B-ADVP
the DT B-NP B-NP
rel-related JJ I-NP I-NP
65-kD JJ I-NP I-NP
protein NN I-NP I-NP
may MD B-VP B-VP
represent VB I-VP I-VP
the DT B-NP B-NP
p65 NN I-NP I-NP
subunit NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
active JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
complex NN I-NP I-NP
. . O O

Lymphocyte NN B-NP B-NP
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
number NN I-NP I-NP
in IN B-PP B-PP
posttraumatic JJ B-NP B-NP
stress NN I-NP I-NP
disorder NN I-NP I-NP
. . O O

OBJECTIVE NN B-NP B-NP
: : O O
The DT B-NP B-NP
authors NNS I-NP I-NP
' POS B-NP B-NP
objective NN I-NP I-NP
was VBD B-VP B-VP
to TO B-VP I-VP
investigate VB I-VP I-VP
the DT B-NP B-NP
possibility NN I-NP I-NP
that IN B-SBAR B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
changes NNS I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
dysregulation NN I-NP I-NP
of IN B-PP B-PP
the DT O B-NP
hypothalamic-pituitary-adrenal JJ O I-NP
( ( O O
HPA JJ B-ADJP I-JJ
) ) O O
axis NN B-NP B-NP
in IN B-PP B-PP
posttraumatic JJ B-NP B-NP
stress NN I-NP I-NP
disorder NN I-NP I-NP
( ( O O
PTSD NN B-NP B-NP
) ) O O
. . O O

METHOD NN B-NP B-NP
: : O O
They PRP B-NP B-NP
measured VBD B-VP B-VP
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
lymphocyte NN B-NP B-NP
cytosolic JJ I-NP I-NP
glucocorticoid NN I-NP I-NP
receptors NNS I-NP I-NP
and CC O I-CC
plasma NN B-NP B-NP
cortisol NN I-NP I-NP
concentrations NNS I-NP I-NP
in IN O B-PP
15 CD B-NP B-NP
consecutively RB I-NP I-NP
admitted VBN I-NP I-NP
male JJ I-NP I-NP
combat NN I-NP I-NP
Vietnam NN I-NP I-NP
veterans NNS I-NP I-NP
with IN B-PP B-PP
PTSD NN B-NP B-NP
and CC B-PP B-PP
in IN B-PP B-PP
a DT B-NP B-NP
normal JJ I-NP I-NP
comparison NN I-NP I-NP
group NN I-NP I-NP
of IN B-PP B-PP
11 CD B-NP B-NP
subjects NNS I-NP I-NP
. . O O

RESULTS NNS B-NP B-NP
: : O O
Both CC O I-CC
the DT B-NP B-NP
patients NNS I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
normal JJ I-NP I-NP
comparison NN I-NP I-NP
subjects NNS I-NP I-NP
showed VBD B-VP B-VP
a DT B-NP B-NP
morning-to-afternoon JJ I-NP I-NP
decline NN I-NP I-NP
in IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
concentrations NNS I-NP I-NP
, , O O
paralleling VBG B-VP B-VP
the DT B-NP B-NP
normal JJ I-NP I-NP
diurnal JJ I-NP I-NP
decline NN I-NP I-NP
in IN B-PP B-PP
cortisol NN B-NP B-NP
levels NNS I-NP I-NP
. . O O

The DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
was VBD B-VP B-VP
63 CD B-NP B-NP
% NN I-NP I-NP
greater JJR B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
morning NN I-NP I-NP
and CC O I-CC
26 CD B-NP B-NP
% NN I-NP I-NP
greater JJR B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
afternoon NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
patients NNS I-NP I-NP
with IN B-PP B-PP
PTSD NN B-NP B-NP
than IN B-PP B-PP
in IN B-PP B-PP
the DT B-NP B-NP
normal JJ I-NP I-NP
subjects NNS I-NP I-NP
. . O O

No DT B-NP B-NP
group NN I-NP I-NP
differences NNS I-NP I-NP
in IN B-PP B-PP
cortisol NN B-NP B-NP
levels NNS I-NP I-NP
were VBD B-VP B-VP
observed VBN I-VP I-VP
, , O O
nor CC O I-CC
were VBD O B-VP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
number NN I-NP I-NP
and CC O I-NP
cortisol NN B-NP I-NP
levels NNS I-NP I-NP
correlated VBD B-ADJP B-VP
. . O O

The DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
morning NN B-NP B-NP
glucocorticoid NN I-NP I-NP
receptors NNS I-NP I-NP
was VBD B-VP B-VP
positively RB B-ADJP I-VP
correlated VBN I-ADJP I-VP
with IN B-PP B-PP
symptoms NNS B-NP B-NP
of IN B-PP B-PP
PTSD NN B-NP B-NP
and CC O I-NP
anxiety NN B-NP I-NP
. . O O

CONCLUSIONS NNS B-NP B-NP
: : O O
These DT B-NP B-NP
results NNS I-NP I-NP
provide VBP B-VP B-VP
further JJ B-NP B-NP
evidence NN I-NP I-NP
for IN B-PP B-PP
a DT B-NP B-NP
dysregulation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HPA JJ I-NP I-NP
axis NN I-NP I-NP
in IN B-PP B-PP
PTSD NN B-NP B-NP
. . O O

The DT B-NP B-NP
finding NN I-NP I-NP
that IN B-SBAR B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
PTSD NN B-NP B-NP
had VBD B-VP B-VP
a DT B-NP B-NP
substantially RB I-NP I-NP
greater JJR I-NP I-NP
number NN I-NP I-NP
of IN B-PP B-PP
lymphocyte NN B-NP B-NP
glucocorticoid NN I-NP I-NP
receptors NNS I-NP I-NP
than IN B-PP B-PP
normal JJ B-NP B-NP
comparison NN I-NP I-NP
subjects NNS I-NP I-NP
is VBZ B-VP B-VP
consistent JJ B-ADJP B-ADJP
with IN B-PP B-PP
the DT B-NP B-NP
authors NNS I-NP I-NP
' POS B-NP B-NP
previous JJ I-NP I-NP
observations NNS I-NP I-NP
of IN B-PP B-PP
low JJ B-NP B-NP
24-hour JJ I-NP I-NP
urinary JJ I-NP I-NP
cortisol NN I-NP I-NP
excretion NN I-NP I-NP
in IN B-PP B-PP
subjects NNS B-NP B-NP
with IN B-PP B-PP
PTSD NN B-NP B-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
receptor NN I-NP I-NP
changes NNS I-NP I-NP
observed VBN B-VP B-NP
are VBP B-VP B-VP
opposite JJ B-ADJP B-ADJP
of IN B-PP B-PP
those DT B-NP B-NP
reported VBN B-VP B-VP
in IN B-PP B-PP
major JJ B-NP B-NP
depressive JJ I-NP I-NP
disorder NN I-NP I-NP
. . O O

The DT B-NP B-NP
present JJ I-NP I-NP
data NNS I-NP I-NP
, , O O
along IN B-PP B-PP
with IN I-PP B-PP
other JJ B-NP B-NP
findings NNS I-NP I-NP
of IN B-PP B-PP
HPA JJ B-NP B-NP
abnormalities NNS I-NP I-NP
in IN B-PP B-PP
PTSD NN B-NP B-NP
, , O O
support VBP B-VP B-VP
the DT B-NP B-NP
possibility NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
greater JJR I-NP I-NP
negative JJ I-NP I-NP
feedback NN I-NP I-NP
sensitivity NN I-NP I-NP
at IN B-PP B-PP
one CD B-NP B-NP
or CC I-NP I-NP
more JJR I-NP I-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HPA JJ I-NP I-NP
axis NN I-NP I-NP
. . O O

A DT B-NP B-NP
thymus-specific JJ I-NP I-NP
member NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HMG NN I-NP I-NP
protein NN I-NP I-NP
family NN I-NP I-NP
regulates VBZ B-VP B-VP
the DT B-NP B-NP
human JJ I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
receptor NN I-NP I-NP
C NN I-NP I-NP
alpha NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

The DT B-NP B-NP
human JJ I-NP I-NP
T NN I-NP I-NP
cell-specific JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
TCF-1 NN B-NP I-NP
alpha NN I-NP I-NP
plays VBZ B-VP B-VP
a DT B-NP B-NP
key JJ I-NP I-NP
role NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
tissue-specific JJ I-NP I-NP
activation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
receptor NN I-NP I-NP
( ( I-NP O
TCR NN I-NP I-NN
) ) I-NP O
C NN I-NP B-NP
alpha NN I-NP I-NP
enhancer NN I-NP I-NP
and CC O I-CC
binds VBZ B-VP B-VP
to TO B-PP B-PP
pyrimidine-rich JJ B-NP B-NP
elements NNS I-NP I-NP
( ( O O
5'-PyCTTTG-3' NN B-NP B-NP
) ) O O
present JJ B-ADJP B-VP
in IN B-PP B-PP
a DT B-NP B-NP
variety NN I-NP I-NP
of IN B-PP B-PP
other JJ B-NP B-NP
T NN I-NP I-NP
cell-specific JJ I-NP I-NP
control NN I-NP I-NP
regions NNS I-NP I-NP
. . O O

Using VBG B-VP B-VP
amino NN B-NP B-NP
acid NN I-NP I-NP
sequence NN I-NP I-NP
information NN I-NP I-NP
derived VBN B-VP B-VP
from IN B-PP B-PP
the DT B-NP B-NP
DNA NN I-NP I-NP
affinity-purified JJ I-NP I-NP
protein NN I-NP I-NP
, , O O
we PRP B-NP B-NP
have VBP B-VP B-VP
now RB I-VP I-VP
isolated VBN I-VP I-VP
cDNA NN B-NP B-NP
clones NNS I-NP I-NP
encoding VBG B-VP B-VP
TCF-1 NN B-NP B-NP
alpha NN I-NP I-NP
. . O O

The DT B-NP B-NP
TCF-1 NN I-NP I-NP
alpha NN I-NP I-NP
cDNA NN I-NP I-NP
contains VBZ B-VP B-VP
a DT B-NP B-NP
single JJ I-NP I-NP
68-amino-acid JJ I-NP I-NP
domain NN I-NP I-NP
that WDT B-NP B-NP
is VBZ B-VP B-VP
homologous JJ B-ADJP B-ADJP
to TO B-PP B-PP
a DT B-NP B-NP
region NN I-NP I-NP
conserved VBN B-VP B-VP
among IN B-PP B-PP
high-mobility JJ B-NP B-NP
group NN I-NP I-NP
( ( O O
HMG NN B-NP B-NP
) ) O O
and CC O I-CC
nonhistone JJ B-NP B-NP
chromosomal JJ I-NP I-NP
proteins NNS I-NP I-NP
. . O O

Expression NN B-NP B-NP
of IN B-PP B-PP
full-length JJ B-NP B-NP
and CC I-NP I-NP
mutant JJ I-NP I-NP
cDNA NN I-NP I-NP
clones NNS I-NP I-NP
in IN B-PP B-PP
bacteria NNS B-NP B-NP
reveal VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
single JJ I-NP I-NP
HMG NN I-NP I-NP
motif NN I-NP I-NP
, , O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
predicted VBN I-VP I-VP
to TO I-VP I-VP
contain VB I-VP I-VP
two CD B-NP B-NP
extended VBN I-NP I-NP
alpha-helical JJ I-NP I-NP
segments NNS I-NP I-NP
, , O O
is VBZ B-VP B-VP
sufficient JJ B-ADJP B-ADJP
to TO B-VP B-VP
direct VB I-VP I-VP
the DT B-NP B-NP
sequence-specific JJ I-NP I-NP
binding NN I-NP I-NP
of IN B-PP B-PP
TCF-1 NN B-NP B-NP
alpha NN I-NP I-NP
to TO B-PP B-PP
DNA NN B-NP B-NP
. . O O

Northern NN B-NP B-NP
blot NN I-NP I-NP
experiments NNS I-NP I-NP
demonstrate VBP B-VP B-VP
further RBR B-ADVP B-ADVP
that IN B-SBAR B-PP
TCF-1 NN B-NP B-NP
alpha NN I-NP I-NP
mRNA NN I-NP I-NP
is VBZ B-VP B-VP
highly RB B-ADJP B-ADVP
tissue NN I-ADJP B-NP
specific JJ I-ADJP I-NP
, , O O
found VBN B-VP B-VP
primarily RB B-ADVP B-ADVP
in IN B-PP B-PP
the DT B-NP B-NP
thymus NN B-NP I-NP
or CC O I-NP
T NN B-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
. . O O

The DT B-NP B-NP
immature JJ I-NP I-NP
CEM NN I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
expresses VBZ B-VP B-VP
relatively RB B-NP B-ADVP
low JJ I-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
TCF-1 NN B-NP B-NP
alpha NN I-NP I-NP
mRNA NN I-NP I-NP
, , O O
which WDT B-NP B-NP
are VBP B-VP B-VP
increased VBN I-VP I-VP
upon IN B-PP B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
these DT B-NP B-NP
cells NNS I-NP I-NP
by IN B-PP B-PP
phorbol NN B-NP B-NP
esters NNS I-NP I-NP
. . O O

Interestingly RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
cloned VBN I-NP I-NP
TCF-1 NN I-NP I-NP
alpha NN I-NP I-NP
protein NN I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
potent JJ I-NP I-NP
transcriptional JJ I-NP I-NP
activator NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
TCR NN I-NP I-NP
alpha NN I-NP I-NP
enhancer NN I-NP I-NP
in IN B-PP B-PP
nonlymphoid JJ B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
, , O O
whereas IN O B-PP
the DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
endogenous JJ I-NP I-NP
protein NN I-NP I-NP
in IN B-PP B-PP
T NN B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
is VBZ B-VP B-VP
strongly RB B-ADJP B-ADJP
dependent JJ I-ADJP I-ADJP
on IN B-PP B-SBAR
an DT B-NP B-NP
additional JJ I-NP I-NP
T NN I-NP I-NP
cell-specific JJ I-NP I-NP
protein NN I-NP I-NP
that WDT B-NP B-NP
interacts VBZ B-VP B-VP
with IN B-PP B-PP
the DT B-NP B-NP
core NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

TCF-1 NN B-NP B-NP
alpha NN I-NP I-NP
is VBZ B-VP B-VP
currently RB B-ADJP B-ADJP
unique JJ I-ADJP I-ADJP
among IN B-PP B-PP
the DT B-NP B-NP
newly RB I-NP I-NP
emerging VBG I-NP I-NP
family NN I-NP I-NP
of IN B-PP B-PP
DNA-binding JJ B-NP B-NP
regulatory JJ I-NP I-NP
proteins NNS I-NP I-NP
that WDT B-NP B-NP
share VBP B-VP B-VP
the DT B-NP B-NP
HMG NN I-NP I-NP
motif NN I-NP I-NP
in IN B-PP B-PP
that IN B-NP B-SBAR
it PRP B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
highly RB I-NP I-NP
tissue-specific JJ I-NP I-NP
RNA NN I-NP I-NP
polymerase NN I-NP I-NP
II CD I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
. . O O

Immune JJ B-NP B-NP
response NN I-NP I-NP
of IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
mononuclear JJ I-NP I-NP
cells NNS I-NP I-NP
to TO B-PP B-PP
HBx-antigen NN B-NP B-NP
of IN B-PP B-PP
hepatitis NN B-NP B-NP
B NN I-NP I-NP
virus NN I-NP I-NP
. . O O

The DT B-NP B-NP
hepatitis NN I-NP I-NP
B NN I-NP I-NP
virus NN I-NP I-NP
genome NN I-NP I-NP
encodes VBZ B-VP B-VP
a DT B-NP B-NP
transcriptional JJ I-NP I-NP
transactivator NN I-NP I-NP
protein NN I-NP I-NP
designated VBN B-VP I-NP
HBxAg NN B-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
investigated VBN I-VP I-VP
whether IN B-SBAR B-PP
this DT B-NP B-NP
antigen NN I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
target NN I-NP I-NP
structure NN I-NP I-NP
for IN B-PP B-PP
human JJ B-NP B-NP
T-lymphocytes NNS I-NP I-NP
. . O O

Using VBG B-VP B-VP
recombinant JJ B-NP B-NP
HBxAg NN I-NP I-NP
protein NN I-NP I-NP
, , O O
we PRP B-NP B-NP
found VBD B-VP B-VP
HBxAg-specific JJ B-NP B-NP
stimulation NN I-NP I-NP
of IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
mononuclear JJ I-NP I-NP
cells NNS I-NP I-NP
in IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
acute JJ B-NP B-NP
hepatitis NN I-NP I-NP
B NN I-NP I-NP
virus NN I-NP I-NP
infection NN I-NP I-NP
( ( O O
6 CD B-NP B-NP
of IN B-PP B-PP
6 CD B-NP B-NP
) ) O O
and CC O I-CC
chronic JJ B-NP B-NP
hepatitis NN I-NP I-NP
B NN I-NP I-NP
virus NN I-NP I-NP
infection NN I-NP I-NP
( ( O O
6 CD B-NP B-NP
of IN B-PP B-PP
17 CD B-NP B-NP
) ) O O
but CC B-PP I-CC
not RB B-PP B-NP
in IN I-PP B-PP
healthy JJ B-NP B-NP
individuals NNS I-NP I-NP
. . O O

With IN B-PP B-PP
HBxAg-specific JJ B-NP B-NP
synthetic JJ I-NP I-NP
polypeptides NNS I-NP I-NP
, , O O
several JJ B-NP B-NP
T-cell NN I-NP I-NP
epitopes NNS I-NP I-NP
were VBD B-VP B-VP
identified VBN I-VP I-VP
. . O O

Most JJS B-NP B-NP
were VBD B-VP B-VP
located JJ I-VP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
carboxyterminal JJ I-NP I-NP
half NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HBxAg NN I-NP I-NP
protein NN I-NP I-NP
. . O O

Five CD B-NP B-NP
T-cell NN I-NP I-NP
clones NNS I-NP I-NP
specific JJ B-ADJP B-ADJP
for IN B-PP B-PP
a DT B-NP B-NP
T-cell NN I-NP I-NP
epitope NN I-NP I-NP
located JJ B-ADJP B-ADJP
at IN B-PP B-PP
the DT B-NP B-NP
carboxyterminal JJ I-NP I-NP
region NN I-NP I-NP
of IN B-PP B-PP
HBxAg NN B-NP B-NP
were VBD B-VP B-VP
established VBN I-VP I-VP
and CC O I-CC
found VBN B-VP B-VP
to TO I-VP I-VP
belong VB I-VP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
CD2/CD4-positive JJ I-NP I-NP
, , I-NP O
CD8-negative JJ I-NP I-NP
subtype NN I-NP I-NP
. . O O

These DT B-NP B-NP
data NNS I-NP I-NP
establish VBP B-VP B-VP
for IN B-PP B-PP
the DT B-NP B-NP
first JJ I-NP I-NP
time NN I-NP I-NP
HBxAg NN B-NP I-NP
as IN B-PP B-PP
an DT B-NP B-NP
antigen NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
cellular JJ I-NP I-NP
immune JJ I-NP I-NP
response NN I-NP I-NP
. . O O

A DT B-NP B-NP
study NN I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
circadian JJ I-NP I-NP
rhythm NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
. . O O

Circadian JJ B-NP B-NP
rhythm NN I-NP I-NP
in IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
( ( O O
GR NN B-NP B-NP
) ) O O
was VBD B-VP B-VP
studied VBN I-VP I-VP
in IN B-PP B-PP
the DT O B-NP
rat NN B-NP I-NP
liver NN I-NP I-NP
and CC O I-CC
human JJ B-ADJP B-NP
peripheral JJ I-ADJP I-NP
leukocytes NNS B-NP I-NP
. . O O

For IN B-PP B-PP
rats NNS B-NP B-NP
exposed VBN B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
natural JJ I-NP I-NP
environmental JJ I-NP I-NP
photic JJ I-NP I-NP
cycle NN I-NP I-NP
or CC O I-CC
a DT B-NP B-NP
12L NN I-NP I-NP
: : I-NP O
12D NN I-NP B-NP
artificial JJ I-NP I-NP
light NN I-NP I-NP
regime NN I-NP I-NP
, , O O
peak JJ B-NP B-NP
values NNS I-NP I-NP
of IN B-PP B-PP
hepatic JJ B-NP B-NP
GR NN I-NP I-NP
were VBD B-VP B-VP
detected VBN I-VP I-VP
between IN B-PP B-PP
23:00 CD B-NP B-NP
and CC I-NP I-CC
02:00 CD I-NP B-NP
h NN I-NP I-NP
. . O O

Except IN B-PP B-PP
for IN I-PP B-PP
a DT B-NP B-NP
4-hour JJ I-NP I-NP
advancement NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
peak NN I-NP I-NP
, , O O
a DT B-NP B-NP
similar JJ I-NP I-NP
circadian JJ I-NP I-NP
rhythm NN I-NP I-NP
of IN B-PP B-PP
hepatic JJ B-NP B-NP
GR NN I-NP I-NP
was VBD B-VP B-VP
detected VBN I-VP I-VP
in IN B-PP B-PP
rats NNS B-NP B-NP
reared VBN B-VP B-VP
under IN B-PP B-PP
a DT B-NP B-NP
reversed VBN I-NP I-NP
lighting NN I-NP I-NP
regimen NNS I-NP I-NP
( ( O O
12D NN B-NP B-NP
: : I-NP O
12L NN I-NP B-NP
; : O O
lights NNS B-NP B-NP
on IN B-ADVP B-PP
between IN B-PP B-PP
18:30 CD B-NP B-NP
and CC I-NP I-CC
06:30 CD I-NP B-NP
h NN I-NP I-NP
) ) O O
. . O O

In IN B-PP B-PP
human JJ B-NP B-NP
leukocytes NNS I-NP I-NP
, , O O
the DT B-NP B-NP
peak JJ I-NP I-NP
value NN I-NP I-NP
of IN B-PP B-PP
GR NN B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
parallel VB I-VP I-VP
that DT B-NP B-NP
of IN B-PP B-PP
plasma NN B-NP B-NP
cortisol NN I-NP I-NP
with IN B-PP B-PP
high JJ B-NP B-NP
and CC I-NP I-NP
low JJ I-NP I-NP
values NNS I-NP I-NP
detected VBN B-VP B-VP
at IN B-PP B-PP
04:00-08:00 CD B-NP B-NP
h NN I-NP I-NP
and CC O I-CC
23:00-24:00 CD B-NP B-NP
h NN I-NP I-NP
, , O O
respectively RB B-ADVP B-ADVP
. . O O

In IN B-PP B-PP
patients NNS B-NP B-NP
suffering VBG B-VP B-VP
from IN B-PP B-PP
Cushing NN B-NP B-NP
's POS B-NP B-NP
syndrome NN I-NP I-NP
, , O O
the DT B-NP B-NP
circadian JJ I-NP I-NP
rhythm NN I-NP I-NP
of IN B-PP B-PP
plasma NN B-NP B-NP
cortisol NN I-NP I-NP
either CC O I-CC
disappeared VBD B-VP B-VP
or CC O I-CC
was VBD B-VP B-VP
inverted VBN I-VP I-VP
while IN B-SBAR B-SBAR
that DT B-NP B-NP
of IN B-PP B-PP
GR NN B-NP B-NP
did VBD B-VP B-VP
not RB I-VP I-VP
significantly RB I-VP I-VP
deviate VB I-VP I-VP
from IN B-PP B-PP
the DT B-NP B-NP
normal JJ I-NP I-NP
subjects NNS I-NP I-NP
. . O O

For IN B-PP B-PP
apoplexic JJ B-NP B-NP
patients NNS I-NP I-NP
with IN B-PP B-PP
lesions NNS B-NP B-NP
localized JJ B-VP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
base NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
brain NN I-NP I-NP
as IN B-SBAR B-SBAR
indicated VBN B-VP B-VP
by IN B-PP B-PP
computerized VBN B-NP B-NP
tomography NN I-NP I-NP
, , O O
the DT B-NP B-NP
diurnal JJ I-NP I-NP
variation NN I-NP I-NP
of IN B-PP B-PP
GR NN B-NP B-NP
was VBD B-VP B-VP
abolished VBN I-VP I-VP
. . O O

Conversely RB B-ADVP B-ADVP
, , O O
diurnal JJ B-NP B-NP
rhythmicity NN I-NP I-NP
persisted VBD B-VP B-VP
in IN B-PP B-PP
apoplexy NN B-NP B-NP
patients NNS I-NP I-NP
whose WP$ B-NP B-NP
lesions NNS I-NP I-NP
were VBD B-VP B-VP
in IN B-PP B-PP
the DT B-NP B-NP
cerebral JJ I-NP I-NP
cortex NN I-NP I-NP
. . O O

Thus RB B-ADVP B-ADVP
, , O O
we PRP B-NP B-NP
postulated VBD B-VP B-VP
that IN B-SBAR B-PP
the DT B-NP B-NP
circadian JJ I-NP I-NP
modification NN I-NP I-NP
of IN B-PP B-PP
GR NN B-NP B-NP
was VBD B-VP B-VP
independent JJ B-ADJP B-ADJP
of IN B-PP B-PP
the DT B-NP B-NP
diurnal JJ I-NP I-NP
fluctuations NNS I-NP I-NP
in IN B-PP B-PP
plasma NN B-NP B-NP
cortisol NN I-NP I-NP
level NN I-NP I-NP
or CC O I-CC
the DT B-NP B-NP
circadian JJ I-NP I-NP
variations NNS I-NP I-NP
in IN B-PP B-PP
environmental JJ B-NP B-NP
lighting NN I-NP I-NP
and CC O I-CC
that IN B-SBAR B-SBAR
the DT B-NP B-NP
rhythmicity NN I-NP I-NP
might MD B-VP B-VP
be VB I-VP I-VP
regulated VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
' [[DQS]] I-NP I-NP
circadian JJ I-NP I-NP
pacemaker NN I-NP I-NP
' [[DQE]] O I-NP
located JJ B-ADJP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
basal JJ I-NP I-NP
brain NN I-NP I-NP
. . O O

These DT B-NP B-NP
diurnal JJ I-NP I-NP
variations NNS I-NP I-NP
in IN B-PP B-PP
GR NN B-NP B-NP
might MD B-VP B-VP
serve VB I-VP I-VP
to TO I-VP I-VP
coordinate VB I-VP I-VP
the DT B-NP B-NP
reactivity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
target NN I-NP I-NP
cells NNS I-NP I-NP
to TO B-PP B-PP
cortisol NN B-NP B-NP
because IN B-SBAR B-PP
the DT B-NP B-NP
diurnal JJ I-NP I-NP
rhythms NNS I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
GR-mediated JJ I-NP I-NP
response NN I-NP I-NP
, , O O
the DT B-NP B-NP
fractional JJ I-NP I-NP
inhibition NN I-NP I-NP
of IN B-PP B-PP
chemotactic JJ B-NP B-NP
migration NN I-NP I-NP
rate NN I-NP I-NP
of IN B-PP B-PP
polymorphonuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
by IN B-PP B-PP
cortisol NN B-NP B-NP
, , O O
were VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
synchronous JJ B-ADJP B-ADJP
with IN B-PP B-PP
those DT B-NP B-NP
of IN B-PP B-PP
GR NN B-NP B-NP
. . O O

Multiple JJ B-NP B-NP
Oct2 NN I-NP I-NP
isoforms NNS I-NP I-NP
are VBP B-VP B-VP
generated VBN I-VP I-VP
by IN B-PP B-PP
alternative JJ B-NP B-NP
splicing NN I-NP I-NP
. . O O

The DT B-NP B-NP
interaction NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
Oct2 NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
cognate JJ I-NP I-NP
octamer NN I-NP I-NP
motif NN I-NP I-NP
ATGCAAAT NN I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
critical JJ I-NP I-NP
determinant NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
lymphoid-specific JJ I-NP I-NP
expression NN I-NP I-NP
of IN B-PP B-PP
immunoglobulin NN B-NP B-NP
genes NNS I-NP I-NP
. . O O

Ectopic JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
cloned VBN B-NP B-NP
Oct2 NN I-NP I-NP
cDNA NN I-NP I-NP
was VBD B-VP B-VP
shown VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
sufficient JJ B-ADJP B-ADJP
to TO B-VP B-VP
reconstitute VB I-VP I-VP
at IN B-NP B-ADVP
least JJS I-NP I-ADVP
some DT I-NP B-NP
aspects NNS I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
regulation NN I-NP I-NP
in IN B-PP B-PP
non-lymphoid JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
describe VBP B-VP B-VP
the DT B-NP B-NP
isolation NN B-NP I-NP
and CC O I-NP
characterization NN B-NP I-NP
of IN B-PP B-PP
multiple JJ B-NP B-NP
cDNAs NNS I-NP I-NP
encoding VBG B-VP B-VP
mouse NN B-NP B-NP
Oct2 NN I-NP I-NP
from IN B-PP B-PP
a DT B-NP B-NP
mature JJ I-NP I-NP
B-cell NN I-NP I-NP
line NN I-NP I-NP
and CC O I-CC
we PRP B-NP B-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
a DT B-NP B-NP
variety NN I-NP I-NP
of IN B-PP B-PP
isoforms NNS B-NP B-NP
of IN B-PP B-PP
this DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
is VBZ B-VP B-VP
generated VBN I-VP I-VP
from IN B-PP B-PP
a DT B-NP B-NP
single JJ I-NP I-NP
gene NN I-NP I-NP
by IN B-PP B-PP
an DT B-NP B-NP
alternative JJ I-NP I-NP
splicing NN I-NP I-NP
mechanism NN I-NP I-NP
. . O O

All PDT B-NP B-ADVP
the DT I-NP B-NP
isoforms NNS I-NP I-NP
retain VBP B-VP B-VP
the DT B-NP B-NP
previously RB I-NP I-NP
characterized VBN I-NP I-NP
POU-domain NN I-NP I-NP
and CC O I-CC
are VBP B-VP B-VP
therefore RB B-ADVP B-ADVP
able JJ B-ADJP B-ADJP
to TO B-VP B-VP
bind VB I-VP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
octamer NN I-NP I-NP
motif NN I-NP I-NP
. . O O

Different JJ B-NP B-NP
amounts NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
various JJ I-NP I-NP
isoforms NNS I-NP I-NP
are VBP B-VP B-VP
present JJ B-ADJP B-ADJP
within IN B-PP B-PP
the DT B-NP B-NP
same JJ I-NP I-NP
B-cell NN I-NP I-NP
regardless RB B-ADVP B-ADVP
of IN B-PP B-PP
the DT B-NP B-NP
developmental JJ I-NP I-NP
stage NN I-NP I-NP
of IN B-PP B-PP
B-cell NN B-NP B-NP
differentiation NN I-NP I-NP
and CC O I-CC
at IN B-ADVP B-ADVP
least JJS I-ADVP I-ADVP
some DT B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
isoforms NNS I-NP I-NP
are VBP B-VP B-VP
conserved VBN I-VP I-VP
between IN B-PP B-PP
mouse NN B-NP B-NP
and CC O I-NP
humans NNS B-NP I-NP
. . O O

In IN B-PP B-PP
cotransfection NN B-NP B-NP
experiments NNS I-NP I-NP
we PRP B-NP B-NP
show VBP B-VP B-VP
that IN B-SBAR I-IN
all PDT B-NP B-NP
the DT I-NP I-NP
isoforms NNS I-NP I-NP
are VBP B-VP B-VP
able JJ B-ADJP B-ADJP
to TO B-VP B-VP
activate VB I-VP I-VP
an DT B-NP B-NP
octamer NN I-NP I-NP
containing VBG B-VP B-VP
promoter NN B-NP B-NP
element NN I-NP I-NP
in IN B-PP B-PP
fibroblasts NNS B-NP B-NP
revealing VBG B-VP B-VP
an DT B-NP B-NP
unexpected JJ I-NP I-NP
functional JJ I-NP I-NP
redundancy NN I-NP I-NP
. . O O

Finally RB B-ADVP B-ADVP
, , O O
we PRP B-NP B-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
one CD B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
isoforms NNS I-NP I-NP
encodes VBZ B-VP B-VP
the DT B-NP B-NP
previously RB I-NP I-NP
described VBN I-NP I-NP
lymphoid-specific JJ I-NP I-NP
Oct2B NN I-NP I-NP
protein NN I-NP I-NP
which WDT B-NP B-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
suggested VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
function NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
octamer NN I-NP I-NP
motif NN I-NP I-NP
in IN B-PP B-PP
the DT I-PP B-NP
context NN I-PP I-NP
of IN I-PP B-PP
the DT O B-NP
immunoglobulin NN B-NP I-NP
heavy-chain NN I-NP I-NP
( ( O O
IgH NN B-NP I-NN
) ) O O
enhancer NN B-NP B-NP
. . O O

Murine JJ B-NP B-NP
and CC I-NP I-NP
human JJ I-NP I-NP
T-lymphocyte NN I-NP I-NP
GATA-3 NN I-NP I-NP
factors NNS I-NP I-NP
mediate VBP B-VP B-VP
transcription NN B-NP B-NP
through IN B-PP B-PP
a DT B-NP B-NP
cis-regulatory JJ I-NP I-NP
element NN I-NP I-NP
within IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
T-cell NN I-NP I-NP
receptor NN I-NP I-NP
delta NN I-NP I-NP
gene NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

A DT B-NP B-NP
family NN I-NP I-NP
of IN B-PP B-PP
transcriptional JJ B-NP B-NP
activators NNS I-NP I-NP
has VBZ B-VP B-VP
recently RB I-VP I-VP
been VBN I-VP I-VP
identified VBN I-VP I-VP
in IN B-PP B-PP
chickens NNS B-NP B-NP
; : O O
these DT B-NP B-NP
transcriptional JJ I-NP I-NP
activators NNS I-NP I-NP
recognize VBP B-VP B-VP
a DT B-NP B-NP
common JJ I-NP I-NP
consensus NN I-NP I-NP
motif NN I-NP I-NP
( ( O O
WGATAR NN B-NP B-NP
) ) O O
through IN B-PP B-PP
a DT B-NP B-NP
conserved VBN I-NP I-NP
C4 NN I-NP I-NP
zinc NN I-NP I-NP
finger NN I-NP I-NP
DNA-binding JJ I-NP I-NP
domain NN I-NP I-NP
. . O O

One CD B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
members NNS I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
multigene JJ I-NP I-NP
family NN I-NP I-NP
, , O O
cGATA-3 NN B-NP B-NP
, , O O
is VBZ B-VP B-VP
most RBS I-VP B-ADVP
abundantly RB I-VP I-ADVP
expressed VBN I-VP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
T-lymphocyte NN I-NP I-NP
cell NN I-NP I-NP
lineage NN I-NP I-NP
. . O O

Analysis NN B-NP B-NP
of IN B-PP B-PP
human JJ B-NP B-NP
and CC I-NP I-NP
murine JJ I-NP I-NP
GATA-3 NN I-NP I-NP
factors NNS I-NP I-NP
shows VBZ B-VP B-VP
a DT B-NP B-NP
striking JJ I-NP I-NP
degree NN I-NP I-NP
of IN B-PP B-PP
amino NN B-NP B-NP
acid NN I-NP I-NP
sequence NN I-NP I-NP
identity NN I-NP I-NP
and CC O I-CC
similar JJ B-NP B-NP
patterns NNS I-NP I-NP
of IN B-PP B-PP
tissue NN B-NP B-NP
specificity NN I-NP I-NP
of IN B-PP B-PP
expression NN B-NP B-NP
in IN B-PP B-PP
these DT B-NP B-NP
three CD I-NP I-NP
organisms NNS I-NP I-NP
. . O O

The DT B-NP B-NP
murine JJ I-NP I-NP
and CC I-NP I-NP
human JJ I-NP I-NP
factors NNS I-NP I-NP
are VBP B-VP B-VP
abundantly RB I-VP I-VP
expressed VBN I-VP I-VP
in IN B-PP B-PP
a DT B-NP B-NP
variety NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
and CC I-NP I-NP
murine JJ I-NP I-NP
T-cell NN I-NP I-NP
lines NNS I-NP I-NP
and CC O I-CC
can MD B-VP B-VP
activate VB I-VP I-VP
transcription NN B-NP B-NP
through IN B-PP B-PP
a DT B-NP B-NP
tissue-specific JJ I-NP I-NP
GATA-binding JJ I-NP I-NP
site NN I-NP I-NP
identified VBN B-VP B-VP
within IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
T-cell NN I-NP I-NP
receptor NN I-NP I-NP
delta NN I-NP I-NP
gene NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

We PRP B-NP B-NP
infer VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT O B-NP
murine JJ B-NP I-NP
and CC O I-NP
human JJ B-ADJP I-NP
GATA-3 NN B-NP I-NP
proteins NNS I-NP I-NP
play VBP B-VP B-VP
a DT B-NP B-NP
central JJ I-NP I-NP
and CC I-NP I-NP
highly RB I-NP I-NP
conserved VBN I-NP I-NP
role NN I-NP I-NP
in IN B-PP B-PP
vertebrate NN B-NP B-NP
T-cell-specific JJ I-NP B-NP
transcriptional JJ I-NP I-NP
regulation NN I-NP I-NP
. . O O

Processing NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
precursor NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
by IN B-PP B-PP
the DT B-NP B-NP
HIV-1 NN I-NP I-NP
protease NN I-NP I-NP
during IN B-PP B-PP
acute JJ B-NP B-NP
infection NN I-NP I-NP
. . O O

Transcription NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type-1 NN I-NP I-NP
( ( O O
HIV-1 NN B-NP I-NN
) ) O O
genome NN B-NP B-NP
is VBZ B-VP B-VP
regulated VBN I-VP I-VP
in IN B-PP B-PP
part NN B-NP B-NP
by IN B-PP B-PP
cellular JJ B-NP B-NP
factors NNS I-NP I-NP
and CC O I-CC
is VBZ B-VP B-VP
stimulated VBN I-VP I-VP
by IN B-PP B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
latently RB B-NP B-NP
infected JJ I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

T-cell NN B-NP B-NP
activation NN I-NP I-NP
also RB B-ADVP B-ADVP
correlates VBZ B-VP B-VP
with IN B-PP B-PP
the DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
factor NN I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
which WDT B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
two CD B-NP B-NP
adjacent JJ I-NP I-NP
sites NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
HIV-1 NN I-NP I-NP
long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
. . O O

This DT B-NP B-NP
factor NN I-NP I-NP
consists VBZ B-VP B-VP
of IN B-PP B-PP
two CD B-NP B-NP
DNA-binding JJ I-NP I-NP
subunits NNS I-NP I-NP
of IN B-PP B-PP
relative JJ B-NP B-NP
molecular JJ I-NP I-NP
mass NN I-NP I-NP
50,000 CD B-NP I-CD
( ( O O
50K CD B-NP B-NP
) ) O O
associated VBN B-VP B-VP
with IN B-PP B-PP
two CD B-NP B-NP
65K CD I-NP I-NP
subunits NNS I-NP I-NP
. . O O

It PRP B-NP B-NP
is VBZ B-VP B-VP
located JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
nucleus NN I-NP I-NP
in IN B-PP B-PP
mature JJ B-NP B-NP
B NN I-NP I-NP
cells NNS I-NP I-NP
, , O O
but CC O I-CC
is VBZ B-VP B-VP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
other JJ B-NP B-NP
cell NN I-NP I-NP
types NNS I-NP I-NP
as IN B-PP B-PP
an DT B-NP B-NP
inactive JJ I-NP I-NP
cytoplasmic JJ I-NP I-NP
complex NN I-NP I-NP
. . O O

External JJ B-NP B-NP
stimuli NNS I-NP I-NP
, , O O
including VBG B-PP B-PP
those DT B-NP B-NP
that WDT B-NP B-NP
activate VBP B-VP B-VP
T NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
result VBP B-VP B-VP
in IN B-PP B-PP
nuclear JJ B-NP B-NP
translocation NN I-NP I-NP
of IN B-PP B-PP
active JJ B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
. . O O

The DT B-NP B-NP
cloning NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
complementary JJ I-NP I-NP
DNA NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
50K CD I-NP I-NP
subunit NN I-NP I-NP
helped VBD B-VP B-VP
to TO I-VP I-VP
identify VB I-VP I-VP
an DT B-NP B-NP
exclusively RB I-NP I-NP
cytoplasmic JJ I-NP I-NP
105K CD I-NP I-NP
precursor NN I-NP I-NP
( ( O O
p105 NN B-NP B-NP
) ) O O
( ( O O
V.B. NNP B-NP B-NP
, , O O
P.K. NNP B-NP B-NP
and CC O I-NP
A.I. NNP B-NP I-NP
, , O O
manuscript NN B-NP B-NP
submitted VBN B-VP B-VP
) ) O O
. . O O

The DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
active JJ B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
might MD B-VP B-VP
therefore RB I-VP I-VP
also RB I-VP I-VP
be VB I-VP I-VP
regulated VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
extent NN I-NP I-NP
of IN B-PP B-PP
processing NN B-NP B-NP
of IN B-PP B-PP
p105 NN B-NP B-NP
. . O O

Because IN B-SBAR B-SBAR
HIV-1 NN B-NP B-NP
requires VBZ B-VP B-VP
active JJ B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
for IN B-PP B-PP
efficient JJ B-NP B-NP
transcription NN I-NP I-NP
, , O O
we PRP B-NP B-NP
tested VBD B-VP B-VP
the DT B-NP B-NP
effect NN I-NP I-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
infection NN I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
processing NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
105K CD I-NP I-NP
precursor NN I-NP I-NP
. . O O

We PRP B-NP B-NP
show VBP B-VP B-VP
here RB B-ADVP B-ADVP
that IN B-SBAR B-PP
the DT B-NP B-NP
HIV-1 NN I-NP I-NP
protease NN I-NP I-NP
can MD B-VP B-VP
process VB I-VP I-VP
p105 NN B-NP B-NP
and CC O I-CC
increases VBZ B-VP B-VP
levels NNS B-NP B-NP
of IN B-PP B-PP
active JJ B-NP B-NP
nuclear JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
complex NN I-NP I-NP
. . O O

Vitamin NN B-NP B-NP
D NN I-NP I-NP
receptor NN I-NP I-NP
expression NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
lymphocytes NNS I-NP I-NP
. . O O

Signal NN B-NP B-NP
requirements NNS I-NP I-NP
and CC O I-CC
characterization NN B-NP B-NP
by IN B-PP B-PP
western NN B-NP B-NP
blots NNS I-NP I-NP
and CC O I-CC
DNA NN B-NP B-NP
sequencing NN I-NP I-NP
. . O O

The DT B-NP B-NP
signals NNS I-NP I-NP
controlling VBG B-VP B-VP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
receptor NN I-NP I-NP
protein NN I-NP I-NP
for IN B-PP B-PP
1 CD B-NP B-NP
alpha,25-dihydroxyvitamin NN I-NP I-NP
D3 NN I-NP I-NP
in IN B-PP B-PP
normal JJ B-NP B-NP
human JJ I-NP I-NP
lymphocytes NNS I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
relationship NN I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
protein NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
classical JJ I-NP I-NP
vitamin NN I-NP I-NP
D NN I-NP I-NP
receptor NN I-NP I-NP
were VBD B-VP B-VP
examined VBN I-VP I-VP
. . O O

Lymphocytes NNS B-NP B-NP
activated VBN B-VP B-VP
with IN B-PP B-PP
the DT B-NP B-NP
OKT3 NN I-NP I-NP
antibody NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
T-cell NN I-NP I-NP
antigen NN I-NP I-NP
receptor NN I-NP I-NP
expressed VBD B-VP B-VP
fewer JJR B-NP B-NP
binding VBG I-NP I-NP
sites NNS I-NP I-NP
as IN B-SBAR B-SBAR
compared VBN B-VP B-VP
to TO B-PP B-PP
lymphocytes NNS B-NP B-NP
that WDT B-NP B-NP
were VBD B-VP B-VP
activated VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
polyclonal JJ I-NP I-NP
activator NN I-NP I-NP
phytohemagglutinin NN I-NP I-NP
( ( O O
PHA NN B-NP B-NP
) ) O O
. . O O

However RB B-ADVP B-ADVP
, , O O
combination NN B-NP B-NP
of IN B-PP B-PP
OKT3 NN B-NP B-NP
and CC O I-NP
phorbol NN B-NP I-NP
myristate NN I-NP I-NP
acetate NN I-NP I-NP
produced VBD B-VP B-VP
a DT B-NP B-NP
concentration NN I-NP I-NP
of IN B-PP B-PP
binding VBG B-NP B-VP
sites NNS I-NP B-NP
similar JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
PHA-activated JJ I-NP I-NP
cells NNS I-NP I-NP
. . O O

The DT B-NP B-NP
receptor NN I-NP I-NP
from IN B-PP B-PP
OKT3 NN B-NP B-NP
and CC O I-NP
OKT3 NN B-ADJP I-NP
+ CC I-ADJP I-NP
phorbol NN I-ADJP I-NP
myristate NN I-ADJP I-NP
acetate-activated JJ I-ADJP I-NP
lymphocytes NNS B-NP I-NP
exhibited VBD B-VP B-VP
decreased VBN B-NP I-VP
binding NN I-NP B-NP
to TO B-PP B-PP
DNA-cellulose NN B-NP B-NP
compared VBN B-VP B-VP
to TO B-PP B-PP
PHA-activated JJ B-NP B-NP
lymphocytes NNS I-NP I-NP
. . O O

In IN B-PP B-PP
lymphocytes NNS B-NP B-NP
activated VBN B-VP B-VP
either CC B-PP I-VP
by IN I-PP B-PP
PHA NN B-NP B-NP
or CC O I-NP
OKT3 NN B-NP I-NP
( ( B-PP O
but CC I-PP I-CC
not RB B-PP I-RB
in IN I-PP B-PP
resting VBG B-NP B-VP
cells NNS I-NP B-NP
) ) O O
, , O O
a DT B-NP B-NP
50-kDa JJ I-NP I-NP
species NNS I-NP I-NP
cross-reacting VBG B-VP B-VP
with IN B-PP B-PP
a DT B-NP B-NP
monoclonal JJ I-NP I-NP
antibody NN I-NP I-NP
against IN B-PP B-PP
the DT B-NP B-NP
intestinal JJ I-NP I-NP
vitamin NN I-NP I-NP
D NN I-NP I-NP
receptor NN I-NP I-NP
was VBD B-VP B-VP
detected VBN I-VP I-VP
. . O O

Finally RB B-ADVP B-ADVP
, , O O
RNA NN B-NP B-NP
from IN B-PP B-PP
activated VBN B-NP B-NP
lymphocytes NNS I-NP I-NP
was VBD B-VP B-VP
amplified VBN I-VP I-VP
by IN B-PP B-PP
polymerase NN B-NP B-NP
chain NN I-NP I-NP
reaction NN I-NP I-NP
using VBG B-VP B-VP
oligonucleotide NN B-NP B-NP
primers NNS I-NP I-NP
flanking VBG B-VP B-VP
the DT B-NP B-NP
196 CD I-NP I-NP
base NN I-NP I-NP
pair NN I-NP I-NP
long JJ I-NP I-NP
region NN I-NP I-NP
encoding VBG B-VP B-VP
the DT B-NP B-NP
DNA-binding JJ I-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
intestinal JJ I-NP I-NP
receptor NN I-NP I-NP
. . O O

The DT B-NP B-NP
amplified VBN I-NP I-NP
product NN I-NP I-NP
showed VBD B-VP B-VP
an DT B-NP B-NP
identical JJ I-NP I-NP
nucleotide NN I-NP I-NP
sequence NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
DNA-binding JJ I-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
intestinal JJ I-NP I-NP
receptor NN I-NP I-NP
. . O O

These DT B-NP B-NP
findings NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-PP
expression NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
1,25-(OH)2D3 NN I-NP I-NP
receptor NN I-NP I-NP
in IN B-PP B-PP
lymphocytes NNS B-NP B-NP
is VBZ B-VP B-VP
triggered VBN I-VP I-VP
by IN B-PP B-PP
distinct JJ B-NP B-NP
and CC I-NP I-NP
contingent JJ I-NP I-NP
signals NNS I-NP I-NP
, , O O
and CC O I-CC
that IN B-SBAR B-SBAR
the DT B-NP B-NP
protein NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
mRNA NN I-NP I-NP
encoding VBG B-VP B-VP
it PRP B-NP B-NP
are VBP B-VP B-VP
identical JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
classical JJ I-NP I-NP
vitamin NN I-NP I-NP
D NN I-NP I-NP
receptor NN I-NP I-NP
. . O O

Cloning NN B-NP B-NP
of IN B-PP B-PP
murine JJ B-NP B-NP
TCF-1 NN I-NP I-NP
, , O O
a DT B-NP B-NP
T NN I-NP I-NP
cell-specific JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
interacting VBG B-VP B-VP
with IN B-PP B-PP
functional JJ B-NP B-NP
motifs NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
CD3-epsilon NN I-NP I-NP
and CC I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
receptor NN I-NP I-NP
alpha NN I-NP I-NP
enhancers NNS I-NP I-NP
. . O O

CD3-epsilon NN B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
is VBZ B-VP B-VP
confined VBN I-VP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
lineage NN I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
recently RB I-VP I-VP
identified VBN I-VP I-VP
and CC O I-CC
cloned VBN B-VP B-VP
a DT B-NP B-NP
human JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
, , O O
TCF-1 NN B-NP B-NP
, , O O
that WDT B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
functional JJ I-NP I-NP
element NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
T NN I-NP I-NP
lymphocyte-specific JJ I-NP I-NP
enhancer NN I-NP I-NP
of IN B-PP B-PP
CD3-epsilon NN B-NP B-NP
. . O O

In IN B-PP B-PP
a DT B-NP B-NP
panel NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
, , O O
TCF-1 NN B-NP B-NP
expression NN I-NP I-NP
was VBD B-VP B-VP
restricted JJ B-ADJP B-ADJP
to TO B-PP B-PP
T NN B-NP B-NP
lineage NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

TCF-1 NN B-NP B-NP
belonged VBD B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
novel JJ I-NP I-NP
family NN I-NP I-NP
of IN B-PP B-PP
genes NNS B-NP B-NP
that WDT B-NP B-NP
contain VBP B-VP B-VP
the DT B-NP B-NP
so-called JJ I-NP I-NP
high JJ I-NP I-NP
mobility NN I-NP I-NP
group NN I-NP I-NP
1 CD I-NP B-NP
( ( I-NP O
HMG NN I-NP I-NP
) ) I-NP O
box NN I-NP I-NP
. . O O

Here RB B-ADVP B-ADVP
we PRP B-NP B-NP
report VBP B-VP B-VP
the DT B-NP B-NP
cloning NN I-NP I-NP
of IN B-PP B-PP
murine JJ B-NP B-NP
TCF-1 NN I-NP I-NP
. . O O

Two CD B-NP B-NP
splice NN I-NP I-NP
alternatives NNS I-NP I-NP
were VBD B-VP B-VP
identified VBN I-VP I-VP
that WDT B-NP B-NP
were VBD B-VP B-VP
not RB I-VP I-VP
previously RB I-VP I-VP
observed VBN I-VP I-VP
in IN B-PP B-PP
human JJ B-NP B-NP
TCF-1 NN I-NP I-NP
. . O O

Murine JJ B-NP B-NP
and CC I-NP I-NP
human JJ I-NP I-NP
TCF-1 NN I-NP I-NP
displayed VBD B-VP B-VP
a DT B-NP B-NP
95.5 CD I-NP I-NP
% NN I-NP I-NP
overall JJ I-NP I-NP
amino NN I-NP I-NP
acid NN I-NP I-NP
homology NN I-NP I-NP
. . O O

Recombinant JJ B-NP B-NP
murine JJ I-NP I-NP
and CC I-NP I-NP
human JJ I-NP I-NP
TCF-1 NN I-NP I-NP
recognized VBD B-VP B-VP
the DT B-NP B-NP
same JJ I-NP I-NP
sequence NN I-NP I-NP
motif NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
CD3-epsilon NN I-NP I-NP
enhancer NN I-NP I-NP
as IN B-SBAR B-SBAR
judged VBN B-VP B-VP
by IN B-PP B-PP
gel NN B-NP B-NP
retardation NN I-NP I-NP
and CC O I-NP
methylation NN B-NP I-NP
interference NN I-NP I-NP
assays NNS B-NP I-NP
. . O O

With IN B-PP B-PP
the DT B-NP B-NP
murine JJ I-NP I-NP
cDNA NN I-NP I-NP
clones NNS I-NP I-NP
several JJ B-NP B-NP
aspects NNS I-NP I-NP
of IN B-PP B-PP
TCF-1 NN B-NP B-NP
were VBD B-VP B-VP
analyzed VBN I-VP I-VP
. . O O

First RB B-ADVP B-ADVP
, , O O
deletion NN B-NP B-NP
analysis NN I-NP I-NP
revealed VBD B-VP B-VP
that IN B-SBAR B-PP
a DT B-NP B-NP
region NN I-NP I-NP
of IN B-PP B-PP
TCF-1 NN B-NP B-NP
containing VBG B-VP B-VP
the DT B-NP B-NP
HMG NN I-NP I-NP
box NN I-NP I-NP
was VBD B-VP B-VP
sufficient JJ B-ADJP B-ADJP
for IN B-PP B-PP
sequence-specific JJ B-NP B-NP
binding NN I-NP I-NP
. . O O

Second RB B-ADVP B-ADVP
, , O O
by IN B-PP B-PP
high JJ B-NP B-NP
stringency NN I-NP I-NP
Northern NN I-NP I-NP
blotting NN I-NP I-NP
and CC O I-CC
in FW B-NP B-NP
situ FW I-NP I-NP
hybridization NN I-NP I-NP
, , O O
TCF-1 NN B-NP B-NP
expression NN I-NP I-NP
was VBD B-VP B-VP
shown VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
confined VBN I-VP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
thymus NN I-NP I-NP
and CC B-PP B-PP
to TO B-PP B-PP
the DT B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
areas NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
spleen NN I-NP I-NP
. . O O

Third RB B-ADVP B-ADVP
, , O O
TCF-1 NN B-NP B-NP
bound VBD B-VP B-VP
specifically RB B-ADVP B-ADVP
to TO B-PP B-PP
a DT B-NP B-NP
functional JJ I-NP I-NP
T NN I-NP I-NP
cell-specific JJ I-NP I-NP
element NN I-NP I-NP
in IN B-PP B-PP
the DT O B-NP
T NN B-NP I-NP
cell NN I-NP I-NP
receptor NN I-NP I-NP
alpha NN I-NP I-NP
( ( O O
TCR-alpha NN B-NP I-NN
) ) O O
enhancer NN B-NP B-NP
. . O O

The DT B-NP B-NP
T NN I-NP I-NP
lineage-specific JJ I-NP I-NP
expression NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
affinity NN I-NP I-NP
for IN B-PP B-PP
functional JJ B-NP B-NP
motifs NNS I-NP I-NP
in IN B-PP B-PP
the DT O B-NP
TCR-alpha NN B-NP I-NP
and CC O I-NP
CD3-epsilon NN B-NP I-NP
enhancers NNS B-NP I-NP
imply VBP B-VP B-VP
an DT B-NP B-NP
important JJ I-NP I-NP
role NN I-NP I-NP
for IN B-PP B-PP
TCF-1 NN B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
establishment NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
mature JJ I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
phenotype NN I-NP I-NP
. . O O

HIV NN B-NP B-NP
enhancer NN I-NP I-NP
activity NN I-NP I-NP
perpetuated VBN B-VP B-VP
by IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
induction NN I-NP I-NP
on IN B-PP B-PP
infection NN B-NP B-NP
of IN B-PP B-PP
monocytes NNS B-NP B-NP
( ( O O
see VB B-VP B-VP
comments NNS B-NP B-NP
) ) O O

Permissiveness NN B-NP B-NP
to TO B-PP B-PP
replication NN B-NP B-NP
of IN B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
( ( O O
HIV NN B-NP B-NP
) ) O O
differs VBZ B-VP B-VP
in IN B-PP B-PP
T NN B-NP B-NP
lymphocytes NNS I-NP I-NP
and CC O I-NP
macrophages NNS B-NP I-NP
. . O O

In IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
HIV NN B-NP B-NP
transcription NN I-NP I-NP
is VBZ B-VP B-VP
poorly RB I-VP I-VP
detected VBN I-VP I-VP
in FW B-ADVP B-NP
vivo FW I-ADVP B-NP
. . O O

Cloned VBN B-NP B-NP
, , I-NP O
normal JJ I-NP I-NP
T NN I-NP I-NP
lymphocytes NNS I-NP I-NP
show VBP B-VP B-VP
very RB O B-ADJP
little JJ O I-ADJP
, , O O
if IN B-SBAR B-SBAR
any DT O B-NP
, , O O
basal JJ B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HIV NN I-NP I-NP
enhancer NN I-NP I-NP
and CC O I-CC
low JJ B-NP B-NP
nuclear JJ I-NP I-NP
expression NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
, , O O
a DT B-NP B-NP
potent JJ I-NP I-NP
transcriptional JJ I-NP I-NP
activator NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HIV NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
fixed JJ B-NP B-NP
tissue NN I-NP I-NP
macrophages NNS I-NP I-NP
express VBP B-VP B-VP
detectable JJ B-NP B-NP
HIV NN I-NP I-NP
proteins NNS I-NP I-NP
, , O O
indicating VBG B-VP B-VP
permanent JJ B-NP B-NP
virus NN I-NP I-NP
transcription NN I-NP I-NP
. . O O

One CD B-NP B-NP
explanation NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
perpetuation NN I-NP I-NP
of IN B-PP B-PP
virus NN B-NP B-NP
infection NN I-NP I-NP
in IN B-PP B-PP
macrophages NNS B-NP B-NP
could MD B-VP B-VP
be VB I-VP I-VP
sustained JJ B-NP B-NP
nuclear JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
expression NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
U937 NN I-NP I-NP
monocytic JJ I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
, , O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
fully RB B-ADJP B-ADJP
permissive JJ I-ADJP I-ADJP
to TO B-PP B-PP
HIV NN B-NP B-NP
replication NN I-NP I-NP
, , O O
is VBZ B-VP B-VP
known VBN I-VP I-VP
to TO I-VP I-VP
express VB I-VP I-VP
only RB B-NP B-NP
low JJ I-NP I-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
nuclear JJ B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
. . O O

We PRP B-NP B-NP
show VBP B-VP B-VP
here RB B-ADVP B-ADVP
that IN B-SBAR B-PP
chronic JJ B-NP B-NP
HIV VBP I-NP I-NP
infection NN I-NP I-NP
results VBZ B-VP B-VP
in IN B-PP B-PP
both CC O I-CC
induction NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
nuclear JJ I-NP I-NP
factor NN I-NP I-NP
with IN B-PP B-PP
antigenic JJ B-NP B-NP
properties NNS I-NP I-NP
indistinguishable JJ B-ADJP B-ADJP
from IN B-PP B-PP
those DT B-NP B-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
and CC O I-CC
permanently RB B-NP B-VP
increased VBN I-NP I-VP
HIV NN I-NP B-NP
enhancer NN I-NP I-NP
activity NN I-NP I-NP
. . O O

This DT B-NP B-NP
phenomenon NN I-NP I-NP
, , O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
independent JJ B-ADJP B-ADJP
of IN B-PP B-PP
tumour NN B-NP B-NP
necrosis NN I-NP I-NP
factor NN I-NP I-NP
, , O O
is VBZ B-VP B-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
HIV NN B-NP B-NP
replication NN I-NP I-NP
, , O O
and CC O I-CC
is VBZ B-VP B-VP
thus RB O B-ADVP
likely JJ B-ADJP B-ADJP
to TO B-VP B-VP
explain VB I-VP I-VP
at IN B-ADVP B-ADVP
least JJS I-ADVP I-ADVP
in IN B-PP B-PP
part NN B-NP B-NP
the DT B-NP B-NP
perpetuation NN I-NP I-NP
of IN B-PP B-PP
HIV NN B-NP B-NP
infection NN I-NP I-NP
in IN B-PP B-PP
monocytes NNS B-NP B-NP
. . O O

Role NN B-NP B-NP
for IN B-PP B-PP
the DT B-NP B-NP
Epstein-Barr JJ I-NP I-NP
virus NN I-NP I-NP
nuclear JJ I-NP I-NP
antigen NN I-NP I-NP
2 CD I-NP I-NP
in IN B-PP B-PP
viral JJ B-NP B-NP
promoter NN I-NP I-NP
switching VBG I-NP B-VP
during IN B-PP B-PP
initial JJ B-NP B-NP
stages NNS I-NP I-NP
of IN B-PP B-PP
infection NN B-NP B-NP
. . O O

During IN B-PP B-PP
latent JJ O B-NP
Epstein-Barr JJ B-NP I-NP
virus NN I-NP I-NP
( ( O O
EBV NN B-NP I-NN
) ) O O
infection NN B-NP B-NP
of IN B-PP B-PP
human JJ B-NP B-NP
B NN I-NP I-NP
lymphocytes NNS I-NP I-NP
, , O O
six CD B-NP B-NP
viral JJ I-NP I-NP
nuclear JJ I-NP I-NP
antigen NN I-NP I-NP
( ( O O
EBNAs NNS B-NP B-NP
) ) O O
are VBP B-VP B-VP
expressed VBN I-VP I-VP
from IN B-PP B-PP
long JJ B-NP B-NP
primary JJ I-NP I-NP
transcripts NNS I-NP I-NP
by IN B-PP B-PP
means NNS I-PP B-NP
of IN I-PP B-PP
alternative JJ B-NP B-NP
splicing NN I-NP I-NP
and CC O I-NP
alternative JJ B-NP I-NP
polyadenylylation NN I-NP I-NP
sites NNS I-NP I-NP
. . O O

These DT B-NP B-NP
transcripts NNS I-NP I-NP
initiate VBP B-VP B-VP
from IN B-PP B-PP
one CD B-NP B-NP
of IN B-PP B-PP
two CD B-NP B-NP
promoters NNS I-NP I-NP
, , O O
Cp NN B-NP I-NP
or CC O I-NP
Wp NN B-NP I-NP
, , O O
that WDT B-NP B-NP
function VBP B-VP B-VP
in IN B-PP B-PP
a DT B-NP B-NP
mutually RB I-NP I-NP
exclusive JJ I-NP I-NP
fashion NN I-NP I-NP
. . O O

Wp NN B-NP B-NP
is VBZ B-VP B-VP
exclusively RB I-VP I-VP
utilized VBN I-VP I-VP
during IN B-PP B-PP
the DT B-NP B-NP
initial JJ I-NP I-NP
stages NNS I-NP I-NP
of IN B-PP B-PP
infection NN B-NP B-NP
of IN B-PP B-PP
primary JJ B-NP B-NP
B NN I-NP I-NP
lymphocytes NNS I-NP I-NP
, , O O
followed VBN B-VP B-VP
by IN B-PP B-PP
a DT B-NP B-NP
switch NN I-NP I-NP
to TO B-PP B-PP
Cp NN B-NP B-NP
usage NN I-NP I-NP
. . O O

These DT B-NP B-NP
studies NNS I-NP I-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
extended VBN I-VP I-VP
to TO I-VP I-VP
show VB I-VP I-VP
that IN B-SBAR B-SBAR
( ( B-LST O
i LS I-LST I-LS
) ) O O
a DT B-NP B-NP
mutant JJ I-NP I-NP
EBV NN I-NP I-NP
strain NN I-NP I-NP
lacking VBG B-VP B-VP
the DT B-NP B-NP
gene NN I-NP I-NP
encoding VBG B-VP B-VP
EBNA NN B-NP B-NP
2 CD I-NP I-NP
fails VBZ B-VP B-VP
to TO I-VP I-VP
switch VB I-VP I-VP
from IN B-PP B-PP
Wp NN B-NP B-NP
to TO B-PP B-PP
Cp NN B-NP B-NP
usage NN B-NP I-NP
in IN B-PP B-PP
primary JJ B-NP B-NP
B NN I-NP I-NP
lymphocytes NNS I-NP I-NP
, , O O
although IN B-SBAR B-SBAR
the DT B-NP B-NP
virus NN I-NP I-NP
contains VBZ B-VP B-VP
a DT B-NP B-NP
functional JJ I-NP I-NP
Cp NN I-NP I-NP
; : O O
( ( B-LST O
ii LS I-LST B-NP
) ) O O
a DT B-NP B-NP
region NN I-NP I-NP
from IN B-NP B-PP
-429 CD I-NP B-NP
to TO I-NP I-NP
-245 CD I-NP I-NP
base NN I-NP I-NP
pairs NNS I-NP I-NP
upstream JJ B-ADJP B-ADJP
of IN B-PP B-PP
Cp NN B-NP B-NP
is VBZ B-VP B-VP
essential JJ B-ADJP B-ADJP
for IN B-PP B-PP
Cp NN B-NP B-NP
activity NN I-NP I-NP
in IN B-PP B-PP
B NN B-NP B-NP
lymphocytes NNS I-NP I-NP
, , O O
but CC O I-CC
only RB B-PP B-ADVP
in IN I-PP B-PP
the DT B-NP B-NP
context NN I-NP I-NP
of IN B-PP B-PP
upstream JJ B-NP B-NP
and CC I-NP I-NP
downstream JJ I-NP I-NP
sequences NNS I-NP I-NP
; : O O
( ( B-LST O
iii LS I-LST B-NP
) ) O O
this DT B-NP B-NP
region NN I-NP I-NP
contains VBZ B-VP B-VP
an DT B-NP B-NP
EBNA NN I-NP I-NP
2-dependent JJ I-NP I-NP
enhancer NN I-NP I-NP
; : O O
and CC O I-CC
( ( B-LST O
iv LS I-LST I-LS
) ) O O
DNase NN B-NP B-NP
I CD I-NP I-NP
protection NN I-NP I-NP
employing VBG B-VP B-VP
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
from IN B-PP B-PP
B NN B-NP B-NP
and CC O I-NP
T NN B-NP I-NP
lymphocytes NNS B-NP I-NP
revealed VBD B-VP B-VP
a DT B-NP B-NP
B-cell-specific JJ I-NP I-NP
footprint NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
region NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
EBNA NN I-NP I-NP
2-dependent JJ I-NP I-NP
enhancer NN I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
support VBP B-VP B-VP
a DT B-NP B-NP
model NN I-NP I-NP
for IN B-PP B-PP
viral JJ B-NP B-NP
promoter NN I-NP I-NP
switching NN I-NP I-NP
during IN B-PP B-PP
the DT B-NP B-NP
initial JJ I-NP I-NP
stages NNS I-NP I-NP
of IN B-PP B-PP
infection NN B-NP B-NP
in IN B-PP B-PP
which WDT B-NP B-NP
Wp NN B-NP B-NP
activity NN I-NP I-NP
leads VBZ B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
EBNA NN B-NP B-NP
2 CD I-NP I-NP
, , O O
followed VBN O B-VP
by IN B-PP B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
Cp NN B-NP B-NP
through IN B-PP B-PP
the DT B-NP B-NP
EBNA NN I-NP I-NP
2-dependent JJ I-NP I-NP
enhancer NN I-NP I-NP
. . O O

Glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
characteristics NNS I-NP I-NP
in IN B-PP B-PP
monocytes NNS B-NP B-NP
of IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
corticosteroid-resistant JJ B-NP B-NP
bronchial JJ I-NP I-NP
asthma NN I-NP I-NP
. . O O

The DT B-NP B-NP
mechanism NN I-NP I-NP
of IN B-PP B-PP
corticosteroid NN B-NP B-NP
resistance NN I-NP I-NP
in IN B-PP B-PP
bronchial JJ B-NP B-NP
asthma NN I-NP I-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
studied VBN I-VP I-VP
by IN B-PP B-PP
determining VBG B-VP B-VP
the DT B-NP B-NP
rank NN I-NP I-NP
order NN I-NP I-NP
of IN B-PP B-PP
potency NN B-NP B-NP
for IN B-PP B-PP
different JJ B-NP B-NP
corticosteroids NNS I-NP I-NP
in IN B-PP B-PP
inhibiting VBG B-VP B-VP
the DT B-NP B-NP
generation NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
3 CD I-NP I-NP
kD NN I-NP I-NP
molecule NN I-NP I-NP
from IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
monocytes NNS I-NP I-NP
isolated VBN B-VP B-VP
from IN B-PP B-PP
corticosteroid-sensitive JJ O B-NP
( ( O O
CS JJ B-ADJP I-JJ
) ) O O
and CC O I-CC
corticosteroid-resistant JJ O B-NP
( ( O O
CR JJ B-ADJP I-JJ
) ) O O
asthmatic JJ B-NP B-NP
subjects NNS I-NP I-NP
, , O O
which WDT B-NP B-NP
augments VBZ B-VP B-VP
leukotriene NN B-NP B-NP
B4 NN I-NP I-NP
( ( O O
LTB4 NN B-NP I-NN
) ) O O
generation NN B-NP B-NP
by IN B-PP B-PP
human JJ B-NP B-NP
neutrophils NNS I-NP I-NP
( ( O O
PMN NN B-NP B-NP
) ) O O
stimulated VBN B-VP B-VP
by IN B-PP B-PP
calcium NN B-NP B-NP
ionophore NN I-NP I-NP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
binding VBG B-NP B-VP
studies NNS I-NP B-NP
with IN B-PP B-PP
( ( B-NP O
3H NN I-NP I-NP
) ) I-NP O
dexamethasone NN I-NP B-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
performed VBN I-VP I-VP
to TO B-VP B-VP
determine VB I-VP I-VP
the DT B-NP B-NP
dissociation NN I-NP I-NP
constant NN I-NP I-NP
( ( O O
Kd NN B-NP B-NP
) ) O O
and CC O I-CC
receptor NN B-NP B-NP
numbers NNS I-NP I-NP
( ( O O
Ro NN B-NP B-NP
) ) O O
in IN B-PP B-PP
the DT B-NP B-NP
monocytes NNS I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
two CD I-NP I-NP
groups NNS I-NP I-NP
of IN B-PP B-PP
subjects NNS B-NP B-NP
. . O O

The DT B-NP B-NP
concentration NN I-NP I-NP
of IN B-PP B-PP
corticosteroid NN B-NP B-NP
producing VBG B-VP B-VP
50 CD B-NP B-NP
% NN I-NP I-NP
inhibition NN I-NP I-NP
( ( O O
IC50 NN B-NP B-NP
) ) O O
was VBD B-VP B-VP
600 CD B-NP B-NP
nM NN I-NP I-NP
, , O O
70 CD B-NP B-NP
nM NN I-NP I-NP
, , O O
and CC O I-CC
0.5 CD B-NP B-NP
nM NN I-NP I-NP
for IN B-PP B-PP
hydrocortisone NN B-NP B-NP
, , O O
methylprednisolone NN B-NP B-NP
, , O O
and CC O I-CC
dexamethasone NN B-NP B-NP
, , O O
respectively RB B-ADVP B-ADVP
, , O O
in IN B-PP B-PP
monocytes NNS B-NP B-NP
from IN B-PP B-PP
CS JJ B-NP B-NP
individuals NNS I-NP I-NP
. . O O

There EX B-NP B-NP
was VBD B-VP B-VP
only RB B-NP B-NP
weak JJ I-NP I-NP
inhibition NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
generation NN I-NP I-NP
of IN B-PP B-PP
enhancing NN B-NP B-NP
activity NN I-NP I-NP
by IN B-PP B-PP
the DT B-NP B-NP
corticosteroids NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
CR JJ I-NP I-NP
asthmatic JJ I-NP I-NP
individuals NNS I-NP I-NP
. . O O

The DT B-NP B-NP
dexamethasone NN I-NP I-NP
Kd NN I-NP I-NP
was VBD B-VP B-VP
2.45 CD B-NP B-NP
+/- CC I-NP I-NP
0.58 CD I-NP I-NP
nM NN I-NP I-NP
( ( O O
mean NN B-NP B-NP
+/- CC O I-NP
SEM NN B-NP I-NP
, , O O
n NN B-NP B-NP
= JJ B-VP I-NP
6 CD B-NP I-NP
) ) O O
in IN B-PP B-PP
the DT O B-NP
CS JJ B-NP I-NP
group NN B-NP I-NP
and CC O I-CC
1.6 CD B-NP B-NP
+/- CC I-NP I-NP
0.35 CD I-NP I-NP
nM NN I-NP I-NP
( ( O O
mean NN B-NP B-NP
+/- CC O I-NP
SEM NN B-NP I-NP
, , O O
n NN B-NP B-NP
= JJ B-VP I-NP
6 CD B-NP I-NP
) ) O O
in IN B-PP B-PP
the DT O B-NP
CR JJ B-NP I-NP
group NN B-NP I-NP
of IN B-PP B-PP
patients NNS B-NP B-NP
( ( O O
p NN B-NP B-NP
= JJ B-VP I-NP
0.14 CD B-NP I-NP
) ) O O
. . O O

The DT B-NP B-NP
Ro NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
CS JJ I-NP I-NP
group NN I-NP I-NP
was VBD B-VP B-VP
3,605 CD B-NP B-NP
+/- CC I-NP I-NP
984 CD I-NP I-NP
binding VBG I-NP B-VP
sites NNS I-NP B-NP
per IN B-PP B-PP
nucleus NN B-NP B-NP
( ( O O
mean NN B-NP I-NP
+/- CC O I-NP
SEM NN B-NP I-NP
, , O O
n NN B-NP B-NP
= JJ B-VP I-NP
6 CD B-NP I-NP
) ) O O
and CC O I-CC
4,757 CD B-NP B-NP
+/- CC I-NP I-NP
692 CD I-NP I-NP
binding VBG I-NP B-VP
sites NNS I-NP B-NP
per IN B-PP B-PP
nucleus NN B-NP B-NP
( ( O O
mean NN B-NP I-NP
+/- CC O I-NP
SEM NN B-NP I-NP
, , O O
n NN B-NP B-NP
= JJ B-VP I-NP
6 CD B-NP I-NP
) ) O O
in IN B-PP B-PP
the DT B-NP B-NP
CR JJ I-NP I-NP
group NN I-NP I-NP
( ( O O
p NN B-NP B-NP
= JJ B-VP I-NP
0.23 CD B-NP I-NP
) ) O O
. . O O

These DT B-NP B-NP
findings NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-PP
corticosteroid NN B-NP B-NP
resistance NN I-NP I-NP
in IN B-PP B-PP
bronchial JJ B-NP B-NP
asthma NN I-NP I-NP
can MD B-VP B-VP
not RB I-VP I-VP
be VB I-VP I-VP
explained VBN I-VP I-VP
by IN B-PP B-PP
abnormalities NNS B-NP B-NP
in IN B-PP B-PP
corticosteroid NN B-NP B-NP
receptor NN I-NP I-NP
characteristics NNS B-NP I-NP
. . O O

Tissue-specific JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
platelet NN I-NP I-NP
GPIIb NN I-NP I-NP
gene NN I-NP I-NP
. . O O

One CD B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
major JJ I-NP I-NP
objectives NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
study NN I-NP I-NP
of IN B-PP B-PP
thrombogenesis NN B-NP B-NP
is VBZ B-VP B-VP
to TO B-VP B-VP
determine VB I-VP I-VP
the DT B-NP B-NP
mechanisms NNS I-NP I-NP
by IN B-PP B-PP
which WDT B-NP B-NP
a DT B-NP B-NP
hematopoietic JJ I-NP I-NP
progenitor NN I-NP I-NP
is VBZ B-VP B-VP
activated VBN I-VP I-VP
and CC O I-VP
committed VBN B-VP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
megakaryocytic JJ I-NP I-NP
lineage NN I-NP I-NP
. . O O

Recent JJ B-NP B-NP
development NN I-NP I-NP
of IN B-PP B-PP
primary JJ B-NP B-NP
cultures NNS I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
megakaryocytes NNS I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
molecular JJ I-NP I-NP
cloning NN I-NP I-NP
of IN B-PP B-PP
genes NNS B-NP B-NP
that WDT B-NP B-NP
are VBP B-VP B-VP
specific JJ B-ADJP B-ADJP
to TO B-PP B-PP
this DT B-NP B-NP
lineage NN I-NP I-NP
offer VBP B-VP B-VP
the DT B-NP B-NP
possibility NN I-NP I-NP
of IN B-PP B-PP
getting VBG B-VP B-VP
some DT B-NP B-NP
insights NNS I-NP I-NP
into IN B-PP B-PP
the DT B-NP B-NP
genetic JJ I-NP I-NP
mechanisms NNS I-NP I-NP
that WDT B-NP B-NP
control VBP B-VP B-VP
megakaryocytopoiesis NNS B-NP B-NP
. . O O

One CD B-NP B-NP
gene NN I-NP I-NP
of IN B-PP B-PP
interest NN B-NP B-NP
is VBZ B-VP B-VP
the DT O B-NP
glycoprotein NN B-NP I-NP
IIb NN I-NP I-NP
( ( O O
GPIIb NN B-NP I-NN
) ) O O
gene NN B-NP B-NP
; : O O
GPIIb NN B-NP B-NP
, , O O
the DT B-NP B-NP
alpha NN I-NP I-NP
subunit NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
platelet NN I-NP I-NP
cytoadhesin NN I-NP I-NP
GPIIb-IIIa NN I-NP I-NP
, , O O
is VBZ B-VP B-VP
produced VBN I-VP I-VP
in IN B-PP B-PP
megakaryocytes NNS B-NP B-NP
at IN B-PP B-PP
an DT B-NP B-NP
early JJ I-NP I-NP
stage NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
differentiation NN I-NP I-NP
, , O O
whereas IN O B-PP
the DT B-NP B-NP
other JJ I-NP I-NP
subunit NN I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
complex NN I-NP I-NP
, , O O
GPIIIa NN B-NP B-NP
, , O O
is VBZ B-VP B-VP
expressed VBN I-VP I-VP
in IN B-PP B-PP
other JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

For IN B-PP B-PP
these DT B-NP B-NP
reasons NNS I-NP I-NP
, , O O
the DT B-NP B-NP
5'-flanking JJ I-NP I-NP
region NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
GPIIb NN I-NP I-NP
gene NN I-NP I-NP
was VBD B-VP B-VP
used VBN I-VP I-VP
to TO B-VP B-VP
identify VB I-VP I-VP
the DT B-NP B-NP
regions NNS I-NP I-NP
that WDT B-NP B-NP
interact VBP B-VP B-VP
with IN B-PP B-PP
DNA-binding JJ B-NP B-NP
nuclear JJ I-NP I-NP
factors NNS I-NP I-NP
. . O O

A DT B-NP B-NP
fragment NN I-NP I-NP
extending VBG B-VP B-VP
from IN B-PP B-PP
-643 CD B-NP B-NP
to TO B-PP I-NP
+33 CD B-NP I-NP
is VBZ B-VP B-VP
capable JJ B-ADJP B-ADJP
of IN B-PP B-PP
controlling VBG B-VP B-VP
the DT B-NP B-NP
tissue-specific JJ I-NP I-NP
expression NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
CAT NN I-NP I-NP
gene NN I-NP I-NP
in IN B-PP B-PP
transfection NN B-NP B-NP
experiments NNS I-NP I-NP
. . O O

Within IN B-PP B-PP
this DT B-NP B-NP
region NN I-NP I-NP
, , O O
we PRP B-NP B-NP
have VBP B-VP B-VP
identified VBN I-VP I-VP
several JJ B-NP B-NP
sequences NNS I-NP I-NP
that WDT B-NP B-NP
are VBP B-VP B-VP
implicated VBN I-VP I-VP
in IN B-PP B-PP
DNA NN B-NP B-NP
protein NN I-NP I-NP
interactions NNS I-NP I-NP
as IN B-SBAR B-SBAR
shown VBN B-VP B-VP
in IN B-PP B-PP
DNAse NN B-NP B-NP
I NN I-NP I-NP
footprints NNS I-NP I-NP
and CC O I-CC
gel NN B-NP B-NP
mobility NN I-NP I-NP
shift NN I-NP I-NP
assays NNS I-NP I-NP
. . O O

One CD B-NP B-NP
region NN I-NP I-NP
, , O O
centered VBN B-ADJP B-VP
at IN B-PP B-PP
-54 CD B-NP B-NP
, , O O
is VBZ B-VP B-VP
similar JJ B-ADJP B-ADJP
to TO B-PP B-PP
a DT B-NP B-NP
nuclear JJ I-NP I-NP
factor NN I-NP I-NP
E1-binding JJ I-NP I-NP
site NN I-NP I-NP
, , O O
and CC O I-CC
a DT B-NP B-NP
region NN I-NP I-NP
located JJ B-ADJP B-ADJP
at IN B-PP B-PP
position NN B-NP B-NP
-233 CD I-NP I-NP
contains VBZ B-VP B-VP
a DT B-NP B-NP
CCAAT NN I-NP I-NP
motif NN I-NP I-NP
. . O O

Two CD B-NP B-NP
domains NNS I-NP I-NP
centered VBN O B-VP
at IN B-PP B-PP
positions NNS B-NP B-NP
-345 CD B-NP I-NP
and CC O I-NP
-540 CD B-NP I-NP
, , B-ADJP O
respectively RB I-ADJP B-ADVP
, , O O
bind VBP B-VP B-VP
proteins NNS B-NP B-NP
that WDT B-NP B-NP
are VBP B-VP B-VP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
megakaryocytic JJ B-NP B-NP
cells NNS I-NP I-NP
and CC O I-CC
nonrelated JJ B-NP B-NP
cells NNS I-NP I-NP
as RB B-PP B-ADVP
well RB B-ADVP I-ADVP
. . O O

Finally RB B-ADVP B-ADVP
, , O O
two CD B-NP B-NP
other JJ I-NP I-NP
domains NNS I-NP I-NP
, , O O
located JJ B-ADJP B-ADJP
at IN B-PP B-PP
positions NNS B-NP B-NP
-460 CD B-NP I-NP
and CC O I-NP
-510 CD B-NP I-NP
, , O O
interact VBP B-VP B-VP
with IN B-PP B-PP
proteins NNS B-NP B-NP
that WDT B-NP B-NP
are VBP B-VP B-VP
only RB B-ADJP B-NP
present JJ I-ADJP I-NP
in IN B-PP B-PP
megakaryocytic JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
deletion NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
region NN I-NP I-NP
containing VBG B-VP B-VP
these DT B-NP B-NP
two CD I-NP I-NP
domains NNS I-NP I-NP
results VBZ B-VP B-VP
in IN B-PP B-PP
a DT B-NP B-NP
significant JJ I-NP I-NP
decrease NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
promoter NN I-NP I-NP
activity NN I-NP I-NP
. . O O

It PRP B-NP B-NP
is VBZ B-VP B-VP
very RB B-ADJP B-ADJP
likely JJ I-ADJP I-ADJP
that IN B-SBAR B-PP
these DT B-NP B-NP
domains NNS I-NP I-NP
bind VBP B-VP B-VP
megakaryocyte-specific JJ B-NP B-NP
nuclear JJ I-NP I-NP
proteins NNS I-NP I-NP
acting VBG B-VP B-VP
as IN B-PP B-PP
positive JJ B-NP B-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
. . O O

Inhibition NN B-NP B-NP
of IN B-PP B-PP
protein NN B-NP B-NP
phosphatases NNS I-NP I-NP
by IN B-PP B-PP
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
induces VBZ B-VP B-VP
AP1 NN B-NP B-NP
in IN B-PP B-PP
human JJ B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

To TO B-VP B-VP
examine VB I-VP I-VP
the DT B-NP B-NP
role NN I-NP I-NP
of IN B-PP B-PP
protein NN B-NP B-NP
phosphatases NNS I-NP I-NP
in IN B-PP B-PP
T NN B-NP B-NP
cell NN I-NP I-NP
activation NN I-NP I-NP
, , O O
Jurkat NN B-NP B-NP
cells NNS I-NP I-NP
were VBD B-VP B-VP
treated VBN I-VP I-VP
with IN B-PP B-PP
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
, , O O
an DT B-NP B-NP
inhibitor NN I-NP I-NP
of IN B-PP B-PP
type NN B-NP B-NP
1 CD I-NP I-NP
and CC I-NP I-CC
2A NN I-NP B-NP
phosphatases NNS I-NP I-NP
, , O O
and CC O I-CC
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
were VBD B-VP B-VP
examined VBN I-VP I-VP
for IN B-PP B-PP
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
AP1 NN B-NP B-NP
as IN B-PP B-PP
a DT B-NP B-NP
measure NN I-NP I-NP
of IN B-PP B-PP
early JJ B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
activation NN I-NP I-NP
. . O O

Okadaic JJ B-NP B-NP
acid NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
a DT B-NP B-NP
potent JJ I-NP I-NP
inducer NN I-NP I-NP
of IN B-PP B-PP
AP1 NN B-NP B-NP
. . O O

In IN B-PP B-PP
contrast NN I-PP B-NP
to TO I-PP B-PP
phorbol NN B-NP B-NP
esters NNS I-NP I-NP
such JJ B-PP B-PP
as IN I-PP I-PP
phorbol NN B-NP B-NP
myristate NN I-NP I-NP
acetate NN I-NP I-NP
( ( O O
PMA NN B-NP B-NP
) ) O O
, , O O
the DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
AP1 NN B-NP B-NP
by IN B-PP B-PP
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
occurs VBZ B-VP B-VP
predominantly RB B-PP B-ADVP
by IN I-PP B-PP
transcriptional JJ B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
the DT O B-NP
jun NN B-NP I-NP
and CC O I-NP
fos NN B-NP I-NP
family NN B-NP I-NP
of IN B-PP B-PP
proto-oncogenes NNS B-NP B-NP
. . O O

Surprisingly RB B-ADVP B-ADVP
, , O O
while IN B-SBAR B-SBAR
the DT B-NP B-NP
addition NN I-NP I-NP
of IN B-PP B-PP
phytohemagglutinin NN B-NP B-NP
further RB B-ADVP B-ADVP
enhanced VBD B-VP B-VP
the DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
AP1 NN B-NP B-NP
, , O O
the DT B-NP B-NP
addition NN I-NP I-NP
of IN B-PP B-PP
PMA NN B-NP B-NP
inhibited VBD B-VP B-VP
it PRP B-NP B-NP
. . O O

Okadaic JJ B-NP B-NP
acid NN I-NP I-NP
treatment NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
dramatically RB I-VP I-VP
increase VB I-VP I-VP
mRNA NN B-NP B-NP
transcripts NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
jun NN I-NP I-NP
family NN I-NP I-NP
of IN B-PP B-PP
proto-oncogenes NNS B-NP B-NP
including VBG B-PP B-VP
c-jun NN B-NP B-NP
, , O O
junD NN B-NP B-NP
, , O O
and CC O I-CC
junB NN B-NP B-NP
and CC O I-NP
to TO B-PP B-PP
a DT B-NP B-NP
lesser JJR I-NP I-NP
extent NN I-NP I-NP
the DT B-NP B-NP
fos NN I-NP I-NP
family NN I-NP I-NP
including VBG B-PP I-NP
c-fos NN B-NP I-NP
and CC O I-NP
fra-1 NN B-NP I-NP
. . O O

By IN B-PP B-PP
comparison NN B-NP B-NP
, , O O
PMA NN B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
very RB I-NP I-NP
inefficient JJ I-NP I-NP
inducer NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
jun NN I-NP I-NP
gene NN I-NP I-NP
family NN I-NP I-NP
in IN B-PP B-PP
Jurkat NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Similar JJ B-ADJP B-ADVP
to TO B-PP B-PP
its PRP$ B-NP B-NP
effect NN I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
AP1 NN B-NP B-NP
by IN B-PP B-PP
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
, , O O
PMA NN B-NP B-NP
inhibits VBZ B-VP B-VP
the DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
mRNA NN I-NP I-NP
by IN B-PP B-PP
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
. . O O

Transfection NN B-NP B-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
promoter NN I-NP I-NP
constructs NNS I-NP I-NP
confirmed VBD B-VP B-VP
the DT B-NP B-NP
marked JJ I-NP I-NP
difference NN I-NP I-NP
between IN B-PP B-PP
PMA NN B-NP B-NP
and CC O I-CC
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
in IN B-PP B-PP
inducing VBG B-VP B-VP
c-jun NN B-NP B-NP
transcription NN I-NP I-NP
. . O O

The DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
AP1 NN B-NP B-NP
by IN B-PP B-PP
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
suggests VBZ B-VP B-VP
that IN B-SBAR B-SBAR
protein NN B-NP B-NP
phosphatases NNS I-NP I-NP
1 CD B-NP B-NP
and CC O I-CC
2A NN B-NP B-NP
( ( O O
PP1 NN B-NP I-NP
and CC O I-NP
PP2A NN B-NP I-NP
) ) O O
may MD B-VP B-VP
be VB I-VP I-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
T NN B-NP B-NP
cell NN I-NP I-NP
activation NN I-NP I-NP
as IN B-PP B-PP
important JJ B-NP B-NP
negative JJ I-NP I-NP
regulators NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
AP1 NN I-NP I-NP
. . O O

Demonstration NN B-NP B-NP
of IN B-PP B-PP
estrogen NN B-NP B-NP
and CC O I-NP
progesterone NN B-NP I-NP
receptors NNS B-NP I-NP
as RB B-CONJP B-ADVP
well RB I-CONJP I-ADVP
as IN I-CONJP B-PP
Ki-67 NN B-NP B-NP
and CC O I-NP
p-145 NN B-NP I-NP
antigens NNS B-NP I-NP
in IN B-PP B-PP
single JJ B-NP B-NP
tumor NN I-NP I-NP
cells NNS I-NP I-NP
from IN B-PP B-PP
blood NN B-NP B-NP
and CC O I-NP
pleural JJ B-ADJP I-NP
effusions NNS B-NP I-NP
using VBG B-VP B-VP
a DT B-NP B-NP
slide NN I-NP I-NP
assay NN I-NP I-NP
. . O O

We PRP B-NP B-NP
describe VBP B-VP B-VP
a DT B-NP B-NP
slide NN I-NP I-NP
assay NN I-NP I-NP
that WDT B-NP B-NP
allows VBZ B-VP B-VP
the DT B-NP B-NP
demonstration NN I-NP I-NP
of IN B-PP B-PP
antigens NNS B-NP B-NP
localized JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
nucleus NN I-NP I-NP
from IN B-PP B-PP
isolated VBN B-NP B-NP
white JJ I-NP I-NP
blood NN I-NP I-NP
cells NNS I-NP I-NP
as RB B-CONJP B-ADVP
well RB I-CONJP I-ADVP
as IN I-CONJP B-SBAR
from IN B-PP B-PP
single JJ B-NP B-NP
tumor NN I-NP I-NP
cells NNS I-NP I-NP
derived VBN B-VP B-VP
from IN B-PP B-PP
malignant JJ B-NP B-NP
effusions NNS I-NP I-NP
. . O O

With IN B-PP B-PP
the DT B-NP B-NP
antibodies NNS I-NP I-NP
Ki-67 NN B-NP I-NP
and CC O I-NP
anti-p-145 NN B-NP I-NP
an DT B-NP B-NP
increased VBN I-NP I-NP
rate NN I-NP I-NP
of IN B-PP B-PP
nuclear JJ B-NP B-NP
and CC I-NP I-NP
nucleolar JJ I-NP I-NP
staining NN I-NP I-NP
resulted VBD B-VP B-VP
in IN B-PP B-PP
cells NNS B-NP B-NP
from IN B-PP B-PP
highly RB B-NP B-NP
malignant JJ I-NP I-NP
lymphomas NNS I-NP I-NP
. . O O

An DT B-NP B-NP
almost RB I-NP I-NP
identical JJ I-NP I-NP
reaction NN I-NP I-NP
was VBD B-VP B-VP
obtained VBN I-VP I-VP
when WRB B-ADVP B-ADVP
tumor NN B-NP B-NP
cells NNS I-NP I-NP
from IN B-PP B-PP
malignant JJ B-NP B-NP
effusions NNS I-NP I-NP
were VBD B-VP B-VP
tested VBN I-VP I-VP
. . O O

Cells NNS B-NP B-NP
isolated VBN B-VP B-VP
from IN B-PP B-PP
the DT B-NP B-NP
blood NN I-NP I-NP
of IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
leukemic JJ B-NP B-NP
spread NN I-NP I-NP
of IN B-PP B-PP
lymphomas NNS B-NP B-NP
of IN B-PP B-PP
low JJ B-NP B-NP
malignancy NN I-NP I-NP
yielded VBD B-VP B-VP
a DT B-NP B-NP
weak JJ I-NP I-NP
staining NN I-NP I-NP
comparable JJ B-ADJP B-ADJP
to TO B-PP B-PP
that DT B-NP B-NP
of IN B-PP B-PP
normal JJ B-NP B-NP
mesothelial JJ I-NP I-NP
cells NNS I-NP I-NP
from IN B-PP B-PP
non-tumorous JJ B-NP B-NP
cavity NN I-NP I-NP
fluids NNS I-NP I-NP
. . O O

The DT B-NP B-NP
detection NN I-NP I-NP
of IN B-PP B-PP
estrogen NN B-NP B-NP
and CC O I-NP
progesterone NN B-NP I-NP
receptors NNS B-NP I-NP
( ( O O
ER NN B-NP B-NP
and CC O I-NP
PR NN B-NP I-NP
) ) O O
localized JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
cell NN I-NP I-NP
nucleus NN I-NP I-NP
can MD B-VP B-VP
be VB I-VP I-VP
achieved VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
same JJ I-NP I-NP
assay NN I-NP I-NP
. . O O

The DT B-NP B-NP
reaction NN I-NP I-NP
is VBZ B-VP B-VP
enhanced VBN I-VP I-VP
by IN B-PP B-PP
incubation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
tumor NN I-NP I-NP
cells NNS I-NP I-NP
for IN B-PP B-PP
30 CD B-NP B-NP
min NN I-NP I-NP
at IN B-PP B-PP
37 CD B-NP B-NP
degrees NNS I-NP I-NP
C NN I-NP B-VP
prior RB B-PP B-ADVP
to TO I-PP B-PP
fixation NN B-NP B-NP
. . O O

Pleural JJ B-NP B-NP
effusions NNS I-NP I-NP
from IN B-PP B-PP
20 CD B-NP B-NP
patients NNS I-NP I-NP
with IN B-PP B-PP
breast NN B-NP B-NP
cancer NN I-NP I-NP
were VBD B-VP B-VP
tested VBN I-VP I-VP
. . O O

ER NN B-NP B-NP
was VBD B-VP B-VP
positive JJ B-ADJP B-ADJP
in IN B-PP B-PP
13 CD B-NP B-NP
and CC O I-CC
PR NN B-NP B-NP
was VBD B-VP B-VP
positive JJ B-ADJP B-ADJP
in IN B-PP B-PP
12 CD B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
20 CD I-NP I-NP
samples NNS I-NP I-NP
. . O O

In IN B-PP B-PP
5 CD B-NP B-NP
cases NNS I-NP I-NP
there EX B-NP B-ADVP
was VBD B-VP B-VP
a DT B-NP B-NP
divergent JJ I-NP I-NP
reaction NN I-NP I-NP
with IN B-PP B-PP
ER NN B-NP B-NP
and CC O I-NP
PR NN B-NP I-NP
antibody NN B-NP I-NP
. . O O

The DT B-NP B-NP
hormone NN I-NP I-NP
receptors NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
primary JJ I-NP I-NP
tumor NN I-NP I-NP
were VBD B-VP B-VP
known VBN I-VP I-VP
in IN B-PP B-PP
15 CD B-NP B-NP
( ( O O
ER NN B-NP I-NP
) ) O O
and CC O I-CC
14 CD B-NP B-NP
( ( O O
PR NN B-NP I-NP
) ) O O
patients NNS B-NP B-NP
, , O O
respectively RB B-ADVP B-ADVP
. . O O

In IN B-PP B-PP
each DT B-NP B-NP
cohort NN I-NP I-NP
there EX B-NP B-NP
was VBD B-VP B-VP
only RB B-NP B-NP
one CD I-NP I-NP
case NN I-NP I-NP
with IN B-PP B-PP
a DT B-NP B-NP
negative JJ I-NP I-NP
reaction NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
primary JJ I-NP I-NP
tumor NN I-NP I-NP
and CC O I-CC
a DT B-NP B-NP
positive JJ I-NP I-NP
reaction NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
isolated VBN I-NP I-NP
tumor NN I-NP I-NP
cells NNS I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
pleural JJ I-NP I-NP
effusions NNS I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
demonstration NN I-NP I-NP
of IN B-PP B-PP
hormone NN B-NP B-NP
receptor NN I-NP I-NP
proteins NNS I-NP I-NP
in IN B-PP B-PP
cells NNS B-NP B-NP
from IN B-PP B-PP
malignant JJ B-NP B-NP
effusions NNS I-NP I-NP
is VBZ B-VP B-VP
possible JJ B-ADJP B-ADJP
and CC O I-CC
that IN B-SBAR B-SBAR
there EX B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
correlation NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
status NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
primary JJ I-NP I-NP
site NN I-NP I-NP
of IN B-PP B-PP
cancer NN B-NP B-NP
. . O O

Transforming VBG B-NP B-VP
growth NN I-NP B-NP
factor-beta NN I-NP I-NP
suppresses VBZ B-VP B-VP
human JJ B-NP B-NP
B NN I-NP I-NP
lymphocyte NN I-NP I-NP
Ig NN I-NP I-NP
production NN I-NP I-NP
by IN B-PP B-PP
inhibiting VBG B-VP B-VP
synthesis NN B-NP B-NP
and CC O I-CC
the DT B-NP B-NP
switch NN I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
membrane NN I-NP I-NP
form NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
secreted JJ I-NP I-NP
form NN I-NP I-NP
of IN B-PP B-PP
Ig NN O B-NP
mRNA NN O I-NP
. . O O

Transforming VBG B-NP B-VP
growth NN I-NP B-NP
factor-beta NN I-NP I-NP
( ( O O
TGF-beta NN B-NP B-NP
) ) O O
inhibits VBZ B-VP B-VP
B NN B-NP B-NP
cell NN I-NP I-NP
Ig NN I-NP I-NP
secretion NN I-NP I-NP
and CC O I-CC
reduces VBZ B-VP B-VP
B NN B-NP B-NP
cell NN I-NP I-NP
membrane NN I-NP I-NP
Ig NN I-NP I-NP
expression NN I-NP I-NP
. . O O

The DT B-NP B-NP
addition NN I-NP I-NP
of IN B-PP B-PP
TGF-beta NN B-NP B-NP
to TO B-PP B-PP
human JJ B-NP B-NP
B NN I-NP I-NP
lymphocyte NN I-NP I-NP
cultures NNS I-NP I-NP
stimulated VBN B-VP B-VP
with IN B-PP B-PP
Staphylococcus FW B-NP B-NP
aureus FW I-NP I-NP
Cowan NN I-NP I-NP
strain NN I-NP I-NP
I NN I-NP I-NP
and CC O I-NP
IL-2 NN B-NP I-NP
completely RB B-ADVP B-ADVP
inhibited VBD B-VP B-VP
B NN B-NP B-NP
cell NN I-NP I-NP
Ig NN I-NP I-NP
secretion NN I-NP I-NP
( ( O O
greater JJR B-ADVP B-NP
than IN B-PP I-NP
90 CD B-NP I-NP
% NN I-NP I-NP
) ) O O
and CC O I-CC
decreased VBD B-VP B-VP
B NN O B-NP
cell NN O I-NP
surface NN O I-NP
IgM NN B-NP I-NP
, , O O
IgD NN B-NP B-NP
, , O O
kappa NN B-NP B-NP
L NN I-NP I-NP
chain NN I-NP I-NP
, , O O
and CC O I-CC
lambda NN B-NP B-NP
L NN I-NP I-NP
chain NN I-NP I-NP
expression NN B-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
TGF-beta NN B-NP B-NP
had VBD B-VP B-VP
only RB B-NP B-NP
minimal JJ I-NP I-NP
effects NNS I-NP I-NP
on IN B-PP B-PP
two CD B-NP B-NP
other JJ I-NP I-NP
B NN I-NP I-NP
cell NN I-NP I-NP
membrane NN I-NP I-NP
proteins NNS I-NP I-NP
, , O O
HLA-DR NN B-NP B-NP
and CC O I-NP
CD20 NN B-NP I-NP
. . O O

Internal JJ B-NP B-NP
labeling NN I-NP I-NP
with IN B-PP B-PP
(35S)methionine NN B-NP B-NP
and CC O I-NP
immunoprecipitation NN B-NP I-NP
with IN B-PP B-PP
anti-IgM JJ B-NP B-NP
, , I-NP O
anti-kappa JJ I-NP I-NP
, , I-NP O
and CC I-NP I-NP
anti-lambda JJ I-NP I-NP
antibodies NNS I-NP I-NP
revealed VBD B-VP B-VP
a DT B-NP B-NP
striking JJ I-NP I-NP
reduction NN I-NP I-NP
in IN B-PP B-PP
kappa NN B-NP B-NP
L NN I-NP I-NP
chain NN I-NP I-NP
in IN B-PP B-PP
the DT I-PP B-NP
presence NN I-PP I-NP
of IN I-PP B-PP
TGF-beta NN B-NP B-NP
. . O O

A DT B-NP B-NP
less RBR I-NP I-NP
pronounced JJ I-NP I-NP
reduction NN I-NP I-NP
in IN B-PP B-PP
lambda NN B-NP B-NP
L NN I-NP I-NP
chain NN I-NP I-NP
and CC O I-CC
microH NN B-NP B-NP
chain NN I-NP I-NP
was VBD B-VP B-VP
also RB I-VP I-VP
noted VBN I-VP I-VP
. . O O

Northern NN B-NP B-NP
blot NN I-NP I-NP
analysis NN I-NP I-NP
of IN B-PP B-PP
RNA NN B-NP B-NP
purified VBN B-VP B-VP
from IN B-PP B-PP
B NN B-NP B-NP
cells NNS I-NP I-NP
treated VBN B-VP B-VP
with IN B-PP B-PP
TGF-beta NN B-NP B-NP
for IN B-PP B-PP
varying VBG B-NP B-VP
time NN I-NP B-NP
intervals NNS I-NP I-NP
revealed VBD B-VP B-VP
a DT B-NP B-NP
significant JJ I-NP I-NP
decrease NN I-NP I-NP
in IN B-PP B-PP
steady JJ B-NP B-NP
state NN I-NP I-NP
kappa NN I-NP I-NP
and CC I-NP I-NP
lambda NN I-NP I-NP
L NN I-NP I-NP
chain NN I-NP I-NP
mRNA NN I-NP I-NP
levels NNS I-NP I-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
a DT B-NP B-NP
significant JJ I-NP I-NP
decrease NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
switch NN I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
membrane NN I-NP I-NP
forms NNS I-NP I-NP
of IN B-PP B-PP
mu NN B-NP B-NP
and CC O I-NP
gamma NN B-NP I-NP
to TO B-PP B-PP
their PRP$ B-NP B-NP
respective JJ I-NP I-NP
secreted JJ I-NP I-NP
forms NNS I-NP I-NP
was VBD B-VP B-VP
noted VBN I-VP I-VP
in IN B-PP B-PP
the DT I-PP B-NP
presence NN I-PP I-NP
of IN I-PP B-PP
TGF-beta NN B-NP B-NP
. . O O

Nuclear JJ B-NP B-NP
run-on JJ I-NP I-NP
experiments NNS I-NP I-NP
demonstrated VBD B-VP B-VP
decreased VBN B-NP I-VP
transcription NN I-NP B-NP
of IN B-PP B-PP
kappa NN B-NP B-NP
L NN I-NP I-NP
chain NN I-NP I-NP
. . O O

The DT B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
TGF-beta NN B-NP B-NP
on IN B-PP B-PP
two CD B-NP B-NP
transcriptional JJ I-NP I-NP
regulatory JJ I-NP I-NP
factors NNS I-NP I-NP
, , O O
Oct-2 NN B-NP B-NP
and CC O I-CC
nuclear JJ B-NP B-NP
factor NN I-NP I-NP
( ( O O
NF NN B-NP I-NN
) ) O O
kappa NN B-NP B-NP
B NN I-NP I-NP
, , O O
known VBN B-VP B-VP
to TO I-VP I-VP
be VB I-VP I-VP
important JJ B-ADJP B-ADJP
in IN B-PP B-PP
Ig NN B-NP B-NP
gene NN I-NP I-NP
transcription NN I-NP I-NP
were VBD B-VP B-VP
examined VBN I-VP I-VP
. . O O

Oct-2 NN B-NP B-NP
mRNA NN I-NP I-NP
levels NNS I-NP I-NP
and CC O I-CC
both DT B-NP B-NP
Oct-2 NN B-NP I-NP
and CC O I-NP
NF-kappa NN B-NP I-NP
B NN I-NP I-NP
proteins NNS B-NP I-NP
in IN B-PP B-PP
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
were VBD B-VP B-VP
not RB I-VP I-VP
altered VBN I-VP I-VP
by IN B-PP B-PP
treatment NN B-NP B-NP
with IN B-PP B-PP
TGF-beta NN B-NP B-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
levels NNS B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
transcriptional JJ I-NP I-NP
factor NN I-NP I-NP
AP-1 NN I-NP I-NP
, , O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
not RB I-VP I-VP
known VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
important JJ B-ADJP B-ADJP
in IN B-PP B-PP
B NN B-NP B-NP
cell NN I-NP I-NP
Ig NN I-NP I-NP
production NN I-NP I-NP
, , O O
were VBD B-VP B-VP
reduced VBN I-VP I-VP
by IN B-PP B-PP
TGF-beta NN B-NP B-NP
. . O O

These DT B-NP B-NP
findings NNS I-NP I-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-SBAR
TGF-beta NN B-NP B-NP
decreases VBZ B-VP B-VP
B NN B-NP B-NP
lymphocyte NN I-NP I-NP
Ig NN I-NP I-NP
secretion NN I-NP I-NP
by IN B-PP B-PP
inhibiting VBG B-VP B-VP
the DT B-NP B-NP
synthesis NN I-NP I-NP
of IN B-PP B-PP
Ig NN B-NP B-NP
mRNA NN I-NP I-NP
and CC O I-CC
inhibiting VBG B-VP B-VP
the DT B-NP B-NP
switch NN I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
membrane NN I-NP I-NP
form NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
secreted JJ I-NP I-NP
forms NNS I-NP I-NP
of IN B-PP B-PP
mu NN B-NP B-NP
and CC O I-NP
gamma NN B-NP I-NP
mRNA NN B-NP I-NP
. . O O

The DT B-NP B-NP
mechanism NN I-NP I-NP
by IN B-PP B-PP
which WDT B-NP B-NP
TGF-beta NN B-NP B-NP
inhibits VBZ B-VP B-VP
Ig NN B-NP B-NP
chain NN I-NP I-NP
synthesis NN I-NP I-NP
is VBZ B-VP B-VP
unclear JJ B-ADJP B-ADJP
although IN B-SBAR B-SBAR
it PRP B-NP B-NP
does VBZ B-VP B-VP
not RB I-VP I-VP
involve VB I-VP I-VP
inhibition NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
binding NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
or CC O I-NP
Oct-2 NN B-NP I-NP
to TO B-PP B-PP
their PRP$ B-NP B-NP
respective JJ I-NP I-NP
target NN I-NP I-NP
sequences NNS I-NP I-NP
. . O O

Differentiation-associated JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
Epstein-Barr JJ I-NP I-NP
virus NN I-NP I-NP
BZLF1 NN I-NP I-NP
transactivator NN I-NP I-NP
protein NN I-NP I-NP
in IN B-PP B-PP
oral JJ B-NP B-NP
hairy JJ I-NP I-NP
leukoplakia NN I-NP I-NP
. . O O

The DT B-NP B-NP
BZLF1 NN I-NP I-NP
protein NN I-NP I-NP
of IN B-PP B-PP
Epstein-Barr JJ B-NP B-NP
virus NN I-NP I-NP
( ( O O
EBV NN B-NP B-NP
) ) O O
is VBZ B-VP B-VP
a DT B-NP B-NP
key JJ I-NP I-NP
immediate-early JJ I-NP I-NP
protein NN I-NP I-NP
which WDT B-NP B-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
shown VBN I-VP I-VP
to TO I-VP I-VP
disrupt VB I-VP I-VP
virus NN B-NP B-NP
latency NN I-NP I-NP
in IN B-PP B-PP
EBV-infected JJ B-NP B-NP
B NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
generated VBN I-VP I-VP
a DT B-NP B-NP
monoclonal JJ I-NP I-NP
antibody NN I-NP I-NP
, , O O
BZ1 NN B-NP B-NP
, , O O
to TO B-PP B-PP
BZLF1 NN B-NP B-NP
which WDT B-NP B-NP
reacts VBZ B-VP B-VP
in IN B-PP B-PP
immunohistology NN B-NP B-NP
, , O O
immunoblotting NN B-NP B-NP
, , O O
and CC O I-CC
immunoprecipitation NN B-NP B-NP
and CC O I-CC
which WDT B-NP B-NP
recognizes VBZ B-VP B-VP
both CC O I-VP
the DT B-NP B-NP
active JJ I-NP I-NP
, , I-NP O
dimeric JJ I-NP I-NP
form NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
inactive JJ I-NP I-NP
, , I-NP O
monomeric JJ I-NP I-NP
form NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
protein NN I-NP I-NP
. . O O

Biopsies NNS B-NP B-NP
of IN B-PP B-PP
oral JJ B-NP B-NP
hairy JJ I-NP I-NP
leukoplakia NN I-NP I-NP
, , O O
an DT B-NP B-NP
AIDS-associated JJ I-NP I-NP
lesion NN I-NP I-NP
characterized VBN B-VP B-VP
by IN B-PP B-PP
high-level JJ B-NP B-NP
EBV NN I-NP I-NP
replication NN I-NP I-NP
, , O O
were VBD B-VP B-VP
examined VBN I-VP I-VP
by IN B-PP B-PP
immunohistochemistry NN B-NP B-NP
using VBG B-VP B-VP
the DT B-NP B-NP
BZ1 NN I-NP I-NP
monoclonal JJ I-NP I-NP
antibody NN I-NP I-NP
. . O O

A DT B-NP B-NP
differentiation-associated JJ I-NP I-NP
pattern NN I-NP I-NP
of IN B-PP B-PP
BZLF1 NN B-NP B-NP
expression NN I-NP I-NP
was VBD B-VP B-VP
observed VBN I-VP I-VP
, , O O
BZ1 NN B-NP B-NP
reacting VBG B-VP B-VP
with IN B-PP B-PP
nuclei NNS B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
upper JJ I-NP I-NP
spinous JJ I-NP I-NP
layer NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
lesion NN I-NP I-NP
. . O O

This DT B-NP B-NP
finding NN I-NP I-NP
suggests VBZ B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
BZLF1 NN I-NP I-NP
promoter NN I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
regulated VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
degree NN I-NP I-NP
of IN B-PP B-PP
squamous JJ B-NP B-NP
differentiation NN I-NP I-NP
. . O O

A DT B-NP B-NP
comparison NN I-NP I-NP
of IN B-PP B-PP
in FW B-NP B-NP
situ FW I-NP I-NP
hybridization NN I-NP I-NP
to TO B-PP B-PP
EBV NN B-NP B-NP
DNA NN I-NP I-NP
and CC O I-CC
viral JJ B-NP B-NP
capsid NN I-NP I-NP
antigen NN I-NP I-NP
staining VBG I-NP B-VP
with IN B-PP B-PP
BZ1 NN B-NP B-NP
reactivity NN I-NP I-NP
suggested VBD B-VP B-VP
that IN B-SBAR B-PP
BZLF1 NN B-NP B-NP
expression NN I-NP I-NP
precedes VBZ B-VP B-VP
rampant JJ B-NP B-NP
virus NN I-NP I-NP
replication NN I-NP I-NP
. . O O

The DT B-NP B-NP
inability NN I-NP I-NP
to TO B-VP B-VP
detect VB I-VP I-VP
EBV NN B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
lower RBR I-NP I-NP
epithelial JJ I-NP I-NP
layers NNS I-NP I-NP
of IN B-PP B-PP
oral JJ B-NP B-NP
hairy JJ I-NP I-NP
leukoplakia NN I-NP I-NP
raises VBZ B-VP B-VP
questions NNS B-NP B-NP
concerning VBG B-PP B-VP
the DT B-NP B-NP
nature NN I-NP I-NP
of IN B-PP B-PP
EBV NN B-NP B-NP
latency NN B-NP I-NP
and CC O I-NP
persistence NN B-NP I-NP
in IN B-PP B-PP
stratified JJ B-NP B-NP
squamous JJ I-NP I-NP
epithelium NN I-NP I-NP
. . O O

Transactivation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
promoter NN I-NP I-NP
by IN B-PP B-PP
human JJ B-NP B-NP
herpesvirus NN I-NP I-NP
6 CD I-NP B-NP
( ( O O
HHV-6 NN B-NP I-NP
) ) O O
strains VBZ B-NP B-VP
GS NN B-NP B-NP
and CC O I-NP
Z-29 NN B-NP I-NP
in IN B-PP B-PP
primary JJ B-NP B-NP
human JJ I-NP I-NP
T NN I-NP I-NP
lymphocytes NNS I-NP I-NP
and CC O I-CC
identification NN B-NP B-NP
of IN B-PP B-PP
transactivating VBG B-NP B-NP
HHV-6 NN I-NP I-NP
( ( I-NP O
GS NN I-NP I-NN
) ) I-NP O
gene NN I-NP B-NP
fragments NNS I-NP I-NP
. . O O

Human JJ B-NP B-NP
herpesvirus NN I-NP I-NP
6 CD I-NP I-NP
( ( O O
HHV-6 NN B-NP B-NP
) ) O O
can MD B-VP B-VP
activate VB I-VP I-VP
the DT O B-NP
human JJ B-NP I-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
( ( O O
HIV NN B-NP I-NN
) ) O O
promoter NN B-NP B-NP
and CC O I-CC
accelerate VB B-VP B-VP
cytopathic JJ B-NP B-NP
effects NNS I-NP I-NP
in IN B-PP B-PP
HIV-infected JJ B-NP B-NP
human JJ I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

This DT B-NP B-NP
study NN I-NP I-NP
examines VBZ B-VP B-VP
the DT B-NP B-NP
regions NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HIV NN I-NP I-NP
promoter NN I-NP I-NP
required VBN B-VP B-VP
for IN B-PP B-PP
HHV-6 NN B-NP B-NP
transactivation NN I-NP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
heterogeneous JJ I-NP I-NP
population NN I-NP I-NP
of IN B-PP B-PP
primary JJ B-NP B-NP
human JJ I-NP I-NP
T NN I-NP I-NP
lymphocytes NNS I-NP I-NP
with IN B-PP B-PP
or CC B-PP I-PP
without IN B-PP I-PP
antigenic JJ B-NP B-NP
stimulation NN I-NP I-NP
. . O O

Two CD B-NP B-NP
different JJ I-NP I-NP
strains NNS I-NP I-NP
of IN B-PP B-PP
HHV-6 NN B-NP B-NP
, , O O
GS NN B-NP I-NP
and CC O I-NP
Z29 NN B-NP I-NP
, , O O
transactivated VBD B-VP B-VP
the DT B-NP B-NP
HIV NN I-NP I-NP
promoter NN I-NP I-NP
. . O O

The DT B-NP B-NP
GS NN I-NP I-NP
strain NN I-NP I-NP
transactivated VBD B-VP B-VP
the DT B-NP B-NP
promoter NN I-NP I-NP
in IN B-PP B-PP
both CC B-NP I-CC
stimulated VBN I-NP B-VP
and CC I-NP I-CC
resting VBG I-NP B-VP
T NN I-NP B-NP
cells NNS I-NP I-NP
, , O O
while IN B-SBAR B-SBAR
the DT B-NP B-NP
Z29 NN I-NP I-NP
strain NN I-NP I-NP
increased VBD B-VP B-VP
HIV NN B-NP B-NP
promoter NN I-NP I-NP
activity NN I-NP I-NP
only RB B-PP B-ADVP
in IN I-PP B-PP
stimulated VBN B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

Three CD B-NP B-NP
DNA NN I-NP I-NP
clones NNS I-NP I-NP
containing VBG B-VP B-VP
HHV-6 NN B-NP B-NP
( ( I-NP O
GS NN I-NP B-NP
) ) I-NP O
genomic JJ I-NP B-NP
fragments NNS I-NP I-NP
transactivated VBD B-VP B-VP
the DT B-NP B-NP
HIV NN I-NP I-NP
promoter NN I-NP I-NP
in IN B-PP B-PP
cotransfected VBN B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

A DT B-NP B-NP
21.4-kb JJ I-NP I-NP
DNA NN I-NP I-NP
clone NN I-NP I-NP
, , O O
pZVB70 NN B-NP B-NP
, , O O
showed VBD B-VP B-VP
the DT B-NP B-NP
highest JJS I-NP I-NP
transactivating NN I-NP I-NP
ability NN I-NP I-NP
, , O O
while IN B-SBAR B-SBAR
two CD B-NP B-NP
other JJ I-NP I-NP
DNA NN I-NP I-NP
fragments NNS I-NP I-NP
, , O O
pZVB10 NN B-NP B-NP
( ( O O
6.2 CD B-NP B-NP
kb NN I-NP I-NP
) ) O O
and CC O I-CC
pZVH14 NN B-NP B-NP
( ( O O
8.7 CD B-NP B-NP
kb NN I-NP I-NP
) ) O O
, , O O
showed VBD B-VP B-VP
lower JJR B-NP B-NP
activity NN I-NP I-NP
. . O O

One CD B-NP B-NP
of IN B-PP B-PP
these DT B-NP B-NP
clones NNS I-NP I-NP
, , O O
pZVH14 NN B-NP B-NP
, , O O
activated VBD B-VP B-VP
the DT B-NP B-NP
HIV NN I-NP I-NP
promoter NN I-NP I-NP
construct NN I-NP I-NP
containing VBG B-VP B-VP
a DT B-NP B-NP
mutation NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
NF NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
site NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
this DT B-NP B-NP
mutated VBN I-NP I-NP
NF NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
promoter NN I-NP I-NP
was VBD B-VP B-VP
not RB I-VP I-VP
transactivated VBN I-VP I-VP
during IN B-PP B-PP
HHV-6 NN B-NP B-NP
( ( I-NP O
GS NN I-NP I-NN
) ) I-NP O
infection NN I-NP B-NP
or CC B-PP B-PP
after IN B-PP B-PP
cotransfection NN B-NP B-NP
with IN B-PP B-PP
pZVB70 NN B-NP B-NP
or CC O I-NP
pZVB10 NN B-NP I-NP
. . O O

These DT B-NP B-NP
data NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
NF NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
sites NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HIV NN I-NP I-NP
promoter NN I-NP I-NP
are VBP B-VP B-VP
essential JJ B-ADJP B-ADJP
for IN B-PP B-PP
its PRP$ B-NP B-NP
transactivation NN I-NP I-NP
during IN B-PP B-PP
HHV-6 NN B-NP B-NP
( ( I-NP O
GS NN I-NP I-NN
) ) I-NP O
infection NN I-NP B-NP
. . O O

By IN B-PP B-PP
increasing VBG B-VP B-VP
HIV NN B-NP B-NP
promoter NN I-NP I-NP
activity NN I-NP I-NP
in IN B-PP B-PP
primary JJ B-NP B-NP
T NN I-NP I-NP
lymphocytes NNS I-NP I-NP
, , O O
HHV-6 NN B-NP B-NP
may MD B-VP B-VP
consequently RB I-VP I-VP
increase VB I-VP I-VP
HIV NN B-NP B-NP
replication NN I-NP I-NP
, , O O
leading VBG B-VP B-PP
to TO B-PP B-PP
an DT B-NP B-NP
increase NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
cytopathic JJ I-NP I-NP
effect NN I-NP I-NP
on IN B-PP B-PP
coinfected VBN B-NP B-NP
human JJ I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

The DT B-NP B-NP
rhombotin NN I-NP I-NP
family NN I-NP I-NP
of IN B-PP B-PP
cysteine-rich JJ B-NP B-NP
LIM-domain JJ I-NP I-NP
oncogenes NNS I-NP I-NP
: : O O
distinct JJ B-NP B-NP
members NNS I-NP I-NP
are VBP B-VP B-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
T-cell NN B-NP B-NP
translocations NNS I-NP I-NP
to TO B-PP B-PP
human JJ B-NP B-NP
chromosomes NNS I-NP I-NP
11p15 NN B-NP I-NP
and CC O I-NP
11p13 NN B-NP I-NP
. . O O

A DT B-NP B-NP
chromosomal NN I-NP I-NP
translocation NN I-NP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
T-cell NN I-NP I-NP
leukemia NN I-NP I-NP
involving VBG B-VP B-VP
the DT B-NP B-NP
short JJ I-NP I-NP
arm NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
chromosome NN I-NP I-NP
11 CD I-NP I-NP
at IN B-PP B-PP
band NN B-NP B-NP
11p15 NN I-NP I-NP
disrupts VBZ B-VP B-VP
the DT B-NP B-NP
rhombotin NN I-NP I-NP
gene NN I-NP I-NP
. . O O

This DT B-NP B-NP
gene NN I-NP I-NP
encodes VBZ B-VP B-VP
a DT B-NP B-NP
protein NN I-NP I-NP
with IN B-PP B-PP
duplicated JJ B-NP B-NP
cysteine-rich JJ I-NP I-NP
regions NNS I-NP I-NP
called VBN B-VP B-VP
LIM NN B-NP B-NP
domains NNS I-NP I-NP
, , O O
which WDT B-NP B-NP
show VBP B-VP B-VP
homology NN B-NP B-NP
to TO B-PP B-PP
zinc-binding JJ B-NP B-NP
proteins NNS I-NP I-NP
and CC B-PP I-CC
to TO B-PP B-PP
iron-sulfur JJ B-NP B-NP
centers NNS I-NP I-NP
of IN B-PP B-PP
ferredoxins NNS B-NP B-NP
. . O O

Two CD B-NP B-NP
homologues NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
rhombotin NN I-NP I-NP
gene NN I-NP I-NP
have VBP B-VP B-VP
now RB I-VP I-VP
been VBN I-VP I-VP
isolated VBN I-VP I-VP
. . O O

One CD B-NP B-NP
of IN B-PP B-PP
these DT B-NP B-NP
, , O O
designated VBN B-VP B-NP
Rhom-2 NN B-NP I-NP
, , O O
is VBZ B-VP B-VP
located JJ B-ADJP B-ADJP
on IN B-PP B-PP
human JJ B-NP B-NP
chromosome NN I-NP I-NP
11 CD I-NP I-NP
at IN B-PP B-PP
band NN B-NP B-NP
11p13 NN I-NP I-NP
, , O O
where WRB B-ADVP B-ADVP
a DT B-NP B-NP
cluster NN I-NP I-NP
of IN B-PP B-PP
T-cell NN B-NP B-NP
leukemia-specific JJ I-NP I-NP
translocations NNS I-NP I-NP
occur VBP B-VP I-NP
; : O O
all DT B-NP B-NP
translocation NN I-NP I-NP
breakpoints NNS I-NP I-NP
at IN B-PP B-PP
11p13 NN B-NP B-NP
are VBP B-VP B-VP
upstream JJ B-ADJP B-ADJP
of IN B-PP B-PP
the DT B-NP B-NP
Rhom-2 NN I-NP I-NP
gene NN I-NP I-NP
. . O O

Human JJ O B-NP
and CC O I-NP
mouse NN B-NP I-NP
Rhom-2 NN B-NP I-NP
are VBP B-VP B-VP
highly RB I-VP I-VP
conserved VBN I-VP I-VP
and CC O I-CC
, , O O
like IN B-PP B-PP
rhombotin NN B-NP B-NP
, , O O
encode VBP B-VP B-VP
two CD B-NP B-NP
tandem JJ I-NP I-NP
cysteine-rich JJ I-NP I-NP
LIM NN I-NP I-NP
domains NNS I-NP I-NP
. . O O

Rhom-2 NN B-NP B-NP
mRNA NN I-NP I-NP
is VBZ B-VP B-VP
expressed VBN I-VP I-VP
in IN B-PP B-PP
early JJ B-NP B-NP
mouse NN I-NP I-NP
development NN I-NP I-NP
in IN B-PP B-PP
central JJ B-NP B-NP
nervous JJ I-NP I-NP
system NN I-NP I-NP
, , O O
lung NN B-NP B-NP
, , O O
kidney NN B-NP B-NP
, , O O
liver NN B-NP B-NP
, , O O
and CC O I-CC
spleen NN B-NP B-NP
but CC O I-CC
only RB B-NP B-NP
very RB I-NP I-NP
low JJ I-NP I-NP
levels NNS I-NP I-NP
occur VBP B-VP B-VP
in IN B-PP B-PP
thymus NN B-NP B-NP
. . O O

The DT B-NP B-NP
other JJ I-NP I-NP
gene NN I-NP I-NP
, , O O
designated VBN B-VP B-VP
Rhom-3 NN B-NP B-NP
, , O O
is VBZ B-VP B-VP
not RB O I-RB
on IN B-PP B-PP
chromosome NN B-NP B-NP
11 CD I-NP I-NP
but CC B-CONJP I-CC
also RB I-CONJP B-ADVP
retains VBZ B-VP B-VP
homology NN B-NP B-NP
to TO B-PP B-PP
the DT B-NP B-NP
LIM NN I-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
rhombotin NN B-NP B-NP
. . O O

Since IN B-SBAR B-PP
the DT B-NP B-NP
Rhom-2 NN I-NP I-NP
gene NN I-NP I-NP
is VBZ B-VP B-VP
such JJ B-NP B-NP
a DT I-NP I-NP
common JJ I-NP I-NP
site NN I-NP I-NP
of IN B-PP B-PP
chromosomal JJ B-NP B-NP
damage NN I-NP I-NP
in IN B-PP B-PP
T-cell NN B-NP B-NP
tumors NNS I-NP I-NP
, , O O
the DT B-NP B-NP
consistency NN I-NP I-NP
of IN B-PP B-PP
translocations NNS B-NP B-NP
near IN B-PP B-PP
the DT B-NP B-NP
rhombotin NN I-NP I-NP
gene NN I-NP I-NP
was VBD B-VP B-VP
further RB I-VP I-VP
examined VBN I-VP I-VP
. . O O

A DT B-NP B-NP
second JJ I-NP I-NP
translocation NN I-NP I-NP
adjacent JJ B-ADJP B-ADJP
to TO B-PP B-PP
rhombotin NN B-NP B-NP
was VBD B-VP B-VP
found VBN B-VP I-VP
and CC O I-CC
at IN B-PP B-PP
the DT B-NP B-NP
same JJ I-NP I-NP
position NN I-NP I-NP
as IN B-PP B-PP
in IN B-PP B-PP
the DT B-NP B-NP
previous JJ I-NP I-NP
example NN I-NP I-NP
. . O O

Therefore RB B-ADVP B-ADVP
, , O O
chromosome NN B-NP B-NP
bands NNS I-NP I-NP
11p15 NN B-NP I-NP
( ( O O
rhombotin NN B-NP B-NP
) ) O O
and CC O I-CC
11p13 NN B-NP B-NP
( ( O O
Rhom-2 NN B-NP I-NP
) ) O O
are VBP B-VP B-VP
consistent JJ B-NP B-NP
sites NNS I-NP I-NP
of IN B-PP B-PP
chromosome NN B-NP B-NP
translocation NN I-NP I-NP
in IN B-PP B-PP
T-cell NN B-NP B-NP
leukemia NN I-NP I-NP
, , O O
with IN B-SBAR B-PP
the DT B-NP B-NP
11p15 NN I-NP I-NP
target NN I-NP I-NP
more RBR B-VP B-ADVP
rarely RB I-VP B-ADJP
involved VBN I-VP I-ADJP
. . O O

The DT B-NP B-NP
results NNS I-NP I-NP
define VBP B-VP B-VP
the DT B-NP B-NP
rhombotin NN I-NP I-NP
gene NN I-NP I-NP
family NN I-NP I-NP
as IN B-PP B-PP
a DT B-NP B-NP
class NN I-NP I-NP
of IN B-PP B-PP
T-cell NN B-NP B-NP
oncogenes NNS I-NP I-NP
with IN B-PP B-PP
duplicated JJ B-NP B-NP
cysteine-rich JJ I-NP I-NP
LIM NN I-NP I-NP
domains NNS I-NP I-NP
. . O O

The DT B-NP B-NP
human JJ I-NP I-NP
myelomonocytic JJ I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
U-937 NN I-NP I-NP
as IN B-PP B-PP
a DT B-NP B-NP
model NN I-NP I-NP
for IN B-PP B-PP
studying VBG B-VP B-VP
alterations NNS B-NP B-NP
in IN B-PP B-PP
steroid-induced JJ B-NP B-NP
monokine NN I-NP I-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
: : O O
marked JJ B-NP B-NP
enhancement NN I-NP I-NP
of IN B-PP B-PP
lipopolysaccharide-stimulated JJ B-NP B-NP
interleukin-1 NN I-NP I-NP
beta NN I-NP I-NP
messenger NN I-NP I-NP
RNA NN I-NP I-NP
levels NNS I-NP I-NP
by IN B-PP B-PP
1,25-dihydroxyvitamin NN B-NP B-NP
D3 NN I-NP I-NP
. . O O

The DT B-NP B-NP
active JJ I-NP I-NP
metabolite NN I-NP I-NP
of IN B-PP B-PP
vitamin NN B-NP B-NP
D NN I-NP I-NP
, , O O
1,25-dihydroxyvitamin NN B-NP B-NP
D3 NN I-NP I-NP
( ( O O
1,25-(OH)2D3 NN B-NP B-NP
) ) O O
, , O O
is VBZ B-VP B-VP
a DT B-NP B-NP
potent JJ I-NP I-NP
regulator NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
monocyte/macrophage JJ I-NP I-NP
function NN I-NP I-NP
in FW B-ADVP B-NP
vitro FW I-ADVP I-NP
. . O O

To TO B-VP B-VP
establish VB I-VP I-VP
a DT B-NP B-NP
model NN I-NP I-NP
for IN B-PP B-PP
1,25-(OH)2D3 NN B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
monocyte NN I-NP I-NP
monokine NN I-NP I-NP
synthesis NN I-NP I-NP
, , O O
three CD B-NP B-NP
human JJ I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
( ( O O
U-937 NN B-NP B-NP
, , O O
THP-1 NN B-NP I-NP
, , O O
and CC O I-CC
HL-60 NN B-NP B-NP
) ) O O
were VBD B-VP B-VP
examined VBN I-VP I-VP
for IN B-PP B-PP
: : O O
1 LS B-LST B-NP
) ) O O
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
functional JJ B-NP B-NP
1,25-(OH)2D3 NN I-NP I-NP
receptors NNS I-NP I-NP
; : O O
2 LS B-LST B-NP
) ) O O
the DT B-NP B-NP
accumulation NN I-NP I-NP
of IN B-PP B-PP
interleukin-1 NN B-NP B-NP
beta NN I-NP I-NP
( ( O O
IL-1 NN B-NP B-NP
beta NN I-NP I-NP
) ) O O
mRNA NN B-NP B-NP
and CC O I-NP
IL-1 NN B-NP I-NP
beta NN I-NP I-NP
protein NN I-NP I-NP
in IN B-PP B-PP
response NN I-PP B-NP
to TO I-PP B-PP
lipopolysaccharide NN B-NP B-NP
( ( O O
LPS NN B-NP B-NP
) ) O O
; : O O
and CC O I-CC
3 LS B-LST B-NP
) ) O O
the DT B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
response NN I-NP I-NP
by IN B-PP B-PP
1,25-(OH)2D3 NN B-NP B-NP
. . O O

All DT B-NP B-NP
three CD I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
expressed VBD B-VP B-VP
vitamin NN B-NP B-NP
D NN I-NP I-NP
receptor NN I-NP I-NP
and CC O I-CC
had VBD B-VP B-VP
increased VBN I-VP B-NP
levels NNS B-NP I-NP
of IN B-PP B-PP
IL-1 NN B-NP B-NP
beta NN I-NP I-NP
mRNA NN I-NP I-NP
in IN B-PP B-PP
response NN I-PP B-NP
to TO I-PP B-PP
LPS NN B-NP B-NP
. . O O

Preincubation NN B-NP B-NP
of IN B-PP B-PP
cells NNS B-NP B-NP
with IN B-PP B-PP
1,25-(OH)2D3 NN B-NP B-NP
augmented VBD B-VP B-VP
IL-1 NN B-NP B-NP
beta NN I-NP I-NP
mRNA NN I-NP I-NP
levels NNS I-NP I-NP
only RB B-PP B-ADVP
in IN I-PP B-PP
U-937 NN B-NP B-NP
and CC O I-NP
HL-60 NN B-NP I-NP
cells NNS B-NP I-NP
. . O O

From IN B-PP B-PP
these DT B-NP B-NP
data NNS I-NP I-NP
, , O O
and CC O I-CC
taking VBG B-VP B-VP
into IN B-PP B-PP
consideration NN B-NP B-NP
their PRP$ B-NP B-NP
state NN B-NP I-NP
of IN B-PP B-PP
differentiation NN B-NP B-NP
and CC O I-NP
relative JJ B-NP I-NP
ease NN I-NP I-NP
of IN B-PP B-PP
culture NN B-NP B-NP
, , O O
U-937 NN B-NP B-NP
was VBD B-VP B-VP
chosen VBN I-VP I-VP
over IN B-PP B-PP
HL-60 NN B-NP B-NP
and CC O I-NP
THP-1 NN B-NP I-NP
as IN B-PP B-PP
the DT B-NP B-NP
cell NN I-NP I-NP
line NN I-NP I-NP
we PRP B-NP B-NP
further RB B-ADVP B-ADVP
characterized VBD B-VP B-VP
. . O O

In IN B-PP B-PP
U-937 NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
optimum JJ B-NP B-NP
time NN B-NP I-NP
and CC O I-NP
dose NN B-NP I-NP
of IN B-PP B-PP
pretreatment NN B-NP B-NP
with IN B-PP B-PP
1,25-(OH)2D3 NN B-NP B-NP
were VBD B-VP B-VP
determined VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
12-24 CD B-NP B-NP
h NN I-NP I-NP
at IN B-PP B-PP
a DT B-NP B-NP
receptor NN I-NP I-NP
saturating JJ I-NP I-NP
concentration NN I-NP I-NP
of IN B-PP B-PP
1,25-(OH)2D3 NN B-NP B-NP
( ( O O
10 CD B-NP B-NP
nM NN I-NP I-NP
) ) O O
. . O O

Preincubation NN B-NP B-NP
of IN B-PP B-PP
cells NNS B-NP B-NP
with IN B-PP B-PP
1,25-(OH)2D3 NN B-NP B-NP
had VBD B-VP B-VP
no DT B-NP B-NP
effect NN I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
time NN I-NP I-NP
course NN I-NP I-NP
of IN B-PP B-PP
IL-1 NN B-NP B-NP
beta NN I-NP I-NP
mRNA NN I-NP I-NP
appearance NN I-NP I-NP
in IN B-PP B-PP
response NN I-PP B-NP
to TO I-PP B-PP
LPS NN B-NP B-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
exposure NN B-NP B-NP
of IN B-PP B-PP
U-937 NN B-NP B-NP
cells NNS I-NP I-NP
to TO B-PP B-PP
1,25-(OH)2D3 NN B-NP B-NP
increased VBD B-VP B-VP
by IN B-PP B-PP
200 CD B-NP B-NP
% NN I-NP I-NP
the DT B-NP B-NP
level NN I-NP I-NP
of IN B-PP B-PP
IL-1 NN B-NP B-NP
beta NN I-NP I-NP
mRNA NN I-NP I-NP
detected VBD B-VP B-VP
and CC O I-CC
decreased VBD B-VP B-VP
by IN B-PP B-PP
three CD B-NP B-NP
orders NNS I-NP I-NP
of IN B-PP B-PP
magnitude NN B-NP B-NP
the DT B-NP B-NP
concentration NN I-NP I-NP
of IN B-PP B-PP
LPS NN B-NP B-NP
required VBN B-VP B-VP
to TO I-VP B-VP
achieve VB I-VP I-VP
steady JJ B-NP B-NP
state NN I-NP I-NP
mRNA NN I-NP I-NP
levels NNS I-NP I-NP
equivalent JJ B-ADJP B-ADJP
to TO B-PP B-PP
those DT B-NP B-NP
observed VBN B-VP B-VP
in IN B-PP B-PP
U-937 NN B-NP B-NP
cells NNS I-NP I-NP
not RB B-VP B-VP
preincubated VBN I-VP I-VP
with IN B-PP B-PP
the DT B-NP B-NP
hormone.2+o NN I-NP I-NP

Cortivazol NN B-NP B-NP
mediated VBD I-NP B-VP
induction NN I-NP B-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
messenger NN I-NP I-NP
ribonucleic JJ I-NP I-NP
acid NN I-NP I-NP
in IN B-PP B-PP
wild-type JJ B-NP B-NP
and CC I-NP I-NP
dexamethasone-resistant JJ I-NP I-NP
human JJ I-NP I-NP
leukemic NN I-NP I-NP
( ( I-NP O
CEM NN I-NP B-NP
) ) I-NP O
cells NNS I-NP I-NP
. . O O

Cortivazol NN B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
phenylpyrazolo JJ I-NP I-NP
glucocorticoid NN I-NP I-NP
of IN B-PP B-PP
high JJ B-NP B-NP
potency NN I-NP I-NP
and CC O I-CC
unusual JJ B-NP B-NP
structure NN I-NP I-NP
. . O O

In IN B-PP B-PP
both CC O I-CC
wild-type JJ O B-NP
and CC O I-NP
highly RB O I-NP
dexamethasone NN B-NP I-NP
( ( O O
dex NN B-NP B-NP
) ) O O
-resistant JJ B-NP B-NP
clones NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
leukemic JJ I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
CEM NN I-NP I-NP
, , O O
exposure NN B-NP B-NP
to TO B-PP B-PP
cortivazol NN B-NP B-NP
leads VBZ B-VP B-VP
to TO B-PP B-PP
cell NN B-NP B-NP
death NN I-NP I-NP
. . O O

It PRP B-NP B-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
shown VBN I-VP I-VP
recently RB B-ADVP B-ADVP
that IN B-SBAR B-PP
in IN B-PP B-PP
wild-type JJ B-NP B-NP
CEM NN I-NP I-NP
cells NNS I-NP I-NP
but CC B-PP I-CC
not RB B-PP I-RB
in IN I-PP B-PP
a DT B-NP B-NP
dex-resistant JJ I-NP I-NP
, , I-NP O
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
( ( I-NP O
GR NN I-NP B-NP
) ) I-NP O
-defective JJ I-NP B-NP
clone NN I-NP I-NP
ICR-27 NN I-NP I-NP
TK-3 NN I-NP I-NP
, , O O
dex NN B-NP B-NP
induces VBZ B-VP B-VP
GR NN B-NP B-NP
mRNA NN I-NP I-NP
. . O O

To TO B-VP B-VP
test VB I-VP I-VP
the DT B-NP B-NP
hypothesis NN I-NP I-NP
that IN B-SBAR B-PP
cortivazol NN B-NP B-NP
acts VBZ B-VP B-VP
in IN B-PP B-PP
dex-resistant JJ B-NP B-NP
cells NNS I-NP I-NP
by IN B-PP B-PP
making VBG B-VP B-VP
use NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
residual JJ I-NP I-NP
GR NN I-NP I-NP
found VBN B-VP B-VP
there RB B-ADVP B-ADVP
, , O O
wild-type JJ B-NP B-NP
and CC I-NP I-NP
dex-resistant JJ I-NP I-NP
clones NNS I-NP I-NP
were VBD B-VP B-VP
treated VBN I-VP I-VP
with IN B-PP B-PP
various JJ B-NP B-NP
concentrations NNS I-NP I-NP
of IN B-PP B-PP
cortivazol NN B-NP B-NP
and CC O I-NP
induction NN B-NP I-NP
of IN B-PP B-PP
GR NN B-NP B-NP
mRNA NN I-NP I-NP
was VBD B-VP B-VP
studied VBN I-VP I-VP
. . O O

Cortivazol NN B-NP B-NP
significantly RB B-ADVP B-VP
induced VBD B-VP I-VP
GR NN B-NP B-NP
mRNA NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
normal JJ I-NP I-NP
CEM-C7 NN I-NP I-NP
as RB B-CONJP B-ADVP
well RB I-CONJP I-ADVP
as IN I-CONJP B-PP
in IN B-PP B-PP
two CD B-NP B-NP
classes NNS I-NP I-NP
of IN B-PP B-PP
dex-resistant JJ B-NP B-NP
clones NNS I-NP I-NP
, , O O
although IN B-SBAR B-SBAR
the DT B-NP B-NP
dex-resistant JJ I-NP I-NP
clones NNS I-NP I-NP
needed VBD B-VP B-VP
at IN B-NP B-NP
least JJS I-NP I-NP
10 CD I-NP I-NP
times NNS I-NP I-NP
more JJR I-NP I-NP
cortivazol NN I-NP I-NP
than IN B-PP B-PP
the DT B-NP B-NP
normal JJ I-NP I-NP
cells NNS I-NP I-NP
for IN B-PP B-PP
significant JJ B-NP B-NP
GR NN I-NP I-NP
mRNA NN I-NP I-NP
induction NN I-NP I-NP
. . O O

Increased VBN B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
GR NN B-NP B-NP
mRNA NN I-NP I-NP
were VBD B-VP B-VP
noticed VBN I-VP I-VP
as RB B-ADVP B-ADVP
early RB I-ADVP I-ADVP
as IN B-PP B-PP
3 CD B-NP B-NP
h NN I-NP I-NP
after IN B-PP B-PP
treatment NN B-NP B-NP
. . O O

A DT B-NP B-NP
general JJ I-NP I-NP
correlation NN I-NP I-NP
between IN B-PP B-PP
induction NN B-NP B-NP
of IN B-PP B-PP
GR NN B-NP B-NP
mRNA NN I-NP I-NP
and CC O I-NP
lysis NN B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
normal JJ I-NP I-NP
and CC I-NP I-NP
dex-resistant JJ I-NP I-NP
cells NNS I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
. . O O

Positive JJ B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
GR NN B-NP B-NP
mRNA NN I-NP I-NP
might MD B-VP B-VP
be VB I-VP I-VP
one CD B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
earliest JJS I-NP I-NP
crucial JJ I-NP I-NP
steps NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
lysis NN I-NP I-NP
of IN B-PP B-PP
normal JJ B-NP B-NP
and CC I-NP I-NP
dex-resistant JJ I-NP I-NP
CEM NN I-NP I-NP
cells NNS I-NP I-NP
, , O O
or CC O I-CC
might MD B-VP B-VP
serve VB I-VP I-VP
as IN B-PP B-PP
a DT B-NP B-NP
marker NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
process NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
lysis NN I-NP I-NP
pathway NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
dex-resistant JJ I-NP I-NP
cells NNS I-NP I-NP
is VBZ B-VP B-VP
defective JJ B-ADJP B-ADJP
in IN B-PP B-PP
that IN B-SBAR B-PP
dex-resistant JJ B-NP B-NP
clones NNS I-NP I-NP
needed VBD B-VP B-VP
significantly RB B-NP B-NP
more JJR I-NP I-NP
cortivazol NN I-NP I-NP
than IN B-PP B-PP
the DT B-NP B-NP
normal JJ I-NP I-NP
cells NNS I-NP I-NP
for IN B-PP B-PP
lysis NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
cells NNS I-NP I-NP
. . O O

Expression NN B-NP B-NP
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
receptors NNS I-NP I-NP
on IN B-PP B-PP
alveolar JJ B-NP B-NP
lymphocytes NNS I-NP I-NP
from IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
pulmonary JJ B-NP B-NP
granulomatous JJ I-NP I-NP
diseases NNS I-NP I-NP
. . O O

1,25(OH)2D3 NN B-NP B-NP
is VBZ B-VP B-VP
known VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
produced VBN I-VP I-VP
at IN B-PP B-PP
sites NNS B-NP B-NP
of IN B-PP B-PP
granulomatous JJ B-NP B-NP
reactions NNS I-NP I-NP
. . O O

In IN B-SBAR B-PP
order NN O B-NP
to TO O B-VP
characterize VB B-VP I-VP
the DT B-NP B-NP
cell NN I-NP I-NP
types NNS I-NP I-NP
that WDT B-NP B-NP
are VBP B-VP B-VP
targets NNS B-NP B-NP
for IN B-PP B-PP
this DT B-NP B-NP
immunoregulatory JJ I-NP I-NP
hormone NN I-NP I-NP
, , O O
we PRP B-NP B-NP
have VBP B-VP B-VP
evaluated VBN I-VP I-VP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
receptors NNS I-NP I-NP
on IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
T-lymphocytes NNS I-NP I-NP
and CC O I-CC
those DT B-NP B-NP
recovered VBN B-VP B-VP
from IN B-PP B-PP
the DT B-NP B-NP
lung NN I-NP I-NP
by IN B-PP B-PP
bronchoalveolar JJ B-NP B-NP
lavage NN I-NP I-NP
from IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
pulmonary JJ B-NP B-NP
granulomatous JJ I-NP I-NP
diseases NNS I-NP I-NP
( ( O O
tuberculosis NN B-NP B-NP
and CC O I-NP
sarcoidosis NN B-NP I-NP
) ) O O
and CC B-PP I-CC
from IN B-PP B-PP
normal JJ B-NP B-NP
control NN I-NP I-NP
subjects NNS I-NP I-NP
using VBG B-VP B-VP
combined JJ B-NP B-NP
autoradiographic JJ I-NP I-NP
and CC I-NP I-NP
immunohistochemical JJ I-NP I-NP
techniques NNS I-NP I-NP
. . O O

Lavage NN B-NP B-NP
T-lymphocytes NNS I-NP I-NP
from IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
tuberculosis NN B-NP B-NP
or CC B-PP I-CC
with IN B-PP B-PP
sarcoidosis NN B-NP B-NP
, , O O
but CC B-CONJP I-CC
not RB I-CONJP I-RB
those DT B-NP B-NP
from IN B-PP B-PP
normal JJ B-NP B-NP
control NN I-NP I-NP
subjects NNS I-NP I-NP
, , O O
expressed VBD B-VP B-VP
1,25(OH)2D3 NN B-NP B-NP
receptors NNS I-NP I-NP
as IN B-SBAR B-SBAR
demonstrated VBN B-VP B-VP
by IN B-PP B-PP
binding NN B-NP B-NP
of IN B-PP B-PP
(3H)1,25(OH)2D3 NN B-NP B-NP
, , O O
which WDT B-NP B-NP
was VBD B-VP B-VP
inhibited VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
excess JJ B-NP B-NP
unlabeled JJ I-NP I-NP
1,25(OH)2D3 NN I-NP I-NP
, , B-PP O
but CC I-PP I-CC
not RB B-PP B-ADVP
by IN I-PP B-PP
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
unlabeled JJ B-NP B-NP
25(OH)D3 NN I-NP I-NP
( ( O O
receptor-positive JJ B-NP B-NP
lymphocytes NNS I-NP I-NP
: : O O
sarcoidosis NN B-NP B-NP
, , O O
20 CD B-NP B-NP
+/- CC I-NP I-CC
12 CD I-NP B-NP
% NN I-NP I-NP
; : O O
tuberculosis NN B-NP B-NP
, , O O
31 CD B-NP B-NP
+/- CC I-NP I-CC
17 CD I-NP B-NP
% NN I-NP I-NP
) ) O O
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
blood NN B-NP B-NP
lymphocytes NNS I-NP I-NP
from IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
granulomatous JJ B-NP B-NP
diseases NNS I-NP I-NP
did VBD B-VP B-VP
not RB I-VP I-VP
express VB I-VP I-VP
detectable JJ B-NP B-NP
1,25(OH)2D3 NN I-NP I-NP
receptors NNS I-NP I-NP
. . O O

The DT B-NP B-NP
percentage NN I-NP I-NP
of IN B-PP B-PP
lavage NN B-NP B-NP
T-lymphocytes NNS I-NP I-NP
expressing VBG B-VP B-VP
1,25(OH)2D3 NN B-NP B-NP
receptors NNS I-NP I-NP
was VBD B-VP B-VP
significantly RB B-ADJP B-ADJP
greater JJR I-ADJP I-ADJP
for IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
tuberculosis NN B-NP B-NP
presenting VBG B-VP B-VP
with IN B-PP B-PP
isolated VBN B-NP B-NP
hilar JJ I-NP I-NP
adenopathy JJ I-NP I-NP
than IN B-PP I-NP
for IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
pulmonary JJ B-NP B-NP
infiltrates NNS B-NP I-NP
and/or CC O I-NP
cavities NNS B-NP I-NP
. . O O

1,25(OH)2D3 NN B-NP B-NP
receptors NNS I-NP I-NP
were VBD B-VP B-VP
expressed VBN I-VP I-VP
to TO B-PP B-PP
a DT B-NP B-NP
greater JJR I-NP I-NP
extent NN I-NP I-NP
on IN B-PP B-PP
CD8+ JJ B-NP B-NP
T-lymphocytes NNS I-NP I-NP
than IN B-PP B-PP
on IN B-PP B-PP
CD4+ JJ B-NP B-NP
T-lymphocytes NNS I-NP I-NP
in IN B-PP B-PP
sarcoidosis NN B-NP B-NP
, , O O
whereas IN O B-PP
a DT B-NP B-NP
greater JJR I-NP I-NP
proportion NN I-NP I-NP
of IN B-PP B-PP
CD4+ JJ B-NP B-NP
than IN B-PP B-PP
of IN B-PP B-PP
CD8+ JJ B-NP B-NP
T-lymphocytes NNS B-NP I-NP
from IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
tuberculosis NN B-NP B-NP
were VBD B-VP B-VP
receptor-positive JJ B-ADJP B-ADJP
. . O O

These DT B-NP B-NP
findings NNS I-NP I-NP
support VBP B-VP B-VP
the DT B-NP B-NP
conclusion NN I-NP I-NP
that IN B-SBAR B-PP
the DT B-NP B-NP
interaction NN I-NP I-NP
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
with IN B-PP B-PP
its PRP$ B-NP B-NP
receptor NN I-NP I-NP
on IN B-PP B-PP
T-lymphocytes NNS B-NP B-NP
may MD B-VP B-VP
play VB I-VP I-VP
an DT B-NP B-NP
important JJ I-NP I-NP
role NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
granulomatous JJ B-NP B-NP
reactions NNS I-NP I-NP
, , O O
but CC O I-CC
because IN B-SBAR B-PP
these DT B-NP B-NP
receptors NNS I-NP I-NP
are VBP B-VP B-VP
expressed VBN I-VP I-VP
on IN B-PP B-PP
different JJ B-NP B-NP
lymphocyte NN I-NP I-NP
populations NNS I-NP I-NP
, , O O
the DT B-NP B-NP
net JJ I-NP I-NP
effect NN I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
potent JJ I-NP I-NP
immunoregulatory JJ I-NP I-NP
molecule NN I-NP I-NP
is VBZ B-VP B-VP
likely RB B-ADJP B-ADJP
different JJ I-ADJP I-ADJP
in IN B-PP B-PP
sarcoidosis NN B-NP B-NP
and CC O I-NP
tuberculosis NN B-NP I-NP
. . O O

Inhibition NN B-NP B-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
factors NNS I-NP I-NP
belonging VBG B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
rel/NF-kappa NN I-NP I-NP
B NN I-NP I-NP
family NN I-NP I-NP
by IN B-PP B-PP
a DT B-NP B-NP
transdominant JJ I-NP I-NP
negative JJ I-NP I-NP
mutant NN I-NP I-NP
. . O O

The DT B-NP B-NP
KBF1 NN I-NP I-NP
factor NN I-NP I-NP
, , O O
which WDT B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
enhancer NN I-NP I-NP
A NN I-NP I-NP
located JJ B-VP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
promoter NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
mouse NN I-NP I-NP
MHC NN I-NP I-NP
class NN I-NP I-NP
I CD I-NP I-NP
gene NN I-NP I-NP
H-2Kb NN I-NP I-NP
, , O O
is VBZ B-VP B-VP
indistinguishable JJ B-ADJP B-ADJP
from IN B-PP B-PP
the DT B-NP B-NP
p50 NN I-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
subunit NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
, , O O
which WDT B-NP B-NP
regulates VBZ B-VP B-VP
a DT B-NP B-NP
series NN I-NP I-NP
of IN B-PP B-PP
genes NNS B-NP B-NP
involved VBN B-VP B-VP
in IN B-PP B-PP
immune JJ B-NP B-NP
and CC I-NP I-NP
inflammatory JJ I-NP I-NP
responses NNS I-NP I-NP
. . O O

The DT B-NP B-NP
KBF1/p50 NN I-NP I-NP
factor NN I-NP I-NP
binds VBZ B-VP B-VP
as IN B-PP B-PP
a DT B-NP B-NP
homodimer NN I-NP I-NP
but CC O I-CC
can MD B-VP B-VP
also RB I-VP I-VP
form VB I-VP I-VP
heterodimers NNS B-NP B-NP
with IN B-PP B-PP
the DT B-NP B-NP
products NNS I-NP I-NP
of IN B-PP B-PP
other JJ B-NP B-NP
members NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
same JJ I-NP I-NP
family NN I-NP I-NP
, , O O
like IN B-PP B-PP
the DT O B-NP
c-rel NN B-NP I-NP
and CC O I-NP
v-rel NN B-NP I-NP
( ( B-NP O
proto NN I-NP B-NP
) ) I-NP O
oncogenes NNS I-NP I-NP
. . O O

The DT B-NP B-NP
dimerization NN I-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
KBF1/p50 NN B-NP B-NP
is VBZ B-VP B-VP
contained VBN I-VP I-VP
between IN B-PP B-PP
amino NN B-NP B-NP
acids NNS I-NP I-NP
201 CD B-NP B-NP
and CC O I-NP
367 CD B-NP I-NP
. . O O

A DT B-NP B-NP
mutant NN I-NP I-NP
of IN B-PP B-PP
KBF1/p50 NN B-NP B-NP
( ( I-NP O
delta NN I-NP B-NP
SP NN I-NP I-NP
) ) O O
, , O O
unable JJ B-ADJP B-ADJP
to TO B-VP B-VP
bind VB I-VP I-VP
to TO B-PP B-PP
DNA NN B-NP B-NP
but CC O I-CC
able JJ B-ADJP B-ADJP
to TO B-VP B-VP
form VB I-VP I-VP
homo- JJ B-NP B-NP
or CC O I-NP
heterodimers NNS B-NP I-NP
, , O O
has VBZ B-VP B-VP
been VBN I-VP I-VP
constructed VBN I-VP I-VP
. . O O

This DT B-NP B-NP
protein NN I-NP I-NP
reduces VBZ B-VP B-VP
or CC O I-VP
abolishes VBZ B-VP I-VP
in FW B-ADVP B-NP
vitro FW I-ADVP I-FW
the DT B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
wild-type JJ B-NP B-NP
proteins NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
same JJ I-NP I-NP
family NN I-NP I-NP
( ( O O
KBF1/p50 NN B-NP B-NP
, , O O
c- NN B-NP I-NP
and CC O I-NP
v-rel NN B-NP I-NP
) ) O O
. . O O

This DT B-NP B-NP
mutant JJ I-NP I-NP
also RB B-ADVP B-ADVP
functions NNS B-VP B-VP
in FW B-ADVP B-NP
vivo FW I-ADVP I-NP
as IN B-PP B-PP
a DT B-NP B-NP
trans-acting JJ I-NP I-NP
dominant JJ I-NP I-NP
negative JJ I-NP I-NP
regulator NN I-NP I-NP
: : O O
the DT B-NP B-NP
transcriptional JJ I-NP I-NP
inducibility NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HIV NN I-NP I-NP
long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
( ( O O
which WDT B-NP B-NP
contains VBZ B-VP B-VP
two CD B-NP B-NP
potential JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
binding NN I-NP I-NP
sites NNS I-NP I-NP
) ) O O
by IN B-PP B-PP
phorbol NN B-NP B-NP
ester NN I-NP I-NP
( ( O O
PMA NN B-NP B-NP
) ) O O
is VBZ B-VP B-VP
inhibited VBN I-VP I-VP
when WRB B-ADVP B-ADVP
it PRP B-NP B-NP
is VBZ B-VP B-VP
co-transfected VBN I-VP I-VP
into IN B-PP B-PP
CD4+ JJ B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
delta NN I-NP I-NP
SP NN I-NP I-NP
mutant NN I-NP I-NP
. . O O

Similarly RB B-ADVP B-ADVP
the DT O B-NP
basal JJ O I-NP
as RB B-CONJP B-ADVP
well RB I-CONJP I-ADVP
as IN I-CONJP B-PP
TNF NN B-NP B-NP
or CC O I-CC
IL1-induced JJ B-ADJP B-NP
activity NN B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
MHC NN I-NP I-NP
class NN I-NP I-NP
I CD I-NP I-NP
H-2Kb NN I-NP I-NP
promoter NN I-NP I-NP
can MD B-VP B-VP
be VB I-VP I-VP
inhibited VBN I-VP I-VP
by IN B-PP B-PP
this DT B-NP B-NP
mutant NN I-NP I-NP
in IN B-PP B-PP
two CD B-NP B-NP
different JJ I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
constitute VBP B-VP B-VP
the DT B-NP B-NP
first JJ I-NP I-NP
formal JJ I-NP I-NP
demonstration NN I-NP I-NP
that IN B-SBAR B-PP
these DT B-NP B-NP
genes NNS I-NP I-NP
are VBP B-VP B-VP
regulated VBN I-VP I-VP
by IN B-PP B-PP
members NNS B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
rel/NF-kappa NN I-NP I-NP
B NN I-NP I-NP
family NN I-NP I-NP
. . O O

Human JJ B-NP B-NP
erythroid JJ I-NP I-NP
5-aminolevulinate NN I-NP I-NP
synthase NN I-NP I-NP
: : O O
promoter NN B-NP B-NP
analysis NN I-NP I-NP
and CC O I-NP
identification NN B-NP I-NP
of IN B-PP B-PP
an DT B-NP B-NP
iron-responsive JJ I-NP I-NP
element NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
mRNA NN I-NP I-NP
. . O O

5-Aminolevulinate NN B-NP B-NP
synthase NN I-NP I-NP
( ( O O
ALAS NN B-NP B-NP
) ) O O
catalyzes VBZ B-VP B-VP
the DT B-NP B-NP
first JJ I-NP I-NP
step NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
heme NN I-NP I-NP
biosynthetic JJ I-NP I-NP
pathway NN I-NP I-NP
. . O O

cDNA NN B-NP B-NP
clones NNS I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
erythroid JJ I-NP I-NP
ALAS NN I-NP I-NP
isozyme NN I-NP I-NP
were VBD B-VP B-VP
isolated VBN I-VP I-VP
from IN B-PP B-PP
a DT B-NP B-NP
fetal JJ I-NP I-NP
liver NN I-NP I-NP
library NN I-NP I-NP
. . O O

It PRP B-NP B-NP
can MD B-VP B-VP
be VB I-VP I-VP
deduced VBN I-VP I-VP
that IN B-SBAR B-PP
the DT B-NP B-NP
erythroid JJ I-NP I-NP
ALAS NN I-NP I-NP
precursor NN I-NP I-NP
protein NN I-NP I-NP
has VBZ B-VP B-VP
a DT B-NP B-NP
molecular JJ I-NP I-NP
weight NN I-NP I-NP
of IN B-PP B-PP
64.6 CD B-NP B-NP
kd NN I-NP I-NP
, , O O
and CC O I-CC
is VBZ B-VP B-VP
similar JJ B-ADJP B-ADJP
in IN B-PP B-PP
size NN B-NP B-NP
to TO B-PP B-PP
the DT B-NP B-NP
previously RB I-NP I-NP
isolated VBN I-NP I-NP
human JJ I-NP I-NP
housekeeping JJ I-NP I-NP
ALAS NN I-NP I-NP
precursor NN I-NP I-NP
of IN B-PP B-PP
molecular JJ B-NP B-NP
weight NN I-NP I-NP
70.6 CD I-NP B-NP
kd NN I-NP I-NP
. . O O

The DT B-NP B-NP
mature JJ I-NP I-NP
mitochondrial JJ I-NP I-NP
forms NNS I-NP I-NP
of IN B-PP B-PP
the DT O B-NP
erythroid JJ O I-NP
and CC O I-NP
housekeeping JJ B-NP I-NP
ALAS NN B-NP I-NP
isozymes NNS I-NP I-NP
are VBP B-VP B-VP
predicted VBN I-VP I-VP
to TO I-VP I-VP
have VB I-VP I-VP
molecular JJ B-NP B-NP
weights NNS I-NP I-NP
of IN B-PP B-PP
59.5 CD B-NP B-NP
kd NN I-NP I-NP
and CC O I-CC
64.6 CD B-NP B-NP
kd NN I-NP I-NP
, , O O
respectively RB B-ADVP B-ADVP
. . O O

The DT B-NP B-NP
two CD I-NP I-NP
isozymes NNS I-NP I-NP
show VBP B-VP B-VP
little JJ B-NP B-NP
amino NN I-NP I-NP
acid NN I-NP I-NP
identity NN I-NP I-NP
in IN B-PP B-PP
their PRP$ B-NP B-NP
N-terminal JJ I-NP I-NP
signal NN I-NP I-NP
sequences NNS I-NP I-NP
but CC O I-CC
have VBP B-VP B-VP
considerable JJ B-NP B-NP
sequence NN I-NP I-NP
identity NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
C-terminal JJ I-NP I-NP
two-thirds CD I-NP I-NP
of IN B-PP B-PP
their PRP$ B-NP B-NP
proteins NNS I-NP I-NP
. . O O

An DT B-NP B-NP
analysis NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
immediate JJ I-NP I-NP
promoter NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
erythroid JJ I-NP I-NP
ALAS NN I-NP I-NP
gene NN I-NP I-NP
revealed VBD B-VP B-VP
several JJ B-NP B-NP
putative JJ I-NP I-NP
erythroid-specific JJ I-NP I-NP
cis-acting JJ I-NP I-NP
elements NNS I-NP I-NP
including VBG B-PP B-PP
both PDT O B-NP
a DT B-NP B-NP
GATA-1 NN I-NP I-NP
and CC O I-CC
an DT B-NP B-NP
NF-E2 NN I-NP I-NP
binding NN B-NP I-NP
site NN I-NP I-NP
. . O O

An DT O B-NP
iron-responsive JJ B-NP I-NP
element NN I-NP I-NP
( ( O O
IRE NN B-NP I-NN
) ) O O
motif NN B-NP B-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
identified VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
5'-untranslated JJ I-NP I-NP
region NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
erythroid JJ I-NP I-NP
ALAS NN I-NP I-NP
mRNA NN I-NP I-NP
, , O O
but CC O I-CC
is VBZ B-VP B-VP
not RB O I-RB
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
housekeeping JJ I-NP I-NP
ALAS NN I-NP I-NP
mRNA NN I-NP I-NP
. . O O

Gel NN B-NP B-NP
retardation NN I-NP I-NP
experiments NNS I-NP I-NP
established VBD B-VP B-VP
that IN B-SBAR B-SBAR
this DT B-NP B-NP
IRE NN I-NP I-NP
motif NN I-NP I-NP
formed VBD B-VP B-VP
a DT B-NP B-NP
protein-RNA JJ B-NP I-NP
complex NN I-NP I-NP
with IN B-PP B-PP
cytosolic JJ B-NP B-NP
extracts NNS I-NP I-NP
from IN B-PP B-PP
human JJ B-NP B-NP
K562 NN I-NP I-NP
cells NNS I-NP I-NP
and CC O I-CC
this DT B-NP B-NP
binding NN I-NP I-NP
was VBD B-VP B-VP
strongly RB I-VP I-VP
competed VBN I-VP I-VP
with IN B-PP B-PP
IRE NN B-NP B-NP
transcripts NNS I-NP I-NP
from IN B-PP B-PP
ferritin NN B-NP B-NP
or CC O I-NP
transferrin NN B-NP I-NP
receptor NN B-NP I-NP
mRNAs NNS B-NP I-NP
. . O O

A DT B-NP B-NP
transcript NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
ALAS NN I-NP I-NP
IRE NN I-NP I-NP
, , O O
mutated VBN B-VP B-VP
in IN B-PP B-PP
the DT B-NP B-NP
conserved VBN I-NP I-NP
loop NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
IRE NN I-NP I-NP
, , O O
did VBD B-VP B-VP
not RB I-VP I-VP
readily RB I-VP I-VP
form VB I-VP I-VP
this DT B-NP B-NP
protein-RNA JJ B-NP I-NP
complex NN I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
IRE NN I-NP I-NP
motif NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
ALAS NN I-NP I-NP
mRNA NN I-NP I-NP
is VBZ B-VP B-VP
functional JJ B-ADJP B-ADJP
and CC O I-CC
imply VBP B-VP B-VP
that IN B-SBAR B-PP
translation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
mRNA NN I-NP I-NP
is VBZ B-VP B-VP
controlled VBN I-VP I-VP
by IN B-PP B-PP
cellular JJ B-NP B-NP
iron NN I-NP I-NP
availability NN I-NP I-NP
during IN B-PP B-PP
erythropoiesis NN B-NP B-NP
. . O O

Human JJ B-NP B-NP
tumor NN I-NP I-NP
necrosis NN I-NP I-NP
factor NN I-NP I-NP
alpha NN I-NP I-NP
gene NN I-NP I-NP
regulation NN I-NP I-NP
in IN B-PP B-PP
phorbol NN B-NP B-NP
ester NN I-NP I-NP
stimulated VBD I-NP B-VP
T NN I-NP B-NP
and CC I-NP I-NP
B NN I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
. . O O

The DT B-NP B-NP
minimal JJ I-NP I-NP
region NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
tumor NN I-NP I-NP
necrosis NN I-NP I-NP
factor NN I-NP I-NP
alpha NN I-NP I-NP
( ( I-NP O
TNF-alpha NN I-NP I-NN
) ) I-NP O
gene NN I-NP B-NP
promoter NN I-NP I-NP
necessary JJ B-ADJP B-ADJP
for IN B-PP B-PP
its PRP$ B-NP B-NP
transcriptional JJ I-NP I-NP
induction NN I-NP I-NP
by IN B-PP B-PP
phorbol NN B-NP B-NP
esters NNS I-NP I-NP
( ( O O
PMA NN B-NP B-NP
) ) O O
in IN B-PP B-PP
human JJ B-NP B-NP
T NN I-NP I-NP
and CC I-NP I-NP
B NN I-NP I-NP
lymphocyte NN I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
localized JJ I-VP B-ADJP
between IN B-PP B-PP
-52 CD B-NP B-NP
and CC O I-NP
+89 CD B-NP I-NP
nucleotides NNS B-NP I-NP
( ( O O
nt NN B-NP B-NP
) ) O O
relative JJ B-ADVP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
gene NN I-NP I-NP
's POS B-NP B-NP
transcriptional JJ I-NP I-NP
start NN I-NP I-NP
site NN I-NP I-NP
. . O O

Comparison NN B-NP B-NP
of IN B-PP B-PP
these DT B-NP B-NP
sequences NNS I-NP I-NP
to TO B-PP B-PP
those DT B-NP B-NP
required VBN B-VP B-VP
to TO B-VP B-VP
mediate VB I-VP I-VP
virus NN B-NP B-NP
or CC O I-NP
lipopolysaccharide NN B-NP I-NP
( ( O O
LPS NN B-NP I-NN
) ) O O
induction NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
gene NN I-NP I-NP
reveal VB B-VP B-VP
significant JJ B-NP B-NP
differences NNS I-NP I-NP
, , O O
and CC O I-CC
thus RB O B-ADVP
, , O O
the DT B-NP B-NP
sequence NN I-NP I-NP
requirements NNS I-NP I-NP
for IN B-PP B-PP
PMA NN B-NP B-NP
induction NN I-NP I-NP
are VBP B-VP B-VP
distinct JJ B-ADJP B-ADJP
from IN B-PP B-PP
those DT B-NP B-NP
that WDT B-NP B-NP
mediate VBP B-VP B-VP
induction NN B-NP B-NP
by IN B-PP B-PP
virus NN B-NP B-NP
or CC O I-NP
LPS NN B-NP I-NP
. . O O

Although IN B-SBAR B-PP
three CD B-NP B-NP
sites NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
TNF-alpha NN I-NP I-NP
promoter NN I-NP I-NP
( ( O O
kappa NN B-NP B-NP
1 CD I-NP I-NP
, , O O
kappa NN B-NP B-NP
2 CD I-NP I-NP
, , O O
and CC O I-CC
kappa NN B-NP B-NP
3 CD I-NP I-NP
) ) O O
specifically RB B-ADVP B-ADVP
bind VBP B-VP B-VP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
in IN B-PP B-PP
lymphoid JJ B-NP B-NP
nuclear JJ I-NP I-NP
extracts NNS I-NP I-NP
, , O O
TNF-alpha NN B-NP B-NP
mRNA NN I-NP I-NP
induction NN I-NP I-NP
by IN B-PP B-PP
PMA NN B-NP B-NP
does VBZ B-VP B-VP
not RB I-VP I-VP
correlate VB I-VP I-VP
with IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
binding NN I-NP I-NP
activities NNS I-NP I-NP
displayed VBN B-VP B-VP
by IN B-PP B-PP
different JJ B-NP B-NP
T NN I-NP I-NP
and CC I-NP I-NP
B NN I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
. . O O

Moreover RB B-ADVP B-ADVP
, , O O
kappa NN B-NP B-NP
1 CD I-NP I-NP
- : O O
kappa NN B-NP B-NP
3 CD I-NP B-NP
can MD B-VP B-VP
each DT I-VP I-VP
be VB I-VP I-VP
deleted VBN I-VP I-VP
from IN B-PP B-PP
the DT B-NP B-NP
TNF-alpha NN I-NP I-NP
promoter NN I-NP I-NP
with IN B-PP B-PP
little JJ B-NP B-NP
effect NN I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
gene NN I-NP I-NP
's POS B-NP B-NP
inducibility NN I-NP I-NP
by IN B-PP B-PP
PMA NN B-NP B-NP
. . O O

Therefore RB B-ADVP B-ADVP
, , O O
TNF-alpha NN B-NP B-NP
mRNA NN I-NP I-NP
induction NN I-NP I-NP
by IN B-PP B-PP
PMA NN B-NP B-NP
, , O O
like IN B-PP B-PP
its PRP$ B-NP B-NP
induction NN I-NP I-NP
by IN B-PP B-PP
virus NN B-NP B-NP
and CC O I-NP
LPS NN B-NP I-NP
, , O O
is VBZ B-VP B-VP
not RB I-VP I-VP
primarily RB I-VP I-VP
mediated VBN I-VP I-VP
by IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
, , O O
but CC B-CONJP I-CC
rather RB I-CONJP B-VP
is VBZ B-VP I-VP
mediated VBN I-VP I-VP
through IN B-PP B-PP
other JJ B-NP B-NP
sequences NNS B-NP I-NP
and CC O I-CC
protein NN B-NP B-NP
factors NNS I-NP I-NP
. . O O

Surprisingly RB B-ADVP B-ADVP
, , O O
multimers NNS B-NP B-NP
of IN B-PP B-PP
kappa NN B-NP B-NP
1 CD I-NP I-NP
- : O O
kappa NN B-NP B-NP
3 CD I-NP B-NP
can MD B-VP B-VP
confer VB I-VP I-VP
PMA NN B-NP B-NP
inducibility NN I-NP I-NP
on IN B-PP B-PP
a DT B-NP B-NP
heterologous JJ I-NP I-NP
promoter NN I-NP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
B NN B-NP I-NP
( ( O O
Raji NN B-NP B-NP
) ) O O
, , O O
but CC B-CONJP I-CC
not RB I-CONJP I-RB
a DT B-NP B-NP
T NN B-NP I-NP
( ( O O
HUT78 NN B-NP I-NN
) ) O O
cell NN B-NP B-NP
line NN I-NP I-NP
. . O O

However WRB O B-ADVP
they PRP B-NP B-NP
are VBP B-VP B-VP
not RB O I-RB
functional JJ B-ADJP B-ADJP
on IN B-PP B-PP
a DT B-NP B-NP
truncated VBN I-NP I-NP
TNF-alpha NN I-NP I-NP
promoter NN I-NP I-NP
, , O O
indicating VBG B-VP B-VP
that IN B-SBAR B-PP
promoter NN B-NP B-NP
context NN I-NP I-NP
and CC O I-NP
cell NN B-NP I-NP
type NN I-NP I-NP
specificity NN I-NP I-NP
influence VBP B-VP B-VP
the DT B-NP B-NP
PMA NN I-NP I-NP
inducible JJ I-NP I-NP
function NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
binding NN I-NP I-NP
sites NNS I-NP I-NP
. . O O

Towards IN B-PP B-PP
a DT B-NP B-NP
molecular JJ I-NP I-NP
understanding NN I-NP I-NP
of IN B-PP B-PP
T-cell NN B-NP B-NP
differentiation NN I-NP I-NP
. . O O

Lymphoid JJ B-NP B-NP
differentiation NN I-NP I-NP
is VBZ B-VP B-VP
one CD B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
best RBS I-NP I-NP
studied VBN I-NP I-NP
examples NNS I-NP I-NP
of IN B-PP B-PP
mammalian JJ B-NP B-NP
development NN I-NP I-NP
. . O O

Here RB B-ADVP B-ADVP
Hans NNP B-NP B-NP
Clevers NNP I-NP I-NP
and CC O I-CC
Michael NNP B-NP B-NP
Owen NNP I-NP I-NP
describe VBP B-VP B-VP
how WRB B-ADVP B-ADVP
the DT B-NP B-NP
cloning NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
genes NNS I-NP I-NP
that WDT B-NP B-NP
encode VBP B-VP B-VP
T-cell-specific JJ I-VP B-NP
membrane NN I-VP I-NP
proteins NNS I-VP I-NP
allows VBZ B-VP B-VP
the DT B-NP B-NP
identification NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
factors NNS I-NP I-NP
that WDT B-NP B-NP
control VBP B-VP B-VP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
T-cell NN I-NP I-NP
genes NNS I-NP I-NP
. . O O

Such JJ B-NP B-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
play VBP B-VP B-VP
a DT B-NP B-NP
key JJ I-NP I-NP
role NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
development NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
mature JJ I-NP I-NP
T-cell NN I-NP I-NP
phenotype NN I-NP I-NP
by IN B-PP B-PP
functioning VBG B-VP B-VP
as IN B-PP B-PP
' [[DQS]] O B-NP
master JJ B-NP I-NP
regulators NNS I-NP I-NP
of IN B-PP B-PP
T-cell NN B-NP B-NP
differentiation NN I-NP I-NP
' [[DQE]] O I-NP
. . O O

Regulation NN B-NP B-NP
of IN B-PP B-PP
jun NN B-NP B-NP
and CC I-NP I-NP
fos NN I-NP I-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
monocytes NNS I-NP I-NP
by IN B-PP B-PP
the DT B-NP B-NP
macrophage NN I-NP I-NP
colony-stimulating JJ I-NP I-NP
factor NN I-NP I-NP
. . O O

The DT B-NP B-NP
macrophage NN B-NP I-NP
colony-stimulating JJ I-NP I-NP
factor NN I-NP I-NP
( ( O O
M-CSF NN B-NP B-NP
) ) O O
is VBZ B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
the DT B-NP B-NP
growth NN B-NP I-NP
and CC O I-NP
differentiation NN B-NP I-NP
of IN B-PP B-PP
mononuclear JJ B-NP B-NP
phagocytes NNS I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
signaling NN I-NP I-NP
events NNS I-NP I-NP
responsible JJ B-ADJP B-ADJP
for IN B-PP B-PP
these DT B-NP B-NP
effects NNS I-NP I-NP
remain VBP B-VP B-VP
unclear JJ B-ADJP B-ADJP
. . O O

The DT B-NP B-NP
present JJ I-NP I-NP
studies NNS I-NP I-NP
have VBP B-VP B-VP
examined VBN I-VP I-VP
the DT B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
M-CSF NN B-NP B-NP
on IN B-PP B-PP
potential JJ B-NP B-NP
signaling NN I-NP I-NP
pathways NNS I-NP I-NP
involving VBG B-VP B-VP
expression NN B-NP B-NP
of IN B-PP B-PP
the DT O B-NP
jun NN B-NP I-NP
and CC O I-NP
fos NN B-NP I-NP
early JJ B-NP I-NP
response NN I-NP I-NP
genes NNS I-NP I-NP
. . O O

Low JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
transcripts NNS I-NP I-NP
were VBD B-VP B-VP
detectable JJ B-ADJP B-ADJP
in IN B-PP B-PP
resting VBG B-NP B-VP
human JJ I-NP B-NP
peripheral JJ I-NP I-NP
blood NN I-NP I-NP
monocytes NNS I-NP I-NP
. . O O

Treatment NN B-NP B-NP
of IN B-PP B-PP
these DT B-NP B-NP
cells NNS I-NP I-NP
with IN B-PP B-PP
10(3) CD B-NP B-NP
units/ml NNS I-NP I-NP
human JJ I-NP B-NP
recombinant JJ I-NP I-NP
M-CSF NN I-NP I-NP
was VBD B-VP B-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
rapid JJ B-NP B-NP
and CC I-NP I-NP
transient JJ I-NP I-NP
increases NNS I-NP I-NP
in IN B-PP B-PP
c-jun NN B-NP B-NP
mRNA NN I-NP I-NP
levels NNS I-NP I-NP
. . O O

Nuclear JJ B-NP B-NP
run-on JJ I-NP I-NP
assays NNS I-NP I-NP
and CC O I-CC
mRNA NN B-NP B-NP
stability NN I-NP I-NP
studies NNS I-NP I-NP
demonstrated VBD B-VP B-VP
that IN B-SBAR B-PP
M-CSF NN B-NP B-NP
regulates VBZ B-VP B-VP
c-jun NN B-NP B-NP
expression NN I-NP I-NP
by IN B-PP B-PP
both CC O I-CC
an DT B-NP B-NP
increase NN I-NP I-NP
in IN B-PP B-PP
transcription NN B-NP B-NP
rate NN I-NP I-NP
and CC O I-CC
a DT B-NP B-NP
prolongation NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
half-life NN I-NP I-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
transcripts NNS I-NP I-NP
. . O O

M-CSF NN B-NP B-NP
treatment NN I-NP I-NP
was VBD B-VP B-VP
also RB I-VP I-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
a DT B-NP B-NP
rapid JJ I-NP I-NP
induction NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
jun-B NN I-NP I-NP
gene NN I-NP I-NP
, , O O
although IN B-SBAR B-SBAR
expression NN B-NP B-NP
of IN B-PP B-PP
this DT B-NP B-NP
gene NN I-NP I-NP
was VBD B-VP B-VP
prolonged JJ I-VP B-ADJP
compared VBN B-VP B-VP
to TO B-PP B-PP
that DT B-NP B-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
. . O O

We PRP B-NP B-NP
further RB B-ADVP B-ADVP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
M-CSF NN B-NP B-NP
increases VBZ B-VP B-VP
c-fos NN B-NP B-NP
mRNA NN I-NP I-NP
levels NNS I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
monocytes NNS I-NP I-NP
through IN B-PP B-PP
control NN B-NP B-NP
at IN B-PP B-PP
both CC B-NP I-CC
the DT I-NP B-NP
transcriptional JJ I-NP I-NP
and CC I-NP I-NP
posttranscriptional JJ I-NP I-NP
levels NNS I-NP I-NP
. . O O

Maximal JJ B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
c-fos NN I-NP I-NP
gene NN I-NP I-NP
was VBD B-VP B-VP
followed VBN I-VP I-VP
by IN B-PP B-PP
that DT B-NP B-NP
for IN B-PP B-PP
the DT B-NP B-NP
fos-B NN I-NP I-NP
gene NN I-NP I-NP
. . O O

Moreover RB B-ADVP B-ADVP
, , O O
M-CSF-induced JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
fos-related JJ I-NP I-NP
gene NN I-NP I-NP
, , O O
fra-1 NN B-NP B-NP
, , O O
was VBD B-VP B-VP
delayed VBN I-VP I-VP
compared VBN B-VP I-VP
to TO B-PP B-PP
that DT B-NP B-NP
for IN B-PP B-PP
both DT B-NP B-NP
c-fos NN B-NP I-NP
and CC O I-NP
fos-B NN B-NP I-NP
. . O O

Taken VBN B-VP B-VP
together RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
results NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-PP
M-CSF NN B-NP B-NP
treatment NN I-NP I-NP
is VBZ B-VP B-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
differential JJ B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
multiple JJ B-NP B-NP
members NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
jun/fos NN I-NP I-NP
family NN I-NP I-NP
and CC O I-CC
that IN B-SBAR B-SBAR
expression NN B-NP B-NP
of IN B-PP B-PP
these DT B-NP B-NP
genes NNS I-NP I-NP
could MD B-VP B-VP
contribute VB I-VP I-VP
to TO B-PP B-PP
nuclear JJ B-NP B-NP
signaling NN I-NP I-NP
mechanisms NNS I-NP I-NP
that WDT B-NP B-NP
regulate VBP B-VP B-VP
a DT B-NP B-NP
specific JJ I-NP I-NP
program NN I-NP I-NP
of IN B-PP B-PP
monocyte NN B-NP B-NP
differentiation NN I-NP I-NP
. . O O

Cloning NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
human JJ I-NP I-NP
homeobox NN I-NP I-NP
gene NN I-NP I-NP
that WDT B-NP B-NP
resembles VBZ B-VP B-VP
a DT B-NP B-NP
diverged JJ I-NP I-NP
Drosophila NN I-NP I-NP
homeobox NN I-NP I-NP
gene NN I-NP I-NP
and CC O I-CC
is VBZ B-VP B-VP
expressed VBN I-VP I-VP
in IN B-PP B-PP
activated VBN B-NP B-NP
lymphocytes NNS I-NP I-NP
. . O O

A DT B-NP B-NP
new JJ I-NP I-NP
homeobox NN I-NP I-NP
gene NN I-NP I-NP
, , O O
HB24 NN B-NP B-NP
, , O O
has VBZ B-VP B-VP
been VBN I-VP I-VP
isolated VBN I-VP I-VP
from IN B-PP B-PP
a DT B-NP B-NP
human JJ I-NP I-NP
B-lymphocyte NN I-NP I-NP
cDNA NN I-NP I-NP
library NN I-NP I-NP
. . O O

Northern JJ|NN B-NP B-NP
blot NN I-NP I-NP
analysis NN I-NP I-NP
of IN B-PP B-PP
polyadenylated JJ B-NP B-NP
RNA NN I-NP I-NP
purified VBN B-VP B-VP
from IN B-PP B-PP
activated VBN B-NP B-NP
human JJ I-NP I-NP
B NN I-NP I-NP
cells NNS I-NP I-NP
revealed VBD B-VP B-VP
a DT B-NP B-NP
single JJ I-NP I-NP
mRNA NN I-NP I-NP
transcript NN I-NP I-NP
of IN B-PP B-PP
approximately RB B-NP B-NP
2.3 CD I-NP I-NP
kb NN I-NP I-NP
. . O O

Two CD B-NP B-NP
cDNA NN I-NP I-NP
clones NNS I-NP I-NP
were VBD B-VP B-VP
sequenced VBN I-VP I-VP
and CC O I-CC
provided VBN B-VP B-VP
2,250 CD B-NP B-NP
nucleotides NNS B-NP I-NP
( ( O O
nt NN B-NP B-NP
) ) O O
of IN B-PP B-PP
DNA NN B-NP B-NP
sequence NN I-NP I-NP
information NN I-NP I-NP
. . O O

There EX B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
single JJ I-NP I-NP
methionine NN I-NP I-NP
codon-initiated JJ I-NP I-NP
open JJ I-NP I-NP
reading NN I-NP I-NP
frame NN I-NP I-NP
of IN B-PP B-PP
1,458 CD B-NP B-NP
nt NN I-NP I-NP
in IN B-PP B-PP
frame NN B-NP B-NP
with IN B-PP B-PP
a DT B-NP B-NP
homeobox NN I-NP I-NP
and CC O I-CC
a DT B-NP B-NP
CAX NN I-NP I-NP
repeat NN I-NP I-NP
, , O O
and CC O I-CC
the DT B-NP B-NP
open JJ I-NP I-NP
reading NN I-NP I-NP
frame NN I-NP I-NP
is VBZ B-VP B-VP
predicted VBN I-VP I-VP
to TO I-VP I-VP
encode VB I-VP I-VP
a DT B-NP B-NP
protein NN I-NP I-NP
of IN B-PP B-PP
51,659 CD B-NP B-NP
daltons NNS I-NP I-NP
. . O O

When WRB B-ADVP B-ADVP
the DT B-NP B-NP
homeodomain NN I-NP I-NP
from IN B-PP B-PP
HB24 NN B-NP B-NP
was VBD B-VP B-VP
compared VBN I-VP I-VP
to TO B-PP B-PP
known JJ O B-NP
mammalian JJ O I-NP
and CC O I-NP
Drosophila NN B-NP I-NP
homeodomains NNS B-NP I-NP
it PRP B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
only RB B-ADJP B-ADJP
moderately RB I-ADJP I-ADJP
conserved VBN I-ADJP I-ADJP
, , O O
but CC O I-CC
when WRB B-ADVP B-ADVP
it PRP B-NP B-NP
was VBD B-VP B-VP
compared VBN I-VP I-VP
to TO B-PP B-PP
a DT B-NP B-NP
highly RB I-NP I-NP
diverged JJ I-NP I-NP
Drosophila FW I-NP I-NP
homeodomain NN I-NP I-NP
, , O O
H2.0 NN B-NP B-NP
, , O O
it PRP B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
80 CD B-NP B-NP
% NN I-NP I-NP
identical JJ B-ADJP B-ADJP
. . O O

The DT B-NP B-NP
HB24 NN I-NP I-NP
mRNA NN I-NP I-NP
was VBD B-VP B-VP
absent JJ B-ADJP B-ADJP
or CC O I-ADJP
present JJ B-ADJP I-ADJP
at IN B-PP B-PP
low JJ B-NP B-NP
levels NNS I-NP I-NP
in IN B-PP B-PP
normal JJ B-NP B-NP
B NN B-NP I-NP
and CC O I-NP
T NN B-NP I-NP
lymphocytes NNS B-NP I-NP
; : O O
however RB B-ADVP B-ADVP
, , O O
with IN B-PP B-PP
the DT B-NP B-NP
appropriate JJ I-NP I-NP
activation NN I-NP I-NP
signal NN I-NP I-NP
HB24 NN B-NP I-NP
mRNA NN I-NP I-NP
was VBD B-VP B-VP
induced VBN I-VP I-VP
within IN B-PP B-PP
several JJ B-NP B-NP
hours NNS I-NP I-NP
even RB B-PP B-ADVP
in IN I-PP B-PP
the DT I-PP B-NP
presence NN I-PP I-NP
of IN I-PP B-PP
cycloheximide NN B-NP B-NP
. . O O

Characterization NN B-NP B-NP
of IN B-PP B-PP
HB24 NN B-NP B-NP
expression NN I-NP I-NP
in IN B-PP B-PP
lymphoid JJ B-NP B-NP
and CC O I-NP
select JJ B-NP I-NP
developing VBG I-NP I-NP
tissues NNS I-NP I-NP
was VBD B-VP B-VP
performed VBN I-VP I-VP
by IN B-PP B-PP
in FW B-NP B-NP
situ FW I-NP I-NP
hybridization NN I-NP I-NP
. . O O

Positive JJ B-NP B-NP
hybridization NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
in IN B-PP B-PP
thymus NN B-NP B-NP
, , O O
tonsil NN B-NP B-NP
, , O O
bone NN B-NP B-NP
marrow NN I-NP I-NP
, , O O
developing VBG B-NP B-VP
vessels NNS I-NP B-NP
, , B-PP O
and CC I-PP I-CC
in IN B-PP B-PP
fetal JJ B-NP B-NP
brain NN I-NP I-NP
. . O O

HB24 NN B-NP B-NP
is VBZ B-VP B-VP
likely JJ B-ADJP B-ADJP
to TO B-VP B-VP
have VB I-VP I-VP
an DT B-NP B-NP
important JJ I-NP I-NP
role NN I-NP I-NP
in IN B-PP B-PP
lymphocytes NNS B-NP B-NP
as RB B-CONJP B-ADVP
well RB I-CONJP I-ADVP
as IN I-CONJP B-PP
in IN B-PP B-PP
certain JJ B-NP B-NP
developing VBG I-NP I-NP
tissues NNS I-NP I-NP
. . O O

Severe JJ B-NP B-NP
5-fluorouracil NN I-NP I-NP
toxicity NN I-NP I-NP
secondary JJ B-ADJP B-ADJP
to TO B-PP B-PP
dihydropyrimidine NN B-NP B-NP
dehydrogenase NN I-NP I-NP
deficiency NN I-NP I-NP
. . O O

A DT B-NP B-NP
potentially RB I-NP I-NP
more RBR I-NP I-NP
common JJ I-NP I-NP
pharmacogenetic JJ I-NP I-NP
syndrome NN I-NP I-NP
. . O O

This DT B-NP B-NP
study NN I-NP I-NP
describes VBZ B-VP B-VP
the DT B-NP B-NP
inheritance NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
defect NN I-NP I-NP
in IN B-PP B-PP
pyrimidine NN B-NP B-NP
catabolism NN I-NP I-NP
and CC O I-CC
its PRP$ B-NP B-NP
association NN I-NP I-NP
with IN B-PP B-PP
drug-induced JJ B-NP B-NP
toxicity NN I-NP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
patient NN I-NP I-NP
receiving VBG B-VP I-NP
5-fluorouracil NN B-NP I-NP
( ( O O
FUra NN B-NP B-NP
) ) O O
as IN B-PP B-PP
adjuvant JJ B-NP B-NP
chemotherapy NN I-NP I-NP
for IN B-PP B-PP
breast NN B-NP B-NP
carcinoma NN I-NP I-NP
. . O O

The DT B-NP B-NP
study NN I-NP I-NP
population NN I-NP I-NP
included VBD B-VP B-VP
the DT B-NP B-NP
affected VBN I-NP I-NP
patient NN I-NP I-NP
( ( O O
proband NN B-NP B-NP
) ) O O
, , O O
nine CD B-NP B-NP
of IN B-PP B-PP
her PRP$ B-NP B-NP
blood NN I-NP I-NP
relatives NNS I-NP I-NP
, , O O
and CC O I-CC
seven CD B-NP B-NP
healthy JJ I-NP I-NP
volunteers NNS I-NP I-NP
. . O O

The DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
dihydropyrimidine NN B-NP B-NP
dehydrogenase NN I-NP I-NP
( ( O O
DPD NN B-NP B-NP
) ) O O
, , O O
the DT B-NP B-NP
initial JJ I-NP I-NP
enzyme NN I-NP I-NP
of IN B-PP B-PP
pyrimidine NN B-NP B-NP
( ( O O
and CC O I-CC
FUra NN B-NP I-NN
) ) O O
catabolism NN B-NP B-NP
, , O O
in IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
mononuclear JJ I-NP I-NP
cells NNS I-NP I-NP
was VBD B-VP B-VP
measured VBN I-VP I-VP
in IN B-PP B-PP
each DT B-NP B-NP
subject NN I-NP I-NP
by IN B-PP B-PP
a DT B-NP B-NP
specific JJ I-NP I-NP
radiometric JJ I-NP I-NP
assay NN I-NP I-NP
using VBG B-VP I-NP
FUra NN B-NP I-NP
as IN B-PP B-PP
the DT B-NP B-NP
substrate NN I-NP I-NP
. . O O

The DT B-NP B-NP
proband NN I-NP I-NP
had VBD B-VP B-VP
no DT B-NP B-NP
detectable JJ I-NP I-NP
DPD NN I-NP I-NP
activity NN I-NP I-NP
. . O O

When WRB B-ADVP B-ADVP
enzyme NN B-NP B-NP
levels NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
proband NN B-NP I-NP
and CC O I-NP
relatives NNS B-NP I-NP
were VBD B-VP B-VP
compared VBN I-VP I-VP
with IN B-PP B-PP
that DT B-NP B-NP
in NN O I-NP
controls NNS B-NP I-NP
, , O O
an DT B-NP B-NP
autosomal JJ I-NP I-NP
recessive JJ I-NP I-NP
pattern NN I-NP I-NP
of IN B-PP B-PP
inheritance NN B-NP B-NP
was VBD B-VP B-VP
demonstrated VBN I-VP I-VP
. . O O

This DT B-NP B-NP
is VBZ B-VP B-VP
the DT B-NP B-NP
third JJ I-NP I-NP
patient NN I-NP I-NP
with IN B-PP B-PP
severe JJ B-NP B-NP
FUra NN I-NP I-NP
toxicity NN I-NP I-NP
secondary JJ B-ADJP B-ADJP
to TO B-PP B-PP
an DT B-NP B-NP
alteration NN I-NP I-NP
in IN B-PP B-PP
pyrimidine NN B-NP B-NP
catabolism NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
second NN I-NP I-NP
from IN B-PP B-PP
our PRP$ B-NP B-NP
clinic NN I-NP I-NP
population NN I-NP I-NP
suggesting VBG B-VP B-VP
that IN B-SBAR B-PP
the DT B-NP B-NP
frequency NN I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
genetic JJ I-NP I-NP
defect NN I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
greater JJR B-ADJP B-ADJP
than IN B-SBAR B-SBAR
previously RB B-ADVP B-ADVP
thought VBN B-VP B-VP
. . O O

Monitoring VBG B-VP B-VP
DPD NN B-NP B-NP
activity NN I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
important JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
management NN I-NP I-NP
of IN B-PP B-PP
patients NNS B-NP B-NP
experiencing VBG B-VP B-VP
severe JJ B-NP B-NP
toxicity NN I-NP I-NP
secondary JJ B-ADJP B-ADJP
to TO B-PP B-PP
FUra NN B-NP B-NP
chemotherapy NN I-NP I-NP
. . O O

Characterization NN B-NP B-NP
of IN B-PP B-PP
an DT B-NP B-NP
immediate-early JJ I-NP I-NP
gene NN I-NP I-NP
induced VBN B-VP B-VP
in IN B-PP B-PP
adherent JJ B-NP B-NP
monocytes NNS I-NP I-NP
that WDT B-NP B-NP
encodes VBZ B-VP B-VP
I NN B-NP B-NP
kappa NN I-NP I-NP
B-like JJ I-NP I-NP
activity NN I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
cloned VBN I-VP I-VP
a DT B-NP B-NP
group NN I-NP I-NP
of IN B-PP B-PP
cDNAs NNS B-NP B-NP
representing VBG B-VP B-VP
mRNAs NNS B-NP B-NP
that WDT B-NP B-NP
are VBP B-VP B-VP
rapidly RB I-VP I-VP
induced VBN I-VP I-VP
following VBG B-PP I-VP
adherence NN B-NP B-NP
of IN B-PP B-PP
human JJ B-NP B-NP
monocytes NNS I-NP I-NP
. . O O

One CD B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
induced VBN I-NP I-NP
transcripts NNS I-NP I-NP
( ( O O
MAD-3 NN B-NP B-NP
) ) O O
encodes VBZ B-VP B-VP
a DT B-NP B-NP
protein NN I-NP I-NP
of IN B-PP B-PP
317 CD B-NP B-NP
amino NN I-NP I-NP
acids NNS I-NP I-NP
with IN B-PP B-PP
one CD B-NP B-NP
domain NN I-NP I-NP
containing VBG B-VP B-VP
five CD B-NP B-NP
tandem JJ I-NP I-NP
repeats NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
cdc10/ankyrin JJ I-NP I-NP
motif NN I-NP I-NP
, , O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
60 CD B-NP B-NP
% NN I-NP I-NP
similar JJ B-ADJP I-NP
( ( O O
46 CD B-NP B-NP
% NN I-NP I-NP
identical JJ B-ADJP I-NP
) ) O O
to TO B-PP B-PP
the DT B-NP B-NP
ankyrin NN I-NP I-NP
repeat NN I-NP I-NP
region NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
precursor NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B/KBF1 NN I-NP I-NP
p50 NN I-NP I-NP
. . O O

The DT B-NP B-NP
C-terminus NN I-NP I-NP
has VBZ B-VP B-VP
a DT B-NP B-NP
putative JJ I-NP I-NP
protein NN I-NP I-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
phosphorylation NN I-NP I-NP
site NN I-NP I-NP
. . O O

In FW B-ADVP B-NP
vitro FW I-ADVP I-NP
translated VBN B-NP I-NP
MAD-3 NN I-NP I-NP
protein NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
specifically RB I-VP I-VP
inhibit VB I-VP I-VP
the DT B-NP B-NP
DNA-binding JJ I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
p50/p65 NN I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
complex NN I-NP I-NP
but CC B-CONJP B-NP
not RB I-CONJP I-NP
that DT B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
p50/p50 NN I-NP I-NP
KBF1 NN I-NP I-NP
factor NN I-NP I-NP
or CC B-PP B-PP
of IN B-PP B-PP
other JJ B-NP B-NP
DNA-binding JJ I-NP I-NP
proteins NNS I-NP I-NP
. . O O

The DT B-NP B-NP
MAD-3 NN I-NP I-NP
cDNA NN I-NP I-NP
encodes VBZ B-VP B-VP
an DT B-NP B-NP
I NN I-NP I-NP
kappa NN I-NP I-NP
B-like JJ I-NP I-NP
protein NN I-NP I-NP
that WDT B-NP B-NP
is VBZ B-VP B-VP
likely JJ B-ADJP B-ADJP
to TO B-VP B-VP
be VB I-VP I-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
regulation NN B-NP B-NP
of IN B-PP B-PP
transcriptional JJ B-NP B-NP
responses NNS I-NP I-NP
to TO B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
, , O O
including VBG B-PP B-PP
adhesion-dependent JJ B-NP B-NP
pathways NNS I-NP I-NP
of IN B-PP B-PP
monocyte NN B-NP B-NP
activation NN I-NP I-NP
. . O O

Reactive JJ B-NP B-NP
oxygen NN I-NP I-NP
intermediates NNS I-NP I-NP
as IN B-PP B-PP
apparently RB B-ADJP B-NP
widely RB I-ADJP I-NP
used VBN I-ADJP I-NP
messengers NNS O I-NP
in IN B-PP B-PP
the DT B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
NF-kappa NN B-NP I-NP
B NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
and CC O I-NP
HIV-1 NN B-NP I-NP
. . O O

Hydrogen NN B-NP B-NP
peroxide NN I-NP I-NP
and CC O I-NP
oxygen NN B-NP I-NP
radicals NNS B-NP I-NP
are VBP B-VP B-VP
agents NNS B-NP B-NP
commonly RB B-VP B-VP
produced VBN I-VP I-VP
during IN B-PP B-PP
inflammatory JJ B-NP B-NP
processes NNS I-NP I-NP
. . O O

In IN B-PP B-PP
this DT B-NP B-NP
study NN I-NP I-NP
, , O O
we PRP B-NP B-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
micromolar JJ B-NP B-NP
concentrations NNS I-NP I-NP
of IN B-PP B-PP
H2O2 NN B-NP B-NP
can MD B-VP B-VP
induce VB I-VP I-VP
the DT B-NP B-NP
expression NN B-NP I-NP
and CC O I-NP
replication NN B-NP I-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
in IN B-PP B-PP
a DT B-NP B-NP
human JJ I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
. . O O

The DT B-NP B-NP
effect NN I-NP I-NP
is VBZ B-VP B-VP
mediated VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
which WDT B-NP B-NP
is VBZ O B-VP
potently RB B-ADVP B-ADVP
and CC O I-CC
rapidly RB B-ADVP B-VP
activated VBN B-VP I-VP
by IN O B-PP
an DT B-NP B-NP
H2O2 NN I-NP I-NP
treatment NN I-NP I-NP
of IN B-PP B-PP
cells NNS B-NP B-NP
from IN B-PP B-PP
its PRP$ B-NP B-NP
inactive JJ I-NP I-NP
cytoplasmic JJ I-NP I-NP
form NN I-NP I-NP
. . O O

N-acetyl-L-cysteine NN B-NP B-NP
( ( O O
NP NN B-NP I-NP
) ) O O
, , O O
a DT B-NP B-NP
well RB I-NP I-NP
characterized VBN I-NP I-NP
antioxidant NN I-NP I-NP
which WDT B-NP B-NP
counteracts VBZ B-VP B-VP
the DT B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
reactive JJ B-NP B-NP
oxygen NN I-NP I-NP
intermediates NNS I-NP I-NP
( ( O O
ROI NN B-NP B-NP
) ) O O
in IN B-PP B-PP
living VBG B-NP B-NP
cells NNS I-NP I-NP
, , O O
prevented VBD B-VP B-VP
the DT B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
by IN B-PP B-PP
H2O2 NN B-NP B-NP
. . O O

NP NN B-NP B-NP
and CC O I-NP
other JJ B-NP I-NP
thiol JJ I-NP I-NP
compounds NNS I-NP I-NP
also RB B-ADVP B-ADVP
blocked VBD B-VP B-VP
the DT B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
by IN B-PP B-PP
cycloheximide NN B-NP B-NP
, , O O
double-stranded JJ B-NP B-NP
RNA NN I-NP I-NP
, , O O
calcium NN B-NP B-NP
ionophore NN I-NP I-NP
, , O O
TNF-alpha NN B-NP B-NP
, , O O
active JJ B-NP B-NP
phorbol NN I-NP I-NP
ester NN I-NP I-NP
, , O O
interleukin-1 NN B-NP B-NP
, , O O
lipopolysaccharide NN B-NP B-NP
and CC O I-NP
lectin NN B-NP I-NP
. . O O

This DT B-NP B-NP
suggests VBZ B-VP B-VP
that IN B-SBAR B-SBAR
diverse JJ B-NP B-NP
agents NNS I-NP I-NP
thought VBN B-VP B-VP
to TO I-VP B-VP
activate VB I-VP I-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
by IN B-PP B-PP
distinct JJ B-NP B-NP
intracellular JJ I-NP I-NP
pathways NNS I-NP I-NP
might MD B-VP B-VP
all DT I-VP I-VP
act VB I-VP I-VP
through IN B-PP B-PP
a DT B-NP B-NP
common JJ I-NP I-NP
mechanism NN I-NP I-NP
involving VBG B-VP B-VP
the DT B-NP B-NP
synthesis NN I-NP I-NP
of IN B-PP B-PP
ROI NN B-NP B-NP
. . O O

ROI NN B-NP B-NP
appear VBP B-VP B-VP
to TO I-VP I-VP
serve VB I-VP I-VP
as IN B-PP B-PP
messengers NNS B-NP B-NP
mediating VBG B-VP B-VP
directly RB B-ADVP B-ADVP
or CC B-ADVP I-ADVP
indirectly RB B-ADVP I-ADVP
the DT B-NP B-NP
release NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
inhibitory JJ I-NP I-NP
subunit NN I-NP I-NP
I NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
from IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
. . O O

HTLV-1 NN B-NP B-NP
Tax NN I-NP I-NP
induces VBZ B-VP B-VP
expression NN B-NP B-NP
of IN B-PP B-PP
various JJ B-NP B-NP
immediate JJ I-NP I-NP
early JJ I-NP I-NP
serum NN I-NP I-NP
responsive JJ I-NP I-NP
genes NNS I-NP I-NP
. . O O

Human JJ B-NP B-NP
T-cell NN I-NP I-NP
leukemia NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP B-NP
( ( O O
HTLV-1 NN B-NP I-NP
) ) O O
is VBZ B-VP B-VP
an DT B-NP B-NP
etiological JJ I-NP I-NP
agent NN I-NP I-NP
of IN B-PP B-PP
adult JJ B-NP B-NP
T-cell NN I-NP I-NP
leukemia NN I-NP I-NP
( ( O O
ATL NN B-NP B-NP
) ) O O
. . O O

We PRP B-NP B-NP
showed VBD B-VP B-VP
here RB B-ADVP B-ADVP
by IN B-PP B-PP
mobility-shift NN B-NP B-NP
assay NN I-NP I-NP
that IN B-SBAR B-PP
T-cell NN B-NP B-NP
lines NNS I-NP I-NP
transformed VBN B-VP B-VP
with IN B-PP B-PP
the DT B-NP B-NP
virus NN I-NP I-NP
contained VBD B-VP B-VP
high JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
AP-1 NN B-NP B-NP
activities NNS I-NP I-NP
. . O O

Consistent JJ B-ADJP B-NP
with IN B-PP B-PP
this DT B-NP B-NP
result NN I-NP I-NP
, , O O
these DT B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
expressed VBD B-VP B-VP
increased VBN B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
mRNAs NNS B-NP B-NP
encoding VBG B-VP B-VP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
proteins NNS I-NP I-NP
, , O O
c-Fos NN B-NP B-NP
, , O O
Fra-1 NN B-NP B-NP
, , O O
c-Jun NN B-NP B-NP
, , O O
JunB NN B-NP B-NP
, , O O
and CC O I-CC
JunD NN B-NP B-NP
. . O O

Previously RB B-ADVP B-ADVP
, , O O
transcription NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
c-fos NN I-NP I-NP
gene NN I-NP I-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
reported VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
transactivated VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
viral JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
, , O O
Tax1 NN B-NP B-NP
. . O O

By IN B-PP B-PP
using VBG B-VP B-VP
the DT B-NP B-NP
human JJ I-NP I-NP
T-cell NN I-NP I-NP
line NN I-NP I-NP
( ( O O
JPX-9 NN B-NP B-NP
) ) O O
, , O O
in IN B-PP B-PP
which WDT B-NP B-NP
expression NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
Tax1 NN I-NP I-NP
is VBZ B-VP B-VP
inducible JJ B-ADJP B-ADJP
, , O O
we PRP B-NP B-NP
showed VBD B-VP B-VP
that IN B-SBAR B-PP
expression NN B-NP B-NP
of IN B-PP B-PP
mRNAs NNS B-NP B-NP
for IN B-PP B-PP
Fra-1 NN B-NP B-NP
, , O O
c-Jun NN B-NP B-NP
, , O O
and CC O I-CC
JunD NN B-NP B-NP
was VBD B-VP B-VP
also RB I-VP I-VP
transactivated VBN I-VP I-VP
by IN B-PP B-PP
Tax1 NN B-NP B-NP
. . O O

Moreover RB B-ADVP B-ADVP
, , O O
Tax1 NN B-NP B-NP
activated VBD B-VP B-VP
expression NN B-NP B-NP
of IN B-PP B-PP
two CD B-NP B-NP
other JJ I-NP I-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
having VBG B-VP B-VP
zinc NN B-NP B-NP
finger NN I-NP I-NP
motifs NNS I-NP I-NP
, , O O
Egr-1 NN B-NP B-NP
and CC O I-NP
Egr-2 NN B-NP I-NP
, , O O
in IN B-PP B-PP
the DT B-NP B-NP
same JJ I-NP I-NP
cells NNS I-NP I-NP
. . O O

The DT B-NP B-NP
Tax1-inducible JJ I-NP I-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
identified VBN B-VP B-VP
here RB B-ADVP B-ADVP
are VBP B-VP B-VP
encoded VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
members NNS I-NP I-NP
of IN B-PP B-PP
immediate JJ B-NP B-NP
early JJ I-NP I-NP
genes NNS I-NP I-NP
under IN B-PP B-PP
the DT B-NP B-NP
control NN I-NP I-NP
of IN B-PP B-PP
growth NN B-NP B-NP
signals NNS I-NP I-NP
. . O O

Thus RB O B-ADVP
, , O O
Tax1 NN B-NP B-NP
was VBD B-VP B-VP
suggested VBN I-VP I-VP
to TO I-VP I-VP
replace VB I-VP I-VP
growth NN B-NP B-NP
signals NNS I-NP I-NP
, , O O
at IN B-ADVP B-ADVP
least JJS I-ADVP I-ADVP
in IN B-PP B-PP
part NN B-NP B-NP
, , O O
by IN B-PP B-PP
this DT B-NP B-NP
mechanism NN I-NP I-NP
. . O O

Contribution NN B-NP B-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
and CC O I-NP
Sp1 NN B-NP I-NP
binding NN B-NP I-NP
motifs NNS I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
replicative JJ I-NP I-NP
capacity NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP I-NP
: : O O
distinct JJ B-NP B-NP
patterns NNS I-NP I-NP
of IN B-PP B-PP
viral JJ B-NP B-NP
growth NN I-NP I-NP
are VBP B-VP B-VP
determined VBN I-VP I-VP
by IN B-PP B-PP
T-cell NN B-NP B-NP
types NNS I-NP I-NP
. . O O

Starting VBG B-VP B-VP
with IN B-PP B-PP
a DT B-NP B-NP
replication-incompetent JJ I-NP I-NP
molecular JJ I-NP I-NP
clone NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP B-NP
, , O O
lacking VBG B-VP B-VP
all PDT O B-NP
the DT O I-NP
NF-kappa NN B-NP I-NP
B NN I-NP I-NP
and CC O I-NP
Sp1 NN B-NP I-NP
binding NN B-NP I-NP
sites NNS I-NP I-NP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
native JJ I-NP I-NP
long JJ B-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
( ( O O
LTR NN B-NP B-NP
) ) O O
, , O O
proviruses NNS B-NP B-NP
containing VBG B-VP B-VP
reconstructed VBN B-NP B-NP
LTRs NNS I-NP I-NP
with IN B-PP B-PP
individual JJ B-NP B-NP
or CC O I-NP
combinations NNS B-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
and CC O I-NP
Sp1 NN B-NP I-NP
elements NNS B-NP I-NP
were VBD B-VP B-VP
generated VBN I-VP I-VP
and CC O I-VP
evaluated VBN B-VP I-VP
for IN B-PP B-PP
their PRP$ B-NP B-NP
capacity NN I-NP I-NP
to TO B-VP B-VP
produce VB I-VP I-VP
virus NN B-NP B-NP
progeny NN I-NP I-NP
following VBG B-PP I-NP
transfection-cocultivation NN B-NP I-NP
. . O O

Virus NN B-NP B-NP
stocks NNS I-NP I-NP
obtained VBN B-VP B-VP
from IN B-PP B-PP
these DT B-NP B-NP
experiments NNS I-NP I-NP
exhibited VBD B-VP B-VP
a DT B-NP B-NP
continuum NN I-NP I-NP
of IN B-PP B-PP
replicative JJ B-NP B-NP
capacities NNS I-NP I-NP
in IN B-PP B-PP
different JJ B-NP B-NP
human JJ I-NP I-NP
T-cell NN I-NP I-NP
types NNS I-NP I-NP
depending VBG B-PP B-VP
on IN B-PP B-PP
which WDT B-NP B-NP
element NN I-NP B-NP
( ( I-NP O
s NNS I-NP B-NP
) ) O O
was VBD B-VP B-VP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
LTR NN I-NP I-NP
. . O O

For IN B-PP B-PP
example NN B-NP B-NP
, , O O
in IN B-PP B-PP
experiments NNS B-NP B-NP
involving VBG B-VP B-VP
proviral JJ B-NP B-NP
clones NNS I-NP I-NP
with IN B-PP B-PP
LTRs NNS B-NP B-NP
containing VBG B-VP B-VP
one CD B-NP B-NP
or CC I-NP I-NP
two CD I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
elements NNS I-NP I-NP
( ( O O
and CC O I-CC
no DT B-NP B-NP
Sp1 NN I-NP I-NP
binding NN I-NP I-NP
sites NNS I-NP I-NP
) ) O O
, , O O
a DT B-NP B-NP
hierarchy NN I-NP I-NP
of IN B-PP B-PP
cellular JJ B-NP B-NP
permissivity NN I-NP I-NP
to TO B-PP B-PP
virus NN B-NP B-NP
replication NN I-NP I-NP
( ( O O
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
lymphocytes NNS I-NP I-NP
= JJ B-VP B-NP
MT4 NN B-NP I-NP
greater JJR B-ADJP B-ADVP
than IN B-PP B-PP
H9 NN B-NP B-ADJP
greater JJR B-ADJP B-ADVP
than IN B-PP B-PP
CEM NN B-NP B-ADJP
greater JJR B-ADJP B-ADVP
than IN B-PP B-PP
Jurkat NN B-NP B-NP
) ) O O
was VBD B-VP B-VP
observed VBN I-VP I-VP
. . O O

Of IN B-PP B-PP
note NN B-NP B-NP
was VBD B-VP B-VP
the DT B-NP B-NP
associated VBN I-NP I-NP
emergence NN I-NP I-NP
of IN B-PP B-PP
second-site JJ B-NP B-NP
LTR NN I-NP I-NP
revertants NNS I-NP I-NP
which WDT B-NP B-NP
involved VBD B-VP B-VP
an DT B-NP B-NP
alteration NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
TATA NN I-NP I-NP
box NN I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
human JJ I-NP I-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP B-NP
LTR NN I-NP I-NP
possesses VBZ B-VP B-VP
functional JJ B-NP B-NP
redundancy NN I-NP I-NP
which WDT B-NP B-NP
ensures VBZ B-VP B-VP
virus NN B-NP B-NP
replication NN I-NP I-NP
in IN B-PP B-PP
different JJ B-NP B-NP
T-cell NN I-NP I-NP
types NNS I-NP I-NP
and CC O I-CC
is VBZ B-VP B-VP
capable JJ B-ADJP B-ADJP
of IN B-PP B-PP
changing VBG B-VP B-VP
depending VBG B-PP I-VP
on IN B-PP B-PP
the DT B-NP B-NP
particular JJ I-NP I-NP
combination NN I-NP I-NP
of IN B-PP B-PP
transcriptional JJ B-NP B-NP
factors NNS I-NP I-NP
present JJ B-ADJP B-ADJP
. . O O

Enhancement NN B-NP B-NP
of IN B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
1 CD I-NP B-NP
replication NN I-NP I-NP
in IN B-PP B-PP
monocytes NNS B-NP B-NP
by IN B-PP B-PP
1,25-dihydroxycholecalciferol NN B-NP B-NP
. . O O

Human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
( ( O O
HIV NN B-NP I-NN
) ) O O
expression NN B-NP B-NP
and CC O I-NP
replication NN B-NP I-NP
are VBP B-VP B-VP
under IN B-PP B-PP
tight JJ B-NP B-NP
regulatory JJ I-NP I-NP
control NN I-NP I-NP
. . O O

We PRP B-NP B-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
1,25-dihydroxycholecalciferol NN B-NP B-NP
( ( O O
1,25-(OH)2D3 NN B-NP I-NP
) ) O O
enhances VBZ B-VP B-VP
the DT B-NP B-NP
replication NN I-NP I-NP
of IN B-PP B-PP
monocyte- NN B-NP B-NP
and CC O I-CC
lymphocyte-tropic JJ B-ADJP B-NP
strains NNS B-NP I-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
up IN B-PP B-PP
to TO I-PP B-PP
10,000-fold RB B-ADVP B-NP
in IN B-PP B-PP
monocyte NN B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
, , O O
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
monocytes NNS I-NP I-NP
, , O O
and CC O I-CC
unfractionated JJ B-NP B-NP
peripheral JJ I-NP I-NP
blood NN I-NP I-NP
mononuclear JJ I-NP I-NP
cells NNS I-NP I-NP
. . O O

1,25(OH)2D3 NN B-NP B-NP
is VBZ B-VP B-VP
therefore RB B-ADVP B-NP
one CD B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
most RBS I-NP I-NP
potent JJ I-NP I-NP
regulators NNS I-NP I-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
replication NN I-NP I-NP
described VBN B-VP B-VP
to TO B-PP B-PP
date NN B-NP B-NP
. . O O

Precursors NNS B-NP B-NP
of IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
enhance VBP B-VP B-VP
HIV-1 NN B-NP B-NP
replication NN I-NP I-NP
in IN B-PP B-PP
proportion NN I-PP B-NP
to TO I-PP B-PP
their PRP$ B-NP B-NP
affinity NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
1,25(OH)2D3 NN I-NP I-NP
intracellular JJ I-NP I-NP
receptor NN I-NP I-NP
, , O O
suggesting VBG B-VP B-VP
that IN B-SBAR B-SBAR
1,25(OH)2D3 NN B-NP B-NP
influences VBZ B-VP B-VP
HIV-1 NN B-NP B-NP
replication NN I-NP I-NP
by IN B-PP B-PP
mechanisms NNS B-NP B-NP
involving VBG B-VP B-VP
this DT B-NP B-NP
receptor NN I-NP I-NP
. . O O

These DT B-NP B-NP
studies NNS I-NP I-NP
may MD B-VP B-VP
have VB I-VP I-VP
important JJ B-NP B-NP
implications NNS I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
design NN I-NP I-NP
of IN B-PP B-PP
effective JJ B-NP B-NP
therapy NN I-NP I-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
infection NN I-NP I-NP
. . O O

Inhibition NN B-NP B-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
replication NN I-NP I-NP
and CC O I-NP
NF-kappa NN B-NP I-NP
B NN I-NP I-NP
activity NN I-NP I-NP
by IN B-PP B-PP
cysteine NN B-NP B-NP
and CC O I-NP
cysteine NN B-NP I-NP
derivatives NNS I-NP I-NP
. . O O

HIV-1 NN B-NP B-NP
proviral JJ I-NP I-NP
DNA NN I-NP I-NP
contains VBZ B-VP B-VP
two CD B-NP B-NP
binding VBG I-NP I-NP
sites NNS I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
. . O O

HIV-1-infected JJ B-NP B-NP
individuals NNS I-NP I-NP
have VBP B-VP B-VP
, , O O
on IN B-PP B-PP
average NN B-NP B-NP
, , O O
abnormally RB B-NP B-NP
high JJ I-NP I-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
tumour NN B-NP B-NP
necrosis NN I-NP I-NP
factor NN I-NP I-NP
alpha NN I-NP I-NP
( ( O O
TNF NN B-NP B-NP
alpha NN I-NP I-NP
) ) O O
and CC O I-CC
abnormally RB B-NP B-NP
low JJ I-NP I-NP
plasma NN I-NP I-NP
cysteine NN I-NP I-NP
levels NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
therefore RB B-ADVP B-ADVP
investigated VBD B-VP B-VP
the DT B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
cysteine NN B-NP B-NP
and CC O I-NP
related JJ B-NP I-NP
thiols NNS I-NP I-NP
on IN B-PP B-PP
HIV-1 NN B-NP B-NP
replication NN I-NP I-NP
and CC O I-NP
NF-kappa NN B-NP I-NP
B NN I-NP I-NP
expression NN I-NP I-NP
. . O O

The DT B-NP B-NP
experiments NNS I-NP I-NP
in IN B-PP B-PP
this DT B-NP B-NP
report NN I-NP I-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
cysteine NN B-NP B-NP
or CC O I-NP
N-acetylcysteine NN B-NP I-NP
( ( O O
NP NN B-NP B-NP
) ) O O
raise VBP B-VP B-VP
the DT B-NP B-NP
intracellular JJ I-NP I-NP
glutathione NN I-NP I-NP
( ( I-NP O
GSH NN I-NP B-NP
) ) I-NP O
level NN I-NP I-NP
and CC O I-CC
inhibit VBP B-VP B-VP
HIV-1 NN B-NP B-NP
replication NN I-NP I-NP
in IN B-PP B-PP
persistently RB O B-NP
infected JJ O I-NP
Molt-4 NN B-NP I-NP
and CC O I-NP
U937 NN B-NP I-NP
cells NNS B-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
inhibition NN B-NP B-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
replication NN I-NP I-NP
appears VBZ B-VP B-VP
not RB I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
directly RB I-VP I-VP
correlated VBN I-VP I-VP
with IN B-PP B-PP
GSH NN B-NP B-NP
levels NNS I-NP I-NP
. . O O

Cysteine NN B-NP B-NP
and CC O I-NP
NP NN B-NP I-NP
also RB B-ADVP B-ADVP
inhibit VBP B-VP B-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
activity NN I-NP I-NP
as IN B-SBAR B-SBAR
determined VBN B-VP B-VP
by IN B-PP B-PP
electrophoretic JJ B-NP B-NP
mobility NN I-NP I-NP
shift NN I-NP I-NP
assays NNS I-NP I-NP
and CC O I-CC
chloramphenicol NN B-NP B-NP
acetyl-transferase NN I-NP I-NP
( ( O O
CAT NN B-NP I-NN
) ) O O
gene NN B-NP B-NP
expression NN I-NP I-NP
under IN B-PP B-PP
control NN B-NP B-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
binding NN I-NP I-NP
sites NNS I-NP I-NP
in IN B-PP B-PP
uninfected JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

This DT B-NP B-NP
suggests VBZ B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
cysteine NN I-NP I-NP
deficiency NN I-NP I-NP
in IN B-PP B-PP
HIV-1-infected JJ B-NP B-NP
individuals NNS I-NP I-NP
may MD B-VP B-VP
cause VB I-VP I-VP
an DT B-NP B-NP
over-expression NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B-dependent JJ I-NP I-NP
genes NNS I-NP I-NP
and CC O I-CC
enhance VB B-VP B-VP
HIV-1 NN B-NP B-NP
replication NN I-NP I-NP
. . O O

NP NN B-NP B-NP
may MD B-VP B-VP
be VB I-VP I-VP
considered VBN I-VP I-VP
for IN B-PP B-PP
the DT B-NP B-NP
treatment NN I-NP I-NP
of IN B-PP B-PP
HIV-1-infected JJ B-NP B-NP
individuals NNS I-NP I-NP
. . O O

Glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
in IN B-PP B-PP
systemic JJ B-NP B-NP
lupus NN I-NP I-NP
erythematosus NN I-NP I-NP
. . O O

Glucocorticosteroids NNS B-NP B-NP
remain VBP B-VP B-VP
the DT B-NP B-NP
major JJ I-NP I-NP
treatment NN I-NP I-NP
modality NN I-NP I-NP
for IN B-PP B-PP
systemic JJ B-NP B-NP
lupus NN I-NP I-NP
erythematosus NN I-NP I-NP
( ( O O
SLE NN B-NP B-NP
) ) O O
, , O O
but CC O I-CC
their PRP$ B-NP B-NP
mechanism NN I-NP I-NP
of IN B-PP B-PP
action NN B-NP B-NP
is VBZ B-VP B-VP
unclear JJ B-ADJP B-ADJP
. . O O

Over IN B-PP B-PP
the DT B-NP B-NP
past JJ I-NP I-NP
decade NN I-NP I-NP
it PRP B-NP B-NP
has VBZ B-VP B-VP
become VBN I-VP I-VP
clear JJ B-ADJP B-ADJP
that IN B-SBAR B-PP
glucocorticosteroid NN B-NP B-NP
receptors NNS I-NP I-NP
play VBP B-VP B-VP
a DT B-NP B-NP
significant JJ I-NP I-NP
role NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
mechanism NN I-NP I-NP
of IN B-PP B-PP
glucocorticosteroid NN B-NP B-NP
action NN I-NP I-NP
. . O O

We PRP B-NP B-NP
studied VBD B-VP B-VP
glucocorticosteroid NN B-NP B-NP
receptor NN I-NP I-NP
density NN B-NP I-NP
and CC O I-NP
affinity NN B-NP I-NP
on IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
mononuclear JJ I-NP I-NP
cells NNS I-NP I-NP
by IN B-PP B-PP
the DT B-NP B-NP
glucocorticosteroid NN I-NP I-NP
binding NN I-NP I-NP
assay NN I-NP I-NP
in IN B-PP B-PP
33 CD B-NP B-NP
patients NNS I-NP I-NP
with IN B-PP B-PP
SLE NN B-NP B-NP
who WP B-NP B-NP
had VBD B-VP B-VP
taken VBN I-VP I-VP
no DT B-NP B-NP
glucocorticosteroid NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
previous JJ I-NP I-NP
6 CD I-NP I-NP
months NNS I-NP I-NP
and CC B-PP I-CC
in IN B-PP B-PP
32 CD B-NP B-NP
healthy JJ I-NP I-NP
controls NNS I-NP I-NP
. . O O

Patients NNS B-NP B-NP
' POS B-NP B-NP
disease NN I-NP I-NP
activity NN I-NP I-NP
was VBD B-VP B-VP
measured VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
SLE NN I-NP I-NP
Disease NN I-NP I-NP
Activity NN I-NP I-NP
Index NN I-NP I-NP
( ( O O
SLEDAI NN B-NP B-NP
) ) O O
. . O O

Glucocorticosteroid NN B-NP B-NP
receptors NNS I-NP I-NP
on IN B-PP B-PP
leukocytes NNS B-NP B-NP
of IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
SLE NN O B-NP
were VBD B-VP B-VP
significantly RB B-ADJP B-ADJP
higher JJR I-ADJP I-ADJP
than IN B-PP B-PP
in IN B-PP B-PP
healthy JJ B-NP B-NP
controls NNS I-NP I-NP
( ( O O
4419 CD B-NP B-NP
+/- CC I-NP I-NP
306 CD I-NP I-NP
vs CC O I-NP
3369 CD B-NP I-NP
+/- CC I-NP I-NP
196 CD I-NP I-NP
, , O O
p NN B-NP B-NP
less JJR B-ADJP B-NP
than IN B-PP I-NP
0.005 CD B-NP I-NP
) ) O O
. . O O

The DT B-NP B-NP
binding NN I-NP I-NP
affinity NN I-NP I-NP
was VBD B-VP B-VP
not RB O I-RB
different JJ B-ADJP B-ADJP
between IN B-PP B-PP
patients NNS B-NP B-NP
and CC O I-NP
controls NNS B-NP I-NP
. . O O

There EX B-NP B-NP
was VBD B-VP B-VP
no DT B-NP B-NP
correlation NN I-NP I-NP
between IN B-PP B-PP
glucocorticosteroid NN B-NP B-NP
receptor NN I-NP I-NP
number NN I-NP I-NP
and CC O I-NP
SLE NN B-NP I-NP
disease NN I-NP I-NP
activity NN I-NP I-NP
. . O O

( ( O O
Changes NNS B-NP B-NP
in IN B-PP B-PP
leucocytic JJ B-NP B-NP
estrogen NN I-NP I-NP
receptor NN I-NP I-NP
levels NNS I-NP I-NP
in IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
gynecomastia NN B-NP B-NP
) ) O O

The DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
estrogen NN B-NP B-NP
receptor NN I-NP I-NP
( ( O O
ER NN B-NP B-NP
) ) O O
in IN B-PP B-PP
human JJ B-NP B-NP
peripheral JJ I-NP I-NP
leucocytes NNS I-NP I-NP
in IN B-PP B-PP
13 CD B-NP B-NP
men NNS I-NP I-NP
with IN B-PP B-PP
gynecomastia NNS B-NP B-NP
were VBD B-VP B-VP
measured VBN I-VP I-VP
by IN B-PP B-PP
radioligand NN B-NP B-NP
binding NN I-NP I-NP
method NN I-NP I-NP
. . O O

The DT B-NP B-NP
results NNS I-NP I-NP
were VBD B-VP B-VP
compared VBN I-VP I-VP
with IN B-PP B-PP
those DT B-NP B-NP
of IN B-PP B-PP
13 CD B-NP B-NP
sex- NN I-NP I-NP
and CC I-NP I-CC
age-matched JJ I-NP B-NP
healthy JJ I-NP I-NP
subjects NNS I-NP I-NP
. . O O

It PRP B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
ER NN B-NP B-NP
in IN B-PP B-PP
leucocytes NNS B-NP B-NP
was VBD B-VP B-VP
significantly RB I-VP I-VP
increased VBN I-VP I-VP
in IN B-PP B-PP
gynecomastia NN B-NP B-NP
( ( O O
Rs NN B-NP B-NP
of IN B-PP B-PP
leucocytes NNS B-NP B-NP
were VBD B-VP B-VP
1054 CD B-NP B-NP
+/- CC I-NP I-NP
254 CD I-NP I-NP
sites/cell NN I-NP I-NP
) ) O O
. . O O

It PRP B-NP B-NP
suggested VBD B-VP B-VP
that IN B-SBAR B-SBAR
increase NN B-NP B-NP
of IN B-PP B-PP
ER NN B-NP B-NP
levels NNS I-NP I-NP
play VBP B-VP B-VP
an DT B-NP B-NP
important JJ I-NP I-NP
role NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
pathogenesis NN I-NP I-NP
of IN B-PP B-PP
gynecomastia NN B-NP B-NP
. . O O

( ( O O
Changes NNS B-NP B-NP
in IN B-PP B-PP
levels NNS B-NP B-NP
of IN B-PP B-PP
leucocytic JJ B-NP B-NP
estrogen NN I-NP I-NP
receptor NN I-NP I-NP
in IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
menopausal JJ B-NP B-NP
type NN I-NP I-NP
II CD I-NP B-NP
diabetes NNS I-NP I-NP
and CC O I-CC
its PRP$ B-NP B-NP
significance NN I-NP I-NP
) ) O O

The DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
estrogen NN B-NP B-NP
receptors NNS I-NP I-NP
( ( O O
ER NN B-NP B-NP
) ) O O
in IN B-PP B-PP
human JJ B-NP B-NP
peripheral JJ I-NP I-NP
leucocytes NNS I-NP I-NP
in IN B-PP B-PP
12 CD B-NP B-NP
women NNS I-NP I-NP
with IN B-PP B-PP
menopausal JJ B-NP B-NP
type NN I-NP I-NP
II CD I-NP B-NP
diabetes NNS I-NP I-NP
was VBD B-VP B-VP
measured VBN B-NP I-VP
with IN B-PP B-PP
radio-ligand JJ B-NP B-NP
binding NN I-NP I-NP
method NN I-NP I-NP
. . O O

The DT B-NP B-NP
results NNS I-NP I-NP
were VBD B-VP B-VP
compared VBN I-VP I-VP
with IN B-PP B-PP
those DT B-NP B-NP
of IN B-PP B-PP
12 CD B-NP B-NP
menopausal JJ I-NP I-NP
women NNS I-NP I-NP
without IN B-PP B-PP
diabetes NNS B-NP B-NP
and CC O I-CC
12 CD B-NP B-NP
normal JJ I-NP I-NP
women NNS I-NP I-NP
of IN B-PP B-PP
childbearing JJ B-NP B-NP
age NN I-NP I-NP
. . O O

It PRP B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
ER NN B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
patients NNS I-NP I-NP
was VBD B-VP B-VP
significantly RB I-VP I-VP
decreased VBN I-VP I-VP
. . O O

Our PRP$ B-NP B-NP
data NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
decrease NN B-NP B-NP
of IN B-PP B-PP
ER NN B-NP B-NP
level NN I-NP I-NP
in IN B-PP B-PP
leukocytes NNS B-NP B-NP
may MD B-VP B-VP
be VB I-VP I-VP
related JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
pathogenesis NN I-NP I-NP
of IN B-PP B-PP
type NN B-NP B-NP
II CD I-NP I-NP
diabetes NNS I-NP I-NP
in IN B-PP B-PP
menopausal JJ B-NP B-NP
period NN I-NP I-NP
. . O O

Lymphocyte NN B-NP B-NP
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
binding NN I-NP I-NP
during IN B-PP B-PP
depression NN B-NP B-NP
and CC B-PP B-PP
after IN B-PP B-PP
clinical JJ B-NP B-NP
recovery NN I-NP I-NP
. . O O

Lymphocyte NN B-NP B-NP
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
binding NN I-NP I-NP
parameters NNS I-NP I-NP
were VBD B-VP B-VP
studied VBN I-VP I-VP
in IN B-PP B-PP
15 CD B-NP B-NP
severely RB I-NP I-NP
depressed JJ I-NP I-NP
patients NNS I-NP I-NP
during IN B-PP B-PP
depression NN B-NP B-NP
and CC B-PP B-PP
after IN B-PP B-PP
clinical JJ B-NP B-NP
recovery NN I-NP I-NP
, , O O
and CC O I-CC
in IN B-PP B-PP
15 CD B-NP B-NP
healthy JJ I-NP I-NP
controls NNS I-NP I-NP
. . O O

There EX B-NP B-NP
was VBD B-VP B-VP
no DT B-NP B-NP
difference NN I-NP I-NP
in IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
number NN B-NP I-NP
or CC O I-NP
affinity NN B-NP I-NP
between IN B-PP B-PP
depressed JJ B-NP B-NP
patients NNS I-NP I-NP
and CC O I-CC
recovered JJ B-NP B-NP
or CC I-NP I-NP
control NN I-NP I-NP
subjects NNS I-NP I-NP
. . O O

Afternoon NN O B-NP
ACTH NN B-NP I-NP
and CC O I-NP
cortisol NN B-NP I-NP
concentrations NNS B-NP I-NP
did VBD B-VP B-VP
not RB I-VP I-VP
differ VB I-VP I-VP
significantly RB B-ADVP B-ADVP
between IN B-PP B-PP
the DT B-NP B-NP
three CD I-NP I-NP
groups NNS I-NP I-NP
. . O O

No DT B-NP B-NP
relationship NN I-NP I-NP
could MD B-VP B-VP
be VB I-VP I-VP
established VBN I-VP I-VP
between IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
binding NN I-NP I-NP
and CC O I-CC
antidepressant JJ B-NP B-NP
medication NN I-NP I-NP
. . O O

These DT B-NP B-NP
data NNS I-NP I-NP
support VBP B-VP B-VP
the DT B-NP B-NP
view NN I-NP I-NP
of IN B-PP B-PP
an DT B-NP B-NP
impaired JJ I-NP I-NP
ligand-induced JJ I-NP I-NP
plasticity NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
regulation NN I-NP I-NP
rather RB B-CONJP B-PP
than IN I-CONJP I-PP
the DT B-NP B-NP
hypothesis NN I-NP I-NP
of IN B-PP B-PP
decreased VBN B-NP B-NP
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
numbers NNS I-NP I-NP
during IN B-PP B-PP
depression NN B-NP B-NP
. . O O

Nuclear JJ B-NP B-NP
association NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
T-cell NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
blocked VBN B-VP B-VP
by IN B-PP B-PP
FK-506 NN B-NP B-NP
and CC O I-NP
cyclosporin NN B-NP I-NP
A NN I-NP I-NP
( ( O O
see VB B-VP B-VP
comments NNS B-NP B-NP
) ) O O

Cyclosporin NN B-NP B-NP
A NN I-NP I-NP
and CC O I-NP
FK506 NN B-NP I-NP
inhibit VBP B-VP B-VP
T- NN O B-NP
and CC O I-NP
B-cell NN B-ADJP I-NP
activation NN B-NP I-NP
and CC O I-CC
other JJ B-NP B-NP
processes NNS I-NP I-NP
essential JJ B-ADJP B-ADJP
to TO B-PP B-PP
an DT B-NP B-NP
effective JJ I-NP I-NP
immune JJ I-NP I-NP
response NN I-NP I-NP
. . O O

In IN B-PP B-PP
T NN B-NP B-NP
lymphocytes NNS I-NP I-NP
these DT B-NP B-NP
drugs NNS I-NP I-NP
disrupt VBP B-VP B-VP
an DT B-NP B-NP
unknown JJ I-NP I-NP
step NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
transmission NN I-NP I-NP
of IN B-PP B-PP
signals NNS B-NP B-NP
from IN B-PP B-PP
the DT B-NP B-NP
T-cell NN I-NP I-NP
antigen NN I-NP I-NP
receptor NN I-NP I-NP
to TO B-PP B-PP
cytokine NN B-NP B-NP
genes NNS I-NP I-NP
that WDT B-NP B-NP
coordinate VBP B-VP B-VP
the DT B-NP B-NP
immune JJ I-NP I-NP
response NN I-NP I-NP
. . O O

The DT B-NP B-NP
putative JJ I-NP I-NP
intracellular JJ I-NP I-NP
receptors NNS I-NP I-NP
for IN B-PP B-PP
FK506 NN B-NP B-NP
and CC O I-NP
cyclosporin NN B-NP I-NP
are VBP B-VP B-VP
cis-trans JJ B-NP B-NP
prolyl JJ I-NP I-NP
isomerases NNS I-NP I-NP
. . O O

Binding NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
drug NN I-NP I-NP
inhibits VBZ B-VP B-VP
isomerase NN B-NP B-NP
activity NN I-NP I-NP
, , O O
but CC O I-CC
studies NNS B-NP B-NP
with IN B-PP B-PP
other JJ B-NP B-NP
prolyl JJ I-NP I-NP
isomerase NN I-NP I-NP
inhibitors NNS I-NP I-NP
and CC O I-CC
analysis NN B-NP B-NP
of IN B-PP B-PP
cyclosporin-resistant JJ B-NP B-NP
mutants NNS I-NP I-NP
in IN B-PP B-PP
yeast NN B-NP B-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
drug NN I-NP I-NP
result VBP B-VP B-VP
from IN B-PP B-PP
the DT B-NP B-NP
formation NN I-NP I-NP
of IN B-PP B-PP
an DT B-NP B-NP
inhibitory JJ I-NP I-NP
complex NN I-NP I-NP
between IN B-PP B-PP
the DT B-NP B-NP
drug NN I-NP I-NP
and CC O I-NP
isomerase NN B-NP I-NP
, , B-PP O
and CC I-PP I-CC
not RB B-PP B-ADVP
from IN I-PP B-PP
inhibition NN B-NP B-NP
of IN B-PP B-PP
isomerase NN B-NP B-NP
activity NN I-NP I-NP
. . O O

A DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
, , O O
NF-AT NN B-NP B-NP
, , O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
essential JJ B-ADJP B-ADJP
for IN B-PP B-PP
early JJ B-NP B-NP
T-cell NN I-NP I-NP
gene NN I-NP I-NP
activation NN I-NP I-NP
, , O O
seems VBZ B-VP B-VP
to TO I-VP I-VP
be VB I-VP I-VP
a DT B-NP B-NP
specific JJ I-NP I-NP
target NN I-NP I-NP
of IN B-PP B-PP
cyclosporin NN B-NP B-NP
A NN I-NP I-NP
and CC O I-NP
FK506 NN B-NP I-NP
action NN B-NP I-NP
because IN B-SBAR B-PP
transcription NN B-NP B-NP
directed VBN B-VP B-VP
by IN B-PP B-PP
this DT B-NP B-NP
protein NN I-NP I-NP
is VBZ B-VP B-VP
blocked VBN I-VP I-VP
in IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
treated VBN B-VP B-VP
with IN B-PP B-PP
these DT B-NP B-NP
drugs NNS I-NP I-NP
, , O O
with IN B-PP B-PP
little JJ B-NP B-NP
or CC I-NP I-NP
no DT I-NP I-NP
effect NN I-NP I-NP
on IN B-PP B-PP
other JJ B-NP B-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
such JJ B-PP B-PP
as IN I-PP I-PP
AP-1 NN B-NP B-NP
and CC O I-NP
NF-kappa NN B-NP I-NP
B NN I-NP I-NP
. . O O

Here RB B-ADVP B-ADVP
we PRP B-NP B-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
NF-AT NN B-NP B-NP
is VBZ B-VP B-VP
formed VBN I-VP I-VP
when WRB B-ADVP B-ADVP
a DT B-NP B-NP
signal NN I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
antigen NN I-NP I-NP
receptor NN I-NP I-NP
induces VBZ B-VP B-VP
a DT B-NP B-NP
pre-existing JJ I-NP I-NP
cytoplasmic JJ I-NP I-NP
subunit NN I-NP I-NP
to TO B-VP B-VP
translocate VB I-VP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
nucleus NN I-NP I-NP
and CC O I-CC
combine VB B-VP B-VP
with IN B-PP B-PP
a DT B-NP B-NP
newly RB I-NP I-NP
synthesized VBN I-NP I-NP
nuclear JJ I-NP I-NP
subunit NN I-NP I-NP
of IN B-PP B-PP
NF-AT NN B-NP B-NP
. . O O

FK506 NN B-NP B-NP
and CC O I-NP
cyclosporin NN B-NP I-NP
A NN I-NP I-NP
block VBP B-VP B-VP
translocation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
cytoplasmic JJ I-NP I-NP
component NN I-NP I-NP
without IN B-PP B-PP
affecting VBG B-VP B-VP
synthesis NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
nuclear JJ I-NP I-NP
subunit NN I-NP I-NP
. . O O

Regulation NN B-NP B-NP
of IN B-PP B-PP
M-CSF NN B-NP B-NP
expression NN I-NP I-NP
by IN B-PP B-PP
M-CSF NN B-NP B-NP
: : O O
role NN B-NP B-NP
of IN B-PP B-PP
protein NN B-NP B-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
and CC O I-NP
transcription NN B-NP I-NP
factor NN I-NP I-NP
NF NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
. . O O

Macrophage-colony-stimulating JJ B-NP B-NP
factor NN I-NP I-NP
( ( O O
M-CSF NN B-NP B-NP
) ) O O
, , O O
also RB B-VP B-VP
referred VBN I-VP I-VP
to TO B-PP B-PP
as IN B-PP B-PP
CSF-1 NN B-NP B-NP
, , O O
regulates VBZ B-VP B-VP
the DT B-NP B-NP
survival NN B-NP I-NP
, , O O
growth NN B-NP B-NP
, , O O
differentiation NN B-NP B-NP
and CC O I-CC
functional JJ B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
monocytes NNS B-NP B-NP
by IN B-PP B-PP
binding VBG B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
single JJ I-NP I-NP
class NN I-NP I-NP
of IN B-PP B-PP
high-affinity JJ B-NP B-NP
cell NN I-NP I-NP
surface NN I-NP I-NP
receptors NNS I-NP I-NP
, , O O
known VBN B-VP B-VP
to TO I-VP I-VP
be VB I-VP I-VP
the DT B-NP B-NP
product NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
c-fms NN I-NP I-NP
protooncogene NN I-NP I-NP
. . O O

The DT B-NP B-NP
detection NN I-NP I-NP
of IN B-PP B-PP
both CC O I-CC
M-CSF NN B-NP B-NP
and CC O I-NP
c-fms NN B-NP I-NP
expression NN B-NP I-NP
by IN B-PP B-PP
cells NNS B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
monocyte NN I-NP I-NP
lineage NN I-NP I-NP
has VBZ B-VP B-VP
suggested VBN I-VP I-VP
that IN B-SBAR B-SBAR
M-CSF NN B-NP B-NP
may MD B-VP B-VP
act VB I-VP I-VP
by IN B-PP B-PP
an DT B-NP B-NP
autocrine JJ I-NP I-NP
mechanism NN I-NP I-NP
. . O O

Interestingly RB B-ADVP B-ADVP
, , O O
it PRP B-NP B-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
shown VBN I-VP I-VP
that IN B-SBAR B-PP
M-CSF NN B-NP B-NP
can MD B-VP B-VP
induce VB I-VP I-VP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
its PRP$ B-NP B-NP
own JJ I-NP I-NP
gene NN I-NP I-NP
. . O O

Although IN B-SBAR B-SBAR
sensitivity NN B-NP B-NP
to TO B-PP B-PP
M-CSF NN B-NP B-NP
can MD B-VP B-VP
be VB I-VP I-VP
modulated VBN I-VP I-VP
by IN B-PP B-PP
regulation NN B-NP B-NP
of IN B-PP B-PP
receptor NN B-NP B-NP
expression NN B-NP I-NP
and CC O I-NP
function NN B-NP I-NP
, , O O
M-CSF NN B-NP I-NP
responsiveness NN I-NP I-NP
is VBZ B-VP B-VP
largely RB I-VP I-VP
determined VBN I-VP I-VP
at IN B-PP B-PP
a DT B-NP B-NP
postreceptor NN I-NP I-NP
level NN I-NP I-NP
. . O O

To TO B-PP B-PP
date NN B-NP B-NP
, , O O
little JJ B-NP B-NP
is VBZ B-VP B-VP
known VBN I-VP I-VP
about IN B-PP B-PP
the DT B-NP B-NP
intracellular JJ I-NP I-NP
pathway NN I-NP I-NP
of IN B-PP B-PP
M-CSF NN B-NP B-NP
signal NN I-NP I-NP
transduction NN I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
therefore RB I-VP I-VP
investigated VBN I-VP I-VP
the DT B-NP B-NP
changes NNS I-NP I-NP
in IN B-PP B-PP
protein NN B-NP B-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
( ( O O
PKC NN B-NP I-NN
) ) O O
activity NN B-NP B-NP
upon IN B-PP B-PP
exposure NN B-NP B-NP
of IN B-PP B-PP
monocytes NNS B-NP B-NP
to TO B-PP B-PP
M-CSF NN B-NP B-NP
. . O O

We PRP B-NP B-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
M-CSF NN B-NP B-NP
activates VBZ B-VP B-VP
and CC O I-VP
translocates VBZ B-VP I-VP
PKC NN B-NP B-NP
. . O O

Inhibition NN B-NP B-NP
of IN B-PP B-PP
PKC NN B-NP B-NP
by IN B-PP B-PP
the DT B-NP B-NP
isoquinoline NN I-NP I-NP
derivative JJ I-NP I-NP
H7 NN I-NP I-NP
abolishes VBZ B-VP B-VP
induction NN B-NP B-NP
of IN B-PP B-PP
M-CSF NN B-NP B-NP
by IN B-PP B-PP
M-CSF NN B-NP B-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
activation NN B-NP B-NP
of IN B-PP B-PP
PKC NN B-NP B-NP
was VBD B-VP B-VP
pertussis-toxin-sensitive JJ B-ADJP B-ADJP
and CC O I-CC
was VBD B-VP B-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
the DT B-NP B-NP
detection NN I-NP I-NP
of IN B-PP B-PP
an DT B-NP B-NP
NF NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
protein NN I-NP I-NP
in IN B-PP B-PP
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
of IN B-PP B-PP
M-CSF-induced JJ B-NP B-NP
blood NN I-NP I-NP
monocytes NNS I-NP I-NP
but CC B-PP I-CC
not RB B-PP I-RB
in IN I-PP B-PP
monocytes NNS B-NP B-NP
exposed VBN B-VP B-VP
to TO B-PP B-PP
medium NN B-NP B-NP
treatment NN I-NP I-NP
only RB B-ADVP B-ADVP
. . O O

The DT B-NP B-NP
results NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-PP
M-CSF NN B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
M-CSF NN B-NP B-NP
involves VBZ B-VP B-VP
G NN B-NP B-NP
proteins NNS I-NP I-NP
, , O O
PKC NN B-NP B-NP
and CC O I-NP
NF NN B-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
. . O O

NF-kappa NN B-NP B-NP
B NN I-NP I-NP
activation NN I-NP I-NP
by IN B-PP B-PP
tumor NN B-NP B-NP
necrosis NN I-NP I-NP
factor NN I-NP I-NP
alpha NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
Jurkat NN I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
is VBZ B-VP B-VP
independent JJ B-ADJP B-ADJP
of IN B-PP B-PP
protein NN B-NP B-NP
kinase NN I-NP I-NP
A NN I-NP I-NP
, , O O
protein NN B-NP B-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
, , O O
and CC O I-CC
Ca(2+)-regulated JJ B-NP B-NP
kinases NNS I-NP I-NP
. . O O

NF-kappa NN B-NP B-NP
B NN I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
DNA-binding JJ I-NP I-NP
regulatory JJ I-NP I-NP
factor NN I-NP I-NP
able JJ B-ADJP B-ADJP
to TO B-VP B-VP
control VB I-VP I-VP
transcription NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
genes NNS B-NP B-NP
, , O O
including VBG B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
( ( O O
HIV NN B-NP B-NP
) ) O O
genes NNS B-NP I-NP
. . O O

In IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
is VBZ B-VP B-VP
activated VBN I-VP I-VP
upon IN B-PP B-PP
cellular JJ B-NP B-NP
treatment NN I-NP I-NP
by IN B-PP B-PP
phorbol NN B-NP B-NP
esters NNS I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
cytokine NN I-NP I-NP
tumor NN B-NP I-NP
necrosis NN I-NP I-NP
factor NN I-NP I-NP
alpha NN I-NP I-NP
( ( O O
TNF NN B-NP B-NP
alpha NN I-NP I-NP
) ) O O
. . O O

In IN B-PP B-PP
the DT B-NP B-NP
present JJ I-NP I-NP
work NN I-NP I-NP
, , O O
we PRP B-NP B-NP
investigated VBD B-VP B-VP
the DT B-NP B-NP
molecular JJ I-NP I-NP
events NNS I-NP I-NP
leading VBG B-VP B-VP
to TO B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
activation NN I-NP I-NP
by IN B-PP B-PP
TNF NN B-NP B-NP
alpha NN I-NP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
human JJ I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
( ( O O
Jurkat NN B-NP B-NP
) ) O O
and CC O I-CC
its PRP$ B-NP B-NP
subclone JJ I-NP I-NP
JCT6 NN I-NP I-NP
, , O O
which WDT B-NP B-NP
presents VBZ B-VP B-VP
a DT B-NP B-NP
deficiency NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
PKA NN I-NP I-NP
transduction NN I-NP I-NP
pathway NN I-NP I-NP
. . O O

We PRP B-NP B-NP
found VBD B-VP B-VP
that IN B-SBAR B-SBAR
in IN B-PP B-PP
both DT B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
, , O O
both CC O I-CC
phorbol NN B-NP B-NP
ester NN I-NP I-NP
and CC O I-NP
TNF NN B-NP I-NP
alpha NN I-NP I-NP
were VBD B-VP B-VP
able JJ B-ADJP B-ADJP
to TO B-VP B-VP
activate VB I-VP I-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
. . O O

Phorbol NN B-NP B-NP
activation NN I-NP I-NP
was VBD B-VP B-VP
positively RB I-VP I-VP
modulated VBN I-VP I-VP
by IN B-PP B-PP
Ca2+ NN B-NP B-NP
influx NN I-NP I-NP
while IN B-SBAR B-LST
TNF NN B-NP B-NP
alpha NN I-NP I-NP
activation NN I-NP I-NP
was VBD B-VP B-VP
not RB O I-RB
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
while IN B-SBAR B-SBAR
PMA NN B-NP B-NP
activation NN I-NP I-NP
was VBD B-VP B-VP
inhibited VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
PKC NN I-NP I-NP
inhibitor NN I-NP I-NP
staurosporin NN I-NP I-NP
, , O O
the DT B-NP B-NP
TNF NN I-NP I-NP
alpha NN I-NP I-NP
effect NN I-NP I-NP
was VBD B-VP B-VP
unchanged JJ B-ADJP B-ADJP
. . O O

TNF NN B-NP B-NP
alpha NN I-NP I-NP
did VBD B-VP B-VP
not RB I-VP I-VP
activate VB I-VP I-VP
cAMP NN B-NP B-NP
production NN I-NP I-NP
and CC O I-CC
its PRP$ B-NP B-NP
signal NN I-NP I-NP
was VBD B-VP B-VP
not RB I-VP I-VP
modulated VBN I-VP I-VP
by IN B-PP B-PP
cAMP NN B-NP B-NP
activators NNS I-NP I-NP
. . O O

Moreover RB B-ADVP B-ADVP
, , O O
cAMP NN B-NP B-NP
activators NNS I-NP I-NP
did VBD B-VP B-VP
not RB I-VP I-VP
activate VB I-VP I-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
in IN B-PP B-PP
Jurkat NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Thus RB B-ADVP B-ADVP
, , O O
TNF NN B-NP B-NP
alpha-induced JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
activation NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
mediated VBN I-VP I-VP
by IN B-PP B-PP
none NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
major JJ I-NP I-NP
signal-mediating JJ I-NP I-NP
kinases NNS I-NP I-NP
such JJ B-PP B-PP
as IN I-PP I-PP
protein NN B-NP B-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
( ( O O
PKC NN B-NP B-NP
) ) O O
, , O O
protein NN B-NP B-NP
kinase NN I-NP I-NP
A NN I-NP I-NP
, , O O
or CC O I-CC
Ca(2+)-regulated JJ B-NP B-NP
kinases NNS I-NP I-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
we PRP B-NP B-NP
found VBD B-VP B-VP
that IN B-SBAR B-PP
cytoplasmic JJ B-NP B-NP
acidification NN I-NP I-NP
facilitated VBD B-VP B-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
activation NN I-NP I-NP
by IN B-PP B-PP
both CC O B-NP
TNF NN B-NP I-NP
alpha NN I-NP I-NP
and CC O I-NP
PKC NN B-NP I-NP
, , O O
by IN B-PP B-PP
a DT B-NP B-NP
mechanism NN I-NP I-NP
that WDT B-NP B-NP
increases VBZ B-VP B-VP
NF-kappa NN B-NP B-NP
B/I NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
dissociation NN I-NP I-NP
without IN B-PP B-PP
affecting VBG B-VP B-VP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
translocation NN I-NP I-NP
step NN I-NP I-NP
. . O O

NF-kappa NN B-NP B-NP
B NN I-NP I-NP
activity NN I-NP I-NP
in IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
stably RB B-VP B-VP
expressing VBG I-VP I-VP
the DT B-NP B-NP
Tax NN I-NP I-NP
protein NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
lymphotropic JJ I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
I CD I-NP I-NP
. . O O

The DT B-NP B-NP
effect NN I-NP I-NP
of IN B-PP B-PP
constitutive JJ B-NP B-NP
Tax NN I-NP I-NP
expression NN I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
interaction NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
with IN B-PP B-PP
its PRP$ B-NP B-NP
recognition NN I-NP I-NP
sequence NN I-NP I-NP
and CC B-PP B-PP
on IN B-PP B-PP
NF-kappa NN B-NP B-NP
B-dependent JJ I-NP I-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
was VBD B-VP B-VP
examined VBN I-VP I-VP
in IN B-PP B-PP
T NN B-NP B-NP
lymphoid JJ I-NP I-NP
Jurkat NN I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
( ( O O
19D NN B-NP B-NP
and CC O I-NP
9J NN B-NP I-NP
) ) O O
stably RB B-VP B-VP
transformed VBN I-VP I-VP
with IN B-PP B-PP
a DT B-NP B-NP
Tax NN I-NP I-NP
expression NN I-NP I-NP
vector NN I-NP I-NP
. . O O

Tax NN B-NP B-NP
expressing NN I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
contained VBD B-VP B-VP
a DT B-NP B-NP
constitutive JJ I-NP I-NP
level NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
, , O O
detectable JJ B-ADJP B-ADJP
by IN B-PP B-PP
mobility NN B-NP B-NP
shift NN I-NP I-NP
assay NN I-NP I-NP
and CC O I-NP
uv NN B-NP I-NP
cross-linking NN I-NP I-NP
using VBG B-VP B-VP
a DT B-NP B-NP
palindromic JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
probe NN I-NP I-NP
homologous JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
interferon NN I-NP I-NP
beta NN I-NP I-NP
PRDII NN I-NP I-NP
site NN I-NP I-NP
. . O O

In IN B-PP B-PP
Jurkat NN B-NP B-NP
and CC O I-NP
NC2.10 NN B-NP I-NP
induction NN B-NP I-NP
with IN B-PP B-PP
phorbol NN B-NP B-NP
esters NNS I-NP I-NP
resulted VBD O B-VP
in IN B-PP B-PP
the DT B-NP B-NP
appearance NN I-NP I-NP
of IN B-PP B-PP
new JJ B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
proteins NNS I-NP I-NP
of IN B-PP B-PP
85 CD B-NP B-NP
, , I-NP O
75 CD I-NP I-NP
, , I-NP O
and CC I-NP I-CC
54 CD I-NP B-NP
kDa NN I-NP I-NP
, , O O
whereas IN O B-PP
in IN B-PP B-PP
Tax NN B-NP B-NP
expressing NN I-NP I-NP
cells NNS I-NP I-NP
the DT B-NP B-NP
85-kDa JJ I-NP I-NP
protein NN I-NP I-NP
and CC O I-CC
a DT B-NP B-NP
92-kDa JJ I-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
protein NN I-NP I-NP
were VBD B-VP B-VP
constitutively RB I-VP I-VP
induced VBN I-VP I-VP
. . O O

Expression NN B-NP B-NP
of IN B-PP B-PP
Tax NN B-NP B-NP
protein NN I-NP I-NP
in IN B-PP B-PP
19D NN B-NP B-NP
and CC O I-NP
9J NN B-NP I-NP
resulted VBD B-VP B-VP
in IN B-PP B-PP
transcription NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
endogenous JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B-dependent JJ I-NP I-NP
granulocyte-macrophage JJ I-NP I-NP
colony NN I-NP I-NP
stimulating NN I-NP I-NP
factor NN I-NP I-NP
gene NN I-NP I-NP
and CC O I-CC
increased VBD B-NP B-VP
basal JJ I-NP B-NP
level NN I-NP I-NP
expression NN I-NP I-NP
of IN B-PP B-PP
transfected VBN B-NP B-NP
NF-kappa NN I-NP I-NP
B-regulated JJ I-NP I-NP
promoters NNS I-NP I-NP
. . O O

Nonetheless RB B-ADVP B-NP
transcription NN B-NP I-NP
of IN B-PP B-PP
both CC O I-CC
the DT B-NP B-NP
endogenous JJ I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
transfected VBN I-NP I-NP
gene NN B-NP I-NP
was VBD B-VP B-VP
inducible JJ B-ADJP B-ADJP
by IN B-PP B-PP
PMA NN B-NP B-NP
treatment NN I-NP I-NP
. . O O

Tax NN B-NP B-NP
expression NN I-NP I-NP
in IN B-PP B-PP
Jurkat NN B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
may MD B-VP B-VP
alter VB I-VP I-VP
the DT B-NP B-NP
stoichiometry NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
proteins NNS I-NP I-NP
and CC O I-CC
thus RB O B-VP
change VB B-VP I-VP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B-regulated JJ I-NP I-NP
promoters NNS I-NP I-NP
. . O O

Regulation NN B-NP B-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
mononuclear JJ I-NP I-NP
cells NNS I-NP I-NP
: : O O
effects NNS B-NP B-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
treatment NN I-NP I-NP
, , O O
Cushing NN B-NP B-NP
's POS B-NP B-NP
disease NN I-NP I-NP
and CC O I-NP
ketoconazole NN B-NP I-NP
. . O O

Glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
( ( O O
GcR NN B-NP B-NP
) ) O O
were VBD B-VP B-VP
determined VBN I-VP I-VP
by IN B-PP B-PP
a DT B-NP B-NP
whole JJ I-NP I-NP
cell NN I-NP I-NP
assay NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
mononulear JJ I-NP I-NP
leukocytes NNS I-NP I-NP
( ( O O
hMNL NN B-NP B-NP
) ) O O
from IN B-PP B-PP
control NN B-NP B-NP
subjects NNS I-NP I-NP
, , O O
patients NNS B-NP B-NP
receiving VBG B-VP B-VP
glucocorticoid NN B-NP B-NP
therapy NN I-NP I-NP
for IN B-PP B-PP
systemic JJ B-NP B-NP
diseases NNS I-NP I-NP
and CC O I-CC
Cushing NN B-NP B-NP
's POS B-NP B-NP
disease NN I-NP I-NP
patients NNS B-NP I-NP
with IN B-PP B-PP
or CC B-PP I-PP
without IN B-PP I-PP
ketoconazole NN B-NP B-NP
therapy NN I-NP I-NP
. . O O

Prolonged JJ B-NP B-NP
corticosteroid NN I-NP I-NP
treatment NN I-NP I-NP
resulted VBD B-VP B-VP
in IN B-PP B-PP
down-regulation NN B-NP B-NP
of IN B-PP B-PP
GcR NN B-NP B-NP
, , O O
while IN B-SBAR B-SBAR
the DT B-NP B-NP
mean NN I-NP I-NP
level NN I-NP I-NP
of IN B-PP B-PP
GcR NN B-NP B-NP
in IN B-PP B-PP
Cushing NN B-NP B-NP
's POS B-NP B-NP
disease NN I-NP I-NP
was VBD B-VP B-VP
normal JJ B-ADJP B-ADJP
. . O O

In IN B-PP B-PP
this DT B-NP B-NP
group NN I-NP I-NP
, , O O
however RB B-ADVP B-ADVP
, , O O
receptor NN B-NP B-NP
levels NNS I-NP I-NP
and CC O I-CC
morning NN B-NP B-NP
plasma NN I-NP I-NP
cortisol NN I-NP I-NP
values NNS I-NP I-NP
showed VBD B-VP B-VP
a DT B-NP B-NP
negative JJ I-NP I-NP
correlation NN I-NP I-NP
, , O O
indicating VBG B-VP B-VP
a DT B-NP B-NP
subtle JJ I-NP I-NP
down-regulatory JJ I-NP I-NP
effect NN I-NP I-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
GcR NN B-NP B-NP
were VBD B-VP B-VP
unaltered JJ B-ADJP B-ADJP
after IN B-SBAR B-PP
these DT B-NP B-NP
patients NNS I-NP I-NP
received VBD B-VP B-VP
ketoconazole NN B-NP B-NP
, , O O
in IN B-PP B-PP
spite NN I-PP B-NP
of IN I-PP B-PP
a DT B-NP B-NP
marked JJ I-NP I-NP
reduction NN I-NP I-NP
in IN B-PP B-PP
morning NN B-NP B-NP
plasma NN I-NP I-NP
cortisol NN I-NP I-NP
and CC O I-CC
urinary JJ B-NP B-NP
free JJ I-NP I-NP
cortisol NN I-NP I-NP
. . O O

We PRP B-NP B-NP
also RB B-ADVP B-ADVP
observed VBD B-VP B-VP
that IN B-SBAR B-SBAR
ketoconazole NN B-NP B-NP
was VBD B-VP B-VP
a DT B-NP B-NP
weak JJ I-NP I-NP
competitor NN I-NP I-NP
of IN B-PP B-PP
GcR NN B-NP B-NP
in IN B-PP B-PP
intact JJ B-NP B-NP
cells NNS I-NP I-NP
, , O O
although IN B-SBAR B-SBAR
it PRP B-NP B-NP
significantly RB B-ADVP B-ADVP
inhibited VBD B-VP B-VP
(3H) NN B-NP B-NP
dexamethasone NN I-NP I-NP
binding NN I-NP I-NP
in IN B-PP B-PP
cytosolic JJ B-NP B-NP
preparations NNS I-NP I-NP
from IN B-PP B-PP
rat NN B-NP B-NP
tissues NNS I-NP I-NP
. . O O

The DT B-NP B-NP
results NNS I-NP I-NP
suggested VBD B-VP B-VP
that IN B-SBAR B-PP
GcR NN B-NP B-NP
in IN B-PP B-PP
hMNL NN B-NP B-NP
are VBP B-VP B-VP
down-regulated VBN I-VP I-VP
by IN B-PP B-PP
synthetic JJ B-NP B-NP
steroids NNS I-NP I-NP
given VBN B-VP B-VP
in FW B-ADVP B-NP
vivo FW I-ADVP I-NP
, , O O
but CC O I-CC
they PRP B-NP B-NP
showed VBD B-VP B-VP
very RB B-NP B-NP
mild JJ I-NP I-NP
down-regulation NN I-NP I-NP
in IN B-PP B-PP
hypercortisolemic JJ B-NP B-NP
patients NNS I-NP I-NP
suffering VBG B-VP B-VP
from IN B-PP B-PP
Cushing NN B-NP B-NP
's POS B-NP B-NP
disease NN I-NP I-NP
. . O O

Finally RB B-ADVP B-ADVP
, , O O
we PRP B-NP B-NP
did VBD B-VP B-VP
not RB I-VP I-VP
observed VBN I-VP I-VP
either CC O I-CC
up-regulation NN B-NP B-NP
or CC O I-NP
antagonism NN B-NP I-NP
of IN B-PP B-PP
GcR NN B-NP B-NP
by IN B-PP B-PP
ketoconazole NN B-NP B-NP
treatment NN I-NP I-NP
, , O O
at IN B-PP B-PP
the DT B-NP B-NP
time NN I-NP I-NP
that IN B-ADVP B-PP
cortisol NN B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
Cushing NN B-NP B-NP
's POS B-NP B-NP
disease NN I-NP I-NP
were VBD B-VP B-VP
reduced VBN I-VP I-VP
. . O O

This DT B-NP B-NP
indicates VBZ B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
beneficial JJ I-NP I-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
ketoconazole NN B-NP B-NP
in IN B-PP B-PP
Cushing NN B-NP B-NP
's POS B-NP B-NP
disease NN I-NP I-NP
are VBP B-VP B-VP
due JJ B-PP B-ADJP
to TO B-PP B-PP
adrenal JJ B-NP B-NP
cortisol NN I-NP I-NP
suppression NN I-NP I-NP
and CC B-PP I-CC
not RB B-PP I-RB
to TO I-PP B-PP
interaction NN B-NP B-NP
with IN B-PP B-PP
GcR NN B-NP B-NP
of IN B-PP B-PP
target NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
and CC O I-CC
that IN B-SBAR B-SBAR
the DT B-NP B-NP
process NN I-NP I-NP
of IN B-PP B-PP
GcR NN B-NP B-NP
regulation NN I-NP I-NP
in IN B-PP B-PP
hMNL NN B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
complex JJ I-NP I-NP
phenomenon NN I-NP I-NP
awaiting VBG B-VP B-VP
further RBR B-NP B-NP
elucidation NN I-NP I-NP
. . O O

Glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
in IN B-PP B-PP
lymphocytes NNS B-NP B-NP
in IN B-PP B-PP
anorexia NN B-NP B-NP
nervosa NN I-NP I-NP
. . O O

OBJECTIVE NN B-NP B-NP
: : O O
The DT B-NP B-NP
aim NN I-NP I-NP
was VBD B-VP B-VP
to TO B-VP I-VP
explore VB I-VP I-VP
the DT B-NP B-NP
down-regulation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
glucocorticoid NN I-NP I-NP
receptors NNS I-NP I-NP
during IN B-PP B-PP
hypercortisolaemia NN B-NP B-NP
in IN B-PP B-PP
anorexia NN B-NP B-NP
nervosa NN I-NP I-NP
. . O O

DESIGN NN B-NP B-NP
: : O O
Urine NN B-NP B-NP
and CC O I-NP
plasma NN B-NP I-NP
samples NNS B-NP I-NP
were VBD B-VP B-VP
obtained VBN I-VP I-VP
for IN B-PP B-PP
cortisol NN B-NP B-NP
determination NN I-NP I-NP
and CC O I-NP
blood NN B-NP I-NP
lymphocytes NNS I-NP I-NP
were VBD B-VP B-VP
isolated VBN I-VP I-VP
for IN B-PP B-PP
receptor NN B-NP B-NP
binding NN I-NP I-NP
studies NNS I-NP I-NP
. . O O

PATIENTS NNS B-NP B-NP
: : O O
Sixteen CD B-NP B-NP
anorexic JJ I-NP I-NP
patients NNS I-NP I-NP
, , O O
aged JJ B-ADJP B-NP
16-27 CD B-NP I-NP
years NNS I-NP I-NP
, , O O
with IN B-PP B-PP
a DT B-NP B-NP
mean NN I-NP I-NP
+/- CC I-NP I-NP
SEM NN I-NP I-NP
body NN I-NP I-NP
mass NN I-NP I-NP
index NN I-NP I-NP
of IN B-PP B-PP
14.2 CD B-NP B-NP
+/- CC I-NP I-NP
2.0 CD I-NP I-NP
( ( O O
ranging VBG B-VP B-VP
from IN B-PP B-PP
11.1 CD B-NP B-NP
to TO B-PP B-PP
17.4 CD B-NP B-NP
) ) O O
, , O O
and CC O I-CC
15 CD B-NP B-NP
normal JJ I-NP I-NP
women NNS I-NP I-NP
were VBD B-VP B-VP
studied VBN I-VP I-VP
. . O O

Six CD B-NP B-NP
patients NNS I-NP I-NP
were VBD B-VP B-VP
reinvestigated VBN I-VP I-VP
after IN B-PP B-PP
a DT B-NP B-NP
significant JJ I-NP I-NP
weight NN I-NP I-NP
gain NN I-NP I-NP
. . O O

MEASUREMENTS NNS B-NP B-NP
: : O O
The DT B-NP B-NP
binding NN B-NP I-NP
capacity NN B-NP I-NP
and CC O I-NP
affinity NN B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
glucocorticoid NN I-NP I-NP
receptors NNS I-NP I-NP
were VBD B-VP B-VP
measured VBN I-VP I-VP
with IN B-PP B-PP
dexamethasone NN B-NP B-NP
as IN B-PP B-PP
ligand NN B-NP B-NP
on IN B-PP B-PP
lymphocytes NNS B-NP B-NP
. . O O

RESULTS NNS B-NP B-NP
: : O O
In IN B-PP B-PP
patients NNS B-NP B-NP
, , O O
both DT B-NP B-NP
total JJ I-NP I-NP
and CC I-NP I-NP
free JJ I-NP I-NP
plasma NN I-NP I-NP
cortisol NN I-NP I-NP
concentrations NNS I-NP I-NP
were VBD B-VP B-VP
higher JJR B-ADJP B-ADJP
than IN B-PP B-PP
in IN B-PP B-PP
the DT B-NP B-NP
normal JJ I-NP I-NP
women NNS I-NP I-NP
, , O O
as IN B-SBAR B-NP
was VBD O B-VP
their PRP$ B-NP B-NP
urinary JJ I-NP I-NP
free JJ I-NP I-NP
cortisol NN I-NP I-NP
; : O O
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
per IN B-PP B-PP
cell NN B-NP B-NP
( ( O O
Ro NN B-NP B-NP
) ) O O
and CC O I-CC
the DT B-NP B-NP
binding NN I-NP I-NP
affinity NN I-NP I-NP
( ( O O
Kd NN B-NP B-NP
) ) O O
for IN B-PP B-PP
dexamethasone NN B-NP B-NP
were VBD B-VP B-VP
, , O O
however RB B-ADVP B-ADVP
, , O O
not RB B-ADJP B-NP
significantly RB I-ADJP I-NP
different JJ I-ADJP I-NP
( ( O O
Ro NN B-NP I-NP
: : O O
7687 CD B-NP B-NP
+/- CC I-NP I-NP
1750 CD I-NP I-NP
vs CC I-NP I-NP
7347 CD I-NP I-NP
+/- CC I-NP I-NP
1285 CD I-NP I-NP
sites/cell NN I-NP I-NP
; : O O
Kd NN B-NP B-NP
: : O O
7.7 CD B-NP B-NP
+/- CC I-NP I-NP
2.4 CD I-NP I-NP
vs CC I-NP I-NP
7.4 CD I-NP I-NP
+/- CC I-NP I-NP
1.7 CD I-NP I-NP
nM NN I-NP I-NP
at IN B-PP B-PP
24 CD B-NP B-NP
degrees NNS I-NP I-NP
C NN I-NP B-ADVP
) ) O O
. . O O

After IN B-PP B-PP
weight NN B-NP B-NP
gain NN I-NP I-NP
( ( O O
14 CD B-NP B-NP
+/- CC I-NP I-NP
2 CD I-NP I-NP
to TO I-NP B-PP
16 CD I-NP B-NP
+/- CC I-NP I-CC
2 CD I-NP B-NP
kg/m2 NN I-NP I-NP
) ) O O
, , O O
receptor NN B-NP B-NP
numbers NNS I-NP I-NP
were VBD B-VP B-VP
8421 CD B-NP B-NP
+/- CC I-NP I-NP
2126 CD I-NP I-NP
( ( O O
pre JJ|RB O I-JJ|RB
) ) O O
and CC O I-CC
9011 CD B-NP B-NP
+/- CC I-NP I-NP
500 CD I-NP I-NP
( ( O O
post JJ|RB O I-JJ|RB
) ) O O
sites/cell NN B-NP B-NP
, , O O
which WDT B-NP B-NP
are VBP B-VP B-VP
not RB O I-RB
significantly RB B-ADJP B-ADJP
different JJ I-ADJP I-ADJP
( ( O O
P NN B-NP B-ADJP
greater JJR B-ADJP I-ADJP
than IN B-PP B-PP
0.2 CD B-NP B-NP
) ) O O
; : O O
the DT B-NP B-NP
Kd NN I-NP I-NP
was VBD B-VP B-VP
unchanged JJ B-ADJP B-ADJP
( ( O O
9.3 CD B-NP B-NP
+/- CC I-NP I-NP
2.6 CD I-NP I-NP
vs CC I-NP I-NP
9.2 CD I-NP I-NP
+/- CC I-NP I-NP
2.4 CD I-NP I-NP
nM NN I-NP I-NP
) ) O O
. . O O

CONCLUSIONS NNS B-NP B-NP
Hypercortisolaemia NN B-NP I-NP
does VBZ B-VP B-VP
not RB I-VP I-VP
down-regulate VB I-VP I-VP
the DT B-NP B-NP
lymphocyte NN I-NP I-NP
glucocorticoid NN I-NP I-NP
receptors NNS I-NP I-NP
in IN B-PP B-PP
anorexia NN B-NP B-NP
nervosa NN I-NP I-NP
and CC O I-CC
a DT B-NP B-NP
post-receptor JJ I-NP I-NP
defect NN I-NP I-NP
might MD B-VP B-VP
be VB I-VP I-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
peripheral JJ B-NP B-NP
tissue NN I-NP I-NP
resistance NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
hormones NNS I-NP I-NP
in IN B-PP B-PP
undernutrition NN B-NP B-NP
. . O O

Tumor NN B-NP B-NP
necrosis NN I-NP I-NP
factor-alpha NN I-NP I-NP
mRNA NN I-NP I-NP
accumulation NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
myelomonocytic JJ I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
. . O O

Role NN B-NP B-NP
of IN B-PP B-PP
transcriptional JJ B-NP B-NP
regulation NN I-NP I-NP
by IN B-PP B-PP
DNA NN B-NP B-NP
sequence NN I-NP I-NP
motifs NNS I-NP I-NP
and CC O I-CC
mRNA NN B-NP B-NP
stabilization NN I-NP I-NP
. . O O

The DT B-NP B-NP
cytokine NN I-NP I-NP
TNF NN I-NP I-NP
mediates VBZ B-VP B-VP
many JJ B-NP B-ADJP
of IN B-PP B-PP
the DT B-NP B-NP
pathologic JJ I-NP I-NP
signs NNS I-NP I-NP
of IN B-PP B-PP
cachexia NN B-NP B-NP
, , O O
inflammation NN B-NP B-NP
, , O O
and CC O I-CC
sepsis NN B-NP B-NP
. . O O

The DT B-NP B-NP
current JJ I-NP I-NP
work NN I-NP I-NP
describes VBZ B-VP B-VP
the DT B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
TNF NN B-NP B-NP
in IN B-PP B-PP
human JJ B-NP B-NP
myelomonocytic JJ I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
after IN B-PP B-PP
PMA NN B-NP B-NP
stimulation NN I-NP I-NP
. . O O

The DT B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
exhibit VBP B-VP B-VP
a DT B-NP B-NP
low JJ I-NP I-NP
level NN I-NP I-NP
of IN B-PP B-PP
constitutive JJ B-NP B-NP
TNF NN I-NP I-NP
mRNA NN I-NP I-NP
expression NN I-NP I-NP
. . O O

Within IN B-PP B-PP
2 CD B-NP B-NP
to TO I-NP I-NP
4 CD I-NP I-NP
h NN I-NP I-NP
of IN B-PP B-PP
PMA NN B-NP B-NP
exposure NN I-NP I-NP
, , O O
steady JJ B-NP B-NP
state NN I-NP I-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
TNF NN B-NP B-NP
mRNA NN I-NP I-NP
are VBP B-VP B-VP
markedly RB I-VP B-ADJP
elevated JJ I-VP I-ADJP
in IN B-PP B-PP
all DT B-NP B-NP
myelomonocytic JJ I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
studied VBN B-VP B-VP
. . O O

This DT B-NP B-NP
rise NN I-NP I-NP
is VBZ B-VP B-VP
due JJ B-PP B-ADJP
to TO B-PP B-PP
increased VBN B-NP B-NP
mRNA NN I-NP I-NP
stability NN I-NP I-NP
, , O O
which WDT B-NP B-NP
increased VBD B-VP B-VP
by IN B-PP B-PP
almost RB B-NP B-ADVP
twofold RB I-NP I-ADVP
, , B-PP O
and CC I-PP I-CC
to TO B-PP B-PP
an DT B-NP B-NP
overall JJ I-NP I-NP
increase NN I-NP I-NP
in IN B-PP B-PP
transcription NN B-NP B-NP
, , O O
which WDT B-NP B-NP
rises VBZ B-VP B-VP
by IN B-PP B-PP
more JJR B-NP B-NP
than IN I-NP I-NP
sixfold RB I-NP B-ADVP
. . O O

At IN B-PP B-PP
the DT B-NP B-NP
level NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
genomic JJ I-NP I-NP
TNF NN I-NP I-NP
gene NN I-NP I-NP
, , O O
a DT B-NP B-NP
DNase NN I-NP I-NP
I CD I-NP I-NP
hypersensitive JJ I-NP I-NP
site NN I-NP I-NP
is VBZ B-VP B-VP
detected VBN I-VP I-VP
within IN B-PP B-PP
the DT B-NP B-NP
TNF NN I-NP I-NP
promoter NN I-NP I-NP
between IN B-PP B-PP
-200 CD B-NP B-NP
to TO I-NP I-NP
-100 CD I-NP I-NP
bp NN I-NP I-NP
relative JJ B-PP B-ADJP
to TO I-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
initiation NN I-NP I-NP
site NN I-NP I-NP
. . O O

Although IN B-SBAR B-PP
absent JJ B-ADJP B-NP
in IN B-PP B-PP
nonexpressing VBG B-NP B-VP
erythroleukemia NN I-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
, , O O
the DT B-NP B-NP
DNase NN I-NP I-NP
I CD I-NP I-NP
site NN I-NP I-NP
is VBZ B-VP B-VP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
uninduced JJ B-NP B-NP
myelomonocytic JJ I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
and CC O I-CC
is VBZ B-VP B-VP
not RB I-VP I-VP
changed VBN I-VP I-VP
after IN B-PP B-PP
PMA NN B-NP B-NP
induction NN I-NP I-NP
. . O O

The DT B-NP B-NP
PMA NN I-NP I-NP
induction NN I-NP I-NP
of IN B-PP B-PP
c-fos NN B-NP B-NP
mRNA NN I-NP I-NP
correlated VBD B-VP B-VP
well RB B-ADVP B-ADVP
with IN B-PP B-PP
TNF NN B-NP B-NP
gene NN I-NP I-NP
induction NN I-NP I-NP
; : O O
expression NN B-NP B-NP
of IN B-PP B-PP
genes NNS B-NP B-NP
encoding VBG B-VP B-VP
other JJ B-NP B-NP
proteins NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
complex NN I-NP I-NP
( ( O O
junB NN B-NP B-NP
and CC O I-NP
junD NN B-NP I-NP
) ) O O
were VBD B-VP B-VP
also RB I-VP I-VP
induced VBN I-VP I-VP
by IN B-PP B-PP
PMA NN B-NP B-NP
. . O O

The DT B-NP B-NP
nuclear JJ I-NP I-NP
extracts NNS I-NP I-NP
from IN B-PP B-PP
resting VBG B-NP B-NP
and CC I-NP I-NP
induced VBN I-NP I-NP
ML-1 NN I-NP I-NP
cells NNS I-NP I-NP
contain VBP B-VP B-VP
proteins NNS B-NP B-NP
binding VBG B-VP B-VP
specifically RB B-ADVP B-ADVP
to TO B-PP B-PP
the DT B-NP B-NP
AP-1 NN B-NP I-NP
, , O O
AP-2 NN B-NP B-NP
, , O O
and CC O I-CC
NF NN B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
sequence NN I-NP I-NP
located JJ B-ADJP B-ADJP
within IN B-PP B-PP
the DT B-NP B-NP
TNF NN I-NP I-NP
promoter NN I-NP I-NP
. . O O

PMA NN B-NP B-NP
induction NN I-NP I-NP
increases VBZ B-VP B-VP
the DT B-NP B-NP
level NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
specific JJ B-NP B-NP
binding VBG I-NP I-NP
complexes NNS I-NP I-NP
relative JJ B-PP B-ADJP
to TO I-PP B-PP
the DT B-NP B-NP
resting VBG I-NP I-NP
cells NNS I-NP I-NP
. . O O

The DT B-NP B-NP
regulatory JJ I-NP I-NP
mechanisms NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
and CC I-NP I-NP
murine JJ I-NP I-NP
TNF NN I-NP I-NP
genes NNS I-NP I-NP
are VBP B-VP B-VP
discussed VBN I-VP I-VP
. . O O

USF-related JJ B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
, , O O
HIV-TF1 NN B-NP B-NP
, , O O
stimulates VBZ B-VP B-VP
transcription NN B-NP B-NP
of IN B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus-1 NN I-NP I-NP
. . O O

The DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
HIV-TF1 NN I-NP I-NP
, , O O
which WDT B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
region NN I-NP I-NP
about IN B-NP B-PP
60 CD I-NP B-NP
bp NN I-NP I-NP
upstream JJ B-ADJP B-ADJP
from IN B-PP B-PP
the DT B-NP B-NP
enhancer NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
immunodeficiency NN I-NP I-NP
virus-1 NN I-NP I-NP
( ( O O
HIV-1 NN B-NP B-NP
) ) O O
, , O O
was VBD B-VP B-VP
purified VBN I-VP I-VP
from IN B-PP B-PP
human JJ B-NP B-NP
B NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

HIV-TF1 NN B-NP B-NP
had VBD B-VP B-VP
a DT B-NP B-NP
molecular JJ I-NP I-NP
weight NN I-NP I-NP
of IN B-PP B-PP
39,000 CD B-NP B-NP
. . O O

Binding NN B-NP B-NP
of IN B-PP B-PP
HIV-TF1 NN B-NP B-NP
to TO B-PP B-PP
the DT B-NP B-NP
HIV NN I-NP I-NP
long JJ B-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
( ( O O
LTR NN B-NP B-NP
) ) O O
activated VBD B-VP B-VP
transcription NN B-NP B-NP
from IN B-PP B-PP
the DT B-NP B-NP
HIV NN I-NP I-NP
promoter NN I-NP I-NP
in FW B-ADVP B-NP
vitro FW I-ADVP I-NP
. . O O

The DT B-NP B-NP
HIV-TF1-binding JJ I-NP I-NP
site NN I-NP I-NP
in IN B-PP B-PP
HIV NN B-NP B-NP
LTR NN I-NP I-NP
was VBD B-VP B-VP
similar JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
site NN I-NP I-NP
recognized VBN B-VP B-VP
by IN B-PP B-PP
upstream JJ B-NP B-NP
stimulatory JJ I-NP I-NP
factor NN I-NP I-NP
( ( O O
USF NN B-NP B-NP
) ) O O
in IN B-PP B-PP
the DT B-NP B-NP
adenovirus NN I-NP I-NP
major JJ I-NP I-NP
late JJ I-NP I-NP
promoter NN I-NP I-NP
. . O O

DNA-binding JJ B-NP B-NP
properties NNS I-NP I-NP
of IN B-PP B-PP
HIV-TF1 NN B-NP B-NP
suggested VBD B-VP B-VP
that IN B-SBAR B-SBAR
HIV-TF1 NN B-NP B-NP
might MD B-VP B-VP
be VB I-VP I-VP
identical JJ B-ADJP B-ADJP
or CC O I-ADJP
related JJ B-ADJP I-ADJP
to TO B-PP B-PP
USF NN B-NP B-NP
. . O O

Interestingly RB B-ADVP B-ADVP
, , O O
treatment NN B-NP B-NP
of IN B-PP B-PP
purified VBN B-NP B-NP
HIV-TF1 NN I-NP I-NP
by IN B-PP B-PP
phosphatase NN B-NP B-NP
greatly RB B-ADVP B-ADVP
reduced VBD B-VP B-VP
its PRP$ B-NP B-NP
DNA-binding JJ I-NP I-NP
activity NN I-NP I-NP
, , O O
suggesting VBG B-VP B-VP
that IN B-SBAR B-PP
phosphorylation NN B-NP B-NP
of IN B-PP B-PP
HIV-TF1 NN B-NP B-NP
was VBD B-VP B-VP
essential JJ B-ADJP B-ADJP
for IN B-PP B-PP
DNA NN B-NP B-NP
binding NN I-NP I-NP
. . O O

The DT B-NP B-NP
disruption NN I-NP I-NP
of IN B-PP B-PP
HIV-TF1-binding JJ B-NP B-NP
site NN I-NP I-NP
induced VBD B-VP B-VP
a DT B-NP B-NP
60 CD B-NP I-NP
% NN I-NP I-NP
decrease NN B-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
level NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
from IN B-PP B-PP
the DT B-NP B-NP
HIV NN I-NP I-NP
promoter NN I-NP I-NP
in FW B-ADVP B-NP
vivo FW I-ADVP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
HIV-TF1 NN B-NP B-NP
is VBZ B-VP B-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
transcriptional JJ B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
. . O O

The DT B-NP B-NP
effect NN I-NP I-NP
of IN B-PP B-PP
toremifene NN B-NP B-NP
therapy NN I-NP I-NP
on IN B-PP B-PP
serum NN B-NP B-NP
immunoglobulin NN I-NP I-NP
levels NNS I-NP I-NP
in IN B-PP B-PP
breast NN B-NP B-NP
cancer NN I-NP I-NP
. . O O

Estrogens NNS B-NP B-NP
and CC O I-NP
anti-estrogens NNS B-NP I-NP
enhance VBP B-VP B-VP
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
immunoglobulin NN B-NP B-NP
( ( I-NP O
Ig NN I-NP I-NN
) ) I-NP O
-secreting NN I-NP B-NP
cells NNS I-NP I-NP
in IN B-PP B-PP
pokeweed NN B-NP B-NP
mitogen NN I-NP I-NP
( ( I-NP O
PWM NN I-NP B-NP
) ) I-NP O
-stimulated JJ I-NP B-NP
lymphocyte NN I-NP I-NP
cultures NNS I-NP I-NP
. . O O

Lymphocytes NNS B-NP B-NP
from IN B-PP B-PP
patients NNS B-NP B-NP
who WP B-NP B-NP
have VBP B-VP B-VP
received VBN I-VP I-VP
anti-estrogen NN B-NP B-NP
therapy NN I-NP I-NP
show VBP B-VP B-VP
similar JJ B-NP B-NP
enhancement NN I-NP I-NP
of IN B-PP B-PP
Ig-secreting JJ B-NP B-NP
cells NNS I-NP I-NP
after IN B-PP B-PP
PWM NN B-NP B-NP
stimulation NN I-NP I-NP
. . O O

In IN B-PP B-PP
this DT B-NP B-NP
study NN I-NP I-NP
the DT B-NP B-NP
effect NN I-NP I-NP
of IN B-PP B-PP
anti-estrogen NN B-NP B-NP
( ( I-NP O
toremifene NN I-NP I-NN
) ) I-NP O
therapy NN I-NP B-NP
on IN B-PP B-PP
serum NN B-NP B-NP
immunoglobulin NN I-NP I-NP
( ( O O
IgA NN B-NP B-NP
, , O O
IgM NN B-NP I-NP
, , O O
IgG NN B-NP I-NP
) ) O O
levels NNS B-NP B-NP
in IN B-PP B-PP
breast NN B-NP B-NP
cancer NN I-NP I-NP
patients NNS I-NP I-NP
was VBD B-VP B-VP
investigated VBN I-VP I-VP
. . O O

Serum NN B-NP B-NP
Ig NN I-NP I-NP
levels NNS I-NP I-NP
were VBD B-VP B-VP
followed VBN I-VP I-VP
up RB B-NP B-ADVP
to TO I-NP B-PP
two CD I-NP B-NP
years NNS I-NP I-NP
after IN B-PP B-PP
or CC B-PP I-PP
during IN B-PP I-PP
the DT B-NP B-NP
therapy NN I-NP I-NP
. . O O

An DT B-NP B-NP
unexpected JJ I-NP I-NP
finding NN I-NP I-NP
was VBD B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
Ig NN I-NP I-NP
levels NNS I-NP I-NP
decreased VBD B-VP B-VP
during IN B-PP B-PP
the DT B-NP B-NP
follow-up JJ I-NP I-NP
period NN I-NP I-NP
. . O O

This DT B-NP B-NP
decrease NN I-NP I-NP
was VBD B-VP B-VP
seen VBN I-VP I-VP
in IN B-PP B-PP
patients NNS B-NP B-NP
who WP B-NP B-NP
responded VBD B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
therapy NN I-NP I-NP
as RB B-CONJP B-ADVP
well RB I-CONJP I-ADVP
as IN I-CONJP B-PP
in IN B-PP B-PP
those DT B-NP B-NP
who WP B-NP B-NP
did VBD B-VP B-VP
not RB O I-RB
. . O O

HIV1 NN B-NP B-NP
infection NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
monocytes NNS B-NP I-NP
and CC O I-CC
macrophages NNS B-NP B-NP
promotes VBZ B-VP B-VP
induction NN B-NP B-NP
or CC O I-NP
translocation NN B-NP I-NP
of IN B-PP B-PP
NF-KB-related JJ B-NP B-NP
factors NNS I-NP I-NP
. . O O

In IN B-PP B-PP
1991 CD B-NP B-NP
, , O O
we PRP B-NP B-NP
demonstrated VBD B-VP B-VP
, , O O
using VBG B-VP B-VP
electrophoretic JJ B-NP B-NP
mobility NN I-NP I-NP
shift NN I-NP I-NP
assays NNS I-NP I-NP
, , O O
that IN B-SBAR B-SBAR
3 CD B-NP B-NP
different JJ I-NP I-NP
factors NNS I-NP I-NP
( ( O O
termed VBN B-VP B-NP
B1 NN B-NP I-NP
, , O O
B2 NN B-NP I-NP
and CC O I-NP
B3 NN B-NP I-NP
) ) O O
with IN B-PP B-PP
affinity NN B-NP B-NP
for IN B-PP B-PP
the DT B-NP B-NP
KB-enhancer JJ|NN I-NP I-NP
target NN I-NP I-NP
sequence NN I-NP I-NP
were VBD B-VP B-VP
specifically RB I-VP I-VP
detected VBN I-VP I-VP
in IN B-PP B-PP
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
from IN B-PP B-PP
HIV1-infected JJ B-NP B-NP
monocytes NNS B-NP I-NP
and CC O I-NP
macrophages NNS B-NP I-NP
. . O O

The DT B-NP B-NP
B2 NN I-NP I-NP
factor NN I-NP I-NP
was VBD B-VP B-VP
induced VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
nuclei NNS I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
cells NNS I-NP I-NP
only RB B-PP B-ADVP
upon IN I-PP B-PP
HIV1 NN B-NP B-NP
infection NN I-NP I-NP
. . O O

The DT B-NP B-NP
B3 NN I-NP I-NP
factor NN I-NP I-NP
was VBD B-VP B-VP
only RB B-ADJP B-ADVP
slightly RB I-ADJP B-ADJP
evident JJ I-ADJP I-ADJP
in IN B-PP B-PP
nuclei NNS B-NP B-NP
of IN B-PP B-PP
uninfected JJ B-NP B-NP
cells NNS I-NP I-NP
but CC O I-CC
was VBD B-VP B-VP
readily RB B-ADJP B-ADJP
detectable JJ I-ADJP I-ADJP
in IN B-PP B-PP
nuclei NNS B-NP B-NP
of IN B-PP B-PP
infected JJ B-NP B-NP
monocytes NNS I-NP I-NP
. . O O

Its PRP$ B-NP B-NP
expression NN I-NP I-NP
remained VBD B-VP B-VP
very RB B-ADJP B-ADJP
low JJ I-ADJP I-ADJP
in IN B-PP B-PP
nuclei NNS B-NP B-NP
of IN B-PP B-PP
HIV1-infected JJ B-NP B-NP
macrophages NNS I-NP I-NP
. . O O

In IN B-PP B-PP
this DT B-NP B-NP
paper NN I-NP I-NP
, , O O
we PRP B-NP B-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
the DT B-NP B-NP
B2 NN I-NP I-NP
factor NN I-NP I-NP
is VBZ B-VP B-VP
expressed VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
cytosol NN I-NP I-NP
of IN B-PP B-PP
monocytes NNS B-NP B-NP
and CC O I-NP
macrophages NNS B-NP I-NP
as IN B-PP B-PP
a DT B-NP B-NP
DNA-binding JJ I-NP I-NP
protein NN I-NP I-NP
, , O O
indicating VBG B-VP B-VP
that IN B-SBAR B-SBAR
it PRP B-NP B-NP
is VBZ B-VP B-VP
not RB I-VP I-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
an DT B-NP B-NP
inhibitor NN I-NP I-NP
( ( O O
IKB NN B-NP B-NP
) ) O O
. . O O

This DT B-NP B-NP
factor NN I-NP I-NP
remained VBD B-VP B-VP
clustered VBN B-ADJP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
cytosol NN I-NP I-NP
and CC O I-CC
was VBD B-VP B-VP
translocated VBN I-VP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
nuclei NNS I-NP I-NP
only RB B-PP B-ADVP
after IN I-PP B-PP
HIV1 NN B-NP B-NP
infection NN I-NP I-NP
. . O O

The DT B-NP B-NP
B3 NN I-NP I-NP
factor NN I-NP I-NP
is VBZ B-VP B-VP
detected VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
cytosol NN I-NP I-NP
only RB O B-ADVP
when WRB B-ADVP B-ADVP
cells NNS B-NP B-NP
are VBP B-VP B-VP
HIV1-infected JJ B-ADJP B-ADJP
. . O O

The DT B-NP B-NP
role NN I-NP I-NP
of IN B-PP B-PP
HIV1 NN B-NP B-NP
infection NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
expression NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
translocation NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
factors NNS I-NP I-NP
is VBZ B-VP B-VP
discussed VBN I-VP I-VP
. . O O

Induction NN B-NP B-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
during IN B-PP B-PP
monocyte NN B-NP B-NP
differentiation NN I-NP I-NP
is VBZ B-VP B-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
HIV-gene JJ B-NP B-NP
expression NN I-NP I-NP
. . O O

Cells NNS B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
monocyte-macrophage JJ I-NP I-NP
lineage NN I-NP I-NP
are VBP B-VP B-VP
important JJ B-NP B-NP
targets NNS I-NP I-NP
of IN B-PP B-PP
HIV NN B-NP B-NP
infection NN I-NP I-NP
. . O O

We PRP B-NP B-NP
report VBP B-VP B-VP
here RB B-ADVP B-ADVP
that IN B-SBAR B-PP
the DT B-NP B-NP
phenotypic JJ I-NP I-NP
differentiation NN I-NP I-NP
of IN B-PP B-PP
monocyte NN B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
induced VBN B-VP B-VP
by IN B-PP B-PP
phorbol NN B-NP B-NP
esters NNS I-NP I-NP
or CC O I-CC
tumour NN B-NP B-NP
necrosis NN I-NP I-NP
factor NN I-NP I-NP
alpha NN I-NP I-NP
( ( O O
TNF NN B-NP B-NP
alpha NN I-NP I-NP
) ) O O
is VBZ B-VP B-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
expression NN B-NP B-NP
of IN B-PP B-PP
nuclear JJ B-NP B-NP
factor NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
( ( O O
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
) ) O O
. . O O

In IN B-PP B-PP
parallel NN I-PP B-NP
with IN I-PP B-PP
such JJ B-NP B-NP
differentiation NN I-NP I-NP
, , O O
HIV NN B-NP B-NP
transcription NN I-NP I-NP
, , O O
monitored VBN B-VP B-VP
using VBG B-VP I-VP
an DT B-NP B-NP
HIV NN I-NP I-NP
long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
reporter NN I-NP I-NP
gene NN I-NP I-NP
construct NN I-NP I-NP
, , O O
is VBZ B-VP B-VP
activated VBN I-VP I-VP
in IN B-PP B-PP
such JJ B-NP B-NP
cells NNS I-NP I-NP
under IN B-PP B-PP
the DT B-NP B-NP
influence NN I-NP I-NP
of IN B-PP B-PP
enhanced VBN B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
expression NN I-NP I-NP
. . O O

Also RB B-ADVP B-ADVP
, , O O
in IN B-PP B-PP
a DT B-NP B-NP
promonocyte JJ I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
chronically RB B-ADJP B-ADVP
infected VBN I-ADJP B-VP
with IN B-PP B-PP
HIV NN B-NP B-NP
, , O O
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
expression NN I-NP I-NP
and CC O I-NP
HIV NN B-NP I-NP
transcription NN I-NP I-NP
were VBD B-VP B-VP
enhanced VBN I-VP I-VP
on IN B-PP B-PP
stimulation NN B-NP B-NP
with IN B-PP B-PP
phorbol NN B-NP B-NP
ester NN I-NP I-NP
or CC O I-NP
TNF NN B-NP I-NP
alpha NN I-NP I-NP
. . O O

Thus RB B-ADVP B-ADVP
, , O O
stimulation NN B-NP B-NP
of IN B-PP B-PP
monocyte NN B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
by IN B-PP B-PP
phorbol NN B-NP B-NP
esters NNS I-NP I-NP
or CC O I-CC
TNF NN B-NP B-NP
alpha NN I-NP I-NP
induces VBZ B-VP B-VP
cell NN B-NP B-NP
differentiation NN I-NP I-NP
and CC O I-CC
activates VBZ B-VP B-VP
HIV NN B-NP B-NP
transcription NN I-NP I-NP
. . O O

Such PDT B-NP B-NP
a DT I-NP I-NP
process NN I-NP I-NP
may MD B-VP B-VP
have VB I-VP I-VP
fundamental JJ B-NP B-NP
implications NNS I-NP I-NP
in IN B-PP B-PP
AIDS NN B-NP B-NP
pathogenesis NN I-NP I-NP
in FW B-ADVP B-NP
vivo FW I-ADVP I-NP
and CC O I-CC
may MD B-VP B-VP
be VB I-VP I-VP
important JJ B-ADJP B-ADJP
in IN B-PP B-PP
disease NN B-NP B-NP
progression NN I-NP I-NP
induced VBN B-VP B-VP
by IN B-PP B-PP
opportunistic JJ B-NP B-NP
infections NNS I-NP I-NP
directly RB B-ADVP B-ADVP
or CC O I-CC
indirectly RB B-ADVP B-VP
involving VBG B-VP I-VP
macrophages NNS B-NP B-NP
. . O O

A DT B-NP B-NP
nuclear JJ I-NP I-NP
factor NN I-NP I-NP
NF-GM2 NN I-NP I-NP
that WDT B-NP B-NP
interacts VBZ B-VP B-VP
with IN B-PP B-PP
a DT B-NP B-NP
regulatory JJ I-NP I-NP
region NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
GM-CSF NN I-NP I-NP
gene NN I-NP I-NP
essential JJ B-ADJP B-ADJP
for IN B-PP B-PP
its PRP$ B-NP B-NP
induction NN I-NP I-NP
in IN B-PP B-PP
responses NNS I-PP B-NP
to TO I-PP B-PP
T-cell NN B-NP B-NP
activation NN I-NP I-NP
: : O O
purification NN B-NP B-NP
from IN B-PP B-PP
human JJ B-NP B-NP
T-cell NN I-NP I-NP
leukemia NN I-NP I-NP
line NN I-NP I-NP
Jurkat NN I-NP I-NP
cells NNS I-NP I-NP
and CC O I-CC
similarity NN B-NP B-NP
to TO B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
. . O O

Activation NN B-NP B-NP
of IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
by IN B-PP B-PP
antigen NN B-NP B-NP
, , O O
lectin NN B-NP B-NP
, , O O
or CC O I-CC
a DT B-NP B-NP
combination NN I-NP I-NP
of IN B-PP B-PP
phorbol-12-myristate NN B-NP B-NP
acetate NN I-NP I-NP
( ( O O
PMA NN B-NP B-NP
) ) O O
and CC O I-CC
calcium NN B-NP B-NP
ionophore NN I-NP I-NP
( ( O O
A23187 NN B-NP B-NP
) ) O O
leads VBZ B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
genes NNS B-NP B-NP
for IN B-PP B-PP
a DT B-NP B-NP
set NN I-NP I-NP
of IN B-PP B-PP
lymphokines NNS B-NP B-NP
, , O O
including VBG B-PP B-PP
granulocyte-macrophage JJ B-NP B-NP
colony-stimulating JJ I-NP I-NP
factor NN I-NP I-NP
( ( O O
GM-CSF NN B-NP B-NP
) ) O O
. . O O

We PRP B-NP B-NP
demonstrated VBD B-VP B-VP
in IN B-PP B-PP
earlier JJR B-NP B-NP
studies NNS I-NP I-NP
that IN B-SBAR B-PP
the DT B-NP B-NP
upstream JJ I-NP I-NP
region NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
mouse NN I-NP I-NP
GM-CSF NN I-NP I-NP
promoter NN I-NP I-NP
at IN B-PP B-PP
positions NNS B-NP B-NP
between IN B-PP B-PP
-95 CD B-NP B-NP
and CC O I-NP
-73 CD B-NP I-NP
is VBZ B-VP B-VP
essential JJ B-ADJP B-ADJP
for IN B-PP B-PP
transcriptional JJ B-NP B-NP
activation NN I-NP I-NP
in IN B-PP B-PP
response NN I-PP B-NP
to TO I-PP B-PP
PMA/A23187 NN B-NP B-NP
. . O O

This DT B-NP B-NP
region NN I-NP I-NP
contains VBZ B-VP B-VP
two CD B-NP B-NP
DNA-binding JJ I-NP I-NP
motifs NNS I-NP I-NP
, , O O
GM2 NN B-NP B-NP
and CC O I-NP
GC-box NN B-NP I-NP
. . O O

The DT B-NP B-NP
GM2 NN I-NP I-NP
sequence NN I-NP I-NP
( ( O O
GGTAGTTCCC NN B-NP B-NP
) ) O O
is VBZ B-VP B-VP
recognized VBN I-VP I-VP
by IN B-PP B-PP
an DT B-NP B-NP
inducible JJ I-NP I-NP
factor NN I-NP I-NP
NF-GM2 NN I-NP I-NP
; : O O
the DT B-NP B-NP
other JJ I-NP I-NP
( ( O O
CCGCCC NN B-NP I-NP
) ) O O
by IN B-PP B-PP
constitutive JJ B-NP B-NP
factors NNS I-NP I-NP
A1 NN B-NP I-NP
, , O O
A2 NN B-NP B-NP
, , O O
and CC O I-CC
B NN B-NP B-NP
. . O O

To TO B-VP B-VP
elucidate VB I-VP I-VP
the DT B-NP B-NP
mechanism NN I-NP I-NP
of IN B-PP B-PP
GM-CSF NN B-NP B-NP
gene NN I-NP I-NP
activation NN I-NP I-NP
, , O O
we PRP B-NP B-NP
have VBP B-VP B-VP
purified VBN I-VP I-VP
the DT B-NP B-NP
inducible JJ I-NP I-NP
factor NN I-NP I-NP
NF-GM2 NN I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
nuclear JJ I-NP I-NP
extract NN I-NP I-NP
of IN B-PP B-PP
stimulated VBN B-NP B-NP
Jurkat NN I-NP I-NP
cells NNS I-NP I-NP
on IN B-PP B-PP
the DT I-PP B-NP
basis NN I-PP I-NP
of IN I-PP B-PP
specific JJ B-NP B-NP
DNA-binding JJ I-NP I-NP
activity NN I-NP I-NP
. . O O

The DT B-NP B-NP
purified VBN I-NP I-NP
NF-GM2 NN I-NP I-NP
consists VBZ B-VP B-VP
of IN B-PP B-PP
50 CD B-NP B-NP
( ( O O
p50 NN B-NP I-NP
) ) O O
and CC O I-CC
65 CD B-NP B-NP
kDa NN B-NP I-NP
( ( O O
p65 NN B-NP B-NP
) ) O O
polypeptides NNS B-NP B-NP
and CC O I-CC
has VBZ B-VP B-VP
a DT B-NP B-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
specific JJ B-ADJP B-ADJP
for IN B-PP B-PP
both CC O I-CC
the DT O B-NP
GM-CSF NN B-NP I-NP
and CC O I-NP
immunoglobulin NN B-NP I-NP
kappa NN I-NP I-NP
( ( O O
GGAAAGTCCC NN B-NP B-NP
) ) O O
enhancers NNS B-NP I-NP
. . O O

Electrophoretically RB B-NP B-ADVP
purified VBN I-NP B-VP
p50 NN I-NP B-NP
alone RB B-ADVP B-ADVP
can MD B-VP B-VP
form VB I-VP I-VP
a DT B-NP B-NP
protein-DNA JJ I-NP I-NP
complex NN I-NP I-NP
, , O O
but CC O I-CC
in IN B-PP B-PP
the DT B-NP B-NP
mixture NN I-NP I-NP
, , O O
p50 NN B-NP B-NP
associates VBZ B-VP B-VP
preferentially RB B-ADVP B-ADVP
with IN B-PP B-PP
p65 NN B-NP B-NP
to TO B-VP B-VP
form VB I-VP I-VP
the DT B-NP B-NP
NF-GM2 NN I-NP I-NP
complex NN I-NP I-NP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
p65 NN B-NP B-NP
gave VBD B-VP B-VP
per FW B-ADVP B-NP
se FW I-ADVP I-NP
, , O O
with IN B-PP B-PP
low JJ B-NP B-NP
affinity NN I-NP I-NP
, , O O
a DT B-NP B-NP
protein-DNA JJ I-NP I-NP
complex NN I-NP I-NP
that WDT B-NP B-NP
migrated VBD B-VP B-VP
more RBR B-ADVP B-ADVP
slowly RB I-ADVP I-ADVP
than IN B-PP B-PP
native JJ B-NP B-NP
NF-GM2 NN I-NP I-NP
complex NN I-NP I-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
an DT B-NP B-NP
antiserum NN I-NP I-NP
against IN B-PP B-PP
KBF1 NN B-NP B-NP
( ( O O
identical JJ B-ADJP B-ADJP
to TO B-PP B-PP
50 CD B-NP B-NP
kDa NN I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
protein NN I-NP I-NP
) ) O O
reacted VBD B-VP B-VP
with IN B-PP B-PP
the DT B-NP B-NP
p50 NN I-NP I-NP
of IN B-PP B-PP
NF-GM2 NN B-NP B-NP
, , O O
indicating VBG B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
NF-GM2 NN I-NP I-NP
polypeptide NN I-NP I-NP
can MD B-VP B-VP
not RB I-VP I-VP
be VB I-VP I-VP
immunologically RB I-VP I-VP
differentiated VBN I-VP I-VP
from IN B-PP B-PP
the DT B-NP B-NP
50 CD I-NP I-NP
kDa NN I-NP I-NP
subunit NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
. . O O

The DT B-NP B-NP
purified VBN I-NP I-NP
NF-GM2 NN I-NP I-NP
activated VBD B-VP B-VP
in FW B-NP B-NP
vitro FW I-NP I-NP
transcription NN I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
enhancer NN I-NP I-NP
, , O O
while IN B-SBAR B-SBAR
it PRP B-NP B-NP
failed VBD B-VP B-VP
to TO I-VP I-VP
stimulate VB I-VP I-VP
transcription NN B-NP B-NP
from IN B-PP B-PP
the DT B-NP B-NP
GM-CSF NN I-NP I-NP
promoter NN I-NP I-NP
harboring VBG B-VP B-VP
the DT B-NP B-NP
GM2 NN I-NP I-NP
sequence NN I-NP I-NP
. . O O

This DT B-NP B-NP
suggests VBZ B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
activation NN I-NP I-NP
mechanism NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
GM-CSF NN I-NP I-NP
gene NN I-NP I-NP
through IN B-PP B-PP
the DT B-NP B-NP
GM2/GC-box JJ|NN I-NP I-NP
sequence NN I-NP I-NP
is VBZ B-VP B-VP
different JJ B-ADJP B-ADJP
from IN B-PP B-PP
that DT B-NP B-NP
of IN B-PP B-PP
genes NNS B-NP B-NP
carrying VBG B-VP B-VP
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
enhancer NN I-NP I-NP
alone RB B-ADVP B-ADVP
. . O O

Glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
in IN B-PP B-PP
normal JJ B-NP B-NP
leukocytes NNS I-NP I-NP
: : O O
effects NNS B-NP B-NP
of IN B-PP B-PP
age NN B-NP B-NP
, , O O
gender NN B-NP I-NP
, , O O
season NN B-NP I-NP
, , O O
and CC O I-CC
plasma NN B-NP B-NP
cortisol NN I-NP I-NP
concentrations NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
measured VBD B-VP B-VP
glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
( ( O O
GR NN B-NP B-NP
) ) O O
in IN B-PP B-PP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
( ( O O
MNL NN B-NP B-NP
) ) O O
isolated VBN B-VP B-VP
from IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
of IN B-PP B-PP
145 CD B-NP B-NP
apparently RB I-NP I-NP
healthy JJ I-NP I-NP
volunteers NNS I-NP I-NP
( ( O O
86 CD B-NP B-NP
men NNS I-NP I-NP
and CC O I-CC
59 CD B-NP B-NP
women NNS I-NP I-NP
) ) O O
. . O O

An DT B-NP B-NP
age-related JJ I-NP I-NP
decrease NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
GR NN B-NP B-NP
was VBD B-VP B-VP
suggested VBN I-VP I-VP
between IN B-PP B-PP
subjects NNS B-NP B-NP
younger JJR B-ADJP B-NP
than IN B-PP I-NP
20 CD B-NP I-NP
years NNS I-NP I-NP
and CC O I-CC
elderly JJ B-NP B-NP
subjects NNS I-NP I-NP
; : O O
there EX B-NP B-NP
was VBD B-VP B-VP
no DT B-NP B-NP
apparent JJ I-NP I-NP
seasonal JJ I-NP I-NP
variation NN I-NP I-NP
in IN B-PP B-PP
GR NN B-NP B-NP
. . O O

Gender NN B-NP B-NP
difference NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
GR NN B-NP B-NP
was VBD B-VP B-VP
not RB O I-RB
significant JJ B-ADJP B-ADJP
, , O O
although IN B-SBAR B-SBAR
women NNS B-NP B-NP
showed VBD B-VP B-VP
slightly RB B-NP B-NP
fewer JJR I-NP I-NP
GR NN I-NP I-NP
. . O O

Eight CD B-NP B-NP
patients NNS I-NP I-NP
with IN B-PP B-PP
dermatomyositis/polymyositis NN B-NP B-NP
were VBD B-VP B-VP
examined VBN I-VP I-VP
to TO B-VP B-VP
determine VB I-VP I-VP
whether IN B-SBAR B-SBAR
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
GR NN B-NP B-NP
in IN B-PP B-PP
MNL NN B-NP B-NP
could MD B-VP B-VP
be VB I-VP I-VP
down-regulated VBN I-VP I-VP
by IN B-PP B-PP
their PRP$ B-NP B-NP
cognate JJ I-NP I-NP
ligands NNS I-NP I-NP
. . O O

The DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
GR NN B-NP B-NP
in IN B-PP B-PP
MNL NN B-NP B-NP
from IN B-PP B-PP
these DT B-NP B-NP
patients NNS I-NP I-NP
was VBD B-VP B-VP
significantly RB I-VP I-VP
decreased VBN I-VP I-VP
one CD B-NP B-NP
month NN I-NP I-NP
after IN B-PP B-PP
the DT B-NP B-NP
initiation NN I-NP I-NP
of IN B-PP B-PP
prednisolone NN B-NP B-NP
therapy NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
in IN B-PP B-PP
normal JJ B-NP B-NP
subjects NNS I-NP I-NP
, , O O
the DT B-NP B-NP
GR NN I-NP I-NP
in IN B-PP B-PP
MNL NN B-NP B-NP
did VBD B-VP B-VP
not RB I-VP I-VP
demonstrate VB I-VP I-VP
circadian JJ B-NP B-NP
variation NN I-NP I-NP
, , O O
in IN B-PP B-PP
contrast NN I-PP B-NP
to TO I-PP B-PP
concentrations NNS B-NP B-NP
of IN B-PP B-PP
plasma NN B-NP B-NP
cortisol NN I-NP I-NP
. . O O

Anti-CD2 JJ B-NP B-NP
receptor NN I-NP I-NP
antibodies NNS I-NP I-NP
activate VBP B-VP B-VP
the DT B-NP B-NP
HIV NN I-NP I-NP
long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
in IN B-PP B-PP
T NN B-NP B-NP
lymphocytes NNS I-NP I-NP
. . O O

The DT B-NP B-NP
CD2 NN I-NP I-NP
T NN I-NP I-NP
lymphocyte NN I-NP I-NP
glycoprotein NN I-NP I-NP
surface NN I-NP I-NP
molecule NN I-NP I-NP
mediates VBZ B-VP B-VP
both CC O I-VP
cell NN B-NP I-VP
to TO I-NP B-PP
cell NN I-NP B-NP
adhesion NN I-NP I-NP
and CC O I-NP
T NN B-NP I-NP
cell NN I-NP I-NP
activation NN I-NP I-NP
, , O O
two CD B-NP B-NP
processes NNS I-NP I-NP
that WDT B-NP B-NP
are VBP B-VP B-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
spread NN I-NP I-NP
of IN B-PP B-PP
HIV NN B-NP B-NP
infection NN I-NP I-NP
. . O O

Treatment NN B-NP B-NP
of IN B-PP B-PP
chronically RB B-NP B-NP
HIV-infected JJ I-NP I-NP
PBMC NN I-NP I-NP
with IN B-PP B-PP
anti-CD2 JJ B-NP B-NP
mAb NN I-NP I-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
shown VBN I-VP I-VP
to TO I-VP I-VP
induce VB I-VP I-VP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
infectious JJ B-NP B-NP
virus NN I-NP I-NP
from IN B-PP B-PP
these DT B-NP B-NP
cultures NNS I-NP I-NP
. . O O

In IN B-PP B-PP
this DT B-NP B-NP
study NN I-NP I-NP
we PRP B-NP B-NP
investigated VBD B-VP B-VP
the DT B-NP B-NP
mechanisms NNS I-NP I-NP
whereby WRB B-ADVP B-VP
anti-CD2 JJ B-NP B-NP
antibodies NNS I-NP I-NP
stimulate VBP B-VP B-VP
viral JJ B-NP B-NP
production NN I-NP I-NP
. . O O

We PRP B-NP B-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
treatment NN B-NP B-NP
of IN B-PP B-PP
transiently RB B-NP B-NP
transfected VBN I-NP I-NP
T NN I-NP I-NP
lymphocytes NNS I-NP I-NP
with IN B-PP B-PP
anti-CD2 JJ B-NP B-NP
antibodies NNS I-NP I-NP
results VBZ B-VP B-VP
in IN B-PP B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
HIV NN I-NP I-NP
long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
CAT NN B-NP B-NP
assays NNS I-NP I-NP
using VBG B-VP B-VP
mutated VBN B-NP I-VP
HIV NN I-NP B-NP
long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat-CAT NN I-NP I-NP
constructs NNS I-NP I-NP
and CC O I-CC
gel NN B-NP B-NP
shift NN I-NP I-NP
assays NNS I-NP I-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
this DT B-NP B-NP
activation NN I-NP I-NP
is VBZ B-VP B-VP
dependent JJ B-ADJP B-ADJP
on IN B-PP B-PP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

These DT B-NP B-NP
studies NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
interaction NN B-NP B-NP
of IN B-PP B-PP
CD2 NN B-NP B-NP
with IN B-PP B-PP
its PRP$ B-NP B-NP
natural JJ I-NP I-NP
ligand NN I-NP I-NP
, , O O
LFA-3 NN B-NP B-NP
, , O O
may MD B-VP B-VP
play VB I-VP I-VP
a DT B-NP B-NP
role NN I-NP I-NP
in IN B-PP B-PP
regulation NN B-NP B-NP
of IN B-PP B-PP
HIV NN B-NP B-NP
expression NN I-NP I-NP
. . O O

Nuclear JJ B-NP B-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
that WDT B-NP B-NP
bind VBP B-VP B-VP
to TO B-PP B-PP
elements NNS B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
IL-2 NN I-NP I-NP
promoter NN I-NP I-NP
. . O O

Induction NN B-NP B-NP
requirements NNS I-NP I-NP
in IN B-PP B-PP
primary JJ B-NP B-NP
human JJ I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

Prior JJ B-NP B-NP
studies NNS I-NP I-NP
have VBP B-VP B-VP
identified VBN I-VP I-VP
several JJ B-NP B-NP
elements NNS I-NP I-NP
that WDT B-NP B-NP
contribute VBP B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
IL-2 NN I-NP I-NP
promoter NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
stimulated VBN I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
, , O O
Jurkat NN B-NP B-NP
. . O O

The DT B-NP B-NP
sites NNS I-NP I-NP
and CC O I-CC
their PRP$ B-NP B-NP
corresponding JJ I-NP I-NP
nuclear JJ I-NP I-NP
binding VBG I-NP I-NP
factors NNS I-NP I-NP
include VBP B-VP B-VP
: : O O
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
, , O O
AP-1 NN B-NP B-NP
, , O O
AP-3 NN B-NP B-NP
, , O O
OCT-1 NN B-NP B-NP
, , O O
and CC O I-CC
NF-AT NN B-NP B-NP
. . O O

The DT B-NP B-NP
latter JJ I-NP I-NP
" [[DQS]] O I-NP
nuclear JJ B-NP I-NP
factor NN I-NP I-NP
for IN B-PP B-PP
activated VBN B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
" [[DQE]] O I-[[DQE]]
likely RB B-ADVP B-ADVP
contributes VBZ B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
tissue NN I-NP I-NP
specificity NN I-NP I-NP
of IN B-PP B-PP
IL-2 NN B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
. . O O

Using VBG B-VP B-VP
electrophoretic JJ B-NP B-NP
mobility NN I-NP I-NP
shift NN I-NP I-NP
assays NNS I-NP I-NP
, , O O
we PRP B-NP B-NP
have VBP B-VP B-VP
studied VBN I-VP I-VP
these DT B-NP B-NP
transcription NN B-NP I-NP
factors NNS I-NP I-NP
in IN B-PP B-PP
primary JJ B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
from IN B-PP B-PP
human JJ B-NP B-NP
blood NN I-NP I-NP
to TO B-VP B-VP
verify VB I-VP I-VP
their PRP$ B-NP B-NP
presence NN I-NP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
physiologic JJ I-NP I-NP
setting NN I-NP I-NP
and CC O I-CC
to TO B-VP B-VP
identify VB I-VP I-VP
the DT B-NP B-NP
signals NNS I-NP I-NP
that WDT B-NP B-NP
stimulate VBP B-VP B-VP
factor NN B-NP B-NP
activity NN I-NP I-NP
. . O O

All DT B-NP B-NP
factors NNS I-NP I-NP
are VBP B-VP B-VP
induced VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
nuclei NNS I-NP I-NP
of IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
upon IN B-PP B-PP
activation NN B-NP B-NP
with IN B-PP B-PP
mitogens NNS B-NP B-NP
but CC B-PP I-CC
not RB B-PP B-ADJP
with IN I-PP B-PP
exogenous JJ B-NP B-NP
IL-2 NN I-NP I-NP
growth NN I-NP I-NP
factor NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
signaling NN I-NP I-NP
requirements NNS I-NP I-NP
and CC O I-CC
sensitivity NN B-NP B-NP
to TO B-PP B-PP
protein NN B-NP B-NP
synthesis NN I-NP I-NP
inhibitors NNS I-NP I-NP
differ VBP B-VP B-VP
considerably RB B-ADVP B-ADVP
. . O O

Only RB B-NP B-NP
the DT I-NP I-NP
activities NNS I-NP I-NP
for IN B-PP B-PP
NF-AT NN B-NP B-NP
and CC O I-NP
AP-1 NN B-NP I-NP
sites NNS B-NP I-NP
require VBP B-VP B-VP
two CD B-NP B-NP
signals NNS I-NP I-NP
for IN B-PP B-PP
optimal JJ B-NP B-NP
induction NN I-NP I-NP
, , O O
i.e. FW B-PP B-NP
, , O O
PMA NN B-NP I-NP
plus CC O I-NP
either CC O I-CC
lectin NN B-NP B-NP
or CC O I-NP
antibody NN B-NP I-NP
to TO B-PP B-PP
the DT O B-NP
CD3 NN B-NP I-NP
or CC O I-NP
CD28 NN B-NP I-NP
surface NN B-NP I-NP
molecules NNS I-NP I-NP
. . O O

Other JJ B-NP B-NP
factors NNS I-NP I-NP
are VBP B-VP B-VP
induced VBN I-VP I-VP
by IN B-PP B-PP
lectin NN B-NP B-NP
, , O O
antibody NN B-NP B-NP
, , O O
and/or CC O I-CC
PMA NN B-NP B-NP
alone RB B-ADVP B-ADVP
. . O O

After IN B-PP B-PP
appropriate JJ B-NP B-NP
stimulation NN I-NP I-NP
, , O O
both CC O I-CC
NF-AT NN B-NP B-NP
and CC O I-NP
AP-1 NN B-NP I-NP
are VBP B-VP B-VP
peculiarly RB B-ADJP B-ADJP
sensitive JJ I-ADJP I-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
protein NN I-NP I-NP
synthesis NN I-NP I-NP
inhibitor NN I-NP I-NP
anisomycin NN I-NP I-NP
. . O O

Our PRP$ B-NP B-NP
data NNS I-NP I-NP
correlate VBP B-VP B-VP
the DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
NF-AT NN B-NP B-NP
and CC O I-NP
AP-1 NN B-NP I-NP
in IN B-PP B-PP
gel NN B-NP B-NP
shift NN I-NP I-NP
assays NNS I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
two CD I-NP I-NP
signals NNS I-NP I-NP
requirements NNS I-NP I-NP
for IN B-PP B-PP
IL-2 NN B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
. . O O

An DT B-NP B-NP
erythroid JJ I-NP I-NP
specific JJ I-NP I-NP
enhancer NN I-NP I-NP
upstream JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
gene NN I-NP I-NP
encoding VBG B-VP B-VP
the DT B-NP B-NP
cell-type JJ I-NP I-NP
specific JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
GATA-1 NN I-NP I-NP
. . O O

The DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
GATA-1 NN I-NP I-NP
is VBZ B-VP B-VP
expressed VBN I-VP I-VP
in IN B-PP B-PP
a DT B-NP B-NP
subset NN I-NP I-NP
of IN B-PP B-PP
hemopoietic JJ B-NP B-NP
cells NNS I-NP I-NP
, , O O
where WRB B-ADVP B-ADVP
it PRP B-NP B-NP
mediates VBZ B-VP B-VP
the DT B-NP B-NP
cell-type JJ I-NP I-NP
specific JJ I-NP I-NP
expression NN I-NP I-NP
of IN B-PP B-PP
several JJ B-NP B-NP
genes NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
cloned VBN I-VP I-VP
the DT O B-NP
mouse NN B-NP I-NP
and CC O I-NP
human JJ B-NP I-NP
GATA-1 NN B-NP I-NP
genes NNS I-NP I-NP
. . O O

A DT B-NP B-NP
region NN I-NP I-NP
upstream JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
first JJ I-NP I-NP
exon NN I-NP I-NP
, , O O
and CC O I-CC
highly RB B-VP B-VP
conserved VBN I-VP I-VP
between IN B-PP B-PP
mouse NN B-NP B-NP
and CC O I-NP
man NN B-NP I-NP
, , O O
acts VBZ B-VP B-VP
as IN B-PP B-PP
an DT B-NP B-NP
erythroid JJ I-NP I-NP
specific JJ I-NP I-NP
enhancer NN I-NP I-NP
in IN B-PP B-PP
transient JJ B-NP B-NP
assays NNS I-NP I-NP
, , O O
if IN B-SBAR B-SBAR
linked VBN B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
GATA-1 NN I-NP I-NP
or CC B-PP B-PP
to TO B-PP B-PP
the DT B-NP B-NP
SV40 NN I-NP I-NP
promoter NN B-NP I-NP
. . O O

The DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
enhancer NN I-NP I-NP
is VBZ B-VP B-VP
almost RB B-ADJP B-ADVP
completely RB I-ADJP B-ADJP
dependent JJ I-ADJP I-ADJP
on IN B-PP B-PP
the DT B-NP B-NP
integrity NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
dimeric JJ I-NP I-NP
GATA-1 NN I-NP I-NP
binding NN I-NP I-NP
site NN I-NP I-NP
. . O O

Demonstration NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
1,25-dihydroxyvitamin NN I-NP I-NP
D3-responsive JJ I-NP I-NP
protein NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
lymphocytes NNS I-NP I-NP
: : O O
immunologic JJ B-NP B-NP
crossreactivity NN I-NP I-NP
and CC O I-CC
inverse JJ B-NP B-NP
regulation NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
vitamin NN I-NP I-NP
D NN I-NP I-NP
receptor NN I-NP I-NP
. . O O

Using VBG B-VP B-VP
Western NN B-NP B-NP
blot NN I-NP I-NP
analysis NN I-NP I-NP
with IN B-PP B-PP
a DT B-NP B-NP
monoclonal JJ I-NP I-NP
antibody NN I-NP I-NP
recognizing VBG B-VP B-VP
a DT B-NP B-NP
17-amino NN I-NP I-NP
acid NN I-NP I-NP
epitope NN I-NP I-NP
of IN B-PP B-PP
the DT O B-NP
1,25-dihydroxyvitamin NN B-NP I-NP
D3 NN I-NP I-NP
( ( O O
1,25(OH)2D3 NN B-NP I-NN
) ) O O
receptor NN B-NP B-NP
, , O O
we PRP B-NP B-NP
have VBP B-VP B-VP
detected VBN I-VP I-VP
two CD B-NP B-NP
crossreacting VBG I-NP I-NP
proteins NNS I-NP I-NP
in IN B-PP B-PP
activated VBN B-NP B-NP
normal JJ I-NP I-NP
human JJ I-NP I-NP
lymphocytes NNS I-NP I-NP
. . O O

The DT B-NP B-NP
smaller JJR I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
two CD I-NP I-NP
proteins NNS I-NP I-NP
( ( O O
50 CD B-NP B-NP
kDa NN I-NP I-NP
) ) O O
was VBD B-VP B-VP
indistinguishable JJ B-ADJP B-ADJP
from IN B-PP B-PP
the DT B-NP B-NP
classical JJ I-NP I-NP
1,25(OH)2D3 NN I-NP I-NP
receptor NN I-NP I-NP
and CC O I-CC
, , O O
similar JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
classical JJ I-NP I-NP
1,25(OH)2D3 NN I-NP I-NP
receptor NN I-NP I-NP
, , O O
was VBD B-VP B-VP
upregulated VBN B-VP I-VP
in IN B-PP B-PP
a DT B-NP B-NP
dose-dependent JJ I-NP I-NP
fashion NN I-NP I-NP
by IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
. . O O

The DT B-NP B-NP
larger JJR I-NP I-NP
crossreacting VBG I-NP I-NP
protein NN I-NP I-NP
exhibited VBD B-VP B-VP
an DT B-NP B-NP
electrophoretic JJ I-NP I-NP
mobility NN I-NP I-NP
of IN B-PP B-PP
80 CD B-NP B-NP
kDa NN I-NP I-NP
, , O O
was VBD B-VP B-VP
localized JJ I-VP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
cell NN I-NP I-NP
cytosol NN I-NP I-NP
, , O O
and CC O I-CC
appeared VBD B-VP B-VP
to TO I-VP I-VP
be VB I-VP I-VP
specific JJ B-ADJP B-ADJP
for IN B-PP B-PP
activated VBN B-NP B-NP
lymphocytes NNS I-NP I-NP
since IN B-SBAR B-SBAR
it PRP B-NP B-NP
was VBD B-VP B-VP
not RB I-VP I-VP
detected VBN I-VP I-VP
in IN B-PP B-PP
several JJ B-NP B-NP
other JJ I-NP I-NP
human JJ I-NP I-NP
cells NNS I-NP I-NP
including VBG B-PP B-VP
monocytes NNS B-NP B-NP
. . O O

More RBR B-ADVP B-ADVP
strikingly RB I-ADVP I-ADVP
, , O O
the DT B-NP B-NP
80-kDa JJ I-NP I-NP
protein NN I-NP I-NP
was VBD B-VP B-VP
downregulated VBN I-VP I-VP
in IN B-PP B-PP
a DT B-NP B-NP
dose-dependent JJ I-NP I-NP
fashion NN I-NP I-NP
by IN B-PP B-PP
1,25(OH)2D3 NN B-NP B-NP
; : O O
this DT B-NP B-NP
effect NN I-NP I-NP
was VBD B-VP B-VP
independent JJ B-ADJP B-ADJP
of IN B-PP B-PP
the DT B-NP B-NP
mode NN I-NP I-NP
of IN B-PP B-PP
lymphocyte NN B-NP B-NP
activation NN I-NP I-NP
and CC O I-CC
specific JJ B-ADJP B-ADVP
for IN B-PP B-PP
the DT B-NP B-NP
1,25(OH)2D3 NN I-NP I-NP
metabolite NN I-NP I-NP
of IN B-PP B-PP
vitamin NN B-NP B-NP
D3 NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
two CD B-NP B-NP
potent JJ I-NP I-NP
immunosuppressive JJ I-NP I-NP
agents NNS I-NP I-NP
, , O O
glucocorticoids NNS B-NP B-NP
and CC O I-CC
cyclosporin NN B-NP B-NP
A DT I-NP I-NP
, , O O
also RB B-ADVP B-ADVP
inhibited VBD B-VP B-VP
the DT B-NP B-NP
80-kDa JJ I-NP I-NP
protein NN I-NP I-NP
. . O O

T-helper-cell JJ B-NP B-NP
determinants NNS I-NP I-NP
in IN B-PP B-PP
protein NN B-NP B-NP
antigens NNS I-NP I-NP
are VBP B-VP B-VP
preferentially RB B-ADVP B-ADJP
located JJ I-ADVP I-ADJP
in IN B-PP B-PP
cysteine-rich JJ B-NP B-NP
antigen NN I-NP I-NP
segments NNS I-NP I-NP
resistant JJ B-ADJP B-ADJP
to TO B-PP B-PP
proteolytic JJ B-NP B-NP
cleavage NN I-NP I-NP
by IN B-PP B-PP
cathepsin NN B-NP B-NP
B NN B-NP I-NP
, , O O
L NN B-NP B-NP
, , O O
and CC O I-CC
D NN B-NP B-NP
. . O O

We PRP B-NP B-NP
report VBP B-VP B-VP
on IN B-PP B-PP
a DT B-NP B-NP
computer NN I-NP I-NP
algorithm NN I-NP I-NP
capable JJ B-ADJP B-ADJP
of IN B-PP B-PP
predicting VBG B-VP B-VP
the DT B-NP B-NP
location NN I-NP I-NP
of IN B-PP B-PP
T-helper-cell NN B-NP B-NP
epitopes NNS I-NP I-NP
in IN B-PP B-PP
protein NN B-NP B-NP
antigen NN B-NP I-NP
( ( O O
Ag NN B-NP B-NP
) ) O O
by IN B-PP B-PP
analysing VBG B-VP B-VP
the DT B-NP B-NP
Ag NN I-NP I-NP
amino NN I-NP I-NP
acid NN I-NP I-NP
sequence NN I-NP I-NP
. . O O

The DT B-NP B-NP
algorithm NN I-NP I-NP
was VBD B-VP B-VP
constructed VBN I-VP I-VP
with IN B-PP B-PP
the DT B-NP B-NP
aim NN I-NP I-NP
of IN B-PP B-PP
identifying VBG B-VP B-VP
segments NNS B-NP B-NP
in IN B-PP B-PP
Ag NN B-NP B-NP
which WDT B-NP B-NP
are VBP B-VP B-VP
resistant JJ B-ADJP B-ADJP
to TO B-PP B-PP
proteolytic JJ B-NP B-NP
degradation NN I-NP I-NP
by IN B-PP B-PP
the DT B-NP B-NP
enzymes NNS I-NP I-NP
cathepsin NN I-NP I-NP
B NN B-NP I-NP
, , O O
L NN B-NP B-NP
, , O O
and CC O I-CC
D NN B-NP B-NP
. . O O

These DT B-NP B-NP
are VBP B-VP B-VP
prominent JJ B-NP B-NP
enzymes NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
endocytic JJ I-NP I-NP
pathway NN I-NP I-NP
through IN B-PP B-PP
which WDT B-NP B-NP
soluble JJ B-NP B-NP
protein NN I-NP I-NP
Ag NN I-NP I-NP
enter VBP B-VP B-VP
APC NN B-NP B-NP
, , O O
and CC O I-CC
resistant JJ B-NP B-NP
segments NNS I-NP I-NP
in IN B-PP B-PP
Ag NN B-NP B-NP
may MD B-VP B-VP
, , O O
therefore RB B-ADVP B-ADVP
, , O O
be VB B-VP B-VP
expected VBN I-VP I-VP
to TO I-VP I-VP
contain VB I-VP I-VP
more JJR B-NP B-NP
T-cell NN I-NP I-NP
determinants NNS I-NP I-NP
than IN B-PP B-PP
susceptible JJ B-NP B-NP
segments NNS I-NP I-NP
. . O O

From IN B-PP B-PP
information NN B-NP B-NP
available JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
literature NN I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
substrate JJ I-NP I-NP
specificity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
three CD I-NP I-NP
enzymes NNS I-NP I-NP
, , O O
it PRP B-NP B-NP
is VBZ B-VP B-VP
clear JJ B-ADJP B-ADJP
that IN B-SBAR B-SBAR
a DT B-NP B-NP
cysteine NN I-NP I-NP
is VBZ B-VP B-VP
not RB I-VP I-VP
accepted VBN I-VP I-VP
in IN B-PP B-PP
any DT B-NP B-NP
of IN B-PP B-PP
the DT O B-NP
S2 NN B-NP I-NP
, , O O
S1 NN B-NP B-NP
, , O O
S1' NN B-NP B-NP
, , O O
and CC O I-CC
S2' NN B-NP B-NP
subsites NNS B-NP I-NP
of IN B-PP B-PP
cathepsin NN B-NP B-NP
B NN B-NP I-NP
and CC O I-NP
L NN B-NP I-NP
, , B-PP O
and CC I-PP I-CC
not RB B-PP B-ADVP
in IN I-PP B-PP
the DT O B-NP
S1 NN B-NP I-NP
and CC O I-NP
S1' NN B-NP I-NP
subsites NNS B-NP I-NP
of IN B-PP B-PP
cathepsin NN B-NP B-NP
D NN I-NP I-NP
. . O O

Moreover RB B-ADVP B-ADVP
, , O O
we PRP B-NP B-NP
have VBP B-VP B-VP
noticed VBN I-VP I-VP
that IN B-SBAR B-SBAR
cysteine-containing JJ B-NP B-NP
T-cell NN I-NP I-NP
determinants NNS I-NP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
protein NN B-NP B-NP
Ag NN I-NP I-NP
are VBP B-VP B-VP
particularly RB B-ADJP B-ADJP
rich JJ I-ADJP I-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
amino NN I-NP I-NP
acids NNS I-NP I-NP
alanine NN B-NP I-NP
, , O O
glycine NN B-NP B-NP
, , O O
lysine NN B-NP B-NP
, , O O
leucine NN B-NP B-NP
, , O O
serine NN B-NP B-NP
, , O O
threonine NN B-NP B-NP
, , O O
and CC O I-CC
valine NN B-NP B-NP
. . O O

By IN B-PP B-PP
searching VBG B-VP B-VP
protein NN B-NP B-NP
Ag NN I-NP I-NP
for IN B-PP B-PP
clusters NNS B-NP B-NP
of IN B-PP B-PP
amino NN B-NP B-NP
acids NNS I-NP I-NP
containing VBG B-VP B-VP
cysteine NN B-NP B-NP
and CC O I-CC
two CD B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
other JJ I-NP I-NP
amino NN I-NP I-NP
acids NNS I-NP I-NP
we PRP B-NP B-NP
were VBD B-VP B-VP
able JJ B-ADJP B-ADJP
to TO B-VP B-VP
predict VB I-VP I-VP
17 CD B-NP B-NP
out IN I-NP B-PP
of IN I-NP B-PP
23 CD I-NP B-NP
empirically RB I-NP I-NP
known VBN I-NP I-NP
T-cell NN I-NP I-NP
determinants NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
Ag NN I-NP I-NP
with IN B-PP B-PP
a DT B-NP B-NP
relatively RB I-NP I-NP
low JJ I-NP I-NP
number NN I-NP I-NP
of IN B-PP B-PP
false JJ O B-NP
( ( O O
positive JJ B-ADJP I-JJ
) ) O O
predictions NNS B-NP B-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
we PRP B-NP B-NP
present VBP B-VP B-VP
a DT B-NP B-NP
new JJ I-NP I-NP
principle NN I-NP I-NP
for IN B-PP B-PP
searching VBG B-VP B-VP
Ag NN B-NP B-NP
for IN B-PP B-PP
potential JJ B-NP B-NP
amphipatic JJ I-NP I-NP
alpha-helical JJ I-NP I-NP
protein NN I-NP I-NP
segments NNS I-NP I-NP
. . O O

Such JJ B-NP B-NP
segments NNS I-NP I-NP
accord VBP B-VP B-VP
well RB B-ADVP B-ADVP
with IN B-PP B-PP
empirically RB B-NP B-NP
known JJ I-NP I-NP
T-cell NN I-NP I-NP
determinants NNS I-NP I-NP
and CC O I-CC
our PRP$ B-NP B-NP
algorithm NN I-NP I-NP
produces VBZ B-VP B-VP
a DT B-NP B-NP
lower JJR I-NP I-NP
number NN I-NP I-NP
of IN B-PP B-PP
false JJ B-NP B-NP
positive JJ I-NP I-NP
predictions NNS I-NP I-NP
than IN B-PP B-PP
the DT B-NP B-NP
principle NN I-NP I-NP
based VBN B-PP B-PP
on IN B-PP B-PP
discrete JJ B-NP B-NP
Fourier NN I-NP I-NP
transformations NNS I-NP I-NP
previously RB B-VP B-VP
described VBN I-VP I-VP
. . O O

A DT B-NP B-NP
human JJ I-NP I-NP
putative JJ I-NP I-NP
lymphocyte NN I-NP I-NP
G0/G1 NN I-NP I-NP
switch NN I-NP I-NP
gene NN I-NP I-NP
containing VBG B-VP B-VP
a DT B-NP B-NP
CpG-rich JJ I-NP I-NP
island NN I-NP I-NP
encodes VBZ B-VP B-VP
a DT B-NP B-NP
small JJ I-NP I-NP
basic JJ I-NP I-NP
protein NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
potential NN I-NP I-NP
to TO B-VP B-VP
be VB I-VP I-VP
phosphorylated VBN I-VP I-VP
. . O O

Genes NNS B-NP B-NP
actively RB B-VP B-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
G0/G1 NN I-NP I-NP
switch NN I-NP I-NP
( ( O O
G0S NN B-NP B-NP
genes NNS I-NP I-NP
) ) O O
may MD B-VP B-VP
be VB I-VP I-VP
differentially RB I-VP I-VP
expressed VBN I-VP I-VP
during IN B-PP B-PP
the DT B-NP B-NP
lectin-induced JJ I-NP I-NP
switch NN I-NP I-NP
of IN B-PP B-PP
lymphocytes NNS B-NP B-NP
from IN B-PP B-PP
the DT B-NP B-NP
G0 NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
G1 NN I-NP I-NP
phases NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
cell NN I-NP I-NP
cycle NN I-NP I-NP
. . O O

This DT B-NP B-NP
paper NN I-NP I-NP
presents VBZ B-VP B-VP
studies NNS B-NP B-NP
of IN B-PP B-PP
G0S2 NN B-NP B-NP
, , O O
a DT B-NP B-NP
member NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
set NN I-NP I-NP
of IN B-PP B-PP
putative JJ B-NP B-NP
G0S NN I-NP I-NP
genes NNS I-NP I-NP
, , O O
for IN B-PP B-PP
which WDT B-NP B-NP
cDNAs NNS B-NP B-NP
were VBD B-VP B-VP
cloned VBN I-VP I-VP
and CC O I-VP
selected VBN B-VP I-VP
on IN B-PP B-PP
the DT I-PP B-NP
basis NN I-PP I-NP
of IN I-PP B-PP
differential JJ B-NP B-NP
cDNA NN I-NP I-NP
hybridization NN I-NP I-NP
. . O O

G0S2 NN B-NP B-NP
mRNA NN I-NP I-NP
increases VBZ B-VP B-VP
transiently RB B-ADVP B-ADVP
within IN B-PP B-PP
1-2 CD B-NP B-NP
hr NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
addition NN I-NP I-NP
of IN B-PP B-PP
lectin NN B-NP B-NP
or CC O I-NP
cycloheximide NN B-NP I-NP
to TO B-PP B-PP
cultured VBN B-NP B-NP
blood NN I-NP I-NP
mononuclear JJ I-NP I-NP
cells NNS I-NP I-NP
. . O O

Comparison NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
nearly RB I-NP I-NP
full-length JJ I-NP I-NP
cDNA NN I-NP I-NP
sequence NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
corresponding JJ I-NP I-NP
genomic JJ I-NP I-NP
sequence NN I-NP I-NP
reveals VBZ B-VP B-VP
one CD B-NP B-NP
small JJ I-NP I-NP
intron NN I-NP I-NP
and CC O I-CC
an DT B-NP B-NP
open JJ I-NP I-NP
reading NN I-NP I-NP
frame NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
second JJ I-NP I-NP
exon NN I-NP I-NP
. . O O

The DT B-NP B-NP
derived VBN I-NP B-VP
103-amino-acid JJ I-NP B-NP
basic JJ I-NP I-NP
protein NN I-NP I-NP
has VBZ B-VP B-VP
two CD B-NP B-NP
potential JJ I-NP I-NP
alpha-helical JJ I-NP I-NP
domains NNS I-NP I-NP
separated VBN B-VP B-VP
by IN B-PP B-PP
a DT B-NP B-NP
hydrophobic JJ I-NP I-NP
region NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
potential NN I-NP I-NP
to TO B-VP B-VP
generate VB I-VP I-VP
turns NNS B-NP B-NP
and CC O I-CC
assume VB B-VP B-VP
a DT B-NP B-NP
beta-sheet JJ I-NP I-NP
conformation NN I-NP I-NP
. . O O

Consistent JJ B-ADJP B-ADJP
with IN B-PP B-PP
involvement NN B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
G0/G1 NN I-NP I-NP
switch NN I-NP I-NP
, , O O
the DT B-NP B-NP
protein NN I-NP I-NP
contains VBZ B-VP B-VP
potential JJ B-NP B-NP
sites NNS I-NP I-NP
for IN B-PP B-PP
phosphorylation NN B-NP B-NP
by IN B-PP B-PP
protein NN B-NP B-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
and CC O I-NP
casein NN B-NP I-NP
kinase NN I-NP I-NP
II CD I-NP I-NP
. . O O

The DT B-NP B-NP
gene NN I-NP I-NP
contains VBZ B-VP B-VP
a DT B-NP B-NP
CpG-rich JJ I-NP I-NP
island NN I-NP I-NP
suggesting VBG B-VP I-NP
expression NN B-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
germ NN I-NP I-NP
line NN I-NP I-NP
. . O O

An DT B-NP B-NP
upstream JJ I-NP I-NP
segment NN I-NP I-NP
contains VBZ B-VP B-VP
tandem JJ B-NP B-NP
dinucleotide NN I-NP I-NP
repeats NNS I-NP I-NP
(CT)19/(CA)16 NN I-NP I-NP
. . O O

There EX B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
suitably RB I-NP I-NP
located JJ I-NP I-NP
TATA NN I-NP I-NP
box NN I-NP I-NP
, , O O
but CC O I-CC
potential JJ B-NP B-NP
sites NNS I-NP I-NP
for IN B-PP B-PP
CCAAT-box NN B-NP B-NP
binding NN I-NP I-NP
factors NNS I-NP I-NP
are VBP B-VP B-VP
far RB B-ADJP B-ADJP
upstream JJ I-ADJP I-ADJP
, , O O
embedded JJ B-ADJP B-ADJP
in IN B-PP B-PP
a DT B-NP B-NP
42-nucleotide JJ I-NP I-NP
repeat NN I-NP I-NP
element NN I-NP I-NP
. . O O

Potential JJ B-NP B-NP
sites NNS I-NP I-NP
for IN B-PP B-PP
transcription NN B-NP B-NP
factors NNS I-NP I-NP
AP1 NN B-NP I-NP
, , O O
AP2 NN B-NP B-NP
, , O O
and CC O I-CC
AP3 NN B-NP B-NP
are VBP B-VP B-VP
consistent JJ B-ADJP B-ADJP
with IN B-PP B-PP
rapid JJ B-NP B-NP
transcriptional JJ I-NP I-NP
activation NN I-NP I-NP
in IN B-PP B-PP
response NN I-PP B-NP
to TO I-PP B-PP
inducing VBG B-NP B-NP
agents NNS I-NP I-NP
. . O O

Synergism NN B-NP B-NP
between IN B-PP B-PP
two CD B-NP B-NP
distinct JJ I-NP I-NP
elements NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HTLV-I NN I-NP I-NP
enhancer NN I-NP I-NP
during IN B-PP B-PP
activation NN B-NP B-NP
by IN B-PP B-PP
the DT B-NP B-NP
trans-activator NN I-NP I-NP
of IN B-PP B-PP
HTLV-I NN B-NP B-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
conducted VBN I-VP I-VP
functional JJ B-NP B-NP
studies NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
enhancer NN I-NP I-NP
elements NNS I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
T-cell NN I-NP I-NP
leukemia NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
I CD I-NP I-NP
( ( O O
HTLV-I NN B-NP B-NP
) ) O O
using VBG B-VP B-VP
the DT B-NP B-NP
human JJ I-NP I-NP
T-cell NN I-NP I-NP
lines NNS I-NP I-NP
Jurkat NN B-NP I-NP
and CC O I-CC
MOLT NN B-NP B-NP
4 CD I-NP I-NP
, , O O
which WDT B-NP B-NP
are VBP B-VP B-VP
negative JJ B-ADJP B-ADJP
for IN B-PP B-PP
HTLV-I NN B-NP B-NP
, , O O
and CC O I-CC
MT-2 NN B-NP B-NP
and CC O I-NP
TL-Mor NN B-NP I-NP
, , O O
which WDT B-NP B-NP
carry VBP B-VP B-VP
the DT B-NP B-NP
proviral JJ I-NP I-NP
genome NN I-NP I-NP
of IN B-PP B-PP
HTLV-I NN B-NP B-NP
. . O O

Two CD B-NP B-NP
distinct JJ I-NP I-NP
elements NNS I-NP I-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
implicated VBN I-VP I-VP
in IN B-PP B-PP
function NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
HTLV-I NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

One CD B-NP B-NP
is VBZ B-VP B-VP
the DT O B-NP
21-base-pair JJ O I-NP
( ( O O
bp NN B-NP I-NN
) ) O O
core NN B-NP B-NP
element NN I-NP I-NP
that WDT B-NP B-NP
is VBZ B-VP B-VP
responsible JJ B-ADJP B-ADJP
for IN B-PP B-PP
trans-activation NN B-NP B-NP
by IN B-PP B-PP
the DT B-NP B-NP
HTLV-I NN I-NP I-NP
trans-activator NN I-NP I-NP
p40tax NN I-NP I-NP
and CC O I-CC
that WDT B-NP B-NP
has VBZ B-VP B-VP
the DT B-NP B-NP
ability NN I-NP I-NP
to TO B-VP B-VP
bind VB I-VP I-VP
to TO B-PP B-PP
cyclic-AMP NN B-NP B-NP
responsive JJ I-NP I-NP
element NN I-NP I-NP
binding NN I-NP I-NP
factor NN I-NP I-NP
( ( I-NP O
CREB NN I-NP B-NP
) ) I-NP O
-like JJ I-NP I-JJ
factor NN I-NP B-NP
( ( I-NP O
s NNS I-NP B-NP
) ) O O
. . O O

The DT B-NP B-NP
other JJ I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
region NN I-NP I-NP
interposed VBN B-ADJP B-VP
between IN B-PP B-PP
the DT B-NP B-NP
21-bp JJ I-NP I-NP
elements NNS I-NP I-NP
. . O O

In IN B-PP B-PP
this DT B-NP B-NP
study NN I-NP I-NP
we PRP B-NP B-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
a DT B-NP B-NP
subfragment NN I-NP I-NP
( ( O O
C26 NN B-NP B-NP
) ) O O
in IN B-PP B-PP
the DT B-NP B-NP
region NN I-NP I-NP
between IN B-PP B-PP
the DT B-NP B-NP
21-bp JJ I-NP I-NP
elements NNS I-NP I-NP
is VBZ B-VP B-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
trans-activation NN B-NP B-NP
by IN B-PP B-PP
p40tax NN B-NP B-NP
, , O O
possibly RB B-PP B-ADVP
through IN I-PP B-PP
binding NN B-NP B-NP
to TO B-PP B-PP
an DT B-NP B-NP
NF-kappa NN I-NP I-NP
B-like JJ I-NP I-NP
nuclear JJ I-NP I-NP
factor NN B-NP I-NP
or CC O I-NP
factors NNS B-NP I-NP
. . O O

Formation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
protein-DNA JJ I-NP I-NP
complex NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
C26 NN I-NP I-NP
subfragment NN I-NP I-NP
was VBD B-VP B-VP
positively RB I-VP I-VP
affected VBN I-VP I-VP
by IN B-PP B-PP
p40tax NN B-NP B-NP
. . O O

The DT B-NP B-NP
C26 NN I-NP I-NP
element NN I-NP I-NP
conferred VBD B-VP B-VP
partial JJ B-NP B-NP
responsiveness NN I-NP I-NP
to TO B-PP B-PP
p40tax NN B-NP B-NP
when WRB B-ADVP B-ADVP
linked VBN B-VP B-VP
to TO B-PP B-PP
one CD B-NP B-NP
copy NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
21-bp JJ I-NP I-NP
element NN I-NP I-NP
that WDT B-NP B-NP
, , O O
by IN B-PP B-PP
itself PRP B-NP B-NP
, , O O
showed VBD B-VP B-VP
little JJ B-NP B-NP
activation NN I-NP I-NP
in IN B-PP B-PP
response NN I-PP B-NP
to TO I-PP B-PP
p40tax NN B-NP B-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
C26 NN I-NP I-NP
element NN I-NP I-NP
alone RB B-ADVP B-ADVP
, , O O
even RB B-ADVP B-NP
when WRB B-ADVP I-NP
repeated VBN B-VP B-VP
, , O O
could MD B-VP B-VP
not RB I-VP I-VP
be VB I-VP I-VP
activated VBN I-VP I-VP
by IN B-PP B-PP
p40tax NN B-NP B-NP
, , O O
unlike IN B-PP B-PP
other JJ B-NP B-NP
NF-kappa NN I-NP I-NP
B-binding JJ I-NP I-NP
elements NNS I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
the DT B-NP B-NP
C26 NN I-NP I-NP
element NN I-NP I-NP
itself PRP B-NP B-NP
was VBD B-VP B-VP
profoundly RB I-VP I-VP
activated VBN I-VP I-VP
upon IN B-PP B-PP
stimulation NN B-NP B-NP
with IN B-PP B-PP
12-O-tetradecanoylphorbol-13-acetate NN B-NP B-NP
. . O O

These DT B-NP B-NP
findings NNS I-NP I-NP
therefore RB B-ADVP B-ADVP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
HTLV-I NN I-NP I-NP
enhancer NN I-NP I-NP
contains VBZ B-VP B-VP
multiple JJ B-NP B-NP
functional JJ I-NP I-NP
elements NNS I-NP I-NP
, , O O
including VBG B-PP B-PP
binding VBG B-NP B-VP
sites NNS I-NP B-NP
for IN B-PP B-PP
at IN B-NP B-NP
least JJS I-NP I-NP
CREB- NN I-NP I-NP
and CC I-NP I-NP
NF-kappa NN I-NP I-NP
B-like JJ I-NP I-NP
factors NNS I-NP I-NP
, , O O
which WDT B-NP B-NP
synergistically RB B-ADVP B-ADVP
cooperate VBP B-VP B-VP
in IN B-PP B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
HTLV-I NN I-NP I-NP
enhancer NN I-NP I-NP
in IN B-PP B-PP
response NN I-PP B-NP
to TO I-PP B-PP
p40tax NN B-NP B-NP
. . O O

Our PRP$ B-NP B-NP
results NNS I-NP I-NP
also RB B-ADVP B-ADVP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
TPA-dependent JJ B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HTLV-I NN I-NP I-NP
enhancer NN I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
mediated VBN I-VP I-VP
through IN B-PP B-PP
the DT B-NP B-NP
C26 NN I-NP I-NP
element NN I-NP I-NP
. . O O

v-erbA NN B-NP B-NP
overexpression NN I-NP I-NP
is VBZ B-VP B-VP
required VBN I-VP I-VP
to TO I-VP I-VP
extinguish VB I-VP I-VP
c-erbA NN B-NP B-NP
function NN I-NP I-NP
in IN B-PP B-PP
erythroid JJ B-NP B-NP
cell NN I-NP I-NP
differentiation NN I-NP I-NP
and CC O I-NP
regulation NN B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
erbA NN I-NP I-NP
target NN I-NP I-NP
gene NN I-NP I-NP
CAII NN I-NP I-NP
. . O O

The DT B-NP B-NP
v-erbA NN I-NP I-NP
oncoprotein NN I-NP I-NP
represents VBZ B-VP B-VP
a DT B-NP B-NP
retrovirus-transduced JJ I-NP I-NP
oncogenic JJ I-NP I-NP
version NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
thyroid NN I-NP I-NP
hormone NN I-NP I-NP
( ( I-NP O
T3/T4 NN I-NP I-NN
) ) I-NP O
receptor NN I-NP B-NP
c-erbA NN I-NP I-NP
( ( I-NP O
type NN I-NP B-NP
alpha NN I-NP I-NP
) ) O O
. . O O

It PRP B-NP B-NP
contributes VBZ B-VP B-VP
to TO B-PP B-PP
virus-induced JJ B-NP B-NP
erythroleukemia NN I-NP I-NP
by IN B-PP B-PP
efficiently RB B-ADVP B-VP
arresting VBG B-VP I-VP
differentiation NN B-NP B-NP
of IN B-PP B-PP
red JJ B-NP B-NP
cell NN I-NP I-NP
progenitors NNS I-NP I-NP
and CC B-PP B-PP
by IN B-PP B-PP
suppressing VBG B-VP B-VP
transcription NN B-NP B-NP
of IN B-PP B-PP
erythrocyte-specific JJ B-NP B-NP
genes NNS I-NP I-NP
. . O O

Here RB B-ADVP B-ADVP
, , O O
we PRP B-NP B-NP
show VBP B-VP B-VP
that IN B-SBAR B-PP
v-erbA NN B-NP B-NP
and CC O I-NP
c-erbA NN B-NP I-NP
bind VBP B-VP B-VP
directly RB B-ADVP B-ADVP
to TO B-PP B-PP
sequences NNS B-NP B-NP
within IN B-PP B-PP
the DT B-NP B-NP
promoter NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
erythrocyte-specific JJ I-NP I-NP
carbonic JJ B-NP I-NP
anhydrase NN I-NP I-NP
II CD I-NP I-NP
( ( O O
CAII NN B-NP B-NP
) ) O O
, , O O
a DT B-NP B-NP
gene NN I-NP I-NP
whose WP$ B-NP B-NP
transcription NN I-NP I-NP
is VBZ B-VP B-VP
efficiently RB I-VP I-VP
suppressed VBN I-VP I-VP
by IN B-PP B-PP
v-erbA NN B-NP B-NP
. . O O

This DT B-NP B-NP
erbA-binding JJ I-NP I-NP
site NN I-NP I-NP
confers VBZ B-VP B-VP
thyroid NN B-NP B-NP
hormone NN I-NP I-NP
responsiveness NN I-NP I-NP
to TO B-PP B-PP
a DT B-NP B-NP
heterologous JJ I-NP I-NP
promoter NN I-NP I-NP
in IN B-PP B-PP
transient JJ B-NP B-NP
expression NN I-NP I-NP
experiments NNS I-NP I-NP
and CC O I-CC
is VBZ B-VP B-VP
a DT B-NP B-NP
target NN I-NP I-NP
for IN B-PP B-PP
efficient JJ B-NP B-NP
down-regulation NN I-NP I-NP
of IN B-PP B-PP
CAII NN B-NP B-NP
transcription NN I-NP I-NP
by IN B-PP B-PP
the DT B-NP B-NP
v-erbA NN I-NP I-NP
oncoprotein NN I-NP I-NP
. . O O

In IN B-PP B-PP
stably RB B-NP B-NP
transformed VBN I-NP I-NP
erythroblasts NNS I-NP I-NP
coexpressing VBG B-VP B-VP
the DT B-NP B-NP
v-erbA NN I-NP I-NP
oncoprotein NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
c-erbA/T3 NN I-NP I-NP
receptor NN I-NP I-NP
at IN B-PP B-PP
an DT B-NP B-NP
approximately RB I-NP I-NP
equimolar JJ I-NP I-NP
ratio NN I-NP I-NP
, , O O
c-erbA NN B-NP B-NP
activity NN I-NP I-NP
is VBZ B-VP B-VP
dominant JJ B-ADJP B-ADJP
over IN B-PP B-PP
v-erbA NN B-NP B-NP
. . O O

T3 NN B-NP B-NP
efficiently RB B-ADVP B-VP
induced VBD B-VP I-VP
erythroid JJ B-NP B-NP
differentiation NN I-NP I-NP
in IN B-PP B-PP
these DT B-NP B-NP
cells NNS I-NP I-NP
, , O O
thus RB O B-ADVP
overcoming VBG B-VP B-VP
the DT B-NP B-NP
v-erbA-mediated JJ I-NP I-NP
differentiation NN I-NP I-NP
arrest NN I-NP I-NP
. . O O

Likewise RB B-ADVP B-ADVP
, , O O
T3 NN B-NP B-NP
activated VBD B-VP B-VP
CAII NN B-NP B-NP
transcription NN I-NP I-NP
as RB B-CONJP B-ADVP
well RB I-CONJP I-ADVP
as IN I-CONJP B-PP
transient JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
T3-responsive JJ I-NP I-NP
reporter NN I-NP I-NP
gene NN I-NP I-NP
containing VBG B-VP B-VP
the DT B-NP B-NP
CAII-specific JJ I-NP I-NP
erbA-binding JJ I-NP I-NP
site NN I-NP I-NP
. . O O

The DT B-NP B-NP
c-erbA-dependent JJ I-NP I-NP
activation NN I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
CAII NN I-NP I-NP
reporter NN I-NP I-NP
construct NN I-NP I-NP
could MD B-VP B-VP
only RB I-VP I-VP
be VB I-VP I-VP
suppressed VBN I-VP I-VP
by IN B-PP B-PP
very RB B-NP B-NP
high JJ I-NP I-NP
amounts NNS I-NP I-NP
of IN B-PP B-PP
v-erbA NN B-NP B-NP
. . O O

Our PRP$ B-NP B-NP
results NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-PP
overexpression NN B-NP B-NP
of IN B-PP B-PP
v-erbA NN B-NP B-NP
is VBZ B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
its PRP$ B-NP B-NP
function NN I-NP I-NP
as IN B-PP B-PP
an DT B-NP B-NP
oncoprotein NN I-NP I-NP
. . O O

Inhibition NN B-NP B-NP
of IN B-PP B-PP
phorbol NN B-NP B-NP
ester-induced JJ I-NP B-NP
monocytic JJ I-NP I-NP
differentiation NN I-NP I-NP
by IN B-PP B-PP
dexamethasone NN B-NP B-NP
is VBZ B-VP B-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
down-regulation NN B-NP B-NP
of IN B-PP B-PP
c-fos NN B-NP B-NP
and CC O I-NP
c-jun NN B-NP I-NP
( ( O O
AP-1 NN B-NP B-NP
) ) O O
. . O O

Previous JJ B-NP B-NP
studies NNS I-NP I-NP
have VBP B-VP B-VP
shown VBN I-VP I-VP
that IN B-SBAR B-PP
treatment NN B-NP B-NP
of IN B-PP B-PP
human JJ B-NP B-NP
myeloid JJ I-NP I-NP
leukemia NN I-NP I-NP
cells NNS I-NP I-NP
with IN B-PP B-PP
12-O-tetradecanoylphorbol-13-acetate NN B-NP B-NP
( ( O O
TPA NN B-NP B-NP
) ) O O
is VBZ B-VP B-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
induction NN B-NP B-NP
of IN B-PP B-PP
monocytic JJ B-NP B-NP
differentiation NN B-NP I-NP
and CC O I-NP
expression NN B-NP I-NP
of IN B-PP B-PP
the DT O B-NP
c-jun NN B-NP I-NP
and CC O I-NP
c-fos NN B-NP I-NP
early JJ B-NP I-NP
response NN I-NP I-NP
genes NNS I-NP I-NP
. . O O

The DT B-NP B-NP
present JJ I-NP I-NP
work NN I-NP I-NP
demonstrates VBZ B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
glucocorticoid NN I-NP I-NP
dexamethasone NN I-NP I-NP
inhibits VBZ B-VP B-VP
TPA-induced JJ B-NP B-NP
increases NNS I-NP I-NP
in IN B-PP B-PP
c-jun NN B-NP B-NP
and CC O I-NP
c-fos NN B-NP I-NP
mRNA NN B-NP I-NP
levels NNS I-NP I-NP
in IN B-PP B-PP
U-937 NN B-NP B-NP
leukemia NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

These DT B-NP B-NP
findings NNS I-NP I-NP
were VBD B-VP B-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
a DT B-NP B-NP
block NN I-NP I-NP
in IN B-PP B-PP
appearance NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
monocytic JJ I-NP I-NP
phenotype NN I-NP I-NP
, , O O
including VBG B-PP B-PP
inhibition NN B-NP B-NP
of IN B-PP B-PP
TPA-induced JJ B-NP B-NP
increases NNS I-NP I-NP
in IN B-PP B-PP
lamin NN B-NP B-NP
A NN I-NP I-NP
, , O O
lamin NN B-NP B-NP
C NN I-NP I-NP
, , O O
and CC O I-CC
vimentin NN B-NP B-NP
transcripts NNS I-NP I-NP
. . O O

Other JJ B-NP B-NP
studies NNS I-NP I-NP
have VBP B-VP B-VP
demonstrated VBN I-VP I-VP
that IN B-SBAR B-PP
TPA-induced JJ B-NP B-NP
monocytic JJ I-NP I-NP
differentiation NN B-NP I-NP
and CC O I-NP
expression NN B-NP I-NP
of IN B-PP B-PP
the DT O B-NP
c-jun NN B-NP I-NP
and CC O I-NP
c-fos NN B-NP I-NP
genes NNS B-NP I-NP
in IN B-PP B-PP
myeloid JJ B-NP B-NP
leukemia NN I-NP I-NP
cells NNS I-NP I-NP
are VBP B-VP B-VP
regulated VBN I-VP I-VP
by IN B-PP B-PP
protein NN B-NP B-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
( ( O O
PKC NN B-NP B-NP
) ) O O
. . O O

The DT B-NP B-NP
finding NN I-NP I-NP
that IN B-SBAR B-PP
dexamethasone NN B-NP B-NP
has VBZ B-VP B-VP
no DT B-NP B-NP
effect NN I-NP I-NP
on IN B-PP B-PP
TPA-induced JJ B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
PKC NN B-NP B-NP
suggests VBZ B-VP B-VP
that IN B-SBAR B-SBAR
this DT B-NP B-NP
glucocorticoid NN I-NP I-NP
inhibits VBZ B-VP B-VP
signals NNS B-NP B-NP
downstream JJ B-ADJP B-ADJP
or CC O I-ADJP
parallel JJ B-ADJP I-ADJP
to TO B-PP B-PP
this DT B-NP B-NP
enzyme NN I-NP I-NP
. . O O

Nuclear JJ B-NP B-NP
run-on JJ I-NP I-NP
assays NNS I-NP I-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
: : O O
( ( B-LST O
1 LS I-LST I-LS
) ) O O
induction NN B-NP B-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
and CC O I-NP
c-fos NN B-NP I-NP
expression NN B-NP I-NP
by IN B-PP B-PP
TPA NN B-NP B-NP
is VBZ B-VP B-VP
regulated VBN I-VP I-VP
by IN B-PP B-PP
transcriptional JJ B-NP B-NP
mechanisms NNS I-NP I-NP
, , O O
( ( B-LST O
2 LS I-LST B-NP
) ) O O
TPA-induced JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
and CC O I-NP
c-fos NN B-NP I-NP
does VBZ B-VP B-VP
not RB I-VP I-VP
require VB I-VP I-VP
protein NN B-NP B-NP
synthesis NN I-NP I-NP
, , O O
and CC O I-CC
( ( B-LST O
3 LS I-LST I-LS
) ) O O
TPA-induced JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
both DT B-NP B-NP
genes NNS I-NP I-NP
is VBZ B-VP B-VP
inhibited VBN I-VP I-VP
at IN B-PP B-PP
the DT B-NP B-NP
transcriptional JJ I-NP I-NP
level NN I-NP I-NP
by IN B-PP B-PP
dexamethasone NN B-NP B-NP
. . O O

To TO B-VP B-VP
further RB I-VP I-VP
define VB I-VP I-VP
the DT B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
dexamethasone NN B-NP B-NP
at IN B-PP B-PP
the DT B-NP B-NP
molecular JJ I-NP I-NP
level NN I-NP I-NP
, , O O
we PRP B-NP B-NP
prepared VBD B-VP B-VP
a DT B-NP B-NP
series NN I-NP I-NP
of IN B-PP B-PP
deleted VBN B-NP B-NP
c-jun NN I-NP I-NP
promoter NN I-NP I-NP
fragments NNS I-NP I-NP
linked VBN B-VP B-VP
to TO B-PP B-PP
the DT O B-NP
chloramphenicol NN B-NP I-NP
acetyltransferase NN I-NP I-NP
( ( O O
CAT NN B-NP I-NN
) ) O O
gene NN B-NP B-NP
. . O O

Increases NNS B-NP B-NP
in IN B-PP B-PP
CAT NN B-NP B-NP
activity NN I-NP I-NP
during IN B-PP B-PP
transient JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
constructs NNS I-NP I-NP
in IN B-PP B-PP
TPA-treated JJ B-NP B-NP
U-937 NN I-NP I-NP
cells NNS I-NP I-NP
could MD B-VP B-VP
be VB I-VP I-VP
assigned VBN I-VP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
region NN I-NP I-NP
( ( O O
-97 CD B-NP B-NP
to TO O B-PP
-20 CD B-NP B-NP
) ) O O
of IN B-PP B-PP
the DT B-NP B-NP
promoter NN I-NP I-NP
that WDT B-NP B-NP
contains VBZ B-VP B-VP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
binding NN I-NP I-NP
site NN I-NP I-NP
. . O O

This DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
CAT NN B-NP B-NP
activity NN I-NP I-NP
was VBD B-VP B-VP
sensitive JJ B-ADJP B-ADJP
to TO B-PP B-PP
dexamethasone NN B-NP B-NP
. . O O

These DT B-NP B-NP
findings NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
dexamethasone NN B-NP B-NP
down-regulates VBZ B-VP B-VP
TPA-induced JJ B-NP B-NP
transcription NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
c-jun NN I-NP I-NP
gene NN I-NP I-NP
during IN B-PP B-PP
monocytic JJ B-NP B-NP
differentiation NN I-NP I-NP
by IN B-PP B-PP
inhibiting VBG B-VP B-VP
activation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
site NN I-NP I-NP
. . O O

Charybdotoxin-sensitive JJ B-NP B-NP
, , I-NP O
Ca(2+)-dependent JJ I-NP I-NP
membrane NN I-NP I-NP
potential JJ I-NP I-NP
changes NNS I-NP I-NP
are VBP B-VP B-VP
not RB I-VP B-ADJP
involved VBN I-VP I-ADJP
in IN B-PP B-PP
human JJ B-NP B-NP
T NN I-NP I-NP
or CC I-NP I-NP
B NN I-NP I-NP
cell NN I-NP I-NP
activation NN B-NP I-NP
and CC O I-NP
proliferation NN B-NP I-NP
. . O O

The DT B-NP B-NP
involvement NN I-NP I-NP
of IN B-PP B-PP
ion NN B-NP B-NP
channels NNS I-NP I-NP
in IN B-PP B-PP
B NN B-NP B-NP
and CC I-NP I-NP
T NN I-NP I-NP
lymphocyte NN I-NP I-NP
activation NN I-NP I-NP
is VBZ B-VP B-VP
supported VBN I-VP I-VP
by IN B-PP B-PP
many JJ B-NP B-NP
reports NNS I-NP I-NP
of IN B-PP B-PP
changes NNS B-NP B-NP
in IN B-PP B-PP
ion NN B-NP B-NP
fluxes NNS I-NP I-NP
and CC O I-CC
membrane NN B-NP B-NP
potential NN I-NP I-NP
after IN B-PP B-PP
mitogen NN B-NP B-NP
binding NN I-NP I-NP
. . O O

Human JJ B-NP B-NP
T NN I-NP I-NP
and CC I-NP I-NP
B NN I-NP I-NP
lymphocytes NNS I-NP I-NP
demonstrate VBP B-VP B-VP
an DT B-NP B-NP
early JJ I-NP I-NP
and CC I-NP I-NP
transient JJ I-NP I-NP
hyperpolarization NN I-NP I-NP
after IN B-PP B-PP
ligand JJ B-NP B-NP
binding NN I-NP I-NP
. . O O

Inasmuch RB B-SBAR B-ADVP
as IN I-SBAR B-PP
the DT B-NP B-NP
change NN I-NP I-NP
in IN B-PP B-PP
membrane NN B-NP B-NP
potential NN I-NP I-NP
is VBZ B-VP B-VP
dependent JJ B-ADJP B-ADJP
on IN B-PP B-PP
elevation NN B-NP B-NP
of IN B-PP B-PP
free JJ B-NP B-NP
cytosolic JJ I-NP I-NP
calcium NN I-NP I-NP
, , O O
the DT B-NP B-NP
hyperpolarization NN I-NP I-NP
is VBZ B-VP B-VP
presumably RB B-ADVP B-ADVP
through IN B-PP B-PP
opening NN B-NP B-NP
of IN B-PP B-PP
Ca(2+)-stimulated JJ B-NP B-NP
K+ NN I-NP I-NP
channels NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
used VBN I-VP I-VP
charybdotoxin NN B-NP B-NP
, , O O
a DT B-NP B-NP
known JJ I-NP I-NP
inhibitor NN I-NP I-NP
of IN B-PP B-PP
Ca(2+)-dependent JJ B-NP B-NP
K+ NN I-NP I-NP
channels NNS I-NP I-NP
, , O O
to TO B-VP B-VP
study VB I-VP I-VP
the DT B-NP B-NP
role NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
channels NNS I-NP I-NP
in IN B-PP B-PP
lymphocyte NN B-NP B-NP
activation NN B-NP I-NP
and CC O I-NP
mitogenesis NN B-NP I-NP
. . O O

We PRP B-NP B-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-SBAR
charybdotoxin NN B-NP B-NP
inhibits VBZ B-VP B-VP
the DT B-NP B-NP
ligand-induced JJ I-NP I-NP
transient JJ I-NP I-NP
membrane NN I-NP I-NP
hyperpolarization NN I-NP I-NP
in IN B-PP B-PP
B NN B-NP B-NP
and CC O I-NP
T NN B-NP I-NP
cells NNS B-NP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
dose-dependent JJ I-NP I-NP
fashion NN I-NP I-NP
, , O O
without IN B-PP B-PP
affecting VBG B-VP B-VP
changes NNS B-NP B-NP
in IN B-PP B-PP
cytosolic JJ B-NP B-NP
Ca2+ NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
blockade NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
Ca(2+)-activated JJ I-NP I-NP
K+ NN I-NP I-NP
channel NN I-NP I-NP
is VBZ B-VP B-VP
not RB I-VP I-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
changes NNS B-NP B-NP
in IN B-PP B-PP
cell-cycle JJ B-NP B-NP
gene NN I-NP I-NP
activation NN I-NP I-NP
, , O O
IL-2 NN B-NP B-NP
production NN I-NP I-NP
, , O O
IL-2R NN B-NP B-NP
expression NN I-NP I-NP
or CC O I-CC
B NN B-NP B-NP
and CC O I-NP
T NN B-NP I-NP
cell NN B-NP I-NP
mitogenesis NN I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
imply VBP B-VP B-VP
that IN B-SBAR B-PP
membrane NN B-NP B-NP
potential JJ I-NP I-NP
changes NNS I-NP I-NP
secondary JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
ligand-dependent JJ I-NP I-NP
opening NN I-NP I-NP
of IN B-PP B-PP
Ca(2+)-activated JJ B-NP B-NP
K+ NN I-NP I-NP
channels NNS I-NP I-NP
are VBP B-VP B-VP
not RB I-VP I-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
B NN B-NP B-NP
and CC O I-NP
T NN B-NP I-NP
lymphocyte NN B-NP I-NP
activation NN B-NP I-NP
and CC O I-NP
mitogenesis NN B-NP I-NP
. . O O

Evaluation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
role NN I-NP I-NP
of IN B-PP B-PP
ligand NN B-NP B-NP
and CC O I-CC
thermal JJ B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
specific JJ B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
by IN B-PP B-PP
in FW B-ADVP B-NP
vitro FW I-ADVP I-FW
synthesized VBN B-NP B-VP
human JJ I-NP B-NP
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
used VBN I-VP I-VP
a DT B-NP B-NP
DNA-binding/immunoprecipitation JJ I-NP I-NP
assay NN I-NP I-NP
to TO B-VP B-VP
analyze VB I-VP I-VP
the DT B-NP B-NP
capacity NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
( ( O O
hGR NN B-NP B-NP
) ) O O
, , O O
generated VBN B-VP B-VP
in IN B-PP B-PP
rabbit NN B-NP B-NP
reticulocyte NN I-NP I-NP
lysates NNS I-NP I-NP
, , O O
to TO B-VP B-VP
bind VB I-VP I-VP
DNA NN B-NP B-NP
. . O O

In FW B-ADVP B-NP
vitro FW I-ADVP I-NP
translated VBN B-NP I-NP
hGR NN I-NP I-NP
was VBD B-VP B-VP
indistinguishable JJ B-ADJP B-ADJP
from IN B-PP B-PP
native JJ B-NP B-NP
hGR NN I-NP I-NP
, , O O
as IN B-SBAR B-SBAR
determined VBN B-VP B-VP
by IN B-PP B-PP
migration NN B-NP B-NP
on IN B-PP B-PP
sodium NN B-NP B-NP
dodecyl NN I-NP I-NP
sulfate-polyacrylamide JJ I-NP I-NP
gels NNS I-NP I-NP
, , O O
sedimentation NN B-NP B-NP
on IN B-PP B-PP
sucrose NN B-NP B-NP
density NN I-NP I-NP
gradients NNS I-NP I-NP
, , O O
and CC O I-CC
reactivity NN B-NP B-NP
with IN B-PP B-PP
antipeptide JJ B-NP B-NP
antibodies NNS I-NP I-NP
generated VBN B-VP B-VP
against IN B-PP B-PP
hGR NN B-NP B-NP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
cell-free JJ B-NP B-NP
synthesized VBN I-NP I-NP
hGR NN I-NP I-NP
was VBD B-VP B-VP
capable JJ B-ADJP B-ADJP
of IN B-PP B-PP
specific JJ B-NP B-NP
binding NN I-NP I-NP
to TO B-PP B-PP
glucocorticoid NN B-NP B-NP
response NN I-NP I-NP
element NN I-NP I-NP
( ( I-NP O
GRE NN I-NP B-NP
) ) I-NP O
-containing JJ I-NP B-NP
DNA NN I-NP I-NP
fragments NNS I-NP I-NP
. . O O

Using VBG B-VP B-VP
this DT B-NP B-NP
assay NN I-NP I-NP
system NN I-NP I-NP
, , O O
we PRP B-NP B-NP
have VBP B-VP B-VP
evaluated VBN I-VP I-VP
the DT B-NP B-NP
contributions NNS I-NP I-NP
of IN B-PP B-PP
ligand NN B-NP B-NP
binding NN I-NP I-NP
and CC O I-NP
heat NN B-NP I-NP
activation NN I-NP I-NP
to TO B-PP B-PP
DNA NN B-NP B-NP
binding NN I-NP I-NP
by IN B-PP B-PP
these DT B-NP B-NP
glucocorticoid NN I-NP I-NP
receptors NNS I-NP I-NP
. . O O

In FW B-ADVP B-NP
vitro FW I-ADVP I-NP
translated VBN B-NP I-NP
hGR NN I-NP I-NP
was VBD B-VP B-VP
capable JJ B-ADJP B-ADJP
of IN B-PP B-PP
selective JJ B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
even RB B-PP B-ADVP
in IN I-PP B-PP
the DT I-PP B-NP
absence NN I-PP I-NP
of IN I-PP B-PP
glucocorticoid NN B-NP B-NP
. . O O

Treatment NN B-NP B-NP
with IN B-PP B-PP
dexamethasone NN B-NP B-NP
or CC O I-CC
the DT B-NP B-NP
antiglucocorticoid JJ I-NP I-NP
RU486 NN I-NP I-NP
had VBD B-VP B-VP
no DT B-NP B-NP
additional JJ I-NP I-NP
effect NN I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
DNA-binding JJ I-NP I-NP
capacity NN I-NP I-NP
when WRB B-ADVP B-ADVP
receptor NN B-NP B-NP
preparations NNS I-NP I-NP
were VBD B-VP B-VP
maintained VBN I-VP I-VP
at IN B-PP B-PP
0 CD B-NP B-NP
C NN I-NP I-NP
( ( O O
no DT B-NP B-NP
activation NN I-NP I-NP
) ) O O
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
addition NN B-NP B-NP
of IN B-PP B-PP
either CC O I-CC
ligand NN B-NP B-NP
or CC O I-NP
antagonist NN B-NP I-NP
in IN B-PP B-PP
combination NN B-NP B-NP
with IN B-PP B-PP
a DT B-NP B-NP
heat NN I-NP I-NP
activation NN I-NP I-NP
step NN I-NP I-NP
promoted VBD B-VP B-VP
DNA NN B-NP B-NP
binding NN I-NP I-NP
by IN B-PP B-PP
approximately RB B-NP B-NP
3-fold RB I-NP I-NP
over IN B-PP I-NP
that DT B-NP I-NP
of IN B-PP B-PP
heat-activated JJ B-NP B-NP
unliganded JJ I-NP I-NP
receptors NNS I-NP I-NP
. . O O

Agonist NN B-NP B-NP
( ( O O
dexamethasone NN B-NP I-NP
) ) O O
was VBD B-VP B-VP
slightly RB B-ADJP B-NP
more JJR I-ADJP I-NP
effective JJ I-ADJP I-NP
in IN B-PP B-PP
supporting VBG B-VP B-VP
specific JJ B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
than IN B-PP B-PP
antagonist NN B-NP B-NP
( ( O O
RU486 NN B-NP B-NP
) ) O O
. . O O

DNA NN B-NP B-NP
binding NN I-NP I-NP
by IN B-PP B-PP
in FW B-ADVP B-NP
vitro FW I-ADVP I-NP
synthesized VBN B-NP I-NP
GR NN I-NP I-NP
was VBD B-VP B-VP
blocked VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
addition NN I-NP I-NP
of IN B-PP B-PP
sodium NN B-NP B-NP
molybdate NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
receptor NN I-NP I-NP
preparations NNS I-NP I-NP
before IN B-PP B-PP
steroid NN B-NP B-NP
addition NN I-NP I-NP
and CC O I-CC
thermal JJ B-NP B-NP
activation NN I-NP I-NP
. . O O

Addition NN B-NP B-NP
of IN B-PP B-PP
KCl NN B-NP B-NP
resulted VBD B-VP B-VP
in IN B-PP B-PP
less RBR B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
either CC B-PP I-CC
due JJ I-PP B-ADJP
to TO I-PP B-PP
blockage NN B-NP B-NP
of IN B-PP B-PP
DNA-receptor JJ B-NP B-NP
complex NN I-NP I-NP
formation NN I-NP I-NP
or CC O I-NP
disruption NN B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
complexes NNS I-NP I-NP
. . O O

The DT B-NP B-NP
specificity NN I-NP I-NP
of IN B-PP B-PP
DNA NN B-NP B-NP
binding NN I-NP I-NP
by IN B-PP B-PP
cell-free JJ B-NP B-NP
synthesized VBN I-NP I-NP
hGR NN I-NP I-NP
was VBD B-VP B-VP
analyzed VBN I-VP I-VP
further RB B-ADVP B-ADVP
by IN B-PP B-PP
examining VBG B-VP B-VP
the DT B-NP B-NP
abilities NNS I-NP I-NP
of IN B-PP B-PP
various JJ B-NP B-NP
DNAs NNS I-NP I-NP
to TO B-VP B-VP
compete VB I-VP I-VP
for IN B-PP B-PP
binding VBG B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
naturally RB I-NP I-NP
occurring VBG I-NP I-NP
GRE NN I-NP I-NP
found VBD B-VP B-VP
in IN B-PP B-PP
the DT B-NP B-NP
mouse NN I-NP I-NP
mammary JJ I-NP I-NP
tumor NN I-NP I-NP
virus-long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
. . O O

Oligonucleotides NNS B-NP B-NP
containing VBG B-VP B-VP
the DT B-NP B-NP
consensus NN I-NP I-NP
GRE NN I-NP I-NP
were VBD B-VP B-VP
the DT B-NP B-NP
most RBS I-NP I-NP
efficient JJ I-NP I-NP
competitors NNS I-NP I-NP
, , O O
and CC O I-CC
fragments NNS B-NP B-NP
containing VBG B-VP B-VP
regulatory JJ B-NP B-NP
sequences NNS I-NP I-NP
from IN B-PP B-PP
glucocorticoid-repressible JJ B-NP B-NP
genes NNS I-NP I-NP
were VBD B-VP B-VP
somewhat RB B-ADJP B-ADJP
competitive JJ I-ADJP I-ADJP
, , O O
whereas IN O B-PP
single JJ B-NP B-NP
stranded JJ I-NP I-NP
oligonucleotides NNS I-NP I-NP
were VBD B-VP B-VP
unable JJ B-ADJP B-ADJP
to TO B-VP B-VP
compete VB I-VP I-VP
for IN B-PP B-PP
mouse NN B-NP B-NP
mammary JJ I-NP I-NP
tumor NN I-NP I-NP
virus-long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
, , O O
except IN B-PP B-PP
when WRB B-ADVP B-ADVP
competitor NN B-NP B-NP
was VBD B-VP B-VP
present JJ B-ADJP B-ADJP
at IN B-PP B-PP
extremely RB B-NP B-NP
high JJ I-NP I-NP
concentrations NNS I-NP I-NP
. . O O

Together RB B-ADVP B-ADVP
these DT B-NP B-NP
studies NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-PP
hGR NN B-NP B-NP
synthesized VBN B-VP B-VP
in IN B-PP B-PP
rabbit NN B-NP B-NP
reticulocyte NN I-NP I-NP
lysates NNS I-NP I-NP
displays VBZ B-VP B-VP
many JJ B-NP B-ADJP
of IN B-PP B-PP
the DT B-NP B-NP
same JJ I-NP I-NP
properties NNS I-NP I-NP
, , O O
including VBG B-PP B-PP
GRE-specific JJ B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
, , O O
observed VBN B-VP B-VP
for IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
cytosolic JJ B-NP B-NP
extracts NNS I-NP I-NP
of IN B-PP B-PP
mammalian JJ B-NP B-NP
cells NNS B-NP I-NP
and CC O I-NP
tissues NNS B-NP I-NP
. . O O

Similarities NNS B-NP B-NP
between IN B-PP B-PP
the DT B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
dexamethasone NN B-NP B-NP
and CC O I-NP
RU486 NN B-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
antiglucocorticoid JJ I-NP I-NP
properties NNS I-NP I-NP
of IN B-PP B-PP
RU486 NN B-NP B-NP
do VBP B-VP B-VP
not RB I-VP I-VP
occur VB I-VP I-VP
at IN B-PP B-PP
the DT B-NP B-NP
level NN I-NP I-NP
of IN B-PP B-PP
specific JJ B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
. . O O

One CD B-NP B-NP
base NN I-NP I-NP
pair NN I-NP I-NP
change NN I-NP I-NP
abolishes VBZ B-VP B-VP
the DT B-NP B-NP
T NN I-NP I-NP
cell-restricted JJ I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
kB-like JJ I-NP I-NP
proto-enhancer NN I-NP I-NP
element NN I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
interleukin NN I-NP I-NP
2 CD I-NP I-NP
promoter NN I-NP I-NP
. . O O

The DT B-NP B-NP
inducible JJ I-NP I-NP
, , I-NP O
T NN I-NP I-NP
cell-specific JJ I-NP I-NP
enhancers NNS I-NP I-NP
of IN B-PP B-PP
murine JJ O B-NP
and CC O I-NP
human JJ O I-NP
Interleukin NN B-NP I-NP
2 CD I-NP I-NP
( ( O O
Il-2 NN B-NP B-NP
) ) O O
genes NNS B-NP B-NP
contain VBP B-VP B-VP
the DT B-NP B-NP
kB-like JJ I-NP I-NP
sequence NN I-NP I-NP
GGGATTTCACC NN I-NP I-NP
as IN B-PP B-PP
an DT B-NP B-NP
essential JJ I-NP I-NP
cis-acting JJ I-NP I-NP
enhancer NN I-NP I-NP
motif NN I-NP I-NP
. . O O

When WRB B-ADVP B-ADVP
cloned VBN B-VP B-VP
in IN B-PP B-PP
multiple JJ B-NP B-NP
copies NNS I-NP I-NP
this DT B-NP B-NP
so-called JJ I-NP I-NP
TCEd NN B-NP I-NP
( ( O O
distal JJ B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
element NN I-NP I-NP
) ) O O
acts VBZ B-VP B-VP
as IN B-PP B-PP
an DT B-NP B-NP
inducible JJ I-NP I-NP
proto-enhancer NN I-NP I-NP
element NN I-NP I-NP
in IN B-PP B-PP
E14 NN B-NP B-NP
T NN I-NP I-NP
lymphoma NN I-NP I-NP
cells NNS I-NP I-NP
, , B-PP O
but CC I-PP I-CC
not RB B-PP I-RB
in IN I-PP B-PP
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

In IN B-PP B-PP
extracts NNS B-NP B-NP
of IN B-PP B-SBAR
induced VBN B-NP B-VP
, , I-NP O
Il-2 NN I-NP B-NP
secreting NN I-NP I-NP
El4 NN I-NP I-NP
cells NNS I-NP B-VP
three CD B-NP B-NP
individual JJ I-NP I-NP
protein NN I-NP I-NP
factors NNS I-NP I-NP
bind VBP B-VP B-VP
to TO B-PP B-PP
TCEd NN B-NP B-NP
DNA NN I-NP I-NP
. . O O

The DT B-NP B-NP
binding NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
most RBS I-NP I-NP
prominent JJ I-NP I-NP
factor NN I-NP I-NP
, , O O
named VBN B-VP B-VP
TCF-1 NN B-NP B-NP
( ( O O
T NN B-NP B-NP
cell NN I-NP I-NP
factor NN I-NP I-NP
1 CD I-NP I-NP
) ) O O
, , O O
is VBZ B-VP B-VP
correlated VBN I-VP I-VP
with IN B-PP B-PP
the DT B-NP B-NP
proto-enhancer NN I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
TCEd NN B-NP B-NP
. . O O

TCF-1 NN B-NP B-NP
consists VBZ B-VP B-VP
of IN B-PP B-PP
two CD B-NP B-NP
polypeptides NNS I-NP I-NP
of IN B-PP B-PP
about RB B-ADVP B-NP
50 CD B-NP I-NP
kD NN I-NP I-NP
and CC O I-CC
105 CD B-NP B-NP
kD NN I-NP I-NP
; : O O
the DT B-NP B-NP
former JJ I-NP I-NP
seems VBZ B-VP B-VP
to TO I-VP I-VP
be VB I-VP I-VP
related JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
50 CD B-NP I-NP
kD NN I-NP I-NP
polypeptide NN B-NP I-NP
of IN B-PP B-PP
NF-kB NN B-NP B-NP
. . O O

Purified VBN B-NP B-NP
NF-kB NN I-NP I-NP
is VBZ B-VP B-VP
also RB B-ADJP B-ADVP
able JJ I-ADJP B-ADJP
to TO B-VP B-VP
bind VB I-VP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
TCEd NN I-NP I-NP
, , O O
but CC O I-CC
TCF-1 NN B-NP B-NP
binds VBZ B-VP B-VP
stronger JJR B-ADVP B-ADJP
than IN B-PP B-SBAR
NF-kB NN B-NP B-NP
to TO B-PP B-PP
TCEd NN B-NP B-NP
DNA NN I-NP I-NP
. . O O

The DT B-NP B-NP
conversion NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
TCEd NN I-NP I-NP
to TO B-PP B-PP
a DT B-NP B-NP
' [[DQS]] I-NP I-NP
perfect JJ I-NP I-NP
' [[DQE]] I-NP I-NP
NF-kB NN I-NP I-NP
binding NN I-NP I-NP
site NN I-NP I-NP
leads VBZ B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
tighter JJR I-NP I-NP
binding NN I-NP I-NP
of IN B-PP B-PP
NF-kB NN B-NP B-NP
to TO B-PP B-PP
TCEd NN B-NP B-NP
DNA NN I-NP I-NP
and CC O I-CC
, , O O
as IN B-PP B-PP
a DT B-NP B-NP
functional JJ I-NP I-NP
consequence NN I-NP I-NP
, , O O
to TO B-PP B-PP
the DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
' [[DQS]] I-NP I-NP
converted VBN I-NP I-NP
' [[DQE]] I-NP I-NP
TCEd NN I-NP I-NP
motifs NNS I-NP I-NP
in IN B-PP B-PP
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Thus RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
substitution NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
underlined VBN I-NP I-NP
A NN I-NP I-NP
residue NN I-NP I-NP
to TO B-PP B-PP
a DT B-NP B-NP
C NN I-NP I-NP
within IN B-PP B-PP
the DT B-NP B-NP
GGGATTTCACC NN I-NP I-NP
motif NN I-NP I-NP
abolishes VBZ B-VP B-VP
its PRP$ B-NP B-NP
T NN I-NP I-NP
cell-restricted JJ I-NP I-NP
activity NN I-NP I-NP
and CC O I-CC
leads VBZ B-VP B-VP
to TO B-PP B-PP
its PRP$ B-NP B-NP
functioning VBG B-VP I-NP
in IN B-PP B-PP
both CC O I-CC
El4 NN B-NP B-NP
cells NNS I-NP I-NP
and CC O I-CC
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
lymphocyte-specific JJ B-NP B-NP
factors NNS I-NP I-NP
binding VBG B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
TCEd NN I-NP I-NP
are VBP B-VP B-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
control NN I-NP I-NP
of IN B-PP B-PP
T NN B-NP B-NP
cell NN I-NP I-NP
specific-transcription NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
Il-2 NN I-NP I-NP
gene NN I-NP I-NP
. . O O

Negative JJ B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP B-NP
expression NN I-NP I-NP
in IN B-PP B-PP
monocytes NNS B-NP B-NP
: : O O
role NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
65-kDa JJ I-NP I-NP
plus CC I-NP I-NP
50-kDa JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
dimer NN I-NP I-NP
. . O O

Although IN B-SBAR B-SBAR
monocytic JJ B-NP B-NP
cells NNS I-NP I-NP
can MD B-VP B-VP
provide VB I-VP I-VP
a DT B-NP B-NP
reservoir NN I-NP I-NP
for IN B-PP B-PP
viral JJ B-NP B-NP
production NN I-NP I-NP
in FW B-ADVP B-NP
vivo FW I-ADVP I-NP
, , O O
their PRP$ B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP I-NP
( ( O O
HIV-1 NN B-NP I-NN
) ) O O
transcription NN B-NP B-NP
can MD B-VP B-VP
be VB I-VP I-VP
either CC O I-CC
latent JJ B-ADJP B-NP
, , O O
restricted JJ B-ADJP I-NP
, , O O
or CC O I-NP
productive JJ B-ADJP I-NP
. . O O

These DT B-NP B-NP
differences NNS I-NP I-NP
in IN B-PP B-PP
gene NN B-NP B-NP
expression NN I-NP I-NP
have VBP B-VP B-VP
not RB I-VP I-VP
been VBN I-VP I-VP
molecularly RB B-ADJP I-VP
defined VBN I-ADJP I-VP
. . O O

In IN B-PP B-PP
THP-1 NN B-NP B-NP
cells NNS I-NP I-NP
with IN B-PP B-PP
restricted JJ B-NP B-NP
HIV NN I-NP I-NP
expression NN I-NP I-NP
, , O O
there EX B-NP B-NP
is VBZ B-VP B-VP
an DT B-NP B-NP
absence NN I-NP I-NP
of IN B-PP B-PP
DNA-protein JJ B-NP B-NP
binding NN I-NP I-NP
complex NN I-NP I-NP
formation NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
HIV-1 NN I-NP I-NP
promoter-enhancer NN I-NP I-NP
associated VBN B-VP B-VP
with IN B-PP B-PP
markedly RB B-ADVP B-NP
less JJR I-ADVP I-NP
viral JJ B-NP I-NP
RNA NN I-NP I-NP
production NN I-NP I-NP
. . O O

This DT B-NP B-NP
absence NN I-NP I-NP
of IN B-PP B-PP
binding NN B-NP B-NP
was VBD B-VP B-VP
localized JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
region NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HIV-1 NN I-NP I-NP
enhancer NN I-NP I-NP
; : O O
the DT B-NP B-NP
65-kDa JJ I-NP I-NP
plus CC I-NP I-NP
50-kDa JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
heterodimer NN I-NP I-NP
was VBD B-VP B-VP
preferentially RB B-ADJP I-VP
lost VBN I-ADJP I-VP
. . O O

Adding VBG B-VP B-VP
purified VBN B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
protein NN I-NP I-NP
to TO B-PP B-PP
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
from IN B-PP B-PP
cells NNS B-NP B-NP
with IN B-PP B-PP
restricted JJ B-NP B-NP
expression NN I-NP I-NP
overcomes VBZ B-VP B-VP
this DT B-NP B-NP
lack NN I-NP I-NP
of IN B-PP B-PP
binding NN B-NP B-NP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
treatment NN B-NP B-NP
of IN B-PP B-PP
these DT B-NP B-NP
nuclear JJ I-NP I-NP
extracts NNS I-NP I-NP
with IN B-PP B-PP
sodium NN B-NP B-NP
deoxycholate NN I-NP I-NP
restored VBD B-VP B-VP
their PRP$ B-NP B-NP
ability NN I-NP I-NP
to TO B-VP B-VP
form VB I-VP I-VP
the DT B-NP B-NP
heterodimer NN I-NP I-NP
, , O O
suggesting VBG B-VP B-VP
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
an DT B-NP B-NP
inhibitor NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
activity NN I-NP I-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
treatment NN B-NP B-NP
of IN B-PP B-PP
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
from IN B-PP B-PP
these DT B-NP B-NP
cells NNS I-NP I-NP
that WDT B-NP B-NP
had VBD B-VP B-VP
restricted JJ B-NP B-NP
expression NN I-NP I-NP
with IN B-PP B-PP
lipopolysaccharide NN B-NP B-NP
increased VBD B-VP B-VP
viral JJ B-NP B-NP
production NN I-NP I-NP
and CC O I-NP
NF-kappa NN B-NP I-NP
B NN I-NP I-NP
activity NN I-NP I-NP
. . O O

Antiserum NN B-NP B-NP
specific JJ B-ADJP I-NP
for IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
binding NN I-NP I-NP
proteins NNS I-NP I-NP
, , O O
but CC B-CONJP I-CC
not RB I-CONJP B-NP
c-rel-specific JJ B-NP I-NP
antiserum NN I-NP I-NP
, , O O
disrupted VBD B-VP B-VP
heterodimer NN B-NP B-NP
complex NN I-NP I-NP
formation NN I-NP I-NP
. . O O

Thus RB B-ADVP B-ADVP
, , O O
both DT B-NP B-NP
NF-kappa NN I-NP I-NP
B-binding JJ I-NP I-NP
complexes NNS I-NP I-NP
are VBP B-VP B-VP
needed VBN I-VP I-VP
for IN B-PP B-PP
optimal JJ B-NP B-NP
viral JJ I-NP I-NP
transcription NN I-NP I-NP
. . O O

Binding NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
65-kDa JJ I-NP I-NP
plus CC I-NP I-NP
50-kDa JJ I-NP I-NP
heterodimer NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
HIV-1 NN I-NP I-NP
enhancer NN I-NP I-NP
can MD B-VP B-VP
be VB I-VP I-VP
negatively RB I-VP I-VP
regulated VBN I-VP I-VP
in IN B-PP B-PP
monocytes NNS B-NP B-NP
, , O O
providing VBG B-VP B-VP
one CD B-NP B-NP
mechanism NN I-NP I-NP
restricting VBG B-VP I-NP
HIV-1 NN B-NP I-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
. . O O

Isolation NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
candidate NN I-NP I-NP
repressor/activator NN B-NP I-NP
, , O O
NF-E1 NN B-NP B-NP
( ( O O
YY-1 NN B-NP I-NP
, , I-NP O
delta NN I-NP I-NP
) ) O O
, , O O
that WDT B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
immunoglobulin NN I-NP I-NP
kappa NN I-NP I-NP
3' JJ I-NP I-NP
enhancer NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
immunoglobulin NN I-NP I-NP
heavy-chain NN I-NP I-NP
mu NN I-NP I-NP
E1 NN I-NP I-NP
site NN I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
determined VBN I-VP I-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
developmental JJ I-NP I-NP
control NN I-NP I-NP
of IN B-PP B-PP
immunoglobulin NN B-NP B-NP
kappa NN I-NP I-NP
3' JJ I-NP I-NP
enhancer NN I-NP I-NP
( ( I-NP O
kappa NN I-NP B-NP
E3' NN I-NP I-NP
) ) I-NP O
activity NN I-NP B-NP
is VBZ B-VP B-VP
the DT B-NP B-NP
result NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
combined JJ I-NP I-NP
influence NN I-NP I-NP
of IN B-PP B-PP
positive- JJ B-NP B-NP
and CC I-NP I-NP
negative-acting JJ I-NP I-NP
elements NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
a DT B-NP B-NP
central JJ I-NP I-NP
core NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
kappa NN I-NP I-NP
E3' NN I-NP I-NP
enhancer NN I-NP I-NP
is VBZ B-VP B-VP
active JJ B-ADJP B-ADJP
at IN B-PP B-PP
the DT B-NP B-NP
pre-B-cell JJ I-NP I-NP
stage NN I-NP I-NP
but CC O I-CC
is VBZ B-VP B-VP
repressed VBN I-VP I-VP
by IN B-PP B-PP
flanking VBG B-NP B-VP
negative-acting JJ I-NP B-NP
elements NNS I-NP I-NP
. . O O

The DT B-NP B-NP
negative-acting JJ I-NP I-NP
sequences NNS I-NP I-NP
repress VBP B-VP B-VP
enhancer NN B-NP B-NP
activity NN I-NP I-NP
in IN B-PP B-PP
a DT O B-NP
position- NN B-NP I-NP
and CC O I-NP
orientation-independent JJ B-ADJP I-NP
manner NN B-NP I-NP
at IN B-PP B-PP
the DT B-NP B-NP
pre-B-cell JJ I-NP I-NP
stage NN I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
isolated VBN I-VP I-VP
a DT B-NP B-NP
human JJ I-NP I-NP
cDNA NN I-NP I-NP
clone NN I-NP I-NP
encoding VBG B-VP B-VP
a DT B-NP B-NP
zinc NN I-NP I-NP
finger NN I-NP I-NP
protein NN I-NP I-NP
( ( O O
NF-E1 NN B-NP B-NP
) ) O O
that WDT B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
negative-acting JJ I-NP I-NP
segment NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
kappa NN I-NP I-NP
E3' NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

This DT B-NP B-NP
protein NN I-NP I-NP
also RB B-ADVP B-ADVP
binds VBZ B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
immunoglobulin NN I-NP I-NP
heavy-chain NN I-NP I-NP
enhancer NN I-NP I-NP
mu NN I-NP I-NP
E1 NN I-NP I-NP
site NN I-NP I-NP
. . O O

NF-E1 NN B-NP B-NP
is VBZ B-VP B-VP
encoded VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
same JJ I-NP I-NP
gene NN I-NP I-NP
as IN B-PP B-PP
the DT B-NP B-NP
YY-1 NN I-NP I-NP
protein NN I-NP I-NP
, , O O
which WDT B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
adeno-associated JJ I-NP I-NP
virus NN I-NP I-NP
P5 NN I-NP I-NP
promoter NN I-NP I-NP
. . O O

NF-E1 NN B-NP B-NP
is VBZ B-VP B-VP
also RB B-ADVP B-ADVP
the DT B-NP B-NP
human JJ I-NP I-NP
homologue NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
mouse NN I-NP I-NP
delta NN I-NP I-NP
protein NN I-NP I-NP
, , O O
which WDT B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
ribosomal JJ B-NP B-NP
protein NN I-NP I-NP
gene NN I-NP I-NP
promoters NNS I-NP I-NP
. . O O

The DT B-NP B-NP
predicted VBN I-NP I-NP
amino NN I-NP I-NP
acid NN I-NP I-NP
sequence NN I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
protein NN I-NP I-NP
contains VBZ B-VP B-VP
features NNS B-NP B-NP
characteristic JJ B-ADJP B-ADJP
of IN B-PP B-PP
transcriptional JJ B-NP B-NP
activators NNS I-NP I-NP
as RB B-CONJP B-CONJP
well RB I-CONJP I-CONJP
as IN I-CONJP I-CONJP
transcriptional JJ B-NP B-NP
repressors NNS I-NP I-NP
. . O O

Cotransfection NN B-NP B-NP
studies NNS I-NP I-NP
with IN B-PP B-PP
this DT B-NP B-NP
cDNA NN I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
it PRP B-NP B-NP
can MD B-VP B-VP
repress VB I-VP I-VP
basal JJ B-NP B-NP
promoter NN I-NP I-NP
activity NN I-NP I-NP
. . O O

The DT B-NP B-NP
apparent JJ I-NP I-NP
dual JJ I-NP I-NP
function NN I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
protein NN I-NP I-NP
is VBZ B-VP B-VP
discussed VBN I-VP I-VP
. . O O

Clone NN B-NP B-NP
pAT NN I-NP I-NP
133 CD I-NP B-NP
identifies VBZ B-VP I-NP
a DT B-NP B-NP
gene NN I-NP I-NP
that WDT B-NP B-NP
encodes VBZ B-VP B-VP
another DT B-NP B-NP
human JJ I-NP I-NP
member NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
class NN I-NP I-NP
of IN B-PP B-PP
growth NN B-NP B-NP
factor-induced JJ I-NP I-NP
genes NNS I-NP I-NP
with IN B-PP B-PP
almost RB B-NP B-NP
identical JJ I-NP I-NP
zinc-finger NN I-NP I-NP
domains NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
report VBP B-VP B-VP
the DT B-NP B-NP
structure NN B-NP I-NP
and CC O I-NP
regulation NN B-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
gene NN I-NP I-NP
represented VBN B-VP B-VP
by IN B-PP B-PP
clone NN B-NP B-NP
pAT NN I-NP I-NP
133 CD I-NP I-NP
, , O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
induced VBN I-VP I-VP
upon IN B-PP B-PP
transition NN B-NP B-NP
from IN B-PP B-PP
a DT B-NP B-NP
resting JJ I-NP I-NP
state NN I-NP I-NP
( ( O O
G0 NN B-NP B-NP
) ) O O
through IN B-PP B-PP
the DT B-NP B-NP
early JJ I-NP I-NP
phase NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
cell NN I-NP I-NP
cycle NN I-NP I-NP
( ( O O
G1 NN B-NP B-NP
) ) O O
. . O O

The DT B-NP B-NP
pAT NN I-NP I-NP
133 CD I-NP I-NP
gene NN I-NP I-NP
is VBZ B-VP B-VP
immediately RB I-VP I-VP
induced VBN I-VP I-VP
, , O O
with IN B-PP B-PP
FOS-like JJ B-NP B-NP
kinetics NNS I-NP I-NP
, , O O
in IN B-PP B-PP
human JJ B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
and CC B-PP I-CC
in IN B-PP B-PP
fibroblasts NNS B-NP B-NP
. . O O

Primary JJ B-NP B-NP
structure NN I-NP I-NP
analysis NN I-NP I-NP
showed VBD B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
encoded VBN I-NP I-NP
protein NN I-NP I-NP
contains VBZ B-VP B-VP
three CD B-NP B-NP
tandem JJ I-NP I-NP
zinc-finger NN I-NP I-NP
sequences NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
type NN I-NP I-NP
Cys2-Xaa12-His2 NN I-NP I-NP
. . O O

This DT B-NP B-NP
zinc-finger NN I-NP I-NP
region NN I-NP I-NP
, , O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
thought VBN I-VP I-VP
to TO I-VP I-VP
bind VB I-VP I-VP
DNA NN B-NP B-NP
in IN B-PP B-PP
a DT B-NP B-NP
sequence-specific JJ I-NP I-NP
manner NN I-NP I-NP
, , O O
is VBZ B-VP B-VP
similar JJ B-ADJP B-ADJP
( ( O O
greater JJR B-NP B-NP
than IN I-NP I-NP
80 CD I-NP I-NP
% NN I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
amino NN I-NP I-NP
acid NN I-NP I-NP
level NN I-NP I-NP
) ) O O
to TO B-PP B-PP
two CD B-NP B-NP
previously RB I-NP I-NP
described VBN I-NP I-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
pAT NN B-NP I-NP
225/EGR1 NN I-NP I-NP
and CC O I-NP
pAT NN B-NP I-NP
591/EGR2 NN I-NP I-NP
. . O O

Except IN B-PP B-PP
for IN I-PP B-PP
the DT B-NP B-NP
conserved VBN I-NP I-NP
zinc-finger NN I-NP I-NP
domains NNS I-NP I-NP
, , O O
the DT B-NP B-NP
amino NN I-NP I-NP
acid NN I-NP I-NP
sequences NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
three CD I-NP I-NP
proteins NNS I-NP I-NP
are VBP B-VP B-VP
distinct JJ B-ADJP B-ADJP
. . O O

This DT B-NP B-NP
structural JJ I-NP I-NP
similarity NN I-NP I-NP
suggests VBZ B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
pAT NN I-NP I-NP
133 CD I-NP I-NP
gene NN I-NP I-NP
encodes VBZ B-VP B-VP
a DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
with IN B-PP B-PP
a DT B-NP B-NP
specific JJ I-NP I-NP
biological JJ I-NP I-NP
function NN I-NP I-NP
. . O O

Comparing VBG B-VP B-VP
the DT B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
related JJ I-NP I-NP
zinc-finger-encoding JJ I-NP I-NP
genes NNS I-NP I-NP
showed VBD B-VP B-VP
coordinate JJ B-NP B-NP
induction NN I-NP I-NP
upon IN B-PP B-PP
mitogenic JJ B-NP B-NP
stimulation NN I-NP I-NP
of IN B-PP B-PP
resting VBG B-NP B-VP
T NN I-NP B-NP
lymphocytes NNS I-NP I-NP
and CC B-PP I-CC
of IN B-PP B-PP
resting VBG B-NP B-VP
fibroblasts NNS I-NP B-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
upon IN B-PP B-PP
transition NN B-NP B-NP
from IN B-PP B-PP
a DT B-NP B-NP
proliferating JJ I-NP I-NP
( ( O O
G1 NN B-NP B-NP
) ) O O
to TO B-PP B-PP
a DT B-NP B-NP
resting JJ I-NP I-NP
state NN B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
cell NN I-NP I-NP
cycle NN I-NP I-NP
the DT B-NP B-NP
three CD I-NP I-NP
genes NNS I-NP I-NP
were VBD B-VP B-VP
differently RB I-VP I-VP
regulated VBN I-VP I-VP
. . O O

In IN B-PP B-PP
human JJ B-NP B-NP
histiocytic JJ I-NP I-NP
U937 NN I-NP I-NP
cells NNS I-NP I-NP
mRNA NN B-NP I-NP
of IN B-PP B-PP
clone NN B-NP B-NP
pAT NN I-NP I-NP
133 CD I-NP B-NP
was VBD B-VP B-VP
constitutively RB I-VP I-VP
expressed VBN I-VP I-VP
, , O O
whereas IN O B-SBAR
mRNA NN B-NP B-NP
of IN B-PP B-PP
pAT NN B-NP B-NP
225/EGR1 NN I-NP I-NP
was VBD B-VP B-VP
induced VBN I-VP I-VP
upon IN B-PP B-PP
induction NN B-NP B-NP
of IN B-PP B-PP
terminal JJ B-NP B-NP
differentiation NN I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
mRNA NN B-NP I-NP
representing VBG B-VP B-VP
pAT NN B-NP B-NP
591/EGR2 NN I-NP I-NP
was VBD B-VP B-VP
not RB I-VP I-VP
expressed VBN I-VP I-VP
in IN B-PP B-PP
these DT B-NP B-NP
cells NNS I-NP I-NP
. . O O

This DT B-NP B-NP
difference NN I-NP I-NP
in IN B-PP B-PP
gene NN B-NP B-NP
regulation NN I-NP I-NP
suggests VBZ B-VP B-VP
distinct JJ B-NP B-NP
biological JJ I-NP I-NP
roles NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
control NN I-NP I-NP
of IN B-PP B-PP
cell NN B-NP B-NP
proliferation NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
respective JJ I-NP I-NP
proteins NNS I-NP I-NP
. . O O

cAMP-dependent JJ B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
proenkephalin NN B-NP B-NP
by IN B-PP B-PP
JunD NN B-NP B-NP
and CC O I-NP
JunB NN B-NP I-NP
: : O O
positive JJ B-NP B-NP
and CC I-NP I-NP
negative JJ I-NP I-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
AP-1 NN B-NP B-NP
proteins NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
JunD NN B-NP B-NP
, , O O
a DT B-NP B-NP
component NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
complex NN I-NP I-NP
, , O O
activates VBZ B-VP B-VP
transcription NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
proenkephalin NN I-NP I-NP
gene NN I-NP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
fashion NN I-NP I-NP
that WDT B-NP B-NP
is VBZ B-VP B-VP
completely RB B-ADJP B-ADJP
dependent JJ I-ADJP I-ADJP
upon IN B-PP B-PP
the DT B-NP B-NP
cAMP-dependent JJ I-NP I-NP
protein NN I-NP I-NP
kinase NN I-NP I-NP
, , O O
protein NN B-NP B-NP
kinase NN I-NP I-NP
A NN I-NP I-NP
. . O O

Activation NN B-NP B-NP
of IN B-PP B-PP
proenkephalin NN B-NP B-NP
transcription NN I-NP I-NP
by IN B-PP B-PP
JunD NN B-NP B-NP
is VBZ B-VP B-VP
dependent JJ B-ADJP B-ADJP
upon IN B-PP B-PP
a DT O B-NP
previously RB O I-NP
characterized VBN O I-NP
cAMP- NN B-NP I-NP
, , O O
phorbol NN B-NP B-NP
ester- NN I-NP I-NP
, , O O
and CC O I-CC
Ca(2+)-inducible JJ B-ADJP B-NP
enhancer NN B-NP I-NP
, , O O
and CC O I-CC
JunD NN B-NP B-NP
is VBZ B-VP B-VP
shown VBN I-VP I-VP
to TO I-VP I-VP
bind VB I-VP I-VP
the DT B-NP B-NP
enhancer NN I-NP I-NP
as IN B-PP B-PP
a DT B-NP B-NP
homodimer NN I-NP I-NP
. . O O

Another DT B-NP B-NP
component NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
transcription NN I-NP I-NP
complex NN I-NP I-NP
, , O O
JunB NN B-NP B-NP
, , O O
is VBZ B-VP B-VP
shown VBN I-VP I-VP
to TO I-VP I-VP
inhibit VB I-VP I-VP
activation NN B-NP B-NP
mediated VBN B-VP B-VP
by IN B-PP B-PP
JunD NN B-NP B-NP
. . O O

As IN B-PP B-PP
a DT B-NP B-NP
homodimer NN I-NP I-NP
JunB NN B-NP I-NP
is VBZ B-VP B-VP
unable JJ B-ADJP B-ADJP
to TO B-VP B-VP
bind VB I-VP I-VP
the DT B-NP B-NP
enhancer NN I-NP I-NP
; : O O
however RB O B-ADVP
in IN B-PP B-PP
the DT I-PP B-NP
presence NN I-PP I-NP
of IN I-PP B-PP
c-Fos NN B-NP B-NP
, , O O
high-affinity JJ B-NP B-NP
binding NN I-NP I-NP
is VBZ B-VP B-VP
observed VBN I-VP I-VP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
JunD NN B-NP B-NP
is VBZ B-VP B-VP
shown VBN I-VP I-VP
to TO I-VP I-VP
activate VB I-VP I-VP
transcription NN B-NP B-NP
of IN B-PP B-PP
genes NNS B-NP B-NP
linked VBN B-VP B-VP
to TO B-PP B-PP
both CC O B-NP
cAMP NN B-NP B-NP
and CC O I-NP
phorbol NN B-NP I-NP
ester NN I-NP I-NP
response NN B-NP I-NP
elements NNS I-NP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
protein NN I-NP I-NP
kinase NN I-NP I-NP
A-dependent JJ I-NP I-NP
fashion NN I-NP I-NP
, , O O
further RB B-ADVP B-ADVP
blurring VBG B-VP B-VP
the DT B-NP B-NP
distinction NN I-NP I-NP
between IN B-PP B-PP
these DT B-NP B-NP
response NN I-NP I-NP
elements NNS I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
transcriptional JJ I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
an DT B-NP B-NP
AP-1-related JJ I-NP I-NP
protein NN I-NP I-NP
is VBZ B-VP B-VP
regulated VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
cAMP-dependent JJ I-NP I-NP
second-messenger NN I-NP I-NP
pathway NN I-NP I-NP
and CC O I-CC
suggest VBP B-VP B-VP
that IN B-SBAR B-PP
JunD NN B-NP B-NP
and CC O I-CC
other JJ B-NP B-NP
AP-1-related JJ I-NP I-NP
proteins NNS I-NP I-NP
may MD B-VP B-VP
play VB I-VP I-VP
an DT B-NP B-NP
important JJ I-NP I-NP
role NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
gene NN B-NP B-NP
expression NN I-NP I-NP
by IN B-PP B-PP
cAMP-dependent JJ B-NP B-NP
intracellular JJ I-NP I-NP
signaling NN I-NP I-NP
pathways NNS I-NP I-NP
. . O O

Glucocorticoid NN B-NP B-NP
resistance NN I-NP I-NP
in IN B-PP B-PP
chronic JJ B-NP B-NP
asthma NN I-NP I-NP
. . O O

Glucocorticoid NN B-NP B-NP
pharmacokinetics NNS I-NP I-NP
, , O O
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
characteristics NNS I-NP I-NP
, , O O
and CC O I-CC
inhibition NN B-NP B-NP
of IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
proliferation NN I-NP I-NP
by IN B-PP B-PP
glucocorticoids NNS B-NP B-NP
in FW B-ADJP B-VP
vitro FW I-ADJP B-NP
. . O O

A DT B-NP B-NP
total NN I-NP I-NP
of IN B-PP B-PP
37 CD B-NP B-NP
chronic JJ I-NP I-NP
, , I-NP O
severe JJ I-NP I-NP
, , I-NP O
nonsmoking JJ I-NP I-NP
asthmatic JJ I-NP I-NP
patients NNS I-NP I-NP
with IN B-PP B-PP
documented JJ|VBN B-NP B-NP
reversible JJ I-NP I-NP
airways NNS I-NP I-NP
obstruction NN I-NP I-NP
were VBD B-VP B-VP
classified VBN I-VP I-VP
as IN B-PP B-PP
glucocorticoid-sensitive JJ B-ADJP B-NP
or CC O I-NP
-resistant JJ B-ADJP I-NP
on IN B-PP B-PP
the DT I-PP B-NP
basis NN I-PP I-NP
of IN I-PP B-PP
changes NNS B-NP B-NP
in IN B-PP B-PP
FEV1 NN B-NP B-NP
, , O O
FVC NN B-NP B-NP
, , O O
and CC O I-CC
peak JJ B-NP B-NP
expiratory NN I-NP I-NP
flow NN I-NP I-NP
( ( O O
PEF NN B-NP B-NP
) ) O O
after IN B-PP B-PP
oral JJ B-NP B-NP
prednisolone NN I-NP I-NP
. . O O

The DT B-NP B-NP
resistant JJ I-NP I-NP
patients NNS I-NP I-NP
showed VBD B-VP B-VP
no DT B-NP B-NP
significant JJ I-NP I-NP
improvements NNS I-NP I-NP
in IN B-PP B-PP
airflow NN B-NP B-NP
limitation NN I-NP I-NP
. . O O

Phytohemagglutinin NN B-NP B-NP
( ( I-NP O
PHA NN I-NP I-NP
) ) I-NP O
-induced JJ I-NP B-NP
proliferation NN I-NP I-NP
of IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
T NN I-NP I-NP
lymphocytes NNS I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
sensitive JJ I-NP I-NP
but CC B-CONJP I-NP
not RB I-CONJP I-NP
the DT B-NP B-NP
resistant JJ I-NP I-NP
asthmatic JJ B-NP I-NP
patients NNS I-NP I-NP
was VBD O B-VP
significantly RB O B-NP
( ( O O
p NN B-NP I-NP
less JJR B-ADJP B-ADJP
than IN B-PP B-PP
0.01 CD B-NP B-NP
) ) O O
inhibited VBN B-VP B-VP
by IN B-PP B-PP
dexamethasone NN B-NP B-NP
( ( O O
10(-7) CD B-NP B-NP
mol/L NN I-NP I-NP
) ) O O
, , O O
reflecting VBG B-VP B-VP
a DT B-NP B-NP
shift NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
dose-response JJ I-NP I-NP
curve NN I-NP I-NP
. . O O

When WRB B-ADVP B-ADVP
all PDT B-NP B-NP
the DT I-NP I-NP
asthmatic JJ I-NP I-NP
patients NNS I-NP I-NP
were VBD B-VP B-VP
analyzed VBN I-VP I-VP
together RB B-ADVP B-ADVP
, , O O
there EX B-NP B-NP
was VBD B-VP B-VP
a DT B-NP B-NP
significant JJ I-NP I-NP
correlation NN I-NP I-NP
between IN B-PP B-PP
the DT B-NP B-NP
degree NN I-NP I-NP
of IN B-PP B-PP
sensitivity NN B-NP B-NP
of IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
to TO B-PP B-PP
dexamethasone NN B-NP B-NP
and CC O I-CC
the DT B-NP B-NP
clinical JJ I-NP I-NP
responsiveness NN I-NP I-NP
to TO B-PP B-PP
prednisolone JJ B-NP B-NP
( ( O O
p NN B-NP I-NP
less RBR B-ADJP B-ADJP
than IN B-PP B-PP
0.01 CD B-NP B-NP
) ) O O
. . O O

No DT B-NP B-NP
differences NNS I-NP I-NP
were VBD B-VP B-VP
observed VBN I-VP I-VP
between IN B-PP B-PP
six CD B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
sensitive JJ I-NP I-NP
and CC I-NP I-NP
resistant JJ I-NP I-NP
patients NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
clearance NN I-NP I-NP
of IN B-PP B-PP
plasma NN B-NP B-NP
prednisolone JJ I-NP I-NP
derived VBN B-VP B-VP
from IN B-PP B-PP
orally RB B-NP B-NP
administered VBN I-NP I-NP
prednisone NN I-NP I-NP
. . O O

Peripheral JJ B-NP B-NP
blood NN I-NP I-NP
mononuclear JJ I-NP I-NP
cell NN I-NP I-NP
glucocorticoid NN I-NP I-NP
receptors NNS I-NP I-NP
were VBD B-VP B-VP
also RB I-VP I-VP
characterized VBN I-VP I-VP
in IN B-PP B-PP
five CD B-NP B-NP
sensitive JJ I-NP I-NP
and CC O I-NP
seven CD B-NP I-NP
resistant JJ I-NP I-NP
patients NNS B-NP I-NP
. . O O

The DT B-NP B-NP
numbers NNS B-NP I-NP
and CC O I-NP
binding NN B-NP I-NP
affinities NNS I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
receptors NNS I-NP I-NP
could MD B-VP B-VP
not RB I-VP I-VP
account VB I-VP I-VP
for IN B-PP B-PP
the DT B-NP B-NP
observed VBN I-NP I-NP
difference NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
susceptibility NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
cells NNS I-NP I-NP
to TO B-PP B-PP
functional JJ B-NP B-NP
inhibition NN I-NP I-NP
by IN B-PP B-PP
dexamethasone NN B-NP B-NP
in FW B-ADJP B-VP
vitro FW I-ADJP B-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
clinical JJ B-NP B-NP
glucocorticoid NN I-NP I-NP
resistance NN I-NP I-NP
in IN B-PP B-PP
chronic JJ B-NP B-NP
asthma NN I-NP I-NP
does VBZ B-VP B-VP
not RB I-VP I-VP
reflect VB I-VP I-VP
abnormal JJ B-NP B-NP
glucocorticoid NN I-NP I-NP
clearance NN I-NP I-NP
but CC O I-CC
may MD B-VP B-VP
be VB I-VP I-VP
due JJ O B-ADJP
at IN B-ADVP B-ADVP
least JJS I-ADVP I-ADVP
partly RB B-ADVP B-ADVP
to TO B-PP B-PP
a DT B-NP B-NP
relative JJ I-NP I-NP
insensitivity NN I-NP I-NP
of IN B-PP B-PP
T NN B-NP B-NP
lymphocytes NNS I-NP I-NP
to TO B-PP B-PP
glucocorticoids NNS B-NP B-NP
. . O O

This DT B-NP B-NP
lack NN I-NP I-NP
of IN B-PP B-PP
sensitivity NN B-NP B-NP
is VBZ B-VP B-VP
unexplained JJ B-ADJP B-ADJP
but CC O I-CC
is VBZ B-VP B-VP
not RB O I-RB
attributable JJ B-ADJP B-ADJP
to TO B-PP B-PP
abnormalities NNS B-NP B-NP
of IN B-PP B-PP
cellular JJ B-NP B-NP
glucocorticoid NN I-NP I-NP
receptors NNS I-NP I-NP
. . O O

Regulation NN B-NP B-NP
of IN B-PP B-PP
interleukin-1 NN B-NP B-NP
beta NN I-NP I-NP
production NN I-NP I-NP
by IN B-PP B-PP
glucocorticoids NNS B-NP B-NP
in IN B-PP B-PP
human JJ B-NP B-NP
monocytes NNS I-NP I-NP
: : O O
the DT B-NP B-NP
mechanism NN I-NP I-NP
of IN B-PP B-PP
action NN B-NP B-NP
depends VBZ B-VP B-VP
on IN B-PP B-PP
the DT B-NP B-NP
activation NN I-NP I-NP
signal NN I-NP I-NP
. . O O

Glucocorticoids NNS B-NP B-NP
are VBP B-VP B-VP
known VBN I-VP I-VP
to TO I-VP I-VP
downregulate VB I-VP I-VP
interleukin-1 NN B-NP B-NP
beta NN I-NP I-NP
production NN I-NP I-NP
in IN B-PP B-PP
monocytic JJ B-NP B-NP
cells NNS I-NP I-NP
by IN B-PP B-PP
two CD B-NP B-NP
different JJ I-NP I-NP
mechanims NNS I-NP I-NP
: : O O
direct JJ B-NP B-NP
inhibition NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
gene NN I-NP I-NP
transcription NN I-NP I-NP
and CC O I-NP
destabilization NN B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
preformed JJ I-NP I-NP
interleukin-1 NN I-NP I-NP
beta NN I-NP I-NP
mRNA NN I-NP I-NP
. . O O

Now RB B-ADVP B-ADVP
we PRP B-NP B-NP
have VBP B-VP B-VP
examined VBN I-VP I-VP
the DT B-NP B-NP
effect NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
nature NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
monocyte NN I-NP I-NP
activating NN I-NP I-NP
signal NN I-NP I-NP
on IN B-PP B-PP
these DT B-NP B-NP
two CD I-NP I-NP
inhibitory JJ I-NP I-NP
mechanims NNS I-NP I-NP
. . O O

When WRB B-ADVP B-ADVP
human JJ B-NP B-NP
monocytes NNS I-NP I-NP
were VBD B-VP B-VP
preincubated VBN I-VP I-VP
with IN B-PP B-PP
dexamethasone NN B-NP B-NP
for IN B-PP B-PP
1 CD B-NP B-NP
hour NN I-NP I-NP
and CC O I-CC
then RB O B-ADVP
stimulated VBN B-VP B-VP
either CC B-PP I-CC
with IN I-PP B-PP
bacterial JJ B-NP B-NP
lipopolysaccharide NN I-NP I-NP
or CC O I-NP
phorbol NN B-NP I-NP
myristate NN I-NP I-NP
, , O O
it PRP B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
that IN B-SBAR B-PP
dexamethasone NN B-NP B-NP
inhibited VBD B-VP B-VP
the DT B-NP B-NP
lipopolysaccharide-induced JJ I-NP I-NP
interleukin-1 NN I-NP I-NP
beta NN I-NP I-NP
protein NN I-NP I-NP
production NN I-NP I-NP
, , O O
but CC O I-CC
the DT B-NP B-NP
phorbol NN I-NP I-NP
myristate-induced JJ I-NP I-NP
production NN I-NP I-NP
was VBD B-VP B-VP
increased VBN I-VP I-VP
3-10 CD B-NP B-NP
fold RB I-NP I-NP
. . O O

This DT B-NP B-NP
difference NN I-NP I-NP
was VBD B-VP B-VP
also RB I-VP I-VP
seen VBN I-VP I-VP
at IN B-PP B-PP
the DT B-NP B-NP
mRNA NN I-NP I-NP
level NN I-NP I-NP
. . O O

When WRB B-ADVP B-ADVP
dexamethasone NN B-NP B-NP
was VBD B-VP B-VP
added VBN I-VP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
cultures NNS I-NP I-NP
3 CD B-NP B-NP
hours NNS I-NP I-NP
after IN B-PP B-PP
the DT B-NP B-NP
stimulators NNS I-NP I-NP
, , O O
it PRP B-NP B-NP
clearly RB B-ADVP B-ADVP
decreased VBD B-VP B-VP
the DT B-NP B-NP
interleukin-1 NN I-NP I-NP
beta NN I-NP I-NP
mRNA NN I-NP I-NP
levels NNS I-NP I-NP
regardless RB B-ADVP B-ADVP
of IN B-PP B-PP
the DT B-NP B-NP
stimulator NN I-NP I-NP
used VBN B-VP B-VP
( ( O O
although IN B-SBAR B-PP
the DT B-NP B-NP
effect NN I-NP I-NP
was VBD B-VP B-VP
clearly RB B-ADJP B-ADVP
weaker JJR I-ADJP B-ADJP
on IN B-PP B-PP
the DT B-NP B-NP
PMA-induced JJ I-NP I-NP
mRNA NN I-NP I-NP
) ) O O
. . O O

Thus RB B-ADVP B-ADVP
these DT B-NP B-NP
data NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
phorbol NN I-NP I-NP
myristate-induced JJ I-NP I-NP
signal NN I-NP I-NP
( ( O O
prolonged JJ B-NP B-NP
protein NN I-NP I-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
activation NN I-NP I-NP
? . O O
) ) O O
can MD B-VP B-VP
not RB I-VP I-VP
be VB I-VP I-VP
inhibited VBN I-VP I-VP
by IN B-PP B-PP
prior JJ B-NP B-NP
incubation NN I-NP I-NP
with IN B-PP B-PP
dexamethasone NN B-NP B-NP
and CC O I-CC
it PRP B-NP B-NP
also RB B-ADVP B-ADVP
protects VBZ B-VP B-VP
the DT B-NP B-NP
induced VBN I-NP I-NP
mRNA NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
degradative JJ I-NP I-NP
action NN I-NP I-NP
of IN B-PP B-PP
dexamethasone NN B-NP B-NP
. . O O

Identification NN B-NP B-NP
of IN B-PP B-PP
transcriptional JJ B-NP B-NP
suppressor NN I-NP I-NP
proteins NNS I-NP I-NP
that WDT B-NP B-NP
bind VBP B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
negative JJ I-NP I-NP
regulatory JJ I-NP I-NP
element NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP I-NP
. . O O

Two CD B-NP B-NP
different JJ I-NP I-NP
proteins NNS I-NP I-NP
which WDT B-NP B-NP
independently RB B-ADVP B-ADVP
bound VBD B-VP B-VP
to TO B-PP B-PP
neighboring VBG B-NP B-NP
sequences NNS I-NP I-NP
within IN B-PP B-PP
the DT B-NP B-NP
negative JJ I-NP I-NP
regulatory JJ I-NP I-NP
element NN I-NP I-NP
( ( O O
NRE NN B-NP B-NP
) ) O O
of IN B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP B-NP
( ( O O
HIV-1 NN B-NP I-NP
) ) O O
were VBD B-VP B-VP
detected VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
nuclear JJ I-NP I-NP
extract NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
virus-infected JJ I-NP I-NP
human JJ I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
. . O O

One CD B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
factors NNS I-NP I-NP
bound VBD B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
novel JJ I-NP I-NP
dyad NN I-NP I-NP
symmetrical JJ I-NP I-NP
sequence NN I-NP I-NP
. . O O

This DT B-NP B-NP
sequence NN I-NP I-NP
is VBZ B-VP B-VP
well RB I-VP I-VP
conserved VBN I-VP I-VP
in IN B-PP B-PP
various JJ B-NP B-NP
HIV-1 NN I-NP I-NP
isolates NNS I-NP I-NP
and CC O I-CC
partial JJ B-NP B-NP
homology NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
with IN B-PP B-PP
the DT B-NP B-NP
promoter JJ I-NP I-NP
region NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
retinoblastoma NN I-NP I-NP
gene NN I-NP I-NP
. . O O

Similar JJ B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
was VBD B-VP B-VP
detected VBN I-VP I-VP
in IN B-PP B-PP
a DT B-NP B-NP
variety NN I-NP I-NP
of IN B-PP B-PP
virus-uninfected JJ B-NP B-NP
human JJ I-NP I-NP
T NN B-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
and CC O I-CC
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
by IN B-PP B-PP
means NNS I-PP B-NP
of IN I-PP B-PP
a DT B-NP B-NP
gel NN I-NP I-NP
mobility NN I-NP I-NP
shift NN I-NP I-NP
assay NN I-NP I-NP
. . O O

The DT B-NP B-NP
other JJ I-NP I-NP
factor NN I-NP I-NP
bound VBN B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
putative JJ I-NP I-NP
AP-1 NN I-NP I-NP
recognition NN I-NP I-NP
sequence NN I-NP I-NP
predicted VBD B-VP B-VP
for IN B-PP B-PP
the DT B-NP B-NP
HIV-1 NN I-NP I-NP
NRE NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
this DT B-NP B-NP
factor NN I-NP I-NP
did VBD B-VP B-VP
not RB I-VP I-VP
bind VB I-VP I-VP
to TO B-PP B-PP
a DT B-NP B-NP
typical JJ I-NP I-NP
AP-1 NN I-NP I-NP
site NN I-NP I-NP
. . O O

The DT B-NP B-NP
insertion NN I-NP I-NP
of IN B-PP B-PP
multiple JJ B-NP B-NP
copies NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
binding VBG I-NP I-NP
site NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
former JJ I-NP I-NP
or CC I-NP I-NP
latter JJ I-NP I-NP
factor NN I-NP I-NP
into IN B-PP B-PP
a DT B-NP B-NP
heterologous JJ I-NP I-NP
promoter NN I-NP I-NP
reduced VBD B-VP B-VP
the DT B-NP B-NP
promoter NN I-NP I-NP
activity NN I-NP I-NP
to TO B-PP B-PP
one-tenth CD B-NP B-NP
or CC O I-NP
one-third CD B-NP I-NP
, , O O
respectively RB B-ADVP B-ADVP
. . O O

Thus RB B-ADVP B-ADVP
, , O O
each DT B-NP B-NP
factor NN I-NP I-NP
may MD B-VP B-VP
function VB I-VP I-VP
as IN B-PP B-PP
a DT B-NP B-NP
novel JJ I-NP I-NP
negative JJ I-NP I-NP
regulator NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
. . O O

Constitutive JJ B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
NF-kB NN B-NP B-NP
in IN B-PP B-PP
human JJ B-NP B-NP
thymocytes NNS I-NP I-NP
. . O O

NF-kB NN B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
eukaryotic JJ I-NP I-NP
transcription NN I-NP I-NP
regulatory JJ I-NP I-NP
factor NN I-NP I-NP
. . O O

In IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
and CC O I-CC
T NN B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
, , O O
NF-kB NN B-NP B-NP
is VBZ B-VP B-VP
bound VBN I-VP I-VP
to TO B-PP B-PP
a DT B-NP B-NP
cytoplasmic JJ I-NP I-NP
proteic JJ I-NP I-NP
inhibitor NN I-NP I-NP
, , O O
the DT B-NP B-NP
IkB NN I-NP I-NP
. . O O

Treatment NN B-NP B-NP
of IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
with IN B-PP B-PP
mitogens NNS B-NP B-NP
( ( O O
phorbol NN B-NP B-NP
esters NNS I-NP I-NP
) ) O O
or CC O I-CC
cytokines NNS B-NP B-NP
( ( O O
TNF NN B-NP B-NP
alpha NN I-NP I-NP
) ) O O
induces VBZ B-VP B-VP
NF-kB NN B-NP B-NP
nuclear JJ I-NP I-NP
translocation NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
subsequent JJ I-NP I-NP
expression NN I-NP I-NP
of IN B-PP B-PP
NF-kB NN B-NP B-NP
dependent JJ I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
genes NNS I-NP I-NP
. . O O

Here RB B-ADVP B-ADVP
we PRP B-NP B-NP
examined VBD B-VP B-VP
the DT B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
NF-kB NN B-NP B-NP
in IN B-PP B-PP
human JJ B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
thymic JJ I-NP I-NP
progenitors NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
report VBP B-VP B-VP
differences NNS B-NP B-NP
in IN B-PP B-PP
(Ca2+)i NN B-NP B-NP
requirement NN I-NP I-NP
for IN B-NP B-PP
NF-kB NN B-NP B-NP
activation NN I-NP I-NP
in IN B-PP B-PP
thymocytes NNS B-NP B-NP
as IN B-SBAR B-SBAR
compared VBN B-VP B-VP
to TO B-PP B-PP
mature JJ B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
our PRP$ B-NP B-NP
results NNS I-NP I-NP
indicated VBD B-VP B-VP
that IN B-SBAR B-SBAR
thymocytes NNS B-NP B-NP
have VBP B-VP B-VP
a DT B-NP B-NP
constitutively RB I-NP I-NP
active JJ I-NP I-NP
form NN I-NP I-NP
of IN B-PP B-PP
NF-kB NN B-NP B-NP
, , O O
suggesting VBG B-VP B-VP
that IN B-SBAR B-SBAR
they PRP B-NP B-NP
are VBP B-VP B-VP
activated VBN I-VP B-ADJP
in FW B-ADVP B-PP
vivo FW I-ADVP B-NP
. . O O

The DT B-NP B-NP
role NN I-NP I-NP
of IN B-PP B-PP
jun NN B-NP B-NP
and CC I-NP I-NP
fos NN I-NP I-NP
gene NN I-NP I-NP
family NN I-NP I-NP
members NNS I-NP I-NP
in IN B-PP B-PP
12-O-tetradecanoylphorbol-13-acetate NN B-NP B-NP
induced VBD I-NP B-VP
hemopoietic JJ I-NP B-NP
differentiation NN I-NP I-NP
. . O O

Terminal JJ B-NP B-NP
differentiation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
leukemic JJ I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
U-937 NN B-NP I-NP
and CC O I-NP
HL-60 NN B-NP I-NP
by IN B-PP B-PP
12-O-tetradecanoylphorbol-13-acetate NN B-NP B-NP
is VBZ B-VP B-VP
accompanied VBN I-VP I-VP
by IN B-PP B-PP
marked JJ B-NP B-NP
changes NNS I-NP I-NP
in IN B-PP B-PP
gene NN B-NP B-NP
expression NN I-NP I-NP
. . O O

In IN B-PP B-PP
this DT B-NP B-NP
study NN I-NP I-NP
, , O O
we PRP B-NP B-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
jun NN B-NP B-NP
and CC I-NP I-NP
fos NN I-NP I-NP
gene NN I-NP I-NP
family NN I-NP I-NP
members NNS I-NP I-NP
is VBZ B-VP B-VP
induced VBN I-VP I-VP
with IN B-PP B-PP
variable JJ B-NP B-NP
kinetics NNS I-NP I-NP
during IN B-PP B-PP
12-O-tetradecanoylphorbol-13-acetate NN B-NP B-NP
induced VBD I-NP B-VP
differentiation NN I-NP B-NP
, , O O
with IN B-PP B-PP
c-jun NN B-NP B-NP
expression NN I-NP I-NP
best RB B-ADVP I-NP
paralleling JJ B-VP I-NP
differentiation NN B-NP I-NP
. . O O

The DT B-NP B-NP
generation NN I-NP I-NP
of IN B-PP B-PP
AP-1 NN B-NP B-NP
complexes NNS I-NP I-NP
, , O O
as IN B-SBAR B-SBAR
measured VBN B-VP B-VP
by IN B-PP B-PP
DNA NN B-NP B-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
, , O O
closely RB B-ADVP B-VP
parallels VBZ B-VP I-VP
morphological JJ B-NP B-NP
differentiation NN I-NP I-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
ability NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
complexes NNS I-NP I-NP
to TO B-VP B-VP
regulate VB I-VP I-VP
gene NN B-NP B-NP
expression NN I-NP I-NP
is VBZ B-VP B-VP
demonstrated VBN I-VP I-VP
by IN B-PP B-PP
increased VBN B-NP B-NP
transcription NN I-NP I-NP
from IN B-PP B-PP
an DT B-NP B-NP
AP-1 NN I-NP I-NP
driven VBN I-NP I-NP
reporter NN I-NP I-NP
construct NN I-NP I-NP
and CC O I-CC
marked JJ B-NP B-NP
increases NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
endogenous JJ B-NP B-NP
AP-1 NN I-NP I-NP
regulated JJ I-NP I-NP
genes NNS I-NP I-NP
. . O O

Differentiation NN B-NP B-NP
assays NNS I-NP I-NP
using VBG B-VP B-VP
water NN B-NP B-NP
soluble JJ I-NP I-NP
phorbol NN I-NP I-NP
esters NNS I-NP I-NP
reveal VBP B-VP B-VP
that IN B-SBAR B-SBAR
differentiation NN B-NP B-NP
becomes VBZ B-VP B-VP
irreversible JJ B-ADJP B-ADJP
soon RB B-ADVP B-ADVP
after IN B-SBAR B-SBAR
AP-1 NN B-NP B-NP
appears VBZ B-VP B-VP
. . O O

This DT B-NP B-NP
tight JJ I-NP I-NP
correlation NN I-NP I-NP
between IN B-PP B-PP
c-jun NN B-NP B-NP
expression NN I-NP I-NP
, , O O
the DT B-NP B-NP
generation NN I-NP I-NP
of IN B-PP B-PP
AP-1 NN B-NP B-NP
activity NN I-NP I-NP
, , O O
and CC O I-CC
differentiation NN B-NP B-NP
suggests VBZ B-VP B-VP
a DT B-NP B-NP
critical JJ I-NP I-NP
role NN I-NP I-NP
for IN B-PP B-PP
this DT O B-NP
gene NN B-NP I-NP
and CC O I-CC
transcriptional JJ B-ADJP B-NP
complex NN B-NP I-NP
during IN B-PP B-PP
this DT B-NP B-NP
process NN I-NP I-NP
. . O O

TCF-1 NN B-NP B-NP
, , O O
a DT B-NP B-NP
T NN I-NP I-NP
cell-specific JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HMG NN I-NP I-NP
box NN I-NP I-NP
family NN I-NP I-NP
, , O O
interacts VBZ B-VP B-VP
with IN B-PP B-PP
sequence NN B-NP B-NP
motifs NNS I-NP I-NP
in IN B-PP B-PP
the DT O B-NP
TCR NN B-NP I-NP
beta NN I-NP I-NP
and CC O I-NP
TCR NN B-NP I-NP
delta NN I-NP I-NP
enhancers NNS B-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
recently RB I-VP I-VP
identified VBN I-VP I-VP
and CC O I-CC
cloned VBN B-VP B-VP
TCF-1 NN B-NP B-NP
, , O O
a DT B-NP B-NP
T NN I-NP I-NP
cell-specific JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
with IN B-PP B-PP
specificity NN B-NP B-NP
for IN B-PP B-PP
the DT B-NP B-NP
AACAAAG NN I-NP I-NP
motif NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
CD3 NN I-NP I-NP
epsilon NN I-NP I-NP
enhancer NN I-NP I-NP
and CC B-PP B-PP
for IN B-PP B-PP
the DT B-NP B-NP
TTCAAAG NN I-NP I-NP
motif NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
TCR NN I-NP I-NP
alpha NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

TCF-1 NN B-NP B-NP
belongs VBZ B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
family NN I-NP I-NP
of IN B-PP B-PP
transcription-regulating JJ B-NP B-NP
proteins NNS I-NP I-NP
which WDT B-NP B-NP
share VBP B-VP B-VP
a DT B-NP B-NP
region NN I-NP I-NP
of IN B-PP B-PP
homology NN B-NP B-NP
termed VBN B-VP B-VP
the DT B-NP B-NP
HMG-box NN I-NP I-NP
. . O O

Here RB B-ADVP B-ADVP
, , O O
we PRP B-NP B-NP
show VBP B-VP B-VP
by IN B-PP B-PP
gel NN B-NP B-NP
retardation NN I-NP I-NP
analysis NN I-NP I-NP
that IN B-SBAR B-PP
TCF-1 NN B-NP B-NP
specifically RB B-ADVP B-ADVP
recognizes VBZ B-VP B-VP
the DT B-NP B-NP
T NN I-NP I-NP
beta NN I-NP I-NP
5 CD I-NP I-NP
element NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
TCR NN I-NP I-NP
beta NN I-NP I-NP
enhancer NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
T NN I-NP I-NP
delta NN I-NP I-NP
7 CD I-NP I-NP
element NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
TCR NN I-NP I-NP
delta NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

Comparison NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
sequences NNS I-NP I-NP
of IN B-PP B-PP
all DT B-NP B-NP
elements NNS I-NP I-NP
recognized VBN B-VP B-VP
by IN B-PP B-PP
TCF-1 NN B-NP B-NP
defines VBZ B-VP B-VP
a DT B-NP B-NP
consensus NN I-NP I-NP
motif NN I-NP I-NP
A/T NN I-NP I-NP
A/T NN I-NP I-NP
C NN I-NP I-NP
A NN I-NP I-NP
A/G NN I-NP I-NP
A NN I-NP I-NP
G NN I-NP I-NP
. . O O

These DT B-NP B-NP
observations NNS I-NP I-NP
imply VBP B-VP B-VP
that IN B-SBAR B-SBAR
TCF-1 NN B-NP B-NP
is VBZ B-VP B-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
control NN I-NP I-NP
of IN B-PP B-PP
several JJ B-NP B-NP
T NN I-NP I-NP
cell-specific JJ I-NP I-NP
genes NNS I-NP I-NP
and CC O I-CC
might MD B-VP B-VP
thus RB I-VP I-VP
play VB I-VP I-VP
an DT B-NP B-NP
important JJ I-NP I-NP
role NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
establishment NN B-NP I-NP
and CC O I-NP
maintenance NN B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
mature JJ I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
phenotype NN I-NP I-NP
. . O O

The DT B-NP B-NP
cellular JJ I-NP I-NP
oncogene NN I-NP I-NP
c-myb NN I-NP I-NP
can MD B-VP B-VP
interact VB I-VP I-VP
synergistically RB B-ADVP B-ADVP
with IN B-PP B-PP
the DT B-NP B-NP
Epstein-Barr JJ I-NP I-NP
virus NN I-NP I-NP
BZLF1 NN I-NP I-NP
transactivator NN I-NP I-NP
in IN B-PP B-PP
lymphoid JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

Regulation NN B-NP B-NP
of IN B-PP B-PP
replicative JJ B-NP B-NP
functions NNS I-NP I-NP
in IN B-PP B-PP
the DT O B-NP
Epstein-Barr JJ B-NP I-NP
virus NN I-NP I-NP
( ( O O
EBV NN B-NP I-NN
) ) O O
genome NN B-NP B-NP
is VBZ B-VP B-VP
mediated VBN I-VP I-VP
through IN B-PP B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
virally RB I-NP I-NP
encoded VBN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
, , O O
Z NN B-NP B-NP
( ( O O
BZLF1 NN B-NP B-NP
) ) O O
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
shown VBN I-VP I-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
Z NN I-NP I-NP
gene NN I-NP I-NP
product NN I-NP I-NP
, , O O
which WDT B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
AP-1 NN B-NP B-NP
sites NNS I-NP I-NP
as IN B-PP B-PP
a DT B-NP B-NP
homodimer NN I-NP I-NP
and CC O I-CC
has VBZ B-VP B-VP
sequence NN B-NP B-NP
similarity NN I-NP I-NP
to TO B-PP B-PP
c-Fos NN B-NP B-NP
, , O O
can MD B-VP B-VP
efficiently RB I-VP I-VP
activate VB I-VP I-VP
the DT B-NP B-NP
EBV NN I-NP I-NP
early JJ I-NP I-NP
promoter NN I-NP I-NP
, , O O
BMRF1 NN B-NP B-NP
, , O O
in IN B-PP B-PP
certain JJ B-NP B-NP
cell NN I-NP I-NP
types NNS I-NP I-NP
( ( O O
i.e. FW B-NP B-NP
, , O O
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
) ) O O
but CC B-CONJP I-CC
not RB I-CONJP I-RB
others NNS B-NP B-NP
( ( O O
i.e. FW B-NP B-NP
, , O O
Jurkat NN B-NP B-NP
cells NNS I-NP I-NP
) ) O O
. . O O

Here RB B-ADVP B-ADVP
we PRP B-NP B-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
the DT B-NP B-NP
c-myb NN I-NP I-NP
proto-oncogene NN I-NP I-NP
product NN I-NP I-NP
, , O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
itself PRP B-NP B-NP
a DT B-NP B-NP
DNA-binding JJ I-NP I-NP
protein NN I-NP I-NP
and CC O I-CC
transcriptional JJ B-NP B-NP
transactivator NN I-NP I-NP
, , O O
can MD B-VP B-VP
interact VB I-VP I-VP
synergistically RB B-ADVP B-ADVP
with IN B-PP B-PP
Z NN B-NP B-NP
in IN B-PP B-PP
activating VBG B-VP B-VP
the DT B-NP B-NP
BMRF1 NN I-NP I-NP
promoter NN I-NP I-NP
in IN B-PP B-PP
Jurkat NN B-NP B-NP
cells NNS I-NP I-NP
( ( O O
a DT B-NP B-NP
T-cell NN I-NP I-NP
line NN I-NP I-NP
) ) O O
or CC O I-CC
Raji NN B-NP B-NP
cells NNS I-NP I-NP
( ( O O
an DT B-NP B-NP
EBV-positive JJ I-NP I-NP
B-cell NN I-NP I-NP
) ) O O
, , O O
whereas IN O B-PP
the DT B-NP B-NP
c-myb NN I-NP I-NP
gene NN I-NP I-NP
product NN I-NP I-NP
by IN B-PP B-PP
itself PRP B-NP B-NP
has VBZ B-VP B-VP
little JJ B-NP B-NP
effect NN I-NP I-NP
. . O O

The DT B-NP B-NP
simian JJ I-NP I-NP
virus NN I-NP I-NP
40 CD I-NP I-NP
early JJ I-NP I-NP
promoter NN I-NP I-NP
is VBZ B-VP B-VP
also RB I-VP I-VP
synergistically RB I-VP I-VP
activated VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
Z/c-myb NN I-NP I-NP
combination NN I-NP I-NP
. . O O

Synergistic JJ B-NP B-NP
transactivation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
BMRF1 NN I-NP I-NP
promoter NN I-NP I-NP
by IN B-PP B-PP
the DT B-NP B-NP
Z/c-myb NN I-NP I-NP
combination NN I-NP I-NP
appears VBZ B-VP B-VP
to TO I-VP I-VP
involve VB I-VP I-VP
direct JJ B-NP B-NP
binding NN I-NP I-NP
by IN B-PP B-PP
the DT B-NP B-NP
Z NN I-NP I-NP
protein NN I-NP I-NP
but CC B-CONJP B-NP
not RB I-CONJP I-NP
the DT B-NP B-NP
c-myb NN I-NP I-NP
protein NN I-NP I-NP
. . O O

A DT B-NP B-NP
30-bp JJ I-NP I-NP
sequence NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
BMRF1 NN I-NP I-NP
promoter NN I-NP I-NP
which WDT B-NP B-NP
contains VBZ B-VP B-VP
a DT B-NP B-NP
Z NN I-NP I-NP
binding NN I-NP I-NP
site NN I-NP I-NP
( ( O O
a DT B-NP B-NP
consensus NN I-NP I-NP
AP-1 NN I-NP I-NP
site NN I-NP I-NP
) ) O O
is VBZ B-VP B-VP
sufficient JJ B-ADJP B-ADJP
to TO B-VP B-VP
transfer VB I-VP I-VP
high-level JJ B-NP B-NP
lymphoid-specific JJ I-NP I-NP
responsiveness NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
Z/c-myb NN I-NP I-NP
combination NN I-NP I-NP
to TO B-PP B-PP
a DT B-NP B-NP
heterologous JJ I-NP I-NP
promoter NN I-NP I-NP
. . O O

That IN B-SBAR B-SBAR
the DT B-NP B-NP
c-myb NN I-NP I-NP
oncogene NN I-NP I-NP
product NN I-NP I-NP
can MD B-VP B-VP
interact VB I-VP I-VP
synergistically RB B-ADVP B-ADVP
with IN B-PP B-PP
an DT B-NP B-NP
EBV-encoded JJ I-NP I-NP
member NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
leucine NN I-NP I-NP
zipper NN I-NP I-NP
protein NN I-NP I-NP
family NN I-NP I-NP
suggests VBZ B-VP B-VP
c-myb NN B-NP B-NP
is VBZ B-VP B-VP
likely JJ B-ADJP B-ADJP
to TO B-VP B-VP
engage VB I-VP I-VP
in IN B-PP B-PP
similar JJ B-NP B-NP
interactions NNS I-NP I-NP
with IN B-PP B-PP
cellularly RB B-NP B-NP
encoded VBN I-NP I-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
. . O O

The DT B-NP B-NP
29-kDa JJ I-NP I-NP
proteins NNS I-NP I-NP
phosphorylated VBN B-VP B-VP
in IN B-PP B-PP
thrombin-activated JJ B-NP B-NP
human JJ I-NP I-NP
platelets NNS I-NP I-NP
are VBP B-VP B-VP
forms NNS B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
estrogen NN I-NP I-NP
receptor-related JJ I-NP I-NP
27-kDa JJ I-NP I-NP
heat NN I-NP I-NP
shock NN I-NP I-NP
protein NN I-NP I-NP
. . O O

Thrombin NN B-NP B-NP
plays VBZ B-VP B-VP
a DT B-NP B-NP
critical JJ I-NP I-NP
role NN I-NP I-NP
in IN B-PP B-PP
platelet NN B-NP B-NP
activation NN I-NP I-NP
, , O O
hemostasis NN B-NP B-NP
, , O O
and CC O I-CC
thrombosis NN B-NP B-NP
. . O O

Cellular JJ B-NP B-NP
activation NN I-NP I-NP
by IN B-PP B-PP
thrombin NN B-NP B-NP
leads VBZ B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
phosphorylation NN I-NP I-NP
of IN B-PP B-PP
multiple JJ B-NP B-NP
proteins NNS I-NP I-NP
, , O O
most JJS B-NP B-NP
of IN B-PP B-PP
which WDT B-NP B-NP
are VBP B-VP B-VP
unidentified JJ B-ADJP B-ADJP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
characterized VBN I-VP I-VP
several JJ B-NP B-NP
29-kDa JJ I-NP I-NP
proteins NNS I-NP I-NP
that WDT B-NP B-NP
are VBP B-VP B-VP
rapidly RB I-VP I-VP
phosphorylated VBN I-VP I-VP
following VBG B-PP I-VP
exposure NN B-NP B-NP
of IN B-PP B-PP
intact JJ B-NP B-NP
human JJ I-NP I-NP
platelets NNS I-NP I-NP
to TO B-PP B-PP
thrombin NN B-NP B-NP
. . O O

A DT B-NP B-NP
murine JJ I-NP I-NP
monoclonal JJ I-NP I-NP
antibody NN I-NP I-NP
raised VBN B-VP B-VP
to TO B-PP B-PP
an DT B-NP B-NP
unidentified JJ I-NP I-NP
estrogen NN I-NP I-NP
receptor-related JJ I-NP I-NP
29-kDa JJ I-NP I-NP
protein NN I-NP I-NP
selectively RB B-ADVP B-ADVP
recognized VBD B-VP B-VP
these DT B-NP B-NP
proteins NNS I-NP I-NP
as RB B-CONJP B-CONJP
well RB I-CONJP I-CONJP
as IN I-CONJP I-CONJP
a DT B-NP B-NP
more RBR I-NP I-NP
basic JJ I-NP I-NP
, , I-NP O
unphosphorylated JJ I-NP I-NP
27-kDa JJ I-NP I-NP
protein NN I-NP I-NP
. . O O

Cellular JJ B-NP B-NP
activation NN I-NP I-NP
by IN B-PP B-PP
thrombin NN B-NP B-NP
led VBN B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
marked JJ I-NP I-NP
shift NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
proportion NN I-NP I-NP
of IN B-PP B-PP
protein NN B-NP B-NP
from IN B-PP B-PP
the DT B-NP B-NP
27-kDa JJ I-NP I-NP
unphosphorylated JJ I-NP I-NP
form NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
29-kDa JJ I-NP I-NP
phosphoprotein NN I-NP I-NP
species NNS I-NP I-NP
. . O O

Using VBG B-VP B-VP
this DT B-NP B-NP
antibody NN I-NP I-NP
, , O O
we PRP B-NP B-NP
isolated VBD B-VP B-VP
and CC O I-VP
sequenced VBD B-VP I-VP
a DT B-NP B-NP
human JJ I-NP I-NP
cDNA NN I-NP I-NP
clone NN I-NP I-NP
encoding VBG B-VP B-VP
a DT B-NP B-NP
protein NN I-NP I-NP
that WDT B-NP B-NP
was VBD B-VP B-VP
identical JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
mammalian JJ I-NP I-NP
27-kDa JJ I-NP I-NP
heat NN I-NP I-NP
shock NN I-NP I-NP
protein NN I-NP I-NP
( ( O O
HSP27 NN B-NP B-NP
) ) O O
, , O O
a DT B-NP B-NP
protein NN I-NP I-NP
of IN B-PP B-PP
uncertain JJ B-NP B-NP
function NN I-NP I-NP
that WDT B-NP B-NP
is VBZ B-VP B-VP
known VBN I-VP I-VP
to TO B-VP I-VP
be VB I-VP I-VP
phosphorylated VBN I-VP I-VP
to TO B-PP B-PP
several JJ B-NP B-NP
forms NNS I-NP I-NP
and CC O I-CC
to TO B-VP B-VP
be VB I-VP I-VP
transcriptionally RB I-VP I-VP
induced VBN I-VP I-VP
by IN B-PP B-PP
estrogen NN B-NP B-NP
. . O O

The DT B-NP B-NP
29-kDa JJ I-NP I-NP
proteins NNS I-NP I-NP
were VBD B-VP B-VP
confirmed VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
phosphorylated VBN B-NP I-VP
forms NNS I-NP B-NP
of IN B-PP B-PP
HSP27 NN B-NP B-NP
by IN B-PP B-PP
immunoprecipitation NN B-NP B-NP
studies NNS I-NP I-NP
. . O O

Thus RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
" [[DQS]] I-NP I-NP
estrogen NN I-NP I-NP
receptor-related JJ I-NP I-NP
protein NN I-NP I-NP
" [[DQE]] O I-[[DQE]]
is VBZ B-VP B-VP
HSP27 NN B-NP B-NP
, , O O
and CC O I-CC
the DT B-NP B-NP
three CD I-NP I-NP
major JJ I-NP I-NP
29-kDa JJ I-NP I-NP
proteins NNS I-NP I-NP
phosphorylated VBN B-VP B-VP
in IN B-PP B-PP
thrombin-activated JJ B-NP B-NP
platelets NNS I-NP I-NP
are VBP B-VP B-VP
forms NNS B-NP B-NP
of IN B-PP B-PP
HSP27 NN B-NP B-NP
. . O O

These DT B-NP B-NP
data NNS I-NP I-NP
suggest VBP B-VP B-VP
a DT B-NP B-NP
role NN I-NP I-NP
for IN B-PP B-PP
HSP27 NN B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
signal NN I-NP I-NP
transduction NN I-NP I-NP
events NNS I-NP I-NP
of IN B-PP B-PP
platelet NN B-NP B-NP
activation NN I-NP I-NP
. . O O

Characterization NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
cofactor NN I-NP I-NP
that WDT B-NP B-NP
regulates VBZ B-VP B-VP
dimerization NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
mammalian JJ I-NP I-NP
homeodomain NN I-NP I-NP
protein NN I-NP I-NP
. . O O

Dimerization NN B-NP B-NP
among IN B-PP B-PP
transcription NN B-NP B-NP
factors NNS I-NP I-NP
has VBZ B-VP B-VP
become VBN I-VP I-VP
a DT B-NP B-NP
recurrent JJ I-NP I-NP
theme NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
eukaryotic JJ B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
. . O O

Hepatocyte NN B-NP B-NP
nuclear JJ I-NP I-NP
factor-1 NN I-NP I-NP
alpha NN I-NP I-NP
( ( O O
HNF-1 NN B-NP B-NP
alpha NN I-NP I-NP
) ) O O
is VBZ B-VP B-VP
a DT B-NP B-NP
homeodomain-containing JJ I-NP I-NP
protein NN I-NP I-NP
that WDT B-NP B-NP
functions VBZ B-VP B-VP
as IN B-PP B-PP
a DT B-NP B-NP
dimer NN I-NP I-NP
. . O O

A DT B-NP B-NP
dimerization NN I-NP I-NP
cofactor NN I-NP I-NP
of IN B-PP B-PP
HNF-1 NN B-NP B-NP
alpha NN I-NP I-NP
( ( O O
DCoH NN B-NP B-NP
) ) O O
was VBD B-VP B-VP
identified VBN I-VP I-VP
that WDT B-NP B-NP
displayed VBD B-VP B-VP
a DT B-NP B-NP
restricted JJ I-NP I-NP
tissue NN I-NP I-NP
distribution NN I-NP I-NP
and CC O I-CC
did VBD B-VP B-VP
not RB I-VP I-VP
bind VB I-VP I-VP
to TO B-PP B-PP
DNA NN B-NP B-NP
, , O O
but CC B-CONJP I-CC
, , I-CONJP O
rather RB I-CONJP B-ADVP
, , O O
selectively RB B-VP B-ADVP
stabilized VBD I-VP B-VP
HNF-1 NN B-NP B-NP
alpha NN I-NP I-NP
dimers NNS I-NP I-NP
. . O O

The DT B-NP B-NP
formation NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
stable JJ I-NP I-NP
tetrameric JJ I-NP I-NP
DCoH-HNF-1 NN I-NP I-NP
alpha NN I-NP I-NP
complex NN I-NP I-NP
, , O O
which WDT B-NP B-NP
required VBD B-VP B-VP
the DT B-NP B-NP
dimerization NN I-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
HNF-1 NN B-NP B-NP
alpha NN I-NP I-NP
, , O O
did VBD B-VP B-VP
not RB I-VP I-VP
change VB I-VP I-VP
the DT B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
characteristics NNS I-NP I-NP
of IN B-PP B-PP
HNF-1 NN B-NP B-NP
alpha NN I-NP I-NP
, , O O
but CC O I-CC
enhanced VBD B-VP B-VP
its PRP$ B-NP B-NP
transcriptional JJ I-NP I-NP
activity NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
DCoH NN B-NP B-NP
did VBD B-VP B-VP
not RB I-VP I-VP
confer VB I-VP I-VP
transcriptional JJ B-NP B-NP
activation NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
GAL4 NN I-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
domain NN I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
DCoH NN B-NP B-NP
regulates VBZ B-VP B-VP
formation NN B-NP B-NP
of IN B-PP B-PP
transcriptionally RB B-NP B-NP
active JJ I-NP I-NP
tetrameric JJ I-NP I-NP
complexes NNS I-NP I-NP
and CC O I-CC
may MD B-VP B-VP
contribute VB I-VP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
developmental JJ I-NP I-NP
specificity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
complex NN I-NP I-NP
. . O O

High JJ B-NP B-NP
affinity NN I-NP I-NP
aldosterone NN I-NP I-NP
binding VBG B-VP B-VP
to TO B-PP B-PP
plasma NN B-NP B-NP
membrane NN I-NP I-NP
rich JJ I-NP I-NP
fractions NNS I-NP I-NP
from IN B-PP B-PP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
: : O O
is VBZ O B-VP
there EX B-NP B-NP
a DT B-NP B-NP
membrane NN I-NP I-NP
receptor NN I-NP I-NP
for IN B-PP B-PP
mineralocorticoids NNS B-NP B-NP
? . O O

In FW B-NP B-NP
vitro FW I-NP I-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
aldosterone NN B-NP B-NP
on IN B-PP B-PP
the DT B-NP B-NP
intracellular JJ I-NP I-NP
concentrations NNS I-NP I-NP
of IN B-PP B-PP
sodium NN B-NP B-NP
, , O O
potassium NN B-NP I-NP
and CC O I-NP
calcium NN B-NP I-NP
, , O O
cell NN B-NP I-NP
volume NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
sodium-proton-antiport NN I-NP I-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
described VBN I-VP I-VP
in IN B-PP B-PP
intact JJ B-NP B-NP
human JJ B-NP I-NP
mononuclear JJ I-NP I-NP
leukocytes NNS I-NP I-NP
( ( O O
HML NN B-NP B-NP
) ) O O
. . O O

In IN B-PP B-PP
the DT B-NP B-NP
present JJ I-NP I-NP
paper NN I-NP I-NP
, , O O
the DT B-NP B-NP
binding NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
(125I)-labeled JJ I-NP I-NP
aldosterone NN I-NP I-NP
derivative JJ I-NP B-ADJP
to TO B-PP B-PP
plasma NN B-NP B-NP
membrane NN I-NP I-NP
rich JJ B-NP I-NP
fractions NNS I-NP I-NP
of IN B-PP B-PP
HML NN B-NP B-NP
was VBD B-VP B-VP
studied VBN I-VP I-VP
. . O O

High JJ B-NP B-NP
affinity NN I-NP I-NP
binding NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
radioligand NN I-NP I-NP
with IN B-PP B-PP
an DT B-NP B-NP
apparent JJ I-NP I-NP
Kd NN I-NP I-NP
of IN B-PP B-PP
approximately RB B-NP B-NP
0.1 CD I-NP I-NP
nM NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
. . O O

Aldosterone NN B-NP B-NP
displaced VBD B-VP B-VP
the DT B-NP B-NP
tracer NN I-NP I-NP
at IN B-PP B-PP
a DT B-NP B-NP
similar JJ I-NP I-NP
Kd NN I-NP I-NP
. . O O

Both CC O I-CC
canrenone NN B-NP B-NP
and CC O I-NP
cortisol NN B-NP I-NP
were VBD B-VP B-VP
inactive JJ B-ADJP B-ADJP
as IN B-PP B-PP
ligands NNS B-NP B-NP
up RB B-PP B-ADVP
to TO I-PP B-PP
concentrations NNS B-NP B-NP
of IN B-PP B-PP
0.1 CD B-NP B-NP
microM NN I-NP I-NP
. . O O

The DT B-NP B-NP
findings NNS I-NP I-NP
are VBP B-VP B-VP
the DT B-NP B-NP
first JJ I-NP I-NP
to TO B-VP B-VP
demonstrate VB I-VP I-VP
membrane NN B-NP B-NP
binding NN I-NP I-NP
sites NNS I-NP I-NP
with IN B-PP B-PP
a DT B-NP B-NP
high JJ I-NP I-NP
affinity NN I-NP I-NP
for IN B-PP B-PP
aldosterone NN B-NP B-NP
, , B-PP O
but CC I-PP I-CC
not RB B-PP I-RB
for IN I-PP B-PP
cortisol NN B-NP B-NP
. . O O

These DT B-NP B-NP
data NNS I-NP I-NP
are VBP B-VP B-VP
perfectly RB B-ADJP B-ADJP
compatible JJ I-ADJP I-ADJP
with IN B-PP B-PP
major JJ B-NP B-NP
properties NNS I-NP I-NP
of IN B-PP B-PP
steroidal JJ B-NP B-NP
effects NNS I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
sodium-proton-antiport NN I-NP I-NP
in IN B-PP B-PP
HML NN B-NP B-NP
and CC O I-CC
thus RB O B-ADVP
very RB B-VP I-ADVP
likely RB I-VP B-VP
represent VBP I-VP I-VP
membrane NN B-NP B-NP
receptors NNS I-NP I-NP
for IN B-PP B-PP
aldosterone NN B-NP B-NP
. . O O

Transcription NN B-NP B-NP
factor NN I-NP I-NP
requirements NNS I-NP I-NP
for IN B-PP B-PP
U2 NN B-NP B-NP
snRNA-encoding JJ I-NP I-NP
gene NN I-NP I-NP
activation NN I-NP I-NP
in IN B-PP B-PP
B NN B-NP B-NP
lymphoid JJ I-NP I-NP
cells NNS I-NP I-NP
. . O O

Transcription NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
human JJ I-NP I-NP
U2 NN I-NP I-NP
small JJ I-NP I-NP
nuclear JJ I-NP I-NP
RNA NN I-NP I-NP
( ( I-NP O
snRNA NN I-NP B-NP
) ) I-NP O
-encoding JJ I-NP B-NP
gene NN I-NP I-NP
in IN B-PP B-PP
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
requires VBZ B-VP B-VP
a DT B-NP B-NP
distal JJ I-NP I-NP
enhancer NN I-NP I-NP
element NN I-NP I-NP
, , O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
composed VBN I-VP I-VP
of IN B-PP B-PP
one CD B-NP B-NP
octamer NN B-NP I-NP
motif NN I-NP I-NP
( ( O O
Oct NN B-NP B-NP
) ) O O
and CC O I-CC
three CD B-NP B-NP
Sp NN I-NP I-NP
1-binding JJ I-NP I-NP
sites NNS I-NP I-NP
. . O O

To TO B-VP B-VP
study VB I-VP I-VP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
requirement NN I-NP I-NP
in IN B-PP B-PP
B-cells NNS B-NP B-NP
, , O O
different JJ B-NP B-NP
U2 NN I-NP I-NP
enhancer NN I-NP I-NP
constructions NNS I-NP I-NP
were VBD B-VP B-VP
transfected VBN I-VP I-VP
into IN B-PP B-PP
the DT B-NP B-NP
lymphoid JJ I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
, , O O
BJA-B NN B-NP B-NP
. . O O

The DT B-NP B-NP
results NNS I-NP I-NP
showed VBD B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
U2 NN B-NP B-NP
snRNA NN I-NP I-NP
transcription NN I-NP I-NP
in IN B-PP B-PP
B-cells NNS B-NP B-NP
also RB B-ADVP B-ADVP
requires VBZ B-VP B-VP
an DT B-NP B-NP
enhancer NN I-NP I-NP
comprising VBG B-VP I-NP
both CC O I-CC
the DT B-NP B-NP
Oct NN I-NP I-NP
and CC O B-PP
at IN B-NP B-NP
least JJS I-NP I-NP
one CD I-NP I-NP
Sp NN I-NP I-NP
1-binding JJ I-NP I-NP
site NN I-NP I-NP
. . O O

Deletion NN B-NP B-NP
of IN B-PP B-PP
all PDT B-NP B-NP
the DT I-NP I-NP
Sp NN I-NP I-NP
1-binding JJ I-NP I-NP
sites NNS I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
enhancer NN I-NP I-NP
reduces VBZ B-VP B-VP
transcription NN B-NP B-NP
by IN B-PP B-PP
80-90 CD B-NP B-NP
% NN I-NP I-NP
in IN B-PP B-PP
HeLa NN B-NP B-NP
, , O O
as RB B-CONJP B-CONJP
well RB I-CONJP I-CONJP
as IN I-CONJP I-CONJP
in IN B-PP B-PP
BJA-B NN B-NP B-NP
cells NNS B-NP I-NP
, , O O
whereas IN O B-PP
the DT B-NP B-NP
removal NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
octamer-binding JJ I-NP I-NP
site NN I-NP I-NP
reduces VBZ B-VP B-VP
transcription NN B-NP B-NP
to TO B-PP B-PP
levels NNS B-NP B-NP
below IN B-PP B-PP
detection NN B-NP B-NP
in IN B-PP B-PP
both DT B-NP B-NP
cell NN I-NP I-NP
types NNS I-NP I-NP
. . O O

Enhancers NNS B-NP B-NP
containing VBG B-VP B-VP
a DT B-NP B-NP
single JJ I-NP I-NP
Oct NN I-NP I-NP
have VBP B-VP B-VP
, , O O
nevertheless RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
capacity NN I-NP I-NP
to TO B-VP B-VP
partially RB I-VP I-VP
activate VB I-VP I-VP
U2 NN B-NP B-NP
snRNA NN I-NP I-NP
transcription NN I-NP I-NP
in IN B-PP B-PP
both DT B-NP B-NP
HeLa NN I-NP I-NP
cells NNS I-NP I-NP
, , O O
in IN B-PP B-PP
which WDT B-NP B-NP
only RB B-NP B-NP
OTF-1 NN I-NP I-NP
is VBZ B-VP B-VP
expressed VBN I-VP I-VP
, , B-PP O
and CC I-PP I-CC
in IN B-PP B-PP
BJA-B NN B-NP B-NP
cells NNS I-NP I-NP
in IN B-PP B-PP
which WDT B-NP B-NP
OTF-2 NN B-NP B-NP
is VBZ B-VP B-VP
the DT B-NP B-NP
predominantly RB I-NP I-NP
expressed VBN I-NP I-NP
octamer-binding JJ I-NP I-NP
factor NN I-NP I-NP
. . O O

The DT B-NP B-NP
most RBS I-NP I-NP
likely JJ I-NP I-NP
interpretation NN I-NP I-NP
of IN B-PP B-PP
our PRP$ B-NP B-NP
results NNS I-NP I-NP
is VBZ B-VP B-VP
that IN B-SBAR I-IN
both CC O I-CC
the DT B-NP B-NP
ubiquitous JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
, , O O
OTF-1 NN B-NP B-NP
, , O O
and CC O I-CC
the DT B-NP B-NP
B-cell-specific JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
, , O O
OTF-2 NN B-NP B-NP
, , O O
can MD B-VP B-VP
activate VB I-VP I-VP
U2 NN B-NP B-NP
snRNA NN I-NP I-NP
transcription NN I-NP I-NP
. . O O

The DT B-NP B-NP
results NNS I-NP I-NP
also RB B-ADVP B-ADVP
revealed VBD B-VP B-VP
a DT B-NP B-NP
similar JJ I-NP I-NP
functional JJ I-NP I-NP
cooperation NN I-NP I-NP
between IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
which WDT B-NP B-NP
bind VBP B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
Oct NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
adjacent JJ I-NP I-NP
Sp NN I-NP I-NP
1-binding JJ I-NP I-NP
site NN B-NP I-NP
in IN B-PP B-PP
BJA-B NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
as IN B-SBAR B-SBAR
has VBZ B-VP B-VP
been VBN I-VP I-VP
observed VBN I-VP I-VP
in IN B-PP B-PP
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
since IN B-SBAR B-PP
a DT B-NP B-NP
template NN I-NP I-NP
which WDT B-NP B-NP
contains VBZ B-VP B-VP
a DT B-NP B-NP
weak JJ I-NP I-NP
binding VBG I-NP I-NP
site NN I-NP I-NP
for IN B-PP B-PP
OTFs NNS B-NP B-NP
expresses VBZ B-VP B-VP
wild-type JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
U2 NN B-NP B-NP
snRNA NN I-NP I-NP
in IN B-PP B-PP
both DT B-NP B-NP
cell NN I-NP I-NP
types NNS I-NP I-NP
when WRB B-ADVP B-ADVP
the DT B-NP B-NP
weak JJ I-NP I-NP
octamer-binding JJ I-NP I-NP
site NN I-NP I-NP
is VBZ B-VP B-VP
combined VBN I-VP I-VP
with IN B-PP B-PP
a DT B-NP B-NP
Sp NN I-NP I-NP
1-binding JJ I-NP I-NP
site NN I-NP I-NP
. . O O

Cortisol NN B-NP B-NP
receptor NN I-NP I-NP
resistance NN I-NP I-NP
: : O O
the DT B-NP B-NP
variability NN I-NP I-NP
of IN B-PP B-PP
its PRP$ B-NP B-NP
clinical JJ B-NP I-NP
presentation NN I-NP I-NP
and CC O I-NP
response NN B-NP I-NP
to TO B-PP B-PP
treatment NN B-NP B-NP
. . O O

Primary JJ B-NP B-NP
( ( I-NP O
partial JJ I-NP I-JJ
) ) I-NP O
cortisol NN I-NP B-NP
receptor NN I-NP I-NP
resistance NN I-NP I-NP
was VBD B-VP B-VP
previously RB I-VP I-VP
reported VBN I-VP I-VP
in IN B-PP B-PP
a DT B-NP B-NP
total NN I-NP I-NP
of IN B-PP B-PP
7 CD B-NP B-NP
patients NNS I-NP I-NP
and CC O I-CC
14 CD B-NP B-NP
asymptomatic JJ I-NP I-NP
family NN I-NP I-NP
members NNS I-NP I-NP
. . O O

Its PRP$ B-NP B-NP
occurrence NN I-NP I-NP
is VBZ B-VP B-VP
considered VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
extremely RB B-ADJP B-ADJP
rare JJ I-ADJP I-ADJP
. . O O

In IN B-PP B-PP
the DT B-NP B-NP
present JJ I-NP I-NP
study NN I-NP I-NP
we PRP B-NP B-NP
report VBP B-VP B-VP
on IN B-PP B-PP
6 CD B-NP B-NP
patients NNS I-NP I-NP
( ( O O
2 CD B-NP B-NP
males NNS I-NP I-NP
and CC O I-CC
4 CD B-NP B-NP
females NNS I-NP I-NP
) ) O O
with IN B-PP B-PP
the DT B-NP B-NP
syndrome NN I-NP I-NP
. . O O

The DT B-NP B-NP
first JJ I-NP I-NP
male JJ I-NP I-NP
patient NN I-NP I-NP
presented VBD B-VP B-VP
with IN B-PP B-PP
mild JJ B-NP B-NP
hypertension NN I-NP I-NP
. . O O

Hydrochlorothiazide NN B-NP B-NP
therapy NN I-NP I-NP
resulted VBD B-VP B-VP
in IN B-PP B-PP
life-threatening JJ B-NP B-NP
hypokalemia NN I-NP I-NP
. . O O

The DT B-NP B-NP
second JJ I-NP I-NP
male JJ I-NP I-NP
patient NN I-NP I-NP
had VBD B-VP B-VP
slight JJ B-NP B-NP
hypertension NN I-NP I-NP
without IN B-PP B-PP
hypokalemia NN B-NP B-NP
. . O O

All DT B-NP B-NP
four CD I-NP I-NP
female JJ I-NP I-NP
patients NNS I-NP I-NP
presented VBD B-VP B-VP
between IN B-PP B-PP
the DT B-NP B-NP
age NN I-NP I-NP
of IN B-PP B-PP
20-30 CD B-NP B-NP
yr NN I-NP I-NP
with IN B-PP B-PP
acne NN B-NP B-NP
, , O O
hirsutism NN B-NP B-NP
, , O O
and CC O I-CC
irregular JJ B-NP B-NP
menstruations NNS I-NP I-NP
. . O O

Low JJ B-NP B-NP
dose NN I-NP I-NP
dexamethasone NN I-NP I-NP
therapy NN I-NP I-NP
( ( O O
1-1.5 CD B-NP B-NP
mg/day NN I-NP I-NP
) ) O O
was VBD B-VP B-VP
of IN B-PP B-PP
clinical JJ B-NP B-NP
benefit NN I-NP I-NP
in IN B-PP B-PP
these DT B-NP B-NP
patients NNS I-NP I-NP
. . O O

All DT B-NP B-NP
patients NNS I-NP I-NP
showed VBD B-VP B-VP
insufficient JJ B-NP B-NP
suppression NN I-NP I-NP
of IN B-PP B-PP
serum NN B-NP B-NP
cortisol NN I-NP I-NP
concentrations NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
overnight JJ I-NP I-NP
1-mg JJ I-NP I-NP
dexamethasone NN I-NP I-NP
test NN I-NP I-NP
. . O O

The DT B-NP B-NP
diurnal JJ I-NP I-NP
rhythm NN I-NP I-NP
of IN B-PP B-PP
ACTH NN B-NP B-NP
and CC O I-NP
cortisol NN B-NP I-NP
was VBD B-VP B-VP
intact JJ B-ADJP B-ADJP
, , O O
albeit IN B-PP B-PP
at IN B-PP B-PP
an DT B-NP B-NP
elevated JJ I-NP I-NP
level NN I-NP I-NP
. . O O

There EX B-NP B-NP
was VBD B-VP B-VP
a DT B-NP B-NP
normal JJ I-NP I-NP
increase NN I-NP I-NP
in IN B-PP B-PP
ACTH NN B-NP B-NP
, , O O
cortisol NN B-NP B-NP
, , O O
and CC O I-CC
GH NN B-NP B-NP
( ( O O
except IN B-PP B-PP
in IN B-PP B-PP
one CD B-NP B-NP
obese JJ I-NP I-NP
patient NN I-NP I-NP
) ) O O
in IN B-PP B-PP
response NN I-PP B-NP
to TO I-PP B-PP
insulin-induced JJ B-NP B-NP
hypoglycemia NN I-NP I-NP
, , O O
while IN B-SBAR B-SBAR
cortisol NN B-NP B-NP
production NN I-NP I-NP
was VBD B-VP B-VP
elevated JJ I-VP B-ADJP
in IN B-PP B-PP
three CD B-NP B-NP
patients NNS I-NP I-NP
. . O O

Circulating VBG B-NP B-VP
adrenal JJ I-NP B-NP
androgen NN I-NP I-NP
levels NNS I-NP I-NP
were VBD B-VP B-VP
increased VBN I-VP I-VP
in IN B-PP B-PP
all DT B-NP B-NP
patients NNS I-NP I-NP
. . O O

Glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
were VBD B-VP B-VP
investigated VBN I-VP I-VP
in IN B-PP B-PP
a DT B-NP B-NP
whole JJ I-NP I-NP
cell NN I-NP I-NP
dexamethasone NN I-NP I-NP
binding NN I-NP I-NP
assay NN I-NP I-NP
in IN B-PP B-PP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
. . O O

In IN B-PP B-PP
the DT B-NP B-NP
first JJ I-NP I-NP
male JJ I-NP I-NP
patient NN I-NP I-NP
, , O O
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
receptors NNS B-NP B-NP
was VBD B-VP B-VP
very RB B-ADJP B-ADJP
low JJ I-ADJP I-ADJP
, , O O
while IN B-SBAR B-SBAR
the DT B-NP B-NP
affinity NN I-NP I-NP
was VBD B-VP B-VP
lower JJR B-ADJP B-ADJP
than IN B-PP B-PP
that DT B-NP B-NP
in IN B-PP B-PP
controls NNS B-NP B-NP
. . O O

A DT B-NP B-NP
lowered JJ I-NP I-NP
affinity NN I-NP I-NP
to TO B-PP B-PP
dexamethasone NN B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
in IN B-PP B-PP
one CD B-NP B-NP
female JJ I-NP I-NP
patient NN I-NP I-NP
, , O O
while IN B-SBAR B-SBAR
a DT B-NP B-NP
lowered JJ I-NP I-NP
number NN I-NP I-NP
of IN B-PP B-PP
receptors NNS B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
in IN B-PP B-PP
three CD B-NP B-NP
patients NNS I-NP I-NP
. . O O

In IN B-PP B-PP
the DT B-NP B-NP
second JJ I-NP I-NP
male JJ I-NP I-NP
patient NN I-NP I-NP
, , O O
no DT B-NP B-NP
abnormalities NNS I-NP I-NP
were VBD B-VP B-VP
found VBN I-VP I-VP
. . O O

As IN B-PP B-PP
a DT B-NP B-NP
bioassay NN I-NP I-NP
for IN B-PP B-PP
glucocorticoid NN B-NP B-NP
action NN I-NP I-NP
we PRP B-NP B-NP
also RB B-ADVP B-ADVP
measured VBD B-VP B-VP
dexamethasone NN B-NP B-NP
suppressibility NN I-NP I-NP
of IN B-PP B-PP
mitogen-stimulated JJ B-NP B-NP
incorporation NN I-NP I-NP
of IN B-PP B-PP
(3H)thymidine NN B-NP B-NP
in IN B-PP B-PP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
. . O O

In IN B-PP B-PP
the DT B-NP B-NP
male JJ I-NP I-NP
patient NN I-NP I-NP
with IN B-PP B-PP
normal JJ B-NP B-NP
receptor NN I-NP I-NP
status NN I-NP I-NP
, , O O
dexamethasone NN B-NP B-NP
suppressibility NN I-NP I-NP
of IN B-PP B-PP
(3H)thymidine NN B-NP B-NP
incorporation NN I-NP I-NP
was VBD B-VP B-VP
significantly RB B-ADJP B-ADJP
lower JJR I-ADJP I-ADJP
than IN B-PP B-PP
that DT B-NP B-NP
in IN B-PP B-PP
healthy JJ B-NP B-NP
controls NNS I-NP I-NP
with IN B-PP B-PP
respect NN I-PP B-NP
to TO I-PP B-VP
both CC O I-VP
maximal JJ B-NP B-NP
suppression NN I-NP I-NP
and CC O I-NP
IC50 NN B-NP I-NP
. . O O

Partial JJ B-NP B-NP
cortisol NN I-NP I-NP
receptor NN I-NP I-NP
resistance NN I-NP I-NP
might MD B-VP B-VP
be VB I-VP I-VP
less RBR B-ADJP B-ADJP
rare JJ I-ADJP I-ADJP
than IN B-SBAR B-SBAR
previously RB B-VP B-ADVP
thought VBN I-VP B-VP
. . O O

In IN B-PP B-PP
the DT B-NP B-NP
six CD I-NP I-NP
patients NNS I-NP I-NP
presented VBN B-VP B-VP
, , O O
at IN B-NP B-ADVP
least JJS I-NP I-ADVP
three CD I-NP B-NP
different JJ I-NP I-NP
forms NNS I-NP I-NP
can MD B-VP B-VP
be VB I-VP I-VP
recognized VBN I-VP I-VP
. . O O

Therapy NN B-NP B-NP
with IN B-PP B-PP
dexamethasone NN B-NP B-NP
was VBD B-VP B-VP
successful JJ B-ADJP B-ADJP
in IN B-PP B-PP
female JJ B-NP B-NP
patients NNS I-NP I-NP
with IN B-PP B-PP
acne NN B-NP B-NP
and CC O I-NP
hirsutism NN B-NP I-NP
, , O O
as IN B-SBAR B-SBAR
the DT B-NP B-NP
secondary JJ I-NP I-NP
increase NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
production NN I-NP I-NP
of IN B-PP B-PP
adrenal JJ B-NP B-NP
androgens NNS I-NP I-NP
was VBD B-VP B-VP
effectively RB I-VP I-VP
controlled VBN I-VP I-VP
. . O O

Kappa NN B-NP B-NP
B-specific JJ I-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
proteins NNS I-NP I-NP
are VBP B-VP B-VP
differentially RB I-VP I-VP
inhibited VBN I-VP I-VP
by IN B-PP B-PP
enhancer NN B-NP B-NP
mutations NNS I-NP I-NP
and CC O I-CC
biological JJ B-NP B-NP
oxidation NN I-NP I-NP
. . O O

Kappa NN B-NP B-NP
B NN I-NP I-NP
( ( O O
kappa NN B-NP B-NP
B NN I-NP I-NP
) ) O O
enhancer NN B-NP B-NP
binding NN I-NP I-NP
proteins NNS I-NP I-NP
isolated VBN B-VP B-VP
from IN B-PP B-PP
the DT B-NP B-NP
nuclei NNS I-NP I-NP
of IN B-PP B-PP
activated VBN B-NP B-NP
human JJ I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
produce VBP B-VP B-VP
two CD B-NP B-NP
distinct JJ I-NP I-NP
nucleoprotein NN I-NP I-NP
complexes NNS I-NP I-NP
when WRB B-ADVP B-ADVP
incubated VBN B-VP B-VP
with IN B-PP B-PP
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
element NN I-NP I-NP
from IN B-PP B-PP
the DT O B-NP
interleukin-2 NN B-NP I-NP
receptor-alpha NN I-NP I-NP
( ( O O
IL-2R NN B-NP B-NP
alpha NN I-NP I-NP
) ) O O
gene NN B-NP B-NP
. . O O

These DT B-NP B-NP
two CD I-NP I-NP
DNA-protein JJ I-NP I-NP
complexes NNS I-NP I-NP
are VBP B-VP B-VP
composed VBN I-VP I-VP
of IN B-PP B-PP
at IN B-NP B-NP
least JJS I-NP I-NP
four CD I-NP I-NP
host NN I-NP I-NP
proteins NNS I-NP I-NP
( ( O O
p50 NN B-NP B-NP
, , O O
p55 NN B-NP I-NP
, , O O
p75 NN B-NP I-NP
, , O O
p85 NN B-NP I-NP
) ) O O
, , O O
each DT B-NP B-NP
of IN B-PP B-PP
which WDT B-NP B-NP
shares VBZ B-VP B-VP
structural JJ B-NP B-NP
similarity NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
v-rel NN I-NP I-NP
oncogene NN I-NP I-NP
product NN I-NP I-NP
. . O O

Nuclear JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
proteins NNS I-NP I-NP
is VBZ B-VP B-VP
induced VBN I-VP I-VP
with IN B-PP B-PP
distinctly RB B-NP B-NP
biphasic JJ I-NP I-NP
kinetics NNS I-NP I-NP
following VBG B-PP B-VP
phorbol NN B-NP B-NP
ester NN I-NP I-NP
activation NN I-NP I-NP
of IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
( ( O O
p55/p75 NN B-NP B-NP
early JJ I-NP I-NP
and CC O I-NP
p50/p85 NN B-NP I-NP
late JJ I-NP I-NP
) ) O O
. . O O

DNA-protein JJ B-NP B-NP
crosslinking NN I-NP I-NP
studies NNS I-NP I-NP
have VBP B-VP B-VP
revealed VBN I-VP I-VP
that IN B-SBAR B-SBAR
the DT O B-NP
more RBR B-ADVP I-NP
rapidly RB I-ADVP B-VP
migrating VBG B-NP I-VP
B2 NN I-NP B-NP
complex NN I-NP I-NP
contains VBZ B-VP B-VP
both CC O I-CC
p50 NN B-NP B-NP
and CC O I-NP
p55 NN B-NP I-NP
while IN B-SBAR B-SBAR
the DT O B-NP
more RBR B-ADVP I-NP
slowly RB I-ADVP B-VP
migrating VBG B-NP I-VP
B1 NN I-NP B-NP
complex NN I-NP I-NP
is VBZ B-VP B-VP
composed VBN I-VP I-VP
of IN B-PP B-PP
p50 NN B-NP B-NP
, , O O
p55 NN B-NP B-NP
, , O O
p75 NN B-NP B-NP
, , O O
and CC O I-CC
p85 NN B-NP B-NP
. . O O

Site-directed JJ B-NP B-NP
mutagenesis NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
wild-type JJ I-NP I-NP
IL-2R NN I-NP I-NP
alpha NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
enhancer NN I-NP I-NP
( ( O O
GGGGAATCTCCC NN B-NP B-NP
) ) O O
has VBZ B-VP B-VP
revealed VBN I-VP I-VP
that IN B-SBAR B-PP
the DT B-NP B-NP
binding NN I-NP I-NP
of IN B-PP B-PP
p50 NN B-NP B-NP
and CC O I-NP
p55 NN B-NP I-NP
( ( O O
B2 NN B-NP B-NP
complex NN I-NP I-NP
) ) O O
is VBZ B-VP B-VP
particularly RB B-ADJP B-ADJP
sensitive JJ I-ADJP I-ADJP
to TO B-PP B-PP
alteration NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
5' JJ I-NP I-NP
triplet NN I-NP I-NP
of IN B-PP B-PP
deoxyguanosine NN B-NP B-NP
residues NNS I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
formation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
B1 NN I-NP I-NP
complex NN I-NP I-NP
, , O O
reflecting VBG B-VP B-VP
the DT B-NP B-NP
binding NN I-NP I-NP
of IN B-PP B-PP
p75 NN B-NP B-NP
and CC O I-NP
p85 NN B-NP I-NP
, , O O
critically RB B-ADVP B-ADVP
depends VBZ B-VP B-VP
upon IN B-PP B-PP
the DT B-NP B-NP
more RBR I-NP I-NP
3' JJ I-NP I-NP
sequences NNS I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
enhancer NN I-NP I-NP
element NN I-NP I-NP
. . O O

DNA NN B-NP B-NP
binding NN I-NP I-NP
by IN B-PP B-PP
all DT B-NP B-NP
four CD I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
Rel-related JJ I-NP I-NP
factors NNS I-NP I-NP
is VBZ B-VP B-VP
blocked VBN I-VP I-VP
by IN B-PP B-PP
selective JJ B-NP B-NP
chemical JJ I-NP I-NP
modification NN I-NP I-NP
of IN B-PP B-PP
lysine NN B-NP B-NP
and CC O I-NP
arginine NN B-NP I-NP
residues NNS B-NP I-NP
, , O O
suggesting VBG B-VP B-VP
that IN B-SBAR B-SBAR
both DT B-NP B-NP
of IN B-PP B-PP
these DT B-NP B-NP
basic JJ I-NP I-NP
amino NN I-NP I-NP
acids NNS I-NP I-NP
are VBP B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
binding VBG B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
element NN I-NP I-NP
. . O O

Similarly RB B-ADVP B-ADVP
, , O O
covalent JJ B-NP B-NP
modification NN I-NP I-NP
of IN B-PP B-PP
free JJ B-NP B-NP
sulfhydryl NN I-NP I-NP
groups NNS I-NP I-NP
with IN B-PP B-PP
diamide NN B-NP B-NP
( ( O O
reversible JJ B-ADJP B-NP
) ) O O
or CC O I-CC
N-ethylmaleimide NN B-NP B-NP
( ( O O
irreversible JJ B-ADJP B-NP
) ) O O
results VBZ B-VP B-VP
in IN B-PP B-PP
a DT B-NP B-NP
complete JJ I-NP I-NP
loss NN I-NP I-NP
of IN B-PP B-PP
DNA NN B-NP B-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
mild JJ B-NP B-NP
oxidation NN I-NP I-NP
with IN B-PP B-PP
glucose NN B-NP B-NP
oxidase NN I-NP I-NP
selectively RB B-ADVP B-ADVP
inhibits VBZ B-VP B-VP
p75 NN B-NP B-NP
and CC O I-NP
p85 NN B-NP I-NP
binding NN B-NP I-NP
while IN B-SBAR B-NP
not RB B-VP B-VP
blocking VBG I-VP I-VP
p50 NN B-NP B-NP
and CC O I-NP
p55 NN B-NP I-NP
interactions NNS B-NP I-NP
. . O O

These DT B-NP B-NP
findings NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-PP
reduced VBN B-NP B-NP
cysteine NN I-NP I-NP
thiols NNS I-NP I-NP
play VBP B-VP B-VP
an DT B-NP B-NP
important JJ I-NP I-NP
role NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
family NN I-NP I-NP
of IN B-PP B-PP
Rel-related JJ B-NP B-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
. . O O

A DT B-NP B-NP
novel JJ I-NP I-NP
mitogen-inducible JJ I-NP I-NP
gene NN I-NP I-NP
product NN I-NP I-NP
related JJ B-ADJP B-ADJP
to TO B-PP B-PP
p50/p105-NF-kappa NN B-NP B-NP
B NN I-NP I-NP
participates VBZ B-VP B-VP
in IN B-PP B-PP
transactivation NN B-NP B-NP
through IN B-PP B-PP
a DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
site NN I-NP I-NP
. . O O

A DT B-NP B-NP
Rel-related JJ I-NP I-NP
, , I-NP O
mitogen-inducible JJ I-NP I-NP
, , I-NP O
kappa NN I-NP I-NP
B-binding JJ I-NP I-NP
protein NN I-NP I-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
cloned VBN I-VP I-VP
as IN B-PP B-PP
an DT B-NP B-NP
immediate-early JJ I-NP I-NP
activation NN I-NP I-NP
gene NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
peripheral JJ I-NP I-NP
blood NN I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

The DT B-NP B-NP
cDNA NN I-NP I-NP
has VBZ B-VP B-VP
an DT B-NP B-NP
open JJ I-NP I-NP
reading NN I-NP I-NP
frame NN I-NP I-NP
of IN B-PP B-PP
900 CD B-NP B-NP
amino NN I-NP I-NP
acids NNS I-NP I-NP
capable JJ B-ADJP B-ADJP
of IN B-PP B-PP
encoding VBG B-VP B-VP
a DT B-NP B-NP
97-kDa JJ I-NP I-NP
protein NN I-NP I-NP
. . O O

This DT B-NP B-NP
protein NN I-NP I-NP
is VBZ B-VP B-VP
most RBS B-ADJP B-ADVP
similar JJ I-ADJP I-ADVP
to TO B-PP B-PP
the DT B-NP B-NP
105-kDa JJ I-NP I-NP
precursor NN I-NP I-NP
polypeptide NN I-NP I-NP
of IN B-PP B-PP
p50-NF-kappa NN B-NP B-NP
B NN I-NP I-NP
. . O O

Like IN B-PP B-PP
the DT B-NP B-NP
105-kDa JJ I-NP I-NP
precursor NN I-NP I-NP
, , O O
it PRP B-NP B-NP
contains VBZ B-VP B-VP
an DT B-NP B-NP
amino-terminal JJ I-NP I-NP
Rel-related JJ I-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
about IN B-NP B-NP
300 CD I-NP I-NP
amino NN I-NP I-NP
acids NNS I-NP I-NP
and CC O I-CC
a DT B-NP B-NP
carboxy-terminal JJ I-NP I-NP
domain NN I-NP I-NP
containing VBG B-VP B-VP
six CD O B-NP
full JJ B-NP I-NP
cell NN I-NP I-NP
cycle NN I-NP I-NP
or CC O I-NP
ankyrin NN B-NP I-NP
repeats NNS B-NP I-NP
. . O O

In FW B-NP B-NP
vitro-translated JJ I-NP I-NP
proteins NNS I-NP I-NP
, , O O
truncated VBN B-VP B-VP
downstream RB B-ADVP B-ADVP
of IN B-PP B-PP
the DT B-NP B-NP
Rel NN I-NP I-NP
domain NN I-NP I-NP
and CC O I-CC
excluding VBG B-VP B-VP
the DT B-NP B-NP
repeats NNS I-NP I-NP
, , O O
bind VBP B-VP B-VP
kappa NN B-NP B-NP
B NN I-NP I-NP
sites NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
refer VBP B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
kappa NN I-NP I-NP
B-binding JJ I-NP I-NP
, , O O
truncated VBN B-NP B-VP
protein NN I-NP B-NP
as IN B-PP B-PP
p50B NN B-NP B-NP
by IN B-PP B-PP
analogy NN B-NP B-NP
with IN B-PP B-PP
p50-NF-kappa NN B-NP B-NP
B NN I-NP I-NP
and CC B-PP I-CC
to TO B-PP B-PP
the DT B-NP B-NP
full-length JJ I-NP I-NP
protein NN I-NP I-NP
as IN B-PP B-PP
p97 NN B-NP B-NP
. . O O

p50B NN B-NP B-NP
is VBZ B-VP B-VP
able JJ B-ADJP B-ADJP
to TO B-VP B-VP
form VB I-VP I-VP
heteromeric JJ B-NP B-NP
kappa NN I-NP I-NP
B-binding JJ I-NP I-NP
complexes NNS I-NP I-NP
with IN B-PP B-PP
RelB NN B-NP B-NP
, , O O
as RB B-CONJP B-CONJP
well RB I-CONJP I-CONJP
as IN I-CONJP I-CONJP
with IN B-PP B-PP
p65 NN B-NP B-NP
and CC O I-NP
p50 NN B-NP I-NP
, , O O
the DT B-NP B-NP
two CD I-NP I-NP
subunits NNS I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
. . O O

Transient-transfection NN B-NP B-NP
experiments NNS I-NP I-NP
in IN B-PP B-PP
embryonal JJ B-NP B-NP
carcinoma NN I-NP I-NP
cells NNS I-NP I-NP
demonstrate VBP B-VP B-VP
a DT B-NP B-NP
functional JJ I-NP I-NP
cooperation NN I-NP I-NP
between IN B-PP B-PP
p50B NN B-NP B-NP
and CC O I-NP
RelB NN B-NP I-NP
or CC O I-NP
p65 NN B-NP I-NP
in IN B-PP B-PP
transactivation NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
reporter NN I-NP I-NP
plasmid NN I-NP I-NP
dependent JJ B-ADJP B-ADJP
on IN B-PP B-PP
a DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
site NN I-NP I-NP
. . O O

The DT B-NP B-NP
data NNS I-NP I-NP
imply VBP B-VP B-VP
the DT B-NP B-NP
existence NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
complex JJ I-NP I-NP
family NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B-like JJ I-NP I-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
. . O O

( ( O O
Changes NNS B-NP B-NP
in IN B-PP B-PP
leucocytic JJ B-NP B-NP
estrogen NN I-NP I-NP
receptor NN I-NP I-NP
levels NNS I-NP I-NP
in IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
climacteric JJ B-NP B-NP
syndrome NN I-NP I-NP
and CC O I-CC
therapeutic JJ B-NP B-NP
effect NN I-NP I-NP
of IN B-PP B-PP
liuwei FW B-NP B-NP
dihuang FW I-NP I-NP
pills NNS I-NP I-NP
) ) O O

The DT B-NP B-NP
numbers NNS I-NP I-NP
of IN B-PP B-PP
estrogen NN B-NP B-NP
receptor NN I-NP I-NP
( ( O O
ER NN B-NP B-NP
) ) O O
in IN B-PP B-PP
human JJ B-NP B-NP
peripheral JJ I-NP I-NP
leucocytes NNS I-NP I-NP
in IN B-PP B-PP
22 CD B-NP B-NP
women NNS I-NP I-NP
with IN B-PP B-PP
climacteric JJ B-NP B-NP
syndrome NN I-NP I-NP
were VBD B-VP B-VP
measured VBN I-VP I-VP
by IN B-PP B-PP
radioligand NN B-NP B-NP
method NN I-NP I-NP
. . O O

The DT B-NP B-NP
results NNS I-NP I-NP
were VBD B-VP B-VP
compared VBN I-VP I-VP
with IN B-PP B-PP
those DT B-NP B-NP
of IN B-PP B-PP
12 CD B-NP B-NP
normal JJ I-NP I-NP
child-bearing-age JJ I-NP I-NP
women NNS I-NP I-NP
. . O O

It PRP B-NP B-NP
wat VBD B-VP B-VP
found VBN I-VP I-VP
that IN B-SBAR B-PP
the DT B-NP B-NP
contents NNS I-NP I-NP
of IN B-PP B-PP
leucocytic JJ B-NP B-NP
ER NN I-NP I-NP
in IN B-PP B-PP
climacteric JJ B-NP B-NP
syndrome NN I-NP I-NP
patients NNS I-NP I-NP
were VBD B-VP B-VP
significantly RB B-ADJP B-ADJP
lower JJR I-ADJP I-ADJP
than IN B-PP B-PP
normal JJ B-NP B-NP
child-bearing-age JJ I-NP I-NP
women NNS I-NP I-NP
. . O O

The DT B-NP B-NP
authors NNS I-NP I-NP
used VBD B-VP B-VP
a DT B-NP B-NP
Chinese JJ I-NP I-NP
prescription NN I-NP I-NP
-- : O O
Liuwei FW B-NP B-NP
Dihuang FW I-NP I-NP
Pills NNS I-NP I-NP
( ( O O
LDP NN B-NP B-NP
) ) O O
to TO B-VP B-VP
treat VB I-VP I-VP
the DT B-NP B-NP
patients NNS I-NP I-NP
for IN B-PP B-PP
2 CD B-NP B-NP
months NNS I-NP I-NP
. . O O

The DT B-NP B-NP
numbers NNS I-NP I-NP
of IN B-PP B-PP
leucocytic JJ B-NP B-NP
ER NN I-NP I-NP
were VBD B-VP B-VP
significantly RB I-VP I-VP
increased VBN I-VP I-VP
after IN B-PP B-PP
treatment NN B-NP B-NP
. . O O

The DT B-NP B-NP
data NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
decrease NN B-NP B-NP
of IN B-PP B-PP
ER NN B-NP B-NP
levels NNS I-NP I-NP
in IN B-PP B-PP
cell NN B-NP B-NP
may MD B-VP B-VP
involve VB I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
pathogenesis NN I-NP I-NP
of IN B-PP B-PP
climacteric JJ B-NP B-NP
syndrome NN I-NP I-NP
. . O O

LDP NN B-NP B-NP
not RB B-CONJP B-VP
only RB I-CONJP B-ADVP
increases VBZ B-VP B-VP
plasma NN B-NP B-NP
estradiol NN I-NP I-NP
levels NNS I-NP I-NP
, , O O
but CC B-CONJP I-CC
also RB I-CONJP B-ADVP
increases VBZ B-VP B-VP
the DT B-NP B-NP
leucocytic JJ I-NP I-NP
ER NN I-NP I-NP
levels NNS I-NP I-NP
. . O O

This DT B-NP B-NP
may MD B-VP B-VP
be VB I-VP I-VP
the DT B-NP B-NP
basis NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
therapeutic JJ I-NP I-NP
effect NN I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
disease NN I-NP I-NP
. . O O

A DT B-NP B-NP
novel JJ I-NP I-NP
primer NN I-NP I-NP
extension NN I-NP I-NP
method NN I-NP I-NP
to TO B-VP B-VP
detect VB I-VP I-VP
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
CAG NN B-NP B-NP
repeats NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
androgen NN I-NP I-NP
receptor NN I-NP I-NP
gene NN I-NP I-NP
in IN B-PP B-PP
families NNS B-NP B-NP
with IN B-PP B-PP
X-linked JJ B-NP B-NP
spinal JJ I-NP I-NP
and CC I-NP I-NP
bulbar JJ I-NP I-NP
muscular JJ I-NP I-NP
atrophy NN I-NP I-NP
. . O O

X-linked JJ B-NP B-NP
spinal JJ I-NP I-NP
and CC I-NP I-NP
bulbar JJ I-NP I-NP
muscular JJ I-NP I-NP
atrophy NN I-NP I-NP
( ( O O
SBMA NN B-NP B-NP
) ) O O
, , O O
an DT B-NP B-NP
adult-onset JJ I-NP I-NP
form NN I-NP I-NP
of IN B-PP B-PP
motor NN B-NP B-NP
neuron NN I-NP I-NP
disease NN I-NP I-NP
, , O O
was VBD B-VP B-VP
recently RB I-VP I-VP
reported VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
caused VBN I-VP I-VP
by IN B-PP B-PP
amplification NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
CAG NN I-NP I-NP
repeats NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
androgen NN I-NP I-NP
receptor NN I-NP I-NP
gene NN I-NP I-NP
. . O O

We PRP B-NP B-NP
report VBP B-VP B-VP
here RB B-ADVP B-ADVP
a DT B-NP B-NP
simple JJ I-NP I-NP
and CC I-NP I-NP
rapid JJ I-NP I-NP
strategy NN I-NP I-NP
to TO B-VP B-VP
detect VB I-VP I-VP
the DT B-NP B-NP
precise JJ I-NP I-NP
number NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
CAGs NNS I-NP I-NP
. . O O

After IN B-SBAR B-PP
the DT B-NP B-NP
DNA NN I-NP I-NP
fragment NN I-NP I-NP
containing VBG B-VP B-VP
the DT B-NP B-NP
CAG NN I-NP I-NP
repeats NNS I-NP I-NP
is VBZ B-VP B-VP
amplified VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
polymerase NN I-NP I-NP
chain NN I-NP I-NP
reaction NN I-NP I-NP
, , O O
a DT B-NP B-NP
primer NN I-NP I-NP
extension NN I-NP I-NP
is VBZ B-VP B-VP
carried VBN I-VP I-VP
out RP B-PRT B-ADVP
; : O O
the DT B-NP B-NP
extension NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
end-labelled JJ I-NP I-NP
reverse JJ I-NP I-NP
primer NN I-NP I-NP
adjacent JJ B-ADJP B-ADJP
to TO B-PP B-PP
3' JJ B-NP B-NP
end NN I-NP I-NP
of IN B-PP B-PP
CAG NN B-NP B-NP
repeats NNS I-NP I-NP
stops VBZ B-VP B-VP
at IN B-PP B-PP
the DT B-NP B-NP
first JJ I-NP I-NP
T NN I-NP I-NP
after IN B-PP B-PP
CAG NN B-NP B-NP
repeats NNS I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
incorporation NN I-NP I-NP
of IN B-PP B-PP
dideoxy JJ B-NP B-NP
ATP NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
reaction NN I-NP I-NP
mixture NN I-NP I-NP
. . O O

The DT B-NP B-NP
resultant JJ I-NP I-NP
primer NN I-NP I-NP
products NNS I-NP I-NP
are VBP B-VP B-VP
analysed VBN I-VP I-VP
by IN B-PP B-PP
denaturing VBG B-VP B-VP
polyacrylamide NN B-NP B-NP
gel NN I-NP I-NP
electrophoresis NN I-NP I-NP
and CC O I-NP
autoradiography NN B-NP I-NP
. . O O

This DT B-NP B-NP
method NN I-NP I-NP
could MD B-VP B-VP
be VB I-VP I-VP
quite RB B-ADJP B-ADJP
useful JJ I-ADJP I-ADJP
to TO B-VP B-VP
detect VB I-VP I-VP
not RB B-CONJP B-ADVP
only RB I-CONJP I-ADVP
CAG NN B-NP B-NP
repeats NNS I-NP I-NP
in IN B-PP B-PP
SBMA NN B-NP B-NP
but CC B-CONJP I-CC
also RB I-CONJP B-NP
other JJ O I-NP
polymorphic JJ O I-NP
dinucleotide JJ B-NP I-NP
and CC O I-NP
trinucleotide JJ B-NP I-NP
repeats NNS B-NP I-NP
. . O O

Activity NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
enhancer NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
interleukin-2 NN I-NP I-NP
receptor NN I-NP I-NP
alpha NN I-NP I-NP
chain NN I-NP I-NP
in IN B-PP B-PP
somatic JJ B-NP B-NP
cell NN I-NP I-NP
hybrids NNS I-NP I-NP
is VBZ B-VP B-VP
accompanied VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
nuclear JJ I-NP I-NP
localization NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
. . O O

The DT B-NP B-NP
two CD I-NP I-NP
nuclear JJ I-NP I-NP
proteins NNS I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
( ( O O
consisting VBG B-VP B-VP
of IN B-PP B-PP
subunits NNS B-NP B-NP
p50 NN B-NP I-NP
and CC O I-NP
p65 NN B-NP I-NP
) ) O O
and CC O I-CC
the DT B-NP B-NP
DNA-binding JJ I-NP I-NP
subunit NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
( ( O O
p50 NN B-NP B-NP
) ) O O
by IN B-PP B-PP
itself PRP B-NP B-NP
, , O O
also RB B-VP B-ADVP
called VBN I-VP B-VP
KBF1 NN B-NP B-NP
, , O O
are VBP B-VP B-VP
constitutively RB I-VP I-VP
expressed VBN I-VP I-VP
and CC O I-CC
localized JJ B-VP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
nucleus NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
T-cell NN I-NP I-NP
line NN I-NP I-NP
IARC NN I-NP I-NP
301.5 CD I-NP I-NP
. . O O

In IN B-SBAR B-PP
order NN O B-NP
to TO O B-VP
define VB B-VP I-VP
the DT B-NP B-NP
roles NNS I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
two CD I-NP I-NP
factors NNS I-NP I-NP
, , O O
which WDT B-NP B-NP
bind VBP B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
same JJ I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
enhancers NNS I-NP I-NP
, , O O
in IN B-PP B-PP
transcription NN B-NP B-NP
activation NN I-NP I-NP
we PRP B-NP B-NP
have VBP B-VP B-VP
prepared VBN I-VP I-VP
somatic JJ B-NP B-NP
cell NN I-NP I-NP
hybrids NNS I-NP I-NP
between IN B-PP B-PP
IARC NN B-NP B-NP
301.5 CD I-NP I-NP
and CC O I-CC
a DT B-NP B-NP
murine JJ I-NP I-NP
myeloma NN I-NP I-NP
. . O O

Most JJS B-NP B-NP
hybrids NNS I-NP I-NP
express VBP B-VP I-NP
both CC O I-CC
KBF1 NN B-NP B-NP
and CC O I-NP
NF-kappa NN B-NP I-NP
B NN I-NP I-NP
in IN B-PP B-PP
their PRP$ B-NP B-NP
nuclei NNS I-NP I-NP
, , O O
but CC O I-CC
one CD B-NP B-NP
hybrid NN I-NP I-NP
expresses VBZ B-VP B-VP
only RB B-NP B-NP
KBF1 NN I-NP I-NP
. . O O

The DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
enhancer NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
gene NN I-NP I-NP
encoding VBG B-VP B-VP
the DT O B-NP
interleukin-2 NN B-NP I-NP
( ( O O
IL-2 NN B-NP I-NN
) ) O O
receptor NN B-NP B-NP
alpha NN I-NP I-NP
chain NN I-NP I-NP
( ( O O
IL-2R NN B-NP B-NP
alpha NN I-NP I-NP
) ) O O
is VBZ B-VP B-VP
functional JJ B-ADJP B-ADJP
only RB B-PP B-ADVP
in IN I-PP B-PP
the DT B-NP B-NP
hybrids NNS I-NP I-NP
expressing VBG B-VP B-VP
nuclear JJ B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
. . O O

These DT B-NP B-NP
findings NNS I-NP I-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
nuclear JJ B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
is VBZ B-VP B-VP
necessary JJ B-ADJP B-ADJP
to TO B-VP B-VP
activate VB I-VP I-VP
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
enhancer NN I-NP I-NP
, , O O
while IN B-SBAR B-SBAR
KBF1 NN B-NP B-NP
by IN B-PP B-SBAR
itself PRP B-NP B-NP
is VBZ B-VP B-VP
not RB O I-RB
sufficient JJ B-ADJP B-ADJP
. . O O

We PRP B-NP B-NP
propose VBP B-VP B-VP
that IN B-SBAR B-PP
KBF1 NN B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
competitive JJ I-NP I-NP
inhibitor NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
and CC O I-CC
discuss VB B-VP B-VP
how WRB B-ADVP B-ADVP
these DT B-NP B-NP
factors NNS I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
transient JJ I-NP I-NP
expression NN I-NP I-NP
of IN B-PP B-PP
IL-2 NN B-NP B-NP
and CC O I-NP
IL-2 NN B-NP I-NP
alpha NN I-NP I-NP
genes NNS B-NP I-NP
during IN B-PP B-PP
the DT B-NP B-NP
immune JJ I-NP I-NP
response NN I-NP I-NP
. . O O

Influence NN B-NP B-NP
of IN B-PP B-PP
estradiol NN B-NP B-NP
and CC O I-NP
tamoxifen NN B-NP I-NP
on IN B-PP B-PP
susceptibility NN B-NP B-NP
of IN B-PP B-PP
human JJ B-NP B-NP
breast NN I-NP I-NP
cancer NN I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
to TO B-PP B-PP
lysis NN B-NP B-NP
by IN B-PP B-PP
lymphokine-activated JJ B-NP B-NP
killer NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

The DT B-NP B-NP
design NN I-NP I-NP
of IN B-PP B-PP
combination NN B-NP B-NP
hormonal JJ I-NP I-NP
and CC I-NP I-NP
immunotherapeutic JJ I-NP I-NP
protocols NNS I-NP I-NP
for IN B-PP B-PP
breast NN B-NP B-NP
cancer NN I-NP I-NP
patients NNS I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
facilitated VBN I-VP I-VP
by IN B-PP B-PP
analysis NN B-NP B-NP
of IN B-PP B-PP
preclinical JJ B-NP B-NP
in FW I-NP B-VP
vitro FW I-NP B-NP
model JJ I-NP I-NP
systems NNS I-NP I-NP
. . O O

Estrogen NN O B-NP
receptor NN O I-NP
positive JJ O I-NP
( ( O O
ER+ JJ B-ADJP I-JJ
: : O O
MCF-7 NN B-NP B-NP
) ) O O
and CC O I-CC
negative JJ O B-NP
( ( O O
ER- JJ B-ADJP I-NP
: : O O
MDA-MB-231 NN B-NP B-NP
) ) O O
human JJ B-NP B-NP
breast NN I-NP I-NP
cancer NN I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
were VBD B-VP B-VP
utilized VBN I-VP I-VP
to TO B-VP B-VP
evaluate VB I-VP I-VP
the DT B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
tamoxifen NN B-NP B-NP
( ( O O
TAM NN B-NP B-NP
) ) O O
and CC O I-CC
estradiol NN B-NP B-NP
( ( O O
E2 NN B-NP I-NP
) ) O O
on IN B-PP B-PP
modulation NN B-NP B-NP
of IN B-PP B-PP
breast NN B-NP B-NP
cancer NN I-NP I-NP
target NN I-NP I-NP
susceptibility NN I-NP I-NP
to TO B-PP B-PP
lysis NN B-NP B-NP
by IN B-PP B-PP
lymphokine-activated JJ B-NP B-NP
killer NN I-NP I-NP
( ( O O
LAK NN B-NP B-NP
) ) O O
cells NNS B-NP I-NP
. . O O

E2-stimulated JJ B-NP B-NP
ER+ JJ I-NP I-NP
cells NNS I-NP I-NP
were VBD B-VP B-VP
more RBR B-ADJP B-ADJP
susceptible JJ I-ADJP I-ADJP
to TO B-PP B-PP
lysis NN B-NP B-NP
by IN B-PP B-PP
LAK NN B-NP B-NP
cells NNS I-NP I-NP
than IN B-PP B-PP
corresponding VBG O B-VP
TAM-treated JJ O B-NP
or CC O I-NP
control NN B-NP I-NP
cells NNS B-NP I-NP
, , O O
while IN B-SBAR B-SBAR
treatment NN B-NP B-NP
of IN B-PP B-PP
ER- JJ B-NP B-NP
cells NNS I-NP I-NP
with IN B-PP B-PP
either CC O I-CC
E2 NN B-NP B-NP
or CC O I-NP
TAM NN B-NP I-NP
alone RB B-ADVP B-ADVP
did VBD B-VP B-VP
not RB I-VP I-VP
alter VB I-VP I-VP
from IN B-PP B-PP
control NN B-NP B-NP
their PRP$ B-NP B-NP
susceptibility NN I-NP I-NP
to TO B-PP B-PP
this DT B-NP B-NP
immune-mediated JJ I-NP I-NP
lysis NN I-NP I-NP
. . O O

All DT B-NP B-NP
ER+ JJ I-NP I-NP
and CC I-NP I-NP
ER- JJ I-NP I-NP
cells NNS I-NP I-NP
tested VBN B-VP B-VP
remained VBD B-VP B-VP
sensitive JJ B-ADJP B-ADJP
after IN B-PP B-PP
treatment NN B-NP B-NP
with IN B-PP B-PP
TAM NN B-NP B-NP
to TO B-PP B-PP
lysis NN B-NP B-NP
by IN B-PP B-PP
LAK NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
an DT O B-NP
adenocarcinoma NN B-NP I-NP
reactive JJ O I-NP
human-mouse JJ B-ADJP I-NP
chimeric JJ I-ADJP I-NP
monoclonal JJ B-NP I-NP
antibody NN I-NP I-NP
( ( O O
ING-1 NN B-NP B-NP
) ) O O
was VBD B-VP B-VP
able JJ B-ADJP B-ADJP
to TO B-VP B-VP
significantly RB I-VP I-VP
boost VB I-VP I-VP
in FW B-ADVP B-NP
vivo FW I-ADVP I-NP
generated VBN B-NP I-NP
LAK NN I-NP I-NP
cell-mediated JJ I-NP I-NP
lysis NN I-NP I-NP
of IN B-PP B-PP
control NN B-NP B-NP
, , O O
E2-treated JJ B-ADJP B-NP
, , O O
and CC O I-CC
TAM-treated JJ B-ADJP B-NP
ER+ JJ B-ADJP I-NP
and CC O I-NP
ER- JJ B-ADJP I-NP
cells NNS B-NP I-NP
. . O O

These DT B-NP B-NP
in FW I-NP B-VP
vitro FW I-NP B-NP
results NNS I-NP I-NP
provide VBP B-VP B-VP
a DT B-NP B-NP
preclinical JJ I-NP I-NP
rationale NN I-NP I-NP
for IN B-PP B-PP
in FW B-NP B-NP
vivo FW I-NP I-NP
testing NN I-NP I-NP
of IN B-PP B-PP
TAM NN B-NP B-NP
, , O O
interleukin-2 NN B-NP B-NP
( ( O O
IL-2 NN B-NP B-NP
) ) O O
, , O O
and CC O I-CC
breast NN B-NP B-NP
cancer NN I-NP I-NP
reactive JJ I-NP I-NP
antibody-dependent JJ I-NP I-NP
cellular JJ I-NP I-NP
cytotoxicity NN I-NP I-NP
facilitating VBG B-VP I-NP
antibody NN B-NP I-NP
in IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
refractory JJ O B-NP
or CC O I-NP
high JJ B-NP I-NP
risk NN I-NP I-NP
breast NN B-NP I-NP
cancer NN I-NP I-NP
. . O O

Glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
and CC O I-NP
inhibition NN B-NP I-NP
of IN B-PP B-PP
3-O-methyl-D-glucose NN B-NP B-NP
uptake NN I-NP I-NP
by IN B-PP B-PP
glucocorticoids NNS B-NP B-NP
in IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
leukocytes NNS I-NP I-NP
from IN B-PP B-PP
normal JJ B-NP B-NP
humans NNS I-NP I-NP
: : O O
correlation NN B-NP B-NP
between IN B-PP B-PP
receptor NN B-NP B-NP
level NN I-NP I-NP
and CC O I-NP
hormone NN B-NP I-NP
effect NN I-NP I-NP
in FW B-ADVP B-NP
vitro FW I-ADVP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
measured VBN I-VP I-VP
the DT B-NP B-NP
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
concentration NN I-NP I-NP
in IN B-PP B-PP
mononuclear JJ B-NP B-NP
and CC I-NP I-NP
polymorphonuclear JJ I-NP I-NP
leukocytes NNS I-NP I-NP
, , O O
both DT B-NP B-NP
of IN B-PP B-PP
which WDT B-NP B-NP
were VBD B-VP B-VP
isolated VBN I-VP I-VP
from IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
from IN B-PP B-PP
ten CD B-NP B-NP
healthy JJ I-NP I-NP
male JJ I-NP I-NP
volunteers NNS I-NP I-NP
. . O O

In IN B-PP B-PP
parallel NN B-NP B-NP
, , O O
the DT B-NP B-NP
inhibitory JJ I-NP I-NP
effect NN I-NP I-NP
of IN B-PP B-PP
dexamethasone NN B-NP B-NP
on IN B-PP B-PP
3-O-methyl-D-glucose NN B-NP B-NP
uptake NN I-NP I-NP
was VBD B-VP B-VP
assayed VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
corresponding JJ I-NP I-NP
mononuclear JJ I-NP I-NP
leukocytes NNS I-NP I-NP
. . O O

The DT B-NP B-NP
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
levels NNS I-NP I-NP
in IN B-PP B-PP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
correlated VBD B-VP B-VP
with IN B-PP B-PP
those DT B-NP B-NP
in IN B-PP B-PP
polymorphonuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
, , O O
and CC O I-CC
there EX B-NP B-NP
was VBD B-VP B-VP
a DT B-NP B-NP
linear JJ I-NP I-NP
relationship NN I-NP I-NP
between IN B-PP B-PP
the DT B-NP B-NP
cellular JJ I-NP I-NP
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
levels NNS I-NP I-NP
and CC O I-CC
glucocorticoid-mediated JJ B-NP B-NP
inhibition NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
uptake NN I-NP I-NP
of IN B-PP B-PP
3-O-methyl-D-glucose NN B-NP B-NP
in IN B-PP B-PP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
. . O O

When WRB B-ADVP B-ADVP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
were VBD B-VP B-VP
incubated VBN I-VP I-VP
in IN B-PP B-PP
the DT I-PP B-NP
presence NN I-PP I-NP
of IN I-PP B-PP
8-bromo-cAMP NN B-NP B-NP
, , O O
cellular JJ B-NP B-NP
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
levels NNS I-NP I-NP
increased VBD B-VP B-VP
and CC O I-CC
a DT B-NP B-NP
more RBR I-NP I-NP
pronounced JJ I-NP I-NP
inhibitory JJ I-NP I-NP
effect NN I-NP I-NP
of IN B-PP B-PP
dexamethasone NN B-NP B-NP
was VBD B-VP B-VP
observed VBN I-VP I-VP
on IN B-PP B-PP
the DT B-NP B-NP
transport NN I-NP I-NP
of IN B-PP B-PP
3-O-methyl-D-glucose NN B-NP B-NP
. . O O

We PRP B-NP B-NP
conclude VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
cellular JJ I-NP I-NP
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
levels NNS I-NP I-NP
in IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
leukocytes NNS I-NP I-NP
reflect VBP B-VP B-VP
in FW B-NP B-NP
vitro FW I-NP I-NP
responsiveness NN I-NP I-NP
to TO B-PP B-PP
glucocorticoids NNS B-NP B-NP
in IN B-PP B-PP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
from IN B-PP B-PP
healthy JJ B-NP B-NP
males NNS I-NP I-NP
, , O O
and CC O I-CC
that IN B-SBAR B-SBAR
the DT B-NP B-NP
individual JJ I-NP I-NP
responsiveness NN I-NP I-NP
may MD B-VP B-VP
alter VB I-VP I-VP
upon IN B-PP B-PP
changes NNS B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
cellular JJ I-NP I-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
. . O O

Stimulation NN B-NP B-NP
of IN B-PP B-PP
interferon NN B-NP B-NP
beta NN I-NP I-NP
gene NN I-NP I-NP
transcription NN I-NP I-NP
in FW B-ADVP B-NP
vitro FW I-ADVP I-NP
by IN B-PP B-PP
purified VBN B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
and CC O I-CC
a DT B-NP B-NP
novel JJ I-NP I-NP
TH NN I-NP I-NP
protein NN I-NP I-NP
. . O O

The DT O B-NP
human JJ O I-NP
interferon NN B-NP I-NP
beta NN I-NP I-NP
( ( O O
IFN-beta NN B-NP B-NP
) ) O O
regulatory JJ B-NP B-NP
element NN I-NP I-NP
consists VBZ B-VP B-VP
of IN B-PP B-PP
multiple JJ B-NP B-NP
enhanson NN I-NP I-NP
domains NNS I-NP I-NP
which WDT B-NP B-NP
are VBP B-VP B-VP
targets NNS B-NP B-NP
for IN B-PP B-PP
transcription NN B-NP B-NP
factors NNS I-NP I-NP
involved VBN B-VP B-VP
in IN B-PP B-PP
inducible JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
promoter NN I-NP I-NP
. . O O

To TO B-VP B-VP
further RB I-VP I-VP
characterize VB I-VP I-VP
the DT B-NP B-NP
protein-DNA JJ I-NP I-NP
interactions NNS I-NP I-NP
mediating VBG B-VP B-VP
IFN-beta NN B-NP B-NP
induction NN I-NP I-NP
, , O O
positive JJ B-NP B-NP
regulatory JJ I-NP I-NP
domain NN I-NP I-NP
( ( O O
PRD NN B-NP B-NP
) ) O O
II CD B-NP B-NP
binding NN I-NP I-NP
proteins NNS I-NP I-NP
were VBD B-VP B-VP
purified VBN I-VP I-VP
from IN B-PP B-PP
phorbol NN B-NP B-NP
ester NN I-NP I-NP
induced JJ B-NP I-NP
Jurkat NN I-NP I-NP
T-cells NNS I-NP I-NP
and CC B-PP I-CC
from IN B-PP B-PP
IFN NN B-NP B-NP
primed VBN B-ADJP B-VP
, , O O
cycloheximide/polyinosinic-polycytidylic JJ B-NP B-NP
acid NN I-NP I-NP
treated VBN B-ADJP I-NP
HeLa NN O I-NP
S3 NN O I-NP
cells NNS O I-NP
. . O O

From IN B-PP B-PP
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
two CD B-NP B-NP
major JJ I-NP I-NP
proteins NNS I-NP I-NP
of IN B-PP B-PP
52 CD B-NP B-NP
and CC O I-NP
45 CD B-NP I-NP
kilodaltons NNS B-NP I-NP
( ( O O
kD NN B-NP B-NP
) ) O O
copurified VBD B-VP B-VP
with IN B-PP B-PP
DNA NN B-NP B-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
, , O O
whereas IN O B-PP
from IN B-PP B-PP
T-cells NNS B-NP B-NP
, , O O
four CD B-NP B-NP
proteins NNS I-NP I-NP
-- : O O
a DT B-NP B-NP
major JJ I-NP I-NP
protein NN I-NP I-NP
of IN B-PP B-PP
52 CD B-NP B-NP
kD NN I-NP I-NP
and CC O I-CC
three CD B-NP B-NP
minor JJ I-NP I-NP
proteins NNS I-NP I-NP
of IN B-PP B-PP
82 CD B-NP B-NP
, , I-NP O
67 CD I-NP I-NP
, , I-NP O
and CC I-NP I-CC
43-47 CD I-NP B-NP
kD NN I-NP I-NP
-- : O O
were VBD B-VP B-VP
purified VBN I-VP I-VP
. . O O

Also RB B-ADVP B-ADVP
, , O O
an DT O B-NP
induction NN B-NP I-NP
specific JJ B-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
protein NN I-NP I-NP
was VBD B-VP B-VP
purified VBN I-VP I-VP
from IN B-PP B-PP
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
that WDT B-NP B-NP
interacted VBD B-VP B-VP
with IN B-PP B-PP
the DT B-NP B-NP
( ( I-NP O
AAGTGA NN I-NP I-NP
) ) I-NP O
4 CD I-NP B-NP
tetrahexamer NN I-NP I-NP
sequence NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
PRDI NN I-NP I-NP
domain NN I-NP I-NP
. . O O

This DT B-NP B-NP
protein NN I-NP I-NP
is VBZ B-VP B-VP
immunologically RB B-ADJP B-ADJP
distinct JJ I-ADJP I-ADJP
from IN B-PP B-PP
IRF-1/ISGF2 NN B-NP B-NP
. . O O

Uninduced JJ O B-NP
or CC O I-NP
Sendai NN B-NP I-NP
virus NN I-NP I-NP
induced JJ B-NP I-NP
HeLa NN I-NP I-NP
extracts NNS I-NP I-NP
were VBD B-VP B-VP
used VBN I-VP I-VP
to TO B-VP B-VP
examine VB I-VP I-VP
transcription NN B-NP B-NP
in FW B-ADVP B-NP
vitro FW I-ADVP I-NP
using VBG B-VP B-VP
a DT B-NP B-NP
series NN I-NP I-NP
of IN B-PP B-PP
IFN NN B-NP B-NP
beta NN I-NP I-NP
promoter NN I-NP I-NP
deletions NNS I-NP I-NP
. . O O

Deletions NNS B-NP B-NP
upstream JJ B-ADJP B-ADJP
of IN B-PP B-PP
the DT B-NP B-NP
PRDII NN I-NP I-NP
element NN I-NP I-NP
increased VBD B-VP B-VP
transcription NN B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
uninduced JJ I-NP I-NP
extract NN I-NP I-NP
, , O O
indicating VBG B-VP B-VP
predominantly RB B-NP B-NP
negative JJ I-NP I-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
promoter NN I-NP I-NP
. . O O

A DT B-NP B-NP
2-4-fold JJ I-NP I-NP
increase NN I-NP I-NP
in IN B-PP B-PP
IFN-beta NN B-NP B-NP
promoter NN I-NP I-NP
transcription NN I-NP I-NP
was VBD B-VP B-VP
observed VBN I-VP I-VP
in IN B-PP B-PP
Sendai NN B-NP B-NP
virus NN I-NP I-NP
induced JJ B-NP I-NP
extracts NNS I-NP I-NP
, , O O
and CC O I-CC
deletion NN B-NP B-NP
of IN B-PP B-PP
PRDI NN B-NP B-NP
and CC O I-NP
PRDII NN B-NP I-NP
elements NNS B-NP I-NP
decreased VBD B-VP B-VP
this DT B-NP B-NP
induced VBN I-NP I-NP
level NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
. . O O

When WRB B-ADVP B-ADVP
purified VBN B-NP B-NP
PRDII NN I-NP I-NP
and CC O I-NP
tetrahexamer NN B-NP I-NP
binding NN I-NP I-NP
proteins NNS I-NP I-NP
were VBD B-VP B-VP
added VBN I-VP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
induced VBN I-NP I-NP
extract NN I-NP I-NP
, , O O
a DT B-NP B-NP
4-fold JJ I-NP I-NP
increase NN I-NP I-NP
in IN B-PP B-PP
transcription NN B-NP B-NP
was VBD B-VP B-VP
observed VBN I-VP I-VP
. . O O

These DT B-NP B-NP
experiments NNS I-NP I-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-SBAR
it PRP B-NP B-NP
is VBZ B-VP B-VP
possible JJ B-ADJP B-ADJP
to TO B-VP B-VP
modulate VB I-VP I-VP
IFN-beta NN B-NP B-NP
transcription NN I-NP I-NP
in FW B-ADVP B-NP
vitro FW I-ADVP I-NP
but CC O I-CC
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
additional JJ B-NP B-NP
proteins NNS I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
required VBN I-VP I-VP
to TO I-VP B-VP
fully RB I-VP I-VP
activate VB I-VP I-VP
IFN-beta NN B-NP B-NP
transcription NN I-NP I-NP
. . O O

Structure NN B-NP B-NP
function NN I-NP I-NP
analysis NN I-NP I-NP
of IN B-PP B-PP
vitamin NN B-NP B-NP
D NN I-NP I-NP
analogs NNS I-NP I-NP
with IN B-PP B-PP
C-ring NN B-NP B-NP
modifications NNS I-NP I-NP
. . O O

Analogs NNS B-NP B-NP
of IN B-PP B-PP
1 CD B-NP B-NP
alpha,25-dihydroxyvitamin NN I-NP I-NP
D3 NN I-NP I-NP
( ( O O
1 CD B-NP B-NP
alpha,25-(OH) NN I-NP I-NP
2D3 NN I-NP I-NP
) ) O O
with IN B-PP B-PP
substitutions NNS B-NP B-NP
on IN B-PP B-PP
C-11 NN B-NP B-NP
were VBD B-VP B-VP
synthesized VBN I-VP I-VP
. . O O

Small JJ B-NP B-NP
apolar JJ I-NP I-NP
substitutions NNS I-NP I-NP
( ( O O
11 CD B-NP B-NP
alpha-methyl NN I-NP I-NP
, , O O
11 CD B-NP B-NP
alpha-fluoromethyl NN I-NP I-NP
) ) O O
did VBD B-VP B-VP
not RB I-VP I-VP
markedly RB I-VP I-VP
decrease VB I-VP I-VP
the DT B-NP B-NP
affinity NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
vitamin NN I-NP I-NP
D NN I-NP I-NP
receptor NN I-NP I-NP
, , O O
but CC O I-CC
larger JJR O B-NP
( ( O O
11 CD B-NP I-NP
alpha-chloromethyl NN I-NP I-NP
or CC O I-CC
11 CD B-NP B-NP
alpha- NN I-NP I-NP
or CC B-NP I-CC
11 CD I-NP B-NP
beta-phenyl NN I-NP I-NP
) ) O O
or CC B-NP I-CC
more RBR I-NP B-NP
polar JJ I-NP I-NP
substitutions NNS I-NP I-NP
( ( O O
11 CD B-NP B-NP
alpha-hydroxymethyl NN I-NP I-NP
, , O O
11 CD B-NP B-NP
alpha-(2-hydroxyethyl NN I-NP I-NP
) ) O O
decreased VBD B-VP B-VP
the DT B-NP B-NP
affinity NN I-NP I-NP
to TO B-PP B-PP
less JJR B-NP B-NP
than IN I-NP I-NP
5 CD I-NP I-NP
% NN I-NP I-NP
of IN B-PP B-PP
that DT B-NP B-NP
of IN B-PP B-PP
1 CD B-NP B-NP
alpha,25-OH)2D3 NN I-NP I-NP
. . O O

Their PRP$ B-NP B-NP
affinity NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
vitamin NN I-NP I-NP
D-binding JJ I-NP I-NP
protein NN I-NP I-NP
, , O O
however RB B-ADVP B-ADVP
, , O O
increased VBD B-VP B-VP
up RB B-ADVP B-ADVP
to TO I-ADVP B-PP
4-fold RB I-ADVP B-NP
. . O O

The DT B-NP B-NP
biological JJ I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
11 CD B-NP B-NP
alpha-methyl-1 NN I-NP I-NP
alpha,25-(OH)2D3 NN I-NP I-NP
closely RB B-ADVP B-ADVP
resembled VBD B-VP B-VP
that DT B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
natural JJ I-NP I-NP
hormone NN I-NP I-NP
on IN B-PP B-PP
normal JJ B-NP B-NP
and CC I-NP I-NP
leukemic JJ I-NP I-NP
cell NN B-NP I-NP
proliferation NN I-NP I-NP
and CC O I-NP
bone NN B-NP I-NP
resorption NN I-NP I-NP
, , O O
whereas IN O B-PP
its PRP$ B-NP B-NP
in FW I-NP B-PP
vivo FW I-NP B-NP
effect NN I-NP I-NP
on IN B-PP B-PP
calcium NN B-NP B-NP
metabolism NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
rachitic JJ I-NP I-NP
chick NN I-NP I-NP
was VBD B-VP B-VP
about IN B-NP B-NP
50 CD I-NP I-NP
% NN I-NP I-NP
of IN B-PP B-PP
that DT B-NP B-NP
of IN B-PP B-PP
1 CD B-NP B-NP
alpha,25-(OH)2D3 NN I-NP I-NP
. . O O

The DT B-NP B-NP
11 CD I-NP I-NP
beta-methyl NN I-NP I-NP
analog NN I-NP I-NP
had VBD B-VP B-VP
a DT O B-NP
greater JJR B-ADVP I-NP
than IN I-ADVP B-PP
10-fold RB I-ADVP B-NP
lower JJR B-NP I-NP
activity NN I-NP I-NP
. . O O

The DT B-NP B-NP
differentiating JJ I-NP I-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
other JJ I-NP I-NP
C-11 NN I-NP I-NP
analogs NNS I-NP I-NP
on IN B-PP B-PP
human JJ B-NP B-NP
promyeloid JJ I-NP I-NP
leukemia NN I-NP I-NP
cells NNS I-NP I-NP
( ( O O
HL-60 NN B-NP B-NP
) ) O O
agreed VBD B-VP B-VP
well RB B-ADVP B-ADVP
with IN B-PP B-PP
their PRP$ B-NP B-NP
bone-resorbing JJ B-NP I-NP
activity NN I-NP I-NP
and CC O I-NP
receptor NN B-NP I-NP
affinity NN I-NP I-NP
, , O O
but CC O I-CC
they PRP B-NP B-NP
demonstrated VBD B-VP B-VP
lower JJR B-NP B-NP
calcemic JJ I-NP I-NP
effects NNS I-NP I-NP
in FW B-ADVP B-VP
vivo FW I-ADVP B-NP
. . O O

Large JJ B-NP B-NP
or CC I-NP I-NP
polar JJ I-NP I-NP
substitutions NNS I-NP I-NP
on IN B-PP B-PP
C-11 NN B-NP B-NP
of IN B-PP B-PP
1 CD B-NP B-NP
alpha,25-(OH)2D3 NN I-NP I-NP
thus RB B-ADVP B-ADVP
impair VBP B-VP B-VP
the DT B-NP B-NP
binding NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
vitamin NN I-NP I-NP
D NN I-NP I-NP
receptor NN I-NP I-NP
but CC O I-CC
increase VBP B-VP B-VP
the DT B-NP B-NP
affinity NN I-NP I-NP
to TO B-PP B-PP
vitamin NN B-NP B-NP
D-binding JJ I-NP I-NP
protein NN I-NP I-NP
. . O O

The DT B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
many JJ B-NP B-NP
C-11-substituted JJ I-NP I-NP
1 CD I-NP I-NP
alpha,25-(OH)2D3 NN I-NP I-NP
analogs NNS I-NP I-NP
on IN B-PP B-PP
HL-60 NN B-NP B-NP
cell NN I-NP I-NP
differentiation NN I-NP I-NP
exceeded VBD B-VP B-VP
their PRP$ B-NP B-NP
activity NN I-NP I-NP
on IN B-PP B-PP
calcium NN B-NP B-NP
metabolism NN I-NP I-NP
. . O O

Transcriptional JJ B-NP B-NP
regulation NN I-NP I-NP
during IN B-PP B-PP
T-cell NN B-NP B-NP
development NN I-NP I-NP
: : O O
the DT B-NP B-NP
alpha NN I-NP I-NP
TCR NN I-NP I-NP
gene NN I-NP I-NP
as IN B-PP B-PP
a DT B-NP B-NP
molecular JJ I-NP I-NP
model NN I-NP I-NP
. . O O

The DT B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
gene NN B-NP B-NP
expression NN I-NP I-NP
during IN B-PP B-PP
lymphocyte NN B-NP B-NP
differentiation NN I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
complex JJ I-NP I-NP
process NN I-NP I-NP
involving VBG B-VP B-VP
interactions NNS B-NP B-NP
between IN B-PP B-PP
multiple JJ B-NP B-NP
positive JJ I-NP I-NP
and CC I-NP I-NP
negative JJ I-NP I-NP
transcriptional JJ I-NP I-NP
regulatory JJ I-NP I-NP
elements NNS I-NP I-NP
. . O O

In IN B-PP B-PP
this DT B-NP B-NP
article NN I-NP I-NP
, , O O
transcriptional JJ B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
archetypal JJ I-NP I-NP
T-cell-specific JJ I-NP I-NP
gene NN I-NP I-NP
, , O O
alpha NN B-NP B-NP
TCR NN I-NP I-NP
, , O O
is VBZ B-VP B-VP
discussed VBN I-VP I-VP
. . O O

Major JJ B-NP B-NP
recent JJ I-NP I-NP
developments NNS I-NP I-NP
, , O O
including VBG B-PP B-PP
the DT B-NP B-NP
identification NN I-NP I-NP
of IN B-PP B-PP
novel JJ B-NP B-NP
families NNS I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
factors NNS I-NP I-NP
that WDT B-NP B-NP
regulate VBP B-VP B-VP
multiple JJ B-NP B-NP
T-cell NN I-NP I-NP
genes NNS I-NP I-NP
during IN B-PP B-PP
thymocyte NN B-NP B-NP
ontogeny NN I-NP I-NP
and CC O I-NP
T-cell NN B-NP I-NP
activation NN I-NP I-NP
, , O O
are VBP B-VP B-VP
described VBN I-VP I-VP
. . O O

Cortisol NN B-NP B-NP
resistance NN I-NP I-NP
in IN B-PP B-PP
acquired VBN B-NP B-NP
immunodeficiency NN I-NP I-NP
syndrome NN I-NP I-NP
. . O O

This DT B-NP B-NP
study NN I-NP I-NP
concerns VBZ B-VP B-VP
9 CD B-NP B-NP
iv NN I-NP I-NP
drug NN I-NP I-NP
abusers NNS I-NP I-NP
with IN B-PP B-PP
acquired VBN B-NP B-NP
immunodeficiency NN I-NP I-NP
syndrome NN I-NP I-NP
( ( O O
AIDS NN B-NP B-NP
) ) O O
who WP B-NP B-NP
developed VBD B-VP B-VP
hypercortisolism NN B-NP B-NP
without IN B-PP B-PP
the DT B-NP B-NP
clinical JJ B-NP I-NP
signs NNS I-NP I-NP
or CC O I-CC
metabolic JJ B-NP B-NP
consequences NNS I-NP I-NP
of IN B-PP B-PP
hypercortisolism NN B-NP B-NP
. . O O

All DT B-NP B-NP
patients NNS I-NP I-NP
were VBD B-VP B-VP
characterized VBN I-VP I-VP
by IN B-PP B-PP
an DT B-NP B-NP
Addisonian JJ I-NP I-NP
picture NN I-NP I-NP
( ( O O
weakness NN B-NP B-NP
, , O O
weight NN B-NP B-NP
loss NN I-NP I-NP
, , O O
hypotension NN B-NP B-NP
, , O O
hyponatremia NN B-NP B-NP
, , O O
and CC O I-CC
intense JJ B-NP B-NP
mucocutaneous JJ I-NP I-NP
melanosis NN I-NP I-NP
) ) O O
. . O O

An DT B-NP B-NP
acquired JJ I-NP I-NP
form NN I-NP I-NP
of IN B-PP B-PP
peripheral JJ B-NP B-NP
resistance NN I-NP I-NP
to TO B-PP B-PP
glucocorticoids NNS B-NP B-NP
was VBD B-VP B-VP
suspected VBN I-VP I-VP
. . O O

We PRP B-NP B-NP
, , O O
therefore RB B-ADVP B-ADVP
, , O O
examined VBD B-VP B-VP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
characteristics NNS I-NP I-NP
on IN B-PP B-PP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
by IN B-PP B-PP
measuring VBG B-VP B-VP
(3H)dexamethasone NN B-NP B-NP
binding NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
effect NN I-NP I-NP
of IN B-PP B-PP
dexamethasone NN B-NP B-NP
on IN B-PP B-PP
(3H)thymidine NN B-NP B-NP
incorporation NN I-NP I-NP
, , O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
one CD B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
activation NN I-NP I-NP
. . O O

Glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
density NN I-NP I-NP
was VBD B-VP B-VP
increased VBN I-VP I-VP
in IN B-PP B-PP
AIDS NN B-NP B-NP
patients NNS I-NP I-NP
with IN B-PP B-PP
an DT B-NP B-NP
Addisonian JJ I-NP I-NP
picture NN I-NP I-NP
( ( O O
group NN B-NP B-NP
1 CD I-NP I-NP
; : O O
16.2 CD B-NP B-NP
+/- CC I-NP I-NP
9.4 CD I-NP I-NP
fmol/million NN I-NP I-NP
cells NNS I-NP I-NP
) ) O O
compared VBN B-VP B-VP
to TO B-PP B-PP
values NNS B-NP B-NP
in IN B-PP B-PP
12 CD B-NP B-NP
AIDS NN I-NP I-NP
patients NNS I-NP I-NP
without IN B-PP B-PP
an DT B-NP B-NP
Addisonian JJ I-NP I-NP
picture NN I-NP I-NP
( ( O O
group NN B-NP B-NP
2 CD I-NP I-NP
; : O O
6.05 CD B-NP B-NP
+/- CC I-NP I-CC
2.6 CD I-NP B-NP
fmol/million NN I-NP I-NP
cells NNS I-NP I-NP
; : O O
P NN B-NP B-NP
less JJR B-NP B-NP
than IN I-NP I-NP
0.01 CD I-NP I-NP
) ) O O
and CC O I-CC
sex- NN B-NP B-NP
and CC O I-NP
age-matched JJ B-ADJP I-NP
controls NNS B-NP I-NP
( ( O O
3.15 CD B-NP B-NP
+/- CC I-NP I-CC
2.3 CD I-NP B-NP
fmol/million NN I-NP I-NP
cells NNS I-NP I-NP
; : O O
P NN B-NP B-NP
less JJR B-NP B-NP
than IN I-NP I-NP
0.01 CD I-NP I-NP
) ) O O
. . O O

The DT B-NP B-NP
affinity NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
( ( O O
Kd NN B-NP B-NP
) ) O O
was VBD B-VP B-VP
strikingly RB I-VP I-VP
decreased VBN I-VP I-VP
( ( O O
9.36 CD B-NP B-NP
+/- CC I-NP I-CC
3.44 CD I-NP B-NP
nM NN I-NP I-NP
in IN B-PP B-PP
group NN B-NP B-NP
1 CD I-NP I-NP
; : O O
3.2 CD B-NP B-NP
+/- CC I-NP I-CC
1.5 CD I-NP B-NP
nM NN I-NP I-NP
in IN B-PP B-PP
group NN B-NP B-NP
2 CD I-NP I-NP
; : O O
2.0 CD B-NP B-NP
+/- CC I-NP I-CC
0.8 CD I-NP B-NP
nM NN I-NP I-NP
in IN B-PP B-PP
controls NNS B-NP B-NP
; : O O
P NN B-NP B-NP
less JJR B-NP B-NP
than IN I-NP I-NP
0.01 CD I-NP I-NP
) ) O O
. . O O

(3H)Thymidine NN B-NP B-NP
incorporation NN I-NP I-NP
was VBD B-VP B-VP
decreased VBN I-VP I-VP
dose-dependently RB B-ADVP B-ADVP
by IN B-PP B-PP
dexamethasone NN B-NP B-NP
in IN B-PP B-PP
controls NNS B-NP B-NP
and CC O I-NP
patients NNS B-NP I-NP
; : O O
the DT B-NP B-NP
effect NN I-NP I-NP
was VBD B-VP B-VP
significantly RB I-VP I-VP
blunted VBN I-VP I-VP
( ( O O
P NN B-NP I-NP
less JJR B-NP B-ADJP
than IN I-NP B-PP
0.05 CD I-NP B-NP
) ) O O
in IN B-PP B-PP
group NN B-NP B-NP
1 CD I-NP I-NP
patients NNS I-NP I-NP
, , O O
which WDT B-NP B-NP
suggests VBZ B-VP B-VP
that IN B-SBAR B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
is VBZ B-VP B-VP
impaired JJ B-ADJP B-ADJP
as IN B-PP B-PP
a DT B-NP B-NP
result NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
abnormality NN I-NP I-NP
. . O O

In IN B-PP B-PP
conclusion NN B-NP B-NP
, , O O
AIDS NN B-NP B-NP
patients NNS I-NP I-NP
with IN B-PP B-PP
hypercortisolism NN B-NP B-NP
and CC O I-CC
clinical JJ B-NP B-NP
features NNS I-NP I-NP
of IN B-PP B-PP
peripheral JJ B-NP B-NP
resistance NN I-NP I-NP
to TO B-PP B-PP
glucocorticoids NNS B-NP B-NP
are VBP B-VP B-VP
characterized VBN I-VP I-VP
by IN B-PP B-PP
abnormal JJ B-NP B-NP
glucocorticoid NN I-NP I-NP
receptors NNS I-NP I-NP
on IN B-PP B-PP
lymphocytes NNS B-NP B-NP
. . O O

Resistance NN B-NP B-NP
to TO B-PP B-PP
glucocorticoids NNS B-NP B-NP
implies VBZ B-VP B-VP
a DT B-NP B-NP
complex JJ I-NP I-NP
change NN I-NP I-NP
in IN B-PP B-PP
immune-endocrine JJ B-NP B-NP
function NN I-NP I-NP
, , O O
which WDT B-NP B-NP
may MD B-VP B-VP
be VB I-VP I-VP
important JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
course NN I-NP I-NP
of IN B-PP B-PP
immunodeficiency NN B-NP B-NP
syndrome NN I-NP I-NP
. . O O

Induction NN B-NP B-NP
of IN B-PP B-PP
monocytic JJ B-NP B-NP
differentiation NN I-NP I-NP
and CC O I-NP
NF-kappa NN B-NP I-NP
B-like JJ I-NP I-NP
activities NNS I-NP I-NP
by IN B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
1 CD I-NP B-NP
infection NN I-NP I-NP
of IN B-PP B-PP
myelomonoblastic JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

The DT B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
1 CD I-NP I-NP
( ( O O
HIV-1 NN B-NP I-NN
) ) O O
infection NN B-NP B-NP
on IN B-PP B-PP
cellular JJ B-NP B-NP
differentiation NN I-NP I-NP
and CC O I-NP
NF-kappa NN B-NP I-NP
B NN I-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
investigated VBN I-VP I-VP
in IN B-PP B-PP
a DT B-NP B-NP
new JJ I-NP I-NP
model NN I-NP I-NP
of IN B-PP B-PP
myeloid JJ B-NP B-NP
differentiation NN I-NP I-NP
. . O O

PLB-985 NN B-NP B-NP
cells NNS I-NP I-NP
represent VBP B-VP B-VP
a DT B-NP B-NP
bipotential JJ I-NP I-NP
myelomonoblastic JJ I-NP I-NP
cell NN I-NP I-NP
population NN I-NP I-NP
capable JJ B-ADJP I-NP
of IN B-PP B-PP
either CC B-NP I-CC
granulocytic JJ I-NP B-NP
or CC I-NP I-NP
monocytic JJ I-NP I-NP
differentiation NN I-NP I-NP
after IN B-PP B-PP
induction NN B-NP B-NP
with IN B-PP B-PP
appropriate JJ B-NP B-NP
inducers NNS I-NP I-NP
. . O O

By IN B-PP B-PP
virtue NN I-PP B-NP
of IN I-PP B-PP
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
CD4 NN B-NP B-NP
on IN B-PP B-PP
the DT B-NP B-NP
cell NN I-NP I-NP
surface NN I-NP I-NP
, , O O
PLB-985 NN B-NP B-NP
cells NNS I-NP I-NP
were VBD B-VP B-VP
chronically RB I-VP I-VP
infected VBN I-VP I-VP
with IN B-PP B-PP
HIV-1 NN B-NP B-NP
strain NN I-NP I-NP
IIIB NN I-NP I-NP
. . O O

PLB-IIIB NN B-NP B-NP
cells NNS I-NP I-NP
clearly RB B-ADVP B-ADVP
possessed VBD B-VP B-VP
a DT B-NP B-NP
more RBR I-NP I-NP
monocytic JJ I-NP I-NP
phenotype NN I-NP I-NP
than IN B-PP B-PP
the DT B-NP B-NP
parental JJ I-NP I-NP
myeloblasts NNS I-NP I-NP
, , O O
as IN B-SBAR B-SBAR
determined VBN B-VP B-VP
by IN B-PP B-PP
differential JJ B-NP B-NP
staining NN I-NP I-NP
, , O O
increased VBN B-NP B-VP
expression NN I-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
myeloid-specific JJ I-NP I-NP
surface NN I-NP I-NP
markers NNS I-NP I-NP
, , O O
and CC O I-CC
transcription NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
c-fms NN I-NP I-NP
proto-oncogene NN I-NP I-NP
. . O O

NF-kappa NN B-NP B-NP
B NN I-NP I-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
was VBD B-VP B-VP
inducible JJ B-ADJP B-ADJP
by IN B-PP B-PP
tumor NN B-NP B-NP
necrosis NN I-NP I-NP
factor NN I-NP I-NP
and CC O I-NP
phorbol NN B-NP I-NP
myristate NN I-NP I-NP
acetate NN I-NP I-NP
in IN B-PP B-PP
PLB-985 NN B-NP B-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
in IN B-PP B-PP
PLB-IIIB NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
constitutive JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
novel JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
complex NN I-NP I-NP
was VBD B-VP B-VP
detected VBN I-VP I-VP
, , O O
composed VBN B-VP B-VP
of IN B-PP B-PP
proteins NNS B-NP B-NP
ranging VBG B-VP B-VP
between IN B-PP B-PP
70 CD B-NP B-NP
and CC I-NP I-CC
110 CD I-NP B-NP
kD NN I-NP I-NP
. . O O

These DT B-NP B-NP
proteins NNS I-NP I-NP
interacted VBD B-VP B-VP
specifically RB B-PP B-ADVP
with IN I-PP B-PP
the DT B-NP B-NP
symmetric JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
site NN I-NP I-NP
from IN B-PP B-PP
the DT O B-NP
interferon NN B-NP I-NP
beta NN I-NP I-NP
( ( O O
IFN-beta NN B-NP I-NN
) ) O O
promoter NN B-NP B-NP
. . O O

Mutations NNS B-NP B-NP
affecting VBG B-VP B-VP
the DT B-NP B-NP
5' JJ I-NP I-NP
guanine JJ I-NP I-NP
residues NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
site NN I-NP I-NP
were VBD B-VP B-VP
unable JJ B-ADJP B-ADJP
to TO B-VP B-VP
compete VB I-VP I-VP
for IN B-PP B-PP
these DT B-NP B-NP
NF-kappa NN I-NP I-NP
B-related JJ I-NP I-NP
proteins NNS I-NP I-NP
. . O O

Inducibility NN B-NP B-NP
of IN B-PP B-PP
endogenous JJ O B-NP
IFN-beta NN B-NP I-NP
and CC O I-NP
IFN-alpha NN B-NP I-NP
RNA NN B-NP I-NP
was VBD B-VP B-VP
also RB I-VP I-VP
increased VBN I-VP I-VP
in IN B-PP B-PP
PLB-IIIB NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

These DT B-NP B-NP
studies NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-PP
HIV-1 NN B-NP B-NP
infection NN I-NP I-NP
of IN B-PP B-PP
myelomonoblastic JJ B-NP B-NP
cells NNS I-NP I-NP
may MD B-VP B-VP
select VB I-VP I-VP
for IN B-PP B-PP
a DT B-NP B-NP
more RBR I-NP I-NP
mature JJ I-NP I-NP
monocytic JJ I-NP I-NP
phenotype NN I-NP I-NP
and CC O I-CC
that IN B-SBAR B-SBAR
unique JJ B-NP B-NP
subunit NN I-NP I-NP
associations NNS I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
proteins NNS I-NP I-NP
may MD B-VP B-VP
contribute VB I-VP I-VP
to TO B-PP B-PP
differential JJ B-NP B-NP
NF-kappa NN I-NP I-NP
B-mediated JJ I-NP I-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
. . O O

The DT B-NP B-NP
AP-1 NN I-NP I-NP
site NN I-NP I-NP
at IN B-PP B-PP
-150 CD B-NP B-NP
bp NN I-NP I-NP
, , O O
but CC B-CONJP I-CC
not RB I-CONJP I-RB
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
site NN I-NP I-NP
, , O O
is VBZ B-VP B-VP
likely JJ B-ADJP B-ADJP
to TO B-VP B-VP
represent VB I-VP I-VP
the DT B-NP B-NP
major JJ I-NP I-NP
target NN I-NP I-NP
of IN B-PP B-PP
protein NN B-NP B-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
interleukin NN I-NP I-NP
2 CD I-NP I-NP
promoter NN I-NP I-NP
. . O O

Stimulation NN B-NP B-NP
of IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
with IN B-PP B-PP
antigen NN B-NP B-NP
results VBZ B-VP B-VP
in IN B-PP B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
several JJ B-NP B-NP
kinases NNS I-NP I-NP
, , O O
including VBG B-PP B-PP
protein NN B-NP B-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
( ( O O
PKC NN B-NP B-NP
) ) O O
, , O O
that WDT B-NP B-NP
may MD B-VP B-VP
mediate VB I-VP I-VP
the DT B-NP B-NP
later JJ I-NP I-NP
induction NN I-NP I-NP
of IN B-PP B-PP
activation-related JJ B-NP B-NP
genes NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
examined VBN I-VP I-VP
the DT B-NP B-NP
potential JJ I-NP I-NP
role NN I-NP I-NP
of IN B-PP B-PP
PKC NN B-NP B-NP
in IN B-PP B-PP
induction NN B-NP B-NP
of IN B-PP B-PP
the DT O B-NP
interleukin NN B-NP I-NP
2 CD I-NP I-NP
( ( O O
IL-2 NN B-NP I-NN
) ) O O
gene NN B-NP B-NP
in IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
stimulated VBN B-VP B-VP
through IN B-PP B-PP
the DT B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
receptor/CD3 NN I-NP I-NP
complex NN I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
previously RB I-VP I-VP
shown VBN I-VP I-VP
that IN B-SBAR B-PP
prolonged JJ B-NP B-NP
treatment NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
untransformed JJ I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
clone NN I-NP I-NP
Ar-5 NN I-NP I-NP
with IN B-PP B-PP
phorbol NN B-NP B-NP
esters NNS I-NP I-NP
results VBZ B-VP B-VP
in IN B-PP B-PP
downmodulation NN B-NP B-NP
of IN B-PP B-PP
the DT O B-NP
alpha NN B-NP I-NP
and CC O I-NP
beta NN B-NP I-NP
isozymes NNS B-NP I-NP
of IN B-PP B-PP
PKC NN B-NP B-NP
, , O O
and CC O I-CC
abrogates VBZ B-VP B-VP
induction NN B-NP B-NP
of IN B-PP B-PP
IL-2 NN B-NP B-NP
mRNA NN I-NP I-NP
and CC O I-NP
protein NN B-NP I-NP
. . O O

Here RB B-ADVP B-ADVP
we PRP B-NP B-NP
show VBP B-VP B-VP
that IN B-SBAR B-PP
phorbol NN B-NP B-NP
ester NN I-NP I-NP
treatment NN I-NP I-NP
also RB B-ADVP B-ADVP
abolishes VBZ B-VP B-VP
induction NN B-NP B-NP
of IN B-PP B-PP
chloramphenicol JJ B-NP B-NP
acetyltransferase NN I-NP I-NP
activity NN I-NP I-NP
in IN B-PP B-PP
Ar-5 NN B-NP B-NP
cells NNS I-NP I-NP
transfected VBN B-VP B-VP
with IN B-PP B-PP
a DT B-NP B-NP
plasmid NN I-NP I-NP
containing VBG B-VP B-VP
the DT B-NP B-NP
IL-2 NN I-NP I-NP
promoter NN I-NP I-NP
linked VBN B-VP B-VP
to TO B-PP B-PP
this DT B-NP B-NP
reporter NN I-NP I-NP
gene NN I-NP I-NP
. . O O

The DT B-NP B-NP
IL-2 NN I-NP I-NP
promoter NN I-NP I-NP
contains VBZ B-VP B-VP
binding VBG B-NP I-VP
sites NNS I-NP B-NP
for IN B-PP B-PP
nuclear JJ B-NP B-NP
factors NNS I-NP I-NP
including VBG B-PP I-NP
NFAT-1 NN B-NP I-NP
, , O O
Oct NN B-NP B-NP
, , O O
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
, , O O
and CC O I-CC
AP-1 NN B-NP B-NP
, , O O
which WDT B-NP B-NP
are VBP B-VP B-VP
all DT B-ADJP B-NP
potentially RB I-ADJP I-NP
sensitive JJ I-ADJP I-NP
to TO B-PP B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
PKC NN B-NP B-NP
. . O O

We PRP B-NP B-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
induction NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
trimer NN I-NP I-NP
of IN B-PP B-PP
the DT O B-NP
NFAT NN B-NP I-NP
and CC O I-NP
Oct NN B-NP I-NP
sites NNS B-NP I-NP
is VBZ B-VP B-VP
not RB O I-RB
sensitive JJ B-ADJP B-ADJP
to TO B-PP B-PP
phorbol NN B-NP B-NP
ester NN I-NP I-NP
treatment NN I-NP I-NP
, , O O
and CC O I-CC
that IN B-SBAR B-SBAR
mutations NNS B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
site NN I-NP I-NP
have VBP B-VP B-VP
no DT B-NP B-NP
effect NN I-NP I-NP
on IN B-PP B-PP
inducibility NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
IL-2 NN I-NP I-NP
promoter NN I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
mutations NNS B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
site NN I-NP I-NP
located JJ B-ADJP B-ADJP
at IN B-PP B-PP
-150 CD B-NP B-NP
bp NN I-NP I-NP
almost RB B-ADVP B-ADVP
completely RB I-ADVP I-ADVP
abrogate VBP B-VP B-VP
induction NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
IL-2 NN I-NP I-NP
promoter NN I-NP I-NP
, , O O
and CC O I-CC
appearance NN B-NP B-NP
of IN B-PP B-PP
an DT B-NP B-NP
inducible JJ I-NP I-NP
nuclear JJ I-NP I-NP
factor NN I-NP I-NP
binding VBG B-VP B-VP
to TO B-PP B-PP
this DT B-NP B-NP
site NN I-NP I-NP
is VBZ B-VP B-VP
sensitive JJ B-ADJP B-ADJP
to TO B-PP B-PP
PKC NN B-NP B-NP
depletion NN I-NP I-NP
. . O O

Moreover RB B-ADVP B-ADVP
, , O O
cotransfections NNS B-NP B-NP
with IN B-PP B-PP
c-fos NN B-NP B-NP
and CC O I-NP
c-jun NN B-NP I-NP
expression NN B-NP I-NP
plasmids NNS I-NP I-NP
markedly RB B-ADVP B-ADVP
enhance VBP B-VP B-VP
induction NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
IL-2 NN I-NP I-NP
promoter NN I-NP I-NP
in IN B-PP B-PP
minimally RB B-NP B-NP
stimulated VBN I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

Our PRP$ B-NP B-NP
results NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
AP-1 NN I-NP I-NP
site NN I-NP I-NP
at IN B-PP B-PP
-150 CD B-NP B-NP
bp NN I-NP I-NP
represents VBZ B-VP B-VP
a DT B-NP B-NP
major JJ I-NP I-NP
, , O O
if IN B-SBAR B-SBAR
not RB O I-RB
the DT B-NP B-NP
only JJ I-NP I-NP
, , O O
site NN B-NP I-NP
of IN B-PP B-PP
PKC NN B-NP B-NP
responsiveness NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
IL-2 NN I-NP I-NP
promoter NN I-NP I-NP
. . O O

Interleukin NN B-NP B-NP
6-induced JJ I-NP I-NP
differentiation NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
human JJ I-NP I-NP
B NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
into IN B-PP B-PP
IgM-secreting JJ B-NP B-NP
plasma NN I-NP I-NP
cells NNS I-NP I-NP
is VBZ B-VP B-VP
mediated VBN I-VP I-VP
by IN B-PP B-PP
c-fos NN B-NP B-NP
. . O O

The DT B-NP B-NP
role NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
protooncogene NN I-NP I-NP
c-fos NN I-NP I-NP
in IN B-PP B-PP
interleukin NN B-NP B-NP
( ( I-NP O
IL NN I-NP B-NP
) ) I-NP O
6-induced JJ I-NP B-NP
B NN I-NP I-NP
cell NN I-NP I-NP
differentiation NN I-NP I-NP
was VBD B-VP B-VP
assessed VBN I-VP I-VP
. . O O

Treatment NN B-NP B-NP
of IN B-PP B-PP
SKW NN B-NP B-NP
6.4 CD I-NP I-NP
cells NNS I-NP I-NP
with IN B-PP B-PP
IL NN B-NP B-NP
6 CD I-NP I-NP
induced VBD B-VP B-VP
a DT B-NP B-NP
transient JJ I-NP I-NP
and CC I-NP I-NP
early JJ I-NP I-NP
stimulation NN I-NP I-NP
of IN B-PP B-PP
c-fos NN B-NP B-NP
sense NN I-NP I-NP
mRNA NN I-NP I-NP
expression NN I-NP I-NP
. . O O

The DT B-NP B-NP
effect NN I-NP I-NP
appeared VBD B-VP B-VP
within IN B-PP B-PP
30 CD B-NP B-NP
min NN I-NP I-NP
and CC O I-CC
returned VBD B-VP B-VP
to TO B-PP B-PP
basal JJ B-NP B-NP
levels NNS I-NP I-NP
after IN B-PP B-PP
2 CD B-NP B-NP
h NN I-NP I-NP
. . O O

The DT B-NP B-NP
addition NN I-NP I-NP
of IN B-PP B-PP
antisense JJ B-NP B-NP
oligonucleotides NNS I-NP I-NP
to TO B-PP B-PP
c-fos NN B-NP B-NP
significantly RB B-ADVP B-ADVP
inhibited VBD B-VP B-VP
IL NN B-NP B-NP
6-induced JJ I-NP I-NP
IgM NN I-NP I-NP
production NN I-NP I-NP
by IN B-PP B-PP
SKW NN B-NP B-NP
6.4 CD I-NP B-NP
cells NNS I-NP I-NP
( ( O O
p NN B-NP B-NP
less JJR B-NP B-ADJP
than IN I-NP B-PP
0.001 CD I-NP B-NP
) ) O O
, , O O
whereas IN O B-PP
control NN B-NP B-NP
oligonucleotides NNS I-NP I-NP
had VBD B-VP B-VP
no DT B-NP B-NP
inhibitory JJ I-NP I-NP
effect NN I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
c-fos NN B-NP B-NP
is VBZ B-VP B-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
IL NN B-NP B-NP
6-induced JJ I-NP I-NP
differentiation NN I-NP I-NP
of IN B-PP B-PP
SKW NN B-NP B-NP
6.4 CD I-NP I-NP
cells NNS I-NP I-NP
into IN B-PP B-PP
IgM-secreting JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

Binding NN B-NP B-NP
of IN B-PP B-PP
erythroid JJ B-NP B-NP
and CC I-NP I-NP
non-erythroid JJ I-NP I-NP
nuclear JJ I-NP I-NP
proteins NNS I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
silencer NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
epsilon-globin-encoding JJ I-NP I-NP
gene NN I-NP I-NP
. . O O

To TO B-VP B-VP
clarify VB I-VP I-VP
the DT B-NP B-NP
molecular JJ I-NP I-NP
mechanisms NNS I-NP I-NP
involved VBN B-VP B-VP
in IN B-PP B-PP
the DT B-NP B-NP
developmental JJ I-NP I-NP
control NN I-NP I-NP
of IN B-PP B-PP
hemoglobin-encoding JJ B-NP B-NP
genes NNS I-NP I-NP
we PRP B-NP B-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
studying VBG I-VP I-VP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
genes NNS I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
cells NNS I-NP I-NP
in IN B-PP B-PP
continuous JJ B-NP B-NP
culture NN I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
previously RB I-VP I-VP
reported VBN I-VP I-VP
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
transcriptional JJ I-NP I-NP
control NN I-NP I-NP
element NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
properties NNS I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
silencer NN I-NP I-NP
extending VBG B-VP B-VP
from IN B-PP B-PP
-392 CD B-NP B-NP
to TO B-PP I-NP
-177 CD B-NP I-NP
bp NN B-NP I-NP
relative JJ B-PP B-ADJP
to TO I-PP B-PP
the DT B-NP B-NP
cap NN I-NP I-NP
site NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
epsilon-globin-encoding JJ I-NP I-NP
gene NN I-NP I-NP
( ( O O
Cao NNP B-NP B-NP
et FW B-NP I-NP
al. FW B-NP I-NP
, , O O
Proc.Natl.Acad.Sci.USA NNP B-NP B-NP
86 CD I-NP I-NP
( ( I-NP O
1989 CD I-NP B-NP
) ) I-NP O
5306-5309 CD I-NP B-NP
) ) O O
. . O O

We PRP B-NP B-NP
also RB B-ADVP B-ADVP
showed VBD B-VP B-VP
that IN B-SBAR B-SBAR
this DT B-NP B-NP
silencer NN I-NP I-NP
has VBZ B-VP B-VP
stronger JJR B-NP B-NP
inhibitory JJ I-NP I-NP
activity NN I-NP I-NP
in IN B-PP B-PP
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
as IN B-SBAR B-SBAR
compared VBN B-VP B-VP
to TO B-PP B-PP
K562 NN B-NP B-NP
human JJ I-NP I-NP
erythroleukemia NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

Using VBG B-VP B-VP
deletion NN B-NP B-NP
mutants NNS I-NP I-NP
and CC O I-CC
cis-cloned JJ B-NP B-NP
synthetic JJ I-NP I-NP
oligodeoxyribonucleotides NNS I-NP I-NP
in IN B-PP B-PP
transient JJ B-NP B-NP
expression NN I-NP I-NP
assays NNS I-NP I-NP
, , O O
nucleotide NN B-NP B-NP
sequences NNS I-NP I-NP
responsible JJ B-ADJP B-ADJP
for IN B-PP B-PP
this DT B-NP B-NP
effect NN I-NP I-NP
have VBP B-VP B-VP
now RB I-VP I-VP
been VBN I-VP I-VP
further RBR I-VP B-ADVP
delimited VBN I-VP B-VP
to TO B-PP B-PP
44 CD B-NP B-NP
bp NN I-NP I-NP
located JJ B-ADJP B-ADJP
from IN B-PP B-PP
-294 CD B-NP B-NP
to TO B-PP I-NP
-251 CD B-NP I-NP
bp NN B-NP I-NP
. . O O

Gel NN B-NP B-NP
electrophoresis NN I-NP I-NP
mobility NN I-NP I-NP
shift NN I-NP I-NP
assays NNS I-NP I-NP
and CC O I-CC
DNaseI NN B-NP B-NP
footprinting NN I-NP I-NP
assays NNS I-NP I-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
these DT B-NP B-NP
negative JJ I-NP I-NP
regulatory JJ I-NP I-NP
sequences NNS I-NP I-NP
are VBP B-VP B-VP
recognized VBN I-VP I-VP
differently RB B-ADVP B-ADVP
by IN B-PP B-PP
proteins NNS B-NP B-NP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
obtained VBN B-VP B-VP
from IN B-PP B-PP
HeLa NN B-NP B-NP
and CC O I-NP
K562 NN B-NP I-NP
cells NNS B-NP I-NP
. . O O

Two CD B-NP B-NP
binding VBG I-NP I-NP
proteins NNS I-NP I-NP
are VBP B-VP B-VP
detected VBN I-VP I-VP
in IN B-PP B-PP
K562 NN B-NP B-NP
nuclear JJ I-NP I-NP
extracts NNS I-NP I-NP
, , O O
while IN B-SBAR B-SBAR
only RB B-NP B-NP
one CD I-NP I-NP
is VBZ B-VP B-VP
found VBN I-VP I-VP
in IN B-PP B-PP
extracts NNS B-NP B-NP
from IN B-PP B-PP
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Possible JJ B-NP B-NP
mechanisms NNS I-NP I-NP
by IN B-PP B-PP
which WDT B-NP B-NP
these DT B-NP B-NP
proteins NNS I-NP I-NP
may MD B-VP B-VP
regulate VB I-VP I-VP
transcription NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
epsilon-globin-encoding JJ I-NP I-NP
gene NN I-NP I-NP
in IN B-PP B-PP
erythroid JJ B-NP B-NP
and CC I-NP I-NP
non-erythroid JJ I-NP I-NP
cells NNS I-NP I-NP
are VBP B-VP B-VP
discussed VBN I-VP I-VP
. . O O

Gangliosides NN B-NP B-NP
suppress VBP B-VP B-VP
tumor NN B-NP B-NP
necrosis NN I-NP I-NP
factor NN I-NP I-NP
production NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
monocytes NNS I-NP I-NP
. . O O

Both CC B-NP I-CC
normal JJ I-NP B-NP
and CC I-NP I-NP
malignant JJ I-NP I-NP
cells NNS I-NP I-NP
contain VBP B-VP B-VP
gangliosides NNS B-NP B-NP
as IN B-PP B-PP
important JJ B-NP B-NP
cell NN I-NP I-NP
membrane NN I-NP I-NP
constituents NNS I-NP I-NP
that WDT B-NP B-NP
, , O O
after IN B-PP B-PP
being VBG B-VP B-VP
shed VBN I-VP I-VP
, , O O
may MD B-VP B-VP
influence VB I-VP I-VP
cells NNS B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
immune JJ I-NP I-NP
system NN I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
studied VBN I-VP I-VP
the DT B-NP B-NP
impact NN I-NP I-NP
of IN B-PP B-PP
gangliosides NNS B-NP B-NP
on IN B-PP B-PP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
TNF NN B-NP B-NP
in IN B-PP B-PP
blood NN B-NP B-NP
monocytes NNS I-NP I-NP
and CC B-PP I-CC
in IN B-PP B-PP
the DT B-NP B-NP
monocytic JJ I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
Mono NN I-NP I-NP
Mac NN I-NP I-NP
6 CD I-NP I-NP
. . O O

Although IN B-SBAR B-SBAR
under IN B-PP B-PP
standard JJ B-NP B-NP
culture NN I-NP I-NP
conditions NNS I-NP I-NP
, , O O
bovine JJ B-NP B-NP
brain NN I-NP I-NP
gangliosides NNS I-NP I-NP
( ( O O
100 CD B-NP B-NP
micrograms/ml NNS I-NP I-NP
) ) O O
suppressed VBD B-VP B-VP
LPS-stimulated JJ B-NP B-NP
TNF NN I-NP I-NP
production NN I-NP I-NP
5-fold RB B-ADVP B-ADVP
in IN B-PP B-PP
PBMC NN B-NP B-NP
and CC O I-CC
10-fold RB B-ADVP B-ADVP
in IN B-PP B-PP
Mono NN B-NP B-NP
Mac NN I-NP I-NP
6 CD I-NP B-NP
cells NNS I-NP I-NP
, , O O
suppression NN B-NP B-NP
was VBD B-VP B-VP
more RBR B-ADJP B-ADJP
efficient JJ I-ADJP I-ADJP
under IN B-PP B-PP
serum-free JJ B-NP B-NP
conditions NNS I-NP I-NP
. . O O

Looking VBG B-VP B-VP
at IN B-PP B-PP
highly RB B-NP B-NP
purified VBN I-NP I-NP
gangliosides NNS I-NP I-NP
, , O O
GD3 NN B-NP B-NP
, , O O
GD1a NN B-NP B-NP
, , O O
GM3 NN B-NP B-NP
, , O O
GM2 NN B-NP B-NP
, , O O
and CC O I-CC
GM1 NN B-NP B-NP
were VBD B-VP B-VP
all DT B-ADJP B-NP
effective JJ I-ADJP I-NP
in IN B-PP B-PP
reducing VBG B-VP B-VP
TNF NN B-NP B-NP
production NN I-NP I-NP
in IN B-PP B-PP
PBMC NN B-NP B-NP
, , B-PP O
and CC I-PP I-CC
in IN B-PP B-PP
Mono NN B-NP B-NP
Mac NN I-NP I-NP
6 CD I-NP I-NP
by IN B-PP B-PP
factor NN B-NP B-NP
10 CD B-NP I-NP
to TO O B-PP
50 CD B-NP B-NP
. . O O

The DT B-NP B-NP
suppressive JJ I-NP I-NP
activity NN I-NP I-NP
was VBD B-VP B-VP
lost VBN I-VP I-VP
in IN B-PP B-PP
molecules NNS B-NP B-NP
, , O O
lacking VBG B-VP B-VP
the DT B-NP B-NP
sugar NN I-NP I-NP
moiety NN I-NP I-NP
or CC O I-CC
the DT B-NP B-NP
lipid NN I-NP I-NP
moiety NN I-NP I-NP
. . O O

Gangliosides NNS B-NP B-NP
appear VBP B-VP B-VP
to TO I-VP I-VP
act VB I-VP I-VP
at IN B-PP B-PP
an DT B-NP B-NP
early JJ I-NP I-NP
step NN I-NP I-NP
of IN B-PP B-PP
activation NN B-NP B-NP
in IN B-PP B-PP
that IN B-NP B-SBAR
TNF NN B-NP B-NP
transcripts NNS I-NP I-NP
were VBD B-VP B-VP
reduced VBN I-VP I-VP
and CC O I-CC
the DT B-NP B-NP
mobilization NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
nuclear JJ I-NP I-NP
factor NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
was VBD B-VP B-VP
blocked VBN I-VP I-VP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
in IN B-PP B-PP
time NN B-NP B-NP
kinetics NNS I-NP I-NP
, , O O
gangliosides NNS B-NP B-NP
were VBD B-VP B-VP
effective JJ B-ADJP B-ADJP
for IN B-PP B-PP
up RB B-NP B-NP
to TO I-NP I-NP
30 CD I-NP I-NP
min NN I-NP I-NP
after IN B-PP B-PP
addition NN B-NP B-NP
of IN B-PP B-PP
LPS NN B-NP B-NP
, , O O
but CC O I-CC
not RB B-ADVP B-ADVP
thereafter RB I-ADVP I-ADVP
. . O O

However RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
CD14 NN I-NP I-NP
Ag NN I-NP I-NP
, , O O
a DT B-NP B-NP
receptor NN I-NP I-NP
molecule NN I-NP I-NP
for IN B-PP B-PP
LPS-LPS NN B-NP B-NP
binding NN I-NP I-NP
protein NN I-NP I-NP
complexes NNS I-NP I-NP
, , O O
was VBD B-VP B-VP
unaffected JJ I-VP B-ADJP
by IN B-PP B-PP
gangliosides NNS B-NP B-NP
. . O O

Finally RB B-ADVP B-ADVP
, , O O
when WRB B-ADVP B-ADVP
using VBG B-VP B-NP
Staphylococcus FW B-NP I-NP
aureus FW I-NP I-NP
or CC O I-CC
platelet NN B-NP B-NP
activating NN I-NP I-NP
factor NN I-NP I-NP
as IN B-PP B-PP
a DT B-NP B-NP
stimulus NN I-NP I-NP
, , O O
gangliosides NNS B-NP B-NP
were VBD B-VP B-VP
able JJ B-ADJP B-ADJP
to TO B-VP B-VP
suppress VB I-VP I-VP
TNF NN B-NP B-NP
production NN I-NP I-NP
in IN B-PP B-PP
Mono NN B-NP B-NP
Mac NN I-NP I-NP
6 CD I-NP B-NP
cells NNS I-NP I-NP
by IN B-PP B-PP
factor NN B-NP B-NP
5 CD B-NP I-NP
to TO O I-NP
10 CD B-NP I-NP
, , O O
as RB B-PP B-ADVP
well RB B-ADVP I-ADVP
. . O O

On IN B-PP B-PP
the DT B-NP B-NP
other JJ I-NP I-NP
hand NN I-NP I-NP
, , O O
phorbol NN B-NP B-NP
ester-induced JJ I-NP I-NP
production NN I-NP I-NP
of IN B-PP B-PP
O2- NN B-NP B-NP
was VBD B-VP B-VP
similar JJ B-ADJP B-ADJP
in IN B-PP B-PP
cells NNS B-NP B-NP
treated VBN B-VP B-VP
with IN B-PP B-PP
and CC B-PP I-PP
without IN B-PP B-PP
gangliosides NNS B-NP B-NP
. . O O

Taken VBN B-VP B-VP
together RB B-ADVP B-ADVP
, , O O
our PRP$ B-NP B-NP
data NNS I-NP I-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
TNF NN B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
in IN B-PP B-PP
monocytes NNS B-NP B-NP
induced VBN B-VP B-VP
by IN B-PP B-PP
different JJ B-NP B-NP
types NNS I-NP I-NP
of IN B-PP B-PP
stimuli NNS B-NP B-NP
can MD B-VP B-VP
be VB I-VP I-VP
blocked VBN I-VP I-VP
by IN B-PP B-PP
gangliosides NNS B-NP B-NP
at IN B-PP B-PP
an DT B-NP B-NP
early JJ I-NP I-NP
step NN I-NP I-NP
of IN B-PP B-PP
signal JJ B-NP B-NP
transduction NN I-NP I-NP
. . O O

T NN B-NP B-NP
cell-specific JJ I-NP I-NP
negative JJ I-NP I-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
cytokine NN I-NP I-NP
IL-4 NN I-NP I-NP
. . O O

IL-4 NN B-NP B-NP
secreted VBN B-VP B-VP
by IN B-PP B-PP
activated VBN B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
pleiotropic JJ I-NP I-NP
cytokine NN I-NP I-NP
affecting VBG B-VP I-NP
growth NN B-NP I-NP
and CC O I-NP
differentiation NN B-NP I-NP
of IN B-PP B-PP
diverse JJ B-NP B-NP
cell NN I-NP I-NP
types NNS I-NP I-NP
such JJ B-PP B-PP
as IN I-PP I-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
B NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
and CC O I-CC
mast NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
investigated VBD B-VP B-VP
the DT B-NP B-NP
upstream JJ I-NP I-NP
regulatory JJ I-NP I-NP
elements NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
IL-4 NN I-NP I-NP
promoter NN I-NP I-NP
. . O O

A DT B-NP B-NP
novel JJ I-NP I-NP
T NN I-NP I-NP
cell-specific JJ I-NP I-NP
negative JJ I-NP I-NP
regulatory JJ I-NP I-NP
element NN I-NP I-NP
( ( O O
NRE NN B-NP B-NP
) ) O O
composed VBN B-VP B-VP
of IN B-PP B-PP
two CD B-NP B-NP
protein-binding JJ I-NP I-NP
sites NNS I-NP I-NP
were VBD B-VP B-VP
mapped VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
5' JJ I-NP I-NP
flanking JJ I-NP I-NP
region NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
IL-4 NN I-NP I-NP
gene NN I-NP I-NP
: : O O
-311CTCCCTTCT-303 NN B-NP B-NP
( ( O O
NRE-I NN B-NP I-NP
) ) O O
and CC O I-CC
-288CTTTTTGCTT-TGC-300 NN B-NP B-NP
( ( O O
NRE-II NN B-NP I-NP
) ) O O
. . O O

A DT B-NP B-NP
T NN I-NP I-NP
cell-specific JJ I-NP I-NP
protein NN I-NP I-NP
Neg-1 NN I-NP I-NP
and CC O I-CC
a DT B-NP B-NP
ubiquitous JJ I-NP I-NP
protein NN I-NP I-NP
Neg-2 NN I-NP I-NP
binding VBG B-VP B-VP
to TO B-PP B-PP
NRE-I NN B-NP B-NP
and CC O I-NP
NRE-II NN B-NP I-NP
, , O O
respectively RB B-ADVP B-ADVP
, , O O
were VBD B-VP B-VP
identified VBN I-VP I-VP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
a DT B-NP B-NP
positive JJ I-NP I-NP
regulatory JJ I-NP I-NP
element NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
45 CD B-NP B-NP
bp NN I-NP I-NP
downstream RB B-ADVP B-ADVP
of IN B-PP B-PP
the DT B-NP B-NP
NRE NN I-NP I-NP
. . O O

The DT B-NP B-NP
enhancer NN I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
PRE NN I-NP I-NP
was VBD B-VP B-VP
completely RB I-VP I-VP
suppressed VBN I-VP I-VP
when WRB B-ADVP B-ADVP
the DT B-NP B-NP
NRE NN I-NP I-NP
was VBD B-VP B-VP
present JJ B-ADJP B-ADJP
. . O O

These DT B-NP B-NP
data NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
IL-4 NN B-NP B-NP
promoter NN I-NP I-NP
activity NN I-NP I-NP
is VBZ B-VP B-VP
normally RB I-VP I-VP
down-regulated VBN I-VP I-VP
by IN B-PP B-PP
an DT B-NP B-NP
NRE NN I-NP I-NP
via IN B-PP B-PP
repression NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
enhancer NN I-NP I-NP
positive JJ I-NP I-NP
regulatory JJ I-NP I-NP
element NN I-NP I-NP
. . O O

These DT B-NP B-NP
data NNS I-NP I-NP
may MD B-VP B-VP
have VB I-VP I-VP
implications NNS B-NP B-NP
for IN B-PP B-PP
the DT B-NP B-NP
stringent JJ I-NP I-NP
control NN I-NP I-NP
of IN B-PP B-PP
IL-4 NN B-NP B-NP
expression NN I-NP I-NP
in IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

( ( O O
Regulatory JJ B-NP B-NP
effect NN I-NP I-NP
of IN B-PP B-PP
insulin NN B-NP B-NP
on IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
peripheral JJ I-NP I-NP
leukocytes NNS I-NP I-NP
) ) O O

The DT B-NP B-NP
regulatory JJ I-NP I-NP
effect NN I-NP I-NP
of IN B-PP B-PP
insulin NN B-NP B-NP
on IN B-PP B-PP
the DT B-NP B-NP
specific JJ I-NP I-NP
binding VBG I-NP I-NP
power NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
( ( O O
GR NN B-NP B-NP
) ) O O
of IN B-PP B-PP
human JJ B-NP B-NP
leukocytes NNS I-NP I-NP
was VBD B-VP B-VP
assessed VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
unoccupied JJ I-NP I-NP
receptor NN I-NP I-NP
sites NNS I-NP I-NP
capable JJ B-ADJP B-ADJP
of IN B-PP B-PP
combining VBG B-VP B-VP
with IN B-PP B-PP
(3H) NN B-NP B-NP
labelled JJ I-NP I-NP
dexamethasone NN I-NP I-NP
measured VBN B-VP B-VP
at IN B-PP B-PP
3 CD B-NP B-NP
and CC I-NP I-CC
24 CD I-NP B-NP
h NN I-NP I-NP
after IN B-PP B-PP
incubation NN B-NP B-NP
with IN B-PP B-PP
various JJ B-NP B-NP
concentrations NNS I-NP I-NP
of IN B-PP B-PP
insulin NN B-NP B-NP
added VBN B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
medium NN I-NP I-NP
. . O O

After IN B-PP B-PP
3 CD B-NP B-NP
h NN I-NP I-NP
incubation NN I-NP I-NP
the DT B-NP B-NP
specific JJ I-NP I-NP
binding VBG I-NP I-NP
power NN I-NP I-NP
with IN B-PP B-PP
(3H) NN B-NP B-NP
Dex NN I-NP I-NP
was VBD B-VP B-VP
decreased VBN I-VP I-VP
by IN B-PP B-PP
23.3 CD B-NP B-NP
+/- CC I-NP I-NP
10.0 CD I-NP I-NP
, , O O
32.2 CD B-NP I-NP
+/- CC I-NP I-NP
13.2 CD I-NP I-NP
and CC O I-NP
54.3 CD B-NP I-NP
+/- CC I-NP I-NP
9.2 CD I-NP I-NP
% NN B-NP I-NP
( ( O O
P NN B-NP B-NP
greater JJR B-ADJP B-ADJP
than IN B-PP B-PP
0.05 CD B-NP B-NP
, , O O
P NN B-NP B-NP
greater JJR B-ADJP B-NP
than IN B-PP I-NP
0.05 CD B-NP I-NP
and CC O I-CC
P NN B-NP B-VP
less JJR B-ADJP B-NP
than IN B-PP I-NP
0.01 CD B-NP I-NP
as IN B-SBAR I-NP
compared VBN B-VP B-PP
with IN B-PP B-PP
the DT B-NP B-NP
control NN I-NP I-NP
value NN I-NP I-NP
of IN B-PP B-PP
100 CD B-NP B-NP
in IN B-PP B-PP
the DT I-PP B-NP
absence NN I-PP I-NP
of IN I-PP B-PP
insulin NN B-NP B-NP
) ) O O
respectively RB B-ADVP B-ADVP
in IN B-PP B-PP
the DT I-PP B-NP
presence NN I-PP I-NP
of IN I-PP B-PP
20 CD B-NP B-NP
mU/L NN I-NP I-NP
( ( O O
physiological JJ B-NP B-NP
testing NN I-NP I-NP
concentration NN I-NP I-NP
) ) O O
, , O O
200 CD B-NP B-NP
mU/L NN I-NP I-NP
( ( O O
physiological JJ B-NP B-NP
upper JJ I-NP I-NP
limit NN I-NP I-NP
) ) O O
and CC O I-CC
2,000 CD B-NP B-NP
mU/L NN I-NP I-NP
( ( O O
pharmacological JJ B-NP B-NP
concentration NN I-NP I-NP
) ) O O
insulin NN B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
incubation NN I-NP I-NP
medium NN I-NP I-NP
. . O O

After IN B-PP B-PP
24 CD B-NP B-NP
h NN I-NP I-NP
incubation NN I-NP I-NP
the DT B-NP B-NP
decrease NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
values NNS I-NP I-NP
increased VBD B-VP B-VP
respectively RB B-ADVP B-ADVP
to TO B-PP B-PP
43.5 CD B-NP B-NP
+/- CC I-NP I-NP
19.0 CD I-NP I-NP
, , O O
56.1 CD B-NP I-NP
+/- CC I-NP I-NP
20.7 CD I-NP I-NP
and CC O I-NP
80.2 CD B-NP I-NP
+/- CC I-NP I-NP
15.5 CD I-NP I-NP
( ( O O
P NN B-NP B-NP
less JJR B-ADJP B-ADJP
than IN B-PP B-PP
0.05 CD B-NP B-NP
, , O O
P NN B-NP B-VP
less JJR B-ADJP B-NP
than IN B-PP I-NP
0.01 CD B-NP I-NP
and CC O I-CC
P NN B-NP B-NP
less JJR B-ADJP B-ADJP
than IN B-PP B-PP
0.01 CD B-NP B-NP
compared VBN B-VP B-VP
with IN B-PP B-PP
control NN B-NP B-NP
) ) O O
. . O O

Thus RB B-ADVP B-ADVP
the DT B-NP B-NP
inhibitory JJ I-NP I-NP
effect NN I-NP I-NP
of IN B-PP B-PP
insulin NN B-NP B-NP
on IN B-PP B-PP
the DT B-NP B-NP
GR NN I-NP I-NP
binding NN I-NP I-NP
power NN I-NP I-NP
is VBZ B-VP B-VP
both CC O I-CC
dose- NN B-NP B-NP
and CC O I-NP
time-dependent JJ B-ADJP I-NP
, , O O
which WDT B-NP B-NP
strongly RB B-ADVP B-ADVP
suggests VBZ B-VP B-VP
that IN B-SBAR B-SBAR
GR NN B-NP B-NP
is VBZ B-VP B-VP
tonically RB I-VP I-VP
controlled VBN I-VP I-VP
by IN B-PP B-PP
insulin NN B-NP B-NP
concentration NN I-NP I-NP
change NN I-NP I-NP
under IN B-PP B-PP
physiological JJ B-NP B-NP
conditions NNS I-NP I-NP
. . O O

Human JJ B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
activation NN I-NP I-NP
through IN B-PP B-PP
the DT B-NP B-NP
activation-inducer JJ I-NP I-NP
molecule/CD69 NN I-NP I-NP
enhances VBZ B-VP B-VP
the DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
factor NN I-NP I-NP
AP-1 NN I-NP I-NP
. . O O

The DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
ascribed VBN I-VP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
early JJ I-NP I-NP
events NNS I-NP I-NP
leading VBG B-VP B-VP
to TO B-PP B-PP
T NN B-NP B-NP
cell NN I-NP I-NP
differentiation NN B-NP I-NP
and CC O I-NP
activation NN B-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
studied VBN I-VP I-VP
the DT B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
AP-1 NN B-NP B-NP
activity NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
peripheral JJ I-NP I-NP
blood NN I-NP I-NP
T NN I-NP I-NP
lymphocytes NNS I-NP I-NP
stimulated VBN B-VP B-VP
through IN B-PP B-PP
the DT B-NP B-NP
activation NN I-NP I-NP
inducer NN I-NP I-NP
molecule NN I-NP I-NP
( ( I-NP O
AIM NN I-NP I-NN
) ) I-NP O
/CD69 NN I-NP B-NP
activation NN I-NP I-NP
pathway NN I-NP I-NP
. . O O

Phorbol NN B-NP B-NP
esters NNS I-NP I-NP
are VBP B-VP B-VP
required VBN I-VP I-VP
to TO B-VP I-VP
induce VB I-VP I-VP
AIM/CD69 NN B-NP B-NP
cell-surface JJ I-NP I-NP
expression NN I-NP I-NP
as RB B-CONJP B-ADVP
well RB I-CONJP I-ADVP
as IN I-CONJP B-PP
for IN B-PP B-PP
triggering VBG B-VP B-VP
the DT B-NP B-NP
proliferation NN I-NP I-NP
of IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
in IN B-PP B-PP
conjunction NN I-PP B-NP
with IN I-PP B-PP
anti-AIM JJ B-NP B-NP
mAb NN I-NP I-NP
. . O O

Mobility NN B-NP B-NP
shift NN I-NP I-NP
assays NNS I-NP I-NP
showed VBD B-VP B-VP
that IN B-SBAR B-SBAR
addition NN B-NP B-NP
of IN B-PP B-PP
anti-AIM JJ B-NP B-NP
mAb NN I-NP I-NP
to TO B-PP B-PP
PMA-treated JJ B-NP B-NP
T NN I-NP I-NP
lymphocytes NNS I-NP I-NP
markedly RB B-ADVP B-ADVP
enhanced VBD B-VP B-VP
the DT B-NP B-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
AP-1 NN B-NP B-NP
to TO B-PP B-PP
its PRP$ B-NP B-NP
cognate JJ I-NP I-NP
sequence NN I-NP I-NP
, , O O
the DT B-NP B-NP
phorbol NN I-NP I-NP
ester NN I-NP I-NP
response NN I-NP I-NP
element NN I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
anti-AIM NN B-NP B-NP
mAb NN I-NP I-NP
did VBD B-VP B-VP
not RB I-VP I-VP
induce VB I-VP I-VP
any DT B-NP B-NP
change NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
, , O O
a DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
whose WP$ B-NP B-NP
activity NN I-NP I-NP
is VBZ B-VP B-VP
also RB I-VP I-VP
regulated VBN I-VP I-VP
by IN B-PP B-PP
protein NN B-NP B-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
. . O O

The DT B-NP B-NP
increase NN I-NP I-NP
in IN B-PP B-PP
AP-1-binding JJ B-NP B-NP
activity NN I-NP I-NP
was VBD B-VP B-VP
accompanied VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
marked JJ I-NP I-NP
stimulation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
of IN B-PP B-PP
c-fos NN B-NP B-NP
but CC B-CONJP B-NP
not RB I-CONJP I-NP
that DT B-NP B-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
. . O O

Blockade NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
DNA-binding JJ I-NP I-NP
complexes NNS I-NP I-NP
with IN B-PP B-PP
an DT B-NP B-NP
anti-Fos JJ I-NP I-NP
mAb NN I-NP I-NP
demonstrated VBD B-VP B-VP
a DT B-NP B-NP
direct JJ I-NP I-NP
participation NN I-NP I-NP
of IN B-PP B-PP
c-Fos NN B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
complexes NNS I-NP I-NP
induced VBN B-VP B-VP
by IN B-PP B-PP
anti-AIM NN B-NP B-NP
mAb NN I-NP I-NP
. . O O

Most JJS B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
activity NN I-NP I-NP
could MD B-VP B-VP
be VB I-VP I-VP
eliminated VBN I-VP I-VP
when WRB O B-ADVP
the DT B-NP B-NP
anti-AIM NN I-NP I-NP
mAb NN I-NP I-NP
was VBD B-VP B-VP
added VBN I-VP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
culture NN I-NP I-NP
medium NN I-NP I-NP
in IN B-PP B-PP
the DT I-PP B-NP
presence NN I-PP I-NP
of IN I-PP B-PP
cycloheximide NN B-NP B-NP
, , O O
suggesting VBG B-VP B-VP
that IN B-SBAR B-PP
de FW B-NP B-NP
novo FW I-NP I-NP
protein NN I-NP I-NP
synthesis NN I-NP I-NP
is VBZ B-VP B-VP
crucial JJ B-ADJP B-ADJP
for IN B-PP B-PP
the DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
AP-1-binding JJ B-NP B-NP
activity NN I-NP I-NP
. . O O

These DT B-NP B-NP
data NNS I-NP I-NP
provide VBP B-VP B-VP
the DT B-NP B-NP
evidence NN I-NP I-NP
that IN B-SBAR B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
human JJ B-NP B-NP
peripheral JJ I-NP I-NP
blood NN I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
through IN B-PP B-PP
the DT B-NP B-NP
AIM NN I-NP I-NP
activation NN I-NP I-NP
pathway NN I-NP I-NP
regulate VBP B-VP B-VP
the DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
AP-1 NN B-NP B-NP
. . O O

Therefore RB B-ADVP B-ADVP
, , O O
this DT B-NP B-NP
pathway NN I-NP I-NP
appears VBZ B-VP B-VP
as IN B-PP B-PP
a DT B-NP B-NP
crucial JJ I-NP I-NP
step NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
initiation NN I-NP I-NP
of IN B-PP B-PP
early JJ B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
activation NN I-NP I-NP
events NNS I-NP I-NP
. . O O

cis-acting JJ B-NP B-NP
sequences NNS I-NP I-NP
required VBN B-VP B-VP
for IN B-PP B-PP
inducible JJ B-NP B-NP
interleukin-2 NN I-NP I-NP
enhancer NN I-NP I-NP
function NN I-NP I-NP
bind VBP B-VP B-VP
a DT B-NP B-NP
novel JJ I-NP I-NP
Ets-related JJ I-NP I-NP
protein NN I-NP I-NP
, , O O
Elf-1 NN B-NP I-NP
. . O O

The DT B-NP B-NP
recent JJ I-NP I-NP
definition NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
consensus NN I-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
sequence NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
Ets NN I-NP I-NP
family NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
factors NNS I-NP I-NP
has VBZ B-VP B-VP
allowed VBN I-VP I-VP
the DT B-NP B-NP
identification NN I-NP I-NP
of IN B-PP B-PP
potential JJ B-NP B-NP
Ets NN I-NP I-NP
binding NN I-NP I-NP
sites NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
promoters NNS B-NP I-NP
and CC O I-NP
enhancers NNS B-NP I-NP
of IN B-PP B-PP
many JJ B-NP B-NP
inducible JJ I-NP I-NP
T-cell NN I-NP I-NP
genes NNS I-NP I-NP
. . O O

In IN B-PP B-PP
the DT B-NP B-NP
studies NNS I-NP I-NP
described VBN B-VP B-VP
in IN B-PP B-PP
this DT B-NP B-NP
report NN I-NP I-NP
, , O O
we PRP B-NP B-NP
have VBP B-VP B-VP
identified VBN I-VP I-VP
two CD B-NP B-NP
potential JJ I-NP I-NP
Ets NNS I-NP I-NP
binding NN I-NP I-NP
sites NNS I-NP I-NP
, , O O
EBS1 NN B-NP B-NP
and CC O I-NP
EBS2 NN B-NP I-NP
, , O O
which WDT B-NP B-NP
are VBP B-VP B-VP
conserved VBN I-VP I-VP
in IN B-PP B-PP
both CC B-NP I-CC
the DT I-NP B-NP
human JJ I-NP I-NP
and CC I-NP I-NP
murine JJ I-NP I-NP
interleukin-2 NN I-NP I-NP
enhancers NNS I-NP I-NP
. . O O

Within IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
enhancer NN I-NP I-NP
, , O O
these DT B-NP B-NP
two CD I-NP I-NP
sites NNS I-NP I-NP
are VBP B-VP B-VP
located JJ O B-ADJP
within IN B-PP B-PP
the DT B-NP B-NP
previously RB I-NP I-NP
defined VBN I-NP I-NP
DNase NN I-NP I-NP
I CD I-NP I-NP
footprints NNS I-NP I-NP
, , O O
NFAT-1 NN B-NP B-NP
and CC O I-NP
NFIL-2B NN B-NP I-NP
, , O O
respectively RB B-ADJP B-ADVP
. . O O

Electrophoretic JJ B-NP B-NP
mobility NN I-NP I-NP
shift NN I-NP I-NP
and CC O I-NP
methylation NN B-NP I-NP
interference NN I-NP I-NP
analyses NNS B-NP I-NP
demonstrated VBD B-VP B-VP
that IN B-SBAR B-PP
EBS1 NN B-NP B-NP
and CC O I-NP
EBS2 NN B-NP I-NP
are VBP B-VP B-VP
essential JJ B-ADJP B-ADJP
for IN B-PP B-PP
the DT B-NP B-NP
formation NN I-NP I-NP
of IN B-PP B-PP
the DT O B-NP
NFAT-1 NN B-NP I-NP
and CC O I-NP
NFIL-2B NN B-NP I-NP
nuclear JJ B-NP I-NP
protein NN I-NP I-NP
complexes NNS I-NP I-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
in FW B-NP B-NP
vitro FW I-NP I-NP
mutagenesis NN I-NP I-NP
experiments NNS I-NP I-NP
demonstrated VBD B-VP B-VP
that IN B-SBAR B-PP
inducible JJ B-NP B-NP
interleukin-2 NN I-NP I-NP
enhancer NN I-NP I-NP
function NN I-NP I-NP
requires VBZ B-VP B-VP
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
either CC O I-CC
EBS1 NN B-NP B-NP
or CC O I-NP
EBS2 NN B-NP I-NP
. . O O

Two CD B-NP B-NP
well-characterized JJ I-NP I-NP
Ets NN I-NP I-NP
family NN I-NP I-NP
members NNS I-NP I-NP
, , O O
Ets-1 NN B-NP B-NP
and CC O I-NP
Ets-2 NN B-NP I-NP
, , O O
are VBP B-VP B-VP
reciprocally RB I-VP I-VP
expressed VBN I-VP I-VP
during IN B-PP B-PP
T-cell NN B-NP B-NP
activation NN I-NP I-NP
. . O O

Surprisingly RB B-ADVP B-ADVP
, , O O
however RB B-ADVP B-ADVP
, , O O
neither DT B-NP B-NP
of IN B-PP B-PP
these DT B-NP B-NP
proteins NNS I-NP I-NP
bound VBD B-VP B-VP
in FW B-ADVP B-NP
vitro FW I-ADVP I-NP
to TO B-PP B-PP
EBS1 NN B-NP B-NP
or CC O I-NP
EBS2 NN B-NP I-NP
. . O O

We PRP B-NP B-NP
therefore RB B-ADVP B-ADVP
screened VBD B-VP B-VP
a DT B-NP B-NP
T-cell NN I-NP I-NP
cDNA NN I-NP I-NP
library NN I-NP I-NP
under IN B-PP B-PP
low-stringency NN B-NP B-NP
conditions NNS I-NP I-NP
with IN B-PP B-PP
a DT B-NP B-NP
probe NN I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
Ets-1 NN B-NP B-NP
and CC O I-CC
isolated VBD B-VP B-VP
a DT B-NP B-NP
novel JJ I-NP I-NP
Ets NN I-NP I-NP
family NN I-NP I-NP
member NN I-NP I-NP
, , O O
Elf-1 NN B-NP B-NP
. . O O

Elf-1 NN B-NP B-NP
contains VBZ B-VP B-VP
a DT B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
domain NN I-NP I-NP
that WDT B-NP B-NP
is VBZ B-VP B-VP
nearly RB B-ADJP B-ADJP
identical JJ I-ADJP I-ADJP
to TO B-PP B-PP
that DT B-NP B-NP
of IN B-PP B-PP
E74 NN B-NP B-NP
, , O O
the DT B-NP B-NP
ecdysone-inducible JJ I-NP I-NP
Drosophila NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
required VBN B-VP B-VP
for IN B-PP B-PP
metamorphosis NN B-NP B-NP
( ( O O
hence RB B-ADVP B-ADVP
the DT B-NP B-NP
name NN I-NP I-NP
Elf-1 NN I-NP I-NP
, , O O
for IN B-PP B-PP
E74-like JJ B-NP B-NP
factor NN I-NP I-NP
1 CD I-NP I-NP
) ) O O
. . O O

Elf-1 NN B-NP B-NP
bound VBD B-VP B-VP
specifically RB B-PP B-ADVP
to TO I-PP B-NP
both CC O I-CC
EBS1 NN B-NP B-NP
and CC O I-NP
EBS2 NN B-NP I-NP
in IN B-PP B-PP
electrophoretic JJ B-NP B-NP
mobility NN I-NP I-NP
shift NN I-NP I-NP
assays NNS I-NP I-NP
. . O O

It PRP B-NP B-NP
also RB B-ADVP B-ADVP
bound VBD B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
purine-rich JJ I-NP I-NP
CD3R NN I-NP I-NP
element NN I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP B-VP
2 CD I-NP B-NP
long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
, , O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
inducible JJ B-NP B-NP
virus NN I-NP I-NP
expression NN I-NP I-NP
in IN B-PP B-PP
response NN I-PP B-NP
to TO I-PP B-PP
signalling NN B-NP B-NP
through IN B-PP B-PP
the DT B-NP B-NP
T-cell NN I-NP I-NP
receptor NN I-NP I-NP
. . O O

Taken VBN B-VP B-VP
together RB B-ADVP B-ADVP
, , O O
these DT B-NP B-NP
results NNS I-NP I-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
multiple JJ B-NP B-NP
Ets NN I-NP I-NP
family NN I-NP I-NP
members NNS I-NP I-NP
with IN B-PP B-PP
apparently RB B-NP B-NP
distinct JJ I-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
specificities NNS I-NP I-NP
regulate VBP B-VP B-VP
differential JJ B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
in IN B-PP B-PP
resting VBG B-NP B-NP
and CC I-NP I-NP
activated VBN I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

Mineralocorticoids NNPS B-NP B-NP
and CC O I-NP
mineralocorticoid NN B-NP I-NP
receptors NNS I-NP I-NP
in IN B-PP B-PP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
in IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
pregnancy-induced JJ B-NP B-NP
hypertension NN I-NP I-NP
. . O O

To TO B-VP B-VP
examine VB I-VP I-VP
the DT B-NP B-NP
role NN I-NP I-NP
of IN B-PP B-PP
mineralocorticoids NNS B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
pathophysiology NN I-NP I-NP
of IN B-PP B-PP
pregnancy-induced JJ B-NP B-NP
hypertension NN I-NP I-NP
( ( O O
PIH NN B-NP B-NP
) ) O O
, , O O
we PRP B-NP B-NP
studied VBD B-VP B-VP
plasma NN B-NP B-NP
aldosterone NN I-NP I-NP
and CC O I-NP
18-hydroxycorticosterone NN B-NP I-NP
levels NNS B-NP I-NP
in IN B-PP B-PP
25 CD B-NP B-NP
women NNS I-NP I-NP
with IN B-PP B-PP
PIH NN B-NP B-NP
and CC O I-CC
25 CD B-NP B-NP
normal JJ I-NP I-NP
pregnant JJ I-NP I-NP
women NNS I-NP I-NP
, , O O
as IN B-PP B-PP
controls NNS B-NP B-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
we PRP B-NP B-NP
evaluated VBD B-VP B-VP
the DT O B-NP
mineralocorticoid NN B-NP I-NP
receptor NN I-NP I-NP
( ( O O
MR NN B-NP I-NN
) ) O O
status NN B-NP B-NP
in IN B-PP B-PP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
2 CD I-NP I-NP
groups NNS I-NP I-NP
. . O O

MR NN B-NP B-NP
count NN I-NP I-NP
was VBD B-VP B-VP
significantly RB B-ADVP B-NP
( ( O O
P NN B-NP I-NP
less JJR B-NP B-ADJP
than IN I-NP B-PP
0.0005 CD I-NP B-NP
) ) O O
decreased VBN B-VP B-VP
in IN B-PP B-PP
the DT B-NP B-NP
PIH NN I-NP I-NP
group NN I-NP I-NP
( ( O O
148 CD B-NP B-NP
+/- CC I-NP I-NP
9 CD I-NP I-NP
binding VBG I-NP I-NP
sites/cell NNS I-NP I-NP
) ) O O
compared VBN B-PP B-PP
with IN B-PP B-PP
the DT B-NP B-NP
control NN I-NP I-NP
group NN I-NP I-NP
( ( O O
300 CD B-NP B-NP
+/- CC I-NP I-NP
17 CD I-NP I-NP
binding VBG I-NP I-NP
sites/cell NNS I-NP I-NP
; : O O
mean NN B-NP B-NP
+/- CC I-NP I-NP
SEM NN I-NP I-NP
) ) O O
. . O O

Plasma NN B-NP B-NP
aldosterone NN I-NP I-NP
in IN B-PP B-PP
women NNS B-NP B-NP
with IN B-PP B-PP
PIH NN B-NP B-NP
was VBD B-VP B-VP
281 CD B-NP B-NP
+/- CC I-NP I-NP
61 CD I-NP I-NP
pmol/L NN I-NP I-NP
; : O O
in IN B-PP B-PP
normal JJ B-NP B-NP
pregnant JJ I-NP I-NP
women NNS I-NP I-NP
it PRP B-NP B-NP
was VBD B-VP B-VP
697 CD B-NP B-NP
+/- CC I-NP I-NP
172 CD I-NP I-NP
pmol/L NN I-NP I-NP
( ( O O
P NN B-NP B-NP
less JJR B-NP B-ADJP
than IN I-NP B-PP
0.025 CD I-NP B-NP
) ) O O
. . O O

Plasma NN B-NP B-NP
18-hydroxycorticosterone NN I-NP I-NP
was VBD B-VP B-VP
also RB B-ADVP B-ADVP
significantly RB O B-NP
( ( O O
P NN B-NP I-NP
less JJR B-NP B-ADJP
than IN I-NP B-PP
0.025 CD I-NP B-NP
) ) O O
lower JJR B-ADJP B-NP
( ( O O
PIH NN B-NP I-NP
, , O O
1071 CD B-NP B-NP
+/- CC I-NP I-CC
149 CD I-NP B-NP
pmol/L NN I-NP I-NP
; : O O
controls NNS B-NP B-NP
, , O O
1907 CD B-NP I-NP
+/- CC I-NP I-NP
318 CD I-NP I-NP
pmol/L NN I-NP I-NP
) ) O O
. . O O

These DT B-NP B-NP
values NNS I-NP I-NP
were VBD B-VP B-VP
determined VBN I-VP I-VP
at IN B-PP B-PP
the DT B-NP B-NP
onset NN I-NP I-NP
of IN B-PP B-PP
clinical JJ B-NP B-NP
symptoms NNS I-NP I-NP
of IN B-PP B-PP
PIH NN B-NP B-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
can MD B-VP B-VP
not RB I-VP I-VP
be VB I-VP I-VP
explained VBN I-VP I-VP
by IN B-PP B-PP
receptor NN B-NP B-NP
down-regulation NN I-NP I-NP
due JJ B-PP B-ADVP
to TO I-PP B-PP
higher JJR B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
mineralocorticoids NNS B-NP B-NP
in IN B-PP B-PP
PIH NN B-NP B-NP
; : O O
a DT B-NP B-NP
hitherto RB I-NP I-NP
unknown JJ I-NP I-NP
mineralocorticoid NN I-NP I-NP
may MD B-VP B-VP
, , O O
thus RB B-ADVP B-ADVP
, , O O
be VB B-VP B-VP
responsible JJ B-ADJP B-ADJP
for IN B-PP B-PP
the DT O B-NP
hypertension NN B-NP I-NP
and CC O I-NP
altered JJ B-NP I-NP
MR NN I-NP I-NP
status NN B-NP I-NP
. . O O

Mineralocorticoid NN B-NP B-NP
effector NN I-NP I-NP
mechanism NN I-NP I-NP
in IN B-PP B-PP
preeclampsia NN B-NP B-NP
. . O O

Mineralocorticoid NN B-NP B-NP
effector NN I-NP I-NP
mechanisms NNS I-NP I-NP
were VBD B-VP B-VP
evaluated VBN I-VP I-VP
in IN B-PP B-PP
29 CD B-NP B-NP
patients NNS I-NP I-NP
with IN B-PP B-PP
preeclampsia NN B-NP B-NP
and CC B-PP B-PP
in IN B-PP B-PP
25 CD B-NP B-NP
uncomplicated JJ I-NP I-NP
pregnancies NNS I-NP I-NP
by IN B-PP B-PP
measurement NN B-NP B-NP
of IN B-PP B-PP
plasma NN B-NP B-NP
aldosterone NN I-NP I-NP
, , O O
levels NNS B-NP B-NP
of IN B-PP B-PP
mineralocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
( ( O O
MR NN B-NP B-NP
) ) O O
in IN B-PP B-PP
mononuclear JJ B-NP B-NP
leucocytes NNS I-NP I-NP
, , O O
and CC O I-CC
subtraction NN B-NP B-NP
potential NN I-NP I-NP
difference NN I-NP I-NP
( ( O O
SPD NN B-NP B-NP
; : O O
rectal JJ B-NP B-NP
minus CC I-NP I-NP
oral JJ I-NP I-NP
values NNS I-NP I-NP
) ) O O
. . O O

Mean NN B-NP B-NP
values NNS I-NP I-NP
for IN B-PP B-PP
plasma NN B-NP B-NP
aldosterone NN I-NP I-NP
were VBD B-VP B-VP
not RB O B-ADJP
different JJ B-ADJP I-ADJP
between IN B-PP B-PP
the DT B-NP B-NP
two CD I-NP I-NP
groups NNS I-NP I-NP
, , O O
but CC O I-CC
significant JJ B-NP B-NP
differences NNS I-NP I-NP
were VBD B-VP B-VP
observed VBN I-VP I-VP
for IN B-PP B-PP
MR NN B-NP B-NP
( ( O O
preeclampsia NN B-NP I-NP
, , O O
81 CD B-NP B-NP
+/- CC I-NP I-NP
44 CD I-NP I-NP
receptors/cell NNS I-NP I-NP
; : O O
controls NNS B-NP B-NP
, , O O
306 CD B-NP I-NP
+/- CC I-NP I-NP
168 CD I-NP I-NP
) ) O O
and CC O I-CC
SPD NN B-NP B-NP
( ( O O
preeclampsia NN B-NP I-NP
, , O O
65 CD B-NP B-NP
+/- CC I-NP I-NP
7 CD I-NP I-NP
mV NN I-NP I-NP
; : O O
controls NNS B-NP B-NP
, , O O
12 CD B-NP I-NP
+/- CC I-NP I-NP
5 CD I-NP I-NP
mV NN I-NP I-NP
) ) O O
. . O O

In IN B-PP B-PP
six CD B-NP B-NP
cases NNS I-NP I-NP
we PRP B-NP B-NP
determined VBD B-VP B-VP
MR NN B-NP B-NP
, , O O
plasma NN B-NP B-NP
aldosterone NN I-NP I-NP
, , O O
and CC O I-CC
SPD NN B-NP B-NP
in IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
preeclampsia NN B-NP B-NP
before IN B-PP I-NP
and CC B-PP I-CC
3 CD B-NP B-NP
months NNS I-NP I-NP
after IN B-PP B-PP
delivery NN B-NP B-NP
. . O O

MR NNS B-NP B-NP
were VBD B-VP B-VP
reduced VBN I-VP I-VP
before IN B-PP B-PP
delivery NN B-NP B-NP
( ( O O
96 CD B-NP B-NP
+/- CC I-NP I-NP
27 CD I-NP I-NP
receptors/cell NNS I-NP I-NP
) ) O O
, , O O
and CC O I-CC
SPD NN B-NP B-NP
increased VBD B-VP B-VP
( ( O O
64 CD B-NP B-NP
+/- CC I-NP I-CC
8 CD I-NP B-NP
mV NN I-NP I-NP
) ) O O
, , O O
with IN B-PP B-PP
both DT B-NP B-NP
parameters NNS I-NP I-NP
normalizing VBG B-VP B-VP
after IN B-PP B-PP
delivery NN B-NP B-NP
( ( O O
MR NN B-NP B-NP
, , O O
242 CD B-NP B-NP
+/- CC I-NP I-NP
79 CD I-NP I-NP
; : O O
SPD NN B-NP B-NP
, , O O
14.0 CD B-NP B-NP
+/- CC I-NP I-CC
4 CD I-NP B-NP
mV NN I-NP I-NP
) ) O O
. . O O

Aldosterone NN B-NP B-NP
levels NNS I-NP I-NP
returned VBD B-VP B-VP
to TO B-PP B-PP
normal JJ B-NP B-NP
nonpregnant JJ I-NP I-NP
values NNS I-NP I-NP
after IN B-PP B-PP
delivery NN B-NP B-NP
. . O O

These DT B-NP B-NP
data NNS I-NP I-NP
suggest VBP B-VP B-VP
an DT B-NP B-NP
important JJ I-NP I-NP
role NN I-NP I-NP
for IN B-PP B-PP
abnormalities NNS B-NP B-NP
in IN B-PP B-PP
mineralocorticoid NN B-NP B-NP
effector NN I-NP I-NP
mechanisms NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
etiology NN I-NP I-NP
of IN B-PP B-PP
preeclampsia NN B-NP B-NP
and CC O I-CC
could MD B-VP B-VP
be VB I-VP I-VP
an DT B-NP B-NP
useful JJ I-NP I-NP
marker NN I-NP I-NP
for IN B-PP B-PP
diagnosis NN B-NP B-NP
. . O O

A DT B-NP B-NP
lymphoid JJ I-NP I-NP
cell-specific JJ I-NP I-NP
nuclear JJ I-NP I-NP
factor NN I-NP I-NP
containing VBG B-VP B-VP
c-Rel-like JJ B-NP B-NP
proteins NNS I-NP I-NP
preferentially RB B-ADVP B-ADVP
interacts VBZ B-VP B-VP
with IN B-PP B-PP
interleukin-6 NN B-NP B-NP
kappa NN I-NP I-NP
B-related JJ I-NP I-NP
motifs NNS I-NP I-NP
whose WP$ B-NP B-NP
activities NNS I-NP I-NP
are VBP B-VP B-VP
repressed VBN I-VP I-VP
in IN B-PP B-PP
lymphoid JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

The DT B-NP B-NP
proto-oncoprotein NN I-NP I-NP
c-Rel NN I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
member NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
nuclear JJ I-NP I-NP
factor NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
family NN I-NP I-NP
, , O O
which WDT B-NP B-NP
includes VBZ B-VP B-VP
the DT O B-NP
p50 NN B-NP I-NP
and CC O I-NP
p65 NN B-NP I-NP
subunits NNS B-NP I-NP
of IN B-PP B-PP
nuclear JJ B-NP B-NP
factor NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
. . O O

We PRP B-NP B-NP
show VBP B-VP B-VP
here RB B-ADVP B-ADVP
that IN B-SBAR B-PP
c-Rel NN B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
kappa NN B-NP B-NP
B NN I-NP I-NP
sites NNS I-NP I-NP
as IN B-PP B-PP
homodimers NNS B-NP B-NP
as RB B-CONJP B-ADVP
well RB I-CONJP I-ADVP
as IN I-CONJP B-PP
heterodimers NNS B-NP B-NP
with IN B-PP B-PP
p50 NN B-NP B-NP
. . O O

These DT B-NP B-NP
homodimers NNS B-NP I-NP
and CC O I-NP
heterodimers NNS B-NP I-NP
show VBP B-VP B-VP
distinct JJ B-NP B-NP
DNA-binding JJ I-NP I-NP
specificities NNS I-NP I-NP
and CC O I-NP
affinities NNS B-NP I-NP
for IN B-PP B-PP
various JJ B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
motifs NNS I-NP I-NP
. . O O

In IN B-PP B-PP
particular JJ B-NP B-NP
, , O O
the DT B-NP B-NP
c-Rel NN I-NP I-NP
homodimer NN I-NP I-NP
has VBZ B-VP B-VP
a DT B-NP B-NP
high JJ I-NP I-NP
affinity NN I-NP I-NP
for IN B-PP B-PP
interleukin-6 NN B-NP B-NP
( ( O O
IL-6 NN B-NP B-NP
) ) O O
and CC O I-CC
beta NN B-NP B-NP
interferon NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
sites NNS B-NP I-NP
. . O O

In IN B-PP B-PP
spite NN I-PP B-NP
of IN I-PP B-PP
its PRP$ B-NP B-NP
association NN I-NP I-NP
with IN B-PP B-PP
p50 NN B-NP B-NP
in FW B-ADVP B-NP
vitro FW I-ADVP I-NP
, , O O
however RB B-ADVP B-ADVP
, , O O
we PRP B-NP B-NP
found VBD B-VP B-VP
a DT B-NP B-NP
lymphoid JJ I-NP I-NP
cell-specific JJ I-NP I-NP
nuclear JJ I-NP I-NP
factor NN I-NP I-NP
in FW B-ADVP B-NP
vivo FW I-ADVP I-NP
that WDT B-NP B-NP
contains VBZ B-VP B-VP
c-Rel NN B-NP B-NP
but CC B-CONJP B-NP
not RB I-CONJP I-NP
p50 NN B-NP B-NP
epitopes NNS B-NP I-NP
; : O O
this DT B-NP B-NP
factor NN I-NP I-NP
, , O O
termed VBN B-VP B-NP
IL-6 NN B-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
binding NN I-NP I-NP
factor NN I-NP I-NP
II CD I-NP B-NP
, , O O
appears VBZ B-VP B-VP
to TO I-VP I-VP
contain VB I-VP I-VP
the DT B-NP B-NP
c-Rel NN I-NP I-NP
homodimer NN I-NP I-NP
and CC O I-CC
preferentially RB B-VP B-VP
recognizes VBZ I-VP I-VP
several JJ B-NP B-NP
IL-6 NN I-NP I-NP
kappa NN I-NP I-NP
B-related JJ I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
motifs NNS I-NP I-NP
. . O O

Although IN B-SBAR B-SBAR
it PRP B-NP B-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
previously RB I-VP I-VP
shown VBN I-VP I-VP
that IN B-SBAR B-PP
the DT B-NP B-NP
IL-6 NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
motif NN I-NP I-NP
functions VBZ B-VP B-VP
as IN B-PP B-PP
a DT B-NP B-NP
potent JJ I-NP I-NP
IL-1/tumor NN I-NP I-NP
necrosis NN I-NP I-NP
factor-responsive JJ I-NP I-NP
element NN I-NP I-NP
in IN B-PP B-PP
nonlymphoid JJ B-NP B-NP
cells NNS I-NP I-NP
, , O O
its PRP$ B-NP B-NP
activity NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
repressed VBN I-VP I-VP
in IN B-PP B-PP
lymphoid JJ B-NP B-NP
cells NNS I-NP I-NP
such JJ B-PP B-PP
as IN I-PP I-PP
a DT B-NP B-NP
Jurkat NN I-NP I-NP
T-cell NN I-NP I-NP
line NN I-NP I-NP
. . O O

We PRP B-NP B-NP
also RB B-ADVP B-ADVP
present VBP B-VP B-VP
evidence NN B-NP B-NP
that IN B-SBAR B-PP
IL-6 NN B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
binding NN I-NP I-NP
factor NN I-NP I-NP
II CD I-NP B-NP
functions VBZ B-VP B-VP
as IN B-PP B-PP
a DT B-NP B-NP
repressor NN I-NP I-NP
specific JJ B-ADJP B-ADJP
for IN B-PP B-PP
IL-6 NN B-NP B-NP
kappa NN I-NP I-NP
B-related JJ I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
motifs NNS I-NP I-NP
in IN B-PP B-PP
lymphoid JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

Modulation NN B-NP B-NP
of IN B-PP B-PP
normal JJ B-NP B-NP
erythroid JJ I-NP I-NP
differentiation NN I-NP I-NP
by IN B-PP B-PP
the DT O B-NP
endogenous JJ B-NP I-NP
thyroid NN I-NP I-NP
hormone NN I-NP I-NP
and CC O I-CC
retinoic JJ B-NP B-NP
acid NN I-NP I-NP
receptors NNS B-NP I-NP
: : O O
a DT B-NP B-NP
possible JJ I-NP I-NP
target NN I-NP I-NP
for IN B-PP B-PP
v-erbA NN B-NP B-NP
oncogene NN I-NP I-NP
action NN I-NP I-NP
. . O O

The DT B-NP B-NP
v-erbA NN I-NP I-NP
oncogene NN I-NP I-NP
, , O O
a DT B-NP B-NP
mutated VBN I-NP I-NP
version NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
thyroid NN I-NP I-NP
hormone NN I-NP I-NP
receptor NN I-NP I-NP
alpha NN I-NP I-NP
( ( O O
c-erbA/TR-alpha NN B-NP B-NP
) ) O O
, , O O
inhibits VBZ B-VP B-VP
erythroid JJ B-NP B-NP
differentiation NN I-NP I-NP
and CC O I-CC
constitutively RB B-VP B-VP
represses VBZ I-VP I-VP
transcription NN B-NP B-NP
of IN B-PP B-PP
certain JJ B-NP B-NP
erythrocyte NN I-NP I-NP
genes NNS I-NP I-NP
, , O O
suggesting VBG B-VP B-VP
a DT B-NP B-NP
normal JJ I-NP I-NP
function NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
proto-oncogene NN I-NP I-NP
c-erbA NN I-NP I-NP
in IN B-PP B-PP
erythropoiesis NN B-NP B-NP
. . O O

Here RB B-ADVP B-ADVP
we PRP B-NP B-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
the DT B-NP B-NP
endogenous JJ I-NP I-NP
thyroid NN I-NP I-NP
hormone NN I-NP I-NP
receptor NN I-NP I-NP
alpha NN I-NP I-NP
( ( O O
c-erbA/TR-alpha NN B-NP B-NP
) ) O O
and CC O I-CC
the DT B-NP B-NP
closely RB I-NP I-NP
related JJ I-NP I-NP
retinoic JJ B-NP I-NP
acid NN I-NP I-NP
receptor NN I-NP I-NP
alpha NN I-NP I-NP
( ( O O
RAR-alpha NN B-NP B-NP
) ) O O
play VBP B-VP B-VP
a DT B-NP B-NP
role NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
normal JJ B-NP B-NP
erythroid JJ I-NP I-NP
differentiation NN I-NP I-NP
. . O O

Retinoic JJ B-NP B-NP
acid NN I-NP I-NP
( ( O O
RA NN B-NP B-NP
) ) O O
distinctly RB B-ADVP B-VP
modulated VBD B-VP I-VP
the DT B-NP B-NP
erythroid JJ I-NP I-NP
differentiation NN I-NP I-NP
program NN I-NP I-NP
of IN B-PP B-PP
normal JJ B-NP B-NP
erythroid JJ I-NP I-NP
progenitors NNS I-NP I-NP
and CC O I-NP
erythroblasts NNS B-NP I-NP
reversibly RB B-VP B-VP
transformed VBN I-VP I-VP
by IN B-PP B-PP
a DT B-NP B-NP
conditional JJ I-NP I-NP
tyrosine NN I-NP I-NP
kinase NN I-NP I-NP
oncogene NN I-NP I-NP
. . O O

When WRB B-ADVP B-ADVP
added VBN B-VP B-VP
pulsewise RB B-ADVP B-ADVP
to TO B-PP B-PP
immature JJ B-NP B-NP
cells NNS I-NP I-NP
, , O O
differentiation NN B-NP B-NP
was VBD B-VP B-VP
accelerated VBN I-VP I-VP
while IN B-SBAR B-SBAR
more RBR B-NP B-NP
mature JJ I-NP I-NP
cells NNS I-NP I-NP
underwent VBD B-VP B-VP
premature JJ B-NP B-NP
cell NN I-NP I-NP
death NN I-NP I-NP
. . O O

Thyroid NN B-NP B-NP
hormone NN I-NP I-NP
( ( O O
T3 NN B-NP B-NP
) ) O O
alone RB B-ADVP B-ADVP
caused VBD B-VP B-VP
similar JJ B-NP B-NP
but CC I-NP I-NP
weaker JJR I-NP I-NP
effects NNS I-NP I-NP
. . O O

Interestingly RB B-ADVP B-ADVP
, , O O
T3 NN B-NP B-NP
strongly RB B-ADVP B-VP
enhanced VBD B-VP I-VP
the DT B-NP B-NP
action NN I-NP I-NP
of IN B-PP B-PP
RA NN B-NP B-NP
, , O O
suggesting VBG B-VP B-VP
cooperative JJ B-NP B-NP
action NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
two CD I-NP I-NP
receptors NNS I-NP I-NP
in IN B-PP B-PP
modulating VBG B-VP B-VP
erythroid JJ B-NP B-NP
differentiation NN I-NP I-NP
. . O O

Expression NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
RAR-alpha NN I-NP I-NP
in IN B-PP B-PP
receptor-negative JJ B-NP B-NP
erythroblasts NNS I-NP I-NP
conferred VBD B-VP B-VP
RA-induced JJ B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
differentiation NN B-NP B-NP
to TO B-PP B-PP
the DT B-NP B-NP
otherwise RB I-NP I-NP
unresponsive JJ I-NP I-NP
cells NNS I-NP I-NP
, , O O
thus RB O B-ADVP
showing VBG B-VP B-VP
that IN B-SBAR B-PP
the DT B-NP B-NP
RAR-alpha NN I-NP I-NP
is VBZ B-VP B-VP
essential JJ B-ADJP B-ADJP
for IN B-PP B-PP
the DT B-NP B-NP
RA NN I-NP I-NP
effect NN I-NP I-NP
. . O O

Likewise RB B-ADVP B-ADVP
, , O O
enhanced VBN B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
exogenous JJ B-NP B-NP
c-erbA/TR-alpha NN I-NP I-NP
in IN B-PP B-PP
erythroblasts NNS B-NP B-NP
rendered VBD B-VP B-VP
them PRP B-NP B-NP
susceptible JJ B-ADJP B-ADJP
to TO B-PP B-PP
modulation NN B-NP B-NP
of IN B-PP B-PP
differentiation NN B-NP B-NP
by IN B-PP B-PP
T3 NN B-NP B-NP
, , O O
suggesting VBG B-VP B-VP
a DT B-NP B-NP
similar JJ I-NP I-NP
function NN I-NP I-NP
of IN B-PP B-PP
both DT B-NP B-NP
receptors NNS I-NP I-NP
. . O O

Leukotriene NN B-NP B-NP
B4 NN I-NP I-NP
stimulates VBZ B-VP B-VP
c-fos NN B-NP B-NP
and CC O I-NP
c-jun NN B-NP I-NP
gene NN B-NP I-NP
transcription NN I-NP I-NP
and CC O I-NP
AP-1 NN B-NP I-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
monocytes NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
examined VBN I-VP I-VP
the DT B-NP B-NP
effect NN I-NP I-NP
of IN B-PP B-PP
leukotriene NN B-NP B-NP
B4 NN I-NP I-NP
( ( O O
LTB4 NN B-NP B-NP
) ) O O
, , O O
a DT B-NP B-NP
potent JJ I-NP I-NP
lipid NN I-NP I-NP
proinflammatory JJ I-NP I-NP
mediator NN I-NP I-NP
, , O O
on IN B-PP B-PP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
proto-oncogenes NNS I-NP I-NP
c-jun NN B-NP I-NP
and CC O I-NP
c-fos NN B-NP I-NP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
we PRP B-NP B-NP
looked VBD B-VP B-VP
at IN B-PP B-PP
the DT B-NP B-NP
modulation NN I-NP I-NP
of IN B-PP B-PP
nuclear JJ B-NP B-NP
factors NNS I-NP I-NP
binding VBG B-VP B-VP
specifically RB B-PP B-ADVP
to TO I-PP B-PP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
element NN I-NP I-NP
after IN B-PP B-PP
LTB4 NN B-NP B-NP
stimulation NN I-NP I-NP
. . O O

LTB4 NN B-NP B-NP
increased VBD B-VP B-VP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
c-fos NN I-NP I-NP
gene NN I-NP I-NP
in IN B-PP B-PP
a DT O B-NP
time- NN B-NP I-NP
and CC O I-NP
concentration-dependent JJ B-ADJP I-NP
manner NN B-NP I-NP
. . O O

The DT B-NP B-NP
c-jun NN I-NP I-NP
mRNA NN I-NP I-NP
, , O O
which WDT B-ADVP B-NP
is VBZ B-VP B-VP
constitutively RB I-VP I-VP
expressed VBN I-VP I-VP
in IN B-PP B-PP
human JJ B-NP B-NP
peripheral-blood NN I-NP I-NP
monocytes NNS I-NP I-NP
at IN B-PP B-PP
relatively RB B-NP B-NP
high JJ I-NP I-NP
levels NNS I-NP I-NP
, , O O
was VBD B-VP B-VP
also RB I-VP B-ADVP
slightly RB I-VP B-ADJP
augmented JJ I-VP I-ADJP
by IN B-PP B-PP
LTB4 NN B-NP B-NP
, , O O
although IN B-SBAR B-PP
to TO B-PP B-PP
a DT B-NP B-NP
much RB I-NP I-NP
lower JJR I-NP I-NP
extent NN I-NP I-NP
than IN B-PP B-PP
c-fos NN B-NP B-NP
. . O O

The DT B-NP B-NP
kinetics NNS I-NP I-NP
of IN B-PP B-PP
expression NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
two CD I-NP I-NP
genes NNS I-NP I-NP
were VBD B-VP B-VP
also RB B-ADJP B-ADVP
slightly RB I-ADJP B-ADJP
different JJ I-ADJP I-ADJP
, , O O
with IN B-PP B-PP
c-fos NN B-NP B-NP
mRNA NN I-NP I-NP
reaching VBG B-VP B-VP
a DT B-NP B-NP
peak NN I-NP I-NP
at IN B-PP B-PP
15 CD B-NP B-NP
min NN I-NP I-NP
after IN B-PP B-PP
stimulation NN B-NP B-NP
and CC O I-NP
c-jun NN B-NP I-NP
at IN B-PP B-PP
30 CD B-NP B-NP
min NN I-NP I-NP
. . O O

Both DT B-NP B-NP
messages NNS I-NP I-NP
rapidly RB B-ADVP B-ADVP
declined VBD B-VP B-VP
thereafter RB B-ADVP B-ADVP
. . O O

Stability NN B-NP B-NP
of IN B-PP B-PP
the DT O B-NP
c-fos NN B-NP I-NP
and CC O I-NP
c-jun NN B-NP I-NP
mRNA NN B-NP I-NP
was VBD B-VP B-VP
not RB I-VP I-VP
affected VBN I-VP I-VP
by IN B-PP B-PP
LTB4 NN B-NP B-NP
, , O O
as IN B-SBAR B-SBAR
assessed VBN B-VP B-VP
after IN B-PP B-PP
actinomycin NN B-NP B-NP
D NN I-NP I-NP
treatment NN I-NP I-NP
. . O O

Nuclear JJ B-NP B-NP
transcription NN I-NP I-NP
studies NNS I-NP I-NP
in FW B-ADVP B-NP
vitro FW I-ADVP I-NP
showed VBD B-VP B-VP
that IN B-SBAR B-SBAR
LTB4 NN B-NP B-NP
increased VBD B-VP B-VP
the DT B-NP B-NP
transcription NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
c-fos NN I-NP I-NP
gene NN I-NP I-NP
7-fold RB B-ADVP B-ADVP
and CC O I-CC
the DT B-NP B-NP
c-jun NN I-NP I-NP
gene NN I-NP I-NP
1.4-fold RB B-ADVP B-ADVP
. . O O

Resting VBG B-NP B-NP
monocytes NNS I-NP I-NP
contained VBD B-VP B-VP
nuclear JJ B-NP B-NP
factors NNS I-NP I-NP
binding VBG B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
element NN I-NP I-NP
, , O O
but CC O I-CC
stimulation NN B-NP B-NP
of IN B-PP B-PP
monocytes NNS B-NP B-NP
with IN B-PP B-PP
LTB4 NN B-NP B-NP
induced VBD B-VP B-VP
greater JJR B-NP B-NP
AP-1-binding JJ I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
nuclear JJ B-NP B-NP
proteins NNS I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
LTB4 NN B-NP B-NP
may MD B-VP B-VP
regulate VB I-VP I-VP
the DT B-NP B-NP
production NN I-NP I-NP
of IN B-PP B-PP
different JJ B-NP B-NP
cytokines NNS I-NP I-NP
by IN B-PP B-PP
modulating VBG B-VP B-VP
the DT B-NP B-NP
yield NN I-NP I-NP
and/or CC O I-CC
the DT B-NP B-NP
function NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
factors NNS I-NP I-NP
such JJ B-PP B-PP
as IN I-PP I-PP
AP-1-binding JJ B-NP B-NP
proto-oncogene NN I-NP I-NP
products NNS I-NP I-NP
. . O O

An DT B-NP B-NP
11-base-pair JJ I-NP I-NP
DNA NN I-NP I-NP
sequence NN I-NP I-NP
motif NN I-NP I-NP
apparently RB B-ADJP B-ADJP
unique JJ I-ADJP I-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
interleukin NN I-NP I-NP
4 CD I-NP I-NP
gene NN I-NP I-NP
confers VBZ B-VP B-VP
responsiveness NN B-NP B-NP
to TO B-PP B-PP
T-cell NN B-NP B-NP
activation NN I-NP I-NP
signals NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
identified VBN I-VP I-VP
a DT B-NP B-NP
DNA NN I-NP I-NP
segment NN I-NP I-NP
that WDT B-NP B-NP
confers VBZ B-VP B-VP
responsiveness NN B-NP B-NP
to TO B-PP B-PP
antigen NN B-NP B-NP
stimulation NN I-NP I-NP
signals NNS I-NP I-NP
on IN B-PP B-PP
the DT O B-NP
human JJ O I-NP
interleukin NN B-NP I-NP
( ( O O
IL NN B-NP B-NP
) ) O O
4 CD B-NP B-NP
gene NN I-NP I-NP
in IN B-PP B-PP
Jurkat NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

The DT B-NP B-NP
human JJ I-NP I-NP
IL-4 NN I-NP I-NP
gene NN I-NP I-NP
, , O O
of IN B-PP B-PP
10 CD B-NP B-NP
kilobases NNS I-NP I-NP
, , O O
is VBZ B-VP B-VP
composed VBN I-VP I-VP
of IN B-PP B-PP
four CD B-NP B-NP
exons NNS I-NP I-NP
and CC O I-CC
three CD B-NP B-NP
introns NNS I-NP I-NP
. . O O

A DT B-NP B-NP
cis-acting JJ I-NP I-NP
element NN I-NP I-NP
( ( O O
P NN B-NP B-NP
sequence NN I-NP I-NP
) ) O O
resides VBZ B-VP B-VP
in IN B-PP B-PP
the DT O B-NP
5' JJ B-NP I-NP
upstream JJ B-NP I-NP
region NN I-NP I-NP
; : O O
no DT B-NP B-NP
additional JJ I-NP I-NP
DNA NN I-NP I-NP
segments NNS I-NP I-NP
with IN B-PP B-PP
enhancer NN B-NP B-NP
activity NN I-NP I-NP
were VBD B-VP B-VP
identified VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
IL-4 NN I-NP I-NP
gene NN I-NP I-NP
. . O O

For IN B-PP B-PP
further JJ B-NP B-NP
mapping NN I-NP I-NP
purposes NNS I-NP I-NP
, , O O
a DT B-NP B-NP
fusion NN I-NP I-NP
promoter NN I-NP I-NP
was VBD B-VP B-VP
constructed VBN I-VP I-VP
with IN B-PP B-PP
the DT B-NP B-NP
granulocyte/macrophage JJ I-NP I-NP
colony-stimulating JJ I-NP I-NP
factor NN I-NP I-NP
basic JJ I-NP I-NP
promoter NN I-NP I-NP
containing VBG B-VP B-VP
60 CD B-NP B-NP
base NN I-NP I-NP
pairs NNS I-NP I-NP
of IN B-PP B-PP
sequence NN B-NP B-NP
upstream JJ B-ADJP B-ADJP
from IN B-PP B-PP
the DT B-NP B-NP
cap NN I-NP I-NP
site NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
mouse NN I-NP I-NP
granulocyte/macrophage JJ I-NP I-NP
colony-stimulating JJ I-NP I-NP
factor NN I-NP I-NP
gene NN I-NP I-NP
and CC O I-CC
various JJ B-NP B-NP
lengths NNS I-NP I-NP
of IN B-PP B-PP
the DT O B-NP
5' JJ B-NP I-NP
upstream JJ B-NP I-NP
sequence NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
IL-4 NN I-NP I-NP
gene NN I-NP I-NP
. . O O

The DT B-NP B-NP
P NN I-NP I-NP
sequence NN I-NP I-NP
was VBD B-VP B-VP
located JJ B-ADJP B-ADJP
between IN B-PP B-PP
positions NNS B-NP B-NP
-79 CD B-NP B-NP
and CC O I-NP
-69 CD B-NP I-NP
relative JJ B-PP I-NP
to TO I-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
start NN I-NP I-NP
site NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
IL-4 NN I-NP I-NP
gene NN I-NP I-NP
, , O O
and CC O I-CC
this DT B-NP B-NP
location NN I-NP I-NP
was VBD B-VP B-VP
confirmed VBN I-VP I-VP
by IN B-PP B-PP
base-substitution NN B-NP B-NP
mutations NNS I-NP I-NP
. . O O

The DT B-NP B-NP
plasmids NNS I-NP I-NP
carrying VBG B-VP B-VP
multiple JJ B-NP B-NP
copies NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
P NN I-NP I-NP
sequence NN I-NP I-NP
showed VBD B-VP B-VP
higher JJR B-NP B-NP
responsiveness NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
stimulation NN I-NP I-NP
. . O O

The DT B-NP B-NP
binding VBG I-NP I-NP
protein NN I-NP I-NP
( ( I-NP O
s NNS I-NP B-NP
) ) O O
that WDT B-NP B-NP
recognize VBP B-VP B-VP
the DT B-NP B-NP
P NN I-NP I-NP
sequence NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
IL-4 NN I-NP I-NP
gene NN I-NP I-NP
were VBD B-VP B-VP
identified VBN I-VP I-VP
by IN B-PP B-PP
DNA-mobility-shift JJ B-NP B-NP
assays NNS I-NP I-NP
. . O O

The DT B-NP B-NP
binding NN I-NP I-NP
of IN B-PP B-PP
NF(P) NN B-NP B-NP
( ( O O
a DT B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
protein NN I-NP I-NP
that WDT B-NP B-NP
specifically RB B-ADVP B-VP
recognizes VBZ B-VP I-VP
the DT B-NP B-NP
P NN I-NP I-NP
sequence NN I-NP I-NP
) ) O O
to TO B-PP B-PP
the DT B-NP B-NP
P NN I-NP I-NP
sequence NN I-NP I-NP
was VBD B-VP B-VP
abolished VBN I-VP I-VP
when WRB B-ADVP B-ADVP
oligonucleotides NNS B-NP B-NP
carrying VBG B-VP B-VP
base NN B-NP B-NP
substitutions NNS I-NP I-NP
were VBD B-VP B-VP
used VBN I-VP I-VP
, , O O
indicating VBG B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
NF(P) NN I-NP I-NP
interaction NN I-NP I-NP
is VBZ B-VP B-VP
sequence-specific JJ B-ADJP B-ADJP
and CC O I-CC
that IN B-SBAR B-SBAR
binding NN B-NP B-NP
specificity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
protein NN I-NP I-NP
paralleled VBD B-VP B-VP
the DT B-NP B-NP
sequence NN I-NP I-NP
requirements NNS I-NP I-NP
for IN B-PP B-PP
IL-4 NN B-NP B-NP
expression NN I-NP I-NP
in FW B-ADVP B-NP
vivo FW I-ADVP I-NP
. . O O

The DT B-NP B-NP
P NN I-NP I-NP
sequence NN I-NP I-NP
does VBZ B-VP B-VP
not RB I-VP I-VP
share VB I-VP I-VP
homology NN B-NP B-NP
with IN B-PP B-PP
the DT O B-NP
5' JJ B-NP I-NP
upstream JJ B-NP I-NP
sequence NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
IL-2 NN I-NP I-NP
gene NN I-NP I-NP
, , O O
even RB B-SBAR B-SBAR
though IN I-SBAR I-SBAR
surrounding VBG B-NP B-NP
sequences NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
IL-4 NN I-NP I-NP
gene NN I-NP I-NP
share NN B-VP I-NP
high JJ B-NP B-NP
homology NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
IL-2 NN I-NP I-NP
gene NN I-NP I-NP
. . O O

We PRP B-NP B-NP
conclude VBP B-VP B-VP
that IN B-SBAR B-SBAR
a DT B-NP B-NP
different JJ I-NP I-NP
set NN I-NP I-NP
of IN B-PP B-PP
proteins NNS B-NP B-NP
recognize VBP B-VP B-VP
IL-2 NN B-NP B-NP
and CC O I-NP
IL-4 NN B-NP I-NP
genes NNS B-NP I-NP
. . O O

Glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
binding NN I-NP I-NP
in IN B-PP B-PP
three CD B-NP B-NP
different JJ I-NP I-NP
cell NN I-NP I-NP
types NNS I-NP I-NP
in IN B-PP B-PP
major JJ B-NP B-NP
depressive JJ I-NP I-NP
disorder NN I-NP I-NP
: : O O
lack NN B-NP B-NP
of IN B-PP B-PP
evidence NN B-NP B-NP
of IN B-PP B-PP
receptor NN B-NP B-NP
binding NN I-NP I-NP
defect NN I-NP I-NP
. . O O

1 LS B-LST B-NP
. . O O
In IN B-SBAR B-SBAR
order NN O I-NN
to TO O B-VP
further RB B-ADVP I-VP
understand VB B-VP I-VP
the DT B-NP B-NP
apparent JJ I-NP I-NP
glucocorticoid NN I-NP I-NP
resistance NN I-NP I-NP
in IN B-PP B-PP
major JJ B-NP B-NP
depressive JJ I-NP I-NP
disorder NN I-NP I-NP
, , O O
circadian JJ B-NP B-NP
variation NN I-NP I-NP
in IN B-PP B-PP
cortisol NN B-NP B-NP
concentration NN I-NP I-NP
, , O O
dexamethasone NN B-NP B-NP
suppression NN I-NP I-NP
and CC O I-NP
glucocorticoid NN B-NP I-NP
receptor NN I-NP I-NP
binding NN I-NP I-NP
in IN B-PP B-PP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
, , O O
polymorphonuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
and CC O I-CC
cultured VBN B-NP B-NP
skin NN I-NP I-NP
fibroblasts NNS I-NP I-NP
were VBD B-VP B-VP
measured VBN I-VP I-VP
in IN B-PP B-PP
rigidly RB B-NP B-NP
defined VBN I-NP I-NP
major JJ I-NP I-NP
depressive JJ I-NP I-NP
disorder NN I-NP I-NP
patients NNS I-NP I-NP
and CC O I-CC
non-depressed JJ B-NP B-NP
psychiatric JJ I-NP I-NP
controls NNS I-NP I-NP
. . O O

2 LS B-LST B-NP
. . O O
Mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
binding VBG B-VP B-VP
to TO B-PP B-PP
glucocorticoid NN B-NP B-NP
correlated VBD B-VP B-VP
significantly RB B-ADVP B-ADVP
with IN B-PP B-PP
polymorphonuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
binding VBG B-VP B-VP
to TO B-PP B-PP
glucocorticoid NN B-NP B-NP
, , O O
but CC O I-CC
both DT B-NP B-NP
determinations NNS I-NP I-NP
failed VBD B-VP B-VP
to TO I-VP I-VP
differentiate VB I-VP I-VP
major JJ B-NP B-NP
depressive JJ I-NP I-NP
disorder NN I-NP I-NP
and CC O I-NP
control NN B-NP I-NP
subjects NNS I-NP I-NP
. . O O

3 LS B-LST I-LS
. . O O
Initial JJ B-NP I-NP
and CC I-NP I-NP
post-dexamethasone JJ I-NP I-NP
in FW I-NP B-NP
vitro FW I-NP I-NP
fibroblast NN I-NP I-NP
binding VBG B-VP B-VP
to TO B-PP B-PP
glucocorticoid NN B-NP B-NP
was VBD B-VP B-VP
not RB O I-RB
different JJ B-ADJP B-ADJP
between IN B-PP B-PP
major JJ B-NP B-NP
depressive JJ I-NP I-NP
disorder NN I-NP I-NP
and CC O I-CC
non-depressed JJ B-NP B-NP
control NN I-NP I-NP
subjects NNS I-NP I-NP
. . O O

4 LS B-LST I-LS
. . O O
The DT B-NP B-NP
phenomenon NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
resistance NN I-NP I-NP
in IN B-PP B-PP
major JJ B-NP B-NP
depressive JJ I-NP I-NP
disorder NN I-NP I-NP
remains VBZ B-VP B-VP
unexplained JJ B-ADJP B-ADJP
. . O O

Kinetics NNS B-NP B-NP
of IN B-PP B-PP
nuclear JJ B-NP B-NP
translocation NN I-NP I-NP
and CC O I-CC
turnover NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
vitamin NN I-NP I-NP
D NN I-NP I-NP
receptor NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
HL60 NN I-NP I-NP
leukemia NN I-NP I-NP
cells NNS I-NP I-NP
and CC O I-CC
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
lymphocytes NNS I-NP I-NP
-- : O O
coincident JJ B-NP B-NP
rise NN I-NP I-NP
of IN B-PP B-PP
DNA-relaxing JJ B-NP B-NP
activity NN I-NP I-NP
in IN B-PP B-PP
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
. . O O

High JJ B-NP B-NP
affinity NN I-NP I-NP
receptors NNS I-NP I-NP
( ( O O
VDR NN B-NP B-NP
) ) O O
for IN B-PP B-PP
1,25-dihydroxycholecalciferol NN B-NP B-NP
( ( O O
calcitriol NN B-NP B-NP
) ) O O
are VBP B-VP B-VP
expressed VBN I-VP I-VP
in IN B-PP B-PP
HL60 NN B-NP B-NP
human JJ I-NP I-NP
leukemia NN I-NP I-NP
cells NNS I-NP I-NP
and CC B-PP I-CC
in IN B-PP B-PP
low JJ B-NP B-NP
numbers NNS I-NP I-NP
in IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
lymphocytes NNS I-NP I-NP
( ( O O
PBL NN B-NP B-NP
) ) O O
. . O O

HL60 NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
expressing VBG B-VP B-VP
some DT B-NP B-NP
characteristics NNS I-NP I-NP
of IN B-PP B-PP
promyelocytes NNS B-NP B-NP
, , O O
can MD B-VP B-VP
be VB I-VP I-VP
induced VBN I-VP I-VP
to TO B-PP B-PP
monocytoid NN B-NP B-NP
differentiation NN I-NP I-NP
by IN B-PP B-PP
calcitriol NN B-NP B-NP
. . O O

Specific JJ B-NP B-NP
nuclear JJ I-NP I-NP
translocation NN I-NP I-NP
of IN B-PP B-PP
(3H)calcitriol/VDR NN B-NP B-NP
was VBD B-VP B-VP
examined VBN I-VP I-VP
after IN B-PP B-PP
exposure NN B-NP B-NP
of IN B-PP B-PP
whole JJ B-NP B-NP
cells NNS I-NP I-NP
to TO B-PP B-PP
10(-9) CD B-NP B-NP
M/l NN I-NP I-NP
calcitriol NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
presence NN B-NP I-NP
and CC O I-NP
absence NN B-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
500-fold JJ I-NP I-NP
excess NN I-NP I-NP
of IN B-PP B-PP
unlabeled JJ B-NP B-NP
ligand NN I-NP I-NP
and CC O I-CC
subsequent JJ B-NP B-NP
isolation NN I-NP I-NP
of IN B-PP B-PP
nuclei NNS B-NP B-NP
. . O O

Specific JJ B-NP B-NP
nuclear JJ I-NP I-NP
translocation NN I-NP I-NP
of IN B-PP B-PP
(3H)calcitriol/VDR NN B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
time NN B-ADJP B-NP
dependent JJ I-ADJP I-NP
reaching VBG B-VP B-VP
a DT B-NP B-NP
maximum NN I-NP I-NP
of IN B-PP B-PP
approximately RB B-NP B-NP
2100 CD I-NP I-NP
binding VBG I-NP I-NP
sites/nucleus NNS I-NP I-NP
after IN B-PP B-PP
3 CD B-NP B-NP
h NN I-NP I-NP
of IN B-PP B-PP
incubation NN B-NP B-NP
in IN B-PP B-PP
HL60 NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
whereas IN O B-PP
a DT B-NP B-NP
maximum NN I-NP I-NP
of IN B-PP B-PP
approximately RB B-NP B-NP
310 CD I-NP I-NP
binding VBG I-NP I-NP
sites/nucleus NNS I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
after IN B-PP B-PP
3 CD B-NP B-NP
h NN I-NP I-NP
in IN B-PP B-PP
PBL NN B-NP B-NP
. . O O

Pulse NN B-NP B-NP
exposure NN I-NP I-NP
of IN B-PP B-PP
HL60 NN B-NP B-NP
to TO B-PP B-PP
radiolabeled VBN B-NP B-NP
hormone NN I-NP I-NP
for IN B-PP B-PP
3 CD B-NP B-NP
h NN I-NP I-NP
followed VBN B-VP B-VP
by IN B-PP B-PP
culture NN B-NP B-NP
in IN B-PP B-PP
medium NN B-NP B-NP
without IN B-PP B-PP
serum NN B-NP B-NP
and CC O I-NP
calcitriol NN B-NP I-NP
lead VBD B-VP B-VP
to TO B-PP B-PP
nuclear JJ B-NP B-NP
retention NN I-NP I-NP
of IN B-PP B-PP
approximately RB B-NP B-NP
1600 CD I-NP I-NP
radiolabeled VBN I-NP I-NP
VDR NN I-NP I-NP
by IN B-PP B-PP
8 CD B-NP B-NP
h NN I-NP I-NP
and CC O I-CC
approximately RB B-NP B-NP
1000 CD I-NP I-NP
VDR NN I-NP I-NP
by IN B-PP B-PP
24 CD B-NP B-NP
h NN I-NP I-NP
. . O O

Radiolabeled VBN B-NP B-NP
VDR NN I-NP I-NP
disappeared VBD B-VP B-VP
from IN B-PP B-PP
the DT B-NP B-NP
nuclear JJ I-NP I-NP
compartment NN I-NP I-NP
with IN B-PP B-PP
a DT B-NP B-NP
halflife NN I-NP I-NP
of IN B-PP B-PP
approximately RB B-NP B-NP
30 CD I-NP I-NP
min NN I-NP I-NP
if IN B-SBAR B-SBAR
cells NNS B-NP B-NP
were VBD B-VP B-VP
cultured VBN I-VP I-VP
with IN B-PP B-PP
identical JJ B-NP B-NP
concentrations NNS I-NP I-NP
of IN B-PP B-PP
unlabeled JJ B-NP B-NP
hormone NN I-NP I-NP
after IN B-PP B-PP
the DT B-NP B-NP
pulse NN I-NP I-NP
( ( O O
pulse/chase-experiments NNS B-NP B-NP
) ) O O
. . O O

No DT B-NP B-NP
difference NN I-NP I-NP
of IN B-PP B-PP
VDR NN B-NP B-NP
retention NN I-NP I-NP
in IN B-PP B-PP
pulse NN B-NP B-NP
and CC O I-NP
pulse/chase-experiments NNS B-NP I-NP
was VBD B-VP B-VP
seen VBN I-VP I-VP
in IN B-PP B-PP
PBL NN B-NP B-NP
, , O O
where WRB B-ADVP B-ADVP
VDR NN B-NP B-NP
halflife NN I-NP I-NP
was VBD B-VP B-VP
approximately RB B-NP B-NP
30 CD I-NP I-NP
min NN I-NP I-NP
. . O O

No DT B-NP B-NP
specific JJ I-NP I-NP
translocation NN I-NP I-NP
into IN B-PP B-PP
the DT B-NP B-NP
nuclear JJ I-NP I-NP
compartment NN I-NP I-NP
was VBD B-VP B-VP
seen VBN I-VP I-VP
when WRB B-ADVP B-ADVP
isolated VBN B-NP B-NP
nuclei NNS I-NP I-NP
were VBD B-VP B-VP
incubated VBN I-VP I-VP
in IN B-PP B-PP
(3H)calcitriol NN B-NP B-NP
. . O O

Radiolabeled VBN B-NP B-NP
hormone/receptor NN I-NP I-NP
complexes NNS I-NP I-NP
of IN B-PP B-PP
nuclei NNS B-NP B-NP
isolated VBN B-VP B-VP
from IN B-PP B-PP
cells NNS B-NP B-NP
exposed VBN B-VP B-VP
for IN B-PP B-PP
3 CD B-NP B-NP
h NN I-NP I-NP
to TO B-PP B-PP
radiolabeled VBN B-NP B-NP
hormone NN I-NP I-NP
-- : O O
in IN B-PP B-PP
contrast NN I-PP B-NP
to TO I-PP B-PP
identical JJ B-NP B-NP
experiments NNS I-NP I-NP
with IN B-PP B-PP
intact JJ B-NP B-NP
cells NNS I-NP I-NP
-- : O O
did VBD B-VP B-VP
not RB I-VP I-VP
disappear VB I-VP I-VP
from IN B-PP B-PP
the DT B-NP B-NP
nuclear JJ I-NP I-NP
compartment NN I-NP I-NP
upon IN B-PP B-PP
incubation NN B-NP B-NP
of IN B-PP B-PP
nuclei NNS B-NP B-NP
with IN B-PP B-PP
identical JJ B-NP B-NP
concentrations NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
unlabeled JJ I-NP I-NP
compound NN I-NP I-NP
. . O O

The DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
DNA NN B-NP B-NP
relaxing NN I-NP I-NP
enzymes NNS I-NP I-NP
( ( O O
e.g. FW B-ADVP B-NP
topoisomerases NNS B-NP I-NP
I CD B-NP I-NP
and CC O I-NP
II CD B-NP I-NP
) ) O O
in IN B-PP B-PP
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
was VBD B-VP B-VP
measured VBN I-VP I-VP
using VBG B-VP I-VP
a DT B-NP B-NP
PBR NN I-NP I-NP
322-relaxation-assay NN I-NP I-NP
. . O O

Enhanced VBN B-NP B-NP
overall JJ I-NP I-NP
enzyme NN I-NP I-NP
activity NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
in IN B-PP B-PP
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
by IN B-PP B-PP
1 CD B-NP B-NP
h NN I-NP I-NP
after IN B-PP B-PP
incubation NN B-NP B-NP
with IN B-PP B-PP
calcitriol NN B-NP B-NP
( ( O O
final JJ B-NP B-NP
ethanol NN I-NP I-NP
concentration NN I-NP I-NP
0.0001 CD B-NP I-NP
% NN I-NP I-NP
v/v NN I-NP I-NP
) ) O O
in IN B-PP B-PP
HL60 NN B-NP B-NP
and CC O I-NP
PBL NN B-NP I-NP
. . O O

The DT B-NP B-NP
enhanced VBN I-NP I-NP
activity NN I-NP I-NP
disappeared VBD B-VP B-VP
after IN B-PP B-PP
2 CD B-NP B-NP
h NN I-NP I-NP
in IN B-PP B-PP
PBL NN B-NP B-NP
, , O O
whereas IN O B-SBAR
it PRP B-NP B-NP
was VBD B-VP B-VP
still RB I-VP I-VP
enhanced VBN I-VP I-VP
by IN B-PP B-PP
4 CD B-NP B-NP
h NN I-NP I-NP
in IN B-PP B-PP
HL60 NN B-NP B-NP
. . O O

No DT B-NP B-NP
effect NN I-NP I-NP
was VBD B-VP B-VP
seen VBN I-VP I-VP
in IN B-PP B-PP
ethanol NN B-NP B-NP
treated JJ I-NP I-NP
controls NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
conclude VBP B-VP B-VP
that IN B-SBAR B-SBAR
a DT B-NP B-NP
specific JJ I-NP I-NP
nuclear JJ I-NP I-NP
translocation NN I-NP I-NP
mechanism NN I-NP I-NP
exists VBZ B-VP B-VP
for IN B-PP B-PP
calcitriol NN B-NP B-NP
in IN B-PP B-PP
both DT B-NP B-NP
cell NN I-NP I-NP
types NNS I-NP I-NP
examined VBN B-VP B-VP
, , O O
most RBS B-ADVP B-ADVP
likely RB I-ADVP I-ADVP
due IN B-PP B-PP
to TO I-PP B-PP
translocation NN B-NP B-NP
of IN B-PP B-PP
receptor NN B-NP B-NP
proteins NNS I-NP I-NP
after IN B-PP B-PP
hormone NN B-NP B-NP
binding NN I-NP I-NP
. . O O

Translocated VBN B-NP B-NP
hormone/receptor NN I-NP I-NP
complexes NNS I-NP I-NP
compete VBP B-VP B-VP
for IN B-PP B-PP
a DT B-NP B-NP
limited JJ I-NP I-NP
number NN I-NP I-NP
of IN B-PP B-PP
specific JJ B-NP B-NP
nuclear JJ I-NP I-NP
binding VBG I-NP I-NP
sites NNS I-NP I-NP
. . O O

Enhanced VBN B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
topoisomerases NNS B-NP B-NP
in IN B-PP B-PP
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
upon IN B-PP B-PP
translocation NN B-NP B-NP
of IN B-PP B-PP
VDR NN B-NP B-NP
might MD B-VP B-VP
reflect VB I-VP I-VP
interaction NN B-NP B-NP
of IN B-PP B-PP
both DT B-NP B-NP
within IN B-PP B-PP
the DT B-NP B-NP
nuclear JJ I-NP I-NP
compartment NN I-NP I-NP
, , O O
thus RB B-ADVP B-ADVP
initiating VBG B-VP B-VP
DNA-unwinding NN B-NP B-NP
, , O O
a DT B-NP B-NP
prerequisite NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
initiation NN I-NP I-NP
. . O O

The DT B-NP B-NP
B NN I-NP I-NP
cell-specific JJ I-NP I-NP
nuclear JJ I-NP I-NP
factor NN I-NP I-NP
OTF-2 NN I-NP I-NP
positively RB B-ADVP B-ADVP
regulates VBZ B-VP B-VP
transcription NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
class NN I-NP I-NP
II CD I-NP I-NP
transplantation NN I-NP I-NP
gene NN I-NP I-NP
, , O O
DRA NN B-NP B-NP
. . O O

The DT B-NP B-NP
promoter NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
major JJ I-NP I-NP
histocompatibility NN I-NP I-NP
class NN I-NP I-NP
II CD I-NP I-NP
gene NN I-NP I-NP
DRA NN I-NP I-NP
contains VBZ B-VP B-VP
an DT B-NP B-NP
octamer NN I-NP I-NP
element NN I-NP I-NP
( ( O O
ATTTGCAT NN B-NP B-NP
) ) O O
that WDT B-NP B-NP
is VBZ B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
efficient JJ B-NP B-NP
DRA NN I-NP I-NP
expression NN I-NP I-NP
in IN B-PP B-PP
B NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Several JJ B-NP B-NP
DNA-binding JJ I-NP I-NP
proteins NNS I-NP I-NP
are VBP B-VP B-VP
known VBN I-VP I-VP
to TO I-VP I-VP
bind VB I-VP I-VP
this DT B-NP B-NP
sequence NN I-NP I-NP
. . O O

The DT B-ADJP B-NP
best RBS I-ADJP I-NP
characterized VBN I-ADJP I-NP
are VBP B-VP B-VP
the DT B-NP B-NP
B NN I-NP I-NP
cell-specific JJ I-NP I-NP
OTF-2 NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
ubiquitous JJ I-NP I-NP
OTF-1 NN I-NP I-NP
. . O O

This DT B-NP B-NP
report NN I-NP I-NP
directly RB B-ADVP B-ADVP
demonstrates VBZ B-VP B-VP
that IN B-SBAR B-PP
OTF-2 NN B-NP B-NP
but CC B-CONJP B-NP
not RB I-CONJP I-NP
OTF-1 NN B-NP B-NP
regulates VBZ B-VP B-VP
the DT B-NP B-NP
DRA NN I-NP I-NP
gene NN I-NP I-NP
. . O O

In FW B-NP B-NP
vitro FW I-NP I-NP
transcription NN I-NP I-NP
analysis NN I-NP I-NP
using VBG B-VP B-VP
protein NN B-NP B-NP
fractions NNS I-NP I-NP
enriched VBN B-ADJP B-VP
for IN B-PP B-PP
the DT B-NP B-NP
octamer-binding JJ I-NP I-NP
protein NN I-NP I-NP
OTF-2 NN I-NP I-NP
demonstrate VBP B-VP B-VP
a DT B-NP B-NP
positive JJ I-NP I-NP
functional JJ I-NP I-NP
role NN I-NP I-NP
for IN B-PP B-PP
OTF-2 NN B-NP B-NP
in IN B-PP B-PP
DRA NN B-NP B-NP
gene NN I-NP I-NP
transcription NN I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
OTF-1-enriched JJ B-NP B-NP
protein NN I-NP I-NP
fractions NNS I-NP I-NP
did VBD B-VP B-VP
not RB I-VP I-VP
affect VB I-VP I-VP
DRA NN B-NP B-NP
gene NN I-NP I-NP
transcription NN I-NP I-NP
although IN B-SBAR B-SBAR
it PRP B-NP B-NP
functionally RB B-ADVP B-ADVP
enhanced VBD B-VP B-VP
the DT B-NP B-NP
transcription NN I-NP I-NP
of IN B-PP B-PP
another DT B-NP B-NP
gene NN I-NP I-NP
. . O O

Recombinant JJ B-NP B-NP
OTF-2 NN I-NP I-NP
protein NN I-NP I-NP
produced VBN B-VP B-VP
by IN B-PP B-PP
in FW B-NP B-NP
vitro FW I-NP I-NP
transcription/translation NN I-NP I-NP
could MD B-VP B-VP
also RB I-VP I-VP
enhance VB I-VP I-VP
DRA NN B-NP B-NP
gene NN I-NP I-NP
transcription NN I-NP I-NP
in FW B-ADVP B-NP
vitro FW I-ADVP I-NP
. . O O

In FW B-NP B-NP
vivo FW I-NP I-NP
transient JJ I-NP I-NP
transfection NN I-NP I-NP
studies NNS I-NP I-NP
utilizing VBG B-VP B-VP
an DT B-NP B-NP
OTF-2 NN I-NP I-NP
expression NN I-NP I-NP
vector NN I-NP I-NP
resulted VBD B-VP B-VP
in IN B-PP B-PP
similar JJ B-NP B-NP
findings NNS I-NP I-NP
: : O O
that IN B-SBAR B-SBAR
OTF-2 NN B-NP B-NP
protein NN I-NP I-NP
enhanced VBD B-VP B-VP
DRA NN B-NP B-NP
gene NN I-NP I-NP
transcription NN I-NP I-NP
, , O O
and CC O I-CC
that IN B-SBAR B-SBAR
this DT B-NP B-NP
effect NN I-NP I-NP
requires VBZ B-VP B-VP
an DT B-NP B-NP
intact JJ I-NP I-NP
octamer NN I-NP I-NP
element NN I-NP I-NP
. . O O

Together RB B-ADVP B-ADVP
these DT B-NP B-NP
results NNS I-NP I-NP
constitute VBP B-VP B-VP
the DT B-NP B-NP
first JJ I-NP I-NP
direct JJ I-NP I-NP
evidence NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
positive JJ I-NP I-NP
role NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
lymphoid-specific JJ I-NP I-NP
octamer-binding JJ I-NP I-NP
factor NN I-NP I-NP
in IN B-PP B-PP
DRA NN B-NP B-NP
gene NN I-NP I-NP
transcription NN I-NP I-NP
. . O O

( ( O O
Regulation NN B-NP B-NP
of IN B-PP B-PP
intracellular JJ B-NP B-NP
cholesterol NN I-NP I-NP
synthesis NN I-NP I-NP
in IN B-PP B-PP
hypercholesterolemia NN B-NP B-NP
by IN B-PP B-PP
glucocorticoids NNS B-NP B-NP
) ) O O

The DT B-NP B-NP
rate NN I-NP I-NP
of IN B-PP B-PP
endogenous JJ B-NP B-NP
cholesterol NN I-NP I-NP
synthesis NN I-NP I-NP
in IN B-PP B-PP
blood NN B-NP B-NP
lymphocytes NNS I-NP I-NP
and CC O I-CC
skin NN B-NP B-NP
fibroblasts NNS I-NP I-NP
from IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
type NN B-NP B-NP
IIa NN I-NP I-NP
hyperlipidemia NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
increased VBN I-VP I-VP
in IN B-PP B-PP
comparison NN I-PP B-NP
with IN I-PP B-PP
healthy JJ B-NP B-NP
donors NNS I-NP I-NP
. . O O

The DT B-NP B-NP
cells NNS I-NP I-NP
of IN B-PP B-PP
hyperlipidemic JJ B-NP B-NP
patients NNS I-NP I-NP
had VBD B-VP B-VP
lowered JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
concomitantly RB B-PP B-ADVP
with IN I-PP B-PP
a DT B-NP B-NP
partial JJ I-NP I-NP
loss NN I-NP I-NP
of IN B-PP B-PP
their PRP$ B-NP B-NP
sensitivity NN I-NP I-NP
to TO B-PP B-PP
glucocorticoids NNS B-NP B-NP
. . O O

In IN B-PP B-PP
fibroblasts NNS B-NP B-NP
from IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
hereditary JJ B-NP B-NP
hypercholesteremia NN I-NP I-NP
of IN B-PP B-PP
homozygous JJ B-NP B-NP
type NN I-NP I-NP
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
did VBD B-VP B-VP
not RB I-VP I-VP
exceed VB I-VP I-VP
10 CD B-NP B-NP
% NN I-NP I-NP
of IN B-PP B-PP
their PRP$ B-NP B-NP
content NN I-NP I-NP
in IN B-PP B-PP
normal JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

The DT B-NP B-NP
decrease NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
in IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
type NN B-NP B-NP
IIa NN I-NP I-NP
hyperlipidemia NN I-NP I-NP
seems VBZ B-VP B-VP
to TO I-VP I-VP
be VB I-VP I-VP
a DT B-NP B-NP
compensatory JJ I-NP I-NP
response NN I-NP I-NP
of IN B-PP B-PP
cells NNS B-NP B-NP
culminating VBG B-VP B-VP
in IN B-PP B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
endogenous JJ B-NP B-NP
cholesterol NN I-NP I-NP
synthesis NN I-NP I-NP
. . O O

Transcription NN B-NP B-NP
factor NN I-NP I-NP
activation NN I-NP I-NP
and CC O I-CC
functional JJ B-NP B-NP
stimulation NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
monocytes NNS I-NP I-NP
. . O O

Activation NN B-NP B-NP
of IN B-PP B-PP
expression NN B-NP B-NP
of IN B-PP B-PP
genes NNS B-NP B-NP
encoding VBG B-VP B-VP
transcription NN B-NP B-NP
factors NNS I-NP I-NP
: : O O
c-fos NN B-NP B-NP
and CC O I-NP
c-jun NN B-NP I-NP
and CC O I-NP
formation NN B-NP I-NP
of IN B-PP B-PP
AP1 NN B-NP B-NP
transcriptional JJ I-NP I-NP
complex NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
monocytes NNS I-NP I-NP
was VBD B-VP B-VP
investigated VBN I-VP I-VP
. . O O

It PRP B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
that IN B-SBAR B-PP
lipopolysaccharide NN B-NP B-NP
induced VBD B-VP B-VP
strongly RB B-ADVP B-ADVP
both CC O I-CC
c-fos NN B-NP B-NP
and CC O I-NP
c-jun NN B-NP I-NP
expression NN B-NP I-NP
as RB B-CONJP B-ADVP
well RB I-CONJP I-ADVP
as IN I-CONJP B-PP
AP1 NN B-NP B-NP
formation NN I-NP I-NP
. . O O

Interferon NN B-NP B-NP
gamma NN I-NP I-NP
activated VBD B-VP B-VP
strongly RB B-ADVP B-ADVP
c-fos NN B-NP B-NP
and CC O I-CC
weakly RB B-ADVP B-ADVP
c-jun NN B-NP B-NP
and CC O I-NP
AP1 NN B-NP I-NP
. . O O

Tumor NN B-NP B-NP
necrosis NN I-NP I-NP
factor NN I-NP I-NP
induced VBD B-VP B-VP
slightly RB B-ADVP B-ADVP
c-fos NN B-NP B-NP
and CC O I-CC
had VBD B-VP B-VP
almost RB B-NP B-NP
no DT I-NP I-NP
effect NN I-NP I-NP
on IN B-PP B-PP
c-jun NN B-NP B-NP
and CC O I-NP
AP1 NN B-NP I-NP
. . O O

The DT B-NP B-NP
data NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
differences NNS B-NP B-NP
in IN B-PP B-PP
functional JJ B-NP B-NP
responses NNS I-NP I-NP
elicited VBN B-VP B-VP
in IN B-PP B-PP
monocytes NNS B-NP B-NP
by IN B-PP B-PP
all DT B-NP B-NP
three CD I-NP I-NP
factors NNS I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
dependent JJ B-ADJP B-ADJP
on IN B-PP B-PP
different JJ B-NP B-NP
routes NNS I-NP I-NP
on IN B-PP B-PP
nuclear JJ B-NP B-NP
signalling NN I-NP I-NP
employed VBN B-VP B-VP
by IN B-PP B-PP
the DT B-NP B-NP
factors NNS I-NP I-NP
. . O O

Corticosteroid NN B-NP B-NP
receptors NNS I-NP I-NP
and CC O I-CC
lymphocyte NN B-NP B-NP
subsets NNS I-NP I-NP
in IN B-PP B-PP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
in IN B-PP B-PP
aging NN B-NP B-NP
. . O O

Plasma NN B-NP B-NP
cortisol NN I-NP I-NP
and CC O I-NP
aldosterone NN B-NP I-NP
levels NNS B-NP I-NP
and CC O I-CC
number NN B-NP B-NP
of IN B-PP B-PP
related JJ B-NP B-NP
receptors NNS I-NP I-NP
in IN B-PP B-PP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
were VBD B-VP B-VP
measured VBN I-VP I-VP
in IN B-PP B-PP
49 CD B-NP B-NP
healthy JJ I-NP I-NP
aged JJ I-NP I-NP
subjects NNS I-NP I-NP
( ( O O
62-97 CD B-NP B-NP
yr NN I-NP I-NP
) ) O O
and CC B-PP I-CC
in IN B-PP B-PP
21 CD B-NP B-NP
adult JJ I-NP I-NP
controls NNS I-NP I-NP
( ( O O
21-50 CD B-NP B-NP
yr NN I-NP I-NP
) ) O O
. . O O

In IN B-PP B-PP
all DT B-NP B-NP
subjects NNS I-NP I-NP
, , O O
in IN B-PP B-PP
addition NN B-NP B-NP
, , O O
lymphocyte NN B-NP B-NP
subsets NNS I-NP I-NP
were VBD B-VP B-VP
determined VBN I-VP I-VP
as IN B-PP B-PP
an DT B-NP B-NP
index NN I-NP I-NP
of IN B-PP B-PP
corticosteroid NN B-NP B-NP
action NN I-NP I-NP
. . O O

The DT B-NP B-NP
mean NN I-NP I-NP
number NN I-NP I-NP
of IN B-PP B-PP
type NN B-NP B-NP
I CD I-NP I-NP
and CC O I-CC
type NN B-NP B-NP
II CD I-NP I-NP
receptors NNS B-NP I-NP
was VBD B-VP B-VP
significantly RB B-ADJP B-ADJP
lower JJR I-ADJP I-ADJP
in IN B-PP B-PP
aged JJ B-NP B-NP
subjects NNS I-NP I-NP
than IN B-PP B-PP
in IN B-PP B-PP
controls NNS B-NP B-NP
( ( O O
respectively RB B-ADVP B-ADVP
, , O O
198 CD B-NP B-NP
+/- CC I-NP I-NP
96 CD I-NP I-NP
and CC I-NP I-NP
272 CD I-NP I-NP
+/- CC I-NP I-NP
97 CD I-NP I-NP
receptors/cell NNS I-NP I-NP
for IN B-PP B-PP
type NN B-NP B-NP
I CD I-NP I-NP
, , O O
and CC O I-CC
1,794 CD B-NP B-NP
+/- CC I-NP I-NP
803 CD I-NP I-NP
and CC I-NP I-NP
3,339 CD I-NP I-NP
+/- CC I-NP I-NP
918 CD I-NP I-NP
for IN B-PP B-PP
type NN B-NP B-NP
II CD I-NP I-NP
receptors NNS B-NP I-NP
) ) O O
. . O O

Plasma NN B-NP B-NP
aldosterone NN B-NP I-NP
and CC O I-CC
cortisol NN B-NP B-NP
and CC O I-NP
lymphocyte NN B-NP I-NP
subsets NNS I-NP I-NP
were VBD B-VP B-VP
not RB O B-ADJP
different JJ B-ADJP I-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
two CD I-NP I-NP
groups NNS I-NP I-NP
. . O O

All DT B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
parameters NNS I-NP I-NP
were VBD B-VP B-VP
also RB I-VP I-VP
tested VBN I-VP I-VP
for IN B-PP B-PP
correlation NN B-NP B-NP
, , O O
and CC O I-CC
a DT B-NP B-NP
significant JJ I-NP I-NP
inverse JJ I-NP I-NP
correlation NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
between IN B-PP B-PP
age NN B-NP B-NP
and CC O I-NP
type NN B-NP I-NP
I CD I-NP I-NP
and CC O I-CC
type NN B-NP B-NP
II CD I-NP I-NP
receptors NNS B-NP I-NP
when WRB B-ADVP B-ADVP
all DT B-NP B-NP
subjects NNS I-NP I-NP
were VBD B-VP B-VP
plotted VBN I-VP I-VP
and CC O I-CC
between IN B-PP B-PP
aged JJ B-NP B-NP
and CC I-NP I-NP
CD4 NN I-NP I-NP
and CC I-NP I-CC
age NN I-NP B-NP
and CC I-NP I-NP
CD4/CD8 NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
aged JJ I-NP I-NP
group NN I-NP I-NP
. . O O

These DT B-NP B-NP
data NNS I-NP I-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
aged JJ B-NP B-NP
subjects NNS I-NP I-NP
have VBP B-VP B-VP
reductions NNS B-NP B-NP
of IN B-PP B-PP
corticosteroid NN B-NP B-NP
receptors NNS I-NP I-NP
that WDT B-NP B-NP
are VBP B-VP B-VP
not RB I-VP I-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
increase NN B-NP B-NP
of IN B-PP B-PP
related JJ B-NP B-NP
steroids NNS I-NP I-NP
and CC O I-CC
that IN B-SBAR B-SBAR
this DT B-NP B-NP
situation NN I-NP I-NP
probably RB B-ADVP B-ADVP
represents VBZ B-VP B-VP
a DT B-NP B-NP
concomitant NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
normal JJ I-NP I-NP
aging NN I-NP I-NP
process NN I-NP I-NP
. . O O

Stable JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
HB24 NN B-NP B-NP
, , O O
a DT B-NP B-NP
diverged JJ I-NP I-NP
human JJ I-NP I-NP
homeobox NN I-NP I-NP
gene NN I-NP I-NP
, , O O
in IN B-PP B-PP
T NN B-NP B-NP
lymphocytes NNS I-NP I-NP
induces VBZ B-VP B-VP
genes NNS B-NP B-NP
involved VBN B-VP B-VP
in IN B-PP B-PP
T NN B-NP B-NP
cell NN I-NP I-NP
activation NN B-NP I-NP
and CC O I-NP
growth NN B-NP I-NP
. . O O

A DT B-NP B-NP
diverged JJ I-NP I-NP
homeobox NN I-NP I-NP
gene NN I-NP I-NP
, , O O
HB24 NN B-NP B-NP
, , O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
known VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
induced VBN I-VP I-VP
following VBG B-PP I-VP
lymphocyte NN B-NP B-NP
activation NN I-NP I-NP
, , O O
was VBD B-VP B-VP
introduced VBN I-VP I-VP
into IN B-PP B-PP
Jurkat NN B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
under IN B-PP B-PP
the DT B-NP B-NP
control NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
constitutive JJ I-NP I-NP
promoter NN I-NP I-NP
. . O O

Stable JJ B-NP B-NP
transfectants NNS I-NP I-NP
of IN B-PP B-PP
HB24 NN B-NP B-NP
were VBD B-VP B-VP
established VBN I-VP I-VP
that WDT B-NP B-NP
expressed VBD B-VP B-VP
high JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
HB24 NN B-NP B-NP
mRNA NN I-NP I-NP
and CC O I-CC
possessed VBD B-VP B-VP
an DT B-NP B-NP
altered JJ I-NP I-NP
phenotype NN I-NP I-NP
suggestive JJ B-ADJP B-ADJP
of IN B-PP B-PP
activated VBN B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

A DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
genes NNS B-NP B-NP
known VBN B-VP B-VP
to TO I-VP I-VP
be VB I-VP I-VP
induced VBN I-VP I-VP
following VBG B-PP I-VP
T NN B-NP B-NP
cell NN I-NP I-NP
activation NN I-NP I-NP
and CC O I-CC
associated VBN B-VP B-VP
with IN B-PP B-PP
cell NN B-NP B-NP
growth NN I-NP I-NP
were VBD B-VP B-VP
increased VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
transfectants NNS I-NP I-NP
, , O O
including VBG B-PP B-PP
c-fos NN B-NP B-NP
, , O O
c-myc NN B-NP I-NP
, , O O
c-myb NN B-NP I-NP
, , O O
HLA-DR NN B-NP I-NP
, , O O
lck NN B-NP I-NP
, , O O
NF-kappa NN B-NP I-NP
B NN I-NP I-NP
, , O O
interleukin-2 NN B-NP B-NP
and CC O I-NP
interleukin-2 NN B-NP I-NP
receptor NN I-NP I-NP
alpha NN I-NP I-NP
( ( O O
IL-2R NN B-NP B-NP
alpha NN I-NP I-NP
) ) O O
. . O O

Analysis NN B-NP B-NP
of IN B-PP B-PP
IL-2R NN B-NP B-NP
alpha NN I-NP I-NP
expression NN I-NP I-NP
by IN B-PP B-PP
transient JJ B-NP B-NP
transfection NN I-NP I-NP
of IN B-PP B-PP
IL-2R NN B-NP B-NP
alpha NN I-NP I-NP
promoter NN I-NP I-NP
constructs NNS I-NP I-NP
into IN B-PP B-PP
the DT B-NP B-NP
HB24 NN I-NP I-NP
transfectants NNS I-NP I-NP
revealed VBD B-VP B-VP
constitutive JJ B-NP B-NP
expression NN I-NP I-NP
( ( O O
about RB B-NP B-NP
60 CD I-NP I-NP
% NN I-NP I-NP
of IN B-PP B-PP
phytohemagglutinin- NN B-NP B-NP
and CC O I-NP
phorbol NN B-ADJP I-NP
ester-activated JJ I-ADJP I-NP
Jurkat NN B-NP I-NP
cells NNS I-NP I-NP
) ) O O
that WDT B-NP B-NP
was VBD B-VP B-VP
dependent JJ B-ADJP B-ADJP
on IN B-PP B-PP
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
site NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
IL-2R NN I-NP I-NP
alpha NN I-NP I-NP
promoter NN I-NP I-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
as IN B-PP B-PP
a DT B-NP B-NP
consequence NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
increased VBN I-NP I-NP
HB24 NN I-NP I-NP
mRNA NN I-NP I-NP
levels NNS I-NP I-NP
, , O O
the DT B-NP B-NP
Jurkat NN I-NP I-NP
HB24 NN I-NP I-NP
transfectants NNS I-NP I-NP
proliferated VBD B-VP B-VP
more RBR B-ADVP B-ADVP
rapidly RB I-ADVP I-ADVP
than IN B-PP B-PP
control NN B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
. . O O

Thus RB B-ADVP B-ADVP
, , O O
stable JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
HB24 NN B-NP B-NP
confers VBZ B-VP B-VP
an DT B-NP B-NP
activation NN I-NP I-NP
phenotype NN I-NP I-NP
on IN B-PP B-PP
a DT B-NP B-NP
human JJ I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
, , O O
implicating VBG B-VP B-VP
this DT B-NP B-NP
gene NN I-NP I-NP
as IN B-PP B-PP
an DT B-NP B-NP
important JJ I-NP I-NP
transcriptional JJ I-NP I-NP
factor NN I-NP I-NP
during IN B-PP B-PP
T NN B-NP B-NP
cell NN I-NP I-NP
activation NN B-NP I-NP
and CC O I-NP
growth NN B-NP I-NP
. . O O

Studies NNS B-NP B-NP
on IN B-PP B-PP
the DT B-NP B-NP
biological JJ I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
triiodothyronine NN B-NP B-NP
sulfate NN I-NP I-NP
. . O O

Hepatic JJ B-NP B-NP
microsomes NNS I-NP I-NP
and CC O I-CC
isolated VBN B-NP B-VP
hepatocytes NNS I-NP B-NP
in IN B-PP B-PP
short JJ B-NP B-NP
term NN I-NP I-NP
culture NN I-NP I-NP
desulfate VBP B-VP B-VP
T3 NN B-NP B-NP
sulfate NN I-NP I-NP
( ( O O
T3SO4 NN B-NP B-NP
) ) O O
. . O O

We PRP B-NP B-NP
, , O O
therefore RB B-ADVP B-ADVP
, , O O
wished VBD B-VP B-VP
to TO I-VP I-VP
determine VB I-VP I-VP
whether IN B-SBAR B-SBAR
T3SO4 NN B-NP B-NP
could MD B-VP B-VP
mimic VB I-VP I-VP
the DT B-NP B-NP
action NN I-NP I-NP
of IN B-PP B-PP
thyroid NN B-NP B-NP
hormone NN I-NP I-NP
in FW B-ADVP B-NP
vitro FW I-ADVP I-NP
. . O O

T3SO4 NN B-NP B-NP
had VBD B-VP B-VP
no DT B-NP B-NP
thyromimetic JJ I-NP I-NP
effect NN I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
Ca(2+)-ATPase NN B-NP B-NP
in IN B-PP B-PP
human JJ B-NP B-NP
erythrocyte NN I-NP I-NP
membranes NNS I-NP I-NP
at IN B-PP B-PP
doses NNS B-NP B-NP
up RB B-NP B-ADVP
to TO I-NP B-PP
10,000 CD I-NP B-NP
times NNS I-NP I-NP
the DT I-NP B-NP
maximally RB I-NP I-NP
effective JJ I-NP I-NP
dose NN I-NP I-NP
of IN B-PP B-PP
T3 NN B-NP B-NP
( ( O O
10/(-10) CD B-NP B-NP
mol/L NN I-NP I-NP
) ) O O
. . O O

In IN B-PP B-PP
GH4C1 NN B-NP B-NP
pituitary JJ I-NP I-NP
cells NNS I-NP I-NP
, , O O
T3SO4 NN B-NP B-NP
failed VBD B-VP B-VP
to TO I-VP I-VP
displace VB I-VP I-VP
(125I)T3 NN B-NP B-NP
from IN B-PP B-PP
nuclear JJ B-NP B-NP
receptors NNS I-NP I-NP
in IN B-PP B-PP
intact JJ B-NP B-NP
cells NNS I-NP I-NP
or CC O I-CC
soluble JJ B-NP B-NP
preparations NNS I-NP I-NP
. . O O

Thus RB B-ADVP B-ADVP
, , O O
T3SO4 NN B-NP B-NP
was VBD B-VP B-VP
not RB O I-RB
directly RB B-ADVP B-ADJP
thyromimetic JJ B-ADJP I-ADJP
in IN B-PP B-PP
either CC O I-CC
an DT B-NP B-NP
isolated VBN I-NP I-NP
human JJ I-NP I-NP
membrane NN I-NP I-NP
system NN I-NP I-NP
or CC O I-CC
a DT B-NP B-NP
pituitary JJ I-NP I-NP
cell NN I-NP I-NP
system NN I-NP I-NP
in IN B-PP B-PP
which WDT B-NP B-NP
nuclear JJ B-NP B-NP
receptor NN I-NP I-NP
occupancy NN I-NP I-NP
correlates VBZ B-VP B-VP
with IN B-PP B-PP
GH NN B-NP B-NP
synthesis NN I-NP I-NP
. . O O

Thyroid NN B-NP B-NP
hormones NNS I-NP I-NP
inhibit VBP B-VP B-VP
(3H)glycosaminoglycan NN B-NP B-NP
synthesis NN I-NP I-NP
by IN B-PP B-PP
cultured VBN B-NP B-NP
human JJ I-NP I-NP
dermal JJ I-NP I-NP
fibroblasts NNS I-NP I-NP
, , O O
and CC O I-CC
T3SO4 NN B-NP B-NP
displayed VBN B-VP B-VP
about IN B-NP B-PP
0.5 CD I-NP B-NP
% NN I-NP I-NP
the DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
T3 NN B-NP B-NP
at IN B-PP B-PP
72 CD B-NP B-NP
h NN I-NP I-NP
. . O O

Human JJ B-NP B-NP
fibroblasts NNS I-NP I-NP
contained VBD B-VP B-VP
roughly RB B-ADVP B-NP
the DT B-NP I-NP
same JJ I-NP I-NP
level NN I-NP I-NP
of IN B-PP B-PP
microsomal JJ B-NP B-NP
p-nitrophenyl NN I-NP I-NP
sulfatase NN I-NP I-NP
activity NN I-NP I-NP
as IN B-PP B-PP
that DT B-NP B-NP
previously RB B-VP I-NP
observed VBN I-VP B-VP
in IN B-PP B-PP
hepatic JJ B-NP B-NP
microsomes NNS I-NP I-NP
. . O O

Propylthiouracil NN B-NP B-NP
( ( O O
50 CD B-NP B-NP
mumol/L NN I-NP I-NP
) ) O O
did VBD B-VP B-VP
not RB I-VP I-VP
affect VB I-VP I-VP
the DT B-NP B-NP
action NN I-NP I-NP
of IN B-PP B-PP
T3SO4 NN B-NP B-NP
, , O O
suggesting VBG B-VP B-VP
that IN B-SBAR B-SBAR
deiodination NN B-NP B-NP
was VBD B-VP B-VP
not RB O I-RB
important JJ B-ADJP B-ADJP
for IN B-PP B-SBAR
this DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
T3SO4 NN B-NP B-NP
. . O O

Thus RB B-ADVP B-ADVP
, , O O
it PRP B-NP B-NP
appears VBZ B-VP B-VP
T3SO4 NN B-NP B-NP
has VBZ B-VP B-VP
no DT B-NP B-NP
intrinsic JJ I-NP I-NP
biological JJ I-NP I-NP
activity NN I-NP I-NP
, , O O
but CC O I-CC
, , O O
under IN B-NP B-PP
certain JJ I-NP B-NP
circumstances NNS B-VP I-NP
, , O O
may MD B-VP B-VP
be VB I-VP I-VP
reactivated VBN B-PP I-VP
by IN B-NP B-PP
desulfation NN O B-NP

Nuclear JJ B-NP B-NP
factor NN I-NP I-NP
of IN B-PP B-PP
activated VBN B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
contains VBZ B-VP B-VP
Fos NN B-NP B-NP
and CC O I-NP
Jun NN B-NP I-NP
. . O O

The DT B-NP B-NP
nuclear JJ I-NP I-NP
factor NN I-NP I-NP
NF-AT NN I-NP I-NP
( ( O O
ref. NN B-NP B-NP
1 CD I-NP I-NP
) ) O O
is VBZ B-VP B-VP
induced VBN I-VP I-VP
in IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
stimulated VBN B-VP B-VP
through IN B-PP B-PP
the DT B-NP B-NP
T-cell NN I-NP I-NP
receptor/CD3 NN I-NP I-NP
complex NN I-NP I-NP
, , O O
and CC O I-CC
is VBZ B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
interleukin-2 NN B-NP B-NP
( ( O O
IL-2 NN B-NP I-NN
) ) O O
gene NN B-NP B-NP
induction NN I-NP I-NP
. . O O

Although IN B-SBAR B-SBAR
NF-AT NN B-NP B-NP
has VBZ B-VP B-VP
not RB I-VP I-VP
been VBN I-VP I-VP
cloned VBN I-VP I-VP
or CC O I-VP
purified VBN B-VP I-VP
, , O O
there EX B-NP B-NP
is VBZ B-VP B-VP
evidence NN B-NP B-NP
that IN B-SBAR B-SBAR
it PRP B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
major JJ I-NP I-NP
target NN I-NP I-NP
for IN B-PP B-PP
immunosuppression NN B-NP B-NP
by IN B-PP B-PP
cyclosporin NN B-NP B-NP
A NN I-NP I-NP
( ( O O
CsA NN B-NP B-NP
) ) O O
and CC O I-CC
FK506 NN B-NP B-NP
( ( O O
refs NNS B-NP B-NP
2-7 CD B-NP I-NP
) ) O O
. . O O

NF-AT NN B-NP B-NP
induction NN I-NP I-NP
may MD B-VP B-VP
require VB I-VP I-VP
two CD B-NP B-NP
activation-dependent JJ I-NP I-NP
events NNS I-NP I-NP
: : O O
the DT B-NP B-NP
CsA-sensitive JJ I-NP I-NP
translocation NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
pre-existing JJ I-NP I-NP
component NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
CsA-resistant JJ I-NP I-NP
synthesis NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
nuclear JJ I-NP I-NP
component NN I-NP I-NP
. . O O

Here RB B-ADVP B-ADVP
we PRP B-NP B-NP
report VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
newly RB I-NP I-NP
synthesized VBN I-NP I-NP
nuclear JJ I-NP I-NP
component NN I-NP I-NP
of IN B-PP B-PP
NF-AT NN B-NP B-NP
is VBZ B-VP B-VP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
AP-1 NN I-NP I-NP
. . O O

We PRP B-NP B-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
inducible JJ I-NP I-NP
nuclear JJ I-NP I-NP
form NN I-NP I-NP
of IN B-PP B-PP
NF-AT NN B-NP B-NP
contains VBZ B-VP B-VP
Fos NN B-NP B-NP
and CC O I-NP
Jun NN B-NP I-NP
proteins NNS B-NP I-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
we PRP B-NP B-NP
identify VBP B-VP B-VP
a DT B-NP B-NP
pre-existing JJ I-NP I-NP
NF-AT-binding JJ I-NP I-NP
factor NN I-NP I-NP
that WDT B-NP B-NP
is VBZ B-VP B-VP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
hypotonic JJ B-NP B-NP
extracts NNS I-NP I-NP
of IN B-PP B-PP
unstimulated JJ B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

On IN B-PP B-PP
the DT I-PP B-NP
basis NN I-PP I-NP
of IN I-PP B-PP
binding NN B-NP B-NP
, , O O
reconstitution NN B-NP I-NP
and CC O I-NP
cotransfection NN B-NP I-NP
experiments NNS B-NP I-NP
, , O O
we PRP B-NP B-NP
propose VBP B-VP B-VP
that IN B-SBAR B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
NF-AT NN B-NP B-NP
occurs VBZ B-VP B-VP
in IN B-PP B-PP
at IN B-NP B-NP
least JJS I-NP I-NP
two CD I-NP I-NP
stages NNS I-NP I-NP
: : O O
a DT B-NP B-NP
CsA-sensitive JJ I-NP I-NP
stage NN I-NP I-NP
involving VBG B-VP B-VP
modification NN B-NP B-NP
and/or CC O I-NP
translocation NN B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
pre-existing JJ I-NP I-NP
NF-AT NN I-NP I-NP
complex NN I-NP I-NP
, , O O
and CC O I-CC
a DT B-NP B-NP
CsA-insensitive JJ I-NP I-NP
stage NN I-NP I-NP
involving VBG B-VP B-VP
the DT B-NP B-NP
addition NN I-NP I-NP
of IN B-PP B-PP
newly RB O B-NP
synthesized VBN O I-NP
Fos NN B-NP I-NP
or CC O I-NP
Fos/Jun NN B-NP I-NP
proteins NNS B-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
pre-existing JJ I-NP I-NP
complex NN I-NP I-NP
. . O O

Interferon-gamma NN B-NP B-NP
potentiates VBZ B-VP B-VP
the DT B-NP B-NP
antiviral JJ I-NP I-NP
activity NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
interferon-stimulated JJ B-NP B-NP
genes NNS I-NP I-NP
induced VBN B-VP B-VP
by IN B-PP B-PP
interferon-alpha NN B-NP B-NP
in IN B-PP B-PP
U937 NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Binding NN B-NP B-NP
of IN B-PP B-PP
type NN B-NP B-NP
I CD I-NP B-NP
interferon NN I-NP I-NP
( ( O O
IFN-alpha/beta NN B-NP B-NP
) ) O O
to TO B-PP B-PP
specific JJ B-NP B-NP
receptors NNS I-NP I-NP
results VBZ B-VP B-VP
in IN B-PP B-PP
the DT B-NP B-NP
rapid JJ I-NP I-NP
transcriptional JJ I-NP I-NP
activation NN I-NP I-NP
, , O O
independent JJ B-ADJP B-ADJP
of IN B-PP B-PP
protein NN B-NP B-NP
synthesis NN I-NP I-NP
, , O O
of IN B-PP B-PP
IFN-alpha-stimulated JJ B-NP B-NP
genes NNS I-NP I-NP
( ( O O
ISGs NNS B-NP B-NP
) ) O O
in IN B-PP B-PP
human JJ B-NP B-NP
fibroblasts NNS I-NP I-NP
and CC O I-CC
HeLa NN B-NP B-NP
and CC O I-NP
Daudi NN B-NP I-NP
cell NN B-NP I-NP
lines NNS I-NP I-NP
. . O O

The DT B-NP B-NP
binding NN I-NP I-NP
of IN B-PP B-PP
ISGF3 NN B-NP B-NP
( ( O O
IFN-stimulated JJ B-NP B-NP
gene NN I-NP I-NP
factor NN I-NP I-NP
3 CD I-NP I-NP
) ) O O
to TO B-PP B-PP
the DT B-NP B-NP
conserved VBN I-NP I-NP
IFN-stimulated JJ B-NP I-NP
response NN I-NP I-NP
element NN I-NP I-NP
( ( O O
ISRE NN B-NP B-NP
) ) O O
results VBZ B-VP B-VP
in IN B-PP B-PP
transcriptional JJ B-NP B-NP
activation NN I-NP I-NP
. . O O

This DT B-NP B-NP
factor NN I-NP I-NP
is VBZ B-VP B-VP
composed VBN I-VP I-VP
of IN B-PP B-PP
a DT B-NP B-NP
DNA-binding JJ I-NP I-NP
protein NN I-NP I-NP
( ( O O
ISGF3 NN B-NP B-NP
gamma NN I-NP I-NP
) ) O O
, , O O
which WDT B-NP B-NP
normally RB B-ADVP B-ADVP
is VBZ B-VP B-VP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
cytoplasm NN I-NP I-NP
, , O O
and CC O I-CC
other JJ B-NP B-NP
IFN-alpha-activated JJ I-NP I-NP
proteins NNS I-NP I-NP
which WDT B-NP B-NP
preexist VBP B-VP B-VP
as IN B-PP B-PP
latent JJ B-NP B-NP
cytoplasmic JJ I-NP I-NP
precursors NNS I-NP I-NP
( ( O O
ISGF3 NN B-NP B-NP
alpha NN I-NP I-NP
) ) O O
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
found VBN I-VP I-VP
that IN B-SBAR B-PP
ISG NN B-NP B-NP
expression NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
monocytic JJ I-NP I-NP
U937 NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
differs VBZ B-VP B-VP
from IN B-PP B-PP
most JJS B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
previously RB B-VP B-VP
examined VBN I-VP I-VP
. . O O

U937 NN B-NP B-NP
cells NNS I-NP I-NP
express VBP B-VP I-NP
both CC O I-CC
type NN B-NP B-NP
I CD I-NP I-NP
and CC O I-CC
type NN B-NP B-NP
II CD I-NP I-NP
IFN NN B-NP I-NP
receptors NNS I-NP I-NP
, , O O
but CC O I-CC
only RB B-NP B-ADVP
IFN-alpha NN I-NP B-NP
is VBZ B-VP B-VP
capable JJ B-ADJP B-ADJP
of IN B-PP B-PP
inducing VBG B-VP B-VP
antiviral JJ B-NP B-NP
protection NN I-NP I-NP
in IN B-PP B-PP
these DT B-NP B-NP
cells NNS I-NP I-NP
. . O O

Pretreatment NN B-NP B-NP
with IN B-PP B-PP
IFN-gamma NN B-NP B-NP
potentiates VBZ B-VP B-VP
the DT B-NP B-NP
IFN-alpha-induced JJ I-NP I-NP
protection NN I-NP I-NP
, , O O
but CC O I-CC
IFN-gamma NN B-NP B-NP
alone RB B-ADVP B-ADVP
does VBZ B-VP B-VP
not RB I-VP I-VP
have VB I-VP I-VP
any DT B-NP B-NP
antiviral JJ I-NP I-NP
activity NN I-NP I-NP
. . O O

ISG15 NN B-NP B-NP
mRNA NN I-NP I-NP
accumulation NN I-NP I-NP
in IN B-PP B-PP
U937 NN B-NP B-NP
cells NNS I-NP I-NP
is VBZ B-VP B-VP
not RB O I-RB
detectable JJ B-ADJP B-ADJP
before IN B-PP B-PP
6 CD B-NP B-NP
h NN I-NP I-NP
of IN B-PP B-PP
IFN-alpha NN B-NP B-NP
treatment NN I-NP I-NP
, , O O
peaks VBZ B-VP B-VP
at IN B-PP B-PP
24 CD B-NP B-NP
h NN I-NP I-NP
, , O O
and CC O I-CC
requires VBZ B-VP B-VP
protein NN B-NP B-NP
synthesis NN I-NP I-NP
. . O O

Although IN B-SBAR B-SBAR
IFN-gamma NN B-NP B-NP
alone RB B-ADVP B-ADVP
does VBZ B-VP B-VP
not RB I-VP I-VP
induce VB I-VP I-VP
ISG NN B-NP B-NP
expression NN I-NP I-NP
, , O O
IFN-gamma NN B-NP B-NP
pretreatment NN I-NP I-NP
markedly RB B-ADVP B-ADVP
increases VBZ B-VP B-VP
and CC O I-VP
hastens VBZ B-VP I-VP
ISG NN B-NP B-NP
expression NN I-NP I-NP
and CC O I-CC
transcriptional JJ B-NP B-NP
induction NN I-NP I-NP
. . O O

Nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
assayed VBN B-VP B-VP
for IN B-PP B-PP
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
ISRE NN B-NP B-NP
binding NN I-NP I-NP
factors NNS I-NP I-NP
by IN B-PP B-PP
electrophoretic JJ B-NP B-NP
mobility NN I-NP I-NP
shift NN I-NP I-NP
assays NNS I-NP I-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
ISGF3 NN B-NP B-NP
is VBZ B-VP B-VP
induced VBN I-VP I-VP
by IN B-PP B-PP
IFN-alpha NN B-NP B-NP
within IN B-PP B-PP
6 CD B-NP B-NP
h NN I-NP I-NP
from IN B-PP B-PP
undetectable JJ B-NP B-NP
basal JJ I-NP I-NP
levels NNS I-NP I-NP
in IN B-PP B-PP
untreated JJ B-NP B-NP
U937 NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

Activation NN B-NP B-NP
of IN B-PP B-PP
ISGF3 NN B-NP B-NP
alpha NN I-NP I-NP
, , O O
the DT B-NP B-NP
latent JJ I-NP I-NP
component NN I-NP I-NP
of IN B-PP B-PP
ISGF3 NN B-NP B-NP
, , O O
occurs VBZ B-VP B-VP
rapidly RB B-ADVP B-ADVP
. . O O

However RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
increase NN I-NP I-NP
in IN B-PP B-PP
ISGF3 NN B-NP B-NP
activity NN I-NP I-NP
ultimately RB B-ADVP B-ADVP
correlates VBZ B-VP B-VP
with IN B-PP B-PP
the DT B-NP B-NP
accumulation NN I-NP I-NP
of IN B-PP B-PP
ISGF3 NN B-NP B-NP
gamma NN I-NP I-NP
induced VBN B-VP B-VP
by IN B-PP B-PP
IFN-alpha NN B-NP B-NP
or CC O I-NP
IFN-gamma NN B-NP I-NP
. . O O

( ( O O
ABSTRACT NN B-NP B-NP
TRUNCATED VBN B-VP B-VP
AT IN B-PP B-PP
250 CD B-NP B-NP
WORDS NNS I-NP I-NP
) ) O O

The DT B-NP B-NP
mechanism NN I-NP I-NP
of IN B-PP B-PP
action NN B-NP B-NP
of IN B-PP B-PP
cyclosporin NN B-NP B-NP
A NN I-NP I-NP
and CC O I-NP
FK506 NN B-NP I-NP
. . O O

CsA NN B-NP B-NP
and CC O I-NP
FK506 NN B-NP I-NP
are VBP B-VP B-VP
powerful JJ B-NP B-NP
suppressors NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
immune JJ I-NP I-NP
system NN I-NP I-NP
, , O O
most RBS B-ADVP B-ADVP
notably RB I-ADVP I-ADVP
of IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

They PRP B-NP B-NP
act VBP B-VP B-VP
at IN B-PP B-PP
a DT B-NP B-NP
point NN I-NP I-NP
in IN B-PP B-PP
activation NN B-NP B-NP
that WDT B-NP B-NP
lies VBZ B-VP B-VP
between IN B-PP B-PP
receptor NN B-NP B-NP
ligation NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
transcription NN I-NP I-NP
of IN B-PP B-PP
early JJ B-NP B-NP
genes NNS I-NP I-NP
. . O O

Here RB B-ADVP B-ADVP
, , O O
Stuart NNP B-NP B-NP
Schreiber NNP I-NP I-NP
and CC O I-CC
Gerald NNP B-NP B-NP
Crabtree NNP I-NP I-NP
review VBP B-VP B-VP
recent JJ B-NP B-NP
findings NNS I-NP I-NP
that WDT B-NP B-NP
indicate VBP O B-VP
CsA NN B-NP B-NP
and CC O I-NP
FK506 NN B-NP I-NP
operate VBP B-VP B-VP
as IN B-PP B-SBAR
prodrugs NNS B-NP B-NP
: : O O
they PRP B-NP B-NP
bind VBP B-VP B-VP
endogenous JJ B-NP B-NP
intracellular JJ I-NP I-NP
receptors NNS I-NP I-NP
, , O O
the DT B-NP B-NP
immunophilins NNS I-NP I-NP
, , O O
and CC O I-CC
the DT B-NP B-NP
resulting VBG I-NP I-NP
complex NN I-NP I-NP
targets VBZ B-VP B-VP
the DT B-NP B-NP
protein NN I-NP I-NP
phosphatase NN I-NP I-NP
, , O O
calcineurin NN B-NP B-NP
, , O O
to TO B-VP B-VP
exert VB I-VP I-VP
the DT B-NP B-NP
immunosuppressive JJ I-NP I-NP
effect NN I-NP I-NP
. . O O

( ( O O
Plasma NN B-NP B-NP
cortisol NN I-NP I-NP
concentration NN I-NP I-NP
and CC O I-NP
blood NN B-NP I-NP
leukocyte NN I-NP I-NP
content NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
in IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
deficiency-cold JJ B-NP B-NP
vs CC I-NP I-NP
deficiency-heat JJ I-NP I-NP
syndromes NNS I-NP I-NP
) ) O O

Plasma NN B-NP B-NP
cortisol NN I-NP I-NP
concentration NN I-NP I-NP
and CC O I-NP
blood NN B-NP I-NP
leukocyte NN I-NP I-NP
content NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
( ( O O
GCR NN B-NP B-NP
) ) O O
were VBD B-VP B-VP
assayed VBN I-VP I-VP
in IN B-PP B-PP
20 CD B-NP B-NP
patients NNS I-NP I-NP
with IN B-PP B-PP
deficiency NN B-NP B-NP
syndromes NNS I-NP I-NP
, , O O
10 CD B-NP B-NP
cold JJ B-ADJP I-NP
in IN B-PP B-PP
property NN B-NP B-NP
( ( O O
deficiency-cold JJ B-ADJP B-NP
) ) O O
, , O O
the DT B-NP B-NP
other JJ I-NP I-NP
10 CD B-NP I-NP
hot JJ B-ADJP B-ADJP
in IN B-PP B-PP
property NN B-NP B-NP
( ( O O
deficiency-heat JJ B-ADJP B-NP
) ) O O
, , O O
and CC O I-CC
also RB O B-ADVP
in IN B-PP B-PP
10 CD B-NP B-NP
healthy JJ I-NP I-NP
individuals NNS I-NP I-NP
as IN B-PP B-PP
normal JJ B-NP B-NP
control NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
purpose NN I-NP I-NP
of IN B-PP B-PP
investigating VBG B-VP B-VP
the DT B-NP B-NP
nature NN I-NP I-NP
of IN B-PP B-PP
cold NN O B-NP
and CC O I-NP
heat NN B-NP I-NP
syndromes NNS B-NP I-NP
. . O O

As IN B-PP B-PP
a DT B-NP B-NP
result NN I-NP I-NP
, , O O
the DT B-NP B-NP
cases NNS I-NP I-NP
of IN B-PP B-PP
deficiency-cold JJ B-NP B-NP
syndrome NN I-NP I-NP
( ( O O
DCS NN B-NP B-NP
) ) O O
had VBD B-VP B-VP
a DT B-NP B-NP
normal JJ I-NP I-NP
concentration NN I-NP I-NP
of IN B-PP B-PP
plasma NN B-NP B-NP
cortisol NN I-NP I-NP
but CC O I-CC
a DT B-NP B-NP
lowered JJ I-NP I-NP
content NN I-NP I-NP
of IN B-PP B-PP
GCR NN B-NP B-NP
in IN B-PP B-PP
leukocytes NNS B-NP B-NP
when WRB B-ADVP B-ADVP
compared VBN B-VP B-VP
with IN B-PP B-PP
the DT B-NP B-NP
normal JJ I-NP I-NP
control NN I-NP I-NP
( ( O O
P NN B-NP B-NP
less JJR B-NP B-ADJP
than IN I-NP B-PP
0.05 CD I-NP B-NP
) ) O O
; : O O
the DT B-NP B-NP
cases NNS I-NP I-NP
of IN B-PP B-PP
deficiency-heat JJ B-NP B-NP
syndrome NN I-NP I-NP
( ( O O
DHS NN B-NP B-NP
) ) O O
had VBD B-VP B-VP
a DT B-NP B-NP
higher JJR I-NP I-NP
concentration NN I-NP I-NP
of IN B-PP B-PP
plasma NN B-NP B-NP
cortisol NN I-NP I-NP
than IN B-PP B-PP
the DT B-NP B-NP
normal JJ I-NP I-NP
control NN I-NP I-NP
( ( O O
P NN B-NP B-NP
less JJR B-NP B-ADJP
than IN I-NP B-PP
0.05 CD I-NP B-NP
) ) O O
and CC O I-CC
a DT B-NP B-NP
slightly RB I-NP I-NP
higher JJR I-NP I-NP
content NN I-NP I-NP
of IN B-PP B-PP
GCR NN B-NP B-NP
in IN B-PP B-PP
leukocytes NNS B-NP B-NP
. . O O

It PRP B-NP B-NP
was VBD B-VP B-VP
concluded VBN I-VP I-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
DCS NN I-NP I-NP
is VBZ B-VP B-VP
characterized VBN I-VP I-VP
by IN B-PP B-PP
diminished VBN B-NP B-NP
biological JJ I-NP I-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
adrenocortical JJ B-NP B-NP
activity NN I-NP I-NP
, , O O
while IN O B-SBAR
the DT B-NP B-NP
DHS NN I-NP I-NP
, , O O
by IN B-PP B-PP
augmented JJ B-NP B-NP
biological JJ I-NP I-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
adrenocortical JJ B-NP B-NP
activity NN I-NP I-NP
. . O O

Specific JJ B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
subunits NNS I-NP I-NP
act VBP B-VP B-VP
in IN B-PP B-PP
concert NN I-PP B-NP
with IN I-PP B-PP
Tat NN B-NP B-NP
to TO B-VP B-VP
stimulate VB I-VP I-VP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP B-NP
transcription NN I-NP I-NP
. . O O

NF-kappa NN B-NP B-NP
B NN I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
protein NN I-NP I-NP
complex NN I-NP I-NP
which WDT B-NP B-NP
functions VBZ B-VP B-VP
in IN B-PP B-PP
concert NN I-PP B-NP
with IN I-PP B-PP
the DT B-NP B-NP
tat-I NN I-NP I-NP
gene NN I-NP I-NP
product NN I-NP I-NP
to TO B-VP B-VP
stimulate VB I-VP I-VP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
( ( O O
HIV NN B-NP I-NN
) ) O O
transcription NN B-NP B-NP
. . O O

To TO B-VP B-VP
determine VB I-VP I-VP
whether IN B-SBAR B-SBAR
specific JJ B-NP B-NP
members NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
family NN I-NP I-NP
contribute VBP B-VP B-VP
to TO B-PP B-PP
this DT B-NP B-NP
effect NN I-NP I-NP
, , O O
we PRP B-NP B-NP
have VBP B-VP B-VP
examined VBN I-VP I-VP
the DT B-NP B-NP
abilities NNS I-NP I-NP
of IN B-PP B-PP
different JJ B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
subunits NNS I-NP I-NP
to TO B-VP B-VP
act VB I-VP I-VP
with IN B-PP B-PP
Tat-I NN B-NP B-NP
to TO B-VP B-VP
stimulate VB I-VP I-VP
transcription NN B-NP B-NP
of IN B-PP B-PP
HIV NN B-NP B-NP
in IN B-PP B-PP
Jurkat NN B-NP B-NP
T-leukemia NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
found VBN I-VP I-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
p49 NN I-NP I-NP
( ( I-NP O
100 CD I-NP B-NP
) ) I-NP O
DNA NN I-NP B-NP
binding NN I-NP I-NP
subunit NN I-NP I-NP
, , O O
together RB B-PP B-ADVP
with IN I-PP B-PP
p65 NN B-NP B-NP
, , O O
can MD B-VP B-VP
act VB I-VP I-VP
in IN B-PP B-PP
concert NN I-PP B-NP
with IN I-PP B-PP
Tat-I NN B-NP B-NP
to TO B-VP B-VP
stimulate VB I-VP I-VP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
HIV-CAT NN B-NP B-NP
plasmid NN I-NP I-NP
. . O O

Little JJ B-NP B-NP
effect NN I-NP I-NP
was VBD B-VP B-VP
observed VBN I-VP I-VP
with IN B-PP B-PP
50-kDa JJ B-NP B-NP
forms NNS I-NP I-NP
of IN B-PP B-PP
p105 NN B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
or CC O I-NP
rel NN B-NP I-NP
, , O O
in IN B-PP B-PP
combination NN B-NP B-NP
with IN B-PP B-PP
p65 NN B-NP B-NP
or CC O I-CC
full-length JJ B-NP B-NP
c-rel NN I-NP I-NP
, , O O
which WDT B-NP B-NP
do VBP B-VP B-VP
not RB I-VP I-VP
stimulate VB I-VP I-VP
the DT B-NP B-NP
HIV NN I-NP I-NP
enhancer NN I-NP I-NP
in IN B-PP B-PP
these DT B-NP B-NP
cells NNS I-NP I-NP
. . O O

These DT B-NP B-NP
findings NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
combination NN I-NP I-NP
of IN B-PP B-PP
p49 NN B-NP B-NP
( ( I-NP O
100 CD I-NP B-NP
) ) O O
and CC O I-CC
p65 NN B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
can MD B-VP B-VP
act VB I-VP I-VP
in IN B-PP B-PP
concert NN I-PP B-NP
with IN I-PP B-PP
the DT B-NP B-NP
tat-I NN I-NP I-NP
gene NN I-NP I-NP
product NN I-NP I-NP
to TO B-VP B-VP
stimulate VB I-VP I-VP
the DT B-NP B-NP
synthesis NN I-NP I-NP
of IN B-PP B-PP
HIV NN B-NP B-NP
RNA NN I-NP I-NP
. . O O

Activation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP B-NP
enhancer NN I-NP I-NP
is VBZ B-VP B-VP
not RB O I-RB
dependent JJ B-ADJP B-ADJP
on IN B-PP B-PP
NFAT-1 NN B-NP B-NP
. . O O

The DT B-NP B-NP
function NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
putative JJ I-NP I-NP
NFAT-1 NN I-NP I-NP
site NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP B-NP
enhancer NN I-NP I-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
analyzed VBN I-VP I-VP
. . O O

Activation NN B-NP B-NP
by IN B-PP B-PP
the DT B-NP B-NP
T-cell NN I-NP I-NP
antigen NN I-NP I-NP
receptor NN I-NP I-NP
is VBZ B-VP B-VP
minimal JJ B-ADJP B-ADJP
in IN B-PP B-PP
Jurkat NN B-NP B-NP
cells NNS I-NP I-NP
and CC O I-CC
is VBZ B-VP B-VP
mediated VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
sites NNS I-NP I-NP
. . O O

The DT B-NP B-NP
putative JJ I-NP I-NP
NFAT-1 NN I-NP I-NP
region NN I-NP I-NP
is VBZ B-VP B-VP
not RB I-VP I-VP
required VBN I-VP I-VP
for IN B-PP B-PP
the DT B-NP B-NP
response NN I-NP I-NP
to TO B-PP B-PP
anti-CD3 NN B-NP B-NP
or CC B-PP I-NP
to TO B-PP B-PP
mitogens NNS B-NP B-NP
in IN B-PP B-PP
T-cell NN B-NP B-NP
, , O O
B-cell NN B-NP B-NP
, , O O
or CC O I-CC
monocyte/macrophage NN B-NP B-NP
leukemia NN I-NP I-NP
lines NNS B-NP I-NP
, , O O
nor CC O I-CC
is VBZ B-VP B-VP
it PRP B-NP B-NP
a DT B-NP B-NP
cis-acting JJ I-NP I-NP
negative JJ I-NP I-NP
regulatory JJ I-NP I-NP
element NN I-NP I-NP
. . O O

Protein NN B-NP B-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
activation NN I-NP I-NP
and CC O I-NP
protooncogene NN B-NP I-NP
expression NN I-NP I-NP
in IN B-PP B-PP
differentiation/retrodifferentiation NN B-NP B-NP
of IN B-PP B-PP
human JJ B-NP B-NP
U-937 NN I-NP I-NP
leukemia NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

Human JJ B-NP B-NP
U-937 NN I-NP I-NP
leukemia NN I-NP I-NP
cells NNS I-NP I-NP
differentiate VBP B-VP B-VP
along IN B-PP B-PP
the DT B-NP B-NP
monocytic JJ I-NP I-NP
lineage NN I-NP I-NP
following VBG B-PP B-VP
3-day JJ B-NP B-NP
exposures NNS I-NP I-NP
to TO B-PP B-PP
12-O-tetradecanoylphorbol-13-acetate NN B-NP B-NP
( ( O O
TPA NN B-NP I-NP
) ) O O
. . O O

This DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
differentiation NN B-NP B-NP
is VBZ B-VP B-VP
accompanied VBN I-VP I-VP
by IN B-PP B-PP
adherence NN B-NP B-NP
and CC O I-NP
loss NN B-NP I-NP
of IN B-PP B-PP
proliferation NN B-NP B-NP
, , O O
as RB B-CONJP B-CONJP
well RB I-CONJP I-CONJP
as IN I-CONJP I-CONJP
expression/repression NN B-NP B-NP
of IN B-PP B-PP
differentiation-associated JJ B-NP B-NP
genes NNS I-NP I-NP
. . O O

Long JJ B-NP B-NP
term NN I-NP I-NP
culture NN I-NP I-NP
of IN B-PP B-PP
TPA-differentiated JJ B-NP B-NP
U-937 NN I-NP I-NP
cells NNS I-NP I-NP
in IN B-PP B-PP
the DT I-PP B-NP
absence NN I-PP I-NP
of IN I-PP B-PP
phorbol NN B-NP B-NP
ester NN I-NP I-NP
for IN B-PP B-PP
32-36 CD B-NP B-NP
days NNS I-NP I-NP
resulted VBD B-VP B-VP
in IN B-PP B-PP
a DT B-NP B-NP
process NN I-NP I-NP
of IN B-PP B-PP
retrodifferentiation NN B-NP B-NP
. . O O

The DT B-NP B-NP
retrodifferentiated VBN I-NP I-NP
cells NNS I-NP I-NP
detached VBD B-VP B-VP
from IN B-PP B-PP
the DT B-NP B-NP
substrate NN I-NP I-NP
and CC O I-CC
reinitiated VBD B-VP B-VP
proliferation NN B-NP B-NP
. . O O

Other JJ B-NP B-NP
cellular JJ I-NP I-NP
parameters NNS I-NP I-NP
, , O O
such JJ B-PP B-PP
as IN I-PP I-PP
glycosidase NN B-NP B-NP
activities NNS I-NP I-NP
, , O O
cytokine NN B-NP B-NP
release NN I-NP I-NP
, , O O
and CC O I-CC
filament NN B-NP B-NP
expression NN I-NP I-NP
, , O O
returned VBD B-VP B-VP
to TO B-PP B-PP
levels NNS B-NP B-NP
similar JJ B-ADJP B-ADJP
to TO B-PP B-PP
that DT B-NP B-NP
observed VBN B-VP B-VP
in IN B-PP B-PP
uninduced JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

Treatment NN B-NP B-NP
of IN B-PP B-PP
U-937 NN B-NP B-NP
cells NNS I-NP I-NP
with IN B-PP B-PP
TPA NN B-NP B-NP
resulted VBD B-VP B-VP
in IN B-PP B-PP
a DT B-NP B-NP
rapid JJ I-NP I-NP
translocation NN I-NP I-NP
of IN B-PP B-PP
protein NN B-NP B-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
( ( O O
PKC NN B-NP B-NP
) ) O O
from IN B-PP B-PP
the DT B-NP B-NP
cytosol NN I-NP I-NP
to TO B-PP B-PP
cell NN B-NP B-NP
membrane NN I-NP I-NP
fractions NNS I-NP I-NP
within IN B-PP B-PP
2-8 CD B-NP B-NP
min NN I-NP I-NP
. . O O

Increased VBN B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
membrane-associated JJ B-NP B-NP
PKC NN I-NP I-NP
activity NN I-NP I-NP
persisted VBD B-VP B-VP
until IN B-PP B-PP
17-29 CD B-NP B-NP
days NNS I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
longer JJR B-NP B-NP
periods NNS I-NP I-NP
of IN B-PP B-PP
incubation NN B-NP B-NP
were VBD B-VP B-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
a DT B-NP B-NP
return NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
distribution NN I-NP I-NP
of IN B-PP B-PP
PKC NN B-NP B-NP
in IN B-PP B-PP
control NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Activation NN B-NP B-NP
of IN B-PP B-PP
PKC NN B-NP B-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
implicated VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
certain JJ B-NP B-NP
immediate JJ I-NP I-NP
early JJ I-NP I-NP
response NN I-NP I-NP
genes NNS I-NP I-NP
, , O O
and CC O I-CC
in IN B-PP B-PP
the DT B-NP B-NP
present JJ I-NP I-NP
studies NNS I-NP I-NP
, , O O
TPA NN B-NP B-NP
rapidly RB B-ADVP B-ADVP
induced VBD B-VP B-VP
c-fos NN B-NP B-NP
and CC O I-NP
c-jun NN B-NP I-NP
gene NN B-NP I-NP
expression NN I-NP I-NP
. . O O

Levels NNS B-NP B-NP
of IN B-PP B-PP
c-fos NN B-NP B-NP
and CC O I-NP
c-jun NN B-NP I-NP
transcripts NNS B-NP I-NP
remained VBD B-VP B-VP
elevated JJ B-ADJP B-ADJP
during IN B-PP B-PP
periods NNS B-NP B-NP
of IN B-PP B-PP
PKC NN B-NP B-NP
activation NN I-NP I-NP
and CC O I-CC
also RB O B-ADVP
returned VBD B-VP B-VP
to TO B-PP B-PP
levels NNS B-NP B-NP
observed VBN B-VP B-VP
in IN B-PP B-PP
control NN B-NP B-NP
cells NNS I-NP I-NP
by IN B-PP B-PP
30-36 CD B-NP B-NP
days NNS I-NP I-NP
, , O O
when WRB B-ADVP B-ADVP
the DT B-NP B-NP
cells NNS I-NP I-NP
entered VBD B-VP B-VP
retrodifferentiation NN B-NP B-NP
. . O O

Staurosporine NN B-NP B-NP
, , O O
a DT B-NP B-NP
nonspecific JJ I-NP I-NP
inhibitor NN I-NP I-NP
of IN B-PP B-PP
PKC NN B-NP B-NP
, , O O
partially RB B-VP B-ADVP
blocked VBD I-VP B-VP
TPA-induced JJ B-NP B-NP
adherence NN I-NP I-NP
and CC O I-NP
growth NN B-NP I-NP
inhibition NN I-NP I-NP
and CC O I-CC
concomitantly RB B-VP B-VP
prevented VBD I-VP I-VP
TPA-induced JJ O B-NP
c-fos NN B-NP I-NP
and CC O I-NP
c-jun NN B-NP I-NP
gene NN B-NP I-NP
expression NN I-NP I-NP
. . O O

( ( O O
ABSTRACT NN B-NP B-NP
TRUNCATED VBN B-VP B-VP
AT IN B-PP B-PP
250 CD B-NP B-NP
WORDS NNS I-NP I-NP
) ) O O

The DT B-NP B-NP
promoter NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
CD19 NN I-NP I-NP
gene NN I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
target NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
B-cell-specific JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
BSAP NN I-NP I-NP
. . O O

The DT B-NP B-NP
CD19 NN I-NP I-NP
protein NN I-NP I-NP
is VBZ B-VP B-VP
expressed VBN I-VP I-VP
on IN B-PP B-PP
the DT B-NP B-NP
surface NN I-NP I-NP
of IN B-PP B-PP
all DT B-NP B-NP
B-lymphoid JJ I-NP I-NP
cells NNS I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
exception NN I-NP I-NP
of IN B-PP B-PP
terminally RB B-NP B-NP
differentiated VBN I-NP I-NP
plasma NN I-NP I-NP
cells NNS I-NP I-NP
and CC O I-CC
has VBZ B-VP B-VP
been VBN I-VP I-VP
implicated VBN I-VP I-VP
as IN B-PP B-PP
a DT B-NP B-NP
signal-transducing JJ I-NP I-NP
receptor NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
control NN I-NP I-NP
of IN B-PP B-PP
proliferation NN B-NP B-NP
and CC O I-NP
differentiation NN B-NP I-NP
. . O O

Here RB B-ADVP B-ADVP
we PRP B-NP B-NP
demonstrate VBP B-VP B-VP
complete JJ B-NP B-NP
correlation NN I-NP I-NP
between IN B-PP B-PP
the DT B-NP B-NP
expression NN I-NP I-NP
pattern NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
CD19 NN I-NP I-NP
gene NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
B-cell-specific JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
BSAP NN I-NP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
large JJ I-NP I-NP
panel NN I-NP I-NP
of IN B-PP B-PP
B-lymphoid JJ B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
. . O O

The DT B-NP B-NP
human JJ I-NP I-NP
CD19 NN I-NP I-NP
gene NN I-NP I-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
cloned VBN I-VP I-VP
, , O O
and CC O I-CC
several JJ B-NP B-NP
BSAP-binding JJ I-NP I-NP
sites NNS I-NP I-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
mapped VBN I-VP I-VP
by IN B-PP B-PP
in FW B-NP B-NP
vitro FW I-NP I-NP
protein-DNA JJ I-NP I-NP
binding NN I-NP I-NP
studies NNS I-NP I-NP
. . O O

In IN B-PP B-PP
particular JJ B-NP B-NP
, , O O
a DT B-NP B-NP
high-affinity JJ I-NP I-NP
BSAP-binding JJ I-NP I-NP
site NN I-NP I-NP
instead RB B-CONJP B-ADVP
of IN I-CONJP B-PP
a DT B-NP B-NP
TATA NN I-NP I-NP
sequence NN I-NP I-NP
is VBZ B-VP B-VP
located JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
-30 CD I-NP I-NP
promoter NN I-NP I-NP
region NN I-NP I-NP
upstream JJ B-ADJP B-ADJP
of IN B-PP B-PP
a DT B-NP B-NP
cluster NN I-NP I-NP
of IN B-PP B-PP
heterogeneous JJ B-NP B-NP
transcription NN I-NP I-NP
start NN I-NP I-NP
sites NNS I-NP I-NP
. . O O

Moreover RB B-ADVP B-ADVP
, , O O
this DT B-NP B-NP
site NN I-NP I-NP
is VBZ B-VP B-VP
occupied VBN I-VP I-VP
by IN B-PP B-PP
BSAP NN B-NP B-NP
in FW B-ADVP B-NP
vivo FW I-ADVP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
CD19-expressing JJ I-NP I-NP
B-cell NN I-NP I-NP
line NN I-NP I-NP
but CC B-PP I-CC
not RB B-PP I-RB
in IN I-PP B-PP
plasma NN B-NP B-NP
or CC O I-NP
HeLa NN B-NP I-NP
cells NNS B-NP I-NP
. . O O

This DT B-NP B-NP
high-affinity JJ I-NP I-NP
site NN I-NP I-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
conserved VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
promoters NNS I-NP I-NP
of IN B-PP B-PP
both CC O I-CC
human JJ O B-NP
and CC O I-NP
mouse NN B-NP I-NP
CD19 NN B-NP I-NP
genes NNS I-NP I-NP
and CC O I-CC
was VBD B-VP B-VP
furthermore RB I-VP I-VP
shown VBN I-VP I-VP
to TO I-VP I-VP
confer VB I-VP I-VP
B-cell NN B-NP B-NP
specificity NN I-NP I-NP
to TO B-PP B-PP
a DT B-NP B-NP
beta-globin NN I-NP I-NP
reporter NN I-NP I-NP
gene NN I-NP I-NP
in IN B-PP B-PP
transient JJ B-NP B-NP
transfection NN I-NP I-NP
experiments NNS I-NP I-NP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
BSAP NN B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
the DT B-NP B-NP
only RB I-NP I-NP
abundant JJ I-NP I-NP
DNA-binding JJ I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
B-cell NN B-NP B-NP
nuclear JJ I-NP I-NP
extracts NNS I-NP I-NP
that WDT B-NP B-NP
interacts VBZ B-VP B-VP
with IN B-PP B-PP
the DT B-NP B-NP
CD19 NN I-NP I-NP
promoter NN I-NP I-NP
. . O O

Together RB B-ADVP B-ADVP
, , O O
this DT B-NP B-NP
evidence NN I-NP I-NP
strongly RB B-ADVP B-ADVP
implicates VBZ B-VP B-VP
BSAP NN B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
CD19 NN I-NP I-NP
gene NN I-NP I-NP
. . O O

Reduced VBN B-NP B-NP
susceptibility NN I-NP I-NP
to TO B-PP B-PP
HIV-1 NN B-NP B-NP
infection NN I-NP I-NP
of IN B-PP B-PP
ethyl-methanesulfonate-treated JJ B-NP B-NP
CEM NN I-NP I-NP
subclones NNS I-NP I-NP
correlates VBZ B-VP B-VP
with IN B-PP B-PP
a DT B-NP B-NP
blockade NN I-NP I-NP
in IN B-PP B-PP
their PRP$ B-NP B-NP
protein NN I-NP I-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
signaling NN I-NP I-NP
pathway NN I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
described VBN I-VP I-VP
the DT B-NP B-NP
isolation NN I-NP I-NP
of IN B-PP B-PP
chemically RB B-NP B-NP
induced VBN I-NP I-NP
CEM NN I-NP I-NP
subclones NNS I-NP I-NP
that WDT B-NP B-NP
express VBP B-VP B-VP
CD4 NN B-NP B-NP
receptors NNS I-NP I-NP
and CC O I-CC
bind VBP B-VP B-VP
soluble JJ B-NP B-NP
gp120 NN I-NP I-NP
, , O O
yet RB O B-ADVP
show VBP B-VP B-VP
a DT B-NP B-NP
markedly RB I-NP I-NP
reduced VBN I-NP I-NP
susceptibility NN I-NP I-NP
to TO B-PP B-PP
infection NN B-NP B-NP
with IN B-PP B-PP
HIV-1 NN B-NP B-NP
. . O O

Two CD B-NP B-NP
subclones NNS I-NP I-NP
were VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
have VB I-VP I-VP
an DT B-NP B-NP
abnormal JJ I-NP I-NP
response NN I-NP I-NP
to TO B-PP B-PP
the DT O B-NP
protein NN B-NP I-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
( ( O O
PKC NN B-NP I-NN
) ) O O
activator NN B-NP B-NP
PMA NN I-NP I-NP
. . O O

PMA NN B-NP B-NP
treatment NN I-NP I-NP
induced VBD B-VP B-VP
CD3 NN B-NP B-NP
and CC O I-NP
CD25 NN B-NP I-NP
( ( O O
IL-2R NN B-NP B-NP
) ) O O
receptors NNS B-NP B-NP
on IN B-PP B-PP
the DT B-NP B-NP
parental JJ I-NP I-NP
line NN I-NP I-NP
and CC O B-PP
on IN B-PP B-PP
other JJ B-NP B-NP
ethyl-methanesulfonate-derived JJ I-NP I-NP
subclones NNS I-NP I-NP
, , B-PP O
but CC I-PP I-CC
not RB B-PP B-PP
on IN I-PP I-PP
these DT B-NP B-NP
two CD I-NP I-NP
mutants NNS I-NP I-NP
. . O O

Direct JJ B-NP B-NP
assays NNS I-NP I-NP
of IN B-PP B-PP
PKC NN B-NP B-NP
activity NN I-NP I-NP
were VBD B-VP B-VP
conducted VBN I-VP I-VP
. . O O

Total JJ B-NP B-NP
cellular JJ I-NP I-NP
PKC NN I-NP I-NP
enzymatic JJ I-NP I-NP
activity NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
normal JJ B-ADJP B-ADJP
in IN B-PP B-PP
these DT B-NP B-NP
subclones NNS I-NP I-NP
. . O O

PMA-induced JJ B-NP B-NP
CD4 NN I-NP I-NP
down-modulation NN I-NP I-NP
occurred VBD B-VP B-VP
normally RB B-ADVP B-ADVP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
activation NN B-NP B-NP
of IN B-PP B-PP
c-raf NN B-NP B-NP
kinase NN I-NP I-NP
was VBD B-VP B-VP
normal JJ B-ADJP B-ADJP
. . O O

Since IN B-SBAR B-SBAR
HIV-1 NN B-NP B-NP
long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
contains VBZ B-VP B-VP
two CD O B-NP
functional JJ O I-NP
nuclear JJ B-NP I-NP
factor NN I-NP I-NP
kB NN I-NP I-NP
( ( O O
NF-kB NN B-NP B-NP
) ) O O
regulatory JJ B-NP B-NP
elements NNS I-NP I-NP
, , O O
we PRP B-NP B-NP
studied VBD B-VP B-VP
the DT B-NP B-NP
ability NN I-NP I-NP
of IN B-PP B-PP
PMA NN B-NP B-NP
to TO B-VP B-VP
induce VB I-VP I-VP
NF-kB NN B-NP B-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
by IN B-PP B-PP
different JJ B-NP B-NP
assays NNS I-NP I-NP
. . O O

Chloramphenicol NN B-NP B-NP
acetyl NN I-NP I-NP
transferase NN I-NP I-NP
( ( O O
CAT NN B-NP B-NP
) ) O O
assays NNS B-NP B-NP
using VBG B-VP B-VP
the DT B-NP B-NP
HIV-1 NN I-NP I-NP
( ( I-NP O
-139 CD I-NP B-NP
) ) I-NP O
long JJ I-NP B-NP
terminal JJ I-NP I-NP
repeat-CAT JJ I-NP I-NP
construct NN I-NP I-NP
showed VBD B-VP B-VP
no DT B-NP B-NP
PMA NN I-NP I-NP
induction NN I-NP I-NP
of IN B-PP B-PP
CAT NN B-NP B-NP
activity NN I-NP I-NP
in IN B-PP B-PP
these DT B-NP B-NP
subclones NNS I-NP I-NP
( ( O O
unlike IN B-PP B-PP
the DT B-NP B-NP
parental JJ I-NP I-NP
line NN I-NP I-NP
and CC O I-CC
other JJ B-NP B-NP
subclones NNS I-NP I-NP
) ) O O
. . O O

Okadaic JJ B-NP B-NP
acid NN I-NP I-NP
, , O O
an DT B-NP B-NP
inhibitor NN I-NP I-NP
of IN B-PP B-PP
phosphatases NNS B-NP B-NP
1 CD B-NP B-NP
and CC O I-NP
2A NN B-NP I-NP
, , O O
did VBD B-VP B-VP
not RB I-VP I-VP
overcome VB I-VP I-VP
the DT B-NP B-NP
defect NN I-NP I-NP
in IN B-PP B-PP
these DT B-NP B-NP
subclones NNS I-NP I-NP
. . O O

Gel NN B-NP B-NP
retardation NN I-NP I-NP
assays NNS I-NP I-NP
, , O O
using VBG B-VP B-VP
a DT B-NP B-NP
32P-probe NN I-NP I-NP
containing VBG B-VP B-VP
the DT B-NP B-NP
HIV-1 NN I-NP I-NP
NF-kB NN I-NP I-NP
probe NN I-NP I-NP
and CC O I-CC
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
from IN B-PP B-PP
PMA-treated JJ B-NP B-NP
cells NNS I-NP I-NP
, , O O
showed VBD B-VP B-VP
significantly RB B-NP I-VP
reduced VBN I-NP I-VP
induction NN I-NP B-NP
of IN B-PP B-PP
nuclear JJ B-NP B-NP
NF-kB NN I-NP I-NP
binding NN I-NP I-NP
proteins NNS I-NP I-NP
in IN B-PP B-PP
these DT B-NP B-NP
two CD I-NP I-NP
subclones NNS I-NP I-NP
compared VBN B-PP B-PP
with IN B-PP B-PP
wild JJ B-NP B-NP
type NN I-NP I-NP
CEM NN I-NP I-NP
and CC O I-CC
a DT B-NP B-NP
control NN I-NP I-NP
subclone NN I-NP I-NP
. . O O

Deoxycholate JJ B-NP B-NP
treatment NN I-NP I-NP
of IN B-PP B-PP
cytoplasmic JJ B-NP B-NP
extracts NNS I-NP I-NP
from IN B-PP B-PP
these DT B-NP B-NP
subclones NNS I-NP I-NP
released VBD B-VP B-VP
much JJ B-NP B-NP
reduced VBN I-NP I-NP
NF-kB NN I-NP I-NP
binding NN I-NP I-NP
proteins NNS I-NP I-NP
from IN B-PP B-PP
their PRP$ B-NP B-NP
cytoplasmic JJ I-NP I-NP
pools NNS I-NP I-NP
. . O O

Thus RB B-ADVP B-ADVP
, , O O
reduced JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
PKC-induced JJ B-NP B-NP
nuclear JJ I-NP I-NP
NF-kB NN I-NP I-NP
activity NN I-NP I-NP
in IN B-PP B-PP
two CD B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
subclones NNS I-NP I-NP
did VBD B-VP B-VP
not RB I-VP I-VP
affect VB I-VP I-VP
their PRP$ B-NP B-NP
normal JJ I-NP I-NP
cell NN I-NP I-NP
growth NN I-NP I-NP
, , O O
but CC O I-CC
correlated VBD B-VP B-VP
with IN B-PP B-PP
a DT B-NP B-NP
pronounced JJ I-NP I-NP
reduction NN I-NP I-NP
in IN B-PP B-PP
their PRP$ B-NP B-NP
susceptibility NN I-NP I-NP
to TO B-PP B-PP
HIV-1 NN B-NP B-NP
infection NN I-NP I-NP
. . O O

Eicosanoids NNS B-NP B-NP
in IN B-PP B-PP
breast NN B-NP B-NP
cancer NN I-NP I-NP
patients NNS I-NP I-NP
before IN B-PP B-PP
and CC B-PP I-PP
after IN B-PP B-PP
mastectomy NN B-NP B-NP
. . O O

In IN B-PP B-PP
19 CD B-NP B-NP
patients NNS I-NP I-NP
with IN B-PP B-PP
a DT B-NP B-NP
malignant JJ I-NP I-NP
breast NN I-NP I-NP
tumor NN I-NP I-NP
, , O O
tumor NN B-NP B-NP
tissue NN I-NP I-NP
and CC O I-NP
blood NN B-NP I-NP
were VBD B-VP B-VP
taken VBN I-VP I-VP
to TO B-VP B-VP
determine VB I-VP I-VP
the DT B-NP B-NP
eicosanoid NN B-NP I-NP
profile NN I-NP I-NP
and CC O I-NP
platelet NN B-NP I-NP
aggregation NN I-NP I-NP
. . O O

Values NNS B-NP B-NP
were VBD B-VP B-VP
compared VBN I-VP I-VP
with IN B-PP B-PP
those DT B-NP B-NP
of IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
benign JJ B-NP B-NP
tumors NNS I-NP I-NP
( ( O O
n NN B-NP B-NP
= JJ B-VP I-NP
4 CD B-NP I-NP
) ) O O
, , O O
or CC O I-CC
undergoing VBG B-VP B-VP
a DT B-NP B-NP
mammary JJ I-NP I-NP
reduction NN I-NP I-NP
( ( O O
n NN B-NP B-NP
= JJ B-VP I-NP
7 CD B-NP I-NP
) ) O O
. . O O

Postoperatively RB B-ADVP B-ADVP
, , O O
blood NN B-NP B-NP
was VBD B-VP B-VP
taken VBN I-VP I-VP
as RB B-PP B-ADVP
well RB B-ADVP I-ADVP
in IN B-SBAR B-SBAR
order NN O I-NN
to TO O B-VP
compare VB B-VP I-VP
pre- JJ B-NP B-NP
and CC I-NP I-NP
postoperative JJ I-NP I-NP
values NNS I-NP I-NP
. . O O

Eicosanoids NNS B-NP B-NP
were VBD B-VP B-VP
measured VBN I-VP I-VP
in IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
monocytes NNS I-NP I-NP
and CC O I-CC
mammary JJ B-NP B-NP
tissue NN I-NP I-NP
by IN B-PP B-PP
means NNS I-PP B-NP
of IN I-PP B-PP
HPLC NN B-NP B-NP
; : O O
furthermore RBR B-ADVP B-NP
, , O O
TXA2 NN B-NP I-NP
, , O O
6-keto-PGF1 NN B-NP I-NP
alpha NN I-NP I-NP
, , O O
and CC O I-CC
PGE2 NN B-NP B-NP
were VBD B-VP B-VP
determined VBN I-VP I-VP
by IN B-PP B-PP
RIA NN B-NP B-NP
. . O O

Differences NNS B-NP B-NP
in IN B-PP B-PP
pre- JJ B-NP B-NP
and CC I-NP I-NP
postoperative JJ I-NP I-NP
values NNS I-NP I-NP
of IN B-PP B-PP
cancer NN B-NP B-NP
patients NNS I-NP I-NP
were VBD B-VP B-VP
seen VBN I-VP I-VP
in IN B-PP B-PP
plasma NN B-NP B-NP
RIA NN I-NP I-NP
values NNS I-NP I-NP
: : O O
PGE2 NN B-NP B-NP
and CC O I-NP
6-k-PGF1 NN B-NP I-NP
alpha NN I-NP I-NP
were VBD B-VP B-VP
significantly RB B-ADJP B-ADJP
higher JJR I-ADJP I-ADJP
preoperatively RB B-ADVP B-ADVP
when WRB B-ADVP B-VP
compared VBN B-VP I-VP
with IN B-PP B-PP
postoperatively RB B-ADVP B-NP
, , O O
however RB O B-ADVP
, , O O
such JJ B-NP B-NP
differences NNS I-NP I-NP
were VBD B-VP B-VP
seen VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
control NN I-NP I-NP
groups NNS I-NP I-NP
as RB B-PP B-ADVP
well RB B-ADVP I-ADVP
. . O O

Compared VBN B-PP B-VP
to TO B-PP B-PP
benign JJ B-NP B-NP
tumor NN I-NP I-NP
or CC O I-CC
mammary JJ B-NP B-NP
reduction NN I-NP I-NP
test NN B-NP I-NP
material NN I-NP B-VP
the DT B-NP B-NP
eicosanoid NN I-NP I-NP
profile NN I-NP I-NP
of IN B-PP B-PP
tissue NN B-NP B-NP
obtained VBN B-VP B-VP
from IN B-PP B-PP
malignant JJ B-NP B-NP
mammary JJ I-NP I-NP
tumors NNS I-NP I-NP
showed VBD B-VP B-VP
important JJ B-NP B-NP
differences NNS I-NP I-NP
. . O O

Except IN B-PP B-PP
for IN I-PP B-PP
PGF2 NN B-NP B-NP
alpha NN I-NP I-NP
, , O O
HHT NN B-NP B-NP
and CC O I-NP
15-HETE NN B-NP I-NP
no DT B-NP B-NP
detectable JJ I-NP I-NP
quantities NNS I-NP I-NP
of IN B-PP B-PP
eicosanoids NNS B-NP B-NP
were VBD B-VP B-VP
found VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
non-tumor JJ I-NP I-NP
material NN I-NP I-NP
, , O O
whereas IN O B-PP
in IN B-PP B-PP
the DT B-NP B-NP
malignant JJ I-NP I-NP
tumor NN I-NP I-NP
material NN I-NP I-NP
substantial JJ B-NP I-NP
quantities NNS I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
eicosanoid NN B-NP B-NP
metabolites NNS I-NP I-NP
were VBD B-VP B-VP
present JJ B-ADJP B-ADJP
. . O O

Statistically RB B-NP B-NP
significant JJ I-NP I-NP
correlations NNS I-NP I-NP
could MD B-VP B-VP
be VB I-VP I-VP
established VBN I-VP I-VP
between IN B-PP B-PP
patient/histopathology NN B-NP B-NP
data NNS I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
results NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
platelet NN I-NP I-NP
aggregation NN I-NP I-NP
assays NNS I-NP I-NP
, , B-PP O
e.g. FW I-PP B-NP
between IN B-PP B-PP
menopausal JJ B-NP B-NP
status NN I-NP I-NP
and CC O I-NP
ADP NN B-NP I-NP
aggregation NN I-NP I-NP
; : O O
oestrogen NN B-NP B-NP
receptor NN I-NP I-NP
( ( O O
+/- CC O I-CC
) ) O O
and CC O I-CC
collagen NN B-NP B-NP
and CC O I-NP
arachidonic JJ B-NP I-NP
acid NN I-NP I-NP
aggregation NN I-NP I-NP
, , O O
inflammatory JJ B-NP B-NP
cell NN I-NP I-NP
infiltration NN I-NP I-NP
score NN I-NP I-NP
and CC O I-CC
arachidonic JJ B-NP B-NP
acid NN I-NP I-NP
aggregation NN I-NP I-NP
and CC O I-NP
fibrosis NN B-NP I-NP
score NN I-NP I-NP
and CC O I-NP
ADP NN B-NP I-NP
aggregation NN I-NP I-NP
. . O O

The DT B-NP B-NP
results NNS I-NP I-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
eicosanoid NN B-NP B-NP
synthesis NN I-NP I-NP
in IN B-PP B-PP
material NN B-NP B-NP
from IN B-PP B-PP
mammary JJ B-NP B-NP
cancer NN I-NP I-NP
patients NNS I-NP I-NP
is VBZ B-VP B-VP
different JJ B-ADJP B-ADJP
from IN B-PP B-PP
that DT B-NP B-NP
in IN B-PP B-PP
benign JJ B-NP B-NP
mammary JJ I-NP I-NP
tissue NN I-NP I-NP
. . O O

The DT B-NP B-NP
implications NNS I-NP I-NP
, , O O
in IN B-PP B-PP
particular JJ B-NP B-NP
, , B-PP O
in IN I-PP B-PP
relation NN I-PP B-NP
to TO I-PP B-PP
future JJ B-NP B-NP
prognosis NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
patient NN I-NP I-NP
, , O O
remain VBP B-VP B-VP
obscure JJ B-ADJP B-ADJP
. . O O

c-myc NN B-NP B-NP
mRNA NN I-NP I-NP
expression NN I-NP I-NP
in IN B-PP B-PP
minor JJ B-NP B-NP
salivary JJ I-NP I-NP
glands NNS I-NP I-NP
of IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
Sjogren NN B-NP B-NP
's POS B-NP B-NP
syndrome NN I-NP I-NP
. . O O

c-myc NN B-NP B-NP
protooncogene NN I-NP I-NP
is VBZ B-VP B-VP
implicated VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
pathogenesis NN I-NP I-NP
of IN B-PP B-PP
B NN B-NP B-NP
cell NN I-NP I-NP
lymphoid JJ I-NP I-NP
malignancies NNS I-NP I-NP
and CC O I-CC
high JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
c-myc NN B-NP B-NP
mRNA NN I-NP I-NP
expression NN I-NP I-NP
are VBP B-VP B-VP
observed VBN I-VP I-VP
in IN B-PP B-PP
activated VBN B-NP B-NP
blood NN I-NP I-NP
mononuclear JJ I-NP I-NP
cells NNS I-NP I-NP
. . O O

Sjogren NN B-NP B-NP
's POS B-NP B-NP
syndrome NN I-NP I-NP
( ( O O
SS NN B-NP B-NP
) ) O O
is VBZ B-VP B-VP
characterized VBN I-VP I-VP
by IN B-PP B-PP
lymphocytic JJ B-NP B-NP
infiltrates NNS I-NP I-NP
of IN B-PP B-PP
exocrine JJ B-NP B-NP
glands NNS I-NP I-NP
, , O O
remarkable JJ B-NP B-NP
B NN I-NP I-NP
cell NN I-NP I-NP
hyperreactivity NN I-NP I-NP
and CC O I-CC
a DT B-NP B-NP
strong JJ I-NP I-NP
predisposition NN I-NP I-NP
to TO B-PP B-PP
B NN B-NP B-NP
cell NN I-NP I-NP
neoplasia NN I-NP I-NP
. . O O

In IN B-PP B-PP
this DT B-NP B-NP
study NN I-NP I-NP
, , O O
c-myc NN B-NP B-NP
protooncogene NN I-NP I-NP
mRNA NN I-NP I-NP
expression NN I-NP I-NP
in IN B-PP B-PP
29 CD B-NP B-NP
labial JJ I-NP I-NP
minor JJ I-NP I-NP
salivary JJ I-NP I-NP
gland NN I-NP I-NP
biopsies NNS I-NP I-NP
from IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
primary JJ B-NP B-NP
SS NNS I-NP I-NP
and CC O I-CC
15 CD B-NP B-NP
controls NNS I-NP I-NP
was VBD B-VP B-VP
examined VBN I-VP I-VP
using VBG B-VP I-VP
in FW B-NP B-NP
situ FW I-NP I-NP
hybridization NN I-NP I-NP
histochemistry NN I-NP I-NP
. . O O

Two CD B-NP B-NP
40mer JJ I-NP I-NP
oligonucleotides NNS I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
1st JJ I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
2nd JJ I-NP I-NP
exon NN B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
c-myc NN I-NP I-NP
gene NN I-NP I-NP
, , O O
labeled VBN B-VP B-VP
with IN B-PP B-PP
35S NN B-NP B-NP
, , O O
were VBD B-VP B-VP
used VBN I-VP I-VP
as IN B-PP B-PP
probes NNS B-NP B-NP
. . O O

To TO B-VP B-VP
detect VB I-VP I-VP
the DT B-NP B-NP
origin NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
cell NN I-NP I-NP
hybridized VBN B-VP B-VP
with IN B-PP B-PP
a DT B-NP B-NP
c-myc NN I-NP I-NP
probe NN I-NP I-NP
, , O O
a DT B-NP B-NP
combined JJ I-NP I-NP
immunochemistry NN I-NP I-NP
in FW I-NP B-NP
situ FW I-NP I-NP
hybridization NN I-NP I-NP
histochemistry NN I-NP I-NP
technique NN I-NP I-NP
was VBD B-VP B-VP
used VBN I-VP I-VP
. . O O

High JJ B-NP B-NP
c-myc NN I-NP I-NP
mRNA NN I-NP I-NP
expression NN I-NP I-NP
was VBD B-VP B-VP
detected VBN I-VP I-VP
on IN B-PP B-PP
acinar JJ B-NP B-NP
epithelial JJ I-NP I-NP
cells NNS I-NP I-NP
. . O O

c-myc NN B-NP B-NP
did VBD B-VP B-VP
not RB I-VP I-VP
correlate VB I-VP I-VP
with IN B-PP B-PP
c-fos NN B-NP B-NP
and CC O I-NP
c-jun NN B-NP I-NP
protein NN B-NP I-NP
expression NN I-NP I-NP
. . O O

Stronger JJR B-NP B-NP
c-myc NN I-NP I-NP
mRNA NN I-NP I-NP
expression NN I-NP I-NP
was VBD B-VP B-VP
detected VBN I-VP I-VP
in IN B-PP B-PP
labial JJ B-NP B-NP
salivary JJ I-NP I-NP
glands NNS I-NP I-NP
of IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
longer JJR B-NP B-NP
disease NN I-NP I-NP
duration NN I-NP I-NP
( ( O O
p NN B-NP B-NP
less JJR B-NP B-ADJP
than IN I-NP B-PP
or CC I-NP I-CC
equal JJ I-NP B-ADJP
to TO I-NP B-PP
0.002 CD I-NP B-NP
) ) O O
and CC O I-CC
more RBR B-NP B-NP
intense JJ I-NP I-NP
T NN I-NP I-NP
lymphocyte NN I-NP I-NP
infiltrates NNS I-NP I-NP
( ( O O
p NN B-NP B-NP
less JJR B-NP B-ADJP
than IN I-NP B-PP
0.05 CD I-NP B-NP
) ) O O
although IN B-SBAR B-PP
these DT B-NP B-NP
patients NNS I-NP I-NP
revealed VBD B-VP B-VP
no DT B-NP B-NP
hypergammaglobulinemia NN I-NP I-NP
. . O O

No DT B-NP B-NP
correlation NN I-NP I-NP
was VBD B-VP B-VP
observed VBN I-VP I-VP
between IN B-PP B-PP
c-myc NN B-NP B-NP
mRNA NN I-NP I-NP
and CC O I-NP
B NN B-NP I-NP
lymphocyte NN I-NP I-NP
monoclonicity NN B-NP I-NP
or CC O I-NP
lymphoma NN B-NP I-NP
. . O O

In IN B-PP B-PP
conclusion NN B-NP B-NP
, , O O
strong JJ B-NP B-NP
c-myc NN I-NP I-NP
mRNA NN I-NP I-NP
expression NN I-NP I-NP
was VBD B-VP B-VP
observed VBN I-VP I-VP
on IN B-PP B-PP
epithelial JJ B-NP B-NP
cells NNS I-NP I-NP
of IN B-PP B-PP
labial JJ B-NP B-NP
salivary JJ I-NP I-NP
glands NNS I-NP I-NP
from IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
primary JJ B-NP B-NP
SS NN I-NP I-NP
. . O O

Our PRP$ B-NP B-NP
findings NNS I-NP I-NP
may MD B-VP B-VP
indicate VB I-VP I-VP
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
reactivated VBN I-NP I-NP
virus NN I-NP I-NP
hosted VBN B-VP B-VP
in IN B-PP B-PP
these DT B-NP B-NP
cells NNS I-NP I-NP
. . O O

Cytoplasmic JJ B-NP B-NP
domain NN I-NP I-NP
heterogeneity NN I-NP I-NP
and CC O I-CC
functions NNS B-NP B-NP
of IN B-PP B-PP
IgG NN B-NP B-NP
Fc NN I-NP I-NP
receptors NNS I-NP I-NP
in IN B-PP B-PP
B NN B-NP B-NP
lymphocytes NNS I-NP I-NP
. . O O

B NN B-NP B-NP
lymphocytes NNS I-NP I-NP
and CC O I-NP
macrophages NNS B-NP I-NP
express VBP B-VP B-VP
closely RB B-NP B-NP
related JJ I-NP I-NP
immunoglobulin NN B-NP I-NP
G NN I-NP I-NP
( ( O O
IgG NN B-NP I-NN
) ) O O
Fc NN B-NP B-NP
receptors NNS I-NP I-NP
( ( O O
Fc NN O B-NP
gamma NN O I-NP
RII NN O I-NP
) ) O O
that WDT B-NP B-NP
differ VBP B-VP B-VP
only RB B-ADVP B-ADVP
in IN I-ADVP B-PP
the DT B-NP B-NP
structures NNS I-NP I-NP
of IN B-PP B-PP
their PRP$ B-NP B-NP
cytoplasmic JJ I-NP I-NP
domains NNS I-NP I-NP
. . O O

Because IN B-PP B-PP
of IN I-PP I-PP
cell NN B-NP B-NP
type-specific JJ I-NP B-NP
alternative JJ I-NP I-NP
messenger NN I-NP I-NP
RNA NN I-NP I-NP
splicing NN I-NP I-NP
, , O O
B-cell NN B-NP B-NP
Fc NN I-NP I-NP
gamma NN I-NP I-NP
RII NN I-NP I-NP
contains VBZ B-VP B-VP
an DT B-NP B-NP
insertion NN I-NP I-NP
of IN B-PP B-PP
47 CD B-NP B-NP
amino NN I-NP I-NP
acids NNS I-NP I-NP
that WDT B-NP B-NP
participates VBZ B-VP B-VP
in IN B-PP B-PP
determining VBG B-VP B-VP
receptor NN B-NP B-NP
function NN I-NP I-NP
in IN B-PP B-PP
these DT B-NP B-NP
cells NNS I-NP I-NP
. . O O

Transfection NN B-NP B-NP
of IN B-PP B-PP
an DT B-NP B-NP
Fc NN I-NP I-NP
gamma NN I-NP I-NP
RII-negative JJ I-NP I-NP
B-cell NN I-NP I-NP
line NN I-NP I-NP
with IN B-PP B-PP
complementary JJ B-NP B-NP
DNA NN I-NP I-NP
's POS B-NP B-NP
encoding VBG B-VP I-NP
the DT B-NP I-NP
two CD I-NP I-NP
splice NN I-NP I-NP
products NNS I-NP I-NP
and CC O I-CC
various JJ B-NP B-NP
receptor NN I-NP I-NP
mutants NNS I-NP I-NP
indicated VBD B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
insertion NN I-NP I-NP
was VBD B-VP B-VP
responsible JJ B-ADJP B-ADJP
for IN B-PP B-PP
preventing VBG B-VP B-NP
both CC O I-NP
Fc NN B-NP I-NP
gamma NN I-NP I-NP
RII-mediated JJ I-NP I-NP
endocytosis NN I-NP I-NP
and CC O I-NP
Fc NN B-NP I-NP
gamma NN I-NP I-NP
RII-mediated JJ I-NP I-NP
antigen NN I-NP I-NP
presentation NN I-NP I-NP
. . O O

The DT B-NP B-NP
insertion NN I-NP I-NP
was VBD B-VP B-VP
not RB I-VP I-VP
required VBN I-VP I-VP
for IN B-PP B-PP
Fc NN B-NP B-NP
gamma NN I-NP I-NP
RII NN I-NP I-NP
to TO B-VP B-VP
modulate VB I-VP I-VP
surface NN B-NP B-NP
immunoglobulin-triggered JJ I-NP I-NP
B-cell NN I-NP I-NP
activation NN I-NP I-NP
. . O O

Instead RB B-ADVP B-ADVP
, , O O
regulation NN B-NP B-NP
of IN B-PP B-PP
activation NN B-NP B-NP
involved VBD B-VP B-VP
a DT B-NP B-NP
region NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
cytoplasmic JJ I-NP I-NP
domain NN I-NP I-NP
common JJ B-ADJP B-ADJP
to TO B-PP B-VP
both CC O I-VP
the DT O B-NP
lymphocyte NN B-NP I-NP
and CC O I-NP
macrophage NN B-NP I-NP
receptor NN B-NP I-NP
isoforms NNS I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
the DT B-NP B-NP
insertion NN I-NP I-NP
did VBD B-VP B-VP
contribute VB I-VP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
formation NN I-NP I-NP
of IN B-PP B-PP
caps NNS B-NP B-NP
in IN B-PP B-PP
response NN I-PP B-NP
to TO I-PP B-PP
receptor NN B-NP B-NP
cross-linking NN I-NP I-NP
, , O O
consistent JJ B-ADJP B-ADJP
with IN B-PP B-PP
suggestions NNS B-NP B-NP
that IN B-SBAR B-SBAR
the DT O B-NP
lymphocyte NN B-NP I-NP
but CC B-CONJP B-NP
not RB I-CONJP I-NP
macrophage NN B-NP I-NP
form NN B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
receptor NN I-NP I-NP
can MD B-VP B-VP
associate VB I-VP I-VP
with IN B-PP B-PP
the DT B-NP B-NP
detergent-insoluble JJ I-NP I-NP
cytoskeleton NN I-NP I-NP
. . O O

Every DT B-NP B-NP
enhancer NN I-NP I-NP
works VBZ B-VP B-VP
with IN B-PP B-PP
every DT B-NP B-NP
promoter NN I-NP I-NP
for IN B-PP B-PP
all PDT B-NP B-NP
the DT I-NP I-NP
combinations NNS I-NP I-NP
tested VBN B-VP B-VP
: : O O
could MD O B-NP
new JJ B-NP I-NP
regulatory JJ I-NP I-NP
pathways NNS I-NP I-NP
evolve VBP B-VP B-VP
by IN B-PP B-PP
enhancer NN B-NP B-NP
shuffling NN I-NP I-NP
? . O O

The DT B-NP B-NP
promoters NNS B-NP I-NP
and CC O I-NP
enhancers NNS B-NP I-NP
of IN B-PP B-PP
cell NN B-NP B-NP
type-specific JJ I-NP I-NP
genes NNS I-NP I-NP
are VBP B-VP B-VP
often RB I-VP I-VP
conserved VBN I-VP I-VP
in IN B-PP B-PP
evolution NN B-NP B-NP
, , O O
and CC O I-CC
hence RB O B-ADVP
one NN B-NP B-NP
might MD B-VP B-VP
expect VB I-VP I-VP
that IN B-SBAR B-PP
a DT B-NP B-NP
given JJ I-NP I-NP
enhancer NN I-NP I-NP
has VBZ B-VP B-VP
evolved VBN I-VP I-VP
to TO I-VP B-PP
work VB I-VP B-NP
best RBS B-ADVP B-NP
with IN B-PP B-PP
its PRP$ B-NP B-NP
own JJ I-NP I-NP
promoter NN I-NP I-NP
. . O O

While IN B-SBAR B-SBAR
this DT B-NP B-NP
expectation NN I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
realized VBN I-VP I-VP
in IN B-PP B-PP
some DT B-NP B-NP
cases NNS I-NP I-NP
, , O O
we PRP B-NP B-NP
have VBP B-VP B-VP
not RB I-VP I-VP
found VBN I-VP I-VP
evidence NN B-NP B-NP
for IN B-PP B-PP
it PRP B-NP B-NP
. . O O

A DT B-NP B-NP
total NN I-NP I-NP
of IN B-PP B-PP
27 CD B-NP B-NP
combinations NNS I-NP I-NP
of IN B-PP B-PP
different JJ B-NP B-NP
promoters NNS B-NP I-NP
and CC O I-NP
enhancers NNS B-NP I-NP
were VBD B-VP B-VP
tested VBN I-VP I-VP
by IN B-PP B-PP
transfection NN B-NP B-NP
into IN B-PP B-PP
cultured VBN B-NP B-NP
cells NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
found VBD B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
relative JJ I-NP I-NP
efficiency NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
enhancers NNS I-NP I-NP
is VBZ B-VP B-VP
approximately RB B-ADVP B-NP
the DT B-NP I-NP
same JJ I-NP I-NP
, , O O
irrespective JJ B-ADJP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
type NN I-NP I-NP
of IN B-PP B-PP
promoter NN B-NP B-NP
used VBN B-VP B-VP
, , O O
i.e. FW O B-NP
, , O O
there EX B-NP B-NP
was VBD B-VP B-VP
no DT B-NP B-NP
strong JJ I-NP I-NP
preference NN I-NP I-NP
for IN B-PP B-PP
any DT B-NP B-NP
given JJ I-NP I-NP
enhancer/promoter JJ I-NP I-NP
combination NN I-NP I-NP
. . O O

Notably RB B-ADVP B-ADVP
, , O O
we PRP B-NP B-NP
do VBP B-VP B-VP
not RB I-VP I-VP
see VB I-VP I-VP
particularly RB B-NP B-NP
strong JJ I-NP I-NP
transcription NN I-NP I-NP
when WRB B-ADVP B-ADVP
the DT B-NP B-NP
immunoglobulin NN I-NP I-NP
kappa NN I-NP I-NP
enhancer NN I-NP I-NP
( ( O O
or CC O I-CC
the DT B-NP B-NP
immunoglobulin NN I-NP I-NP
heavy JJ I-NP I-NP
chain NN I-NP I-NP
enhancer NN I-NP I-NP
) ) O O
is VBZ B-VP B-VP
used VBN I-VP I-VP
to TO B-VP I-VP
activate VB I-VP I-VP
a DT B-NP B-NP
kappa NN I-NP I-NP
gene NN I-NP I-NP
promoter NN I-NP I-NP
. . O O

We PRP B-NP B-NP
propose VBP B-VP B-VP
that IN B-SBAR B-SBAR
a DT B-NP B-NP
generally RB I-NP I-NP
permissive JJ I-NP I-NP
enhancer/promoter JJ I-NP I-NP
interaction NN I-NP I-NP
is VBZ B-VP B-VP
of IN B-PP B-PP
evolutionary JJ B-NP B-NP
benefit NN I-NP I-NP
for IN B-PP B-PP
higher JJR B-NP B-NP
eukaryotes NNS I-NP I-NP
: : O O
by IN B-PP B-PP
enhancer NN B-NP B-NP
shuffling NN I-NP I-NP
, , O O
genes NNS B-NP B-NP
could MD B-VP B-VP
be VB I-VP I-VP
easily RB I-VP I-VP
brought VBN I-VP I-VP
under IN B-PP B-PP
a DT B-NP B-NP
new JJ I-NP I-NP
type NN I-NP I-NP
of IN B-PP B-PP
inducibility/cell NN B-NP B-NP
type NN I-NP I-NP
specificity NN I-NP I-NP
. . O O

Heterodimerization NN B-NP B-NP
and CC O I-NP
transcriptional JJ B-NP I-NP
activation NN I-NP I-NP
in FW B-ADVP B-NP
vitro FW I-ADVP I-NP
by IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
proteins NNS I-NP I-NP
. . O O

The DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
family NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
proteins NNS I-NP I-NP
represents VBZ B-VP B-VP
multiple JJ B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
, , O O
rel NN B-NP B-NP
related JJ B-NP I-NP
polypeptides NNS I-NP I-NP
that WDT B-NP B-NP
contribute VBP B-VP B-VP
to TO B-PP B-PP
regulation NN B-NP B-NP
of IN B-PP B-PP
genes NNS B-NP B-NP
involved VBN B-VP B-VP
in IN B-PP B-PP
immune JJ B-NP B-NP
responsiveness NN I-NP I-NP
and CC O I-NP
inflammation NN B-NP I-NP
, , O O
as RB B-CONJP B-CONJP
well RB I-CONJP I-CONJP
as IN I-CONJP I-CONJP
activation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
HIV NN I-NP I-NP
long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
. . O O

In IN B-PP B-PP
this DT B-NP B-NP
study NN I-NP I-NP
multiple JJ O I-NP
NF-kappa NN B-NP I-NP
B NN I-NP I-NP
related JJ B-NP I-NP
polypeptides NNS I-NP I-NP
ranging VBG B-VP B-VP
from IN B-PP B-PP
85 CD I-PP B-NP
to TO I-PP I-NP
45 CD O I-NP
kDa NN O I-NP
were VBD B-VP B-VP
examined VBN I-VP I-VP
for IN B-PP B-PP
their PRP$ B-NP B-NP
capacity NN I-NP I-NP
to TO B-VP B-VP
interact VB I-VP I-VP
with IN B-PP B-PP
the DT B-NP B-NP
PRDII NN I-NP I-NP
regulatory JJ I-NP I-NP
element NN I-NP I-NP
of IN B-PP B-PP
interferon NN B-NP B-NP
beta NN I-NP I-NP
and CC O I-CC
were VBD B-VP B-VP
shown VBN I-VP I-VP
to TO I-VP I-VP
possess VB I-VP I-VP
distinct JJ B-NP B-NP
intrinsic JJ I-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
affinities NNS I-NP I-NP
for IN B-PP B-PP
this DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
site NN I-NP I-NP
and CC O I-CC
form VB B-VP B-VP
multiple JJ B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
homo- JJ I-NP I-NP
and CC I-NP I-NP
heterodimer NN I-NP I-NP
complexes NNS I-NP I-NP
in IN B-PP B-PP
co-renaturation NN B-NP B-NP
experiments NNS I-NP I-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
using VBG B-VP B-VP
DNA NN B-NP B-NP
templates NNS I-NP I-NP
containing VBG B-VP B-VP
two CD B-NP B-NP
copies NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
PRDII NN I-NP I-NP
domain NN I-NP I-NP
linked VBN B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
rabbit NN I-NP I-NP
beta NN I-NP I-NP
globin NN I-NP I-NP
gene NN I-NP I-NP
, , O O
the DT B-NP B-NP
purified VBN I-NP I-NP
polypeptides NNS I-NP I-NP
specifically RB B-ADVP B-ADVP
stimulated VBD B-VP B-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
dependent JJ B-NP I-NP
transcription NN I-NP I-NP
in IN B-PP B-PP
an DT B-NP B-NP
in FW I-NP B-VP
vitro FW I-NP B-NP
reconstitution NN I-NP I-NP
assay NN I-NP I-NP
as IN B-PP B-PP
heterodimers NNS B-NP B-NP
but CC B-PP I-CC
not RB B-PP B-SBAR
as IN I-PP I-SBAR
p50 NN B-NP B-NP
homodimers NNS I-NP I-NP
. . O O

These DT B-NP B-NP
experiments NNS I-NP I-NP
emphasize VBP B-VP B-VP
the DT B-NP B-NP
role NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
dimerization NN I-NP I-NP
as IN B-PP B-PP
a DT B-NP B-NP
distinct JJ I-NP I-NP
level NN I-NP I-NP
of IN B-PP B-PP
transcriptional JJ B-NP B-NP
control NN I-NP I-NP
that WDT B-NP B-NP
may MD B-VP B-VP
permit VB I-VP I-VP
functional JJ B-NP B-NP
diversification NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
limited JJ I-NP I-NP
number NN I-NP I-NP
of IN B-PP B-PP
regulatory JJ B-NP B-NP
proteins NNS I-NP I-NP
. . O O

Oct2 NN B-NP B-NP
transactivation NN I-NP I-NP
from IN B-PP B-PP
a DT B-NP B-NP
remote JJ I-NP I-NP
enhancer NN I-NP I-NP
position NN I-NP I-NP
requires VBZ B-VP B-VP
a DT B-NP B-NP
B-cell-restricted JJ I-NP I-NP
activity NN I-NP I-NP
. . O O

Previous JJ B-NP B-NP
cotransfection NN I-NP I-NP
experiments NNS I-NP I-NP
had VBD B-VP B-VP
demonstrated VBN I-VP I-VP
that IN B-SBAR B-PP
ectopic JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
lymphocyte-specific JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
Oct2 NN I-NP I-NP
could MD B-VP B-VP
efficiently RB I-VP I-VP
activate VB I-VP I-VP
a DT B-NP B-NP
promoter NN I-NP I-NP
containing VBG B-VP B-VP
an DT B-NP B-NP
octamer NN I-NP I-NP
motif NN I-NP I-NP
. . O O

Oct2 NN B-NP B-NP
expression NN I-NP I-NP
was VBD B-VP B-VP
unable JJ B-ADJP B-ADJP
to TO B-VP B-VP
stimulate VB I-VP I-VP
a DT B-NP B-NP
multimerized JJ I-NP I-NP
octamer NN I-NP I-NP
enhancer NN I-NP I-NP
element NN I-NP I-NP
in IN B-PP B-PP
HeLa NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
however RB B-ADVP B-ADVP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
tested VBN I-VP I-VP
a DT B-NP B-NP
variety NN I-NP I-NP
of IN B-PP B-PP
Oct2 NN B-NP B-NP
isoforms VBZ I-NP B-VP
generated VBN B-VP I-VP
by IN B-PP B-PP
alternative JJ B-NP B-NP
splicing NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
capability NN I-NP I-NP
to TO B-VP B-VP
activate VB I-VP I-VP
an DT B-NP B-NP
octamer NN I-NP I-NP
enhancer NN I-NP I-NP
in IN B-PP B-PP
nonlymphoid JJ B-NP B-NP
cells NNS I-NP I-NP
and CC O I-CC
a DT B-NP B-NP
B-cell NN I-NP I-NP
line NN I-NP I-NP
. . O O

Our PRP$ B-NP B-NP
analyses NNS I-NP I-NP
show VBP B-VP B-VP
that IN B-SBAR B-SBAR
several JJ B-NP B-NP
Oct2 NN I-NP I-NP
isoforms NNS I-NP I-NP
can MD B-VP B-VP
stimulate VB I-VP I-VP
from IN B-PP B-PP
a DT B-NP B-NP
remote JJ I-NP I-NP
position NN I-NP I-NP
but CC O I-CC
that IN B-SBAR B-SBAR
this DT B-NP B-NP
stimulation NN I-NP I-NP
is VBZ B-VP B-VP
restricted JJ I-VP B-ADJP
to TO B-PP B-PP
B NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

This DT B-NP B-NP
result NN I-NP I-NP
indicates VBZ B-VP B-VP
the DT B-NP B-NP
involvement NN I-NP I-NP
of IN B-PP B-PP
either CC O I-CC
a DT B-NP B-NP
B-cell-specific JJ I-NP I-NP
cofactor NN I-NP I-NP
or CC O I-CC
a DT B-NP B-NP
specific JJ I-NP I-NP
modification NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
cofactor NN I-NP I-NP
or CC O I-CC
the DT B-NP B-NP
Oct2 NN I-NP I-NP
protein NN I-NP I-NP
in IN B-PP B-PP
Oct2-mediated JJ B-NP B-NP
enhancer NN I-NP I-NP
activation NN I-NP I-NP
. . O O

Mutational JJ B-NP B-NP
analyses NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
carboxy-terminal JJ I-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
Oct2 NN B-NP B-NP
is VBZ B-VP B-VP
critical JJ B-ADJP B-ADJP
for IN B-PP B-PP
enhancer NN B-NP B-NP
activation NN I-NP I-NP
. . O O

Moreover RB B-ADVP B-ADVP
, , O O
this DT B-NP B-NP
domain NN I-NP I-NP
conferred VBD B-VP B-VP
enhancing NN B-NP B-NP
activity NN I-NP I-NP
when WRB O B-ADVP
fused VBN B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
Oct1 NN I-NP I-NP
protein NN I-NP I-NP
, , O O
which WDT B-NP B-NP
by IN B-PP B-PP
itself PRP B-NP B-NP
was VBD B-VP B-VP
unable JJ B-ADJP B-ADJP
to TO B-VP B-VP
stimulate VB I-VP I-VP
from IN B-PP B-PP
a DT B-NP B-NP
remote JJ I-NP I-NP
position NN I-NP I-NP
. . O O

The DT B-NP B-NP
glutamine-rich JJ I-NP I-NP
activation NN I-NP I-NP
domain NN I-NP I-NP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
amino-terminal JJ I-NP I-NP
portion NN I-NP I-NP
of IN B-PP B-PP
Oct2 NN B-NP B-NP
and CC O I-CC
the DT B-NP B-NP
POU NN I-NP I-NP
domain NN I-NP I-NP
contribute VBP B-VP B-VP
only RB B-ADVP B-ADVP
marginally RB I-ADVP I-ADVP
to TO B-PP B-PP
the DT B-NP B-NP
transactivation NN I-NP I-NP
function NN I-NP I-NP
from IN B-PP B-PP
a DT B-NP B-NP
distal JJ I-NP I-NP
position NN I-NP I-NP
. . O O

Induction NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
POU NN I-NP I-NP
domain NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
Oct-2 NN I-NP I-NP
during IN B-PP B-PP
T-cell NN B-NP B-NP
activation NN I-NP I-NP
by IN B-PP B-PP
cognate JJ B-NP B-NP
antigen NN I-NP I-NP
. . O O

Oct-2 NN B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
that WDT B-NP B-NP
binds VBZ B-VP B-VP
specifically RB B-PP B-ADVP
to TO I-PP B-PP
octamer NN B-NP B-NP
DNA NN I-NP I-NP
motifs NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
promoters NNS I-NP I-NP
of IN B-PP B-PP
immunoglobulin NN B-NP B-NP
and CC O I-NP
interleukin-2 NN B-NP I-NP
genes NNS B-NP I-NP
. . O O

All DT B-NP B-NP
tumor NN I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
B-cell NN I-NP I-NP
lineage NN I-NP I-NP
and CC O I-CC
a DT B-NP B-NP
few JJ I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
T-cell NN I-NP I-NP
lineage NN I-NP I-NP
express VBP B-VP B-VP
Oct-2 NN B-NP B-NP
. . O O

To TO B-VP B-VP
address VB I-VP I-VP
the DT B-NP B-NP
role NN I-NP I-NP
of IN B-PP B-PP
Oct-2 NN B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
T-cell NN I-NP I-NP
lineage NN I-NP I-NP
, , O O
we PRP B-NP B-NP
studied VBD B-VP B-VP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
Oct-2 NN B-NP B-NP
mRNA NN I-NP I-NP
and CC O I-NP
protein NN B-NP I-NP
in IN B-PP B-PP
nontransformed JJ O B-NP
human JJ O I-NP
and CC O I-NP
mouse NN B-NP I-NP
T NN B-NP I-NP
cells NNS I-NP I-NP
. . O O

Oct-2 NN B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
in IN B-PP B-PP
CD4+ JJ B-NP B-NP
and CC I-NP I-NP
CD8+ JJ I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
prepared VBN B-VP B-VP
from IN B-PP B-PP
human JJ B-NP B-NP
peripheral JJ I-NP I-NP
blood NN I-NP I-NP
and CC B-PP I-CC
in IN B-PP B-PP
mouse NN B-NP B-NP
lymph NN I-NP I-NP
node NN I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

In IN B-PP B-PP
a DT B-NP B-NP
T-cell NN I-NP I-NP
clone NN I-NP I-NP
specific JJ B-ADJP B-ADJP
for IN B-PP B-PP
pigeon NN B-NP B-NP
cytochrome NN I-NP I-NP
c NN I-NP I-NP
in IN B-PP B-PP
the DT I-PP B-NP
context NN I-PP I-NP
of IN I-PP B-PP
I-Ek NN B-NP B-NP
, , O O
Oct-2 NN B-NP B-NP
was VBD B-VP B-VP
induced VBN I-VP I-VP
by IN B-PP B-PP
antigen NN B-NP B-NP
stimulation NN I-NP I-NP
, , O O
with IN B-SBAR B-PP
the DT B-NP B-NP
increase NN I-NP I-NP
in IN B-PP B-PP
Oct-2 NN B-NP B-NP
protein NN I-NP I-NP
seen VBN B-VP B-VP
first RB B-ADVP B-ADVP
at IN B-PP B-PP
3 CD B-NP B-NP
h NN I-NP I-NP
after IN B-PP B-PP
activation NN B-NP B-NP
and CC O I-CC
continuing VBG B-VP B-VP
for IN B-PP B-PP
at IN B-NP B-NP
least JJS I-NP I-NP
24 CD I-NP I-NP
h NN I-NP I-NP
. . O O

Oct-2 NN B-NP B-NP
mRNA NN I-NP I-NP
induction NN I-NP I-NP
during IN B-PP B-PP
antigen-driven JJ B-NP B-NP
T-cell NN I-NP I-NP
activation NN I-NP I-NP
was VBD B-VP B-VP
blocked VBN I-VP I-VP
by IN B-PP B-PP
cyclosporin NN B-NP B-NP
A NN I-NP I-NP
, , O O
as RB B-CONJP B-CONJP
well RB I-CONJP I-CONJP
as IN I-CONJP I-CONJP
by IN B-PP B-PP
protein NN B-NP B-NP
synthesis NN I-NP I-NP
inhibitors NNS I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
Oct-2 NN B-NP B-NP
participates VBZ B-VP B-VP
in IN B-PP B-PP
transcriptional JJ B-NP B-NP
regulation NN I-NP I-NP
during IN B-PP B-PP
T-cell NN B-NP B-NP
activation NN I-NP I-NP
. . O O
The DT B-NP B-NP
relatively RB I-NP I-NP
delayed VBN I-NP I-NP
kinetics NNS I-NP I-NP
of IN B-PP B-PP
Oct-2 NN B-NP B-NP
induction NN I-NP I-NP
suggests VBZ B-VP B-VP
that IN B-SBAR B-SBAR
Oct-2 NN B-NP B-NP
mediates VBZ B-VP B-VP
the DT B-NP B-NP
changes NNS I-NP I-NP
in IN B-PP B-PP
gene NN B-NP B-NP
expression NN I-NP I-NP
which WDT B-NP B-NP
occur VBP B-VP B-VP
many JJ B-NP B-NP
hours NNS B-NP I-NP
or CC O I-NP
days NNS B-NP I-NP
following VBG B-PP B-VP
antigen NN B-NP B-NP
stimulation NN I-NP I-NP
of IN B-PP B-PP
T NN B-NP B-NP
lymphocytes NNS I-NP I-NP
. . O O

( ( O O
Changes NNS B-NP B-NP
in IN B-PP B-PP
plasma NN B-NP B-NP
interleukin-1 NN I-NP I-NP
and CC O I-CC
their PRP$ B-NP B-NP
possible JJ I-NP I-NP
relationship NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
changes NNS I-NP I-NP
in IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
in IN B-PP B-PP
aged JJ B-NP B-NP
long-distance JJ I-NP I-NP
runner NN I-NP I-NP
) ) O O

For IN B-PP B-PP
the DT B-NP B-NP
study NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
changes NNS I-NP I-NP
in IN B-PP B-PP
plasma NN B-NP B-NP
interleukin-1 NN B-NP I-NP
( ( O O
IL-1 NN B-NP B-NP
) ) O O
and CC O I-CC
their PRP$ B-NP B-NP
possible JJ I-NP I-NP
relationship NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
changes NNS I-NP I-NP
in IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
( ( O O
GR NN B-NP B-NP
) ) O O
, , O O
plasma NN B-NP B-NP
IL-1 NN I-NP I-NP
and CC O I-NP
GR NN B-NP I-NP
in IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
leukocytes NNS I-NP I-NP
in IN B-PP B-PP
aged JJ B-NP B-NP
long-distance JJ I-NP I-NP
runner NN I-NP I-NP
were VBD B-VP B-VP
measured VBN I-VP I-VP
simultaneously RB B-ADVP B-ADVP
. . O O

The DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
IL-1 NN B-NP B-NP
was VBD B-VP B-VP
expressed VBN I-VP I-VP
as IN B-PP B-PP
its PRP$ B-NP B-NP
ability NN I-NP I-NP
to TO B-VP B-VP
stimulate VB I-VP I-VP
3H-TdR NN B-NP B-NP
incorporation NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
thymocytes NNS I-NP I-NP
of IN B-PP B-PP
C57 NN B-NP B-NP
mice NNS I-NP I-NP
. . O O

GR NN B-NP B-NP
was VBD B-VP B-VP
determined VBN I-VP I-VP
by IN B-PP B-PP
whole JJ B-NP B-NP
cell NN I-NP I-NP
assay NN I-NP I-NP
with IN B-PP B-PP
3H-Dex NN B-NP B-NP
. . O O

The DT B-NP B-NP
results NNS I-NP I-NP
showed VBD B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
plasma NN B-NP B-NP
IL-1 NN I-NP I-NP
in IN B-PP B-PP
aged JJ B-NP B-NP
long-distance JJ I-NP I-NP
runner NN I-NP I-NP
was VBD B-VP B-VP
209 CD B-NP B-NP
% NN I-NP I-NP
, , O O
223 CD B-NP B-NP
% NN I-NP I-NP
and CC O I-CC
145 CD B-NP B-NP
% NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
control NN I-NP I-NP
at IN B-PP B-PP
14.7-18.7 CD B-NP B-NP
, , I-NP O
3.8-7.0 CD I-NP I-NP
and CC I-NP I-NP
1.5-2.6 CD I-NP I-NP
KD NN I-NP I-NP
fractions NNS B-NP I-NP
. . O O

The DT B-NP B-NP
GR NN I-NP I-NP
in IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
leukocytes NNS I-NP I-NP
in IN B-PP B-PP
aged JJ B-NP B-NP
runner NN I-NP I-NP
was VBD B-VP B-VP
65 CD B-NP B-NP
% NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
control NN I-NP I-NP
. . O O

Possible JJ B-NP B-NP
relationship NN I-NP I-NP
between IN B-PP B-PP
the DT B-NP B-NP
changes NNS I-NP I-NP
in IN B-PP B-PP
IL-1 NN B-NP B-NP
and CC O I-NP
GR NN B-NP I-NP
in NN O I-NP
aged JJ B-NP B-NP
long-distance JJ I-NP I-NP
runner NN I-NP I-NP
and CC O I-CC
its PRP$ B-NP B-NP
physiological JJ I-NP I-NP
significance NN I-NP I-NP
are VBP B-VP B-VP
discussed VBN I-VP I-VP
. . O O

Transcription NN B-NP B-NP
factor NN I-NP I-NP
AP-2 NN I-NP I-NP
activates VBZ B-VP B-VP
gene NN B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
HTLV-I NN B-NP B-NP
. . O O

The DT B-NP B-NP
HTLV-I NN I-NP I-NP
LTR NN I-NP I-NP
contains VBZ B-VP B-VP
three CD B-NP B-NP
conserved VBN I-NP I-NP
regulatory JJ I-NP I-NP
elements NNS I-NP I-NP
known VBN B-VP B-VP
as IN B-PP B-PP
21 CD B-NP B-NP
base NN I-NP I-NP
pair NN I-NP I-NP
repeats NNS I-NP I-NP
which WDT B-NP B-NP
are VBP B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
stimulation NN B-NP B-NP
of IN B-PP B-PP
gene NN B-NP B-NP
expression NN I-NP I-NP
by IN B-PP B-PP
the DT B-NP B-NP
transactivator NN I-NP I-NP
protein NN I-NP I-NP
tax NN I-NP I-NP
. . O O

Mutagenesis NN B-NP B-NP
indicates VBZ B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
21 CD I-NP I-NP
bp NN I-NP I-NP
repeats NNS I-NP I-NP
can MD B-VP B-VP
be VB I-VP I-VP
subdivided VBN I-VP I-VP
into IN B-PP B-PP
three CD B-NP B-NP
motifs NNS I-NP I-NP
, , O O
A NN B-NP B-NP
, , O O
B NN B-NP I-NP
and CC O I-NP
C NN B-NP I-NP
, , O O
each DT B-NP B-NP
of IN B-PP B-PP
which WDT B-NP B-NP
influences VBZ B-VP B-VP
the DT B-NP B-NP
level NN I-NP I-NP
of IN B-PP B-PP
tax NN B-NP B-NP
activation NN I-NP I-NP
. . O O

The DT B-NP B-NP
A NN I-NP I-NP
site NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
21 CD I-NP I-NP
bp NN I-NP I-NP
repeat NN I-NP I-NP
has VBZ B-VP B-VP
strong JJ B-NP B-NP
homology NN I-NP I-NP
with IN B-PP B-PP
previously RB B-NP B-NP
described VBN I-NP I-NP
binding VBG I-NP I-NP
sites NNS I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
AP-2 NN I-NP I-NP
. . O O

We PRP B-NP B-NP
demonstrated VBD B-VP B-VP
that IN B-SBAR B-PP
AP-2 NN B-NP B-NP
mRNA NN I-NP I-NP
was VBD B-VP B-VP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
T-lymphocytes NNS B-NP B-NP
and CC O I-CC
that IN B-SBAR B-SBAR
cellular JJ B-NP B-NP
factors NNS I-NP I-NP
from IN B-PP B-PP
both CC B-NP I-CC
non-transformed JJ I-NP B-NP
and CC I-NP I-NP
transformed VBN I-NP I-NP
T-lymphocytes NNS I-NP I-NP
specifically RB B-ADVP B-ADVP
bound VBD B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
consensus NN I-NP I-NP
motif NN I-NP I-NP
for IN B-PP B-PP
AP-2 NN B-NP B-NP
in IN B-PP B-PP
each DT B-NP B-NP
21 CD I-NP I-NP
bp NN I-NP I-NP
. . O O

To TO B-VP B-VP
determine VB I-VP I-VP
the DT B-NP B-NP
role NN I-NP I-NP
of IN B-PP B-PP
AP-2 NN B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HTLV-I NN I-NP I-NP
LTR NN I-NP I-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
, , O O
we PRP B-NP B-NP
used VBD B-VP B-VP
an DT B-NP B-NP
AP-2 NN I-NP I-NP
cDNA NN I-NP I-NP
in IN B-PP B-PP
DNA NN B-NP B-NP
binding NN I-NP I-NP
and CC O I-CC
transient JJ B-NP B-NP
expression NN I-NP I-NP
assays NNS B-NP I-NP
. . O O

Gel NN B-NP B-NP
retardation NN I-NP I-NP
and CC O I-NP
methylation NN B-NP I-NP
interference NN I-NP I-NP
studies NNS B-NP I-NP
revealed VBD B-VP B-VP
that IN B-SBAR B-PP
bacterially RB B-NP B-NP
produced VBN I-NP I-NP
AP-2 NN I-NP I-NP
bound VBD B-VP B-VP
specifically RB B-ADVP B-ADVP
and CC O I-CC
with IN B-PP B-PP
high JJ B-NP B-NP
affinity NN I-NP I-NP
to TO B-PP B-PP
all DT B-NP B-NP
three CD I-NP I-NP
21 CD I-NP I-NP
bp NN I-NP I-NP
repeats NNS I-NP I-NP
, , O O
and CC O I-CC
that IN B-SBAR B-SBAR
it PRP B-NP B-NP
required VBD B-VP B-VP
the DT B-NP B-NP
core NN I-NP I-NP
sequence NN I-NP I-NP
AGGC NN I-NP I-NP
for IN B-PP B-PP
specific JJ B-NP B-NP
binding NN I-NP I-NP
. . O O

Binding NN B-NP B-NP
of IN B-PP B-PP
AP-2 NN B-NP B-NP
prevented VBD B-VP B-VP
the DT B-NP B-NP
subsequent JJ I-NP I-NP
binding NN I-NP I-NP
of IN B-PP B-PP
members NNS B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
CREB/ATF NN I-NP I-NP
family NN I-NP I-NP
to TO B-PP B-PP
an DT B-NP B-NP
adjacent JJ I-NP I-NP
regulatory JJ I-NP I-NP
motif NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
21 CD I-NP I-NP
bp NN I-NP I-NP
repeat NN I-NP I-NP
. . O O

Transfection NN B-NP B-NP
of IN B-PP B-PP
an DT B-NP B-NP
AP-2 NN I-NP I-NP
expression NN I-NP I-NP
construct NN I-NP I-NP
into IN B-PP B-PP
T-lymphocytes NNS B-NP B-NP
activated VBD B-VP B-VP
gene NN B-NP B-NP
expression NN I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
HTLV-I NN I-NP I-NP
LTR NN I-NP I-NP
. . O O

At IN B-NP B-ADVP
least JJS I-NP I-ADVP
two CD I-NP B-NP
21 CD I-NP I-NP
bp NN I-NP I-NP
repeats NNS I-NP I-NP
were VBD B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
high JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
AP-2 NN B-NP B-NP
activation NN I-NP I-NP
and CC O I-NP
mutagenesis NN B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
AP-2 NN I-NP I-NP
consensus NN I-NP I-NP
binding NN I-NP I-NP
sequences NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
21 CD I-NP I-NP
bp NN I-NP I-NP
repeats NNS I-NP I-NP
eliminate VBP B-VP B-VP
this DT B-NP B-NP
activation NN I-NP I-NP
. . O O

( ( O O
ABSTRACT NN B-NP B-NP
TRUNCATED VBN B-VP B-VP
AT IN B-PP B-PP
250 CD B-NP B-NP
WORDS NNS I-NP I-NP
) ) O O

Cell NN B-NP B-NP
cycle-dependent JJ I-NP I-NP
initiation NN I-NP I-NP
and CC O I-CC
lineage-dependent JJ B-NP B-NP
abrogation NN I-NP I-NP
of IN B-PP B-PP
GATA-1 NN B-NP B-NP
expression NN I-NP I-NP
in IN B-PP B-PP
pure JJ B-NP B-NP
differentiating VBG I-NP I-NP
hematopoietic JJ I-NP I-NP
progenitors NNS I-NP I-NP
. . O O

The DT B-NP B-NP
programmed VBN I-NP I-NP
activation/repression NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
factors NNS I-NP I-NP
in IN B-PP B-PP
early JJ B-NP B-NP
hematopoietic JJ I-NP I-NP
differentiation NN I-NP I-NP
has VBZ B-VP B-VP
not RB I-VP I-VP
yet RB I-VP I-VP
been VBN I-VP I-VP
explored VBN I-VP I-VP
. . O O

The DT B-NP B-NP
DNA-binding JJ I-NP I-NP
protein NN I-NP I-NP
GATA-1 NN I-NP I-NP
is VBZ B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
normal JJ B-NP B-NP
erythroid JJ I-NP I-NP
development NN I-NP I-NP
and CC O I-CC
regulates VBZ B-VP B-VP
erythroid-expressed JJ B-NP B-NP
genes NNS I-NP I-NP
in IN B-PP B-PP
maturing VBG B-NP B-NP
erythroblasts NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
analyzed VBD B-VP B-VP
GATA-1 NN B-NP B-NP
expression NN I-NP I-NP
in IN B-PP B-PP
early JJ B-NP B-NP
human JJ I-NP I-NP
adult JJ I-NP I-NP
hematopoiesis NN I-NP I-NP
by IN B-PP B-PP
using VBG B-VP B-VP
an DT B-NP B-NP
in FW I-NP B-PP
vitro FW I-NP B-NP
system NN I-NP I-NP
in IN B-PP B-PP
which WDT B-NP B-NP
" [[DQS]] B-NP B-NP
pure JJ I-NP I-NP
" [[DQE]] I-NP I-[[DQE]]
early JJ I-NP B-NP
hematopoietic JJ I-NP I-NP
progenitors NNS I-NP I-NP
are VBP B-VP B-VP
induced VBN I-VP I-VP
to TO B-PP B-PP
gradual JJ B-NP B-NP
and CC I-NP I-NP
synchronized VBD I-NP B-VP
differentiation NN I-NP B-NP
selectively RB B-ADVP B-ADVP
along IN B-PP B-PP
the DT B-NP B-NP
erythroid JJ I-NP I-NP
or CC I-NP I-NP
granulocyte-macrophage JJ I-NP I-NP
pathway NN I-NP I-NP
by IN B-PP B-PP
differential JJ B-NP B-NP
treatment NN I-NP I-NP
with IN B-PP B-PP
hematopoietic JJ B-NP B-NP
growth NN I-NP I-NP
factors NNS I-NP I-NP
. . O O

The DT B-NP B-NP
GATA-1 NN I-NP I-NP
gene NN I-NP I-NP
, , O O
though IN B-SBAR B-SBAR
virtually RB B-ADJP B-NP
silent JJ I-ADJP I-NP
in IN B-PP B-PP
quiescent JJ B-NP B-NP
progenitors NNS I-NP I-NP
, , O O
is VBZ B-VP B-VP
activated VBN I-VP I-VP
after IN B-PP B-PP
entrance NN B-NP B-NP
into IN B-PP B-PP
the DT B-NP B-NP
cell NN I-NP I-NP
cycle NN I-NP I-NP
upon IN B-PP B-PP
stimulation NN B-NP B-NP
with IN B-PP B-PP
hematopoietic JJ B-NP B-NP
growth NN I-NP I-NP
factors NNS I-NP I-NP
. . O O

Subsequently RB B-ADVP B-ADVP
, , O O
increasing VBG B-NP B-NP
expression NN I-NP I-NP
along IN B-PP B-PP
the DT B-NP B-NP
erythroid JJ I-NP I-NP
pathway NN I-NP I-NP
contrasts VBZ B-VP B-VP
with IN B-PP B-PP
an DT B-NP B-NP
abrupt JJ I-NP I-NP
downregulation NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
granulocyte-macrophage JJ I-NP I-NP
lineage NN I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
suggest VBP B-VP B-VP
a DT B-NP B-NP
microenvironment-directed JJ I-NP I-NP
, , I-NP O
two-step JJ I-NP I-NP
model NN I-NP I-NP
for IN B-PP B-PP
GATA-1 NN B-NP B-NP
expression NN I-NP I-NP
in IN B-PP B-PP
differentiating VBG B-NP B-VP
hematopoietic JJ I-NP B-NP
progenitors NNS I-NP I-NP
that WDT B-NP B-NP
involves VBZ B-VP B-VP
( ( B-LST O
i LS I-LST B-PP
) ) O O
cycle-dependent JJ B-NP I-NP
initiation NN I-NP I-NP
and CC O I-CC
( ( B-LST O
ii LS I-LST B-NP
) ) O O
lineage-dependent JJ B-NP B-NP
maintenance NN B-NP I-NP
or CC O I-NP
suppression NN B-NP I-NP
. . O O

Hypothetically RB B-ADVP B-ADVP
, , O O
on/off JJ B-NP B-NP
switches NNS I-NP I-NP
of IN B-PP B-PP
lineage-restricted JJ B-NP B-NP
transactivators NNS I-NP I-NP
may MD B-VP B-VP
underlie VB I-VP I-VP
the DT B-NP B-NP
binary JJ I-NP I-NP
fate NN I-NP I-NP
decisions NNS I-NP I-NP
of IN B-PP B-PP
hematopoietic JJ B-NP B-NP
progenitors NNS I-NP I-NP
. . O O

( ( O O
Age-related JJ B-NP B-NP
changes NNS I-NP I-NP
in IN B-PP B-PP
glucocorticoid NN B-NP B-NP
and CC O I-NP
mineralocorticoid NN B-NP I-NP
receptors NNS B-NP I-NP
in IN B-PP B-PP
lymphocytes NNS B-NP B-NP
of IN B-PP B-PP
healthy JJ B-NP B-NP
persons NNS I-NP I-NP
and CC O I-CC
patients NNS B-NP B-NP
with IN B-PP B-PP
hypertension NN B-NP B-NP
) ) O O

It PRP B-NP B-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
found VBN I-VP I-VP
that IN B-SBAR B-PP
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
in IN B-PP B-PP
lymphocytes NNS B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
peripheral JJ I-NP I-NP
blood NN I-NP I-NP
of IN B-PP B-PP
healthy JJ B-NP B-NP
elderly JJ I-NP I-NP
subjects NNS I-NP I-NP
increases VBZ B-VP B-VP
, , O O
while IN B-SBAR B-SBAR
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
mineralocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
decreases VBZ B-VP B-VP
. . O O

The DT B-NP B-NP
mechanisms NNS I-NP I-NP
of IN B-PP B-PP
hormone-receptor NN B-NP B-NP
interactions NNS I-NP I-NP
in IN B-PP B-PP
hypertension NN B-NP B-NP
are VBP B-VP B-VP
activated VBN I-VP I-VP
: : O O
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
and CC O I-NP
mineralocorticoid NN B-NP I-NP
binding NN B-NP I-NP
sites NNS I-NP I-NP
grows VBZ B-VP B-VP
in IN B-PP B-PP
hypertensive JJ B-NP B-NP
patients NNS I-NP I-NP
. . O O

Still RB B-ADVP B-ADVP
a DT B-NP B-NP
more RBR I-NP I-NP
essential JJ I-NP I-NP
rise NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
receptors NNS B-NP B-NP
is VBZ B-VP B-VP
observed VBN I-VP I-VP
in IN B-PP B-PP
mid-age JJ B-NP B-NP
hypertensive NN I-NP I-NP
patients NNS I-NP I-NP
than IN B-PP B-PP
in IN B-PP B-PP
elderly JJ B-NP B-NP
ones NNS I-NP I-NP
. . O O

In FW B-NP B-NP
vivo FW I-NP I-NP
footprint NN I-NP I-NP
analysis NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HLA-DRA NN I-NP I-NP
gene NN I-NP I-NP
promoter NN I-NP I-NP
: : O O
cell-specific JJ B-NP B-NP
interaction NN I-NP I-NP
at IN B-PP B-PP
the DT B-NP B-NP
octamer NN I-NP I-NP
site NN I-NP I-NP
and CC O I-NP
up-regulation NN B-NP I-NP
of IN B-PP B-PP
X NN B-NP B-NP
box NN I-NP I-NP
binding NN I-NP I-NP
by IN B-PP B-PP
interferon NN B-NP B-NP
gamma NN I-NP I-NP
. . O O

Analysis NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
major JJ I-NP I-NP
histocompatibility NN I-NP I-NP
complex NN I-NP I-NP
class NN I-NP I-NP
II CD I-NP I-NP
gene NN I-NP I-NP
promoter NN I-NP I-NP
DRA NN I-NP I-NP
has VBZ B-VP B-VP
previously RB I-VP I-VP
identified VBN I-VP I-VP
at IN B-NP B-NP
least JJS I-NP I-NP
five CD I-NP I-NP
cis-acting JJ I-NP I-NP
regions NNS I-NP I-NP
required VBN B-VP B-VP
for IN B-PP B-PP
maximal JJ B-NP B-NP
expression NN I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
examined VBN I-VP I-VP
the DT B-NP B-NP
DRA NN I-NP I-NP
promoter NN I-NP I-NP
for IN B-PP B-PP
protein-DNA JJ B-NP B-NP
interactions NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
intact JJ I-NP I-NP
cell NN I-NP I-NP
, , O O
which WDT B-NP B-NP
may MD B-VP B-VP
mediate VB I-VP I-VP
transcriptional JJ B-NP B-NP
activation NN I-NP I-NP
. . O O

Using VBG B-VP B-VP
in FW B-NP B-NP
vivo FW I-NP B-NP
genomic JJ I-NP I-NP
footprinting NN I-NP I-NP
we PRP B-NP B-NP
identified VBD B-VP B-VP
interactions NNS B-NP B-NP
in IN B-PP B-PP
B-cell NN B-NP B-NP
lines NNS I-NP I-NP
at IN B-PP B-PP
the DT B-NP B-NP
octamer NN I-NP I-NP
site NN I-NP I-NP
and CC O I-CC
the DT O B-NP
Y NN B-NP I-NP
, , O O
X1 NN B-NP B-NP
, , O O
and CC O I-CC
X2 NN B-NP B-NP
boxes NNS B-NP I-NP
. . O O

Class NN B-NP B-NP
II CD I-NP I-NP
antigen NN I-NP I-NP
expressing VBG I-NP I-NP
T-cell NN I-NP I-NP
lines NNS I-NP I-NP
maintained VBD B-VP B-VP
contacts NNS B-NP B-NP
identical JJ B-ADJP B-ADJP
to TO B-PP B-PP
B-cell NN B-NP B-NP
lines NNS I-NP I-NP
, , O O
while IN B-SBAR B-SBAR
class NN B-NP B-NP
II-negative JJ I-NP I-NP
T-cell NN I-NP I-NP
lines NNS I-NP I-NP
exhibited VBD B-VP B-VP
no DT B-NP B-NP
interactions NNS I-NP I-NP
. . O O

In IN B-PP B-PP
lymphoid JJ B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
, , O O
the DT B-NP B-NP
octamer NN I-NP I-NP
site NN I-NP I-NP
is VBZ B-VP B-VP
occupied VBN I-VP I-VP
and CC O I-VP
required VBN B-VP I-VP
for IN B-PP B-PP
maximal JJ B-NP B-NP
expression NN I-NP I-NP
. . O O

This DT B-NP B-NP
is VBZ B-VP B-VP
most RBS B-ADVP B-ADVP
likely RB I-ADVP I-ADVP
due JJ B-PP B-ADJP
to TO I-PP B-PP
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
lymphoid-specific JJ I-NP I-NP
OTF-2 NN I-NP I-NP
factor NN I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
the DT B-NP B-NP
class NN I-NP I-NP
II-positive JJ I-NP I-NP
nonlymphoid JJ I-NP I-NP
glioblastoma NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
does VBZ B-VP B-VP
not RB I-VP I-VP
exhibit VB I-VP I-VP
interactions NNS B-NP B-NP
at IN B-PP B-PP
the DT B-NP B-NP
octamer NN I-NP I-NP
site NN I-NP I-NP
despite IN B-PP B-PP
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
ubiquitous JJ I-NP I-NP
OTF-1 NN I-NP I-NP
factor NN I-NP I-NP
and CC O I-CC
an DT B-NP B-NP
open JJ I-NP I-NP
binding VBG I-NP I-NP
site NN I-NP I-NP
. . O O

Thus RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
DRA NN I-NP I-NP
promoter NN I-NP I-NP
discriminates VBZ B-VP B-VP
against IN B-PP B-PP
OTF-1 NN B-NP B-NP
activation NN I-NP I-NP
at IN B-PP B-PP
the DT B-NP B-NP
level NN I-NP I-NP
of IN B-PP B-PP
DNA NN B-NP B-NP
binding NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
glioblastoma NN I-NP I-NP
line NN I-NP I-NP
. . O O

Interferon NN B-NP B-NP
gamma NN I-NP I-NP
induces VBZ B-VP B-VP
class NN B-NP B-NP
II CD I-NP I-NP
expression NN I-NP I-NP
in IN B-PP B-PP
this DT B-NP B-NP
glioblastoma NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
and CC O I-CC
, , O O
in IN B-PP B-PP
parallel NN B-NP B-NP
, , B-VP O
up-regulates VBZ I-VP B-VP
X1 NN B-NP B-NP
and CC O I-NP
X2 NN B-NP I-NP
box NN B-NP I-NP
protein-DNA JJ I-NP I-NP
interactions NNS I-NP I-NP
, , O O
while IN B-SBAR B-SBAR
all DT B-NP B-NP
other JJ I-NP I-NP
interactions NNS I-NP I-NP
remain VBP B-VP B-VP
unchanged JJ B-ADJP B-ADJP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-PP
interferon NN B-NP B-NP
gamma NN I-NP I-NP
functions VBZ B-VP B-VP
on IN B-PP B-PP
a DT B-NP B-NP
poised VBN I-NP I-NP
promoter NN I-NP I-NP
by IN B-PP B-PP
altering VBG B-VP B-VP
weak JJ B-NP B-NP
, , I-NP O
nonproductive JJ I-NP I-NP
interactions NNS I-NP I-NP
at IN B-PP B-PP
the DT B-NP B-NP
X NN I-NP I-NP
boxes NNS I-NP B-VP
to TO B-PP B-PP
strong JJ B-NP B-NP
interactions NNS I-NP I-NP
. . O O

These DT B-NP B-NP
findings NNS I-NP I-NP
provide VBP B-VP B-VP
direct JJ B-NP B-NP
in FW I-NP B-VP
vivo FW I-NP B-NP
evidence NN I-NP I-NP
to TO B-VP B-VP
strongly RB I-VP I-VP
suggest VB I-VP I-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
modulation NN I-NP I-NP
of IN B-PP B-PP
X1 NN B-NP B-NP
and CC O I-NP
X2 NN B-NP I-NP
interactions NNS B-NP I-NP
is VBZ B-VP B-VP
an DT B-NP B-NP
important JJ I-NP I-NP
constituent NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
interferon NN I-NP I-NP
gamma NN I-NP I-NP
induction NN I-NP I-NP
pathway NN I-NP I-NP
. . O O

Simple JJ B-NP B-NP
derivation NN I-NP I-NP
of IN B-PP B-PP
TFIID-dependent JJ B-NP B-NP
RNA NN I-NP I-NP
polymerase NN I-NP I-NP
II CD I-NP I-NP
transcription NN I-NP I-NP
systems NNS I-NP I-NP
from IN B-PP B-PP
Schizosaccharomyces FW B-NP B-NP
pombe FW I-NP I-NP
and CC O I-CC
other JJ B-NP B-NP
organisms NNS I-NP I-NP
, , O O
and CC O I-CC
factors NNS B-NP B-NP
required VBN B-VP B-VP
for IN B-PP B-PP
transcriptional JJ B-NP B-NP
activation NN I-NP I-NP
. . O O

Resolution NN B-NP B-NP
of IN B-PP B-PP
whole JJ B-NP B-NP
cell NN I-NP I-NP
extract NN I-NP I-NP
through IN B-PP B-PP
two CD B-NP B-NP
chromatographic JJ I-NP I-NP
steps NNS I-NP I-NP
yields VBZ B-VP B-VP
a DT B-NP B-NP
single JJ I-NP I-NP
protein NN I-NP I-NP
fraction NN I-NP I-NP
requiring VBG B-VP B-VP
only RB B-NP B-NP
the DT I-NP I-NP
addition NN I-NP I-NP
of IN B-PP B-PP
TFIID NN B-NP B-NP
for IN B-PP B-PP
the DT B-NP B-NP
initiation NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
at IN B-PP B-PP
RNA NN B-NP B-NP
polymerase NN I-NP I-NP
II CD I-NP B-NP
promoters NNS I-NP I-NP
. . O O

This DT B-NP B-NP
approach NN I-NP I-NP
allows VBZ B-VP B-VP
the DT B-NP B-NP
convenient JJ I-NP I-NP
generation NN I-NP I-NP
of IN B-PP B-PP
RNA NN B-NP B-NP
polymerase NN I-NP I-NP
II CD I-NP I-NP
transcription NN I-NP I-NP
systems NNS I-NP I-NP
from IN B-PP B-PP
Saccharomyces FW B-NP B-NP
cerevisiae FW I-NP I-NP
, , O O
human JJ B-NP B-NP
lymphocytes NNS I-NP I-NP
, , O O
and CC O I-CC
Schizosaccharomyces FW B-NP B-NP
pombe FW I-NP I-NP
. . O O

TFIIDs NNS B-NP B-NP
from IN B-PP B-PP
all DT B-NP B-NP
three CD I-NP I-NP
organisms NNS I-NP I-NP
are VBP B-VP B-VP
interchangeable JJ B-ADJP B-ADJP
among IN B-PP B-PP
all DT B-NP B-NP
three CD I-NP I-NP
systems NNS I-NP I-NP
. . O O

The DT O B-NP
S. FW B-NP I-NP
cerevisiae FW I-NP I-NP
and CC O I-CC
Sch. FW B-NP B-NP
pombe FW I-NP I-NP
systems NNS B-NP I-NP
support VBP B-VP B-VP
effects NNS B-NP B-NP
of IN B-PP B-PP
acidic JJ B-NP B-NP
activator NN I-NP I-NP
proteins NNS I-NP I-NP
, , O O
provided VBN B-PP B-VP
a DT B-NP B-NP
further JJ I-NP I-NP
protein NN I-NP I-NP
fraction NN I-NP I-NP
from IN B-PP B-PP
S. FW B-NP B-NP
cerevisiae FW I-NP I-NP
is VBZ B-VP B-VP
supplied VBN I-VP I-VP
. . O O

This DT B-NP B-NP
further JJ I-NP I-NP
fraction NN I-NP I-NP
is VBZ B-VP B-VP
distinct JJ B-ADJP B-ADJP
from IN B-PP B-PP
the DT B-NP B-NP
mediator NN I-NP I-NP
of IN B-PP B-PP
transcriptional JJ B-NP B-NP
activation NN I-NP I-NP
described VBN B-VP B-VP
previously RB B-ADVP B-ADVP
and CC O I-CC
represents VBZ B-VP B-VP
a DT B-NP B-NP
second JJ I-NP I-NP
component NN I-NP I-NP
in IN B-PP B-PP
addition NN I-PP B-NP
to TO I-PP B-PP
general JJ B-NP B-NP
initiation NN I-NP I-NP
factors NNS I-NP I-NP
that WDT B-NP B-NP
may MD B-VP B-VP
facilitate VB I-VP I-VP
a DT B-NP B-NP
response NN I-NP I-NP
to TO B-PP B-PP
acidic JJ B-NP B-NP
activators NNS I-NP I-NP
. . O O

NF-kappa NN B-NP B-NP
B-dependent JJ I-NP I-NP
induction NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
p50 NN I-NP I-NP
subunit NN I-NP I-NP
gene NN I-NP I-NP
promoter NN I-NP I-NP
underlies VBZ B-VP B-VP
self-perpetuation NN B-NP B-NP
of IN B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
transcription NN I-NP I-NP
in IN B-PP B-PP
monocytic JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

The DT B-NP B-NP
molecular JJ I-NP I-NP
mechanisms NNS I-NP I-NP
underlying VBG B-VP B-VP
the DT B-NP B-NP
sustained JJ I-NP I-NP
nuclear JJ I-NP I-NP
translocation NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
observed VBN B-VP B-VP
in IN B-PP B-PP
U937 NN B-NP B-NP
monocytic JJ I-NP I-NP
cells NNS I-NP I-NP
chronically RB B-VP B-VP
infected VBN I-VP I-VP
with IN B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
( ( O O
HIV NN B-NP B-NP
) ) O O
were VBD B-VP B-VP
studied VBN I-VP I-VP
. . O O

The DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
promoter NN I-NP I-NP
regulating VBG B-VP B-VP
the DT B-NP B-NP
synthesis NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
p105 NN I-NP I-NP
precursor NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
p50 NN I-NP I-NP
subunit NN I-NP I-NP
was VBD B-VP B-VP
enhanced VBN I-VP I-VP
in IN B-PP B-PP
these DT B-NP B-NP
cells NNS I-NP I-NP
. . O O

Deletions NNS B-NP B-NP
in IN B-PP B-PP
this DT B-NP B-NP
promoter NN I-NP I-NP
indicated VBD B-VP B-VP
that IN B-SBAR B-SBAR
this DT B-NP B-NP
upregulation NN I-NP I-NP
was VBD B-VP B-VP
mediated VBN I-VP I-VP
through IN B-PP B-PP
the DT B-NP B-NP
NF-kappa NN B-NP I-NP
B- NN I-NP I-NP
but CC B-CONJP B-NP
not RB I-CONJP I-NP
the DT B-NP B-NP
AP-1-binding JJ I-NP I-NP
motif NN B-NP I-NP
, , O O
by IN B-PP B-PP
bona FW B-NP B-NP
fide FW I-NP I-NP
p50/p65 NN I-NP I-NP
heterodimers NNS I-NP I-NP
. . O O

Analysis NN B-NP B-NP
of IN B-PP B-PP
cytosolic JJ B-NP B-NP
extracts NNS I-NP I-NP
indicated VBD B-VP B-VP
that IN B-SBAR B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
levels NNS I-NP I-NP
were VBD B-VP B-VP
increased VBN I-VP I-VP
in IN B-PP B-PP
HIV-infected JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN I-PP B-NP
to TO I-PP B-PP
the DT B-NP B-NP
transient JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
activation NN I-NP I-NP
induced VBN B-VP B-VP
by IN B-PP B-PP
phorbol NN B-NP B-NP
ester NN I-NP I-NP
, , O O
the DT B-NP B-NP
permanent JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
translocation NN I-NP I-NP
induced VBN B-VP B-VP
by IN B-PP B-PP
HIV NN B-NP B-NP
infection NN I-NP I-NP
was VBD B-VP B-VP
not RB O I-RB
dependent JJ B-ADJP B-ADJP
on IN B-PP B-PP
PKC NN B-NP B-NP
isoenzymes NNS I-NP I-NP
alpha NN B-NP I-NP
and CC O I-NP
beta NN B-NP I-NP
as IN B-SBAR B-SBAR
shown VBN B-VP B-VP
by IN B-PP B-PP
the DT B-NP B-NP
use NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
specific JJ I-NP I-NP
inhibitor NN I-NP I-NP
( ( O O
GF NN B-NP B-NP
109203X NN I-NP I-NP
) ) O O
. . O O

These DT B-NP B-NP
observations NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
during IN B-PP B-PP
chronic JJ B-NP B-NP
HIV NN I-NP I-NP
infection NN I-NP I-NP
of IN B-PP B-PP
U937 NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
continuous JJ O B-NP
NF-kappa NN O I-NP
B NN O I-NP
( ( O O
p50/p65 NN B-NP I-NN
) ) O O
translocation NN B-NP B-NP
results VBZ B-VP B-VP
in IN B-PP B-PP
p105 NN B-NP B-NP
promoter NN I-NP I-NP
upregulation NN I-NP I-NP
with IN B-PP B-PP
subsequent JJ B-NP B-NP
cytosolic JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
accumulation NN I-NP I-NP
, , O O
ready JJ B-ADJP B-ADJP
for IN B-PP B-PP
further JJ B-NP B-NP
translocation NN I-NP I-NP
. . O O

This DT B-NP B-NP
HIV-mediated JJ I-NP I-NP
mechanism NN I-NP I-NP
results VBZ B-VP B-VP
in IN B-PP B-PP
a DT B-NP B-NP
self-perpetuating JJ I-NP I-NP
loop NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
production NN I-NP I-NP
. . O O

The DT B-NP B-NP
development NN I-NP I-NP
of IN B-PP B-PP
functionally RB B-NP B-NP
responsive JJ I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

The DT B-NP B-NP
work NN I-NP I-NP
reviewed VBN B-VP B-VP
in IN B-PP B-PP
this DT B-NP B-NP
article NN I-NP I-NP
separates VBZ B-VP B-VP
T NN B-NP B-NP
cell NN I-NP I-NP
development NN I-NP I-NP
into IN B-PP B-PP
four CD B-NP B-NP
phases NNS I-NP I-NP
. . O O

First JJ B-ADJP B-NP
is VBZ B-VP B-VP
an DT B-NP B-NP
expansion NN I-NP I-NP
phase NN I-NP I-NP
prior RB B-PP B-ADVP
to TO I-PP B-PP
TCR NN B-NP B-NP
rearrangement NN I-NP I-NP
, , O O
which WDT B-NP B-NP
appears VBZ B-VP B-VP
to TO I-VP I-VP
be VB I-VP I-VP
correlated VBN I-VP I-VP
with IN B-PP B-PP
programming NN B-NP B-NP
of IN B-PP B-PP
at IN B-NP B-ADVP
least JJS I-NP I-ADVP
some DT I-NP B-NP
response NN I-NP I-NP
genes NNS I-NP I-NP
for IN B-PP B-PP
inducibility NN B-NP B-NP
. . O O

This DT B-NP B-NP
phase NN I-NP I-NP
can MD B-VP B-VP
occur VB I-VP I-VP
to TO B-PP B-PP
some DT B-NP B-NP
extent NN I-NP I-NP
outside IN B-ADVP B-ADVP
of IN B-PP B-PP
the DT B-NP B-NP
thymus NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
profound JJ I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
deficit NN I-NP I-NP
of IN B-PP B-PP
nude JJ B-NP B-NP
mice NNS I-NP I-NP
indicates VBZ B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
thymus NN I-NP I-NP
is VBZ B-VP B-VP
by IN B-PP B-PP
far RB B-ADVP B-ADVP
the DT B-NP B-NP
most RBS I-NP I-NP
potent JJ I-NP I-NP
site NN I-NP I-NP
for IN B-PP B-PP
inducing VBG B-VP B-VP
the DT B-NP B-NP
expansion NN I-NP I-NP
per FW B-ADVP B-NP
se FW I-ADVP I-NP
, , O O
even RB B-SBAR B-SBAR
if IN I-SBAR I-SBAR
other JJ B-NP B-NP
sites NNS I-NP I-NP
can MD B-VP B-VP
induce VB I-VP I-VP
some DT B-NP B-NP
response NN I-NP I-NP
acquisition NN I-NP I-NP
. . O O

Second JJ B-ADJP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
controlled JJ I-NP I-NP
phase NN I-NP I-NP
of IN B-PP B-PP
TCR NN B-NP B-NP
gene NN I-NP I-NP
rearrangement NN I-NP I-NP
. . O O

The DT B-NP B-NP
details NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
regulatory JJ I-NP I-NP
mechanism NN I-NP I-NP
that WDT B-NP B-NP
selects VBZ B-VP B-VP
particular JJ B-NP B-NP
loci NNS I-NP I-NP
for IN B-PP B-PP
rearrangement NN B-NP B-NP
are VBP B-VP B-VP
still RB I-VP I-VP
not RB I-VP I-VP
known VBN I-VP I-VP
. . O O

It PRP B-NP B-NP
seems VBZ B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
rearrangement NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
TCR NN I-NP I-NP
gamma NN I-NP I-NP
loci NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
gamma NN I-NP I-NP
delta NN I-NP I-NP
lineage NN I-NP I-NP
may MD B-VP B-VP
not RB I-VP I-VP
always RB I-VP I-VP
take VB I-VP I-VP
place NN B-NP B-NP
at IN B-PP B-PP
a DT B-NP B-NP
developmental JJ I-NP I-NP
stage NN I-NP I-NP
strictly RB B-ADJP B-ADJP
equivalent JJ I-ADJP I-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
rearrangement NN I-NP I-NP
of IN B-PP B-PP
TCR NN B-NP B-NP
beta NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
alpha NN I-NP I-NP
beta NN I-NP I-NP
lineage NN I-NP I-NP
, , O O
and CC O I-CC
it PRP B-NP B-NP
is VBZ B-VP B-VP
not RB O I-RB
clear JJ B-ADJP B-ADJP
just RB B-ADVP B-ADVP
how WRB I-ADVP B-ADVP
early RB I-ADVP I-ADVP
the DT B-NP B-NP
two CD I-NP I-NP
lineages NNS I-NP I-NP
diverge VBP B-VP B-VP
. . O O

In IN B-PP B-PP
the DT B-NP B-NP
TCR NN I-NP I-NP
alpha NN I-NP I-NP
beta NN I-NP I-NP
lineage NN I-NP I-NP
, , O O
however RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
final JJ I-NP I-NP
gene NN I-NP I-NP
rearrangement NN I-NP I-NP
events NNS I-NP I-NP
are VBP B-VP B-VP
accompanied VBN I-VP I-VP
by IN B-PP B-PP
rapid JJ B-NP B-NP
proliferation NN I-NP I-NP
and CC O I-CC
an DT B-NP B-NP
interruption NN I-NP I-NP
in IN B-PP B-PP
cellular JJ B-NP B-NP
response NN I-NP I-NP
gene NN I-NP I-NP
inducibility NN I-NP I-NP
. . O O

The DT B-NP B-NP
loss NN I-NP I-NP
of IN B-PP B-PP
conventional JJ B-NP B-NP
responsiveness NN I-NP I-NP
is VBZ B-VP B-VP
probably RB I-VP I-VP
caused VBN I-VP I-VP
by IN B-PP B-PP
alterations NNS B-NP B-NP
at IN B-PP B-PP
the DT B-NP B-NP
level NN I-NP I-NP
of IN B-PP B-PP
signaling NN B-NP B-NP
, , O O
and CC O I-CC
may MD B-VP B-VP
be VB I-VP I-VP
a DT B-NP B-NP
manifestation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
physiological JJ I-NP I-NP
state NN I-NP I-NP
that WDT B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
precondition NN I-NP I-NP
for IN B-PP B-PP
selection NN B-NP B-NP
. . O O

Third JJ B-ADJP B-NP
is VBZ B-VP B-VP
the DT B-NP B-NP
complex JJ I-NP I-NP
process NN I-NP I-NP
of IN B-PP B-PP
selection NN B-NP B-NP
. . O O

Whereas IN B-SBAR B-PP
peripheral JJ B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
can MD B-VP B-VP
undergo VB I-VP I-VP
forms NNS B-NP B-NP
of IN B-PP B-PP
positive JJ B-NP B-NP
selection NN I-NP I-NP
( ( O O
by IN B-PP B-PP
antigen-driven JJ B-NP B-NP
clonal JJ I-NP I-NP
expansion NN I-NP I-NP
) ) O O
and CC O I-CC
negative JJ B-NP B-NP
selection NN I-NP I-NP
( ( O O
by IN B-PP B-PP
abortive JJ B-NP B-NP
stimulation NN I-NP I-NP
leading VBG B-VP B-VP
to TO B-PP B-PP
anergy NN B-NP B-NP
or CC O I-NP
death NN B-NP I-NP
) ) O O
, , O O
neither DT B-NP B-NP
is VBZ B-VP B-VP
exactly RB B-NP B-NP
the DT I-NP I-NP
same JJ I-NP I-NP
phenomenon NN I-NP I-NP
that WDT B-NP B-NP
occurs VBZ B-VP B-VP
in IN B-PP B-PP
the DT B-NP B-NP
thymic JJ I-NP I-NP
cortex NN I-NP I-NP
. . O O

Negative JJ B-NP B-NP
selection NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
cortex NN I-NP I-NP
appears VBZ B-VP B-VP
to TO I-VP I-VP
be VB I-VP I-VP
a DT B-NP B-NP
suicidal JJ I-NP I-NP
inversion NN I-NP I-NP
of IN B-PP B-PP
antigen NN B-NP B-NP
responsiveness NN I-NP I-NP
: : O O
instead RB B-PP B-PP
of IN I-PP I-PP
turning VBG B-VP B-VP
on IN B-PRT B-PP
IL-2 NN B-NP B-NP
expression NN I-NP I-NP
, , O O
the DT B-NP B-NP
activated VBN I-NP I-NP
cell NN I-NP I-NP
destroys VBZ B-VP B-VP
its PRP$ B-NP B-NP
own JJ I-NP I-NP
chromatin NN I-NP I-NP
. . O O

The DT B-NP B-NP
genes NNS I-NP I-NP
that WDT B-NP B-NP
need VBP B-VP B-VP
to TO I-VP I-VP
be VB I-VP I-VP
induced VBN I-VP I-VP
for IN B-PP B-PP
this DT B-NP B-NP
response NN I-NP I-NP
are VBP B-VP B-VP
not RB I-VP I-VP
yet RB I-VP I-VP
identified VBN I-VP I-VP
, , O O
but CC O I-CC
it PRP B-NP B-NP
is VBZ B-VP B-VP
unquestionably RB B-ADVP B-ADVP
a DT B-NP B-NP
form NN I-NP I-NP
of IN B-PP B-PP
activation NN B-NP B-NP
. . O O

It PRP B-NP B-NP
is VBZ B-VP B-VP
interesting JJ B-ADJP B-ADJP
that IN B-SBAR B-SBAR
in IN B-PP B-PP
humans NNS B-NP B-NP
and CC O I-NP
rats NNS B-NP I-NP
, , O O
cortical JJ B-NP B-NP
thymocytes NNS I-NP I-NP
undergoing VBG B-VP B-VP
negative JJ B-NP B-NP
selection NN I-NP I-NP
can MD B-VP B-VP
still RB I-VP I-VP
induce VB I-VP I-VP
IL-2R NN B-NP B-NP
alpha NN I-NP I-NP
expression NN I-NP I-NP
and CC O I-CC
even RB B-VP B-VP
be VB I-VP I-VP
rescued VBN I-VP I-VP
in FW B-ADVP B-NP
vitro FW I-ADVP I-NP
, , O O
if IN B-SBAR B-SBAR
exogenous JJ B-NP B-NP
IL-2 NN I-NP I-NP
is VBZ B-VP B-VP
provided VBN I-VP I-VP
. . O O

Perhaps RB B-ADVP B-ADVP
murine JJ B-NP B-NP
thymocytes NNS I-NP I-NP
are VBP B-VP B-VP
denied VBN I-VP I-VP
this DT B-NP B-NP
form NN I-NP I-NP
of IN B-PP B-PP
rescue NN B-NP B-NP
because IN B-SBAR B-SBAR
they PRP B-NP B-NP
shut VBD B-VP B-VP
off RP B-PRT B-PRT
IL-2R NN B-NP B-NP
beta NN I-NP I-NP
chain NN I-NP I-NP
expression NN I-NP I-NP
at IN B-PP B-PP
an DT B-NP B-NP
earlier JJR I-NP I-NP
stage NN I-NP I-NP
or CC O I-CC
because IN B-SBAR B-SBAR
they PRP B-NP B-NP
may MD B-VP B-VP
be VB I-VP I-VP
uncommonly RB O B-NP
Bcl-2 NN B-NP I-NP
deficient JJ B-ADJP I-NP
( ( O O
cf. VBP B-VP B-VP
Sentman NNP B-NP B-NP
et FW I-NP I-NP
al. FW I-NP I-NP
, , I-NP O
1991 CD I-NP B-NP
; : O O
Strasser NNP B-NP B-NP
et FW I-NP I-NP
al. FW I-NP I-NP
, , I-NP O
1991 CD I-NP B-NP
) ) O O
. . O O

Even RB B-ADVP B-ADVP
so RB I-ADVP I-ADVP
, , O O
medullary JJ B-NP B-NP
thymocytes NNS I-NP I-NP
remain VBP B-VP B-VP
at IN B-ADJP B-ADVP
least JJS I-ADJP I-ADVP
partially RB I-ADJP B-ADVP
susceptible JJ I-ADJP I-ADVP
to TO B-PP B-PP
negative JJ B-NP B-NP
selection NN I-NP I-NP
even RB B-SBAR B-ADVP
as IN I-SBAR B-SBAR
they PRP B-NP B-NP
continue VBP B-VP B-VP
to TO I-VP I-VP
mature VB I-VP I-VP
. . O O

SRC-related JJ B-NP B-NP
proto-oncogenes NNS I-NP I-NP
and CC O I-CC
transcription NN B-NP B-NP
factors NNS I-NP I-NP
in IN B-PP B-PP
primary JJ B-NP B-NP
human JJ I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
: : O O
modulation NN B-NP B-NP
by IN B-PP B-PP
cyclosporin NN B-NP B-NP
A NN I-NP I-NP
and CC O I-NP
FK506 NN B-NP I-NP
. . O O

Activation NN B-NP B-NP
of IN B-PP B-PP
T NN B-NP B-NP
lymphocytes NNS I-NP I-NP
induces VBZ B-VP B-VP
transcription NN B-NP B-NP
of IN B-PP B-PP
genes NNS B-NP B-NP
encoding VBG B-VP B-VP
for IN B-PP B-PP
lymphokines NNS B-NP B-NP
. . O O

Interleukin-2 NN B-NP B-NP
( ( O O
IL-2 NN B-NP I-NP
) ) O O
gene NN B-NP B-NP
expression NN I-NP I-NP
is VBZ B-VP B-VP
controlled VBN I-VP I-VP
transcriptionally RB B-ADVP B-ADVP
by IN B-PP B-PP
the DT B-NP B-NP
cooperative JJ I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
specific JJ B-NP B-NP
trans-activating JJ I-NP I-NP
factors NNS I-NP I-NP
that WDT B-NP B-NP
bind VBP B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
IL-2 NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

Cyclosporin NN B-NP B-NP
A NN I-NP I-NP
( ( O O
CsA NN B-NP B-NP
) ) O O
and CC O I-CC
FK506 NN B-NP B-NP
inhibit VBP B-VP B-VP
the DT B-NP B-NP
production NN I-NP I-NP
of IN B-PP B-PP
IL-2 NN B-NP B-NP
in IN B-PP B-PP
T NN B-NP B-NP
lymphocytes NNS I-NP I-NP
at IN B-PP B-PP
the DT B-NP B-NP
level NN I-NP I-NP
of IN B-PP B-PP
gene NN B-NP B-NP
transcription NN I-NP I-NP
. . O O

A DT B-NP B-NP
member NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
src NN I-NP I-NP
gene NN I-NP I-NP
family NN I-NP I-NP
, , O O
the DT B-NP B-NP
lymphocyte-specific JJ I-NP I-NP
protein NN I-NP I-NP
tyrosine NN I-NP I-NP
kinase NN I-NP I-NP
, , O O
p56lck NN B-NP B-NP
, , O O
has VBZ B-VP B-VP
been VBN I-VP I-VP
implicated VBN I-VP I-VP
in IN B-PP B-PP
IL-2 NN B-NP B-NP
production NN I-NP I-NP
. . O O

CsA NN B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
not RB I-VP I-RB
to TO I-VP B-VP
inhibit VB I-VP I-VP
lck NN B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
, , O O
nor CC O I-CC
the DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
lck NN I-NP I-NP
gene NN I-NP I-NP
product NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
CsA NN B-NP B-NP
and CC O I-NP
FK506 NN B-NP I-NP
inhibit VBP B-VP B-VP
the DT B-NP B-NP
appearance NN I-NP I-NP
of IN B-PP B-PP
DNA NN B-NP B-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
factors NNS B-NP B-NP
that WDT B-NP B-NP
bind VBP B-VP B-VP
to TO B-PP B-PP
the DT O B-NP
NF-AT NN B-NP I-NP
and CC O I-NP
AP-1 NN B-NP I-NP
sites NNS B-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
IL-2 NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

Since IN B-SBAR B-PP
the DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
NF-AT NN B-NP B-NP
and CC O I-NP
AP-1 NN B-NP I-NP
is VBZ B-VP B-VP
induced VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
same JJ I-NP I-NP
stimuli NNS I-NP I-NP
that WDT B-NP B-NP
stimulate VBP B-VP B-VP
IL-2 NN B-NP B-NP
production NN I-NP I-NP
, , O O
these DT B-NP B-NP
results NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
immunosuppressant JJ I-NP I-NP
action NN I-NP I-NP
of IN B-PP B-PP
CsA NN B-NP B-NP
and CC O I-NP
FK506 NN B-NP I-NP
is VBZ B-VP B-VP
exerted VBN I-VP I-VP
at IN B-PP B-PP
the DT B-NP B-NP
level NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
trans-activating JJ I-NP I-NP
factors NNS I-NP I-NP
. . O O

TAR-independent JJ B-NP B-NP
transactivation NN I-NP I-NP
by IN B-PP B-PP
Tat NN B-NP B-NP
in IN B-PP B-PP
cells NNS B-NP B-NP
derived VBN B-VP B-VP
from IN B-PP B-PP
the DT B-NP B-NP
CNS NN I-NP I-NP
: : O O
a DT B-NP B-NP
novel JJ I-NP I-NP
mechanism NN I-NP I-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
gene NN I-NP I-NP
regulation NN I-NP I-NP
. . O O

The DT B-NP B-NP
Tat NN I-NP I-NP
protein NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP B-NP
( ( O O
HIV-1 NN B-NP I-NP
) ) O O
is VBZ B-VP B-VP
essential JJ B-ADJP B-ADJP
for IN B-PP B-PP
productive JJ B-NP B-NP
infection NN I-NP I-NP
and CC O I-CC
is VBZ B-VP B-VP
a DT B-NP B-NP
potential JJ I-NP I-NP
target NN I-NP I-NP
for IN B-PP B-PP
antiviral JJ B-NP B-NP
therapy NN I-NP I-NP
. . O O

Tat NN B-NP B-NP
, , O O
a DT B-NP B-NP
potent JJ I-NP I-NP
activator NN I-NP I-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
, , O O
serves VBZ B-VP B-VP
to TO I-VP I-VP
greatly RB I-VP I-VP
increase VB I-VP I-VP
the DT B-NP B-NP
rate NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
directed VBN B-VP B-VP
by IN B-PP B-PP
the DT B-NP B-NP
viral JJ I-NP I-NP
promoter NN I-NP I-NP
. . O O

This DT B-NP B-NP
induction NN I-NP I-NP
, , O O
which WDT B-NP B-NP
seems VBZ B-VP B-VP
to TO I-VP I-VP
be VB I-VP I-VP
an DT B-NP B-NP
important JJ I-NP I-NP
component NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
progression NN I-NP I-NP
of IN B-PP B-PP
acquired VBN B-NP B-NP
immune JJ I-NP I-NP
deficiency NN I-NP I-NP
syndrome NN I-NP I-NP
( ( O O
AIDS NN B-NP B-NP
) ) O O
, , O O
may MD B-VP B-VP
be VB I-VP I-VP
due JJ B-PP B-ADJP
to TO I-PP B-PP
increased VBN B-NP B-NP
transcriptional JJ I-NP I-NP
initiation NN I-NP I-NP
, , O O
increased VBN B-NP B-VP
transcriptional JJ I-NP B-NP
elongation NN I-NP I-NP
, , O O
or CC O I-CC
a DT B-NP B-NP
combination NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
processes NNS I-NP I-NP
. . O O

Much JJ B-NP B-NP
attention NN I-NP I-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
focused VBN I-VP I-VP
on IN B-PP B-PP
the DT B-NP B-NP
interaction NN I-NP I-NP
of IN B-PP B-PP
Tat NN B-NP B-NP
with IN B-PP B-PP
a DT B-NP B-NP
specific JJ I-NP I-NP
RNA NN I-NP I-NP
target NN I-NP I-NP
termed VBN B-VP I-NP
TAR NN B-NP I-NP
( ( O O
transactivation NN B-NP B-NP
responsive NN I-NP I-NP
) ) O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
leader NN I-NP I-NP
sequence NN I-NP I-NP
of IN B-PP B-PP
all DT B-NP B-NP
HIV-1 NN I-NP I-NP
mRNAs NNS I-NP I-NP
. . O O

This DT B-NP B-NP
interaction NN I-NP I-NP
is VBZ B-VP B-VP
believed VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
an DT B-NP B-NP
important JJ I-NP I-NP
component NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
mechanism NN I-NP I-NP
of IN B-PP B-PP
transactivation NN B-NP B-NP
. . O O

In IN B-PP B-PP
this DT B-NP B-NP
report NN I-NP I-NP
we PRP B-NP B-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
in IN B-PP B-PP
certain JJ B-NP B-NP
CNS-derived JJ I-NP I-NP
cells NNS I-NP I-NP
Tat NN B-NP I-NP
is VBZ B-VP B-VP
capable JJ B-ADJP B-ADJP
of IN B-PP B-PP
activating VBG B-VP B-VP
HIV-1 NN B-NP B-NP
through IN B-PP B-PP
a DT B-NP B-NP
TAR-independent JJ I-NP I-NP
pathway NN I-NP I-NP
. . O O

A DT B-NP B-NP
Tat-responsive JJ I-NP I-NP
element NN I-NP I-NP
is VBZ B-VP B-VP
found VBN I-VP I-VP
upstream RB B-ADVP B-ADVP
within IN B-PP B-PP
the DT B-NP B-NP
viral JJ I-NP I-NP
promoter NN I-NP I-NP
that WDT B-NP B-NP
in IN B-PP B-PP
glial-derived JJ B-NP B-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
allows VBZ B-VP B-VP
transactivation NN B-NP B-NP
in IN B-PP B-PP
the DT I-PP B-NP
absence NN I-PP I-NP
of IN I-PP B-PP
TAR NN B-NP B-NP
. . O O

Deletion NN B-NP B-NP
mapping NN I-NP I-NP
and CC O I-NP
hybrid NN B-NP I-NP
promoter NN I-NP I-NP
constructs NNS I-NP I-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
newly RB I-NP I-NP
identified VBN I-NP I-NP
Tat-responsive JJ I-NP I-NP
element NN I-NP I-NP
corresponds VBZ B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
sequence NN I-NP I-NP
within IN B-PP B-PP
the DT B-NP B-NP
viral JJ I-NP I-NP
long JJ B-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
( ( O O
LTR NN B-NP B-NP
) ) O O
previously RB B-VP B-VP
identified VBN I-VP I-VP
as IN B-PP B-PP
the DT B-NP B-NP
HIV-1 NN I-NP I-NP
enhancer NN I-NP I-NP
, , O O
or CC O I-CC
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
domain NN I-NP I-NP
. . O O

DNA NN B-NP B-NP
band-shift JJ I-NP I-NP
analysis NN I-NP I-NP
reveals VBZ B-VP B-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
in IN B-PP B-PP
glial JJ B-NP B-NP
cells NNS I-NP I-NP
that WDT B-NP B-NP
differs VBZ B-VP B-VP
from IN B-PP B-PP
that DT B-NP B-NP
present JJ B-ADJP I-NP
in IN B-PP B-PP
T NN B-NP B-NP
lymphoid JJ I-NP I-NP
cells NNS I-NP I-NP
. . O O

Further RB B-ADVP B-ADVP
, , O O
we PRP B-NP B-NP
observe VBP B-VP B-VP
that IN B-SBAR B-PP
TAR-deleted JJ B-NP B-NP
mutants NNS I-NP I-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
demonstrate VBP B-VP B-VP
normal JJ B-NP B-NP
late JJ I-NP I-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
in IN B-PP B-PP
glial JJ B-NP B-NP
cells NNS I-NP I-NP
as IN B-SBAR B-SBAR
evidenced VBN B-VP B-VP
by IN B-PP B-PP
syncytia NN B-NP B-NP
formation NN B-NP I-NP
and CC O I-NP
production NN B-NP I-NP
of IN B-PP B-PP
viral JJ B-NP B-NP
p24 NN I-NP I-NP
antigen NN I-NP I-NP
. . O O

( ( O O
ABSTRACT NN B-NP B-NP
TRUNCATED VBN B-VP B-VP
AT IN B-PP B-PP
250 CD B-NP B-NP
WORDS NNS I-NP I-NP
) ) O O

Bcl-2 NN B-NP B-NP
: : O O
a DT B-NP B-NP
repressor NN I-NP I-NP
of IN B-PP B-PP
lymphocyte NN B-NP B-NP
death NN I-NP I-NP
. . O O

The DT B-NP B-NP
genes NNS B-NP I-NP
and CC O I-NP
mechanisms NNS B-NP I-NP
that WDT B-NP B-NP
control VBP B-VP B-VP
programmed VBN B-NP I-VP
cell NN I-NP B-NP
death NN I-NP I-NP
are VBP B-VP B-VP
currently RB B-ADVP B-ADVP
the DT B-NP B-NP
subject NN I-NP I-NP
of IN B-PP B-PP
intense JJ B-NP B-NP
study NN I-NP I-NP
. . O O

The DT B-NP B-NP
bcl-2 NN I-NP I-NP
gene NN I-NP I-NP
, , O O
a DT B-NP B-NP
repressor NN I-NP I-NP
of IN B-PP B-PP
lymphocyte NN B-NP B-NP
death NN I-NP I-NP
, , O O
is VBZ B-VP B-VP
perhaps RB B-ADVP B-NP
the DT B-NP I-NP
best JJS I-NP I-NP
understood VBN I-NP I-NP
of IN B-PP B-PP
the DT O B-NP
programmed VBN B-NP I-NP
cell NN I-NP I-NP
death NN I-NP I-NP
associated JJ B-NP I-NP
genes NNS I-NP I-NP
. . O O

Here RB B-ADVP B-ADVP
, , O O
Stanley NNP B-NP B-NP
Korsmeyer NNP I-NP I-NP
provides VBZ B-VP B-VP
a DT B-NP B-NP
brief JJ I-NP I-NP
overview NN I-NP I-NP
of IN B-PP B-PP
bcl-2 NN B-NP B-NP
, , O O
concentrating VBG B-VP B-VP
on IN B-PP B-PP
its PRP$ B-NP B-NP
roles NNS I-NP I-NP
in IN B-PP B-PP
B- NN B-NP B-NP
and CC O I-NP
T-cell NN B-NP I-NP
development NN B-NP I-NP
and CC B-PP I-CC
in IN B-PP B-PP
oncogenesis NN B-NP B-NP
. . O O

Mitogen NN B-NP B-NP
stimulation NN I-NP I-NP
of IN B-PP B-PP
T-cells NNS B-NP B-NP
increases VBZ B-VP B-VP
c-Fos NN B-NP B-NP
and CC O I-NP
c-Jun NN B-NP I-NP
protein NN B-NP I-NP
levels NNS I-NP I-NP
, , O O
AP-1 NN B-NP B-NP
binding NN I-NP I-NP
and CC O I-NP
AP-1 NN B-NP I-NP
transcriptional JJ I-NP I-NP
activity NN I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
analysed VBN I-VP I-VP
the DT B-NP B-NP
effect NN I-NP I-NP
of IN B-PP B-PP
mitogenic JJ B-NP B-NP
lectins NNS I-NP I-NP
on IN B-PP B-PP
c-Fos NN B-NP B-NP
and CC O I-NP
c-Jun NN B-NP I-NP
protein NN B-NP I-NP
levels NNS I-NP I-NP
as RB B-CONJP B-ADVP
well RB I-CONJP I-ADVP
as IN I-CONJP B-PP
on IN B-PP B-PP
activator NN B-NP B-NP
protein-1 NN I-NP I-NP
( ( O O
AP-1 NN B-NP I-NN
) ) O O
binding NN B-NP B-NP
and CC O I-NP
enhancer NN B-NP I-NP
activity NN I-NP I-NP
in IN B-PP B-PP
Jurkat NN B-NP B-NP
T-cells NNS I-NP I-NP
. . O O

Both CC O I-CC
c-Fos NN B-NP B-NP
and CC O I-NP
c-Jun NN B-NP I-NP
protein NN B-NP I-NP
levels NNS I-NP I-NP
were VBD B-VP B-VP
increased VBN I-VP I-VP
after IN B-PP B-PP
Con NN B-NP B-NP
A NN I-NP I-NP
and CC O I-NP
PHA NN B-NP I-NP
stimulation NN B-NP I-NP
. . O O

Since IN B-SBAR B-SBAR
T-cell NN B-NP B-NP
stimulation NN I-NP I-NP
increases VBZ B-VP B-VP
both CC O I-CC
intracellular JJ O B-NP
Ca2+ NN B-NP I-NP
and CC O I-NP
cAMP NN B-NP I-NP
levels NNS B-NP I-NP
and CC O I-CC
activates VBZ B-VP B-VP
protein NN B-NP B-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
( ( O O
PKC NN B-NP B-NP
) ) O O
, , O O
the DT B-NP B-NP
possible JJ I-NP I-NP
involvement NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
intracellular JJ I-NP I-NP
messengers NNS I-NP I-NP
in IN B-PP B-PP
c-Fos NN B-NP B-NP
and CC O I-NP
c-Jun NN B-NP I-NP
induction NN B-NP I-NP
was VBD B-VP B-VP
tested VBN I-VP I-VP
. . O O

PMA NN B-NP B-NP
, , O O
which WDT B-NP B-NP
directly RB B-ADVP B-ADVP
activates VBZ B-VP B-VP
PKC NN B-NP B-NP
, , O O
mimicked VBD B-VP B-VP
the DT B-NP B-NP
effect NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
lectins NNS I-NP I-NP
on IN B-PP B-PP
c-Fos NN B-NP B-NP
and CC O I-NP
c-Jun NN B-NP I-NP
, , O O
but CC O I-CC
elevation NN B-NP B-NP
of IN B-PP B-PP
either CC O I-CC
intracellular JJ O B-NP
Ca2+ NN B-NP I-NP
or CC O I-NP
cAMP NN B-NP I-NP
levels NNS B-NP I-NP
had VBD B-VP B-VP
little JJ B-NP B-NP
or CC I-NP I-NP
no DT I-NP I-NP
effect NN I-NP I-NP
. . O O

The DT B-NP B-NP
mitogen-induced JJ I-NP I-NP
increase NN I-NP I-NP
of IN B-PP B-PP
c-Fos NN B-NP B-NP
and CC O I-NP
c-Jun NN B-NP I-NP
immunoreactivity NN B-NP I-NP
was VBD B-VP B-VP
inhibited VBN I-VP I-VP
by IN B-PP B-PP
H-7 NN B-NP B-NP
, , O O
a DT B-NP B-NP
kinase NN I-NP I-NP
inhibitor NN I-NP I-NP
with IN B-PP B-PP
relatively RB B-NP B-NP
high JJ I-NP I-NP
specificity NN I-NP I-NP
for IN B-PP B-PP
PKC NN B-NP B-NP
, , O O
and CC O I-CC
less RBR B-ADVP B-ADJP
efficiently RB I-ADVP I-ADJP
by IN B-PP B-PP
H-8 NN B-NP B-NP
, , O O
a DT B-NP B-NP
structurally RB I-NP I-NP
related JJ I-NP I-NP
kinase NN I-NP I-NP
inhibitor NN I-NP I-NP
less RBR B-ADJP B-ADJP
active JJ I-ADJP I-ADJP
on IN B-PP B-PP
PKC NN B-NP B-NP
, , O O
but CC O I-CC
more RBR B-ADJP B-NP
active JJ I-ADJP I-NP
on IN B-PP B-PP
cyclic JJ B-NP B-NP
nucleotide-dependent JJ I-NP I-NP
kinases NNS I-NP I-NP
. . O O

Con NN B-NP B-NP
A NN I-NP I-NP
stimulation NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
increase VB I-VP I-VP
both CC O I-CC
binding NN B-NP B-NP
of IN B-PP B-PP
AP-1 NN B-NP B-NP
to TO B-PP B-PP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
consensus NN I-NP I-NP
sequence NN I-NP I-NP
, , O O
TRE NN B-NP B-NP
, , O O
and CC O I-CC
AP-1 NN B-NP B-NP
enhancer NN I-NP I-NP
activity NN I-NP I-NP
, , O O
in IN B-PP B-PP
Jurkat NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

PMA NN B-NP B-NP
was VBD B-VP B-VP
also RB I-VP I-VP
found VBN I-VP I-VP
to TO I-VP I-VP
increase VB I-VP I-VP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
enhancer NN I-NP I-NP
activity NN I-NP I-NP
, , O O
whereas IN O B-PP
elevation NN B-NP B-NP
of IN B-PP B-PP
Ca2+ NN B-NP B-NP
or CC O I-NP
cAMP NN B-NP I-NP
had VBD B-VP B-VP
only RB B-NP B-NP
minor JJ I-NP I-NP
effects NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
conclude VBP B-VP B-VP
that IN B-SBAR B-PP
stimulation NN B-NP B-NP
with IN B-PP B-PP
mitogenic JJ B-NP B-NP
lectins NNS I-NP I-NP
is VBZ B-VP B-VP
sufficient JJ B-ADJP B-ADJP
to TO B-VP B-VP
increase VB I-VP I-VP
both CC O I-CC
c-Fos NN B-NP B-NP
and CC O I-NP
c-Jun NN B-NP I-NP
protein NN B-NP I-NP
levels NNS I-NP I-NP
, , O O
AP-1 NN B-NP B-NP
binding NN I-NP I-NP
and CC O I-NP
AP-1 NN B-NP I-NP
enhancer NN I-NP I-NP
activity NN I-NP I-NP
in IN B-PP B-PP
Jurkat NN B-NP B-NP
cells NNS I-NP I-NP
and CC O I-CC
that IN B-SBAR B-SBAR
they PRP B-NP B-NP
act VBP B-VP B-VP
via IN B-PP B-PP
mechanisms NNS B-NP B-NP
that WDT B-NP B-NP
could MD B-VP B-VP
involve VB I-VP I-VP
the DT B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
PKC NN B-NP B-NP
. . O O

Functional JJ B-NP B-NP
interaction NN I-NP I-NP
between IN B-PP B-PP
the DT B-NP B-NP
two CD I-NP I-NP
zinc NN I-NP I-NP
finger NN I-NP I-NP
domains NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
v-erb NN I-NP I-NP
A NN I-NP I-NP
oncoprotein NN I-NP I-NP
. . O O

The DT B-NP B-NP
v-erb NN I-NP I-NP
A NN I-NP I-NP
oncogene NN I-NP I-NP
of IN B-PP B-PP
avian JJ B-NP B-NP
erythroblastosis NN I-NP I-NP
virus NN I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
mutated VBN I-NP I-NP
and CC I-NP I-NP
virally RB I-NP I-NP
transduced VBN I-NP I-NP
copy NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
host NN I-NP I-NP
cell NN I-NP I-NP
gene NN I-NP I-NP
encoding VBG B-VP B-VP
a DT B-NP B-NP
thyroid NN I-NP I-NP
hormone NN I-NP I-NP
receptor NN I-NP I-NP
. . O O

The DT B-NP B-NP
protein NN I-NP I-NP
expressed VBN B-VP B-VP
by IN B-PP B-PP
the DT B-NP B-NP
v-erb NN I-NP I-NP
A NN I-NP I-NP
oncogene NN I-NP I-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
DNA NN B-NP B-NP
and CC O I-CC
acts VBZ B-VP B-VP
as IN B-PP B-PP
a DT B-NP B-NP
dominant JJ I-NP I-NP
negative JJ I-NP I-NP
inhibitor NN I-NP I-NP
of IN B-PP B-PP
both CC O I-CC
the DT B-NP B-NP
thyroid NN I-NP I-NP
hormone NN I-NP I-NP
receptor NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
closely RB I-NP I-NP
related JJ I-NP I-NP
retinoic JJ I-NP I-NP
acid NN I-NP I-NP
receptor NN I-NP I-NP
. . O O

The DT B-NP B-NP
v-erb NN I-NP I-NP
A NN I-NP I-NP
protein NN I-NP I-NP
has VBZ B-VP B-VP
sustained VBN I-VP I-VP
two CD B-NP B-NP
amino NN I-NP I-NP
acid NN I-NP I-NP
alterations NNS I-NP I-NP
within IN B-PP B-PP
its PRP$ B-NP B-NP
DNA-binding JJ I-NP I-NP
domain NN I-NP I-NP
relative JJ B-PP B-ADJP
to TO I-PP B-PP
that DT B-NP B-NP
of IN B-PP B-PP
c-erb NN B-NP B-NP
A NN I-NP I-NP
, , O O
one CD B-NP B-NP
of IN B-PP B-PP
which WDT B-NP B-NP
, , O O
at IN B-PP B-PP
serine NN B-NP B-NP
61 CD I-NP I-NP
, , O O
is VBZ B-VP B-VP
known VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
important JJ B-ADJP B-ADJP
for IN B-PP B-PP
v-erb NN B-NP B-NP
A NN I-NP I-NP
function NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
neoplastic JJ I-NP I-NP
cell NN I-NP I-NP
. . O O

We PRP B-NP B-NP
report VBP B-VP B-VP
here RB B-ADVP B-ADVP
that IN B-SBAR B-PP
the DT B-NP B-NP
second JJ I-NP I-NP
alteration NN I-NP I-NP
, , O O
at IN B-PP B-PP
threonine NN B-NP B-NP
78 CD I-NP I-NP
, , O O
also RB B-ADVP B-ADVP
plays VBZ B-VP B-VP
an DT B-NP B-NP
important JJ I-NP I-NP
, , I-NP O
although IN I-NP B-SBAR
more RBR I-NP B-NP
indirect JJ I-NP I-NP
, , I-NP O
role NN I-NP I-NP
: : O O
alteration NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
sequence NN I-NP I-NP
at IN B-PP B-PP
threonine NN B-NP B-NP
78 CD I-NP I-NP
such JJ B-SBAR I-NP
that IN I-SBAR B-SBAR
it PRP B-NP B-NP
resembles VBZ B-VP B-VP
that DT B-NP B-NP
of IN B-PP B-PP
c-erb NN B-NP B-NP
A NN I-NP I-NP
can MD B-VP B-VP
act VB I-VP I-VP
as IN B-PP B-PP
an DT B-NP B-NP
intragenic JJ I-NP I-NP
suppressor NN I-NP I-NP
and CC O I-CC
can MD B-VP B-VP
partially RB I-VP I-VP
restore VB I-VP I-VP
function NN B-NP B-NP
to TO B-PP B-PP
a DT B-NP B-NP
v-erb NN I-NP I-NP
A NN I-NP I-NP
protein NN I-NP I-NP
rendered VBN B-VP B-VP
defective JJ B-ADJP B-NP
due JJ B-PP I-NP
to TO I-PP B-PP
a DT B-NP B-NP
mutation NN I-NP I-NP
at IN B-PP B-PP
position NN B-NP B-NP
61 CD I-NP I-NP
. . O O

Threonine NN B-NP B-NP
78 CD I-NP I-NP
lies VBZ B-VP B-VP
within IN B-PP B-PP
the DT B-NP B-NP
D-box NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
v-erb NN I-NP I-NP
A NN I-NP I-NP
protein NN I-NP I-NP
, , O O
a DT B-NP B-NP
region NN I-NP I-NP
thought VBN B-VP B-VP
to TO I-VP B-VP
mediate VB I-VP I-VP
receptor-receptor JJ B-NP B-NP
dimerizations NNS I-NP I-NP
, , O O
and CC O I-CC
is VBZ B-VP B-VP
not RB O I-RB
in IN B-PP B-PP
physical JJ B-NP B-NP
proximity NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
serine NN I-NP I-NP
at IN B-PP B-PP
position NN B-NP B-NP
61 CD I-NP I-NP
. . O O

It PRP B-NP B-NP
therefore RB B-ADVP B-ADVP
appears VBZ B-VP B-VP
that IN B-SBAR B-SBAR
an DT B-NP B-NP
indirect JJ I-NP I-NP
interaction NN I-NP I-NP
occurs VBZ B-VP B-VP
between IN B-PP B-PP
these DT B-NP B-NP
two CD I-NP I-NP
sites NNS I-NP I-NP
and CC O I-CC
that IN B-SBAR B-SBAR
this DT B-NP B-NP
interaction NN I-NP I-NP
is VBZ B-VP B-VP
crucial JJ B-ADJP B-ADJP
for IN B-PP B-PP
v-erb NN B-NP B-NP
A NN I-NP I-NP
function NN I-NP I-NP
. . O O

Pax-5 NN B-NP B-NP
encodes VBZ B-VP B-VP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
BSAP NN I-NP I-NP
and CC O I-CC
is VBZ B-VP B-VP
expressed VBN I-VP I-VP
in IN B-PP B-PP
B NN B-NP B-NP
lymphocytes NNS I-NP I-NP
, , O O
the DT B-NP B-NP
developing VBG I-NP I-NP
CNS NNS I-NP I-NP
, , O O
and CC O I-CC
adult JJ B-NP B-NP
testis NN I-NP I-NP
. . O O

BSAP NN B-NP B-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
identified VBN I-VP I-VP
previously RB B-ADVP B-ADVP
as IN B-PP B-PP
a DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
that WDT B-NP B-NP
is VBZ B-VP B-VP
expressed VBN I-VP I-VP
at IN B-PP B-PP
early JJ B-NP B-NP
, , I-NP O
but CC I-NP I-CC
not RB I-NP I-RB
late JJ I-NP B-ADJP
, , I-NP O
stages NNS I-NP B-NP
of IN B-PP B-PP
B-cell NN B-NP B-NP
differentiation NN I-NP I-NP
. . O O

Biochemical JJ B-NP B-NP
purification NN I-NP I-NP
and CC O I-NP
cDNA NN B-NP I-NP
cloning NN I-NP I-NP
has VBZ B-VP B-VP
now RB I-VP I-VP
revealed VBN I-VP I-VP
that IN B-SBAR B-PP
BSAP NN B-NP B-NP
belongs VBZ B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
family NN I-NP I-NP
of IN B-PP B-PP
paired JJ B-NP B-NP
domain NN I-NP I-NP
proteins NNS I-NP I-NP
. . O O

BSAP NN B-NP B-NP
is VBZ B-VP B-VP
encoded VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
Pax-5 NN I-NP I-NP
gene NN I-NP I-NP
and CC O I-CC
has VBZ B-VP B-VP
been VBN I-VP I-VP
highly RB I-VP I-VP
conserved VBN I-VP I-VP
between IN B-PP B-PP
human JJ B-NP B-NP
and CC O I-NP
mouse NN B-NP I-NP
. . O O

An DT B-NP B-NP
intact JJ I-NP I-NP
paired JJ I-NP I-NP
domain NN I-NP I-NP
was VBD B-VP B-VP
shown VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
both CC O I-CC
necessary JJ B-ADJP B-NP
and CC O I-NP
sufficient JJ B-ADJP I-NP
for IN B-PP B-PP
DNA NN B-NP B-NP
binding NN I-NP I-NP
of IN B-PP B-PP
BSAP NN B-NP B-NP
. . O O

Binding VBG B-NP B-NP
studies NNS I-NP I-NP
with IN B-PP B-PP
several JJ B-NP B-NP
BSAP NN I-NP I-NP
recognition NN I-NP I-NP
sequences NNS I-NP I-NP
demonstrated VBD B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
sequence NN I-NP I-NP
specificity NN I-NP I-NP
of IN B-PP B-PP
BSAP NN B-NP B-NP
differs VBZ B-VP B-VP
from IN B-PP B-PP
that DT B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
distantly RB I-NP I-NP
related JJ I-NP I-NP
paired JJ I-NP I-NP
domain NN I-NP I-NP
protein NN I-NP I-NP
Pax-1 NN I-NP I-NP
. . O O

During IN B-PP B-PP
embryogenesis NN B-NP B-NP
, , O O
the DT B-NP B-NP
BSAP NN I-NP I-NP
gene NN I-NP I-NP
is VBZ B-VP B-VP
transiently RB I-VP I-VP
expressed VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
mesencephalon NN B-NP I-NP
and CC O I-NP
spinal JJ B-NP I-NP
cord NN I-NP I-NP
with IN B-PP B-PP
a DT B-NP B-NP
spatial JJ I-NP I-NP
and CC I-NP I-NP
temporal JJ I-NP I-NP
expression NN I-NP I-NP
pattern NN I-NP I-NP
that WDT B-NP B-NP
is VBZ B-VP B-VP
distinct JJ B-ADJP B-ADJP
from IN B-PP B-PP
that DT B-NP B-NP
of IN B-PP B-PP
other JJ B-NP B-NP
Pax NN I-NP I-NP
genes NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
developing VBG I-NP I-NP
central JJ B-NP I-NP
nervous JJ I-NP I-NP
system NN I-NP I-NP
( ( O O
CNS NN B-NP B-NP
) ) O O
. . O O

Later RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
BSAP NN I-NP I-NP
gene NN I-NP I-NP
shifts VBZ B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
fetal JJ I-NP I-NP
liver NN I-NP I-NP
where WRB B-ADVP B-ADVP
it PRP B-NP B-NP
correlates VBZ B-VP B-VP
with IN B-PP B-PP
the DT B-NP B-NP
onset NN I-NP I-NP
of IN B-PP B-PP
B NN B-NP B-NP
lymphopoiesis NN I-NP I-NP
. . O O

BSAP NN B-NP B-NP
expression NN I-NP I-NP
persists VBZ B-VP B-VP
in IN B-PP B-PP
B NN B-NP B-NP
lymphocytes NNS I-NP I-NP
and CC O I-CC
is VBZ B-VP B-VP
also RB I-VP I-VP
seen VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
testis NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
adult JJ I-NP I-NP
mouse NN I-NP I-NP
. . O O

All DT B-NP B-NP
of IN B-PP B-PP
this DT B-NP B-NP
evidence NN I-NP I-NP
indicates VBZ B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
BSAP NN I-NP I-NP
may MD B-VP B-VP
not RB B-CONJP I-VP
only RB I-CONJP I-VP
play VB B-VP I-VP
an DT B-NP B-NP
important JJ I-NP I-NP
role NN I-NP I-NP
in IN B-PP B-PP
B-cell NN B-NP B-NP
differentiation NN I-NP I-NP
but CC B-CONJP I-CC
also RB I-CONJP B-ADVP
in IN B-PP B-PP
neural JJ B-NP B-NP
development NN I-NP I-NP
and CC O I-NP
spermatogenesis NN B-NP I-NP
. . O O

Okadaic JJ B-NP B-NP
acid NN I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
potent JJ I-NP I-NP
inducer NN I-NP I-NP
of IN B-PP B-PP
AP-1 NN B-NP B-NP
, , O O
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
, , O O
and CC O I-CC
tumor NN B-NP B-NP
necrosis NN I-NP I-NP
factor-alpha NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
B NN I-NP I-NP
lymphocytes NNS I-NP I-NP
. . O O

Treatment NN B-NP B-NP
of IN B-PP B-PP
human JJ B-NP B-NP
B NN I-NP I-NP
lymphocytes NNS I-NP I-NP
with IN B-PP B-PP
an DT B-NP B-NP
optimal JJ I-NP I-NP
concentration NN I-NP I-NP
of IN B-PP B-PP
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
, , O O
an DT B-NP B-NP
inhibitor NN I-NP I-NP
of IN B-PP B-PP
phosphatases NNS B-NP B-NP
1 CD B-NP B-NP
and CC O I-NP
2A NN B-NP I-NP
, , O O
resulted VBD B-VP B-VP
in IN B-PP B-PP
the DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
, , O O
AP-1 NN B-NP B-NP
and CC O I-CC
a DT B-NP B-NP
marked JJ I-NP I-NP
increase NN I-NP I-NP
in IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
levels NNS I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
no DT B-NP B-NP
effect NN I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
octamer NN I-NP I-NP
binding NN I-NP I-NP
proteins NNS I-NP I-NP
, , O O
Oct-1 NN B-NP B-NP
or CC O I-NP
Oct-2 NN B-NP I-NP
, , O O
were VBD B-VP B-VP
found VBN I-VP I-VP
. . O O

Since IN B-SBAR B-SBAR
both CC O I-CC
AP-1 NN B-NP B-NP
and CC O I-NP
NF-kappa NN B-NP I-NP
B NN I-NP I-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
reported VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
important JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
the DT O B-NP
tumor NN B-NP I-NP
necrosis NN I-NP I-NP
factor-alpha NN I-NP I-NP
( ( O O
TNF-alpha NN B-NP I-NN
) ) O O
gene NN B-NP B-NP
we PRP B-NP B-NP
examined VBD B-VP B-VP
the DT B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
on IN B-PP B-PP
TNF-alpha NN B-NP B-NP
mRNA NN I-NP I-NP
levels NNS I-NP I-NP
. . O O

Treatment NN B-NP B-NP
with IN B-PP B-PP
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
resulted VBD B-VP B-VP
in IN B-PP B-PP
a DT B-NP B-NP
striking JJ I-NP I-NP
increase NN I-NP I-NP
in IN B-PP B-PP
TNF-alpha NN B-NP B-NP
mRNA NN I-NP I-NP
transcripts NNS I-NP I-NP
within IN B-PP B-PP
1 CD B-NP B-NP
h NN I-NP I-NP
of IN B-PP B-PP
stimulation NN B-NP B-NP
and CC O I-NP
large JJ B-NP I-NP
amounts NNS I-NP I-NP
of IN B-PP B-PP
TNF-alpha NN B-NP B-NP
were VBD B-VP B-VP
released VBN B-NP I-VP
into IN B-PP B-PP
the DT B-NP B-NP
culture NN I-NP I-NP
media NNS I-NP I-NP
. . O O

Although IN B-SBAR B-SBAR
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
provides VBZ B-VP B-VP
a DT B-NP B-NP
potent JJ I-NP I-NP
inductive JJ I-NP I-NP
signal NN I-NP I-NP
for IN B-PP B-PP
AP-1 NN B-NP B-NP
and CC O I-NP
NF-kappa NN B-NP I-NP
B NN I-NP I-NP
it PRP B-NP B-NP
did VBD B-VP B-VP
not RB I-VP I-VP
induce VB I-VP I-VP
either CC O I-VP
B NN B-NP B-NP
cell NN I-NP I-NP
proliferation NN I-NP I-NP
or CC O I-NP
immunoglobulin NN B-NP I-NP
secretion NN I-NP I-NP
. . O O

A DT B-NP B-NP
novel JJ I-NP I-NP
Ets-related JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
, , O O
Elf-1 NN B-NP B-NP
, , O O
binds VBZ B-VP B-VP
to TO B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
2 CD I-NP I-NP
regulatory JJ I-NP I-NP
elements NNS I-NP I-NP
that WDT B-NP B-NP
are VBP B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
inducible JJ B-NP B-NP
trans JJ I-NP I-NP
activation NN I-NP I-NP
in IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP I-NP
( ( O O
HIV-1 NN B-NP I-NN
) ) O O
and CC O I-CC
HIV-2 NN B-NP B-NP
are VBP B-VP B-VP
structurally RB B-NP B-ADVP
related JJ I-NP B-NP
retroviruses NNS I-NP I-NP
which WDT B-NP B-NP
both DT B-ADVP B-NP
cause VBP B-VP B-VP
AIDS NN B-NP B-NP
in IN B-PP B-PP
humans NNS B-NP B-NP
. . O O

Although IN B-SBAR B-SBAR
both DT B-NP B-NP
viruses NNS I-NP I-NP
establish VBP B-VP B-VP
latency NN B-NP B-NP
in IN B-PP B-PP
quiescent JJ B-NP B-NP
human-peripheral-blood JJ I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
, , O O
the DT B-NP B-NP
asymptomatic JJ I-NP I-NP
phase NN I-NP I-NP
of IN B-PP B-PP
HIV-2 NN B-NP B-NP
infection NN I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
more JJR B-ADJP B-ADJP
prolonged JJ I-ADJP I-ADJP
than IN B-PP B-PP
that DT B-NP B-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
. . O O

The DT B-NP B-NP
latent JJ I-NP I-NP
phases NNS I-NP I-NP
of IN B-PP B-PP
both CC O I-CC
HIV-1 NN B-NP B-NP
and CC O I-NP
HIV-2 NN B-NP I-NP
infection NN B-NP I-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
shown VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
disrupted VBN I-VP I-VP
by IN B-PP B-PP
T-cell NN B-NP B-NP
activation NN I-NP I-NP
, , O O
a DT B-NP B-NP
process NN I-NP I-NP
that WDT B-NP B-NP
requires VBZ B-VP B-VP
host NN B-NP B-NP
cell NN I-NP I-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
. . O O

In IN B-PP B-PP
the DT B-NP B-NP
case NN I-NP I-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
, , O O
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
is VBZ B-VP B-VP
sufficient JJ B-ADJP B-ADJP
for IN B-PP B-PP
inducible JJ B-NP B-NP
transcriptional JJ I-NP I-NP
activation NN I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
factors NNS B-NP B-NP
in IN B-PP B-PP
addition NN I-PP B-NP
to TO I-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
are VBP B-VP B-VP
required VBN I-VP I-VP
to TO I-VP I-VP
activate VB I-VP I-VP
HIV-2 NN B-NP B-NP
transcription NN I-NP I-NP
in IN B-PP B-PP
infected JJ B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

In IN B-PP B-PP
this DT B-NP B-NP
report NN I-NP I-NP
, , O O
we PRP B-NP B-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
a DT B-NP B-NP
novel JJ I-NP I-NP
Ets-related JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
, , O O
Elf-1 NN B-NP B-NP
, , O O
binds VBZ B-VP B-VP
specifically RB B-ADVP B-ADVP
to TO B-PP B-PP
two CD B-NP B-NP
purine-rich JJ I-NP I-NP
motifs NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
HIV-2 NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

Mutagenesis NN B-NP B-NP
experiments NNS I-NP I-NP
demonstrated VBD B-VP B-VP
that IN B-SBAR B-SBAR
these DT B-NP B-NP
Elf-1 NN I-NP I-NP
binding NN I-NP I-NP
sites NNS I-NP I-NP
are VBP B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
induction NN B-NP B-NP
of IN B-PP B-PP
HIV-2 NN B-NP B-NP
transcription NN I-NP I-NP
following VBG B-PP B-VP
T-cell-receptor-mediated JJ B-NP B-NP
T-cell NN I-NP I-NP
activation NN I-NP I-NP
. . O O

Moreover RB B-ADVP B-ADVP
, , O O
Elf-1 NN B-NP B-NP
is VBZ B-VP B-VP
the DT B-NP B-NP
only JJ I-NP I-NP
factor NN I-NP I-NP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
activated VBN B-NP B-NP
T-cell NN I-NP I-NP
nuclear JJ I-NP I-NP
extracts NNS I-NP I-NP
that WDT B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
these DT B-NP B-NP
sites NNS I-NP I-NP
in IN B-PP B-PP
electrophoretic JJ B-NP B-NP
mobility NN I-NP I-NP
shift NN I-NP I-NP
assays NNS I-NP I-NP
. . O O

Thus RB B-ADVP B-ADVP
, , O O
Elf-1 NN B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
novel JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
that WDT B-NP B-NP
appears VBZ B-VP B-VP
to TO I-VP I-VP
be VB I-VP I-VP
required VBN I-VP I-VP
for IN B-PP B-PP
the DT B-NP B-NP
T-cell-receptor-mediated JJ I-NP I-NP
trans JJ I-NP I-NP
activation NN I-NP I-NP
of IN B-PP B-PP
HIV-2 NN B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
may MD B-VP B-VP
explain VB I-VP I-VP
differences NNS B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
clinical JJ I-NP I-NP
spectra NNS I-NP I-NP
of IN B-PP B-PP
diseases NNS B-NP B-NP
caused VBN B-VP B-VP
by IN B-PP B-PP
HIV-1 NN B-NP B-NP
and CC O I-NP
HIV-2 NN B-NP I-NP
and CC O I-CC
may MD B-VP B-VP
also RB I-VP I-VP
have VB I-VP I-VP
implications NNS B-NP B-NP
for IN B-PP B-PP
the DT B-NP B-NP
design NN I-NP I-NP
of IN B-PP B-PP
therapeutic JJ B-NP B-NP
approaches NNS I-NP I-NP
to TO B-PP B-PP
HIV-2 NN B-NP B-NP
infection NN I-NP I-NP
. . O O

Human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP I-NP
Nef NN I-NP I-NP
protein NN I-NP I-NP
inhibits VBZ B-VP B-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
induction NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

Human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP B-NP
( ( O O
HIV-1 NN B-NP I-NP
) ) O O
can MD B-VP B-VP
establish VB I-VP I-VP
a DT B-NP B-NP
persistent JJ I-NP I-NP
and CC I-NP I-NP
latent JJ I-NP I-NP
infection NN I-NP I-NP
in IN B-PP B-PP
CD4+ JJ B-NP B-NP
T NN I-NP I-NP
lymphocytes NNS I-NP I-NP
( ( O O
W.C.Greene NNP B-NP B-NP
, , O O
N.Engl.J. NNP B-NP B-NP
Med.324 NNP I-NP I-NP
: : I-NP O
308-317 CD I-NP B-NP
, , O O
1991 CD B-NP I-NP
; : O O
S.M.Schnittman NNP B-NP B-NP
, , O O
M.C.Psallidopoulos NNP B-NP B-NP
, , O O
H.C. NNP B-NP B-NP
Lane NNP I-NP I-NP
, , O O
L.Thompson NNP B-NP B-NP
, , O O
M.Baseler NNP B-NP B-NP
, , O O
F.Massari NNP B-NP B-NP
, , O O
C.H.Fox NNP B-NP B-NP
, , O O
N.P.Salzman NNP B-NP B-NP
, , O O
and CC O I-CC
A.S.Fauci NNP B-NP B-NP
, , O O
Science NNP B-NP B-NP
245 CD I-NP I-NP
: : I-NP O
305-308 CD I-NP B-NP
, , O O
1989 CD B-NP I-NP
) ) O O
. . O O

Production NN B-NP B-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
from IN B-PP B-PP
latently RB B-NP B-NP
infected JJ I-NP I-NP
cells NNS I-NP I-NP
requires VBZ B-VP B-VP
host NN B-NP B-NP
cell NN I-NP I-NP
activation NN I-NP I-NP
by IN B-PP B-PP
T-cell NN B-NP B-NP
mitogens NNS I-NP I-NP
( ( O O
T.Folks NNP B-NP B-NP
, , O O
D.M.Powell NNP B-NP B-NP
, , O O
M.M.Lightfoote NNP B-NP B-NP
, , O O
S.Benn NNP B-NP B-NP
, , O O
M.A. NNP B-NP B-NP
Martin NNP I-NP I-NP
, , O O
and CC O I-CC
A.S.Fauci NNP B-NP B-NP
, , O O
Science NNP B-NP B-NP
231 CD I-NP I-NP
: : I-NP O
600-602 CD I-NP B-NP
, , O O
1986 CD B-NP I-NP
; : O O
D.Zagury NNP B-NP B-NP
, , O O
J. NNP B-NP B-NP
Bernard NNP I-NP I-NP
, , O O
R.Leonard NNP B-NP B-NP
, , O O
R.Cheynier NNP B-NP B-NP
, , O O
M.Feldman NNP B-NP B-NP
, , O O
P.S.Sarin NNP B-NP B-NP
, , O O
and CC O I-CC
R.C. NNP B-NP B-NP
Gallo NNP I-NP I-NP
, , O O
Science NNP B-NP B-NP
231 CD I-NP I-NP
: : I-NP O
850-853 CD I-NP B-NP
, , O O
1986 CD B-NP B-NP
) ) O O
. . O O

This DT B-NP B-NP
activation NN I-NP I-NP
is VBZ B-VP B-VP
mediated VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
host NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
( ( O O
G.Nabel NNP B-NP B-NP
and CC O I-NP
D.Baltimore NNP B-NP I-NP
, , O O
Nature NNP B-NP B-NP
( ( I-NP O
London NNP I-NP B-NP
) ) I-NP O
326 CD I-NP B-NP
: : I-NP O
711-717 CD I-NP B-NP
, , O O
1987 CD B-NP B-NP
) ) O O
. . O O

We PRP B-NP B-NP
report VBP B-VP B-VP
here RB B-ADVP B-ADVP
that IN B-SBAR B-PP
the DT B-NP B-NP
HIV-1-encoded JJ I-NP I-NP
Nef NN I-NP I-NP
protein NN I-NP I-NP
inhibits VBZ B-VP B-VP
the DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
DNA-binding JJ I-NP I-NP
activity NN I-NP I-NP
by IN B-PP B-PP
T-cell NN B-NP B-NP
mitogens NNS I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
Nef NN B-NP B-NP
does VBZ B-VP B-VP
not RB I-VP I-VP
affect VB I-VP I-VP
the DT B-NP B-NP
DNA-binding JJ I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
other JJ B-NP B-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
implicated VBN B-VP B-VP
in IN B-PP B-PP
HIV-1 NN B-NP B-NP
regulation NN I-NP I-NP
, , O O
including VBG B-PP B-PP
SP-1 NN B-NP B-NP
, , O O
USF NN B-NP B-NP
, , O O
URS NN B-NP B-NP
, , O O
and CC O I-CC
NF-AT NN B-NP B-NP
. . O O

Additionally RB B-ADVP B-ADVP
, , O O
Nef NN B-NP B-NP
inhibits VBZ B-VP B-VP
the DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
HIV-1- NN B-NP B-NP
and CC O I-NP
interleukin NN B-ADJP I-NP
2-directed JJ I-ADJP I-NP
gene NN B-NP I-NP
expression NN I-NP I-NP
, , O O
and CC O I-CC
the DT B-NP B-NP
effect NN I-NP I-NP
on IN B-PP B-PP
HIV-1 NN B-NP B-NP
transcription NN I-NP I-NP
depends VBZ B-VP B-VP
on IN B-PP B-PP
an DT B-NP B-NP
intact JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B-binding JJ I-NP I-NP
site NN I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
defective JJ B-NP B-NP
recruitment NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
may MD B-VP B-VP
underlie VB I-VP I-VP
Nef NN B-NP B-NP
's POS B-NP B-NP
negative JJ I-NP I-NP
transcriptional JJ I-NP I-NP
effects NNS I-NP I-NP
on IN B-PP B-PP
the DT O B-NP
HIV-1 NN B-NP I-NP
and CC O I-NP
interleukin NN B-NP I-NP
2 CD I-NP B-NP
promoters NNS B-NP I-NP
. . O O

Further JJ B-NP B-NP
evidence NN I-NP I-NP
suggests VBZ B-VP B-VP
that IN B-SBAR B-SBAR
Nef NN B-NP B-NP
inhibits VBZ B-VP B-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
induction NN I-NP I-NP
by IN B-PP B-PP
interfering VBG B-VP B-VP
with IN B-PP B-PP
a DT B-NP B-NP
signal NN I-NP I-NP
derived VBN B-VP B-VP
from IN B-PP B-PP
the DT B-NP B-NP
T-cell NN I-NP I-NP
receptor NN I-NP I-NP
complex NN I-NP I-NP
. . O O

( ( O O
Effect NN B-NP B-NP
of IN B-PP B-PP
antihypertensive JJ B-NP B-NP
therapy NN I-NP I-NP
with IN B-PP B-PP
captopril NN B-NP B-NP
on IN B-PP B-PP
gluco- JJ B-NP B-NP
and CC O I-NP
mineralocorticoid NN B-NP I-NP
receptors NNS B-NP I-NP
of IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
lymphocytes NNS I-NP I-NP
in IN B-PP B-PP
hypertensive JJ B-NP B-NP
patients NNS I-NP I-NP
of IN B-PP B-PP
various JJ B-NP B-NP
age NN I-NP I-NP
) ) O O

Binding NN B-NP B-NP
of IN B-PP B-PP
3H-dexamethasone NN B-NP B-NP
and CC O I-NP
3H-aldosterone NN B-NP I-NP
by IN B-PP B-PP
peripheral JJ B-NP B-NP
lymphocyte NN I-NP I-NP
receptors NNS I-NP I-NP
was VBD B-VP B-VP
investigated VBN I-VP I-VP
in IN B-PP B-PP
healthy JJ B-NP B-NP
persons NNS I-NP I-NP
and CC O I-CC
hypertensive JJ B-NP B-NP
patients NNS I-NP I-NP
before IN B-PP B-PP
and CC B-PP I-PP
after IN B-PP I-PP
2-week JJ B-NP B-NP
captopril NN I-NP I-NP
treatment NN I-NP I-NP
. . O O

The DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
and CC O I-NP
mineralocorticoid NN B-NP I-NP
binding NN B-NP I-NP
sites NNS I-NP I-NP
was VBD B-VP B-VP
increased VBN I-VP I-VP
in IN B-PP B-PP
hypertensives NNS B-NP B-NP
vs CC O I-NP
normotensives NNS B-NP I-NP
. . O O

The DT B-NP B-NP
treatment NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
ACE NN I-NP I-NP
inhibitor NN I-NP I-NP
captopril NN I-NP I-NP
led VBD B-VP B-VP
to TO B-PP B-PP
activation NN B-NP B-NP
of IN B-PP B-PP
hormone-receptor NN B-NP B-NP
interactions NNS I-NP I-NP
. . O O

There EX B-NP B-NP
was VBD B-VP B-VP
a DT B-NP B-NP
more RBR I-NP I-NP
marked JJ I-NP I-NP
rise NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
receptors NNS B-NP B-NP
in IN B-PP B-PP
middle-aged JJ O B-NP
( ( O O
44-55 CD B-NP I-NP
years NNS I-NP I-NP
) ) O O
hypertensives NNS B-NP B-NP
vs CC O I-CC
elderly JJ O B-NP
( ( O O
61-80 CD B-NP I-NP
years NNS I-NP I-NP
) ) O O
subjects NNS B-NP B-NP
after IN B-PP B-PP
captopril NN B-NP B-NP
treatment NN I-NP I-NP
. . O O

Leukotriene NN B-NP B-NP
B4 NN I-NP I-NP
transcriptionally RB B-ADVP B-ADVP
activates VBZ B-VP B-VP
interleukin-6 NN B-NP B-NP
expression NN I-NP I-NP
involving VBG B-VP B-VP
NK-chi NN B-NP B-NP
B NN I-NP I-NP
and CC O I-NP
NF-IL6 NN B-NP I-NP
. . O O

Leukotriene NN B-NP B-NP
B4 NN I-NP I-NP
( ( O O
LTB4 NN B-NP B-NP
) ) O O
is VBZ B-VP B-VP
a DT B-NP B-NP
notable JJ I-NP I-NP
participant NN I-NP I-NP
in IN B-PP B-PP
inflammation NN B-NP B-NP
and CC O I-NP
chemotaxis NN B-NP I-NP
. . O O

It PRP B-NP B-NP
is VBZ B-VP B-VP
, , O O
however RB B-ADVP B-ADVP
, , O O
still RB B-ADJP B-ADVP
unclear JJ I-ADJP B-ADJP
whether IN B-SBAR B-SBAR
LTB4 NN B-NP B-NP
acts VBZ B-VP B-VP
in IN B-PP B-PP
this DT B-NP B-NP
regard NN I-NP I-NP
directly RB B-ADVP B-ADVP
or CC B-ADVP I-ADVP
indirectly RB B-ADVP I-ADVP
by IN B-PP B-PP
stimulating VBG B-VP B-VP
the DT B-NP B-NP
release NN I-NP I-NP
of IN B-PP B-PP
chemotactic JJ B-NP B-NP
and CC I-NP I-NP
inflammatory JJ I-NP I-NP
cytokines NNS I-NP I-NP
. . O O

Here RB B-ADVP B-ADVP
we PRP B-NP B-NP
report VBP B-VP B-VP
that IN B-SBAR B-SBAR
LTB4 NN B-NP B-NP
induces VBZ B-VP B-VP
synthesis NN B-NP B-NP
of IN B-PP B-PP
interleukin NN B-NP B-NP
( ( O O
IL NN B-NP B-NP
) ) O O
-6 CD B-NP B-NP
by IN B-PP B-PP
human JJ B-NP B-NP
blood NN I-NP I-NP
monocytes NNS I-NP I-NP
through IN B-PP B-PP
transcriptional JJ B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
IL-6 NN I-NP I-NP
gene NN I-NP I-NP
. . O O

We PRP B-NP B-NP
furthermore RB B-ADVP B-ADVP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
this DT B-NP B-NP
process NN I-NP I-NP
involves VBZ B-VP B-VP
activation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
NF-chi NN I-NP I-NP
B NN I-NP I-NP
and CC O I-CC
, , O O
to TO B-PP B-PP
a DT B-NP B-NP
lesser JJR I-NP I-NP
extent NN I-NP I-NP
, , O O
of IN B-PP B-PP
NF-IL6 NN B-NP B-NP
, , O O
while IN B-SBAR B-SBAR
the DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
AP-1 NN I-NP I-NP
, , O O
shown VBN B-VP B-VP
to TO I-VP I-VP
otherwise RB I-VP I-VP
confer VB I-VP I-VP
IL-6 NN B-NP B-NP
inducibility NN I-NP I-NP
, , O O
appeared VBD B-VP B-VP
to TO I-VP I-VP
be VB I-VP I-VP
unaffected JJ I-VP B-ADJP
by IN B-PP B-PP
LTB4 NN B-NP B-NP
. . O O

Involvement NN B-NP B-NP
of IN B-PP B-PP
NF-chi NN B-NP B-NP
B NN I-NP I-NP
and CC O I-NP
NF-IL6 NN B-NP I-NP
in IN B-PP B-PP
induction NN B-NP B-NP
of IN B-PP B-PP
IL-6 NN B-NP B-NP
transcription NN I-NP I-NP
by IN B-PP B-PP
monocytes NNS B-NP B-NP
was VBD B-VP B-VP
demonstrated VBN I-VP I-VP
using VBG B-VP I-VP
deleted JJ B-NP B-NP
forms NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
IL-6 NN I-NP I-NP
promoter NN I-NP I-NP
. . O O

Activation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
IL-6 NN I-NP I-NP
promoter NN I-NP I-NP
by IN B-PP B-PP
LTB4 NN B-NP B-NP
was VBD B-VP B-VP
not RB B-CONJP I-VP
only RB I-CONJP I-VP
associated VBN B-VP I-VP
with IN B-PP B-PP
accumulation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
respective JJ I-NP I-NP
transcripts NNS I-NP I-NP
but CC O I-CC
resulted VBD B-VP B-VP
in IN B-PP B-PP
synthesis NN B-NP B-NP
of IN B-PP B-PP
functional JJ B-NP B-NP
IL-6 NN I-NP I-NP
protein NN I-NP I-NP
as RB B-PP B-ADVP
well RB B-ADVP I-ADVP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
LTB4 NN B-NP B-NP
mediated VBD B-VP B-VP
transactivation NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
heterologous JJ I-NP I-NP
promoter NN I-NP I-NP
construct NN I-NP I-NP
containing VBG B-VP B-VP
the DT B-NP B-NP
NF-chi NN I-NP I-NP
B NN I-NP I-NP
or CC O I-CC
the DT B-NP B-NP
NF-IL6 NN I-NP I-NP
enhancer NN B-NP I-NP
, , O O
but CC B-CONJP I-CC
not RB I-CONJP I-RB
the DT B-NP B-NP
AP-1 NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

The DT B-NP B-NP
signaling NN I-NP I-NP
events NNS I-NP I-NP
mediating VBG B-VP B-VP
this DT B-NP B-NP
effect NN I-NP I-NP
appeared VBD B-VP B-VP
to TO I-VP I-VP
involve VB I-VP I-VP
the DT B-NP B-NP
release NN I-NP I-NP
of IN B-PP B-PP
H2O2 NN B-NP B-NP
, , O O
since IN B-SBAR B-SBAR
LTB4 NN B-NP B-NP
failed VBD B-VP B-VP
to TO I-VP I-VP
induce VB I-VP I-VP
NF-chi NN B-NP B-NP
B NN I-NP I-NP
or CC O I-NP
NF-IL6 NN B-NP I-NP
in IN B-PP B-PP
the DT I-PP B-NP
presence NN I-PP I-NP
of IN I-PP B-PP
the DT B-NP B-NP
scavenger NN I-NP I-NP
of IN B-PP B-PP
H2O2 NN B-NP B-NP
, , O O
N-acetyl-L-cysteine NN B-NP B-NP
. . O O

Estrogen NN B-NP B-NP
binding NN I-NP I-NP
sites NNS I-NP I-NP
in IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
monocytes NNS I-NP I-NP
and CC O I-NP
effects NNS B-NP I-NP
of IN B-PP B-PP
danazol NN B-NP B-NP
on IN B-PP B-PP
their PRP$ B-NP B-NP
sites NNS I-NP I-NP
in FW B-ADVP B-VP
vitro FW I-ADVP B-NP
. . O O

1 LS B-LST B-NP
. . O O
This DT B-NP B-NP
study NN I-NP I-NP
was VBD B-VP B-VP
designed VBN I-VP I-VP
to TO B-VP I-VP
investigate VB I-VP I-VP
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
estrogen NN O B-NP
type NN B-NP I-NP
I CD I-NP I-NP
( ( O O
high JJ B-NP B-NP
affinity NN I-NP I-NP
, , O O
low JJ B-NP B-NP
capacity NN I-NP I-NP
) ) O O
and CC O I-CC
type NN B-NP B-NP
II CD I-NP I-NP
( ( O O
low JJ B-NP B-NP
affinity NN I-NP I-NP
, , O O
high JJ B-NP B-NP
capacity NN I-NP I-NP
) ) O O
binding NN B-NP B-NP
sites NNS I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
peripheral JJ I-NP I-NP
blood NN I-NP I-NP
monocytes NNS I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
danazol NN B-NP B-NP
on IN B-PP B-PP
these DT B-NP B-NP
sites NNS I-NP I-NP
. . O O

2 LS B-LST I-LS
. . O O
These DT B-NP B-NP
two CD I-NP I-NP
types NNS I-NP I-NP
of IN B-PP B-PP
estrogen NN B-NP B-NP
binding NN I-NP I-NP
sites NNS I-NP I-NP
existed VBD B-VP B-VP
in IN B-PP B-PP
human JJ B-NP B-NP
peripheral JJ I-NP I-NP
blood NN I-NP I-NP
monocytes NNS I-NP I-NP
. . O O

3 LS B-LST I-LS
. . O O
Danazol NN B-NP I-NP
bound VBD B-VP B-VP
to TO B-PP B-PP
these DT B-NP B-NP
sites NNS I-NP I-NP
in IN B-PP B-PP
high JJ B-NP B-NP
concentration NN I-NP I-NP
( ( O O
10(-6) CD B-NP B-NP
M NN I-NP I-NP
, , O O
clinical JJ B-ADJP B-NP
serum NN B-NP I-NP
concentration NN I-NP I-NP
during IN B-PP B-PP
danazol NN B-NP B-NP
therapy NN I-NP I-NP
) ) O O
and CC O I-CC
decreased VBD B-VP B-VP
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
both DT B-NP B-NP
sites NNS I-NP I-NP
. . O O

4 LS B-LST I-LS
. . O O
It PRP B-NP B-NP
is VBZ B-VP B-VP
suggested VBN I-VP I-VP
that IN B-SBAR B-SBAR
danazol NN B-NP B-NP
has VBZ B-VP B-VP
an DT B-NP B-NP
anti-estrogenic JJ I-NP I-NP
action NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
monocytes NNS I-NP I-NP
through IN B-PP B-PP
the DT B-NP B-NP
competition NN B-NP I-NP
and CC O I-NP
suppression NN B-NP I-NP
of IN B-PP B-PP
estrogen NN B-NP B-NP
binding NN I-NP I-NP
sites NNS I-NP I-NP
as IN B-SBAR B-SBAR
seen VBN B-VP B-VP
in IN B-PP B-PP
the DT B-NP B-NP
estrogen NN I-NP I-NP
target NN I-NP I-NP
organ NN I-NP I-NP
. . O O

( ( O O
Mechanism NN B-NP B-NP
of IN B-PP B-PP
action NN B-NP B-NP
of IN B-PP B-PP
steroid NN B-NP B-NP
hormones NNS I-NP I-NP
. . I-NP O
I LS I-NP I-LS
. . I-NP O
Estrogens NNS I-NP I-NNS
) ) O O

The DT B-NP B-NP
steroid NN I-NP I-NP
hormone NN I-NP I-NP
are VBP B-VP B-VP
very RB B-NP B-NP
versatile JJ I-NP I-NP
molecules NNS I-NP I-NP
: : O O
although IN B-SBAR B-SBAR
they PRP B-NP B-NP
are VBP B-VP B-VP
related JJ B-ADJP B-ADJP
among IN B-PP B-PP
them PRP B-NP B-NP
by IN B-PP B-PP
their PRP$ B-NP B-NP
chemical JJ I-NP I-NP
structure NN I-NP I-NP
, , O O
they PRP B-NP B-NP
have VBP B-VP B-VP
very RB B-NP B-NP
diverse JJ I-NP I-NP
functions NNS I-NP I-NP
and CC O I-CC
including VBG B-PP B-NP
antagonic JJ B-NP I-NP
. . O O

Their PRP$ B-NP B-NP
action NN I-NP I-NP
mechanism NN I-NP I-NP
is VBZ B-VP B-VP
not RB I-VP I-VP
completely RB I-VP I-VP
cleared VBN I-VP I-VP
. . O O

The DT B-NP B-NP
estrogens NNS I-NP I-NP
participate VBP B-VP B-VP
in IN B-PP B-PP
the DT B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
practically RB B-NP B-NP
all PDT I-NP I-NP
the DT I-NP I-NP
reproductive JJ I-NP I-NP
and CC I-NP I-NP
sexual JJ I-NP I-NP
events NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
female NN I-NP I-NP
, , O O
although IN B-SBAR B-SBAR
the DT B-NP B-NP
intracellular JJ I-NP I-NP
actions NNS I-NP I-NP
by IN B-PP B-PP
which WDT B-NP B-NP
they PRP B-NP B-NP
take VBP B-VP B-VP
place NN B-NP B-NP
are VBP B-VP B-VP
not RB I-VP I-VP
well RB I-VP I-VP
known VBN I-VP I-VP
and CC O I-CC
the DT B-NP B-NP
proposed JJ I-NP I-NP
models NNS I-NP I-NP
do VBP B-VP B-VP
not RB I-VP I-VP
adequately RB I-VP I-VP
satisfy VB I-VP I-VP
the DT B-NP B-NP
questions NNS I-NP I-NP
. . O O

Currently RB B-ADVP B-ADVP
it PRP B-NP B-NP
is VBZ B-VP B-VP
accepted VBN I-VP I-VP
the DT B-NP B-NP
existence NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
cytoplasmic JJ I-NP I-NP
and/or CC I-NP I-NP
nuclear JJ I-NP I-NP
receptor NN I-NP I-NP
, , O O
without IN B-PP B-PP
explaining VBG B-VP B-VP
satisfactorily RB B-ADVP B-ADVP
how WRB B-ADVP I-ADVP
the DT B-NP B-NP
hormones NNS I-NP I-NP
come VBN B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
nucleus NN I-NP I-NP
. . O O

The DT B-NP B-NP
endocrine JJ I-NP I-NP
events NNS I-NP I-NP
that WDT B-NP B-NP
are VBP O B-VP
rapidly RB B-ADVP I-VP
expressed VBN B-VP I-VP
( ( O O
seconds NNS B-NP B-NP
) ) O O
are VBP B-VP B-VP
due JJ B-PP B-ADJP
to TO I-PP B-PP
a DT B-NP B-NP
possible JJ I-NP I-NP
interaction NN I-NP I-NP
with IN B-PP B-PP
cellular JJ B-NP B-NP
membrane NN I-NP I-NP
. . O O

The DT B-NP B-NP
purpose NN I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
review NN I-NP I-NP
is VBZ B-VP B-VP
to TO B-VP B-VP
analyze VB I-VP I-VP
and CC O I-VP
concilliate VB B-VP I-VP
the DT B-NP B-NP
reported VBN I-NP I-NP
data NNS I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
mechanism NN I-NP I-NP
of IN B-PP B-PP
action NN B-NP B-NP
of IN B-PP B-PP
estrogens NNS B-NP B-NP
. . O O

Stable JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
transdominant JJ B-NP B-NP
Rev NN I-NP I-NP
protein NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
inhibits VBZ B-VP B-VP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
replication NN I-NP I-NP
. . O O

The DT O B-NP
human JJ B-NP I-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
( ( O O
HIV NN B-NP I-NN
) ) O O
Rev NN B-NP B-NP
protein NN I-NP I-NP
is VBZ B-VP B-VP
essential JJ B-ADJP B-ADJP
for IN B-PP B-PP
viral JJ B-NP B-NP
structural JJ I-NP I-NP
protein NN I-NP I-NP
expression NN I-NP I-NP
( ( O O
Gag NN B-NP B-NP
, , O O
Pol NN B-NP I-NP
, , O O
and CC O I-CC
Env NN B-NP B-NP
) ) O O
and CC B-PP I-CC
, , I-PP O
hence RB I-PP B-ADVP
, , O O
for IN B-PP B-PP
viral JJ B-NP B-NP
replication NN I-NP I-NP
. . O O

In IN B-PP B-PP
transient JJ B-NP B-NP
transfection NN I-NP I-NP
assays NNS I-NP I-NP
, , O O
mutant JJ B-NP B-NP
forms NNS I-NP I-NP
of IN B-PP B-PP
Rev NN B-NP B-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
identified VBN I-VP I-VP
that WDT B-NP B-NP
inhibit VBP B-VP B-VP
wild-type JJ B-NP B-NP
Rev NN I-NP I-NP
activity NN I-NP I-NP
and CC O I-CC
therefore RB O B-VP
suppress VBP B-VP I-VP
viral JJ B-NP B-NP
replication NN I-NP I-NP
. . O O

To TO B-VP B-VP
determine VB I-VP I-VP
whether IN B-SBAR B-SBAR
such JJ B-NP B-NP
transdominant JJ I-NP I-NP
Rev NN I-NP I-NP
proteins NNS I-NP I-NP
could MD B-VP B-VP
provide VB I-VP I-VP
long-term JJ B-NP B-NP
protection NN I-NP I-NP
against IN B-PP B-PP
HIV NN B-NP B-NP
infection NN I-NP I-NP
without IN B-PP B-PP
affecting VBG B-VP B-VP
T NN B-NP B-NP
cell NN I-NP I-NP
function NN I-NP I-NP
, , O O
T NN B-NP B-NP
leukemia NN I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
were VBD B-VP B-VP
stably RB I-VP I-VP
transduced VBN I-VP I-VP
with IN B-PP B-PP
a DT B-NP B-NP
retroviral JJ I-NP I-NP
vector NN I-NP I-NP
encoding VBG B-VP B-VP
a DT B-NP B-NP
transdominant JJ I-NP I-NP
mutant NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
Rev NN I-NP I-NP
protein NN I-NP I-NP
, , O O
M10 NN B-NP B-NP
. . O O

While IN B-SBAR B-SBAR
all PDT B-NP B-NP
the DT I-NP I-NP
M10-expressing JJ I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
remained VBD B-VP B-VP
infectable JJ B-ADJP B-ADJP
by IN B-PP B-PP
HIV-1 NN B-NP B-NP
, , O O
these DT B-NP B-NP
same JJ I-NP I-NP
cells NNS I-NP I-NP
failed VBD B-VP B-VP
to TO I-VP I-VP
support VB I-VP I-VP
a DT B-NP B-NP
productive JJ I-NP I-NP
replication NN I-NP I-NP
cycle NN I-NP I-NP
when WRB B-ADVP B-VP
infected VBN B-VP I-VP
with IN B-PP B-PP
a DT B-NP B-NP
cloned VBN I-NP I-NP
isolate NN I-NP I-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
two CD B-NP B-NP
out IN I-NP B-PP
of IN I-NP B-PP
three CD I-NP B-NP
M10-expressing JJ I-NP I-NP
CEM NN I-NP I-NP
clones NNS I-NP I-NP
were VBD B-VP B-VP
also RB B-ADJP B-ADJP
resistant JJ I-ADJP I-ADJP
to TO B-PP B-PP
highly RB B-NP B-NP
productive JJ I-NP I-NP
infection NN I-NP I-NP
by IN B-PP B-PP
a DT B-NP B-NP
heterogeneous JJ I-NP I-NP
HIV-1 NN I-NP I-NP
pool NN I-NP I-NP
. . O O

Expression NN B-NP B-NP
of IN B-PP B-PP
M10 NN B-NP B-NP
did VBD B-VP B-VP
not RB I-VP I-VP
affect VB I-VP I-VP
induction NN B-NP B-NP
of IN B-PP B-PP
HIV NN B-NP B-NP
transcription NN I-NP I-NP
mediated VBN B-VP B-VP
by IN B-PP B-PP
the DT B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
regulatory JJ I-NP I-NP
element NN I-NP I-NP
or CC O I-NP
Tat NN B-NP I-NP
. . O O

Importantly RB B-ADVP B-ADVP
, , O O
constitutive JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
Rev NN B-NP B-NP
M10 NN I-NP I-NP
did VBD B-VP B-VP
not RB I-VP I-VP
alter VB I-VP I-VP
the DT B-NP B-NP
secretion NN I-NP I-NP
of IN B-PP B-PP
interleukin NN B-NP B-NP
2 CD I-NP I-NP
in IN B-PP B-PP
response NN I-PP B-NP
to TO I-PP B-PP
mitogen NN B-NP B-NP
stimulation NN I-NP I-NP
of IN B-PP B-PP
EL-4 NN B-NP B-NP
and CC O I-NP
Jurkat NN B-NP I-NP
cells NNS B-NP I-NP
. . O O

The DT B-NP B-NP
inhibition NN I-NP I-NP
of IN B-PP B-PP
HIV NN B-NP B-NP
infection NN I-NP I-NP
in IN B-PP B-PP
cells NNS B-NP B-NP
stably RB B-VP B-VP
expressing VBG I-VP I-VP
a DT B-NP B-NP
transdominant JJ I-NP I-NP
Rev NN I-NP I-NP
protein NN I-NP I-NP
, , O O
in IN B-PP B-PP
the DT I-PP B-NP
absence NN I-PP I-NP
of IN I-PP B-PP
any DT B-NP B-NP
deleterious JJ I-NP I-NP
effect NN I-NP I-NP
on IN B-PP B-PP
T NN B-NP B-NP
cell NN I-NP I-NP
function NN I-NP I-NP
, , O O
suggests VBZ B-VP B-VP
that IN B-SBAR B-SBAR
such PDT B-NP B-NP
a DT I-NP I-NP
strategy NN I-NP I-NP
could MD B-VP B-VP
provide VB I-VP I-VP
a DT B-NP B-NP
therapeutic JJ I-NP I-NP
effect NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
T NN I-NP I-NP
lymphocytes NNS I-NP I-NP
of IN B-PP B-PP
acquired VBN B-NP B-NP
immunodeficiency NN I-NP I-NP
syndrome NN I-NP I-NP
patients NNS I-NP I-NP
. . O O

Glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
in IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
lupus NN B-NP B-NP
nephritis NN I-NP I-NP
: : O O
relationship NN B-NP B-NP
between IN B-PP B-PP
receptor NN B-NP B-NP
levels NNS I-NP I-NP
in IN B-PP B-PP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
and CC O I-NP
effect NN B-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
therapy NN I-NP I-NP
. . O O

We PRP B-NP B-NP
investigated VBD B-VP B-VP
the DT B-NP B-NP
clinical JJ I-NP I-NP
significance NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
determination NN I-NP I-NP
in IN B-PP B-PP
20 CD B-NP B-NP
patients NNS I-NP I-NP
with IN B-PP B-PP
systemic JJ B-NP B-NP
lupus NN I-NP I-NP
erythematosus NN I-NP I-NP
( ( O O
SLE NN B-NP B-NP
) ) O O
who WP B-NP B-NP
afterwards RB B-ADVP B-ADVP
developed VBD B-VP B-VP
nephrotic JJ B-NP B-NP
syndrome NN I-NP I-NP
. . O O

Glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
concentrations NNS I-NP I-NP
in IN B-PP B-PP
mononuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
( ( O O
MNL NNS B-NP B-NP
) ) O O
in IN B-PP B-PP
these DT B-NP B-NP
patients NNS I-NP I-NP
were VBD B-VP B-VP
comparable JJ B-ADJP B-ADJP
with IN B-PP B-PP
those DT B-NP B-NP
in IN B-PP B-PP
both CC O B-NP
other JJ B-NP I-NP
patients NNS I-NP I-NP
with IN B-PP B-PP
SLE NN B-NP B-NP
and CC O I-CC
healthy JJ B-NP B-NP
persons NNS I-NP I-NP
. . O O

Improvement NN B-NP B-NP
in IN B-PP B-PP
urinary JJ B-NP B-NP
protein NN I-NP I-NP
excretion NN I-NP I-NP
and CC B-PP I-CC
in IN B-PP B-PP
disease NN B-NP B-NP
activity NN I-NP I-NP
, , O O
which WDT B-NP B-NP
was VBD B-VP B-VP
scored VBN I-VP I-VP
according VBG B-PP I-VP
to TO B-PP B-PP
the DT B-NP B-NP
SLE NNP I-NP I-NP
Disease NNP I-NP I-NP
Activity NNP I-NP I-NP
Index NNP I-NP I-NP
system NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
University NNP I-NP I-NP
of IN B-PP B-PP
Toronto NNP B-NP B-NP
, , O O
closely RB B-ADVP B-ADVP
related JJ B-VP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
concentrations NNS I-NP I-NP
in IN B-PP B-PP
MNL NN B-NP B-NP
isolated VBN B-VP B-VP
from IN B-PP B-PP
the DT B-NP B-NP
corresponding JJ I-NP I-NP
patients NNS I-NP I-NP
. . O O

In IN B-PP B-PP
summary NN B-NP B-NP
, , O O
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
determination NN I-NP I-NP
in IN B-PP B-PP
patients NNS B-NP B-NP
with IN B-PP B-PP
lupus NN B-NP B-NP
nephritis NN I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
a DT B-NP B-NP
predictive JJ I-NP I-NP
clue NN I-NP I-NP
for IN B-PP B-PP
assessing VBG B-VP B-VP
responsiveness NN B-NP B-NP
to TO B-PP B-PP
glucocorticoid NN B-NP B-NP
therapy NN I-NP I-NP
. . O O

Selection NN B-NP B-NP
of IN B-PP B-PP
optimal JJ B-NP B-NP
kappa NN I-NP I-NP
B/Rel NN I-NP I-NP
DNA-binding JJ I-NP I-NP
motifs NNS I-NP I-NP
: : O O
interaction NN B-NP B-NP
of IN B-PP B-PP
both DT B-NP B-NP
subunits NNS I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
with IN B-PP B-PP
DNA NN B-NP B-NP
is VBZ B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
transcriptional JJ B-NP B-NP
activation NN I-NP I-NP
. . O O

Analysis NN B-NP B-NP
of IN B-PP B-PP
the DT O B-NP
p50 NN B-NP I-NP
and CC O I-NP
p65 NN B-NP I-NP
subunits NNS B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
complex NN I-NP I-NP
has VBZ B-VP B-VP
revealed VBN I-VP I-VP
that IN B-SBAR B-PP
both DT B-NP B-NP
proteins NNS I-NP I-NP
can MD B-VP B-VP
interact VB I-VP I-VP
with IN B-PP B-PP
related JJ B-NP B-NP
DNA NN I-NP I-NP
sequences NNS I-NP I-NP
through IN B-PP B-PP
either CC O I-CC
homo- JJ B-NP B-ADJP
or CC O I-CC
heterodimer NN B-NP B-NP
formation NN B-NP I-NP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
the DT B-NP B-NP
product NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
proto-oncogene NN I-NP I-NP
c-rel NN I-NP I-NP
can MD B-VP B-VP
bind VB I-VP I-VP
to TO B-PP B-PP
similar JJ B-NP B-NP
DNA NN I-NP I-NP
motifs NNS I-NP I-NP
by IN B-PP B-PP
itself PRP B-NP B-NP
or CC B-PP I-CC
as IN B-PP B-PP
a DT B-NP B-NP
heterodimer NN I-NP I-NP
with IN B-PP B-PP
p50 NN B-NP B-NP
or CC O I-NP
p65 NN B-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
these DT B-NP B-NP
studies NNS I-NP I-NP
have VBP B-VP B-VP
used VBN I-VP I-VP
a DT B-NP B-NP
limited JJ I-NP I-NP
number NN I-NP I-NP
of IN B-PP B-PP
known JJ B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
DNA NN I-NP I-NP
motifs NNS I-NP I-NP
, , O O
and CC O I-CC
the DT B-NP B-NP
question NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
optimal JJ I-NP I-NP
DNA NN I-NP I-NP
sequences NNS I-NP I-NP
preferred VBN B-VP B-VP
by IN B-PP B-PP
each DT B-NP B-NP
homodimer NN I-NP I-NP
has VBZ B-VP B-VP
not RB I-VP I-VP
been VBN I-VP I-VP
addressed VBN I-VP I-VP
. . O O

Using VBG B-VP B-VP
purified VBN O I-VP
recombinant JJ O B-NP
p50 NN B-NP I-NP
, , O O
p65 NN B-NP B-NP
, , O O
and CC O I-CC
c-Rel NN B-NP B-NP
proteins NNS B-NP I-NP
, , O O
optimal JJ B-NP B-NP
DNA-binding JJ I-NP I-NP
motifs NNS I-NP I-NP
were VBD B-VP B-VP
selected VBN I-VP I-VP
from IN B-PP B-PP
a DT B-NP B-NP
pool NN I-NP I-NP
of IN B-PP B-PP
random JJ B-NP B-NP
oligonucleotides NNS I-NP I-NP
. . O O

Alignment NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
selected VBN I-NP I-NP
sequences NNS I-NP I-NP
allowed VBD B-VP B-VP
us PRP B-NP B-NP
to TO B-VP B-VP
predict VB I-VP I-VP
a DT B-NP B-NP
consensus NN I-NP I-NP
sequence NN I-NP I-NP
for IN B-PP B-PP
binding NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
individual JJ I-NP I-NP
homodimeric JJ I-NP I-NP
Rel-related JJ I-NP I-NP
proteins NNS I-NP I-NP
, , O O
and CC O I-CC
DNA-protein NN B-NP B-NP
binding NN I-NP I-NP
analysis NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
selected VBN I-NP I-NP
DNA NN I-NP I-NP
sequences VBZ I-NP B-VP
revealed VBD B-VP I-VP
sequence NN B-NP B-NP
specificity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
proteins NNS I-NP I-NP
. . O O

Contrary JJ B-PP B-ADVP
to TO I-PP B-PP
previous JJ B-NP B-NP
assumptions NNS I-NP I-NP
, , O O
we PRP B-NP B-NP
observed VBD B-VP B-VP
that IN B-SBAR B-PP
p65 NN B-NP B-NP
homodimers NNS I-NP I-NP
can MD B-VP B-VP
interact VB I-VP I-VP
with IN B-PP B-PP
a DT B-NP B-NP
subset NN I-NP I-NP
of IN B-PP B-PP
DNA NN B-NP B-NP
sequences VBZ I-NP B-VP
not RB B-VP I-VP
recognized VBN I-VP I-VP
by IN B-PP B-PP
p50 NN B-NP B-NP
homodimers NNS I-NP I-NP
. . O O

Differential JJ B-NP B-NP
binding NN I-NP I-NP
affinities NNS I-NP I-NP
were VBD B-VP B-VP
also RB I-VP I-VP
obtained VBN I-VP I-VP
with IN B-PP B-PP
p50- NN B-NP B-NP
and CC O I-CC
c-Rel-selected JJ B-ADJP B-NP
sequences NNS B-NP I-NP
. . O O

Using VBG B-VP B-VP
either CC O I-CC
a DT O B-NP
p50- NN B-NP I-NP
or CC O I-NP
p65-selected JJ B-ADJP I-NP
kappa NN B-NP I-NP
B NN I-NP I-NP
motif NN I-NP I-NP
, , O O
which WDT B-NP B-NP
displayed VBD B-VP B-VP
differential JJ B-NP B-NP
binding NN I-NP I-NP
with IN B-PP B-PP
respect NN I-PP B-NP
to TO I-PP B-PP
the DT B-NP B-NP
other JJ I-NP I-NP
protein NN I-NP I-NP
, , O O
little JJ B-NP B-ADJP
to TO I-NP B-PP
no DT I-NP B-NP
binding NN I-NP I-NP
was VBD B-VP B-VP
observed VBN I-VP I-VP
with IN B-PP B-PP
the DT B-NP B-NP
heterodimeric JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
complex NN I-NP I-NP
. . O O

Similarly RB B-ADVP B-ADVP
, , O O
in IN B-PP B-PP
transfection NN B-NP B-NP
experiments NNS I-NP I-NP
in IN B-PP B-PP
which WDT B-NP B-NP
the DT B-NP B-NP
selective JJ I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
binding NN I-NP I-NP
sites NNS I-NP I-NP
were VBD B-VP B-VP
used VBN I-VP I-VP
to TO B-VP B-VP
drive VB I-VP I-VP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
chloramphenicol NN I-NP I-NP
acetyltransferase NN I-NP I-NP
reporter NN I-NP I-NP
construct NN I-NP I-NP
, , O O
the DT O B-NP
p65- NN B-NP I-NP
and CC O I-CC
p50-selected JJ B-ADJP B-NP
motifs NNS B-NP I-NP
were VBD B-VP B-VP
activated VBN I-VP I-VP
only RB B-PP B-ADVP
in IN I-PP B-PP
the DT I-PP B-NP
presence NN I-PP I-NP
of IN I-PP B-PP
p65 NN B-NP B-NP
and CC O I-NP
p50/65 NN B-NP I-NP
( ( O O
a DT B-NP B-NP
chimeric JJ I-NP I-NP
protein NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
p50 NN B-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
domain NN I-NP I-NP
and CC O I-NP
p65 NN B-NP I-NP
activation NN I-NP I-NP
domain NN I-NP I-NP
) ) O O
expression NN B-NP B-NP
vectors NNS I-NP I-NP
, , O O
respectively RB B-ADVP B-ADVP
, , O O
and CC O I-CC
neither DT B-NP B-NP
demonstrated VBD B-VP B-VP
a DT B-NP B-NP
significant JJ I-NP I-NP
response NN I-NP I-NP
to TO B-PP B-PP
stimuli NNS B-NP B-NP
that WDT B-NP B-NP
induce VBP B-VP B-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
activity NN I-NP I-NP
. . O O

These DT B-NP B-NP
findings NNS I-NP I-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
interaction NN B-NP B-NP
of IN B-PP B-PP
both DT B-NP B-NP
subunits NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
heterodimeric JJ I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
complex NN I-NP I-NP
with IN B-PP B-PP
DNA NN B-NP B-NP
is VBZ B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
DNA NN B-NP B-NP
binding NN I-NP I-NP
and CC O I-CC
transcriptional JJ B-NP B-NP
activation NN I-NP I-NP
and CC O I-CC
suggest VBP B-VP B-VP
that IN B-SBAR B-PP
transcriptional JJ B-NP B-NP
activation NN I-NP I-NP
mediated VBN B-VP B-VP
by IN B-PP B-PP
the DT B-NP B-NP
individual JJ I-NP I-NP
rel-related JJ I-NP I-NP
proteins NNS I-NP I-NP
will MD B-VP B-VP
differ VB I-VP I-VP
dramatically RB B-ADVP B-ADVP
, , O O
depending VBG B-PP B-VP
on IN B-PP B-PP
the DT B-NP B-NP
specific JJ I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
motifs NNS I-NP I-NP
present JJ B-ADJP B-ADJP
. . O O

Characterization NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
new JJ I-NP I-NP
tissue-specific JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
binding VBG B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
simian JJ I-NP I-NP
virus NN I-NP I-NP
40 CD I-NP I-NP
enhancer NN I-NP I-NP
TC-II NN I-NP I-NP
( ( I-NP O
NF-kappa NN I-NP B-NP
B NN I-NP I-NP
) ) I-NP O
element NN I-NP B-NP
. . O O

We PRP B-NP B-NP
have VBP O B-VP
biochemically RB B-ADVP B-ADVP
and CC O I-ADVP
functionally RB B-ADVP I-ADVP
characterized VBN B-VP B-VP
a DT B-NP B-NP
new JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
, , O O
NP-TCII NN B-NP B-NP
, , O O
which WDT B-NP B-NP
is VBZ B-VP B-VP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
nuclei NNS B-NP B-NP
from IN B-PP B-PP
unstimulated JJ O B-NP
T NN B-NP I-NP
and CC O I-NP
B NN B-NP I-NP
lymphocytes NNS B-NP I-NP
but CC O I-CC
is VBZ B-VP B-VP
not RB I-VP I-VP
found VBN I-VP I-VP
in IN B-PP B-PP
nonhematopoietic JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

This DT B-NP B-NP
factor NN I-NP I-NP
has VBZ B-VP B-VP
a DT B-NP B-NP
DNA-binding JJ I-NP I-NP
specificity NN I-NP I-NP
similar JJ B-ADJP B-ADJP
to TO B-PP B-PP
that DT B-NP B-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
but CC O I-CC
is VBZ B-VP B-VP
unrelated JJ B-ADJP B-ADJP
to TO B-PP B-PP
this DT B-NP B-NP
or CC I-NP I-NP
other JJ I-NP I-NP
Rel NN I-NP I-NP
proteins NNS I-NP I-NP
by IN B-PP B-PP
functional JJ B-NP B-NP
and CC I-NP I-NP
biochemical JJ I-NP I-NP
criteria NNS I-NP I-NP
. . O O

It PRP B-NP B-NP
can MD B-VP B-VP
also RB I-VP I-VP
be VB I-VP I-VP
distinguished VBN I-VP I-VP
from IN B-PP B-PP
other JJ B-NP B-NP
previously RB I-NP I-NP
described VBN I-NP B-VP
lymphocyte-specific JJ I-NP B-NP
DNA-binding JJ I-NP I-NP
proteins NNS I-NP I-NP
. . O O

The DT B-NP B-NP
candidate NN I-NP I-NP
oncoprotein NN I-NP I-NP
Bcl-3 NN I-NP I-NP
is VBZ B-VP B-VP
an DT B-NP B-NP
antagonist NN I-NP I-NP
of IN B-PP B-PP
p50/NF-kappa NN B-NP B-NP
B-mediated JJ I-NP I-NP
inhibition NN I-NP I-NP
. . O O

The DT B-NP B-NP
candidate NN I-NP I-NP
oncogene NN I-NP I-NP
bcl-3 NN I-NP I-NP
was VBD B-VP B-VP
discovered VBN I-VP I-VP
as IN B-PP B-PP
a DT B-NP B-NP
translocation NN I-NP I-NP
into IN B-PP B-PP
the DT B-NP B-NP
immunoglobulin NN I-NP I-NP
alpha-locus NN I-NP I-NP
in IN B-PP B-PP
some DT B-NP B-NP
cases NNS I-NP I-NP
of IN B-PP B-PP
B-cell NN B-NP B-NP
chronic JJ I-NP B-NP
lymphocytic JJ I-NP I-NP
leukaemias NNS I-NP I-NP
. . O O

The DT B-NP B-NP
protein NN I-NP I-NP
Bcl-3 NN I-NP I-NP
contains VBZ B-VP B-VP
seven CD B-NP B-NP
so-called JJ I-NP I-NP
ankyrin NN I-NP I-NP
repeats NNS I-NP I-NP
. . O O

Similar JJ B-NP B-NP
repeat NN I-NP I-NP
motifs NNS I-NP I-NP
are VBP B-VP B-VP
found VBN I-VP I-VP
in IN B-PP B-PP
a DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
diverse JJ B-NP B-NP
regulatory JJ I-NP I-NP
proteins NNS I-NP I-NP
but CC O I-CC
the DT B-NP B-NP
motifs NNS I-NP I-NP
of IN B-PP B-PP
Bcl-3 NN B-NP B-NP
are VBP B-VP B-VP
most RBS B-ADJP B-ADVP
closely RB I-ADJP I-ADVP
related JJ I-ADJP B-ADJP
to TO B-PP B-PP
those DT B-NP B-NP
found VBN B-VP B-VP
in IN B-PP B-PP
I NN B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
proteins NNS I-NP I-NP
in IN B-PP B-PP
which WDT B-NP B-NP
the DT B-NP B-NP
ankyrin NN I-NP I-NP
repeat NN I-NP I-NP
domain NN I-NP I-NP
is VBZ B-VP B-VP
thought VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
directly RB I-VP B-ADJP
involved VBN I-VP I-ADJP
in IN B-PP B-PP
inhibition NN B-NP B-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
activity NN I-NP I-NP
. . O O

No DT B-NP B-NP
biological JJ I-NP I-NP
function NN I-NP I-NP
has VBZ B-VP B-VP
yet RB I-VP I-VP
been VBN I-VP I-VP
described VBN I-VP I-VP
for IN B-PP B-PP
Bcl-3 NN B-NP B-NP
, , O O
but CC O I-CC
it PRP B-NP B-NP
was VBD B-VP B-VP
noted VBN I-VP I-VP
recently RB B-ADVP B-ADVP
that IN B-SBAR B-SBAR
Bcl-3 NN B-NP B-NP
interferes VBZ B-VP B-VP
with IN B-PP B-PP
DNA-binding NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
p50 NN I-NP I-NP
subunit NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
in FW B-ADVP B-NP
vitro FW I-ADVP I-NP
. . O O

Here RB B-ADVP B-ADVP
we PRP B-NP B-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
Bcl-3 NN B-NP B-NP
can MD B-VP B-VP
aid VB I-VP I-VP
kappa NN B-NP B-NP
B NN I-NP I-NP
site-dependent JJ I-NP I-NP
transcription NN I-NP I-NP
in FW B-ADVP B-NP
vivo FW I-ADVP I-NP
by IN B-PP B-PP
counteracting VBG B-VP B-VP
the DT B-NP B-NP
inhibitory JJ I-NP I-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
p50/NF-kappa NN B-NP B-NP
B NN I-NP I-NP
homodimers NNS I-NP I-NP
. . O O

Bcl-3 NN B-NP B-NP
may MD B-VP B-VP
therefore RB I-VP I-VP
aid VB I-VP I-VP
activation NN B-NP B-NP
of IN B-PP B-PP
select JJ B-NP B-NP
NF-kappa NN I-NP I-NP
B-regulated JJ I-NP I-NP
genes NNS I-NP I-NP
, , O O
including VBG B-PP B-PP
those DT B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
. . O O

A DT B-NP B-NP
microtitre NN I-NP I-NP
assay NN I-NP I-NP
system NN I-NP I-NP
for IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
: : O O
decreased VBN B-NP B-NP
receptor NN I-NP I-NP
concentration NN I-NP I-NP
in IN B-PP B-PP
myocardial JJ B-NP B-NP
infarction NN I-NP I-NP
. . O O

A DT B-NP B-NP
major JJ I-NP I-NP
difficulty NN I-NP I-NP
in IN B-PP B-PP
determination NN B-NP B-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
sites NNS I-NP I-NP
is VBZ B-VP B-VP
the DT B-NP B-NP
very RB I-NP I-NP
complicated JJ I-NP I-NP
assay NN I-NP I-NP
procedure NN I-NP I-NP
. . O O

Therefore RB B-ADVP B-ADVP
, , O O
we PRP B-NP B-NP
describe VBP B-VP B-VP
a DT B-NP B-NP
microtitre NN I-NP I-NP
assay NN I-NP I-NP
system NN I-NP I-NP
for IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
which WDT B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
whole-cell JJ I-NP I-NP
competitive JJ I-NP I-NP
binding NN I-NP I-NP
radioassay NN I-NP I-NP
using VBG B-VP B-VP
(3H)-dexamethasone NN B-NP B-NP
as IN B-PP B-PP
radioligand NN B-NP B-NP
. . O O

This DT B-NP B-NP
modification NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
previously RB I-NP I-NP
described VBN I-NP I-NP
protocol NN I-NP I-NP
simplifies VBZ B-VP B-VP
and CC O I-VP
reduces VBZ B-VP I-VP
laboratory NN B-NP B-NP
work NN I-NP I-NP
and CC O I-CC
allows VBZ B-VP B-VP
assay NN B-NP B-NP
reproducibility NN I-NP I-NP
to TO B-VP B-VP
be VB I-VP I-VP
controlled VBN I-VP I-VP
more RBR B-ADVP B-ADVP
reliably RB I-ADVP I-ADVP
. . O O

Thus RB B-VP B-ADVP
enabled VBN I-VP B-VP
to TO I-VP I-VP
perform VB I-VP I-VP
the DT B-NP B-NP
test NN I-NP I-NP
on IN B-PP B-PP
multiple JJ B-NP B-NP
blood NN I-NP I-NP
samples NNS I-NP I-NP
in IN B-PP B-PP
parallel NN B-NP B-NP
, , O O
we PRP B-NP B-NP
investigated VBD B-VP B-VP
cardiac JJ B-NP B-NP
infarction NN I-NP I-NP
patients NNS I-NP I-NP
over IN B-PP B-PP
a DT B-NP B-NP
12-day JJ I-NP I-NP
period NN I-NP I-NP
to TO B-VP B-VP
test VB I-VP I-VP
if IN B-SBAR B-PP
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
binding NN I-NP I-NP
is VBZ B-VP B-VP
altered VBN I-VP I-VP
in IN B-PP B-PP
this DT B-NP B-NP
' [[DQS]] I-NP I-NP
stressful JJ I-NP I-NP
' [[DQE]] I-NP I-NP
disease NN I-NP I-NP
. . O O

On IN B-PP B-PP
the DT B-NP B-NP
first JJ I-NP I-NP
day NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
disease NN I-NP I-NP
, , O O
glucocorticoid NN B-NP B-NP
receptor NN I-NP I-NP
capacity NN I-NP I-NP
was VBD B-VP B-VP
significantly RB I-VP I-VP
decreased VBN I-VP I-VP
without IN B-PP B-PP
alteration NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
receptor-ligand JJ I-NP I-NP
affinity NN I-NP I-NP
, , O O
whereas IN O B-PP
on IN B-PP B-PP
days NNS B-NP B-NP
4 CD B-NP I-NP
and CC O I-NP
12 CD B-NP I-NP
the DT B-NP B-NP
number NN I-NP I-NP
of IN B-PP B-PP
receptor NN B-NP B-NP
sites NNS I-NP I-NP
was VBD B-VP B-VP
normal JJ B-ADJP B-ADJP
again RB B-ADVP B-ADVP
. . O O

This DT B-NP B-NP
result NN I-NP I-NP
fits VBZ B-VP B-VP
well RB B-ADVP B-ADVP
into IN B-PP B-PP
the DT B-NP B-NP
general JJ I-NP I-NP
observation NN I-NP I-NP
of IN B-PP B-PP
stress-induced JJ B-NP B-NP
down-regulation NN I-NP I-NP
of IN B-PP B-PP
immune JJ B-NP B-NP
responses NNS I-NP I-NP
. . O O

Regulation NN B-NP B-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
expression NN I-NP I-NP
during IN B-PP B-PP
induction NN B-NP B-NP
of IN B-PP B-PP
monocytic JJ B-NP B-NP
differentiation NN I-NP I-NP
by IN B-PP B-PP
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
. . O O

The DT B-NP B-NP
present JJ I-NP I-NP
work NN I-NP I-NP
has VBZ B-VP B-VP
examined VBN I-VP I-VP
the DT B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
, , O O
an DT B-NP B-NP
inhibitor NN I-NP I-NP
of IN B-PP B-PP
type NN O B-NP
1 CD B-NP I-NP
and CC O I-CC
2A NN B-NP B-NP
protein NN B-NP I-NP
phosphatases NNS I-NP I-NP
, , O O
on IN B-PP B-PP
the DT B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
expression NN I-NP I-NP
during IN B-PP B-PP
monocytic JJ B-NP B-NP
differentiation NN I-NP I-NP
of IN B-PP B-PP
U-937 NN B-NP B-NP
leukemia NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

The DT B-NP B-NP
results NNS I-NP I-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
treatment NN I-NP I-NP
is VBZ B-VP B-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
induction NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
differentiated VBN I-NP I-NP
monocyte NN I-NP I-NP
phenotype NN I-NP I-NP
characterized VBN B-VP B-VP
by IN B-PP B-PP
: : O O
( ( B-LST O
a LS I-LST I-LS
) ) O O
growth NN B-NP B-NP
arrest NN I-NP I-NP
; : O O
( ( B-LST O
b LS I-LST I-LS
) ) O O
increases NNS B-NP B-NP
in IN B-PP B-PP
Mac-1 NN B-NP B-NP
cell NN I-NP I-NP
surface NN I-NP I-NP
antigen NN I-NP I-NP
expression NN I-NP I-NP
; : O O
( ( B-LST O
c LS I-LST I-LS
) ) O O
down-regulation NN B-NP B-NP
of IN B-PP B-PP
c-myc NN B-NP B-NP
transcripts NNS I-NP I-NP
; : O O
and CC O I-CC
( ( B-LST O
d LS I-LST I-LS
) ) O O
induction NN B-NP B-NP
of IN B-PP B-PP
tumor NN B-NP B-NP
necrosis NN I-NP I-NP
factor NN I-NP I-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
. . O O

This DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
monocytic JJ B-NP B-NP
differentiation NN I-NP I-NP
was VBD B-VP B-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
transient JJ B-NP B-NP
increases NNS I-NP I-NP
in IN B-PP B-PP
c-jun NN B-NP B-NP
mRNA NN I-NP I-NP
levels NNS I-NP I-NP
, , O O
which WDT B-NP B-NP
were VBD B-VP B-VP
maximal JJ B-ADJP B-ADJP
at IN B-PP B-PP
6 CD B-NP B-NP
h NN I-NP I-NP
. . O O

Similar JJ B-NP B-NP
effects NNS I-NP I-NP
were VBD B-VP B-VP
obtained VBN I-VP I-VP
for IN B-PP B-PP
the DT B-NP B-NP
c-fos NN I-NP I-NP
gene NN I-NP I-NP
. . O O

Run-on JJ B-NP B-NP
analysis NN I-NP I-NP
demonstrated VBD B-VP B-VP
detectable JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
transcription NN I-NP I-NP
in IN B-PP B-PP
U-937 NN B-NP B-NP
cells NNS I-NP I-NP
and CC O I-CC
that IN B-SBAR B-SBAR
this DT B-NP B-NP
rate NN I-NP I-NP
is VBZ B-VP B-VP
increased VBN I-VP I-VP
approximately RB B-ADVP B-ADVP
40-fold RB I-ADVP B-ADVP
following VBG B-PP B-VP
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
exposure NN I-NP I-NP
. . O O

c-jun NN B-NP B-NP
mRNA NN I-NP I-NP
levels NNS I-NP I-NP
were VBD B-VP B-VP
superinduced VBN I-VP I-VP
in IN B-PP B-PP
cells NNS B-NP B-NP
treated VBN B-VP B-VP
with IN B-PP B-PP
both CC O I-CC
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
and CC O I-NP
cycloheximide NN B-NP I-NP
, , O O
whereas IN O B-PP
inhibition NN B-NP B-NP
of IN B-PP B-PP
protein NN B-NP B-NP
synthesis NN I-NP I-NP
had VBD B-VP B-VP
little JJ O B-ADJP
, , O O
if IN B-SBAR B-SBAR
any DT B-ADJP B-NP
, , O O
effect NN B-NP B-NP
on IN B-PP B-PP
okadaic JJ B-NP B-NP
acid-induced JJ I-NP I-NP
c-jun NN I-NP I-NP
transcription NN I-NP I-NP
. . O O

The DT B-NP B-NP
half-life NN I-NP I-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
mRNA NN I-NP I-NP
was VBD B-VP B-VP
similar JJ B-ADJP B-ADJP
( ( O O
45-50 CD B-NP B-NP
min NN I-NP I-NP
) ) O O
in IN B-PP B-PP
both CC B-NP I-CC
untreated JJ I-NP B-NP
and CC I-NP I-NP
okadaic JJ I-NP I-NP
acid-induced JJ I-NP I-NP
cells NNS I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
treatment NN B-NP B-NP
with IN B-PP B-PP
both DT B-NP B-NP
okadaic JJ B-NP I-NP
acid NN I-NP I-NP
and CC O I-NP
cycloheximide NN B-NP I-NP
was VBD B-VP B-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
stabilization NN B-NP B-NP
( ( O O
t NN B-NP B-NP
1/2 CD I-NP I-NP
= JJ B-VP I-NP
90 CD B-NP I-NP
min NN I-NP I-NP
) ) O O
of IN B-PP B-PP
c-jun NN B-NP B-NP
transcripts NNS I-NP I-NP
. . O O

Taken VBN B-VP B-VP
together RB B-ADVP B-ADVP
, , O O
these DT B-NP B-NP
findings NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
induction NN I-NP I-NP
of IN B-PP B-PP
c-jun NN B-NP B-NP
transcription NN I-NP I-NP
by IN B-PP B-PP
okadaic JJ B-NP B-NP
acid NN I-NP I-NP
is VBZ B-VP B-VP
controlled VBN I-VP I-VP
primarily RB B-ADVP B-ADVP
by IN B-PP B-PP
a DT B-NP B-NP
transcriptional JJ I-NP I-NP
mechanism NN I-NP I-NP
. . O O

Since IN B-SBAR B-PP
previous JJ B-NP B-NP
studies NNS I-NP I-NP
have VBP B-VP B-VP
demonstrated VBN I-VP I-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
c-jun NN I-NP I-NP
gene NN I-NP I-NP
is VBZ B-VP B-VP
autoinduced VBN I-VP I-VP
by IN B-PP B-PP
Jun/AP-1 NN B-NP B-NP
, , O O
we PRP B-NP B-NP
also RB B-ADVP B-ADVP
studied VBD B-VP B-VP
transcription NN B-NP B-NP
of IN B-PP B-PP
c-jun NN O B-NP
promoter NN O I-NP
( ( O O
positions NNS B-NP B-NP
-132/+170 CD B-NP I-NP
) ) O O
-reporter JJ B-NP B-NP
gene NN I-NP I-NP
constructs NNS I-NP I-NP
with IN B-PP B-PP
and CC B-PP I-PP
without IN B-PP I-PP
a DT B-NP B-NP
mutated VBN I-NP I-NP
AP-1 NN I-NP I-NP
element NN I-NP I-NP
. . O O

( ( O O
ABSTRACT NN B-NP B-NP
TRUNCATED VBN B-VP B-VP
AT IN B-PP B-PP
250 CD B-NP B-NP
WORDS NNS I-NP I-NP
) ) O O

Activation NN B-NP B-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
by IN B-PP B-PP
interleukin NN B-NP B-NP
2 CD I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
blood NN I-NP I-NP
monocytes NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
report VBP B-VP B-VP
here RB B-ADVP B-ADVP
that IN B-SBAR B-PP
interleukin NN B-NP B-NP
2 CD I-NP I-NP
( ( O O
IL-2 NN B-NP B-NP
) ) O O
acts VBZ B-VP B-VP
on IN B-PP B-PP
human JJ B-NP B-NP
blood NN I-NP I-NP
monocytes NNS I-NP I-NP
by IN B-PP B-PP
enhancing VBG B-VP B-VP
binding NN B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
to TO B-PP B-PP
its PRP$ B-NP B-NP
consensus NN I-NP I-NP
sequence NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
5' JJ I-NP I-NP
regulatory JJ I-NP I-NP
enhancer NN I-NP I-NP
region NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
IL-2 NN I-NP I-NP
receptor NN I-NP I-NP
alpha NN I-NP I-NP
chain NN I-NP I-NP
( ( O O
p55 NN B-NP B-NP
) ) O O
. . O O

Similarly RB B-ADVP B-ADVP
, , O O
IL-2 NN B-NP B-NP
activates VBZ B-VP B-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
monocytic JJ I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
U NN I-NP I-NP
937 CD I-NP B-NP
, , B-PP O
but CC I-PP I-CC
not RB B-PP I-RB
in IN I-PP B-PP
resting VBG B-NP B-VP
human JJ I-NP B-NP
T-cells NNS I-NP I-NP
. . O O

This DT B-NP B-NP
effect NN I-NP I-NP
is VBZ B-VP B-VP
detectable JJ B-ADJP B-ADJP
within IN B-PP B-PP
15 CD B-NP B-NP
min NN I-NP I-NP
and CC O I-CC
peaks VBZ B-VP B-VP
1 CD B-NP B-NP
h NN I-NP I-NP
after IN B-PP B-PP
exposure NN B-NP B-NP
to TO B-PP B-PP
IL-2 NN B-NP B-NP
. . O O

Enhanced VBN B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
is VBZ B-VP B-VP
followed VBN I-VP I-VP
by IN B-PP B-PP
functional JJ B-NP B-NP
activation NN I-NP I-NP
in IN B-PP B-PP
that IN B-NP B-NP
inducibility NN B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
IL-2 NN I-NP I-NP
receptor NN I-NP I-NP
alpha NN I-NP I-NP
chain NN I-NP I-NP
is VBZ B-VP B-VP
mediated VBN I-VP I-VP
by IN B-PP B-PP
enhanced VBN B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
binding NN I-NP I-NP
and CC O I-CC
that IN B-NP B-SBAR
a DT B-NP B-NP
heterologous JJ I-NP I-NP
promoter NN I-NP I-NP
containing VBG B-VP B-VP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
consensus NN I-NP I-NP
sequence NN I-NP I-NP
( ( O O
-291 CD B-NP B-NP
to TO O B-PP
-245 CD B-NP B-NP
) ) O O
of IN B-PP B-PP
the DT B-NP B-NP
IL-2 NN I-NP I-NP
receptor NN I-NP I-NP
alpha NN I-NP I-NP
chain NN I-NP I-NP
gene NN I-NP I-NP
is VBZ B-VP B-VP
activated VBN I-VP I-VP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
IL-2 NN B-NP B-NP
is VBZ B-VP B-VP
capable JJ B-ADJP B-ADJP
of IN B-PP B-PP
increasing VBG B-VP B-VP
transcript NN B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
p50 NN I-NP I-NP
gene NN I-NP I-NP
coding VBG B-VP B-VP
for IN B-PP B-PP
the DT B-NP B-NP
p50 NN I-NP I-NP
subunit NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
, , O O
whereas IN O B-PP
mRNA NN B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
p65 NN I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
gene NN I-NP I-NP
remained VBD B-VP B-VP
unchanged JJ B-ADJP B-ADJP
. . O O

Single JJ B-NP B-NP
point NN I-NP I-NP
estimation NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
in IN B-PP B-PP
lymphocytes NNS B-NP B-NP
of IN B-PP B-PP
normal JJ B-NP B-NP
subjects NNS I-NP I-NP
and CC B-PP I-CC
of IN B-PP B-PP
children NNS B-NP B-NP
under IN B-PP B-PP
long JJ B-NP B-NP
term NN I-NP I-NP
glucocorticoid NN I-NP I-NP
treatment NN I-NP I-NP
. . O O

A DT B-NP B-NP
single JJ I-NP I-NP
point NN I-NP I-NP
assay NN I-NP I-NP
of IN B-PP B-PP
glucocorticoid NN B-NP B-NP
receptors NNS I-NP I-NP
( ( O O
GR NN B-NP B-NP
) ) O O
in IN B-PP B-PP
human JJ B-NP B-NP
lymphocytes NNS I-NP I-NP
based VBN B-PP B-VP
on IN B-PP B-PP
the DT B-NP B-NP
measurement NN I-NP I-NP
of IN B-PP B-PP
specific JJ B-NP B-NP
dexamethasone NN I-NP I-NP
binding NN I-NP I-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
developed VBN I-VP I-VP
and CC O I-VP
compared VBN B-VP I-VP
with IN B-PP B-PP
a DT B-NP B-NP
common JJ I-NP I-NP
multi-point JJ I-NP I-NP
Scatchard NN I-NP I-NP
analysis NN I-NP I-NP
. . O O

The DT B-NP B-NP
assay NN I-NP I-NP
conditions NN I-NP I-NP
- : O O
concentration NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
ligand NN I-NP I-NP
20 CD B-NP I-NP
nmol/l NN I-NP I-NP
, , O O
incubation NN B-NP B-NP
time NN I-NP I-NP
2 CD I-NP B-NP
h NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
cell NN I-NP I-NP
count NN I-NP I-NP
2-6 CD I-NP B-NP
mil. CD I-NP I-NP
cells/tube NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
assay NN I-NP I-NP
volume NN I-NP I-NP
0.25 CD I-NP B-NP
ml NN I-NP I-NP
were VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
optimal JJ B-ADJP B-ADJP
. . O O

An DT B-NP B-NP
attempt NN I-NP I-NP
was VBD B-VP B-VP
also RB I-VP I-VP
undertaken VBN I-VP I-VP
to TO B-VP I-VP
use VB I-VP I-VP
a DT B-NP B-NP
cell NN I-NP I-NP
harvester NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
separation NN I-NP I-NP
of IN B-PP B-PP
cells NNS B-NP B-NP
from IN B-PP B-PP
unbound JJ B-NP B-NP
ligand NN I-NP I-NP
. . O O

Though IN B-SBAR B-SBAR
specifically RB B-NP B-NP
bound VBN I-NP I-NP
dexamethasone NN I-NP I-NP
measured VBN B-VP B-VP
by IN B-PP B-PP
whole-cell JJ B-NP B-NP
assay NN I-NP I-NP
and CC O I-CC
that DT B-NP B-NP
using VBG B-VP I-NP
cell NN B-NP I-NP
harvester NN I-NP I-NP
correlated VBD B-VP B-VP
well RB B-ADVP B-ADVP
, , O O
almost RB B-PP B-NP
by IN I-PP I-NP
one CD B-NP I-NP
order NN I-NP I-NP
lower JJR B-NP B-NP
values NNS I-NP I-NP
obtained VBN B-VP B-VP
with IN B-PP B-PP
the DT B-NP B-NP
latter JJ I-NP I-NP
method NN I-NP I-NP
render VBP B-VP B-VP
it PRP B-NP B-NP
non-applicable JJ B-ADJP B-ADJP
for IN B-PP B-PP
receptor NN B-NP B-NP
quantitation NN I-NP I-NP
. . O O

The DT B-NP B-NP
results NNS I-NP I-NP
from IN B-PP B-PP
9 CD B-NP B-NP
healthy JJ I-NP I-NP
volunteers NNS I-NP I-NP
( ( O O
average JJ B-NP B-NP
GR NN I-NP I-NP
concentration NN I-NP I-NP
7131 CD B-NP B-NP
+/- CC I-NP I-NP
1256 CD I-NP I-NP
sites/cell NNS I-NP I-NP
) ) O O
correlated VBD B-VP B-VP
excellently RB B-ADVP B-ADVP
with IN B-PP B-PP
those DT B-NP B-NP
obtained VBN B-VP B-VP
by IN B-PP B-PP
the DT B-NP B-NP
Scatchard NN I-NP I-NP
analysis NN I-NP I-NP
. . O O

The DT B-NP B-NP
single JJ I-NP I-NP
point NN I-NP I-NP
assay NN I-NP I-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
also RB I-VP I-VP
applied VBN I-VP I-VP
for IN B-PP B-PP
determination NN B-NP B-NP
of IN B-PP B-PP
GH NN B-NP B-NP
in IN B-PP B-PP
10 CD B-NP B-NP
children NNS I-NP I-NP
treated VBN B-VP B-VP
with IN B-PP B-PP
large JJ B-NP B-NP
doses NNS I-NP I-NP
of IN B-PP B-PP
prednisone NN B-NP B-NP
. . O O

The DT B-NP B-NP
average JJ I-NP I-NP
values NNS I-NP I-NP
from IN B-PP B-PP
healthy JJ B-NP B-NP
volunteers NNS I-NP I-NP
did VBD B-VP B-VP
not RB I-VP I-VP
differ VB I-VP I-VP
significantly RB B-ADVP B-ADVP
from IN B-PP B-PP
those DT B-NP B-NP
found VBN B-VP B-VP
in IN B-PP B-PP
these DT B-NP B-NP
children NNS I-NP I-NP
, , O O
though RB O B-ADVP
much RB B-NP B-NP
broader JJR I-NP I-NP
range NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
in IN B-PP B-PP
patients NNS B-NP B-NP
. . O O

A DT B-NP B-NP
novel JJ I-NP I-NP
B NN I-NP I-NP
cell-derived JJ I-NP I-NP
coactivator NN I-NP I-NP
potentiates VBZ B-VP B-VP
the DT B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
immunoglobulin NN B-NP B-NP
promoters NNS I-NP I-NP
by IN B-PP B-PP
octamer-binding JJ B-NP B-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
. . O O

A DT B-NP B-NP
novel JJ I-NP I-NP
B NN I-NP I-NP
cell-restricted JJ I-NP I-NP
activity NN I-NP I-NP
, , O O
required VBN B-VP B-VP
for IN B-PP B-PP
high JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
octamer/Oct-dependent JJ B-NP B-NP
transcription NN I-NP I-NP
from IN B-PP B-PP
an DT O B-NP
immunoglobulin NN B-NP I-NP
heavy JJ I-NP I-NP
chain NN I-NP I-NP
( ( O O
IgH NN B-NP I-NN
) ) O O
promoter NN B-NP B-NP
, , O O
was VBD B-VP B-VP
detected VBN I-VP I-VP
in IN B-PP B-PP
an DT B-NP B-NP
in FW I-NP B-NP
vitro FW I-NP I-NP
system NN I-NP I-NP
consisting VBG B-VP B-VP
of IN B-PP B-PP
HeLa NN B-NP B-NP
cell-derived JJ I-NP I-NP
extracts NNS I-NP I-NP
complemented VBN B-VP B-VP
with IN B-PP B-PP
fractionated VBN B-NP B-NP
B NN I-NP I-NP
cell NN I-NP I-NP
nuclear JJ I-NP I-NP
proteins NNS I-NP I-NP
. . O O

The DT B-NP B-NP
factor NN I-NP I-NP
responsible JJ B-ADJP I-NP
for IN B-PP B-PP
this DT B-NP B-NP
activity NN I-NP I-NP
was VBD B-VP B-VP
designated VBN I-VP I-VP
Oct NN B-NP B-NP
coactivator NN I-NP I-NP
from IN B-PP B-PP
B NN B-NP B-NP
cells NNS I-NP I-NP
( ( O O
OCA-B NN B-NP B-NP
) ) O O
. . O O

OCA-B NN B-NP B-NP
stimulates VBZ B-VP B-VP
the DT B-NP B-NP
transcription NN I-NP I-NP
from IN B-PP B-PP
an DT B-NP B-NP
IgH NN I-NP I-NP
promoter NN I-NP I-NP
in IN B-PP B-PP
conjunction NN I-PP B-NP
with IN I-PP B-PP
either CC O I-CC
Oct-1 NN B-NP B-NP
or CC O I-NP
Oct-2 NN B-NP I-NP
but CC O I-CC
shows VBZ B-VP B-VP
no DT B-NP B-NP
significant JJ I-NP I-NP
effect NN I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
octamer/Oct-dependent JJ I-NP I-NP
transcription NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
ubiquitously RB I-NP I-NP
expressed VBN I-NP I-NP
histone NN I-NP I-NP
H2B NN I-NP I-NP
promoter NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
transcription NN I-NP I-NP
of IN B-PP B-PP
USF- NN B-NP B-NP
and CC O I-CC
Sp1-regulated JJ B-ADJP B-NP
promoters NNS B-NP I-NP
. . O O

Taken VBN B-VP B-VP
together RB B-ADVP B-ADVP
, , O O
our PRP$ B-NP B-NP
results NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
OCA-B NN B-NP B-NP
is VBZ B-VP B-VP
a DT O B-NP
tissue- NN B-NP I-NP
, , O O
promoter- NN B-NP B-NP
, , O O
and CC O I-CC
factor-specific JJ B-ADJP B-NP
coactivator NN B-NP I-NP
and CC O I-CC
that IN B-SBAR B-SBAR
OCA-B NN B-NP B-NP
may MD B-VP B-VP
be VB I-VP I-VP
a DT B-NP B-NP
major JJ I-NP I-NP
determinant NN I-NP I-NP
for IN B-PP B-PP
B NN B-NP B-NP
cell-specific JJ I-NP I-NP
activation NN I-NP I-NP
of IN B-PP B-PP
immunoglobulin NN B-NP B-NP
promoters NNS I-NP I-NP
. . O O

In IN B-PP B-PP
light NN I-PP B-NP
of IN I-PP B-PP
the DT B-NP B-NP
evidence NN I-NP I-NP
showing VBG B-VP B-VP
physical JJ B-NP B-NP
and CC I-NP I-NP
functional JJ I-NP I-NP
interactions NNS I-NP I-NP
between IN B-PP B-PP
Oct NN B-NP B-NP
factors NNS I-NP I-NP
and CC O I-NP
OCA-B NN B-NP I-NP
, , O O
we PRP B-NP B-NP
propose VBP B-VP B-VP
a DT B-NP B-NP
mechanism NN I-NP I-NP
of IN B-PP B-PP
action NN B-NP B-NP
for IN B-PP B-PP
OCA-B NN B-NP B-NP
and CC O I-CC
discuss VBP B-VP B-VP
the DT B-NP B-NP
implications NNS I-NP I-NP
of IN B-PP B-PP
OCA-B NN B-NP B-NP
for IN B-PP B-PP
the DT B-NP B-NP
transcriptional JJ I-NP I-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
other JJ B-NP B-NP
tissue-specific JJ I-NP I-NP
promoters NNS I-NP I-NP
. . O O

The DT B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
tumor NN I-NP I-NP
necrosis NN I-NP I-NP
factor NN I-NP I-NP
alpha NN I-NP I-NP
promoter NN I-NP I-NP
region NN I-NP I-NP
in IN B-PP B-PP
macrophage NN B-NP B-NP
, , O O
T NN B-NP B-NP
cell NN I-NP I-NP
, , O O
and CC O I-CC
B NN B-NP B-NP
cell NN I-NP I-NP
lines NNS B-NP I-NP
. . O O

The DT B-NP B-NP
1311-base JJ I-NP I-NP
pair NN I-NP I-NP
human JJ I-NP I-NP
tumor NN I-NP I-NP
necrosis NN I-NP I-NP
factor NN I-NP I-NP
( ( I-NP O
TNF NN I-NP I-NN
) ) I-NP O
alpha NN I-NP B-NP
promoter NN I-NP I-NP
region NN I-NP I-NP
was VBD B-VP B-VP
fused VBN I-VP I-VP
to TO B-PP B-PP
the DT O B-NP
luciferase NN B-NP I-NP
( ( O O
Luc NN B-NP I-NN
) ) O O
reporter NN B-NP B-NP
gene NN I-NP I-NP
and CC O I-CC
studied VBN B-VP B-VP
in IN B-PP B-PP
a DT B-NP B-NP
transient JJ I-NP I-NP
transfection NN I-NP I-NP
system NN I-NP I-NP
in IN B-PP B-PP
three CD B-NP B-NP
TNF NN I-NP I-NP
producing NN I-NP I-NP
cell NN I-NP I-NP
lines NNS I-NP I-NP
, , O O
the DT B-NP B-NP
U937 NN I-NP I-NP
macrophage NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
, , O O
the DT B-NP B-NP
MLA NN I-NP I-NP
144 CD I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
, , O O
and CC O I-CC
the DT B-NP B-NP
729-6 CD I-NP I-NP
B NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
. . O O

This DT B-NP B-NP
full JJ I-NP I-NP
length NN I-NP I-NP
promoter NN I-NP I-NP
construct NN I-NP I-NP
can MD B-VP B-VP
be VB I-VP I-VP
induced VBN I-VP I-VP
by IN B-PP B-PP
phorbol NN B-NP B-NP
13-myristate NN I-NP I-NP
acetate NN I-NP I-NP
( ( O O
PMA NN B-NP B-NP
) ) O O
in IN B-PP B-PP
each DT B-NP B-NP
of IN B-PP B-PP
these DT B-NP B-NP
cell NN I-NP I-NP
types NNS I-NP I-NP
. . O O

Analysis NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
series NN I-NP I-NP
of IN B-PP B-PP
5'-truncations NNS B-NP B-NP
showed VBD B-VP B-VP
several JJ B-NP B-NP
peaks NNS I-NP I-NP
of IN B-PP B-PP
basal JJ B-NP B-NP
and CC I-NP I-NP
PMA NN I-NP I-NP
induced JJ I-NP I-NP
activity NN I-NP I-NP
suggesting VBG B-VP B-VP
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
several JJ B-NP B-NP
positive JJ I-NP I-NP
and CC I-NP I-NP
negative JJ I-NP I-NP
regulatory JJ I-NP I-NP
elements NNS I-NP I-NP
. . O O

A DT B-NP B-NP
PMA NN I-NP I-NP
responsive JJ I-NP I-NP
element NN I-NP I-NP
was VBD B-VP B-VP
localized JJ I-VP B-ADJP
to TO B-PP B-PP
a DT B-NP B-NP
region NN I-NP I-NP
between IN B-PP B-PP
-95 CD B-NP B-NP
and CC O I-CC
-36 CD B-NP B-NP
bp NN B-NP I-NP
relative JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
start NN I-NP I-NP
site NN I-NP I-NP
. . O O

Within IN B-PP B-PP
this DT B-NP B-NP
region NN I-NP I-NP
, , O O
single JJ B-NP B-NP
AP-2- NN I-NP I-NP
and CC I-NP I-CC
AP-1-like JJ I-NP B-NP
consensus NN I-NP I-NP
sequences NNS I-NP I-NP
were VBD B-VP B-VP
noted VBN I-VP I-VP
. . O O

These DT O B-NP
AP-2 NN B-NP I-NP
and CC O I-NP
AP-1 NN B-NP I-NP
sites NNS B-NP I-NP
were VBD B-VP B-VP
each DT I-VP B-NP
modified VBN I-VP B-VP
with IN B-PP B-PP
a DT B-NP B-NP
double JJ I-NP I-NP
point NN I-NP I-NP
mutation NN I-NP I-NP
. . O O

A DT O B-NP
modest JJ O I-NP
( ( O O
20-50 CD B-NP B-NP
% NN I-NP I-NP
) ) O O
reduction NN B-NP B-NP
in IN B-PP B-PP
TNF NN B-NP B-NP
promoter NN I-NP I-NP
activity NN I-NP I-NP
was VBD B-VP B-VP
observed VBN I-VP I-VP
with IN B-PP B-PP
the DT B-NP B-NP
AP-2 NN I-NP I-NP
site NN I-NP I-NP
mutation NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
mutation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
site NN I-NP I-NP
markedly RB B-ADVP B-ADVP
diminished VBD B-VP B-VP
both CC B-NP I-CC
the DT I-NP B-NP
basal JJ I-NP I-NP
and CC I-NP I-NP
PMA-activated JJ I-NP I-NP
promoter NN I-NP I-NP
activity NN I-NP I-NP
. . O O

Also RB B-ADVP B-NP
co-transfections NNS B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
wild-type JJ I-NP I-NP
promoter NN I-NP I-NP
construct NN I-NP I-NP
with IN B-PP B-PP
an DT B-NP B-NP
AP-1/c-jun NN I-NP I-NP
expression NN I-NP I-NP
vector NN I-NP I-NP
resulted VBD B-VP B-VP
in IN B-PP B-PP
augmented JJ B-NP B-NP
basal JJ I-NP I-NP
and CC I-NP I-NP
PMA-induced JJ I-NP I-NP
promoter NN I-NP I-NP
activity NN I-NP I-NP
. . O O

Redox NN B-NP B-NP
status NN I-NP I-NP
of IN B-PP B-PP
cells NNS B-NP B-NP
influences VBZ B-VP B-VP
constitutive JJ B-NP B-ADJP
or CC I-NP I-CC
induced VBN I-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
translocation NN I-NP I-NP
and CC O I-NP
HIV NN B-NP I-NP
long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
activity NN I-NP I-NP
in IN B-PP B-PP
human JJ O B-NP
T NN B-NP I-NP
and CC O I-CC
monocytic JJ B-ADJP B-NP
cell NN B-NP I-NP
lines NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
tested VBN I-VP I-VP
the DT B-NP B-NP
hypothesis NN I-NP I-NP
that IN B-SBAR B-PP
cellular JJ B-NP B-NP
activation NN I-NP I-NP
events NNS I-NP I-NP
occurring VBG B-VP B-VP
in IN B-PP B-PP
T NN B-NP B-NP
lymphocytes NNS I-NP I-NP
and CC O I-CC
monocytes NNS B-NP B-NP
and CC O I-CC
mediated VBN B-VP B-VP
through IN B-PP B-PP
translocation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
are VBP B-VP B-VP
dependent JJ B-ADJP B-ADJP
upon IN B-PP B-PP
the DT B-NP B-NP
constitutive JJ I-NP I-NP
redox NN I-NP I-NP
status NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
cells NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
used VBD B-VP B-VP
phenolic JJ B-NP B-NP
, , I-NP O
lipid-soluble JJ I-NP I-NP
, , I-NP O
chain-breaking JJ I-NP I-NP
antioxidants NNS I-NP I-NP
( ( O O
butylated VBN B-NP B-NP
hydroxyanisole NN I-NP I-NP
( ( O O
BHA NN B-NP B-NP
) ) O O
, , O O
nordihydroquairetic JJ B-NP B-NP
acid NN I-NP I-NP
, , O O
or CC O I-CC
alpha-tocopherol NN B-NP B-NP
( ( O O
vitamin NN B-NP I-NP
E NN I-NP I-NP
) ) O O
to TO B-VP B-VP
show VB I-VP I-VP
that IN B-SBAR B-SBAR
peroxyl JJ B-NP B-NP
radical JJ I-NP I-NP
scavenging NN I-NP I-NP
in IN B-PP B-PP
unstimulated JJ O B-NP
and CC O I-NP
PMA- NN B-NP I-NP
or CC O I-CC
TNF-stimulated JJ B-ADJP B-NP
cells NNS B-NP I-NP
blocks VBZ B-VP B-VP
the DT B-NP B-NP
functions NNS I-NP I-NP
depending VBG B-PP B-VP
on IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
activation NN I-NP I-NP
. . O O

BHA NN B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
suppress VB I-VP I-VP
not RB B-CONJP B-ADVP
only RB I-CONJP I-ADVP
PMA- NN B-NP B-NP
or CC O I-NP
TNF-induced JJ B-ADJP I-NP
, , O O
but CC B-CONJP I-CC
also RB I-CONJP B-ADVP
constitutive JJ B-ADJP B-ADJP
, , B-NP O
HIV-enhancer JJ I-NP B-NP
activity NN I-NP I-NP
concomitant JJ B-ADJP B-ADJP
to TO B-PP B-PP
an DT B-NP B-NP
inhibition NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
in IN B-PP B-PP
both CC O I-CC
lymphoblastoid JJ O B-NP
T NN O I-NP
( ( O O
J.Jhan NN B-NP B-NP
) ) O O
and CC O I-CC
monocytic JJ O B-NP
( ( O O
U937 NN B-NP I-NP
) ) O O
cell NN B-NP I-NP
lines NNS I-NP I-NP
. . O O

This DT B-NP B-NP
was VBD B-VP B-VP
also RB B-ADVP B-ADJP
true JJ B-ADJP I-ADJP
for IN B-PP B-PP
KBF NN B-NP B-NP
( ( O O
p50 NN B-NP B-NP
homodimer NN I-NP I-NP
) ) O O
binding NN B-NP B-NP
activity NN I-NP I-NP
in IN B-PP B-PP
U937 NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Secretion NN B-NP B-NP
of IN B-PP B-PP
TNF NN B-NP B-NP
, , O O
the DT B-NP B-NP
product NN I-NP I-NP
of IN B-PP B-PP
another DT B-NP B-NP
NF-kappa NN I-NP I-NP
B-dependent JJ I-NP I-NP
gene NN I-NP I-NP
, , O O
was VBD B-VP B-VP
abolished VBN I-VP I-VP
by IN B-PP B-PP
BHA NN B-NP B-NP
in IN B-PP B-PP
PMA-stimulated JJ B-NP B-NP
U937 NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

The DT B-NP B-NP
anti-oxidative JJ I-NP I-NP
effect NN I-NP I-NP
of IN B-PP B-PP
BHA NN B-NP B-NP
was VBD B-VP B-VP
accompanied VBN I-VP I-VP
by IN B-PP B-PP
an DT B-NP B-NP
increase NN I-NP I-NP
in IN B-PP B-PP
thiol NN B-NP B-NP
, , O O
but CC B-CONJP I-CC
not RB I-CONJP B-NP
glutathione NN B-NP I-NP
, , O O
content NN B-NP B-NP
in IN B-PP B-PP
stimulated VBN B-NP B-NP
and CC I-NP I-NP
unstimulated JJ I-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
, , O O
whereas IN O B-PP
TNF NN B-NP B-NP
stimulation NN I-NP I-NP
itself PRP B-NP B-NP
barely RB B-ADVP B-ADVP
modified VBD B-VP B-VP
the DT B-NP B-NP
cellular JJ I-NP I-NP
thiol NN I-NP I-NP
level NN I-NP I-NP
. . O O

Oxidative JJ B-NP B-NP
stress NN I-NP I-NP
obtained VBN B-VP B-VP
by IN B-PP B-PP
the DT B-NP B-NP
addition NN I-NP I-NP
of IN B-PP B-PP
H2O2 NN B-NP B-NP
to TO B-PP B-PP
the DT B-NP B-NP
culture NN I-NP I-NP
medium NN I-NP I-NP
of IN B-PP B-PP
J.Jhan NN B-NP B-NP
or CC O I-NP
U937 NN B-NP I-NP
cells NNS B-NP I-NP
could MD B-VP B-VP
not RB O I-VP
by IN B-PP B-PP
itself PRP B-NP B-NP
induce VB B-VP B-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
activation NN I-NP I-NP
. . O O

These DT B-NP B-NP
observations NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-PP
TNF NN B-NP B-NP
and CC O I-NP
PMA NN B-NP I-NP
do VBP B-VP B-VP
not RB I-VP I-VP
lead VB I-VP I-VP
to TO B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
activation NN I-NP I-NP
through IN B-PP B-PP
induction NN B-NP B-NP
of IN B-PP B-PP
changes NNS B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
cell NN I-NP I-NP
redox NN I-NP I-NP
status NN I-NP I-NP
. . O O

Rather RB B-ADVP B-ADVP
, , O O
TNF NN B-NP B-NP
and CC O I-NP
PMA NN B-NP I-NP
can MD B-VP B-VP
exert VB I-VP I-VP
their PRP$ B-NP B-NP
effect NN I-NP I-NP
only RB B-SBAR B-ADVP
if IN I-SBAR B-PP
cells NNS B-NP B-NP
are VBP B-VP B-VP
in IN B-PP B-PP
an DT B-NP B-NP
appropriate JJ I-NP I-NP
redox NN I-NP I-NP
status NN I-NP I-NP
, , O O
because IN B-SBAR B-PP
prior JJ B-NP B-NP
modification NN I-NP I-NP
toward IN B-PP B-PP
reduction NN B-NP B-NP
with IN B-PP B-PP
BHA NN B-NP B-NP
treatment NN I-NP I-NP
prevents VBZ B-VP B-VP
this DT I-VP B-NP
activation NN I-VP I-NP
. . O O

It PRP B-NP B-NP
appears VBZ B-VP B-VP
that IN B-SBAR B-SBAR
a DT B-NP B-NP
basal JJ I-NP I-NP
redox NN I-NP I-NP
equilibrium NN I-NP I-NP
tending VBG B-VP B-VP
toward IN B-PP B-PP
oxidation NN B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
prerequisite NN I-NP I-NP
for IN B-PP B-PP
full JJ B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
transduction NN B-NP B-NP
pathways NNS I-NP I-NP
regulating VBG B-VP B-VP
the DT B-NP B-NP
activity NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B-dependent JJ I-NP I-NP
genes NNS I-NP I-NP
. . O O

Expression NN B-NP B-NP
of IN B-PP B-PP
c-fos NN B-NP B-NP
, , O O
c-jun NN B-NP I-NP
and CC O I-NP
jun NN B-NP I-NP
B NN I-NP I-NP
in IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
lymphocytes NNS I-NP I-NP
from IN B-PP B-PP
young JJ B-NP B-NP
and CC I-NP I-NP
elderly JJ I-NP I-NP
adults NNS I-NP I-NP
. . O O

The DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
c-fos NN B-NP B-NP
, , O O
c-jun NN B-NP I-NP
and CC O I-NP
jun NN B-NP I-NP
B NN I-NP I-NP
proto-oncogenes NNS B-NP I-NP
was VBD B-VP B-VP
studied VBN I-VP I-VP
in IN B-PP B-PP
phytohemagglutinin NN B-NP B-NP
( ( O O
PHA NN B-NP B-NP
) ) O O
activated VBN B-NP B-VP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
lymphocytes NNS I-NP I-NP
( ( O O
PBL NN B-NP B-NP
) ) O O
from IN B-PP B-PP
young JJ B-NP B-NP
and CC I-NP I-NP
aged JJ I-NP I-NP
humans NNS I-NP I-NP
. . O O

Specific JJ B-NP B-NP
mRNAs NNS I-NP I-NP
for IN B-PP B-PP
c-fos NN B-NP B-NP
and CC O I-NP
c-jun NN B-NP I-NP
were VBD B-VP B-VP
detectable JJ B-ADJP B-ADJP
within IN B-PP B-PP
30 CD B-NP B-NP
min NN I-NP I-NP
after IN B-PP B-PP
cell NN B-NP B-NP
activation NN I-NP I-NP
and CC O I-CC
reached VBD B-VP B-VP
maximal JJ B-NP B-NP
levels NNS I-NP I-NP
within IN B-PP B-PP
2 CD B-NP B-NP
h NN I-NP I-NP
. . O O

Both CC O I-CC
c-fos NN B-NP B-NP
and CC O I-NP
jun NN B-NP I-NP
B NN I-NP I-NP
mRNAs NNS B-NP I-NP
decreased VBD B-VP B-VP
to TO B-PP B-PP
pre-activation NN B-NP B-NP
levels NNS I-NP I-NP
within IN B-PP B-PP
6 CD B-NP B-NP
h NN I-NP I-NP
, , O O
while IN B-SBAR B-SBAR
c-jun NN B-NP B-NP
mRNA NN I-NP I-NP
remained VBD B-VP B-VP
elevated JJ B-ADJP B-ADJP
. . O O

In IN B-PP B-PP
PHA-activated JJ B-NP B-NP
PBL NN I-NP I-NP
, , O O
no DT B-NP B-NP
age-related JJ I-NP I-NP
differences NNS I-NP I-NP
were VBD B-VP B-VP
observed VBN I-VP I-VP
in IN B-PP B-PP
c-fos NN B-NP B-NP
or CC O I-NP
jun NN B-NP I-NP
B NN I-NP I-NP
mRNA NN B-NP I-NP
expression NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
c-jun NN B-NP B-NP
mRNA NN I-NP I-NP
levels NNS I-NP I-NP
decreased VBD B-VP B-VP
significantly RB B-ADVP B-NP
( ( O O
1.73 CD B-NP I-NP
+/- CC I-NP I-NP
0.08 CD I-NP I-NP
vs. CC O I-NP
1.16 CD B-NP I-NP
+/- CC I-NP I-NP
0.09 CD I-NP I-NP
arbitrary JJ B-NP I-NP
units NNS I-NP I-NP
, , O O
P NN B-NP B-NP
&lt[[SEMICOLON]] JJR B-VP I-NP
0.01 CD B-NP I-NP
, , O O
young JJ B-ADJP I-NP
vs. CC O I-NP
old JJ B-ADJP I-NP
) ) O O
in IN B-PP B-PP
PBL NN B-NP B-NP
from IN B-PP B-PP
elderly JJ B-NP B-NP
individuals NNS I-NP I-NP
activated VBN B-VP B-VP
with IN B-PP B-PP
PHA NN B-NP B-NP
. . O O

Because IN B-SBAR B-SBAR
previous JJ B-NP B-NP
work NN I-NP I-NP
has VBZ B-VP B-VP
demonstrated VBN I-VP I-VP
that IN B-SBAR B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
from IN B-PP B-PP
elderly JJ B-NP B-NP
individuals NNS I-NP I-NP
may MD B-VP B-VP
display VB I-VP I-VP
normal JJ B-NP B-NP
proliferative JJ I-NP I-NP
responses NNS I-NP I-NP
when WRB B-ADVP B-ADVP
activated VBN B-VP B-VP
via IN B-PP B-PP
the DT B-NP B-NP
anti-CD2 JJ I-NP I-NP
pathway NN I-NP I-NP
, , O O
c-jun NN B-NP I-NP
and CC O I-NP
jun NN B-NP I-NP
B NN I-NP I-NP
mRNA NN B-NP I-NP
expression NN I-NP I-NP
was VBD B-VP B-VP
also RB I-VP I-VP
studied VBN I-VP I-VP
in IN B-PP B-PP
anti-CD2-activated JJ B-NP B-NP
purified VBN I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

No DT B-NP B-NP
age-related JJ I-NP I-NP
differences NNS I-NP I-NP
were VBD B-VP B-VP
found VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
either DT B-NP B-NP
of IN B-PP B-PP
these DT B-NP B-NP
two CD I-NP I-NP
proto-oncogenes NNS I-NP I-NP
by IN B-PP B-PP
anti-CD2 NN B-NP B-NP
activated JJ I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
decreased VBN I-NP I-NP
IL-2 NN I-NP I-NP
production NN I-NP I-NP
and CC O I-CC
proliferative JJ B-NP B-NP
response NN I-NP I-NP
displayed VBN B-VP B-VP
by IN B-PP B-PP
PHA-activated JJ B-NP B-NP
PBL NN I-NP I-NP
from IN B-PP B-PP
elderly JJ B-NP B-NP
adults NNS I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
related JJ B-ADJP B-ADJP
to TO B-PP B-PP
age-related JJ B-NP B-NP
changes NNS I-NP I-NP
in IN B-PP B-PP
c-jun NN B-NP B-NP
mRNA NN I-NP I-NP
expression NN I-NP I-NP
and CC B-PP B-PP
in IN B-PP B-PP
the DT B-NP B-NP
ratio NN I-NP I-NP
of IN B-PP B-PP
c-fos NN B-NP B-NP
to TO B-PP B-PP
c-jun NN B-NP B-NP
mRNA NN B-NP I-NP
. . O O

Characterization NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
novel JJ I-NP I-NP
T NN I-NP I-NP
lymphocyte NN I-NP I-NP
protein NN I-NP I-NP
which WDT B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
site NN I-NP I-NP
related JJ B-ADJP B-ADJP
to TO B-PP B-PP
steroid/thyroid JJ B-NP B-NP
hormone NN B-NP I-NP
receptor NN I-NP I-NP
response NN I-NP I-NP
elements NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
negative JJ I-NP I-NP
regulatory JJ I-NP I-NP
sequence NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
previously RB I-VP I-VP
identified VBN I-VP I-VP
a DT B-NP B-NP
T NN I-NP I-NP
lymphocyte NN I-NP I-NP
protein NN I-NP I-NP
which WDT B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
site NN I-NP I-NP
within IN B-PP B-PP
the DT B-NP B-NP
LTR NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP I-NP
( ( O O
HIV-1 NN B-NP I-NN
) ) O O
and CC O I-CC
exerts VBZ B-VP B-VP
an DT B-NP B-NP
inhibitory JJ I-NP I-NP
effect NN I-NP I-NP
on IN B-PP B-PP
virus NN B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
. . O O

The DT B-NP B-NP
palindromic JJ I-NP I-NP
site NN I-NP I-NP
( ( O O
site NN B-NP B-NP
B NN I-NP I-NP
) ) O O
recognized VBN B-VP B-VP
by IN B-PP B-PP
this DT B-NP B-NP
protein NN I-NP I-NP
is VBZ B-VP B-VP
related JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
palindromic JJ I-NP I-NP
binding VBG I-NP I-NP
sites NNS I-NP I-NP
of IN B-PP B-PP
members NNS B-NP B-NP
of IN B-PP B-PP
the DT O B-NP
steroid/thyroid JJ B-NP I-NP
hormone NN B-NP I-NP
receptor NN I-NP I-NP
family NN I-NP I-NP
. . O O

Here RB B-ADVP B-ADVP
we PRP B-NP B-NP
characterize VBP B-VP B-VP
the DT B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
protein NN I-NP I-NP
binding VBG B-VP B-VP
to TO B-PP B-PP
this DT B-NP B-NP
site NN I-NP I-NP
as IN B-PP B-PP
a DT B-NP B-NP
100 CD I-NP I-NP
kD NN I-NP I-NP
protein NN I-NP I-NP
which WDT B-NP B-NP
is VBZ B-VP B-VP
most RBS B-ADJP B-ADVP
abundant JJ I-ADJP I-ADVP
in IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
and CC O I-CC
which WDT B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-PP
site NN B-NP B-NP
B NN I-NP I-NP
as IN B-PP B-PP
a DT B-NP B-NP
200 CD I-NP I-NP
kD NN I-NP I-NP
complex NN I-NP I-NP
. . O O

This DT B-NP B-NP
protein NN I-NP I-NP
is VBZ B-VP B-VP
distinct JJ B-ADJP B-ADJP
from IN B-PP B-PP
other JJ B-NP B-NP
members NNS I-NP I-NP
of IN B-PP B-PP
the DT O B-NP
steroid/thyroid JJ B-NP I-NP
hormone NN B-NP I-NP
receptor NN I-NP I-NP
family NN I-NP I-NP
including VBG B-PP B-VP
the DT B-NP B-NP
COUP NN I-NP I-NP
protein NN I-NP I-NP
which WDT B-NP B-NP
has VBZ B-VP B-VP
a DT B-NP B-NP
closely RB I-NP I-NP
related JJ I-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
specificity NN I-NP I-NP
. . O O

A DT B-NP B-NP
mechanism NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
antiinflammatory JJ I-NP I-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
corticosteroids NNS B-NP B-NP
: : O O
the DT B-NP B-NP
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
regulates VBZ B-VP B-VP
leukocyte NN B-NP B-NP
adhesion NN I-NP I-NP
to TO B-PP B-PP
endothelial JJ B-NP B-NP
cells NNS I-NP I-NP
and CC O I-NP
expression NN B-NP I-NP
of IN B-PP B-PP
endothelial-leukocyte JJ B-NP B-NP
adhesion NN I-NP I-NP
molecule NN I-NP I-NP
1 CD I-NP I-NP
and CC O I-CC
intercellular JJ B-NP B-NP
adhesion NN I-NP I-NP
molecule NN I-NP I-NP
1 CD I-NP I-NP
. . O O

Corticosteroids NNS B-NP B-NP
are VBP B-VP B-VP
the DT B-NP B-NP
preeminent JJ I-NP I-NP
antiinflammatory JJ I-NP I-NP
agents NNS I-NP I-NP
although IN B-SBAR B-PP
the DT B-NP B-NP
molecular JJ I-NP I-NP
mechanisms NNS I-NP I-NP
that WDT B-NP B-NP
impart VBP B-VP B-VP
their PRP$ B-NP B-NP
efficacy NN I-NP I-NP
have VBP B-VP B-VP
not RB I-VP I-VP
been VBN I-VP I-VP
defined VBN I-VP I-VP
. . O O

The DT B-NP B-NP
endothelium NN I-NP I-NP
plays VBZ B-VP B-VP
a DT B-NP B-NP
critical JJ I-NP I-NP
role NN I-NP I-NP
in IN B-PP B-PP
inflammation NN B-NP B-NP
by IN B-PP B-PP
directing VBG B-VP B-VP
circulating VBG B-NP B-NP
leukocytes NNS I-NP I-NP
into IN B-PP B-PP
extravascular JJ B-NP B-NP
tissues NNS I-NP I-NP
by IN B-PP B-PP
expressing VBG B-VP B-VP
adhesive JJ B-NP B-NP
molecules NNS I-NP I-NP
for IN B-PP B-PP
leukocytes NNS B-NP B-NP
( ( O O
e.g. FW B-PP B-NP
, , B-NP O
endothelial-leukocyte JJ I-NP B-NP
adhesion NN I-NP I-NP
molecule NN I-NP I-NP
1 CD O B-NP
( ( O O
ELAM-1 NN O I-NP
) ) O O
and CC B-NP I-CC
intercellular JJ I-NP B-NP
adhesion NN I-NP I-NP
molecule NN I-NP I-NP
1 CD O B-NP
( ( O O
ICAM-1 NN O I-NP
) ) O O
. . O O

We PRP B-NP B-NP
therefore RB B-ADVP B-ADVP
determined VBD B-VP B-VP
whether IN B-SBAR B-SBAR
corticosteroids NNS B-NP B-NP
suppress VBP B-VP B-VP
inflammation NN B-NP B-NP
by IN B-PP B-PP
inhibiting VBG B-VP B-VP
endothelial JJ B-NP B-NP
expression NN I-NP I-NP
of IN B-PP B-PP
adhesion NN B-NP B-NP
molecules NNS I-NP I-NP
for IN B-PP B-PP
neutrophils NNS B-NP B-NP
( ( O O
polymorphonuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
) ) O O
. . O O

Preincubation NN B-NP B-NP
of IN B-PP B-PP
endothelial JJ B-NP B-NP
cells NNS I-NP I-NP
with IN B-PP B-PP
endotoxin NN B-NP B-NP
( ( O O
lipopolysaccharide NN B-NP B-NP
( ( O O
LPS NN B-NP I-NP
) ) O O
, , O O
1 CD B-NP B-NP
microgram/ml NN I-NP I-NP
) ) O O
led VBD B-VP B-VP
to TO B-PP B-PP
a DT B-NP B-NP
4-fold JJ I-NP I-NP
increase NN I-NP I-NP
in IN B-PP B-PP
subsequent JJ B-NP B-NP
adherence NN I-NP I-NP
of IN B-PP B-PP
polymorphonuclear JJ B-NP B-NP
leukocytes NNS I-NP I-NP
( ( O O
P NN B-NP B-NP
< JJR B-VP I-NP
0.0001 CD B-NP I-NP
, , O O
n NN B-NP I-NP
= JJ B-VP I-NP
10 CD B-NP I-NP
) ) O O
to TO B-PP B-PP
endothelial JJ B-NP B-NP
cells NNS I-NP I-NP
, , O O
an DT B-NP B-NP
increase NN I-NP I-NP
that WDT B-NP B-NP
was VBD B-VP B-VP
markedly RB I-VP I-VP
attenuated VBN I-VP I-VP
when WRB B-ADVP B-ADVP
endothelial JJ B-NP B-NP
cells NNS I-NP I-NP
were VBD B-VP B-VP
treated VBN I-VP I-VP
with IN B-PP B-PP
dexamethasone NN B-NP B-NP
( ( O O
IC50 NN B-NP B-NP
< JJR B-VP I-NP
1 CD B-NP I-NP
nM NN I-NP I-NP
, , O O
P NN B-NP B-NP
< JJR B-VP I-NP
0.0001 CD B-NP I-NP
, , O O
n NN B-NP B-NP
= JJ B-VP I-NP
6 CD B-NP I-NP
or CC O I-NP
7 CD B-NP I-NP
) ) O O
during IN B-PP B-PP
preincubation NN B-NP B-NP
with IN B-PP B-PP
LPS NN B-NP B-NP
. . O O

Moreover RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
steroid NN I-NP I-NP
receptor NN I-NP I-NP
agonist NN I-NP I-NP
cortisol NN I-NP I-NP
( ( O O
10 CD B-NP B-NP
microM NN I-NP I-NP
) ) O O
, , O O
but CC B-CONJP I-CC
not RB I-CONJP I-RB
its PRP$ B-NP B-NP
inactive JJ I-NP I-NP
metabolite NN I-NP I-NP
tetrahydrocortisol NN I-NP I-NP
( ( O O
10 CD B-NP B-NP
microM NN I-NP I-NP
) ) O O
, , O O
diminished VBD B-VP B-VP
LPS-induced JJ B-NP B-NP
endothelial JJ I-NP I-NP
cell NN I-NP I-NP
adhesiveness NN I-NP I-NP
. . O O

Further JJ B-NP B-NP
evidence NN I-NP I-NP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
action NN I-NP I-NP
of IN B-PP B-PP
dexamethasone NN B-NP B-NP
was VBD B-VP B-VP
mediated VBN I-VP I-VP
through IN B-PP B-PP
ligation NN B-NP B-NP
of IN B-PP B-PP
corticosteroid NN B-NP B-NP
receptors NNS I-NP I-NP
( ( O O
human JJ B-NP B-NP
glucocorticoid NN I-NP I-NP
receptors NNS I-NP I-NP
( ( O O
hGRs NNS B-NP B-NP
) ) O O
) ) O O
was VBD B-VP B-VP
provided VBN I-VP I-VP
by IN B-PP B-PP
experiments NNS B-NP B-NP
utilizing VBG B-VP B-VP
the DT B-NP B-NP
steroid NN I-NP I-NP
antagonist NN I-NP I-NP
RU-486 NN I-NP I-NP
. . O O

RU-486 NN B-NP B-NP
( ( O O
10 CD B-NP B-NP
microM NN I-NP I-NP
) ) O O
, , O O
which WDT B-NP B-NP
prevents VBZ B-VP B-VP
translocation NN B-NP B-NP
of IN B-PP B-PP
ligated VBN B-NP B-NP
hGR NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
nucleus NN I-NP I-NP
by IN B-PP B-PP
inhibiting VBG B-VP B-VP
dissociation NN B-NP B-NP
of IN B-PP B-PP
hGR NN B-NP B-NP
from IN B-PP B-PP
heat NN B-NP B-NP
shock NN I-NP I-NP
protein NN I-NP I-NP
90 CD I-NP B-NP
, , O O
completely RB B-ADVP B-VP
aborted VBD B-VP I-VP
the DT B-NP B-NP
effect NN I-NP I-NP
of IN B-PP B-PP
dexamethasone NN B-NP B-NP
on IN B-PP B-PP
adhesiveness NN B-NP B-NP
of IN B-PP B-PP
endothelial JJ B-NP B-NP
cells NNS I-NP I-NP
( ( O O
P NN B-NP B-NP
< JJR B-VP I-NP
0.0005 CD B-NP I-NP
, , O O
n NN B-NP I-NP
= JJ B-VP I-NP
3 CD B-NP I-NP
) ) O O
. . O O

Treatment NN B-NP B-NP
of IN B-PP B-PP
endothelial JJ B-NP B-NP
cells NNS I-NP I-NP
with IN B-PP B-PP
LPS NN B-NP B-NP
( ( O O
1 CD B-NP B-NP
microgram/ml NN I-NP I-NP
) ) O O
stimulated VBD B-VP B-VP
transcription NN B-NP B-NP
of IN B-PP B-PP
ELAM-1 NN B-NP B-NP
, , O O
as IN B-SBAR B-SBAR
shown VBN B-VP B-VP
by IN B-PP B-PP
Northern NN B-NP B-NP
blot NN I-NP I-NP
analysis NN I-NP I-NP
, , O O
and CC O I-CC
expression NN B-NP B-NP
of IN B-PP B-PP
membrane-associated JJ B-NP B-NP
ELAM-1 NN B-NP I-NP
and CC O I-NP
ICAM-1 NN B-NP I-NP
, , O O
as IN B-SBAR B-SBAR
shown VBN B-VP B-VP
by IN B-PP B-PP
quantitative JJ B-NP B-NP
immunofluorescence NN I-NP I-NP
( ( O O
both DT B-NP B-NP
P NN I-NP I-NP
< JJR B-VP I-NP
0.001 CD B-NP I-NP
, , O O
n NN B-NP I-NP
= JJ B-VP I-NP
9 CD B-NP I-NP
) ) O O
. . O O

Dexamethasone NN B-NP B-NP
markedly RB B-ADVP B-VP
inhibited VBD B-VP I-VP
LPS-stimulated JJ B-NP B-NP
accumulation NN I-NP I-NP
of IN B-PP B-PP
mRNA NN B-NP B-NP
for IN B-PP B-PP
ELAM-1 NN B-NP B-NP
and CC O I-NP
expression NN B-NP I-NP
of IN B-PP B-PP
ELAM-1 NN B-NP B-NP
and CC O I-NP
ICAM-1 NN B-NP I-NP
( ( O O
IC50 NN B-NP B-NP
< JJR B-VP I-NP
10 CD B-NP I-NP
nM NN I-NP I-NP
, , O O
both DT B-NP B-NP
P NN I-NP I-NP
< JJR B-VP I-NP
0.001 CD B-NP I-NP
, , O O
n NN B-NP I-NP
= JJ B-VP I-NP
4-9 CD B-NP I-NP
) ) O O
; : O O
inhibition NN B-NP B-NP
of IN B-PP B-PP
expression NN B-NP B-NP
by IN B-PP B-PP
dexamethasone NN B-NP B-NP
was VBD B-VP B-VP
reversed VBN I-VP I-VP
by IN B-PP B-PP
RU-486 NN B-NP B-NP
( ( O O
both DT B-NP B-NP
P NN I-NP I-NP
< JJR B-VP I-NP
0.005 CD B-NP I-NP
, , O O
n NN B-NP I-NP
= JJ B-VP I-NP
4-6 CD B-NP I-NP
) ) O O
. . O O

As IN B-SBAR B-PP
in IN B-PP B-PP
the DT B-NP B-NP
adhesion NN I-NP I-NP
studies NNS I-NP I-NP
, , O O
cortisol NN B-NP B-NP
but CC B-CONJP B-NP
not RB I-CONJP I-NP
tetrahydrocortisol NN B-NP B-NP
inhibited VBD B-VP B-VP
expression NN B-NP B-NP
of IN B-PP B-PP
ELAM-1 NN B-NP B-NP
and CC O I-NP
ICAM-1 NN B-NP I-NP
( ( O O
both DT B-NP B-NP
P NN I-NP I-NP
< JJR B-VP I-NP
0.005 CD B-NP I-NP
, , O O
n NN B-NP B-NP
= JJ B-VP I-NP
3 CD B-NP I-NP
or CC O I-NP
4 CD B-NP I-NP
) ) O O
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
sodium NN B-NP B-NP
salicylate NN I-NP I-NP
( ( O O
1 CD B-NP B-NP
mM NN I-NP I-NP
) ) O O
inhibited VBD B-VP B-VP
neither CC O I-CC
adhesion NN B-NP B-NP
nor CC O I-NP
expression NN B-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
adhesion NN I-NP I-NP
molecules NNS I-NP I-NP
. . O O

These DT B-NP B-NP
studies NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-PP
antagonism NN B-NP B-NP
by IN B-PP B-PP
dexamethasone NN B-NP B-NP
of IN B-PP B-PP
endotoxin-induced JJ B-NP B-NP
inflammation NN I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
specific JJ I-NP I-NP
instance NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
general JJ I-NP I-NP
biological JJ I-NP I-NP
principle NN I-NP I-NP
that IN B-SBAR B-PP
the DT B-NP B-NP
glucocorticoid NN I-NP I-NP
receptor NN I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
hormone-dependent JJ I-NP I-NP
regulator NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
. . O O

Membrane NN B-NP B-NP
receptors NNS I-NP I-NP
for IN B-PP B-PP
aldosterone NN B-NP B-NP
: : O O
a DT B-NP B-NP
novel JJ I-NP I-NP
pathway NN I-NP I-NP
for IN B-PP B-PP
mineralocorticoid NN B-NP B-NP
action NN I-NP I-NP
. . O O

Rapid JJ B-NP B-NP
nongenomic JJ I-NP I-NP
in FW I-NP B-NP
vitro FW I-NP I-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
aldosterone NN B-NP B-NP
on IN B-PP B-PP
intracellular JJ B-NP B-NP
electrolytes NNS I-NP I-NP
, , O O
cell NN B-NP B-NP
volume NN I-NP I-NP
, , O O
and CC O I-CC
Na(+)-H+ JJ B-NP B-NP
antiport NN I-NP I-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
found VBN I-VP I-VP
in IN B-PP B-PP
human JJ B-NP B-NP
mononuclear JJ I-NP I-NP
leukocytes NNS I-NP I-NP
( ( O O
HML NN B-NP B-NP
) ) O O
. . O O

Binding NN B-NP B-NP
of IN B-PP B-PP
125I-labeled JJ B-NP B-NP
aldosterone NN I-NP I-NP
to TO B-PP B-PP
plasma NN B-NP B-NP
membranes NNS I-NP I-NP
of IN B-PP B-PP
HML NN B-NP B-NP
shares VBZ B-VP B-VP
important JJ B-NP B-NP
features NNS I-NP I-NP
with IN B-PP B-PP
these DT B-NP B-NP
functional JJ I-NP I-NP
data NNS I-NP I-NP
. . O O

This DT B-NP B-NP
includes VBZ B-VP B-VP
a DT B-NP B-NP
very RB I-NP I-NP
low JJ I-NP I-NP
apparent JJ I-NP I-NP
dissociation NN B-NP I-NP
constant NN I-NP I-NP
( ( O O
Kd NN B-NP B-NP
) ) O O
of IN B-PP B-PP
0.1 CD B-NP B-NP
nM NN I-NP I-NP
for IN B-PP B-PP
both CC O B-NP
aldosterone NN B-NP I-NP
and CC O I-CC
the DT B-NP B-NP
effect NN I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
Na(+)-H(+)-antiport NN I-NP I-NP
, , O O
a DT B-NP B-NP
high JJ I-NP I-NP
turnover NN I-NP I-NP
rate NN I-NP I-NP
, , O O
and CC O I-CC
the DT B-NP B-NP
almost RB I-NP I-NP
exclusive JJ I-NP I-NP
binding NN I-NP I-NP
selectivity NN I-NP I-NP
for IN B-PP B-PP
aldosterone NN B-NP B-NP
. . O O

Dexamethasone NN B-NP B-NP
, , O O
RU NN B-NP B-NP
26988 CD I-NP I-NP
, , O O
corticosterone NN B-NP I-NP
, , O O
ouabain NN B-NP I-NP
, , O O
amiloride NN B-NP I-NP
, , O O
and CC O I-CC
18-hydroxyprogesterone NN B-NP B-NP
were VBD B-VP B-VP
inactive JJ B-ADJP B-ADJP
as IN B-PP B-PP
ligands NNS B-NP B-NP
. . O O

Deoxycorticosterone NN B-NP B-NP
acetate NN I-NP I-NP
had VBD B-VP B-VP
an DT B-NP B-NP
intermediate JJ I-NP I-NP
activity NN I-NP I-NP
with IN B-PP B-PP
an DT B-NP B-NP
apparent JJ I-NP I-NP
Kd NN I-NP I-NP
of IN B-PP B-PP
100 CD B-NP B-NP
nM NN I-NP I-NP
. . O O

These DT B-NP B-NP
findings NNS I-NP I-NP
are VBP B-VP B-VP
the DT B-NP B-NP
first JJ I-NP I-NP
to TO B-VP B-VP
demonstrate VB I-VP I-VP
membrane NN B-NP B-NP
binding NN I-NP I-NP
of IN B-PP B-PP
aldosterone NN B-NP B-NP
being VBG B-VP B-VP
compatible JJ B-ADJP B-ADJP
with IN B-PP B-PP
major JJ B-NP B-NP
aspects NNS I-NP I-NP
of IN B-PP B-PP
its PRP$ B-NP B-NP
nongenomic JJ I-NP I-NP
effects NNS I-NP I-NP
. . O O

Reticuloendotheliosis NN B-NP B-NP
virus NN I-NP I-NP
long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
elements NNS I-NP I-NP
are VBP B-VP B-VP
efficient JJ B-NP B-NP
promoters NNS I-NP I-NP
in IN B-PP B-PP
cells NNS B-NP B-NP
of IN B-PP B-PP
various JJ B-NP B-NP
species NNS B-NP I-NP
and CC O I-CC
tissue NN B-NP B-NP
origin NN B-NP I-NP
, , O O
including VBG B-PP B-PP
human JJ B-NP B-NP
lymphoid JJ I-NP I-NP
cells NNS I-NP I-NP
. . O O

Promiscuous JJ B-NP B-NP
transcriptional JJ I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
reticuloendotheliosis NN I-NP I-NP
virus NN I-NP I-NP
( ( O O
REV NN B-NP B-NP
) ) O O
long JJ B-NP B-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
( ( O O
LTR NN B-NP B-NP
) ) O O
was VBD B-VP B-VP
detected VBN I-VP I-VP
in IN B-PP B-PP
transient JJ B-NP B-NP
expression NN I-NP I-NP
assays NNS I-NP I-NP
using VBG B-VP B-VP
LTR-chloramphenicol NN B-NP B-NP
acetyltransferase-encoding JJ I-NP I-NP
gene NN I-NP I-NP
chimeras NNS I-NP I-NP
, , O O
and CC O I-CC
cells NNS B-NP B-NP
of IN B-PP B-PP
diverse JJ B-NP B-NP
species NNS B-NP I-NP
and CC O I-CC
tissue NN B-NP B-NP
type NN B-NP I-NP
; : O O
levels NNS B-NP B-NP
of IN B-PP B-PP
expression NN B-NP B-NP
from IN B-PP B-PP
two CD B-NP B-NP
different JJ I-NP I-NP
REV NN I-NP I-NP
LTRs NNS I-NP I-NP
correlate VBP B-VP B-VP
with IN B-PP B-PP
reports NNS B-NP B-NP
of IN B-PP B-PP
pathogenicity NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
respective JJ I-NP I-NP
viruses NNS I-NP I-NP
in FW B-ADVP B-NP
vivo FW I-ADVP B-NP
. . O O

REVs NNS B-NP B-NP
do VBP B-VP B-VP
not RB I-VP I-VP
encode VB I-VP I-VP
a DT B-NP B-NP
transactivator NN I-NP I-NP
targeted VBN B-VP B-VP
to TO B-PP B-PP
the DT B-NP B-NP
viral JJ I-NP I-NP
LTR NN I-NP I-NP
, , O O
and CC O I-CC
cells NNS B-NP B-NP
infected VBN B-VP B-VP
with IN B-PP B-PP
Marek NN B-NP B-NP
's POS B-NP B-NP
disease NN I-NP I-NP
virus NN I-NP I-NP
, , O O
a DT B-NP B-NP
herpesvirus NN I-NP I-NP
with IN B-PP B-PP
an DT B-NP B-NP
overlapping VBG I-NP I-NP
host NN I-NP I-NP
range NN I-NP I-NP
, , O O
do VBP B-VP B-VP
not RB I-VP I-VP
express VB I-VP I-VP
factors NNS B-NP B-NP
that WDT B-NP B-NP
preferentially RB B-ADVP B-ADVP
enhance VBP B-VP B-VP
expression NN B-NP B-NP
from IN B-PP B-PP
REV NN B-NP B-NP
or CC O I-CC
avian JJ B-NP B-NP
sarcoma/leukemia NN I-NP I-NP
virus NN I-NP I-NP
LTRs NNS I-NP I-NP
. . O O

REV NN B-NP B-NP
LTRs NNS I-NP I-NP
work VBP B-VP B-VP
efficiently RB B-ADVP B-ADVP
in IN B-PP B-PP
human JJ B-NP B-NP
lymphoid JJ I-NP I-NP
cells NNS I-NP I-NP
, , O O
and CC O I-CC
are VBP B-VP B-VP
viable JJ B-NP B-NP
alternatives NNS I-NP I-NP
to TO B-PP B-PP
promoters NNS B-NP B-NP
commonly RB B-VP B-VP
used VBN I-VP I-VP
for IN B-PP B-PP
expression NN B-NP B-NP
of IN B-PP B-PP
cloned VBN B-NP B-NP
genes NNS I-NP I-NP
. . O O

They PRP B-NP B-NP
may MD B-VP B-VP
also RB I-VP I-VP
prove VB I-VP I-VP
useful JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
identification NN I-NP I-NP
of IN B-PP B-PP
new JJ B-NP B-NP
, , I-NP O
ubiquitous JJ I-NP I-NP
cellular JJ I-NP I-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
. . O O

Natural JJ B-NP B-NP
variants NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HIV-1 NN I-NP I-NP
long JJ I-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
: : O O
analysis NN B-NP B-NP
of IN B-PP B-PP
promoters NNS B-NP B-NP
with IN B-PP B-PP
duplicated JJ B-NP B-NP
DNA NN I-NP I-NP
regulatory JJ I-NP I-NP
motifs NNS I-NP I-NP
. . O O

Sequence NN B-NP B-NP
variation NN I-NP I-NP
in IN B-PP B-PP
the DT O B-NP
long JJ B-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
( ( O O
LTR NN B-NP I-NN
) ) O O
region NN B-NP B-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
was VBD B-VP B-VP
analyzed VBN I-VP I-VP
in IN B-PP B-PP
viral JJ B-NP B-NP
isolates NNS I-NP I-NP
of IN B-PP B-PP
17 CD B-NP B-NP
infected JJ I-NP I-NP
individuals NNS I-NP I-NP
. . O O

Two CD B-NP B-NP
classes NNS I-NP I-NP
of IN B-PP B-PP
LTR NN B-NP B-NP
size NN I-NP I-NP
variants NNS I-NP I-NP
were VBD B-VP B-VP
found VBN I-VP I-VP
. . O O

One CD B-NP B-NP
HIV-1 NN I-NP I-NP
variant NN I-NP I-NP
was VBD B-VP B-VP
detected VBN I-VP I-VP
containing VBG I-VP I-VP
an DT B-NP B-NP
additional JJ I-NP I-NP
binding VBG I-NP I-NP
site NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
Sp1 NN I-NP I-NP
. . O O

Another DT B-NP B-NP
LTR NN I-NP I-NP
size NN I-NP I-NP
variation NN I-NP I-NP
was VBD B-VP B-VP
observed VBN I-VP I-VP
in IN B-PP B-PP
four CD B-NP B-NP
patients NNS I-NP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
region NN I-NP I-NP
just RB B-ADJP B-NP
upstream JJ I-ADJP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
enhancer NN I-NP I-NP
. . O O

This DT B-NP B-NP
variation NN I-NP I-NP
was VBD B-VP B-VP
the DT B-NP B-NP
result NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
duplication NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
short JJ I-NP I-NP
DNA NN I-NP I-NP
sequence NN I-NP I-NP
( ( O O
CTG-motif NN B-NP B-NP
) ) O O
. . O O

Cell NN B-NP B-NP
culture NN I-NP I-NP
experiments NNS I-NP I-NP
demonstrated VBD B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
natural JJ I-NP I-NP
variant NN I-NP I-NP
with IN B-PP B-PP
four CD B-NP B-NP
Sp1 NN I-NP I-NP
sites NNS I-NP I-NP
had VBD B-VP B-VP
a DT B-NP B-NP
slightly RB I-NP I-NP
higher JJR I-NP I-NP
promoter NN B-NP I-NP
activity NN I-NP I-NP
and CC O I-CC
viral JJ B-NP B-NP
replication NN I-NP I-NP
rate NN I-NP I-NP
than IN B-PP B-PP
the DT B-NP B-NP
isogenic JJ I-NP I-NP
control NN I-NP I-NP
LTR NN I-NP I-NP
with IN B-PP B-PP
three CD B-NP B-NP
Sp1 NN I-NP I-NP
sites NNS I-NP I-NP
. . O O

No DT B-NP B-NP
positive JJ I-NP I-NP
effect NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
duplicated JJ I-NP I-NP
CTG-motif NN I-NP I-NP
could MD B-VP B-VP
be VB I-VP I-VP
detected VBN I-VP I-VP
. . O O

In IN B-SBAR B-PP
order NN O B-NP
to TO O B-VP
measure VB B-VP I-VP
small JJ B-NP B-NP
differences NNS I-NP I-NP
in IN B-PP B-PP
virus NN B-NP B-NP
production NN I-NP I-NP
more RBR B-ADVP B-ADVP
accurately RB I-ADVP I-ADVP
, , O O
equal JJ B-NP B-NP
amounts NNS I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
size NN I-NP I-NP
variant NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
wild-type JJ I-NP I-NP
plasmid NN I-NP I-NP
were VBD B-VP B-VP
cotransfected VBN I-VP I-VP
into IN B-PP B-PP
T-cells NNS B-NP B-NP
. . O O

The DT B-NP B-NP
virus NN I-NP I-NP
with IN B-PP B-PP
four CD B-NP B-NP
Sp1 NN I-NP I-NP
sites NNS I-NP I-NP
did VBD B-VP B-VP
outgrow VB I-VP I-VP
the DT B-NP B-NP
three CD I-NP I-NP
Sp1 NN I-NP I-NP
virus NN I-NP I-NP
in IN B-PP B-PP
35 CD B-NP B-NP
days NNS I-NP I-NP
of IN B-PP B-PP
culture NN B-NP B-NP
and CC O I-NP
CTG-monomer NN B-NP I-NP
virus NN I-NP I-NP
outcompeted VBD B-VP B-VP
the DT B-NP B-NP
CTG-dimer NN I-NP I-NP
virus NN I-NP I-NP
in IN B-PP B-PP
42 CD B-NP B-NP
days NNS I-NP I-NP
. . O O

Based VBN B-PP B-VP
on IN B-PP B-PP
these DT B-NP B-NP
results NNS I-NP I-NP
we PRP B-NP B-NP
estimate VBP B-VP B-VP
a DT B-NP B-NP
5-10 CD I-NP I-NP
% NN I-NP I-NP
difference NN I-NP I-NP
in IN B-PP B-PP
virus NN B-NP B-NP
production NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
LTR NN I-NP I-NP
variants NNS I-NP I-NP
when WRB B-ADVP B-VP
compared VBN B-VP I-VP
to TO B-PP B-PP
that DT B-NP B-NP
of IN B-PP B-PP
wild-type NN B-NP B-NP
. . O O

SCL NN B-NP B-NP
and CC O I-NP
related JJ B-NP I-NP
hemopoietic JJ I-NP I-NP
helix-loop-helix JJ I-NP I-NP
transcription NN I-NP I-NP
factors NNS I-NP I-NP
. . O O

The DT O B-NP
helix-loop-helix JJ O I-NP
( ( O O
HLH JJ B-ADJP I-JJ
) ) O O
proteins NNS B-NP B-NP
are VBP B-VP B-VP
a DT B-NP B-NP
family NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
factors NNS I-NP I-NP
that WDT B-NP B-NP
include VBP B-VP B-VP
proteins NNS B-NP B-NP
critical JJ B-ADJP B-ADJP
to TO B-PP B-PP
differentiation NN B-NP B-NP
and CC O I-NP
development NN B-NP I-NP
in IN B-PP B-PP
species NNS B-NP B-NP
ranging VBG B-VP B-VP
from IN B-PP B-PP
plants NNS B-NP B-NP
to TO B-PP B-PP
mammals NNS B-NP B-NP
. . O O

Five CD B-NP B-NP
members NNS I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
family NN I-NP I-NP
( ( O O
MYC NN B-NP B-NP
, , O O
SCL NN B-NP I-NP
, , O O
TAL-2 NN B-NP I-NP
, , O O
LYL-1 NN B-NP I-NP
and CC O I-NP
E2A NN B-NP I-NP
) ) O O
are VBP B-VP B-VP
implicated VBN I-VP I-VP
in IN B-PP B-PP
oncogenic JJ B-NP B-NP
events NNS I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
lymphoid JJ I-NP I-NP
tumors NNS I-NP I-NP
because IN B-PP B-PP
of IN I-PP I-PP
their PRP$ B-NP B-NP
consistent JJ I-NP I-NP
involvement NN I-NP I-NP
in IN B-PP B-PP
chromosomal JJ B-NP B-NP
translocations NNS I-NP I-NP
. . O O

Although IN B-SBAR B-SBAR
activated VBN B-VP B-VP
in IN B-PP B-PP
T NN B-NP B-NP
cell NN I-NP I-NP
leukemias NNS I-NP I-NP
, , O O
expression NN B-NP B-NP
of IN B-PP B-PP
SCL NN B-NP B-NP
and CC O I-NP
LYL-1 NN B-NP I-NP
is VBZ B-VP B-VP
low JJ B-ADJP B-ADJP
or CC O I-ADJP
undetectable JJ B-ADJP I-ADJP
in IN B-PP B-PP
normal JJ B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
populations NNS I-NP I-NP
. . O O

SCL NN B-NP B-NP
is VBZ B-VP B-VP
expressed VBN I-VP I-VP
in IN B-PP B-PP
erythroid JJ O B-NP
, , O O
megakaryocyte NN B-NP I-NP
and CC O I-NP
mast NN B-NP I-NP
cell NN I-NP I-NP
populations NNS B-NP I-NP
( ( O O
the DT B-NP B-NP
same JJ I-NP I-NP
cell NN I-NP I-NP
lineages NNS I-NP I-NP
as IN B-PP B-PP
GATA-1 NN B-NP B-NP
, , O O
a DT B-NP B-NP
zinc-finger NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
) ) O O
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
both CC O I-CC
SCL NN B-NP B-NP
and CC O I-NP
GATA-1 NN B-NP I-NP
undergo VBP B-VP B-VP
coordinate JJ B-NP B-NP
modulation NN I-NP I-NP
during IN B-PP B-PP
chemically RB B-NP B-NP
induced VBN I-NP I-NP
erythroid JJ I-NP I-NP
differentiation NN I-NP I-NP
of IN B-PP B-PP
mouse NN B-NP B-NP
erythroleukemia NN I-NP I-NP
cells NNS I-NP I-NP
and CC O I-CC
are VBP B-VP B-VP
down-modulated VBN I-VP I-VP
during IN B-PP B-PP
myeloid JJ B-NP B-NP
differentiation NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
K562 NN I-NP I-NP
cells NNS I-NP I-NP
, , O O
thus RB B-ADVP B-ADVP
implying VBG B-VP B-VP
a DT B-NP B-NP
role NN I-NP I-NP
for IN B-PP B-PP
SCL NN B-NP B-NP
in IN B-PP B-PP
erythroid JJ B-NP B-NP
differentiation NN I-NP I-NP
events NNS I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
in IN B-PP B-PP
contrast NN I-PP B-NP
to TO I-PP B-PP
GATA-1 NN B-NP B-NP
, , O O
SCL NN B-NP B-NP
is VBZ B-VP B-VP
expressed VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
developing VBG I-NP I-NP
brain NN I-NP I-NP
. . O O

Studies NNS B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
function NN I-NP I-NP
of IN B-PP B-PP
SCL NN B-NP B-NP
suggest VBP B-VP B-VP
it PRP B-NP B-NP
is VBZ B-VP B-VP
also RB B-ADJP B-ADJP
important JJ I-ADJP I-ADJP
in IN B-PP B-PP
proliferation NN B-NP B-NP
and CC O I-NP
self-renewal JJ B-ADJP I-NP
events NNS B-NP I-NP
in IN B-PP B-PP
erythroid JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

Transcription NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
hypersensitive JJ I-NP I-NP
site NN I-NP I-NP
HS2 NN I-NP I-NP
enhancer NN I-NP I-NP
in IN B-PP B-PP
erythroid JJ B-NP B-NP
cells NNS I-NP I-NP
. . O O

In IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
genome NN I-NP I-NP
, , O O
the DT B-NP B-NP
erythroid-specific JJ I-NP I-NP
hypersensitive JJ I-NP I-NP
site NN I-NP I-NP
HS2 NN I-NP I-NP
enhancer NN I-NP I-NP
regulates VBZ B-VP B-VP
the DT B-NP B-NP
transcription NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
downstream JJ I-NP I-NP
beta-like JJ I-NP I-NP
globin NN I-NP I-NP
genes NNS I-NP I-NP
10-50 CD B-NP B-NP
kilobases NNS I-NP I-NP
away RB B-ADVP B-ADVP
. . O O

The DT B-NP B-NP
mechanism NN I-NP I-NP
of IN B-PP B-PP
HS2 NN B-NP B-NP
enhancer NN I-NP I-NP
function NN I-NP I-NP
is VBZ B-VP B-VP
not RB I-VP I-VP
known VBN I-VP I-VP
. . O O

The DT B-NP B-NP
present JJ I-NP I-NP
study NN I-NP I-NP
employs VBZ B-VP B-VP
RNA NN B-NP B-NP
protection NN I-NP I-NP
assays NNS I-NP I-NP
to TO B-VP B-VP
analyze VB I-VP I-VP
the DT B-NP B-NP
transcriptional JJ I-NP I-NP
status NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
HS2 NN I-NP I-NP
enhancer NN I-NP I-NP
in IN B-PP B-PP
transfected VBN O B-NP
recombinant JJ O I-NP
chloramphenicol NN B-NP I-NP
acetyltransferase NN I-NP I-NP
( ( O O
CAT NN B-NP B-NP
) ) O O
plasmids NNS B-NP I-NP
. . O O

In IN B-PP B-PP
erythroid JJ B-NP B-NP
K562 NN I-NP I-NP
cells NNS I-NP I-NP
in IN B-PP B-PP
which WDT B-NP B-NP
the DT B-NP B-NP
HS2 NN I-NP I-NP
enhancer NN I-NP I-NP
is VBZ B-VP B-VP
active JJ B-ADJP B-ADJP
, , O O
the DT B-NP B-NP
HS2 NN I-NP I-NP
sequence NN I-NP I-NP
directs VBZ B-VP B-VP
the DT B-NP B-NP
synthesis NN I-NP I-NP
of IN B-PP B-PP
long JJ B-NP B-NP
enhancer NN I-NP I-NP
transcripts NNS I-NP I-NP
that WDT B-NP B-NP
are VBP B-VP B-VP
initiated VBN I-VP I-VP
apparently RB B-ADVP B-ADVP
from IN B-PP B-PP
within IN B-PP I-PP
the DT B-NP B-NP
enhancer NN I-NP I-NP
and CC O I-CC
elongated VBN B-VP B-VP
through IN B-PP B-PP
the DT B-NP B-NP
intervening VBG I-NP I-NP
DNA NN I-NP I-NP
into IN B-PP B-PP
the DT B-NP B-NP
cis-linked JJ I-NP I-NP
CAT NN I-NP I-NP
gene NN I-NP I-NP
. . O O

In IN B-PP B-PP
nonerythroid JJ B-NP B-NP
HL-60 NN I-NP I-NP
cells NNS I-NP I-NP
in IN B-PP B-PP
which WDT B-NP B-NP
the DT B-NP B-NP
HS2 NN I-NP I-NP
enhancer NN I-NP I-NP
is VBZ B-VP B-VP
inactive JJ B-ADJP B-ADJP
, , O O
long JJ B-NP B-NP
enhancer NN I-NP I-NP
transcripts NNS I-NP I-NP
are VBP B-VP B-VP
not RB O I-RB
detectable JJ B-ADJP B-ADJP
. . O O

Splitting VBG B-VP B-VP
the DT B-NP B-NP
HS2 NN I-NP I-NP
enhancer NN I-NP I-NP
between IN B-PP B-PP
two CD B-NP B-NP
tandem JJ I-NP I-NP
Ap1 NN I-NP I-NP
sites NNS I-NP I-NP
abolishes VBZ B-VP B-VP
the DT B-NP B-NP
synthesis NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
group NN I-NP I-NP
of IN B-PP B-PP
long JJ B-NP B-NP
enhancer NN I-NP I-NP
transcripts NNS I-NP I-NP
and CC O I-CC
results VBZ B-VP B-VP
in IN B-PP B-PP
loss NN B-NP B-NP
of IN B-PP B-PP
enhancer NN B-NP B-NP
function NN I-NP I-NP
and CC O I-CC
transcriptional JJ B-NP B-NP
silencing NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
cis-linked JJ I-NP I-NP
CAT NN I-NP I-NP
gene NN I-NP I-NP
. . O O

In IN B-PP B-PP
directing VBG B-VP B-VP
the DT B-NP B-NP
synthesis NN I-NP I-NP
of IN B-PP B-PP
RNA NN B-NP B-NP
through IN B-PP B-PP
the DT B-NP B-NP
intervening VBG I-NP I-NP
DNA NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
gene NN I-NP I-NP
by IN B-PP B-PP
a DT O B-NP
tracking NN B-NP I-NP
and CC O I-NP
transcription NN B-NP I-NP
mechanism NN B-NP I-NP
, , O O
the DT B-NP B-NP
HS2 NN I-NP I-NP
enhancer NN I-NP I-NP
may MD O B-VP
( ( O O
i LS O B-NP
) ) O O
open VB B-NP B-VP
up RP I-NP B-ADVP
the DT I-NP B-NP
chromatin NN O I-NP
structure NN B-NP I-NP
of IN I-NP B-PP
a DT I-NP B-NP
gene NN B-VP I-NP
domain NN O I-NP
and CC O I-CC
( ( O O
ii LS O B-NP
) ) O O
deliver VB O B-VP
enhancer NN B-NP B-NP
binding NN I-NP I-NP
proteins NNS I-NP I-NP
to TO O B-PP
the DT B-NP B-NP
promoter NN B-VP I-NP
sequence NN I-VP I-NP
where WRB B-NP B-ADVP
they PRP I-NP B-NP
may MD O B-VP
stimulate VB B-NP I-VP
the DT I-NP B-NP
transcription NN O I-NP
of IN B-NP B-PP
the DT I-NP B-NP
gene NN I-NP I-NP
at IN O B-PP

Phorbol NN B-NP B-NP
ester NN I-NP I-NP
reduces VBZ B-VP B-VP
constitutive JJ B-NP B-NP
nuclear JJ I-NP I-NP
NF NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
and CC O I-CC
inhibits VBZ B-VP B-VP
HIV-1 NN B-NP B-NP
production NN I-NP I-NP
in IN B-PP B-PP
mature JJ B-NP B-NP
human JJ I-NP I-NP
monocytic JJ I-NP I-NP
cells NNS I-NP I-NP
. . O O

NF NN B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
potent JJ I-NP I-NP
mediator NN I-NP I-NP
of IN B-PP B-PP
specific JJ B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
monocytes NNS I-NP I-NP
and CC O I-CC
has VBZ B-VP B-VP
been VBN I-VP I-VP
shown VBN I-VP I-VP
to TO I-VP I-VP
play VB I-VP I-VP
a DT B-NP B-NP
role NN I-NP I-NP
in IN B-PP B-PP
transcription NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
HIV-1 NN I-NP I-NP
genome NN I-NP I-NP
in IN B-PP B-PP
promonocytic JJ B-NP B-NP
leukemias NNS I-NP I-NP
. . O O

There EX B-NP B-NP
is VBZ B-VP B-VP
little JJ B-NP B-NP
information NN I-NP I-NP
available JJ B-ADJP B-ADJP
on IN B-PP B-PP
the DT B-NP B-NP
response NN I-NP I-NP
of IN B-PP B-PP
NF NN B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
to TO B-PP B-PP
cytokines NNS B-NP B-NP
in IN B-PP B-PP
normal JJ B-NP B-NP
human JJ I-NP I-NP
monocytes NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
used VBN I-VP I-VP
a DT B-NP B-NP
32P-labeled JJ I-NP I-NP
oligonucleotide NN I-NP I-NP
derived VBN B-VP B-VP
from IN B-PP B-PP
human JJ B-NP B-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
( ( O O
HIV-1 NN B-NP B-NP
) ) O O
long JJ B-NP B-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
, , O O
which WDT B-NP B-NP
contains VBZ B-VP B-VP
a DT B-NP B-NP
tandem JJ I-NP I-NP
repeat NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
NF NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
binding NN I-NP I-NP
sequence NN I-NP I-NP
, , O O
as IN B-PP B-PP
a DT B-NP B-NP
probe NN I-NP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
gel NN I-NP I-NP
retardation NN I-NP I-NP
assay NN I-NP I-NP
to TO B-VP B-VP
study VB I-VP I-VP
this DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
. . O O

Using VBG B-VP B-VP
this DT B-NP B-NP
assay NN I-NP I-NP
, , O O
we PRP B-NP B-NP
have VBP B-VP B-VP
detected VBN I-VP I-VP
NF NN B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
in IN B-PP B-PP
extracts NNS B-NP B-NP
of IN B-PP B-PP
nuclei NNS B-NP B-NP
from IN B-PP B-PP
normal JJ B-NP B-NP
human JJ I-NP I-NP
monocytes NNS I-NP I-NP
. . O O

Treatment NN B-NP B-NP
of IN B-PP B-PP
normal JJ B-NP B-NP
monocytes NNS I-NP I-NP
with IN B-PP B-PP
12-0-tetradecanoyl JJ B-NP B-NP
phorbol-13-acetate NN I-NP I-NP
( ( O O
TPA NN B-NP B-NP
) ) O O
for IN B-PP B-PP
4-24 CD B-NP B-NP
h NN I-NP I-NP
caused VBD B-VP B-VP
the DT B-NP B-NP
complete JJ I-NP I-NP
disappearance NN I-NP I-NP
of IN B-PP B-PP
NF NN B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
from IN B-PP B-PP
nuclear JJ B-NP B-NP
extracts NNS I-NP I-NP
of IN B-PP B-PP
monocytes NNS B-NP B-NP
. . O O

A DT B-NP B-NP
similar JJ I-NP I-NP
result NN I-NP I-NP
was VBD B-VP B-VP
obtained VBN I-VP I-VP
with IN B-PP B-PP
the DT B-NP B-NP
mature JJ I-NP I-NP
monocytic JJ I-NP I-NP
leukemia NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
THP-1 NN I-NP I-NP
. . O O

The DT B-NP B-NP
constitutive JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
SP1 NN I-NP I-NP
was VBD B-VP B-VP
unaffected JJ I-VP B-ADJP
by IN B-PP B-PP
addition NN B-NP B-NP
of IN B-PP B-PP
TPA NN B-NP B-NP
. . O O

The DT B-NP B-NP
disappearance NN I-NP I-NP
of IN B-PP B-PP
NF NN B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
nucleus NN I-NP I-NP
was VBD B-VP B-VP
concentration NN B-NP B-NP
dependent JJ B-ADJP I-NP
between IN B-PP B-PP
10 CD B-NP B-NP
and CC I-NP I-NP
50 CD I-NP I-NP
ng/ml NN I-NP I-NP
of IN B-PP B-PP
phorbol NN B-NP B-NP
ester NN I-NP I-NP
. . O O

In IN B-PP B-PP
THP-1 NN B-NP B-NP
cells NNS I-NP I-NP
, , O O
TPA NN B-NP B-NP
also RB B-ADVP B-ADVP
induced VBD B-VP B-VP
a DT B-NP B-NP
new JJ I-NP I-NP
, , I-NP O
faster-migrating JJ I-NP I-NP
NF NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
species NNS I-NP I-NP
not RB B-VP B-VP
induced VBN I-VP I-VP
in IN B-PP B-PP
monocytes NNS B-NP B-NP
. . O O

Protein NN B-NP B-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
inhibitor NN I-NP I-NP
staurosporine NN I-NP I-NP
, , O O
but CC B-CONJP I-CC
not RB I-CONJP B-NP
cyclic JJ B-NP I-NP
nucleotide-dependent JJ I-NP I-NP
protein NN I-NP I-NP
kinase NN I-NP I-NP
inhibitor NN I-NP I-NP
HA-1004 NN I-NP I-NP
, , O O
also RB B-ADVP B-ADVP
dramatically RB B-ADVP B-VP
reduced VBD B-VP I-VP
constitutive JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
nuclear JJ B-NP B-NP
NF NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
. . O O

Finally RB B-ADVP B-ADVP
, , O O
TPA NN B-NP B-NP
addition NN I-NP I-NP
to TO B-PP B-PP
monocytes NNS B-NP B-NP
infected VBN B-VP B-VP
with IN B-PP B-PP
HIV-1 NN B-NP B-NP
inhibited VBD B-VP B-VP
HIV-1 NN B-NP B-NP
replication NN I-NP I-NP
, , O O
as IN B-SBAR B-SBAR
determined VBN B-VP B-VP
by IN B-PP B-PP
reverse JJ B-NP B-NP
transcriptase NN I-NP I-NP
assays NNS I-NP I-NP
, , O O
in IN B-PP B-PP
a DT B-NP B-NP
concentration-dependent JJ I-NP I-NP
manner NN I-NP I-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
are VBP B-VP B-VP
in IN B-PP B-PP
striking JJ B-NP B-NP
contrast NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
increase NN I-NP I-NP
in IN B-PP B-PP
nuclear JJ B-NP B-NP
NF NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
and CC O I-NP
HIV-1 NN B-NP I-NP
replication NN I-NP I-NP
induced VBN B-VP B-VP
by IN B-PP B-PP
phorbol NN B-NP B-NP
esters NNS I-NP I-NP
in IN B-PP B-PP
promonocytic JJ B-NP B-NP
leukemia NN I-NP I-NP
cells NNS I-NP I-NP
U937 NN B-NP I-NP
and CC O I-NP
HL-60 NN B-NP I-NP
, , O O
and CC O I-CC
emphasize VBP B-VP B-VP
the DT B-NP B-NP
importance NN I-NP I-NP
of IN B-PP B-PP
studying VBG B-VP B-VP
cytokine NN B-NP B-NP
regulation NN I-NP I-NP
of IN B-PP B-PP
HIV-1 NN B-NP B-NP
in IN B-PP B-PP
normal JJ B-NP B-NP
monocytes NNS I-NP I-NP
. . O O

Ablation NN B-NP B-NP
of IN B-PP B-PP
transplanted VBN B-NP B-NP
HTLV-I NN I-NP I-NP
Tax-transformed JJ I-NP I-NP
tumors NNS I-NP I-NP
in IN B-PP B-PP
mice NNS B-NP B-NP
by IN B-PP B-PP
antisense JJ B-NP B-NP
inhibition NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
( ( O O
published VBN B-NP B-NP
erratum NN I-NP I-NP
appears VBZ B-VP B-VP
in IN B-PP B-PP
Science NNP B-NP B-NP
1993 CD I-NP I-NP
Mar NNP I-NP B-NP
12 CD I-NP I-NP
; : I-NP O
259 CD I-NP B-NP
( ( I-NP O
5101 CD I-NP B-NP
) ) I-NP O
: : I-NP O
1523 CD I-NP B-NP
) ) O O

Mice NNS B-NP B-NP
transgenic JJ B-ADJP B-ADJP
for IN B-PP B-PP
the DT O B-NP
human JJ B-NP I-NP
T NN I-NP I-NP
cell NN I-NP I-NP
leukemia NN I-NP I-NP
virus NN I-NP I-NP
( ( O O
HTLV-I NN B-NP I-NN
) ) O O
Tax NN B-NP B-NP
gene NN I-NP I-NP
develop VBP B-VP B-VP
fibroblastic JJ B-NP B-NP
tumors NNS I-NP I-NP
that WDT B-NP B-NP
express VBP B-VP B-VP
NF-kappa NN B-NP B-NP
B-inducible JJ I-NP I-NP
early JJ I-NP I-NP
genes NNS I-NP I-NP
. . O O

In FW B-NP B-NP
vitro FW I-NP I-NP
inhibition NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
expression NN I-NP I-NP
by IN B-PP B-PP
antisense JJ B-NP B-NP
oligodeoxynucleotides NNS B-NP I-NP
( ( O O
ODNs NNS B-NP B-NP
) ) O O
inhibited VBD B-VP B-VP
growth NN B-NP B-NP
of IN B-PP B-PP
these DT B-NP B-NP
culture-adapted JJ I-NP I-NP
Tax-transformed JJ I-NP I-NP
fibroblasts NNS I-NP I-NP
as RB B-CONJP B-CONJP
well RB I-CONJP I-CONJP
as IN I-CONJP I-CONJP
an DT B-NP B-NP
HTLV-I-transformed JJ I-NP I-NP
human JJ I-NP I-NP
lymphocyte NN I-NP I-NP
line NN I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
antisense JJ B-NP B-NP
inhibition NN I-NP I-NP
of IN B-PP B-PP
Tax NN B-NP B-NP
itself PRP B-NP B-NP
had VBD B-VP B-VP
no DT B-NP B-NP
apparent JJ I-NP I-NP
effect NN I-NP I-NP
on IN B-PP B-PP
cell NN B-NP B-NP
growth NN I-NP I-NP
. . O O

Mice NNS B-NP B-NP
treated VBN B-VP B-VP
with IN B-PP B-PP
antisense NN B-NP B-NP
to TO B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
ODNs NNS I-NP I-NP
showed VBD B-VP B-VP
rapid JJ B-NP B-NP
regression NN I-NP I-NP
of IN B-PP B-PP
transplanted VBN B-NP B-NP
fibrosarcomas NNS I-NP I-NP
. . O O

This DT B-NP B-NP
suggests VBZ B-VP B-VP
that IN B-SBAR B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
expression NN I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
necessary JJ B-ADJP B-ADJP
for IN B-PP B-PP
the DT B-NP B-NP
maintenance NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
malignant JJ I-NP I-NP
phenotype NN I-NP I-NP
and CC O I-CC
provides VBZ B-VP B-VP
a DT B-NP B-NP
therapeutic JJ I-NP I-NP
approach NN I-NP I-NP
for IN B-PP B-PP
HTLV-I-associated JJ B-NP B-NP
disease NN I-NP I-NP
. . O O

Inhibition NN B-NP B-NP
of IN B-PP B-PP
anti-CD3 JJ B-NP B-NP
monoclonal JJ I-NP I-NP
antibody-induced JJ I-NP I-NP
T-cell NN I-NP I-NP
proliferation NN I-NP I-NP
by IN B-PP B-PP
dexamethasone NN B-NP B-NP
, , O O
isoproterenol NN B-NP B-NP
, , O O
or CC O I-CC
prostaglandin NN B-NP B-NP
E2 NN I-NP I-NP
either CC O I-CC
alone RB B-ADVP B-ADVP
or CC O I-CC
in IN B-PP B-PP
combination NN B-NP B-NP
. . O O

1 LS B-LST I-LS
. . O O
The DT B-NP B-NP
purpose NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
studies NNS I-NP I-NP
was VBD B-VP B-VP
to TO B-VP I-VP
investigate VB I-VP I-VP
the DT B-NP B-NP
modulation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
proliferation NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
obtained VBN B-VP B-VP
from IN B-PP B-PP
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
by IN B-PP B-PP
dexamethasone NN B-NP B-NP
( ( O O
DEX NN B-NP B-NP
) ) O O
, , O O
isoproterenol NN B-NP B-NP
( ( O O
ISO NN B-NP B-NP
) ) O O
, , O O
and CC O I-CC
prostaglandin NN B-NP B-NP
E2 NN I-NP I-NP
( ( O O
PGE2 NN B-NP B-NP
) ) O O
. . O O

The DT B-NP B-NP
former JJ I-NP I-NP
two CD I-NP I-NP
substances NNS I-NP I-NP
interact VBP B-VP B-VP
with IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
via IN B-PP B-PP
the DT O B-NP
glucocorticoid NN B-NP I-NP
and CC O I-CC
beta-adrenergic JJ B-ADJP B-NP
receptors NNS B-NP I-NP
respectively RB B-ADVP B-ADVP
. . O O

When WRB B-ADVP B-ADVP
occupied VBN B-VP B-VP
by IN B-PP B-PP
their PRP$ B-NP B-NP
natural JJ I-NP I-NP
ligands NNS I-NP I-NP
, , O O
glucocorticosteroids NNS B-NP I-NP
and CC O I-NP
catecholamines NNS B-NP I-NP
, , O O
these DT B-NP B-NP
receptors NNS I-NP I-NP
have VBP B-VP B-VP
a DT B-NP B-NP
role NN I-NP I-NP
in IN B-PP B-PP
modulating VBG B-VP B-VP
T-cell NN B-NP B-NP
function NN I-NP I-NP
during IN B-PP B-PP
stress NN B-NP B-NP
. . O O

During IN B-PP B-PP
the DT B-NP B-NP
inflammatory JJ I-NP I-NP
response NN I-NP I-NP
increased VBN B-NP B-VP
levels NNS I-NP B-NP
of IN B-PP B-PP
PGE2 NN B-NP B-NP
bind VBP B-VP B-VP
to TO B-PP B-PP
their PRP$ B-NP B-NP
receptors NNS I-NP I-NP
on IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
and CC O I-CC
thus RB O B-VP
alter VBP B-VP I-VP
responsiveness NN B-NP B-NP
. . O O

Proliferation NN B-NP B-NP
of IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
was VBD B-VP B-VP
induced VBN I-VP I-VP
by IN B-PP B-PP
immobilized VBN B-NP B-NP
anti-CD3 JJ I-NP I-NP
monoclonal JJ B-NP I-NP
antibody NN I-NP I-NP
( ( O O
mAb NN B-NP B-NP
) ) O O
in IN B-PP B-PP
the DT B-NP B-NP
presence NN B-NP I-NP
or CC O I-NP
absence NN B-NP I-NP
of IN B-PP B-PP
an DT B-NP B-NP
additional JJ I-NP I-NP
costimulatory JJ I-NP I-NP
signal NN I-NP I-NP
delivered VBN B-VP B-VP
by IN B-PP B-PP
anti-CD28 JJ B-NP B-NP
mAb NN I-NP I-NP
. . O O

2 LS B-LST B-NP
. . O O
Various JJ B-NP B-NP
physiologic JJ I-NP I-NP
concentrations NNS I-NP I-NP
of IN B-PP B-PP
DEX NN B-NP B-NP
, , O O
ISO NN B-NP B-NP
, , O O
or CC O I-CC
PGE2 NN B-NP B-NP
were VBD B-VP B-VP
added VBN I-VP I-VP
at IN B-PP B-PP
the DT B-NP B-NP
time NN I-NP I-NP
of IN B-PP B-PP
initiation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
cultures NNS I-NP I-NP
and CC O I-CC
subsequent JJ B-NP B-NP
proliferation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
unstimulated JJ I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
was VBD B-VP B-VP
determined VBN I-VP I-VP
. . O O

The DT B-NP B-NP
results NNS I-NP I-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
physiologic JJ B-NP B-NP
concentrations NNS I-NP I-NP
of IN B-PP B-PP
all DT B-NP B-NP
three CD I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
agents NNS I-NP I-NP
inhibit VBP B-VP B-VP
the DT B-NP B-NP
anti-CD3 JJ I-NP I-NP
mAb-induced JJ I-NP I-NP
proliferation NN I-NP I-NP
of IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

3 LS B-LST I-LS
. . O O
Although IN B-SBAR B-PP
DEX NN B-NP B-NP
and CC O I-NP
PGE2 NN B-NP I-NP
were VBD B-VP B-VP
equipotent JJ B-ADJP B-ADJP
in IN B-PP B-PP
suppressing JJ B-VP B-NP
T-cell NN B-NP I-NP
proliferation NN I-NP I-NP
, , O O
ISO NN B-NP B-NP
was VBD B-VP B-VP
much RB B-ADJP B-ADJP
less RBR I-ADJP I-ADJP
effective JJ I-ADJP I-ADJP
. . O O

4 LS B-LST I-LS
. . O O
Because IN B-SBAR B-PP
concomitant JJ B-NP B-NP
elevations NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
peripheral JJ I-NP I-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
substances NNS I-NP I-NP
may MD B-VP B-VP
occur VB I-VP I-VP
, , O O
experiments NNS B-NP B-NP
were VBD B-VP B-VP
performed VBN I-VP I-VP
to TO B-VP B-VP
determine VB I-VP I-VP
the DT B-NP B-NP
T-cell NN I-NP I-NP
inhibitory JJ I-NP I-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
DEX NN B-NP B-NP
together RB B-PP B-ADVP
with IN I-PP B-PP
either CC O I-CC
PGE2 NN B-NP B-NP
or CC O I-NP
ISO NN B-NP I-NP
. . O O

Synergistic JJ B-NP B-NP
suppression NN I-NP I-NP
of IN B-PP B-PP
T-cell NN B-NP B-NP
proliferation NN I-NP I-NP
was VBD B-VP B-VP
observed VBN I-VP I-VP
when WRB B-ADVP B-ADVP
various JJ B-NP B-NP
concentrations NNS I-NP I-NP
of IN B-PP B-PP
DEX NN B-NP B-NP
and CC O I-NP
PGE2 NN B-NP I-NP
, , O O
but CC B-CONJP I-CC
not RB I-CONJP B-NP
DEX NN B-NP I-NP
and CC O I-NP
ISO NN B-NP I-NP
, , O O
were VBD B-VP B-VP
added VBN I-VP I-VP
to TO B-PP B-PP
cultures NNS B-NP B-NP
. . O O

This DT B-NP B-NP
synergistic JJ I-NP I-NP
suppression NN I-NP I-NP
could MD B-VP B-VP
not RB I-VP I-VP
be VB I-VP I-VP
explained VBN I-VP I-VP
by IN B-PP B-PP
an DT B-NP B-NP
increase NN I-NP I-NP
in IN B-PP B-PP
cAMP NN B-NP B-NP
accumulation NN I-NP I-NP
in IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
stimulated VBN B-VP B-VP
with IN B-PP B-PP
DEX NN B-NP B-NP
and CC O I-NP
PGE2 NN B-NP I-NP
. . O O

5 LS B-LST I-LS
. . O O
Finally RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
addition NN I-NP I-NP
of IN B-PP B-PP
anti-CD28 JJ B-NP B-NP
mAb NN I-NP I-NP
to TO B-PP B-PP
anti-CD3 JJ B-NP B-NP
mAb-stimulated JJ I-NP I-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
overcame VBD B-VP B-VP
much JJ B-NP B-ADJP
of IN B-PP B-PP
the DT B-NP B-NP
suppression NN I-NP I-NP
of IN B-PP B-PP
proliferation NN B-NP B-NP
induced VBN B-VP B-VP
by IN B-PP B-PP
PGE2 NN B-NP B-NP
or CC O I-NP
ISO NN B-NP I-NP
but CC O I-CC
less RBR B-ADVP B-ADJP
so RB I-ADVP I-ADJP
than IN B-PP B-PP
that DT B-NP B-NP
induced VBN B-VP B-VP
by IN B-PP B-PP
DEX NN B-NP B-NP
. . O O

Targeted VBN B-NP B-NP
degradation NN I-NP I-NP
of IN B-PP B-PP
c-Fos NN B-NP B-NP
, , O O
but CC B-CONJP I-CC
not RB I-CONJP B-NP
v-Fos NN B-NP I-NP
, , O O
by IN B-PP B-PP
a DT B-NP B-NP
phosphorylation-dependent JJ I-NP I-NP
signal NN I-NP I-NP
on IN B-PP B-PP
c-Jun NN B-NP B-NP
. . O O

The DT B-NP B-NP
proto-oncogene NN I-NP I-NP
products NNS I-NP I-NP
c-Fos NN B-NP I-NP
and CC O I-NP
c-Jun NN B-NP I-NP
heterodimerize VBP B-VP B-VP
through IN B-PP B-PP
their PRP$ B-NP B-NP
leucine NN I-NP I-NP
zippers NNS I-NP I-NP
to TO B-VP B-VP
form VB I-VP I-VP
the DT B-NP B-NP
AP-1 NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
. . O O

The DT B-NP B-NP
transcriptional JJ I-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
heterodimer NN I-NP I-NP
is VBZ B-VP B-VP
regulated VBN I-VP I-VP
by IN B-PP B-PP
signal-dependent JJ O B-NP
phosphorylation NN B-NP I-NP
and CC O I-NP
dephosphorylation NN B-NP I-NP
events NNS B-NP I-NP
. . O O

The DT B-NP B-NP
stability NN I-NP I-NP
of IN B-PP B-PP
c-Fos NN B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
also RB I-VP I-VP
be VB I-VP I-VP
controlled VBN I-VP I-VP
by IN B-PP B-PP
intracellular JJ B-NP B-NP
signal NN I-NP I-NP
transduction NN I-NP I-NP
. . O O

In IN B-PP B-PP
transient JJ B-NP B-NP
expression NN I-NP I-NP
and CC O I-NP
in FW B-NP B-NP
vitro FW I-NP I-NP
degradation NN I-NP I-NP
experiments NNS B-NP I-NP
, , O O
the DT B-NP B-NP
stability NN I-NP I-NP
of IN B-PP B-PP
c-Fos NN B-NP B-NP
was VBD B-VP B-VP
decreased VBN I-VP I-VP
when WRB B-ADVP B-ADVP
the DT B-NP B-NP
protein NN I-NP I-NP
was VBD B-VP B-VP
dimerized JJ I-VP B-ADJP
with IN B-PP B-PP
phosphorylated VBN B-NP B-NP
c-Jun NN I-NP I-NP
. . O O

c-Jun NN B-NP B-NP
protein NN I-NP I-NP
isolated VBN B-VP B-VP
from IN B-PP B-PP
phorbol NN B-NP B-NP
ester-induced JJ I-NP I-NP
cells NNS I-NP I-NP
did VBD B-VP B-VP
not RB I-VP I-VP
target VB I-VP I-VP
c-Fos NN B-NP B-NP
for IN B-PP B-PP
degradation NN B-NP B-NP
, , O O
which WDT B-NP B-NP
suggests VBZ B-VP B-VP
that IN B-SBAR B-PP
c-Fos NN B-NP B-NP
is VBZ B-VP B-VP
transiently RB I-VP I-VP
stabilized VBN I-VP I-VP
after IN B-PP B-PP
stimulation NN B-NP B-NP
of IN B-PP B-PP
cell NN B-NP B-NP
growth NN I-NP I-NP
. . O O

v-Fos NN B-NP B-NP
protein NN I-NP I-NP
, , O O
the DT B-NP B-NP
retroviral JJ I-NP I-NP
counterpart NN I-NP I-NP
of IN B-PP B-PP
c-Fos NN B-NP B-NP
, , O O
was VBD B-VP B-VP
not RB O I-RB
susceptible JJ B-ADJP B-ADJP
to TO B-PP B-PP
degradation NN B-NP B-NP
targeted VBN B-VP B-VP
by IN B-PP B-PP
c-Jun NN B-NP B-NP
. . O O

Mutations NNS B-NP B-NP
in IN B-PP B-PP
the DT B-NP B-NP
Pit-1 NN I-NP I-NP
gene NN I-NP I-NP
in IN B-PP B-PP
children NNS B-NP B-NP
with IN B-PP B-PP
combined JJ B-NP B-NP
pituitary JJ I-NP I-NP
hormone NN I-NP I-NP
deficiency NN I-NP I-NP
. . O O

Pit-1 NN B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
pituitary-specific JJ I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
that WDT B-NP B-NP
binds VBZ B-VP B-VP
to TO B-PP B-NP
and CC O I-CC
transactivates VBZ B-VP B-VP
promoters NNS B-NP B-NP
of IN B-PP B-PP
growth NN B-NP B-NP
hormone NN I-NP I-NP
and CC O I-NP
prolactin NN B-NP I-NP
genes NNS I-NP I-NP
. . O O

In IN B-PP B-PP
three CD B-NP B-NP
unrelated JJ I-NP I-NP
Japanese JJ I-NP I-NP
children NNS I-NP I-NP
with IN B-PP B-PP
combined JJ B-NP B-NP
pituitary JJ I-NP I-NP
hormone NN I-NP I-NP
deficiency NN I-NP I-NP
, , O O
we PRP B-NP B-NP
identified VBD B-VP B-VP
three CD B-NP B-NP
point NN I-NP I-NP
mutations NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
Pit-1 NN I-NP I-NP
gene NN I-NP I-NP
, , O O
Pro24Leu NN B-NP B-NP
, , O O
Arg143Gln NN B-NP B-NP
, , O O
and CC O I-CC
Arg271Trp NN B-NP B-NP
, , O O
located JJ O B-ADJP
on IN B-PP B-PP
the DT B-NP B-NP
major JJ I-NP I-NP
transactivation NN I-NP I-NP
region NN I-NP I-NP
, , O O
POU-specific JJ B-NP B-NP
domain NN I-NP I-NP
, , O O
and CC O I-CC
POU-homeodomain NN B-NP B-NP
, , O O
respectively RB B-ADJP B-ADVP
. . O O

Calcitriol NN B-NP B-NP
: : O O
a DT B-NP B-NP
hematolymphopoietrope NN I-NP I-NP
? . O O
( ( O O
editorial NN B-NP B-NP
) ) O O

A DT B-NP B-NP
MEDLINE NN I-NP I-NP
search NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
English-language JJ I-NP I-NP
literature NN I-NP I-NP
was VBD B-VP B-VP
conducted VBN I-VP I-VP
using VBG B-VP B-VP
the DT B-NP B-NP
indexing NN I-NP I-NP
terms NNS I-NP I-NP
' [[DQS]] O B-NP
immunology NN B-NP I-NP
, , O O
calcitriol NN B-NP I-NP
and CC O I-NP
vitamin NN B-NP I-NP
D NN I-NP I-NP
' [[DQE]] O B-VP
to TO B-VP I-VP
identify VB I-VP I-VP
studies NNS B-NP B-NP
indicating VBG B-VP B-VP
a DT B-NP B-NP
role NN I-NP I-NP
for IN B-PP B-PP
calcitriol NN B-NP B-NP
as IN B-PP B-PP
a DT B-NP B-NP
primary JJ I-NP I-NP
immunomodulator NN I-NP I-NP
. . O O

Sixty-six CD B-NP B-NP
papers NNS I-NP I-NP
published VBN B-VP B-VP
between IN B-PP B-PP
January NNP B-NP B-NP
1956 CD I-NP I-NP
and CC O I-CC
June NNP B-NP B-NP
1991 CD I-NP I-NP
were VBD B-VP B-VP
identified VBN I-VP I-VP
. . O O

Forty-five CD B-NP B-NP
of IN B-PP B-PP
these DT B-NP B-NP
reports NNS I-NP I-NP
are VBP B-VP B-VP
cited VBN I-VP I-VP
in IN B-PP B-PP
this DT B-NP B-NP
review NN I-NP I-NP
. . O O

The DT B-NP B-NP
data NNS I-NP I-NP
strongly RB B-ADVP B-ADVP
suggest VBP B-VP B-VP
an DT B-NP B-NP
endocrine NN I-NP I-NP
, , I-NP O
autocrine NN I-NP I-NP
and/or CC I-NP I-NP
paracrine NN I-NP I-NP
role NN I-NP I-NP
for IN B-PP B-PP
calcitriol NN B-NP B-NP
in IN B-PP B-PP
immune JJ B-NP B-NP
regulation NN I-NP I-NP
. . O O

No DT B-NP B-NP
unifying JJ I-NP I-NP
hypothesis NN I-NP I-NP
has VBZ B-VP B-VP
yet RB I-VP I-VP
emerged VBN I-VP I-VP
explaining VBG I-VP I-VP
this DT B-NP B-NP
collection NN I-NP I-NP
of IN B-PP B-PP
data NNS B-NP B-NP
. . O O

This DT B-NP B-NP
paper NN I-NP I-NP
provides VBZ B-VP B-VP
a DT B-NP B-NP
brief JJ I-NP I-NP
review NN I-NP I-NP
of IN B-PP B-PP
immune JJ B-NP B-NP
properties NNS I-NP I-NP
currently RB B-VP B-VP
attributed VBN I-VP I-VP
to TO B-PP B-PP
calcitriol NN B-NP B-NP
. . O O

Activation NN B-NP B-NP
of IN B-PP B-PP
protein NN B-NP B-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
and CC O I-NP
elevation NN B-NP I-NP
of IN B-PP B-PP
cAMP NN B-NP B-NP
interact VBP B-VP B-VP
synergistically RB I-VP B-ADVP
to TO I-VP B-VP
raise VB I-VP I-VP
c-Fos NN B-NP B-NP
and CC O I-NP
AP-1 NN B-NP I-NP
activity NN B-NP I-NP
in IN B-PP B-PP
Jurkat NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
earlier RBR I-VP B-NP
found VBN I-VP B-VP
that IN B-SBAR B-SBAR
in IN B-PP B-PP
Jurkat NN B-NP B-NP
cells NNS I-NP I-NP
activation NN B-NP I-NP
of IN B-PP B-PP
protein NN B-NP B-NP
kinase NN I-NP I-NP
C NN I-NP I-NP
( ( O O
PKC NN B-NP B-NP
) ) O O
enhances VBZ B-VP B-VP
the DT O B-NP
cyclic JJ B-NP I-NP
adenosine NN I-NP I-NP
monophosphate NN I-NP I-NP
( ( O O
cAMP NN B-NP I-NN
) ) O O
accumulation NN B-NP B-NP
induced VBN B-VP B-VP
by IN B-PP B-PP
adenosine NN B-NP B-NP
receptor NN I-NP I-NP
stimulation NN I-NP I-NP
or CC O I-NP
activation NN B-NP I-NP
of IN B-PP B-PP
Gs NN B-NP B-NP
. . O O

Here RB B-ADVP B-ADVP
we PRP B-NP B-NP
have VBP B-VP B-VP
therefore RB I-VP I-VP
examined VBN I-VP I-VP
the DT B-NP B-NP
effect NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
phorbol NN I-NP I-NP
ester NN I-NP I-NP
PMA NN B-NP I-NP
( ( O O
phorbol NN B-NP B-NP
12-myristate NN I-NP I-NP
13-acetate NN I-NP I-NP
) ) O O
which WDT B-NP B-NP
stimulates VBZ B-VP B-VP
PKC NN B-NP B-NP
and CC O I-CC
a DT B-NP B-NP
combination NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
adenosine NN I-NP I-NP
receptor NN I-NP I-NP
agonist NN I-NP I-NP
NECA NN B-NP I-NP
( ( O O
5'-(N-ethyl)-carboxamido JJ|NN B-NP B-NP
adenosine NN I-NP I-NP
) ) O O
and CC O I-CC
forskolin NN B-NP B-NP
to TO B-VP B-VP
raise VB I-VP I-VP
cAMP NN B-NP B-NP
, , O O
on IN B-PP B-PP
the DT B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
c-Fos NN B-NP B-NP
and CC O I-NP
Jun NN B-NP I-NP
and CC B-PP B-PP
on IN B-PP B-PP
the DT B-NP B-NP
binding VBG B-NP I-NP
and CC O I-NP
transcriptional JJ B-NP I-NP
activity NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
, , O O
activator NN B-NP B-NP
protein-1 NN I-NP I-NP
( ( O O
AP-1 NN B-NP B-NP
) ) O O
. . O O

PMA NN B-NP B-NP
treatment NN I-NP I-NP
caused VBD B-VP B-VP
a DT O B-NP
concentration- NN B-NP I-NP
and CC O I-NP
time-dependent JJ B-ADJP I-NP
increase NN B-NP I-NP
in IN B-PP B-PP
both CC O B-NP
c-Fos NN B-NP I-NP
and CC O I-NP
Jun NN B-NP I-NP
immunoreactivity NN B-NP I-NP
in IN B-PP B-PP
contrast NN I-PP B-NP
to TO I-PP B-PP
cAMP NN B-NP B-NP
elevation NN I-NP I-NP
that WDT B-NP B-NP
had VBD B-VP B-VP
only RB B-NP B-NP
a DT I-NP I-NP
slight JJ I-NP I-NP
effect NN I-NP I-NP
. . O O

Both CC O I-CC
PMA NN B-NP B-NP
and CC O I-CC
the DT B-NP B-NP
combination NN I-NP I-NP
of IN B-PP B-PP
NECA NN B-NP B-NP
and CC O I-NP
forskolin NN B-NP I-NP
acted VBD B-VP B-VP
together RB B-ADVP B-ADVP
either CC O I-CC
to TO B-VP B-VP
increase VB I-VP I-VP
( ( O O
c-Fos NN B-NP B-NP
) ) O O
or CC O I-CC
decrease VB B-VP B-VP
( ( O O
Jun NN B-NP I-NN
) ) O O
protein NN B-NP B-NP
levels NNS I-NP I-NP
as RB B-PP B-ADVP
well RB I-PP I-ADVP
as IN I-PP B-PP
increasing VBG B-VP B-VP
AP-1 NN B-NP B-NP
binding NN I-NP I-NP
, , O O
as IN B-SBAR B-SBAR
judged VBN B-VP B-VP
by IN B-PP B-PP
gel-shift NN B-NP B-NP
assay NN I-NP I-NP
, , O O
and CC O I-CC
AP-1 NN B-NP B-NP
transcriptional JJ I-NP I-NP
activity NN I-NP I-NP
. . O O

Furthermore RB B-ADVP B-ADVP
there EX B-NP B-NP
was VBD B-VP B-VP
a DT B-NP B-NP
clear-cut JJ I-NP I-NP
synergy NN I-NP I-NP
between IN B-PP B-PP
the DT B-NP B-NP
PKC NN I-NP I-NP
stimulator NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
cAMP NN I-NP I-NP
elevating NN I-NP I-NP
agents NNS I-NP I-NP
. . O O

The DT B-NP B-NP
results NNS I-NP I-NP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
simultaneous JJ I-NP I-NP
activation NN B-NP I-NP
of IN B-PP B-PP
PKC NN B-NP B-NP
and CC O I-NP
elevation NN B-NP I-NP
of IN B-PP B-PP
cAMP NN B-NP B-NP
leads VBZ B-VP B-VP
to TO B-PP B-PP
an DT B-NP B-NP
enhanced VBN I-NP I-NP
AP-1 NN I-NP I-NP
transcriptional JJ I-NP I-NP
activity NN I-NP I-NP
in IN B-PP B-PP
a DT B-NP B-NP
T-leukemia NN I-NP I-NP
cell NN I-NP I-NP
line NN I-NP I-NP
, , O O
suggesting VBG B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
previously RB I-NP I-NP
observed VBN I-NP I-NP
interaction NN I-NP I-NP
between IN B-PP B-PP
the DT B-NP B-NP
parallel JJ I-NP I-NP
signal NN I-NP I-NP
transduction NN I-NP I-NP
pathways NNS I-NP I-NP
may MD B-VP B-VP
have VB I-VP I-VP
functional JJ B-NP B-NP
consequences NNS I-NP I-NP
at IN B-PP B-PP
the DT B-NP B-NP
level NN I-NP I-NP
of IN B-PP B-PP
gene NN B-NP B-NP
transcription NN I-NP I-NP
. . O O

The DT B-NP B-NP
use NN I-NP I-NP
of IN B-PP B-PP
interferon-gamma-treated JJ B-NP B-NP
U937 NN I-NP I-NP
cells NNS I-NP I-NP
in IN B-PP B-PP
chemiluminescence NN B-NP B-NP
assays NNS I-NP I-NP
to TO B-VP B-VP
detect VB I-VP I-VP
red JJ B-NP B-NP
cell NN I-NP I-NP
, , O O
platelet NN B-NP I-NP
and CC O I-NP
granulocyte NN B-NP I-NP
antibodies NNS I-NP I-NP
of IN B-PP B-PP
potential JJ B-NP B-NP
clinical JJ I-NP I-NP
significance NN I-NP I-NP
. . O O

The DT O B-NP
chemiluminescent JJ O I-NP
( ( O O
CL JJ B-ADJP I-JJ
) ) O O
response NN B-NP B-NP
of IN B-PP B-PP
interferon-gamma-treated JJ B-NP B-NP
U937 NN I-NP I-NP
( ( O O
IFN-U937 NN B-NP B-NP
) ) O O
cells NNS B-NP B-VP
to TO B-PP B-PP
sensitized VBN B-NP B-NP
target NN I-NP I-NP
cells NNS I-NP I-NP
has VBZ B-VP B-VP
been VBN I-VP I-VP
used VBN I-VP I-VP
to TO B-VP B-VP
detect VB I-VP I-VP
red JJ B-NP B-NP
cell NN I-NP I-NP
, , O O
platelet NN B-NP I-NP
and CC O I-NP
granulocyte NN B-NP I-NP
antibodies NNS I-NP I-NP
. . O O

A DT B-NP B-NP
clone NN I-NP I-NP
of IN B-PP B-PP
U937 NN B-NP B-NP
cells NNS I-NP I-NP
was VBD B-VP B-VP
selected VBN I-VP I-VP
which WDT B-NP B-NP
expressed VBD B-VP B-VP
Fc NN B-NP B-NP
receptor NN I-NP I-NP
I NN I-NP I-NP
( ( O O
Fc NN B-NP B-NP
gamma NN I-NP I-NP
RI NN I-NP I-NP
) ) O O
and CC O I-CC
which WDT B-NP B-NP
, , O O
after IN B-PP B-PP
incubation NN B-NP B-NP
with IN B-PP B-PP
IFN-gamma NN B-NP B-NP
for IN B-PP B-PP
72 CD B-NP B-NP
h NN I-NP I-NP
, , O O
was VBD B-VP B-VP
capable JJ B-ADJP B-ADJP
of IN B-PP B-PP
generating VBG B-VP B-VP
high JJ B-NP B-NP
levels NNS I-NP I-NP
of IN B-PP B-PP
lucigenin-enhanced JJ B-NP B-NP
CL NN I-NP I-NP
. . O O

The DT B-NP B-NP
CL NN I-NP I-NP
responses NNS I-NP I-NP
of IN B-PP B-PP
IFN-U937 NN B-NP B-NP
cells NNS I-NP I-NP
and CC O I-CC
peripheral JJ B-NP B-NP
blood NN I-NP I-NP
human JJ I-NP I-NP
monocytes NNS I-NP I-NP
to TO B-PP B-VP
sensitized VBN B-NP I-VP
red JJ B-NP B-NP
cells NNS I-NP I-NP
, , O O
platelets NNS B-NP I-NP
or CC O I-NP
granulocytes NNS B-NP I-NP
were VBD B-VP B-VP
then RB I-VP I-VP
compared VBN I-VP I-VP
. . O O

Assays NNS B-NP B-NP
using VBG B-VP B-VP
monocytes NNS B-NP B-NP
or CC O I-CC
IFN-U937 NN B-NP B-NP
cells NNS I-NP I-NP
were VBD B-VP B-VP
of IN B-PP B-PP
comparable JJ B-NP B-NP
sensitivity NN I-NP I-NP
for IN B-PP B-PP
detection NN B-NP B-NP
of IN B-PP B-PP
antibodies NNS B-NP B-NP
against IN B-PP B-PP
all DT B-NP B-NP
three CD I-NP I-NP
types NNS I-NP I-NP
of IN B-PP B-PP
target NN B-NP B-NP
cell NN I-NP I-NP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
the DT B-NP B-NP
use NN I-NP I-NP
of IN B-PP B-PP
IFN-U937 NN B-NP B-NP
cells NNS I-NP I-NP
reduced VBD B-VP B-VP
interassay JJ B-NP B-NP
variation NN I-NP I-NP
and CC O I-CC
simplified VBD|VBN B-VP B-NP
assay NN B-NP I-NP
performance NN I-NP I-NP
. . O O

The DT B-NP B-NP
potential JJ I-NP I-NP
clinical JJ I-NP I-NP
usefulness NN I-NP I-NP
of IN B-PP B-PP
these DT B-NP B-NP
CL NN I-NP I-NP
assays NNS I-NP I-NP
was VBD B-VP B-VP
suggested VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
ability NN I-NP I-NP
of IN B-PP B-PP
both CC O I-CC
monocytes NNS B-NP B-NP
and CC O I-CC
IFN-U937 NN B-NP B-NP
cells NNS I-NP I-NP
to TO B-VP B-VP
respond VB I-VP I-VP
to TO B-PP B-PP
red JJ B-NP B-NP
cells NNS I-NP I-NP
, , O O
platelets NNS B-NP I-NP
or CC O I-NP
granulocytes NNS B-NP I-NP
sensitized VBN B-VP B-VP
with IN B-PP B-PP
sera NN B-NP B-NP
from IN B-PP B-PP
pregnant JJ B-NP B-NP
women NNS I-NP I-NP
whose WP$ B-NP B-NP
babies NNS I-NP I-NP
had VBD B-VP B-VP
either CC O I-VP
haemolytic JJ B-NP B-NP
disease NN I-NP I-NP
of IN I-NP B-PP
the DT I-NP B-NP
newborn JJ I-NP I-NP
( ( O O
HDN NN B-NP B-NP
) ) O O
, , O O
alloimmune JJ B-NP B-NP
thrombocytopenia NN I-NP I-NP
or CC O I-CC
alloimmune JJ B-NP B-NP
neutropenia NN I-NP I-NP
respectively RB B-ADVP B-ADVP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
monocytes NNS B-NP B-NP
and CC O I-CC
IFN-U937 NN B-NP B-NP
cells NNS I-NP I-NP
both DT B-NP I-DT
responded VBD B-VP B-VP
to TO B-PP B-PP
red JJ B-NP B-NP
cells NNS I-NP I-NP
sensitized VBN B-VP B-VP
with IN B-PP B-PP
antibodies NNS B-NP B-NP
against IN B-PP B-PP
a DT B-NP B-NP
variety NN I-NP I-NP
of IN B-PP B-PP
specificities NNS B-NP B-NP
of IN B-PP B-PP
assumed VBN B-NP B-NP
( ( I-NP O
although IN I-NP B-PP
not RB I-NP B-NP
documented VBN I-NP I-NP
) ) I-NP O
clinical JJ I-NP I-NP
significance NN I-NP I-NP
for IN B-PP B-PP
blood NN B-NP B-NP
transfusion NN I-NP I-NP
recipients NNS I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
monocytes NNS B-NP B-NP
and CC O I-CC
IFN-U937 NN B-NP B-NP
cells NNS I-NP I-NP
responded VBD B-VP B-VP
only RB B-ADVP B-ADVP
weakly RB I-ADVP I-ADVP
to TO B-PP B-PP
red JJ B-NP B-NP
cells NNS I-NP I-NP
sensitized VBN B-VP B-VP
with IN B-PP B-PP
either CC I-PP I-CC
anti-D JJ B-NP B-ADJP
in IN B-PP B-PP
sera NN B-NP B-NP
from IN B-PP B-PP
mothers NNS B-NP B-NP
of IN B-PP B-PP
babies NNS B-NP B-NP
unaffected JJ B-VP B-ADJP
by IN B-PP B-PP
HDN NN B-NP B-NP
, , B-PP O
or CC I-PP I-CC
with IN B-PP B-PP
antisera NNS B-NP B-NP
containing VBG B-VP B-VP
high JJ B-NP B-NP
titre NN I-NP I-NP
antibodies NNS I-NP I-NP
with IN B-PP B-PP
specificities NNS B-NP B-NP
not RB B-VP B-VP
normally RB I-VP I-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
significantly RB B-NP B-NP
reduced VBN I-NP I-NP
red JJ I-NP I-NP
cell NN I-NP I-NP
survival NN I-NP I-NP
. . O O

Photoaffinity NN B-NP B-NP
labeling NN I-NP I-NP
of IN B-PP B-PP
plasma NN B-NP B-NP
membrane NN I-NP I-NP
receptors NNS I-NP I-NP
for IN B-PP B-PP
aldosterone NN B-NP B-NP
from IN B-PP B-PP
human JJ B-NP B-NP
mononuclear JJ I-NP I-NP
leukocytes NNS I-NP I-NP
. . O O

Non-genomic JJ B-NP B-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
aldosterone NN B-NP B-NP
on IN B-PP B-PP
the DT B-NP B-NP
sodium-proton-antiport NN I-NP I-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
shown VBN I-VP I-VP
in IN B-PP B-PP
human JJ B-NP B-NP
mononuclear JJ I-NP I-NP
leukocytes NNS I-NP I-NP
which WDT B-NP B-NP
could MD B-VP B-VP
be VB I-VP I-VP
related JJ B-ADJP B-ADJP
to TO B-PP B-PP
a DT B-NP B-NP
new JJ I-NP I-NP
aldosterone NN I-NP I-NP
membrane NN I-NP I-NP
receptor NN I-NP I-NP
. . O O

In IN B-PP B-PP
the DT B-NP B-NP
present JJ I-NP I-NP
paper NN I-NP I-NP
plasma NN B-NP I-NP
membranes NNS I-NP I-NP
from IN B-PP B-PP
human JJ B-NP B-NP
mononuclear JJ I-NP I-NP
leukocytes NNS I-NP I-NP
were VBD B-VP B-VP
covalently RB I-VP I-VP
photolabeled VBN I-VP I-VP
with IN B-PP B-PP
a DT B-NP B-NP
(125I)-aldosterone NN I-NP I-NP
derivative NN I-NP I-NP
. . O O

Sodium NN B-NP B-NP
dodecyl NN I-NP I-NP
sulfate-polyacrylamide JJ I-NP I-NP
gel NN I-NP I-NP
electrophoresis NN I-NP I-NP
showed VBD B-VP B-VP
significant JJ B-NP B-NP
aldosterone NN I-NP I-NP
binding NN I-NP I-NP
at IN B-PP B-PP
a DT B-NP B-NP
molecular JJ I-NP I-NP
weight NN I-NP I-NP
of IN B-PP B-PP
approximately RB B-NP B-NP
50000 CD I-NP I-NP
Dalton NN I-NP I-NP
which WDT B-NP B-NP
was VBD B-VP B-VP
absent JJ B-ADJP B-ADJP
with IN B-PP B-PP
1 CD B-NP B-NP
microM NN I-NP I-NP
cold JJ B-NP I-NP
aldosterone NN I-NP I-NP
, , O O
but CC B-CONJP I-CC
not RB I-CONJP B-NP
cortisol NN B-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
binding VBG I-NP I-NP
media NNS I-NP I-NP
. . O O

The DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
sulfhydryl NN I-NP I-NP
agent NN I-NP I-NP
dithiothreitol NN I-NP I-NP
did VBD B-VP B-VP
not RB I-VP I-VP
affect VB I-VP I-VP
results NNS B-NP B-NP
suggesting VBG B-VP B-VP
the DT B-NP B-NP
absence NN I-NP I-NP
of IN B-PP B-PP
disulfide NN B-NP B-NP
bridges NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
steroid NN I-NP I-NP
binding NN I-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
receptor NN I-NP I-NP
. . O O

These DT B-NP B-NP
data NNS I-NP I-NP
are VBP B-VP B-VP
the DT B-NP B-NP
first JJ I-NP I-NP
to TO B-VP B-VP
define VB I-VP I-VP
the DT B-NP B-NP
molecular JJ I-NP I-NP
weight NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
membrane NN I-NP I-NP
receptor NN I-NP I-NP
for IN B-PP B-PP
aldosterone NN B-NP B-NP
. . O O

Alpha-lipoic JJ B-NP B-NP
acid NN I-NP I-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
potent JJ I-NP I-NP
inhibitor NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
activation NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
. . O O

Acquired VBN B-NP B-NP
immunodeficiency NN I-NP I-NP
syndrome NN I-NP I-NP
( ( O O
AIDS NN B-NP B-NP
) ) O O
results VBZ B-VP B-VP
from IN B-PP B-PP
infection NN B-NP B-NP
with IN B-PP B-PP
a DT B-NP B-NP
human JJ I-NP I-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
( ( O O
HIV NN B-NP B-NP
) ) O O
. . O O

The DT O B-NP
long JJ B-NP I-NP
terminal JJ I-NP I-NP
repeat NN I-NP I-NP
( ( O O
LTR NN B-NP I-NN
) ) O O
region NN B-NP B-NP
of IN B-PP B-PP
HIV NN B-NP B-NP
proviral JJ I-NP I-NP
DNA NN I-NP I-NP
contains VBZ B-VP B-VP
binding VBG B-NP I-VP
sites NNS I-NP B-NP
for IN B-PP B-PP
nuclear JJ B-NP B-NP
factor NN I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
( ( O O
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
) ) O O
, , O O
and CC O I-CC
this DT B-NP B-NP
transcriptional JJ I-NP I-NP
activator NN I-NP I-NP
appears VBZ B-VP B-VP
to TO I-VP I-VP
regulate VB I-VP I-VP
HIV NN B-NP B-NP
activation NN I-NP I-NP
. . O O

Recent JJ B-NP B-NP
findings NNS I-NP I-NP
suggest VBP B-VP B-VP
an DT B-NP B-NP
involvement NN I-NP I-NP
of IN B-PP B-PP
reactive JJ B-NP B-NP
oxygen NN I-NP I-NP
species NNS I-NP I-NP
( ( O O
ROS NN B-NP B-NP
) ) O O
in IN B-PP B-PP
signal NN B-NP B-NP
transduction NN I-NP I-NP
pathways NNS I-NP I-NP
leading VBG B-VP B-VP
to TO B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
activation NN I-NP I-NP
. . O O

The DT B-NP B-NP
present JJ I-NP I-NP
study NN I-NP I-NP
was VBD B-VP B-VP
based VBN I-VP I-VP
on IN B-PP B-PP
reports NNS B-NP B-NP
that IN B-SBAR B-PP
antioxidants NNS B-NP B-NP
which WDT B-NP B-NP
eliminate VBP B-VP B-VP
ROS NN B-NP B-NP
should MD B-VP B-VP
block VB I-VP I-VP
the DT B-NP B-NP
activation NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
and CC O I-CC
subsequently RB B-ADVP B-ADVP
HIV NN B-NP B-NP
transcription NN I-NP I-NP
, , O O
and CC O I-CC
thus RB O B-ADVP
antioxidants NNS B-NP B-NP
can MD B-VP B-VP
be VB I-VP I-VP
used VBN I-VP I-VP
as IN B-PP B-PP
therapeutic JJ B-NP B-NP
agents NNS I-NP I-NP
for IN B-PP B-PP
AIDS NN B-NP B-NP
. . O O

Incubation NN B-NP B-NP
of IN B-PP B-PP
Jurkat NN B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
( ( O O
1 CD B-NP B-NP
x CC I-NP I-NP
10(6) CD I-NP I-NP
cells/ml NNS I-NP I-NP
) ) O O
with IN B-PP B-PP
a DT B-NP B-NP
natural JJ I-NP I-NP
thiol NN I-NP I-NP
antioxidant NN I-NP I-NP
, , I-NP O
alpha-lipoic JJ I-NP B-NP
acid NN I-NP I-NP
, , O O
prior JJ B-PP B-PP
to TO I-PP I-PP
the DT B-NP B-NP
stimulation NN I-NP I-NP
of IN B-PP B-PP
cells NNS B-NP B-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
inhibit VB I-VP I-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
activation NN I-NP I-NP
induced VBN B-VP B-VP
by IN B-PP B-PP
tumor NN B-NP B-NP
necrosis NN I-NP I-NP
factor-alpha NN I-NP I-NP
( ( O O
25 CD B-NP B-NP
ng/ml NN I-NP I-NP
) ) O O
or CC B-PP I-CC
by IN B-PP B-PP
phorbol NN B-NP B-NP
12-myristate NN I-NP I-NP
13-acetate NN I-NP I-NP
( ( O O
50 CD B-NP B-NP
ng/ml NN I-NP I-NP
) ) O O
. . O O

The DT B-NP B-NP
inhibitory JJ I-NP I-NP
action NN I-NP I-NP
of IN B-PP B-PP
alpha-lipoic JJ B-NP B-NP
acid NN I-NP I-NP
was VBD B-VP B-VP
found VBN I-VP I-VP
to TO I-VP I-VP
be VB I-VP I-VP
very RB B-ADJP B-ADJP
potent JJ I-ADJP I-ADJP
as IN B-SBAR B-PP
only RB B-NP B-NP
4 CD I-NP I-NP
mM NN I-NP I-NP
was VBD B-VP B-VP
needed VBN I-VP I-VP
for IN B-PP B-PP
a DT B-NP B-NP
complete JJ I-NP I-NP
inhibition NN I-NP I-NP
, , O O
whereas IN O B-PP
20 CD B-NP B-NP
mM NN I-NP I-NP
was VBD B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
N-acetylcysteine NN B-NP B-NP
. . O O

These DT B-NP B-NP
results NNS I-NP I-NP
indicate VBP B-VP B-VP
that IN B-SBAR B-SBAR
alpha-lipoic JJ B-NP B-NP
acid NN I-NP I-NP
may MD B-VP B-VP
be VB I-VP I-VP
effective JJ B-ADJP B-ADJP
in IN B-PP B-PP
AIDS NN B-NP B-NP
therapeutics NNS I-NP I-NP
. . O O

Activation NN B-NP B-NP
of IN B-PP B-PP
lymphokine NN B-NP B-NP
genes NNS I-NP I-NP
in IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
: : O O
role NN B-NP B-NP
of IN B-PP B-PP
cis-acting JJ B-NP B-NP
DNA NN I-NP I-NP
elements NNS I-NP I-NP
that WDT B-NP B-NP
respond VBP B-VP B-VP
to TO B-PP B-PP
T NN B-NP B-NP
cell NN I-NP I-NP
activation NN I-NP I-NP
signals NNS I-NP I-NP
. . O O

Activation NN B-NP B-NP
of IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
is VBZ B-VP B-VP
initiated VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
recognition NN I-NP I-NP
of IN B-PP B-PP
antigen NN B-NP B-NP
on IN B-PP B-PP
antigen NN B-NP B-NP
presenting NN I-NP I-NP
cells NNS I-NP I-NP
to TO B-VP B-VP
exert VB I-VP I-VP
the DT B-NP B-NP
effector NN I-NP I-NP
functions NNS I-NP I-NP
in IN B-PP B-PP
immune JJ B-NP B-NP
and CC I-NP I-NP
inflammatory JJ I-NP I-NP
responses NNS I-NP I-NP
. . O O

Two CD B-NP B-NP
types NNS I-NP I-NP
of IN B-PP B-PP
helper NN B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
( ( O O
Th NN B-NP B-NP
) ) O O
clones NNS B-NP B-NP
( ( O O
Th1 NN B-NP B-NP
and CC O I-NP
Th2 NN B-NP I-NP
) ) O O
are VBP B-VP B-VP
defined VBN I-VP I-VP
on IN B-PP B-PP
the DT I-PP B-NP
basis NN I-PP I-NP
of IN I-PP B-PP
different JJ B-NP B-NP
patterns NNS I-NP I-NP
of IN B-PP B-PP
cytokine NN B-NP B-NP
( ( O O
lymphokine NN B-NP I-NN
) ) O O
secretion NN B-NP B-NP
. . O O

They PRP B-NP B-NP
determine VBP B-VP B-VP
the DT B-NP B-NP
outcome NN I-NP I-NP
of IN B-PP B-PP
an DT B-NP B-NP
antigenic JJ I-NP I-NP
response NN I-NP I-NP
toward IN B-PP B-PP
humoral JJ B-NP B-NP
or CC I-NP I-NP
cell-mediated JJ I-NP I-NP
immunity NN I-NP I-NP
. . O O

Although IN B-SBAR B-SBAR
lymphokine NN B-NP B-NP
genes NNS I-NP I-NP
are VBP B-VP B-VP
coordinately RB I-VP I-VP
regulated VBN I-VP I-VP
upon IN B-PP B-PP
antigen NN B-NP B-NP
stimulation NN I-NP I-NP
, , O O
they PRP B-NP B-NP
are VBP B-VP B-VP
regulated VBN I-VP I-VP
by IN B-PP B-PP
the DT B-NP B-NP
mechanisms NNS I-NP I-NP
common JJ B-ADJP B-ADJP
to TO B-PP B-PP
all DT B-NP B-NP
as RB B-CONJP I-NP
well RB I-CONJP I-NP
as IN I-CONJP I-NP
those DT B-NP I-DT
which WDT B-NP B-NP
are VBP B-VP B-VP
unique JJ B-ADJP B-ADJP
to TO B-PP B-PP
each DT B-NP B-NP
gene NN I-NP I-NP
. . O O

For IN B-PP B-PP
most JJS B-NP B-NP
lymphokine NN I-NP I-NP
genes NNS I-NP I-NP
, , O O
a DT B-NP B-NP
combination NN I-NP I-NP
of IN B-PP B-PP
phorbol NN B-NP B-NP
esters NNS I-NP I-NP
( ( O O
phorbol NN B-NP B-NP
12-myristate NN I-NP I-NP
13 CD I-NP B-NP
acetate NN I-NP I-NP
, , O O
PMA NN B-NP B-NP
) ) O O
and CC O I-CC
calcium NN B-NP B-NP
ionophores NNS I-NP I-NP
( ( O O
A23187 NN B-NP B-NP
) ) O O
is VBZ B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
their PRP$ B-NP B-NP
maximal JJ I-NP I-NP
induction NN I-NP I-NP
. . O O

Yet RB O B-NP
phorbol NN B-NP I-NP
ester NN I-NP I-NP
alone RB B-ADVP B-ADVP
or CC O I-CC
calcium NN B-NP B-NP
ionophore NN I-NP I-NP
alone RB B-ADVP B-ADVP
produce VBP B-VP B-VP
several JJ B-NP B-NP
lymphokines NNS I-NP I-NP
. . O O

The DT B-NP B-NP
production NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
granulocyte-macrophage JJ I-NP I-NP
colony NN I-NP I-NP
stimulating NN I-NP I-NP
factor NN I-NP I-NP
( ( O O
GM-CSF NN B-NP B-NP
) ) O O
is VBZ B-VP B-VP
completely RB B-ADJP B-ADJP
dependent JJ I-ADJP I-ADJP
on IN B-PP B-PP
the DT B-NP B-NP
two CD I-NP I-NP
signals NNS I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
previously RB I-VP I-VP
found VBN I-VP I-VP
a DT B-NP B-NP
cis-acting JJ I-NP I-NP
region NN I-NP I-NP
spanning VBG B-VP B-VP
the DT B-NP B-NP
GM-CSF NN I-NP I-NP
promoter NN I-NP I-NP
region NN I-NP I-NP
( ( O O
positions NNS B-NP B-NP
-95 CD B-NP I-NP
to TO O B-PP
+27 CD B-NP B-NP
) ) O O
that WDT B-NP B-NP
confers VBZ B-VP B-VP
inducibility NN B-NP B-NP
to TO B-PP B-PP
reporter NN B-NP B-NP
genes NNS I-NP I-NP
in IN B-PP B-PP
transient JJ B-NP B-NP
transfection NN I-NP I-NP
assays NNS I-NP I-NP
. . O O

Further JJ B-NP B-NP
analysis NN I-NP I-NP
identified VBD B-VP B-VP
three CD B-NP B-NP
elements NNS I-NP I-NP
required VBN B-VP B-VP
for IN B-PP B-PP
efficient JJ B-NP B-NP
induction NN I-NP I-NP
, , O O
referred VBN B-VP B-VP
to TO B-PP B-PP
as IN B-PP B-PP
GM2 NN B-NP B-NP
, , O O
GC-box NN B-NP I-NP
and CC O I-NP
conserved VBN B-NP I-NP
lymphokine NN I-NP I-NP
element NN I-NP I-NP
( ( O O
CLE0 NN B-NP B-NP
) ) O O
. . O O

GM2 NN B-NP B-NP
defines VBZ B-VP B-VP
a DT B-NP B-NP
binding VBG I-NP I-NP
site NN I-NP I-NP
for IN B-PP B-PP
protein NN B-NP B-NP
( ( I-NP O
s NNS I-NP B-NP
) ) O O
whose WP$ B-NP B-NP
binding NN I-NP I-NP
is VBZ B-VP B-VP
inducible JJ B-ADJP B-ADJP
by IN B-PP B-PP
PMA NN B-NP B-NP
. . O O

One CD B-NP B-NP
protein NN I-NP I-NP
, , O O
NF-GM2 NN B-NP B-NP
is VBZ B-VP B-VP
similar JJ B-ADJP B-ADJP
to TO B-PP B-PP
the DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
NF-kB NN I-NP I-NP
. . O O

GC-box NN B-NP B-NP
is VBZ B-VP B-VP
a DT B-NP B-NP
binding VBG I-NP I-NP
site NN I-NP I-NP
for IN B-PP B-PP
constitutively RB B-NP B-NP
bound VBN I-NP I-NP
proteins NNS I-NP I-NP
. . O O

CLEO NN B-NP B-NP
defines VBZ B-VP B-VP
a DT B-NP B-NP
binding VBG I-NP I-NP
site NN I-NP I-NP
for IN B-PP B-PP
protein NN B-NP B-NP
( ( I-NP O
s NNS I-NP B-NP
) ) O O
whose WP$ B-NP B-NP
optimum NN I-NP I-NP
binding NN I-NP I-NP
is VBZ B-VP B-VP
stimulated VBN I-VP I-VP
by IN B-PP B-PP
PMA NN B-NP B-NP
and CC O I-NP
A23187 NN B-NP I-NP
. . O O

Viral JJ B-NP B-NP
trans-activators NNS I-NP I-NP
such JJ B-PP B-PP
as IN I-PP I-PP
Tax NN B-NP B-NP
( ( O O
human JJ B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
leukemia NN I-NP I-NP
virus-1 NN I-NP I-NP
, , O O
HTLV-1 NN B-NP B-NP
) ) O O
and CC O I-CC
E2 NN B-NP B-NP
( ( O O
bovine JJ B-NP B-NP
papilloma NN I-NP I-NP
virus NN I-NP I-NP
, , O O
BPV NN B-NP B-NP
) ) O O
proteins NNS B-NP B-NP
are VBP B-VP B-VP
other JJ B-NP B-NP
agents NNS I-NP I-NP
which WDT B-NP B-NP
activate VBP B-VP B-VP
lymphokine NN B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
by IN B-PP B-PP
bypassing VBG B-VP B-VP
T NN B-NP B-NP
cell NN I-NP I-NP
receptor NN I-NP I-NP
( ( O O
TCR NN B-NP B-NP
) ) O O
mediated JJ B-NP B-NP
signaling NN I-NP I-NP
. . O O

The DT B-NP B-NP
trans-activation NN I-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
E2 NN B-NP B-NP
and CC O I-NP
Tax NN B-NP I-NP
is VBZ B-VP B-VP
interchangeable JJ B-ADJP B-ADJP
although IN B-SBAR B-SBAR
they PRP B-NP B-NP
have VBP B-VP B-VP
no DT B-NP B-NP
obvious JJ I-NP I-NP
sequence NN I-NP I-NP
homology NN I-NP I-NP
between IN B-PP B-PP
them PRP B-NP B-NP
. . O O

The DT B-NP B-NP
viral JJ I-NP I-NP
trans-activators NNS I-NP I-NP
appear VBP B-VP B-VP
to TO I-VP I-VP
target VB I-VP I-VP
specific JJ B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
protein NN I-NP I-NP
such JJ B-PP B-PP
as IN I-PP I-PP
NF-kB NN B-NP B-NP
and CC O I-NP
Sp1 NN B-NP I-NP
to TO B-PP B-PP
cis-acting JJ B-NP B-NP
DNA NN I-NP I-NP
site NN I-NP I-NP
and CC O I-CC
promote VB B-VP B-VP
lymphokine NN B-NP B-NP
gene NN I-NP I-NP
expression NN I-NP I-NP
without IN B-PP B-PP
TCR-mediated JJ B-NP B-NP
stimulation NN I-NP I-NP
. . O O

I NN B-NP B-NP
kappa NN I-NP I-NP
B/MAD-3 NN I-NP I-NP
masks VBZ B-VP B-VP
the DT B-NP B-NP
nuclear JJ I-NP I-NP
localization NN I-NP I-NP
signal NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
p65 NN I-NP I-NP
and CC O I-CC
requires VBZ B-VP B-VP
the DT B-NP B-NP
transactivation NN I-NP I-NP
domain NN I-NP I-NP
to TO B-VP B-VP
inhibit VB I-VP I-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
p65 NN I-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
. . O O

The DT B-NP B-NP
active JJ I-NP I-NP
nuclear JJ I-NP I-NP
form NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
complex NN I-NP I-NP
is VBZ B-VP B-VP
composed VBN I-VP I-VP
of IN B-PP B-PP
two CD B-NP B-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
subunits NNS I-NP I-NP
, , O O
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
p65 NN I-NP I-NP
and CC O I-NP
NF-kappa NN B-NP I-NP
B NN I-NP I-NP
p50 NN I-NP I-NP
, , O O
both DT B-NP B-NP
of IN B-PP B-PP
which WDT B-NP B-NP
share VBP B-VP B-VP
extensive JJ B-NP B-NP
N-terminal JJ I-NP I-NP
sequence NN I-NP I-NP
homology NN I-NP I-NP
with IN B-PP B-PP
the DT B-NP B-NP
v-rel NN I-NP I-NP
oncogene NN I-NP I-NP
product NN I-NP I-NP
. . O O

The DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
p65 NN I-NP I-NP
subunit NN I-NP I-NP
provides VBZ B-VP B-VP
the DT B-NP B-NP
transactivation NN I-NP I-NP
activity NN I-NP I-NP
in IN B-PP B-PP
this DT B-NP B-NP
complex JJ I-NP I-NP
and CC O I-CC
serves VBZ B-VP B-VP
as IN B-PP B-PP
an DT B-NP B-NP
intracellular JJ I-NP I-NP
receptor NN I-NP I-NP
for IN B-PP B-PP
a DT B-NP B-NP
cytoplasmic JJ I-NP I-NP
inhibitor NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
, , O O
termed VBN B-VP B-NP
I NN B-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
p50 NN I-NP I-NP
alone RB B-ADVP B-ADVP
fails VBZ B-VP B-VP
to TO I-VP I-VP
stimulate VB I-VP I-VP
kappa NN B-NP B-NP
B-directed JJ I-NP I-NP
transcription NN I-NP I-NP
, , O O
and CC O I-CC
based VBN B-PP B-VP
on IN B-PP B-PP
prior JJ B-NP B-NP
in FW I-NP B-PP
vitro FW I-NP B-NP
studies NNS I-NP I-NP
, , O O
is VBZ B-VP B-VP
not RB I-VP I-VP
directly RB I-VP I-VP
regulated VBN I-VP I-VP
by IN B-PP B-PP
I NN B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
. . O O

To TO B-VP B-VP
investigate VB I-VP I-VP
the DT B-NP B-NP
molecular JJ I-NP I-NP
basis NN I-NP I-NP
for IN B-PP B-PP
the DT B-NP B-NP
critical JJ I-NP I-NP
regulatory JJ I-NP I-NP
interaction NN I-NP I-NP
between IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
and CC O I-NP
I NN B-NP I-NP
kappa NN I-NP I-NP
B/MAD-3 NN I-NP I-NP
, , O O
a DT B-NP B-NP
series NN I-NP I-NP
of IN B-PP B-PP
human JJ B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
p65 NN I-NP I-NP
mutants NNS I-NP I-NP
was VBD B-VP B-VP
identified VBN I-VP I-VP
that WDT B-NP B-NP
functionally RB B-ADVP B-ADVP
segregated VBD B-VP B-VP
DNA NN B-NP B-NP
binding NN I-NP I-NP
, , O O
I NN B-NP B-NP
kappa NN I-NP I-NP
B-mediated JJ I-NP I-NP
inhibition NN I-NP I-NP
, , O O
and CC O I-CC
I NN B-NP B-NP
kappa NN I-NP I-NP
B-induced JJ I-NP I-NP
nuclear JJ I-NP I-NP
exclusion NN I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
transcription NN I-NP I-NP
factor NN I-NP I-NP
. . O O

Results NNS B-NP B-NP
from IN B-PP B-PP
in FW B-NP B-NP
vivo FW I-NP I-NP
expression NN I-NP I-NP
studies NNS I-NP I-NP
performed VBN B-VP B-VP
with IN B-PP B-PP
these DT B-NP B-NP
NF-kappa NN I-NP I-NP
B NN I-NP I-NP
p65 NN I-NP I-NP
mutants NNS I-NP I-NP
revealed VBD B-VP B-VP
the DT B-NP B-NP
following NN I-NP I-NP
: : O O
1 LS B-LST I-LS
) ) O O
I NN B-NP B-NP
kappa NN I-NP I-NP
B/MAD-3 NN I-NP I-NP
completely RB B-ADVP B-ADVP
inhibits VBZ B-VP B-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
p65-dependent JJ I-NP I-NP
transcriptional JJ I-NP I-NP
activation NN I-NP I-NP
mediated VBN B-VP B-VP
through IN B-PP B-PP
the DT B-NP B-NP
human JJ I-NP I-NP
immunodeficiency NN I-NP I-NP
virus NN I-NP I-NP
type NN I-NP I-NP
1 CD I-NP I-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
enhancer NN I-NP I-NP
in IN B-PP B-PP
human JJ B-NP B-NP
T NN I-NP I-NP
lymphocytes NNS I-NP I-NP
, , O O
2 LS B-LST B-NP
) ) O O
the DT B-NP B-NP
binding NN I-NP I-NP
of IN B-PP B-PP
I NN B-NP B-NP
kappa NN I-NP I-NP
B/MAD-3 NN I-NP I-NP
to TO B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
p65 NN I-NP I-NP
is VBZ B-VP B-VP
sufficient JJ B-ADJP B-ADJP
to TO B-VP B-VP
retarget VB I-VP I-VP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
p65 NN I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
nucleus NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
cytoplasm NN I-NP I-NP
, , O O
3 LS B-LST B-NP
) ) O O
selective JJ B-NP B-NP
deletion NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
functional JJ I-NP I-NP
nuclear JJ I-NP I-NP
localization NN I-NP I-NP
signal NN I-NP I-NP
present JJ B-ADJP B-ADJP
in IN B-PP B-PP
the DT B-NP B-NP
Rel NN I-NP I-NP
homology NN I-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
p65 NN I-NP I-NP
disrupts VBZ B-VP B-VP
its PRP$ B-NP B-NP
ability NN I-NP I-NP
to TO B-VP B-VP
engage VB I-VP I-VP
I NN B-NP B-NP
kappa NN I-NP I-NP
B/MAD-3 NN I-NP I-NP
, , O O
and CC O I-CC
4 LS B-LST B-NP
) ) O O
the DT B-NP B-NP
unique JJ I-NP I-NP
C-terminus NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
p65 NN I-NP I-NP
attenuates VBZ B-VP B-VP
its PRP$ B-NP B-NP
own JJ I-NP I-NP
nuclear JJ I-NP I-NP
localization NN I-NP I-NP
and CC O I-CC
contains VBZ B-VP B-VP
sequences NNS B-NP B-NP
that WDT B-NP B-NP
are VBP B-VP B-VP
required VBN I-VP I-VP
for IN B-PP B-PP
I NN B-NP B-NP
kappa NN I-NP I-NP
B-mediated JJ I-NP I-NP
inhibition NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
p65 NN I-NP I-NP
DNA NN I-NP I-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
. . O O

Together RB B-ADVP B-ADVP
, , O O
these DT B-NP B-NP
findings NNS I-NP I-NP
suggest VBP B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
nuclear JJ B-NP I-NP
localization NN I-NP I-NP
signal NN I-NP I-NP
and CC O I-NP
transactivation NN B-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
p65 NN I-NP I-NP
constitute VBP B-VP B-VP
a DT B-NP B-NP
bipartite JJ I-NP I-NP
system NN I-NP I-NP
that WDT B-NP B-NP
is VBZ B-VP B-VP
critically RB I-VP I-VP
involved VBN I-VP I-VP
in IN B-PP B-PP
the DT B-NP B-NP
inhibitory JJ I-NP I-NP
function NN I-NP I-NP
of IN B-PP B-PP
I NN B-NP B-NP
kappa NN I-NP I-NP
B/MAD-3 NN I-NP I-NP
. . O O

Unexpectedly RB B-ADVP B-ADVP
, , O O
our PRP$ B-NP B-NP
in FW I-NP B-PP
vivo FW I-NP B-NP
studies NNS I-NP I-NP
also RB B-ADVP B-ADVP
demonstrate VBP B-VP B-VP
that IN B-SBAR B-PP
I NN B-NP B-NP
kappa NN I-NP I-NP
B/MAD-3 NN I-NP I-NP
binds VBZ B-VP B-VP
directly RB B-ADVP B-ADVP
to TO B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
p50 NN I-NP I-NP
. . O O

This DT B-NP B-NP
interaction NN I-NP I-NP
is VBZ B-VP B-VP
functional JJ B-ADJP B-ADJP
as IN B-SBAR B-SBAR
it PRP B-NP B-NP
leads VBZ B-VP B-VP
to TO B-PP B-PP
retargeting NN B-NP B-NP
of IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
p50 NN I-NP I-NP
from IN B-PP B-PP
the DT B-NP B-NP
nucleus NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
cytoplasm NN I-NP I-NP
. . O O

However RB B-ADVP B-ADVP
, , O O
no DT B-NP B-NP
loss NN I-NP I-NP
of IN B-PP B-PP
DNA NN B-NP B-NP
binding NN I-NP I-NP
activity NN I-NP I-NP
is VBZ B-VP B-VP
observed VBN I-VP I-VP
, , O O
presumably RB B-ADVP B-PP
reflecting VBG B-VP B-VP
the DT B-NP B-NP
unique JJ I-NP I-NP
C-terminal JJ I-NP I-NP
domain NN I-NP I-NP
that WDT B-NP B-NP
is VBZ B-VP B-VP
distinct JJ B-ADJP B-ADJP
from IN B-PP B-PP
that DT B-NP B-NP
present JJ B-ADJP I-NP
in IN B-PP B-PP
NF-kappa NN B-NP B-NP
B NN I-NP I-NP
p65 NN I-NP I-NP
. . O O

Surrogate NN B-NP B-NP
thyroglobulin NN I-NP I-NP
receptors NNS I-NP I-NP
and CC O I-CC
T NN B-NP B-NP
cell NN I-NP I-NP
proliferation NN I-NP I-NP
in IN B-PP B-PP
Hashimoto NN B-NP B-NP
's POS B-NP B-NP
thyroiditis NN I-NP I-NP
. . O O

Immunoglobulin NN B-NP B-NP
molecules NNS I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
surface NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
B NN I-NP I-NP
lymphocyte NN I-NP I-NP
are VBP B-VP B-VP
the DT B-NP B-NP
endogenous JJ I-NP I-NP
" [[DQS]] I-NP I-NP
receptors NNS I-NP I-NP
" [[DQE]] O I-NP
to TO B-PP B-PP
which WDT B-NP B-NP
specific JJ B-NP B-NP
antigens NNS I-NP I-NP
bind VBP B-VP I-NP
. . O O

Studies NNS B-NP B-NP
in IN B-PP B-PP
mice NNS B-NP B-NP
have VBP B-VP B-VP
shown VBN I-VP I-VP
that IN B-SBAR B-SBAR
a DT B-NP B-NP
monoclonal JJ I-NP I-NP
antibody NN I-NP I-NP
, , O O
conjugated VBN B-VP B-VP
with IN B-PP B-PP
palmitate NN B-NP B-NP
to TO B-VP B-VP
provide VB I-VP I-VP
a DT B-NP B-NP
lipid NN I-NP I-NP
tail NN I-NP I-NP
, , O O
can MD B-VP B-VP
be VB I-VP I-VP
inserted VBN I-VP I-VP
into IN B-PP B-PP
the DT B-NP B-NP
cell NN I-NP I-NP
membrane NN I-NP I-NP
to TO B-VP B-VP
provide VB I-VP I-VP
a DT B-NP B-NP
" [[DQS]] I-NP I-NP
surrogate JJ I-NP I-NP
" [[DQE]] I-NP I-NP
antigen NN I-NP I-NP
receptor NN I-NP I-NP
. . O O

We PRP B-NP B-NP
have VBP B-VP B-VP
investigated VBN I-VP I-VP
whether IN B-SBAR B-PP
a DT B-NP B-NP
palmitate JJ I-NP I-NP
conjugate NN I-NP I-NP
of IN B-PP B-PP
a DT B-NP B-NP
human JJ I-NP I-NP
monoclonal JJ I-NP I-NP
antibody NN I-NP I-NP
specific JJ B-ADJP B-ADJP
for IN B-PP B-PP
thyroglobulin NN B-NP B-NP
( ( O O
TG NN B-NP B-NP
) ) O O
could MD B-VP B-VP
function VB I-VP I-VP
as IN B-PP B-PP
a DT B-NP B-NP
surrogate JJ I-NP I-NP
TG NN I-NP I-NP
receptor NN I-NP I-NP
on IN B-PP B-PP
blood NN B-NP B-NP
mononuclear JJ I-NP I-NP
cells NNS I-NP I-NP
separated VBN B-VP B-VP
into IN B-PP B-PP
fractions NNS B-NP B-NP
enriched VBN B-VP B-VP
for IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
or CC O I-CC
depleted VBN B-VP B-VP
of IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
( ( O O
non-T JJ B-NP B-NP
cells NNS I-NP I-NP
) ) O O
. . O O

Using VBG B-VP B-VP
flow NN B-NP B-NP
cytometry NN I-NP I-NP
, , O O
we PRP B-NP B-NP
detected VBD B-VP B-VP
surrogate JJ B-NP B-NP
TG NN I-NP I-NP
receptors NNS I-NP I-NP
on IN B-PP B-PP
non-T JJ B-NP B-NP
( ( B-PP O
but CC I-PP I-CC
not RB B-PP I-RB
on IN I-PP B-PP
T NN B-NP B-NP
) ) O O
cells NNS B-NP B-NP
from IN B-PP B-PP
11 CD B-NP B-NP
of IN I-NP B-PP
11 CD I-NP B-NP
individuals NNS I-NP I-NP
studied VBN B-VP I-VBN
( ( O O
5 CD B-NP B-NP
Hashimoto NN I-NP I-NP
patients NNS I-NP I-NP
and CC O I-CC
6 CD B-NP B-NP
control NN I-NP I-NP
donors NNS I-NP I-NP
) ) O O
. . O O

In IN B-PP B-PP
contrast NN B-NP B-NP
, , O O
endogenous JJ B-NP B-NP
TG NN I-NP I-NP
receptors NNS I-NP I-NP
could MD B-VP B-VP
only RB I-VP I-VP
be VB I-VP I-VP
detected VBN I-VP I-VP
on IN B-PP B-PP
non-T JJ B-NP B-NP
cells NNS I-NP I-NP
from IN B-PP B-PP
1 CD B-NP B-NP
of IN I-NP B-PP
3 CD I-NP B-NP
Hashimoto NN I-NP I-NP
patients NNS I-NP I-NP
and CC B-PP I-CC
from IN B-PP B-PP
0 CD B-NP B-NP
of IN I-NP B-PP
4 CD I-NP B-NP
control NN I-NP I-NP
donors NNS I-NP I-NP
. . O O

Because IN B-PP B-PP
of IN I-PP I-PP
the DT B-NP B-NP
efficient JJ I-NP I-NP
binding NN I-NP I-NP
of IN B-PP B-PP
TG NN B-NP B-NP
by IN B-PP B-PP
surrogate JJ B-NP B-NP
receptors NNS I-NP I-NP
on IN B-PP B-PP
non-T JJ B-NP B-NP
cells NNS I-NP I-NP
, , O O
we PRP B-NP B-NP
assessed VBD B-VP B-VP
the DT B-NP B-NP
ability NN I-NP I-NP
of IN B-PP B-PP
such JJ B-NP B-NP
cells NNS I-NP I-NP
to TO B-VP B-VP
present VB I-VP I-VP
TG NN B-NP B-NP
to TO B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Proliferation NN B-NP B-NP
in IN B-PP B-PP
response NN I-PP B-NP
to TO I-PP B-PP
TG NN B-NP B-NP
was VBD B-VP B-VP
observed VBN I-VP I-VP
in IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
from IN B-PP B-PP
only RB B-NP B-NP
1 CD I-NP I-NP
of IN I-NP I-NP
5 CD I-NP I-NP
Hashimoto NN I-NP I-NP
patients NNS I-NP I-NP
. . O O

This DT B-NP B-NP
low JJ I-NP I-NP
frequency NN I-NP I-NP
of IN B-PP B-PP
response NN B-NP B-NP
was VBD B-VP B-VP
no RB B-ADJP B-ADJP
different JJ I-ADJP I-ADJP
from IN B-PP B-PP
that DT B-NP B-NP
previously RB B-VP I-NP
detected VBN I-VP I-NP
using VBG B-VP I-NP
cultures NNS B-NP I-NP
of IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
and CC O I-CC
autologous JJ B-NP B-NP
dendritic JJ I-NP I-NP
cells NNS I-NP I-NP
. . O O

Therefore RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
successful JJ I-NP I-NP
generation NN I-NP I-NP
of IN B-PP B-PP
surrogate JJ B-NP B-NP
receptors NNS I-NP I-NP
on IN B-PP B-PP
non-T JJ B-NP B-NP
cells NNS I-NP I-NP
is VBZ B-VP B-VP
not RB I-VP I-VP
associated VBN I-VP I-VP
with IN B-PP B-PP
more RBR B-NP B-NP
efficient JJ I-NP I-NP
TG NN I-NP I-NP
presentation NN I-NP I-NP
of IN B-PP B-PP
T NN B-NP B-NP
cells NNS I-NP I-NP
. . O O

Furthermore RB B-ADVP B-ADVP
, , O O
the DT B-NP B-NP
significance NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
present JJ I-NP I-NP
study NN I-NP I-NP
is VBZ B-VP B-VP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
T NN I-NP I-NP
cells NNS I-NP I-NP
, , B-NP O
not RB I-NP I-RB
the DT B-NP B-NP
antigen-presenting JJ I-NP I-NP
cells NNS I-NP I-NP
, , O O
are VBP B-VP B-VP
likely JJ B-ADJP B-ADJP
to TO B-VP B-VP
be VB I-VP I-VP
the DT B-NP B-NP
limiting VBG I-NP I-NP
element NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
T NN I-NP I-NP
cell NN I-NP I-NP
proliferative JJ I-NP I-NP
response NN I-NP I-NP
to TO B-PP B-PP
TG NN B-NP B-NP
and CC O I-CC
other JJ B-NP B-NP
thyroid NN I-NP I-NP
autoantigens NNS I-NP I-NP
. . O O

Aldosterone-specific JJ B-NP B-NP
membrane NN I-NP I-NP
receptors NNS I-NP I-NP
and CC O I-CC
rapid JJ B-NP B-NP
non-genomic JJ I-NP I-NP
actions NNS I-NP I-NP
of IN B-PP B-PP
mineralocorticoids NNS B-NP B-NP
. . O O

Functional JJ B-NP B-NP
studies NNS I-NP I-NP
in IN B-PP B-PP
extrarenal JJ B-NP B-NP
, , I-NP O
non-epithelial JJ I-NP I-NP
cells NNS I-NP I-NP
such JJ B-PP B-PP
as IN I-PP I-PP
smooth JJ B-NP B-NP
muscle NN I-NP I-NP
cells NNS I-NP I-NP
and CC O I-CC
more RBR B-ADVP B-VP
recently RB I-ADVP I-VP
circulating VBG B-NP I-VP
human JJ I-NP B-NP
lymphocytes NNS I-NP I-NP
have VBP B-VP B-VP
provided VBN I-VP I-VP
increasing VBG B-NP I-VP
evidence NN I-NP B-NP
that IN B-SBAR B-SBAR
aldosterone NN B-NP B-NP
produces VBZ B-VP B-VP
not RB B-CONJP I-RB
only RB I-CONJP I-RB
classical JJ B-NP B-NP
genomic JJ I-NP I-NP
effects NNS I-NP I-NP
, , O O
but CC B-CONJP I-CC
also RB I-CONJP B-ADVP
rapid JJ B-NP B-ADJP
, , I-NP O
non-genomic JJ I-NP B-NP
effects NNS I-NP I-NP
on IN B-PP B-PP
transmembrane NN B-NP B-NP
electrolyte NN I-NP I-NP
movements NNS I-NP I-NP
. . O O

These DT B-NP B-NP
involve VBP B-VP B-VP
activation NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
sodium/proton NN I-NP I-NP
exchanger NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
cell NN I-NP I-NP
membrane NN I-NP I-NP
at IN B-PP B-PP
very RB B-NP B-NP
low JJ I-NP I-NP
, , I-NP O
physiological JJ I-NP I-NP
concentrations NNS I-NP I-NP
of IN B-PP B-PP
aldosterone NN B-NP B-NP
with IN B-PP B-PP
an DT B-NP B-NP
acute JJ I-NP I-NP
onset NN I-NP I-NP
within IN B-PP B-PP
1-2 CD B-NP B-NP
min NN I-NP I-NP
. . O O

A DT B-NP B-NP
second JJ I-NP I-NP
messenger NN I-NP I-NP
cascade NN I-NP I-NP
involved VBN B-VP B-VP
is VBZ B-VP B-VP
the DT B-NP B-NP
inositol NN I-NP I-NP
1,4,5-trisphosphate/calcium NN I-NP I-NP
pathway NN I-NP I-NP
which WDT B-NP B-NP
responds VBZ B-VP B-VP
over IN B-PP B-PP
the DT B-NP B-NP
same JJ I-NP I-NP
rapid JJ I-NP I-NP
time NN I-NP I-NP
course NN I-NP I-NP
. . O O

Such JJ B-NP B-NP
changes NNS I-NP I-NP
clearly RB B-ADVP B-ADVP
can MD B-VP B-VP
not RB I-VP I-VP
be VB I-VP I-VP
explained VBN I-VP I-VP
by IN B-PP B-PP
genomic JJ B-NP B-NP
mechanisms NNS I-NP I-NP
, , O O
which WDT B-NP B-NP
are VBP B-VP B-VP
responsible JJ B-ADJP B-ADJP
for IN B-PP B-PP
later JJ B-NP B-NP
effects NNS I-NP I-NP
than IN B-PP B-PP
the DT O B-NP
membrane NN B-NP I-NP
related JJ B-NP I-NP
rapid JJ I-NP I-NP
responses NNS I-NP I-NP
. . O O

The DT B-NP B-NP
mechanisms NNS I-NP I-NP
underlying VBG B-VP B-VP
these DT B-NP B-NP
rapid JJ I-NP I-NP
effects NNS I-NP I-NP
of IN B-PP B-PP
aldosterone NN B-NP B-NP
on IN B-PP B-PP
electrolytes NNS B-NP B-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
extensively RB I-VP I-VP
studied VBN I-VP I-VP
in IN B-PP B-PP
human JJ B-NP B-NP
lymphocytes NNS I-NP I-NP
, , O O
which WDT B-NP B-NP
thus RB B-ADVP B-ADVP
may MD B-VP B-VP
represent VB I-VP I-VP
valuable JJ B-NP B-NP
tools NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
delineation NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
receptor-effector JJ I-NP I-NP
mechanisms NNS I-NP I-NP
involved VBN B-VP B-VP
. . O O

The DT B-NP B-NP
unique JJ I-NP I-NP
characteristics NNS I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
new JJ I-NP I-NP
pathway NN I-NP I-NP
for IN B-PP B-PP
steroid NN B-NP B-NP
action NN I-NP I-NP
include VBP B-VP B-VP
its PRP$ B-NP B-NP
rapid JJ I-NP I-NP
time NN I-NP I-NP
course NN I-NP I-NP
, , O O
10,000-fold JJ B-NP B-NP
selectivity NN I-NP I-NP
for IN B-PP B-PP
aldosterone NN B-NP B-NP
over IN B-PP B-PP
cortisol NN B-NP B-NP
and CC O I-CC
the DT B-NP B-NP
ineffectiveness NN I-NP I-NP
of IN B-PP B-PP
spironolactones NNS B-NP B-NP
, , O O
classical JJ B-NP B-NP
mineralocorticoid NN I-NP I-NP
antagonists NNS I-NP I-NP
, , O O
as IN B-PP B-SBAR
antagonists NNS B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
response NN I-NP I-NP
. . O O

Cellular JJ O B-NP
immune JJ O I-NP
and CC O I-NP
cytokine NN B-NP I-NP
pathways NNS B-NP I-NP
resulting VBG B-VP B-VP
in IN B-PP B-PP
tissue NN B-NP B-NP
factor NN I-NP I-NP
expression NN I-NP I-NP
and CC O I-NP
relevance NN B-NP I-NP
to TO B-PP B-PP
septic JJ B-NP B-NP
shock NN I-NP I-NP
. . O O

Cells NNS B-NP B-NP
of IN B-PP B-PP
monocyte NN B-NP B-NP
lineage NN I-NP I-NP
serve VBP B-VP B-VP
as IN B-PP B-PP
effector NN B-NP B-NP
cells NNS I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
cellular JJ I-NP I-NP
immune JJ I-NP I-NP
response NN I-NP I-NP
. . O O

In IN B-PP B-PP
addition NN B-NP B-NP
, , O O
they PRP B-NP B-NP
respond VBP B-VP B-VP
to TO B-PP B-PP
LPS NN B-NP B-NP
and CC O I-NP
cytokines NNS B-NP I-NP
with IN B-PP B-PP
activation NN B-NP B-NP
and CC O I-NP
expression NN B-NP I-NP
of IN B-PP B-PP
inflammatory JJ B-NP B-NP
effector NN I-NP I-NP
gene NN I-NP I-NP
products NNS I-NP I-NP
similar JJ B-ADJP B-ADJP
to TO B-PP B-PP
those DT B-NP B-NP
elicited VBN B-VP B-VP
by IN B-PP B-PP
the DT O B-NP
antigen NN B-NP I-NP
driven JJ B-NP I-NP
response NN I-NP I-NP
. . O O

The DT B-NP B-NP
response NN I-NP I-NP
to TO B-PP B-PP
antigen NN B-NP B-NP
proceeds VBZ B-VP B-VP
at IN B-PP B-PP
the DT B-NP B-NP
T NN I-NP I-NP
helper NN I-NP I-NP
cell NN I-NP I-NP
level NN I-NP I-NP
through IN B-PP B-PP
two CD B-NP B-NP
independent JJ I-NP I-NP
forms NNS I-NP I-NP
of IN B-PP B-PP
cellular JJ B-NP B-NP
collaboration NN I-NP I-NP
, , O O
contact NN B-NP B-NP
and CC O I-NP
lymphokine NN B-NP I-NP
. . O O

We PRP B-NP B-NP
review VBP B-VP B-VP
the DT B-NP B-NP
control NN I-NP I-NP
of IN B-PP B-PP
expression NN B-NP B-NP
of IN B-PP B-PP
the DT O B-NP
Tissue NN B-NP I-NP
Factor NN I-NP I-NP
( ( O O
TF NN B-NP I-NN
) ) O O
gene NN B-NP B-NP
and CC O I-CC
the DT B-NP B-NP
function NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
TF NN I-NP I-NP
protein NN I-NP I-NP
. . O O

The DT B-NP B-NP
enhanced VBN I-NP I-NP
initiation NN I-NP I-NP
of IN B-PP B-PP
transcription NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
TF NN I-NP I-NP
gene NN I-NP I-NP
appears VBZ B-VP B-VP
to TO I-VP I-VP
require VB I-VP I-VP
engagement NN B-NP B-NP
of IN B-PP B-PP
a DT B-NP B-NP
56 CD I-NP I-NP
bp NN I-NP I-NP
LPS NN I-NP I-NP
Response NN I-NP I-NP
Element NN I-NP I-NP
, , O O
an DT B-NP B-NP
enhancer NN I-NP I-NP
that WDT B-NP B-NP
is VBZ B-VP B-VP
engaged VBN I-VP I-VP
by IN B-PP B-PP
both DT B-NP B-NP
AP-1 NN B-NP I-NP
type NN I-NP I-NP
heterodimeric JJ I-NP I-NP
complexes NNS I-NP I-NP
as RB B-CONJP B-CONJP
well RB I-CONJP I-CONJP
as IN I-CONJP I-CONJP
NF NN B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
like IN B-NP B-PP
heterodimeric JJ I-NP B-NP
complexes NNS I-NP I-NP
. . O O

Dissociation NN B-NP B-NP
of IN B-PP B-PP
NF NN B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
from IN B-PP B-PP
Ig NN B-NP B-NP
kappa NN I-NP I-NP
B NN I-NP I-NP
by IN B-PP B-PP
cytokine NN B-NP B-NP
and CC O I-NP
LPS NN B-NP I-NP
stimulation NN B-NP I-NP
, , O O
and CC O I-CC
possibly RB B-ADVP B-VP
activated VBN B-NP I-VP
T NN I-NP B-NP
cells NNS I-NP I-NP
, , O O
may MD B-VP B-VP
represent VB I-VP I-VP
a DT B-NP B-NP
common JJ I-NP I-NP
pathway NN I-NP I-NP
to TO B-PP B-PP
induction NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
TF NN B-NP I-NP
and CC O I-CC
other JJ B-NP B-NP
inflammatory JJ I-NP I-NP
genes NNS B-NP I-NP
. . O O

Enhancement NN B-NP B-NP
of IN B-PP B-PP
expression NN B-NP B-NP
of IN B-PP B-PP
TF NN B-NP B-NP
is VBZ B-VP B-VP
observed VBN I-VP I-VP
upon IN B-PP B-PP
adhesion NN B-NP B-NP
of IN B-PP B-PP
Mo NN B-NP B-NP
to TO B-PP B-PP
endothelial JJ B-NP B-NP
cells NNS I-NP I-NP
and CC O I-CC
extracellular JJ B-NP B-NP
matrix JJ I-NP I-NP
proteins NNS I-NP I-NP
, , O O
as RB B-CONJP B-CONJP
well RB I-CONJP I-CONJP
as IN I-CONJP I-CONJP
upon IN B-PP B-PP
engagement NN B-NP B-NP
of IN B-PP B-PP
leukocyte NN B-NP B-NP
integrins NNS I-NP I-NP
. . O O

The DT B-NP B-NP
biological JJ I-NP I-NP
effects NNS I-NP I-NP
that WDT B-NP B-NP
follow VBP B-VP B-VP
from IN B-PP B-PP
expression NN B-NP B-NP
of IN B-PP B-PP
TF NN B-NP B-NP
by IN B-PP B-PP
vascular JJ B-NP B-NP
cells NNS I-NP I-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
resolved VBN I-VP I-VP
by IN B-PP B-PP
analysis NN B-NP B-NP
of IN B-PP B-PP
function NN B-NP B-NP
aided VBN B-VP B-VP
by IN B-PP B-PP
the DT B-NP B-NP
use NN I-NP I-NP
of IN B-PP B-PP
recombinant JJ B-NP B-NP
full JJ I-NP I-NP
length NN I-NP I-NP
TF NN I-NP I-NP
and CC O I-CC
truncated VBN B-NP B-NP
surface NN I-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
TF NN B-NP B-NP
. . O O

The DT B-NP B-NP
rules NNS I-NP I-NP
of IN B-PP B-PP
assembly NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
cognate JJ I-NP I-NP
ligands NNS I-NP I-NP
of IN B-PP B-PP
TF NN B-NP B-NP
, , B-NP O
namely RB I-NP B-ADVP
the DT B-NP B-NP
zymogen NN I-NP I-NP
plasma NN I-NP I-NP
factors NNS I-NP I-NP
VII NN I-NP I-NP
and CC O I-CC
the DT B-NP B-NP
serine NN I-NP I-NP
protease NN I-NP I-NP
factor NN I-NP I-NP
VIIa NN I-NP I-NP
, , O O
with IN B-PP B-PP
the DT B-NP B-NP
soluble JJ I-NP I-NP
surface NN I-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
TF NN B-NP B-NP
in IN B-PP B-PP
free JJ B-NP B-NP
solution NN I-NP I-NP
, , O O
in IN B-PP B-PP
the DT B-NP B-NP
presence NN I-NP I-NP
of IN B-PP B-PP
phospholipid JJ B-NP B-NP
surfaces NNS I-NP I-NP
and CC O I-CC
cell NN B-NP B-NP
surface NN I-NP I-NP
and CC B-PP I-CC
of IN B-PP B-PP
the DT B-NP B-NP
anchored VBN I-NP I-NP
TF NN I-NP I-NP
molecule NN I-NP I-NP
have VBP B-VP B-VP
been VBN I-VP I-VP
described VBN I-VP I-VP
. . O O

It PRP B-NP B-NP
is VBZ B-VP B-VP
evident JJ B-ADJP B-ADJP
that IN B-SBAR B-PP
assembly NN B-NP B-NP
of IN B-PP B-PP
the DT B-NP B-NP
surface NN I-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
TF NN B-NP B-NP
with IN B-PP B-PP
VIIa NN B-NP B-NP
to TO B-VP B-VP
form VB I-VP I-VP
the DT B-NP B-NP
binary JJ I-NP I-NP
TF.VIIa NN I-NP I-NP
complex NN I-NP I-NP
induces VBZ B-VP B-VP
a DT B-NP B-NP
significant JJ I-NP I-NP
increase NN I-NP I-NP
in IN B-PP B-PP
the DT B-NP B-NP
Kcat NN I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
catalytic JJ I-NP I-NP
domain NN I-NP I-NP
of IN B-PP B-PP
VIIa NN B-NP B-NP
for IN B-PP B-PP
small JJ B-NP B-NP
peptidyl JJ I-NP I-NP
substrates NNS I-NP I-NP
and CC B-PP I-CC
more JJR B-ADVP B-NP
profoundly RB I-ADVP I-NP
for IN B-PP B-PP
protein NN B-NP B-NP
substrate NN I-NP I-NP
. . O O

This DT B-NP B-NP
provides VBZ B-VP B-VP
substantial JJ B-NP B-NP
evidence NN I-NP I-NP
for IN B-PP B-PP
an DT B-NP B-NP
allosteric JJ I-NP I-NP
effect NN I-NP I-NP
on IN B-PP B-PP
the DT B-NP B-NP
catalytic JJ I-NP I-NP
cleft NN I-NP I-NP
of IN B-PP B-PP
VIIa NN B-NP B-NP
that WDT B-NP B-NP
is VBZ B-VP B-VP
imparted VBN I-VP I-VP
by IN B-PP B-PP
binding VBG B-VP B-VP
to TO B-PP B-PP
TF NN B-NP B-NP
, , O O
its PRP$ B-NP B-NP
cognate JJ I-NP I-NP
catalytic JJ I-NP I-NP
cofactor NN I-NP I-NP
. . O O

It PRP B-NP B-NP
is VBZ B-VP B-VP
also RB B-ADJP B-ADVP
evident JJ I-ADJP B-ADJP
that IN B-SBAR B-SBAR
the DT B-NP B-NP
TF.VIIa NN I-NP I-NP
complex NN I-NP I-NP
is VBZ B-VP B-VP
proteolytically RB B-ADJP B-ADVP
active JJ I-ADJP B-ADJP
and CC O I-CC
can MD B-VP B-VP
activate VB I-VP I-VP
the DT B-NP B-NP
zymogen NN I-NP I-NP
plasma NN I-NP I-NP
factor NN I-NP I-NP
X NN I-NP I-NP
to TO B-PP B-PP
the DT B-NP B-NP
serine NN I-NP I-NP
protease NN I-NP I-NP
Xa NN I-NP I-NP
in IN B-PP B-PP
free JJ B-NP B-NP
solution NN I-NP I-NP
, , O O
inferring VBG B-VP B-VP
that IN B-SBAR B-PP
extended VBN B-NP B-NP
substrate NN I-NP I-NP
recognition NN I-NP I-NP
by IN B-PP B-PP
induced VBN B-NP B-NP
structural JJ I-NP I-NP
loci NNS I-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
TF.VIIa NN I-NP I-NP
complex NN I-NP I-NP
are VBP B-VP B-VP
created VBN I-VP I-VP
from IN B-PP B-PP
either DT B-NP B-NP
or CC O I-CC
both DT B-NP B-NP
proteins NNS B-NP I-NP
to TO B-VP B-VP
constitute VB I-VP I-VP
a DT B-NP B-NP
new JJ I-NP I-NP
recognition NN I-NP I-NP
structure NN I-NP I-NP
. . O O

It PRP B-NP B-NP
is VBZ B-VP B-VP
also RB B-ADJP B-ADJP
evident JJ I-ADJP I-ADJP
that IN B-SBAR B-PP
association NN B-NP B-NP
of IN B-PP B-PP
X NN B-NP B-NP
with IN B-PP B-PP
charged JJ B-NP B-NP
phospholipid JJ I-NP I-NP
surfaces NNS I-NP I-NP
enhances VBZ B-VP B-VP
the DT B-NP B-NP
proteolytic JJ I-NP I-NP
activation NN I-NP I-NP
of IN B-PP B-PP
this DT B-NP B-NP
zymogen NN I-NP I-NP
by IN B-PP B-PP
increasing VBG B-VP B-VP
recognition NN B-NP B-NP
and CC O I-NP
susceptibility NN B-NP I-NP
of IN B-PP B-PP
the DT B-NP B-NP
sessile NN I-NP I-NP
peptide NN I-NP I-NP
bond NN I-NP I-NP
deduced VBN B-VP B-VP
from IN B-PP B-PP
the DT B-NP B-NP
markedly RB B-ADVP I-NP
decreased VBN B-NP I-NP
Km NN I-NP I-NP
and CC O I-CC
increased VBN B-NP B-NP
Kcat NN I-NP I-NP
. . O O
